background
regulatori
tgf
cytokin
gene
polymorph
associ
allerg
diseas
differ
popul
like
caucasian
chines
indian
howev
associ
tgf
gene
polymorph
food
allergi
fa
japanes
children
evalu
far
clarifi
relationship
polymorph
regulatori
cytokin
gene
fa
atopi
polymorph
tgf
fa
patient
compar
nonfa
atop
control
method
one
hundredeleven
childhood
fa
patient
mean
year
age
atop
control
children
without
fa
mean
year
age
recruit
fa
patient
atop
control
sensit
hous
dust
mite
respect
dna
sampl
subject
genotyp
use
real
time
pcr
result
odd
ratio
aa
genotyp
ci
food
allergi
risk
compar
atop
control
subject
p
studi
power
achiev
signific
level
allel
greater
valu
therefor
consid
associ
enough
statist
power
support
find
signif
differ
frequenc
tgf
gene
polymorph
group
conclus
result
indic
gene
polymorph
associ
food
allergi
suscept
atop
japanes
children
find
encourag
studi
elucid
function
relationship
gene
polymorph
fa
pathogenesi
abstract
withdrawn
safeti
assess
bacteri
cholin
oxidas
protein
introduc
transgen
crop
background
previous
transgen
brassica
juncea
express
bacteri
cholin
oxidas
protein
show
enhanc
allergen
evalu
whofao
guidelin
present
studi
cholin
oxidas
protein
deriv
arthrobact
globiformi
assess
allergen
toxic
method
invitro
heat
stabil
protein
assess
cholin
oxidas
induc
allergen
assess
balbc
mice
ige
reactiv
cholin
oxidas
protein
assess
atop
patient
sera
acut
toxic
cholin
oxidas
protein
also
assess
mice
model
result
cholin
oxidas
protein
stabl
hour
react
cholin
oxidas
antibodi
immunoblot
specif
ige
level
low
cholin
oxidas
treat
mice
compar
control
ova
sensit
mice
show
high
ige
level
intraven
challeng
cholin
oxidas
induc
advers
reaction
iv
challeng
ova
led
anaphylaxi
ova
sensit
mice
cholin
oxidas
sensit
mice
demonstr
releas
similar
control
splenic
cultur
supernat
howev
ova
sensit
mice
show
higher
level
histolog
analysi
lung
tissu
cholin
oxidas
sensit
mice
show
intact
epithelium
normal
airway
wherea
ova
sensit
mice
show
narrow
airway
increas
eosinophil
infiltr
elisa
allerg
patient
sera
reveal
low
specif
ige
bind
mean
od
cholin
oxidas
protein
acut
toxic
studi
cholin
oxidas
protein
mice
model
show
signific
differ
control
growth
bodi
weight
food
consumpt
blood
biochem
indic
histopatholog
gut
tissu
mice
fed
cholin
oxidas
show
normal
gastric
mucosa
line
normal
villi
jejunum
ileum
section
conclus
bacteri
cholin
oxidas
protein
heat
stabl
fail
elicit
allerg
respons
mice
model
data
indic
cholin
oxidas
protein
may
safe
use
transgen
crop
identif
amino
acid
critic
igebind
sequenti
epitop
bovin
similar
epitop
correspond
human
sequenc
abstract
withdrawn
cxc
cc
chemokin
produc
human
respiratori
epithelium
ilja
striz
eliska
krasna
libor
kolesar
antonij
slavcev
marcela
jaresova
jaromir
musil
institut
clinic
experiment
medicin
depart
immunolog
pragu
czech
republ
univers
hospit
motol
pulmonari
depart
pragu
czech
republ
chemokin
regul
leukocyt
traffick
physiolog
turnov
recruit
mucos
surfac
inflammatori
reaction
respiratori
epithelium
abil
respond
local
gener
cytokin
might
import
sourc
chemokin
attract
divers
cell
popul
respect
aim
studi
compar
capac
differ
proinflammatori
cytokin
stimul
gene
express
product
releas
multipl
cc
cxc
chemokin
respiratori
epitheli
cell
line
chemokin
distribut
studi
also
bronchoalveolar
lavag
fluid
bal
exhal
breath
condens
ebc
patient
undergo
lung
transplant
total
chemokin
chemokin
receptor
gene
studi
use
oligoarray
system
superarray
inc
cultur
human
alveolar
typeii
like
cell
stimul
multipl
concentr
tnf
alpha
ifn
gamma
beta
chemokin
level
cultur
supernat
bal
ebc
measur
use
multiplex
immunoluminometr
assay
luminex
elisa
repetit
experi
epitheli
cell
constitut
express
mrna
groalpha
grobeta
grogamma
chemokin
attract
preferenti
neutrophil
cell
stimul
beta
tnf
alpha
upregul
mrna
express
chemokin
specif
mononuclear
cell
recruit
mip
beta
rant
mip
alpha
induct
itac
attract
activ
lymphocyt
ifn
gamma
potent
stimulu
induct
epitheli
cell
relat
cytokin
result
moder
upregul
cc
cxc
chemokin
compar
potent
effect
beta
stimul
epithelium
deriv
chemokin
abund
bal
fluid
rare
detect
ebc
conclud
data
respiratori
epitheli
cell
involv
regul
influx
differ
popul
inflammatori
cell
releas
multipl
cc
cxc
chemokin
highli
coordin
manner
diarrhea
proteinlos
gastroenteropathi
intestin
lymphangiectasia
inl
rare
entiti
congenit
acquir
character
abnorm
dilat
lymphat
throughout
intestin
tract
disord
lead
leakag
lymph
caus
hypoproteinemia
lymphopenia
hypogamaglobulinemia
lead
depress
humor
cellular
immun
system
case
report
year
old
woman
rural
mexico
histori
asthma
year
present
chief
complaint
diarrhea
month
evacu
day
refer
colic
pain
abdomin
distens
flatul
recurr
symmetr
system
edema
patient
show
fatigu
weak
muscl
spasm
well
myalgia
fascicul
lost
lb
develop
onychomycosi
toenail
recal
show
clinic
sign
symptom
childhood
medic
team
clear
diagnosi
laboratori
reveal
lymphopenia
hypoalbuminemia
hypogammaglobulinemia
hypocalcemia
neg
hiv
elisa
stool
level
elev
ct
chest
abdomen
normal
esophagogastroduodenoscopi
colonoscopi
perform
show
gastriti
duoden
biopsi
demonstr
dilat
lymphat
white
villi
spot
discuss
lack
elev
level
protein
urin
along
depress
serum
level
igg
drew
attent
gastrointestin
tract
like
portal
protein
loss
detect
elev
level
stool
collect
add
support
diagnosi
inl
duoden
biopsi
characterist
histolog
find
demonstr
dilat
lymphat
white
spot
confirm
diagnosi
treatment
primari
inl
symptomat
margin
effect
treat
patient
strict
dietari
lipid
restrict
pancreat
enzym
probiot
diuret
mediumchain
triglycerid
multivitamin
patient
show
mark
respons
regain
normal
weight
diarrhea
edema
sporad
present
date
seventh
report
case
primari
inl
mexico
knowledg
describ
literatur
biphas
present
atrial
natriuret
peptid
receptor
npra
signal
human
dendrit
cell
control
treg
develop
weidong
zhang
xueqin
cao
gari
hellermann
xiaoyuan
kong
dongq
chen
jiawang
wang
richard
f
lockey
shyam
mohapatra
univers
south
florida
intern
medicin
tampa
unit
state
jame
haley
va
hospit
intern
medicin
tampa
unit
state
natriuret
peptid
np
key
endogen
factor
control
inflamm
immun
toler
latter
essenti
maintain
immun
homeostasi
control
autoreact
cell
prevent
onset
autoimmun
diseas
achiev
toler
transplant
mechan
regul
anpnpra
signal
dc
crucial
understand
anp
regul
innat
immun
failur
signal
might
contribut
autoimmun
diseas
chronic
inflamm
tissu
damag
herein
role
ctermin
np
anp
one
toler
induc
np
modul
dc
function
examin
result
demonstr
contrast
anp
prime
dc
induc
regulatori
treg
cell
anp
receptor
npra
bind
affect
induct
tgf
express
control
manner
also
downregul
affect
npra
express
result
demonstr
key
player
integr
anpnpra
signal
innat
immun
provid
insight
inhibit
irnp
affect
anpnpra
signal
promot
tolerogen
phenotyp
dc
thu
found
tendenc
toward
preval
ever
got
asthma
diagnosi
current
asthma
slightli
common
compar
year
earlier
howev
use
asthma
medic
increas
suffer
asthma
symptom
decreas
furthermor
selfreport
allergi
increas
especi
toward
furri
pet
discuss
studi
popul
repres
sampl
swedish
adult
popul
one
cautiou
gener
result
howev
apart
gender
school
employe
differ
substanti
gener
work
popul
furthermor
two
studi
popul
homogen
respect
gender
age
occup
geograph
habitat
studi
method
ident
conclus
result
impli
small
increas
asthma
allergi
period
swedish
adult
azienda
ospedaliera
universitaria
san
martino
azienda
ospedaliera
universitaria
san
martino
genoa
itali
gp
simg
sezion
genova
gp
simg
sezion
genova
genoa
itali
gp
assimefac
gp
assimefac
genoa
itali
background
despit
asthma
control
treatment
adher
larg
investig
current
literatur
appropri
gener
practition
prescrib
patient
asthma
less
studi
begin
continu
profession
develop
cpd
program
rhiniti
asthma
part
arga
allergopati
respiratori
studio
di
monitoraggio
lineeguida
gina
e
aria
studi
support
italian
drug
agenc
aifa
drug
prescript
healthcar
resourc
util
physician
adher
studi
perform
materi
method
observ
patient
follow
gp
patient
diagnosi
asthma
patient
hospit
asthma
exacerb
mean
age
yr
among
patient
treat
associ
beta
agonistinh
steroid
coupl
antileukotrien
antihistamin
theophyllin
system
steroid
prednison
betamethason
prescrib
patient
among
receiv
therapi
patient
receiv
oral
antihistamin
patient
prescrib
tiotropium
although
asthma
indic
approv
total
amount
prescrib
asthma
drug
patient
low
could
last
maximum
two
month
prescrib
drug
beta
short
act
bronchodil
drug
box
patient
patient
evalu
specialist
allergist
pneumonologist
hospit
visit
specialist
discharg
hospit
underw
spirometr
evalu
patient
hospit
twice
year
conclus
regardless
effort
nation
intern
societi
diffus
asthma
diagnosi
treatment
guidelin
asthma
still
undervalu
untreat
gener
practition
could
princip
caus
hospit
asthma
exacerb
observ
group
patient
could
interest
evalu
cpd
blend
program
residenti
plu
distanc
learn
cours
content
tailor
physician
knowledg
healthcar
resourc
utilis
drug
prescript
would
abl
improv
asthma
manag
elicit
rhiniti
conjunct
especi
younger
gener
twodimension
igebind
spectrum
c
japonica
pollen
allergen
demonstr
mani
allergen
remain
identifi
present
molecular
clone
immunochem
character
novel
c
japonica
pollen
allergen
belong
aspartyl
proteas
famili
method
tofm
analysi
high
igebind
protein
term
reveal
intern
amino
acid
sequenc
base
sequenc
inform
cdnaencod
clone
racepcr
allergen
produc
recombin
protein
use
baculovirusinsect
cell
cultur
system
purifi
doubl
chromatograph
techniqu
use
histrap
hitrap
q
column
put
matur
recombin
produc
upon
autolysi
incub
acet
buffer
ph
use
elisa
experi
proteolyt
activ
test
use
fitccasein
substrat
differ
ph
substrat
specif
evalu
use
seri
proteas
inhibitor
result
cdna
encod
amino
acid
polypeptid
calcul
molecular
weight
isoelectr
point
kda
respect
homolog
search
reveal
polypeptid
sequenc
show
ident
plant
aspartyl
proteasenucleoid
dna
bind
protein
famili
member
elisa
demonstr
purifi
recogn
pollinosi
patient
ige
frequenc
also
show
aspartyl
proteaselik
proteolyt
activ
demonstr
enzymat
matur
upon
autolysi
conclus
first
plant
aspartyl
proteas
identifi
allergen
might
well
open
new
investig
plant
aspartyl
proteas
allergen
avail
sequenc
recombin
allergen
product
could
use
develop
futur
diagnost
techniqu
therapeut
approach
background
hereditari
angioedema
hae
character
recurr
skin
swell
abdomin
pain
attack
potenti
lifethreaten
upper
airway
obstruct
classic
hae
type
ii
caus
mutat
complement
inhibitor
gene
result
quantitatv
qualit
defici
inhibitor
contrast
novel
hae
type
affect
mainli
women
inhibitor
concentr
activ
plasma
normal
hae
type
iii
hae
normal
inhibitor
hypothes
abnorm
coagul
factor
xii
molecul
may
lead
inappropri
activ
kininform
cascad
therefor
perform
search
mutat
gene
method
twenti
unrel
index
patient
famili
hereditari
angioedema
normal
inhibitor
activ
screen
mutat
coagul
factor
xii
gene
sequenc
exon
splice
junction
gene
subsequ
besid
control
individu
anoth
six
index
patient
well
patient
idiopath
angioedema
select
sequenc
exon
gene
result
two
differ
nonconserv
missens
mutat
locat
exactli
posit
within
exon
name
second
posit
codon
acg
encod
matur
protein
identifi
five
twenti
patient
screen
show
heterozyg
cya
transvers
predict
threoninetolysin
substitut
one
addit
patient
show
heterozyg
cyg
transvers
result
threoninetoarginin
substitut
sequenc
exon
anoth
six
index
patient
reveal
one
patient
heterozyg
mutat
thu
unrel
patient
wildtyp
threonin
substitut
basic
amino
acid
residu
mutat
found
healthi
control
individu
n
cosegreg
phenotyp
seven
famili
altogeth
affect
women
provid
strong
support
caus
diseas
final
mutat
also
identifi
patient
idiopath
angioedema
thu
mutat
may
also
play
role
subgroup
singular
angioedema
case
affect
famili
member
conclus
find
provid
strong
support
coagul
factor
xii
gene
new
angioedema
gene
subcutan
background
disinhibit
kallikrein
result
excess
bradykinin
respons
sign
symptom
hereditari
angioedema
hae
highli
potent
specif
plasma
kallikrein
inhibitor
ecallantid
shown
amelior
symptom
hae
method
patient
year
age
older
document
hae
nabv
patient
patient
treat
singl
acut
hae
attack
doubleblind
placebocontrol
stage
particip
openlabel
extens
patient
given
mg
treat
acut
hae
attack
anatom
site
locationsabdomin
peripher
laryng
outcom
measur
hour
haespecif
treatment
outcom
score
to
chang
baselin
mean
symptom
complex
sever
msc
score
to
msc
composit
score
measur
attack
site
time
onset
respons
time
signific
improv
overal
respons
record
safeti
assess
treatmentemerg
advers
event
teae
seriou
advers
event
sae
result
interim
data
present
patient
treat
acut
hae
attack
men
women
median
age
year
rang
year
mean
to
hour
hour
q
improv
mean
msc
chang
baselin
hour
clinicallysignific
improv
median
time
onset
overal
improv
minut
time
onset
signific
overal
improv
minut
safeti
data
patient
includ
teae
mild
moder
sever
resolv
without
sequela
relat
teae
patient
relat
event
experienc
patient
includ
diarrhea
nausea
inject
site
reaction
patient
hae
myalgia
headach
cough
pruritu
patient
total
sae
occur
patient
unrel
sae
anaphylact
reaction
report
previous
assess
relat
resolv
without
sequela
conclus
repeat
dose
ecallantid
acut
hae
attack
result
onset
overal
improv
minut
signific
overal
improv
hour
ecallantid
gener
well
toler
major
advers
event
mild
moder
sever
resolv
without
sequela
background
new
type
hereditari
angioedema
describ
recent
character
recurr
bout
angioedema
variou
organ
normal
inhibitor
observ
mainli
women
aim
conduct
detail
studi
clinic
featur
condit
method
total
patient
hereditari
angioedema
normal
inhibitor
belong
unrel
famili
examin
use
standard
questionnair
result
major
patient
hereditari
angioedema
normal
inhibitor
skin
swell
tongu
swell
abdomin
pain
attack
laryng
edema
uvular
edema
also
frequent
wherea
edema
episod
organ
rare
facial
swell
tongu
involv
occur
consider
frequent
compar
hereditari
angioedema
due
inhibitor
defici
number
patient
recurr
edema
one
organ
higher
classic
hereditari
angioedema
number
patient
diseas
onset
adulthood
significantli
higher
hereditari
angioedema
normal
inhibitor
compar
classic
hereditari
angioedema
erythema
marginatum
observ
subgroup
patient
famili
coagul
factor
xii
mutat
show
symptom
patient
longterm
treatment
consist
tranexam
acid
attenu
androgen
conclus
hereditari
angioedema
normal
inhibitor
level
show
characterist
pattern
clinic
symptom
main
clinic
featur
includ
skin
swell
tongu
swell
abdomin
pain
attack
mani
differ
clinic
symptom
cours
diseas
type
hereditari
angioedema
classic
hereditari
angioedema
due
genet
inhibitor
defici
skin
reactiv
autolog
serum
safeti
inhibitor
nsaidintoler
patient
urticaria
andor
angioedema
mauro
cancian
raffael
bendo
elena
ossi
giusepp
realdi
clinica
medica
univers
padova
medic
surgic
scienc
depart
padova
itali
background
pseudoallerg
reaction
par
nonsteroid
antiinflammatori
drug
nsaid
common
chronic
urticaria
cu
aspirin
relat
drug
impair
symptom
patient
moreov
group
otherwis
normal
subject
develop
urticaria
andor
angioedema
ua
intak
nsaid
also
exist
although
inhibit
cyclooxigenas
cox
pathway
seem
play
central
role
nsaidintoler
high
preval
skin
reactiv
autolog
serum
also
report
nsaidinduc
ua
point
possibl
involv
immun
system
pathogenesi
form
method
patient
experienc
nsaidinduc
ua
recruit
gave
inform
consent
histori
cu
exacerb
nsaid
wherea
remain
report
acut
ua
nsaid
intak
case
ua
elicit
singl
nsaid
whilst
patient
signal
advers
skin
reaction
two
coxinhibitor
none
patient
present
nasal
polyp
evid
asthma
sinus
oral
toler
test
conduct
differ
day
singleblind
placebo
control
challeng
increas
amount
convent
nimesulid
mg
whole
dose
meloxicam
mg
highli
select
celecoxib
mg
eterocoxib
mg
coxinhibitor
test
continu
whole
dose
reach
ua
appear
furthermor
skin
reactiv
assess
subject
basal
condit
well
whenev
challengeinduc
advers
reaction
occur
result
patient
develop
skin
symptom
placebo
day
toler
four
coxinhibitor
experienc
ua
nimesulid
meloxicam
celecoxib
eterocoxib
patient
cu
show
posit
cutan
respons
whilst
subject
skin
test
basal
serum
sampl
collect
challengeinduc
ua
alway
elicit
neg
result
conclus
find
confirm
highli
select
coxinhibitor
repres
safest
antiinflammatori
drug
nsaidinduc
ua
although
well
known
coxib
intak
recommend
subject
renal
cardiovascular
diseas
moreov
result
strengthen
concept
cutan
reactiv
almost
exclus
confin
chronic
urticaria
autoimmun
involv
pathogenesi
nsaidinduc
par
treatment
skin
swell
pasteur
inhibitor
concentr
patient
hereditari
angioedema
background
gum
arab
use
emulsifi
thicken
agent
stabil
food
pharmaceut
industri
lithographi
cosmet
exposur
gum
arab
report
caus
occasion
case
occup
asthma
ingest
commonli
caus
immedi
allerg
symptom
method
worker
candi
factori
examin
suspect
occup
allergi
hard
boil
candi
cover
spray
dri
gum
arab
rotat
drum
worker
pour
gum
arab
powder
respiratori
skin
symptom
skin
symptom
spirometri
histamin
challeng
test
exhal
breath
pef
measur
skin
prick
test
spt
gum
arab
ige
measur
cutan
bronchial
challeng
test
gum
arab
carri
patch
test
carri
patient
eczemat
skin
diseas
addit
spt
data
subject
examin
food
allergi
symptom
evalu
subject
posit
spt
gum
arab
receiv
postal
questionnair
result
four
worker
occup
asthma
caus
gum
arab
posit
spt
gum
arab
specif
ige
gum
arab
kul
three
patient
posit
bronchial
challeng
test
gum
arab
one
posit
skin
challeng
test
one
patient
signific
pef
decreas
expos
gum
arab
work
posit
skin
challeng
immedi
oral
symptom
associ
ingest
gum
arab
none
signific
allergi
one
worker
contact
dermat
caus
thiuram
chemic
anoth
posit
spt
hous
dust
mite
work
relat
allergi
carmin
red
use
candi
five
worker
occup
diseas
patient
test
food
allergi
posit
spt
gum
arab
also
posit
spt
pollen
food
return
questionnair
time
skin
test
gum
arab
associ
allerg
symptom
suspect
three
two
report
gum
arab
ingest
associ
oral
symptom
questionnair
one
gum
arab
spt
posit
patient
without
respiratori
symptom
occup
histori
work
candi
factori
year
ago
conclus
occup
allergi
caus
ige
mediat
allergi
gum
arab
risk
exposur
occup
ingest
gum
arab
caus
symptom
patient
determin
elev
exhal
nitric
oxid
eno
among
bakeri
worker
south
africa
background
sever
asthma
copd
character
clinic
exacerb
gp
often
requir
decid
hospitalis
home
treatment
patient
aim
evalu
ambulatori
measur
oxygen
satur
could
safe
effect
verifi
correl
measur
schedul
visit
exacerb
defin
patient
pattern
requir
hospitalis
assess
possibl
databas
registr
gp
set
method
gp
pneumologist
enrol
studi
target
evalu
ptz
gp
pneumologist
physician
provid
puls
oxymet
measur
fill
specif
questionnair
requir
outpati
attend
diseas
exacerb
result
descript
analysi
result
provid
patient
divid
two
popul
accord
necess
hospitalis
comparison
paramet
regist
gp
specialist
set
perform
rel
import
measur
gp
pneumologist
evalu
discuss
present
ongo
studi
provid
import
inform
util
safeti
measur
obstruct
patient
evalu
exacerb
result
use
defin
guidelin
exacerb
manag
total
ige
urban
black
south
african
teenag
influenc
atopi
helminth
infect
michael
levin
red
cross
war
memori
children
hospit
allergi
clinic
cape
town
south
africa
background
ige
level
usual
elev
allerg
diseas
highest
atop
eczema
follow
atop
asthma
allerg
rhiniti
genet
factor
believ
play
role
total
ige
level
higher
level
seen
black
african
subject
total
ige
also
rais
parasit
infect
thu
higher
total
ige
level
black
african
could
due
environment
rather
genet
factor
studi
investig
use
total
ige
level
assess
atopi
black
african
aim
object
studi
determin
total
ige
level
unselect
urban
black
african
high
school
children
correl
atopi
ascari
sensit
method
two
hundr
twenti
urban
xhosa
children
mean
age
year
attend
school
cape
town
studi
atop
statu
assess
mean
specif
allergen
sensit
alk
skin
prick
test
inhal
food
allergen
self
report
asthma
bronchial
hyperrespons
measur
methacholin
challeng
total
ige
ascari
specif
ige
measur
caprast
pharmacia
total
ige
level
subanalys
accord
atop
statu
ascari
sensitis
order
establish
rang
total
ige
atop
subject
ascari
sensitis
subject
nonatop
non
ascari
sensitis
subject
result
total
ige
level
markedli
skew
toward
left
distribut
gaussian
lognorm
distribut
mean
total
ige
kul
median
kul
interquartil
rang
kul
kul
skin
prick
test
posit
aeroallergen
subject
thirti
four
percent
elev
ascari
ige
total
ige
higher
atop
versu
nonatop
subject
correl
number
posit
skin
prick
test
kruskal
walli
anovar
p
self
report
asthma
p
bronchial
hyperrespons
p
addit
total
ige
correl
ascari
ige
p
subject
ascari
sensitis
median
total
ige
kul
similar
level
seen
peopl
genet
origin
conclus
studi
demonstr
total
ige
correl
one
hand
atopi
bronchial
hyper
respons
self
report
asthma
hand
ascari
sensitis
likelihood
helminth
infect
rather
genet
differ
thu
major
factor
determin
popul
specif
ige
rang
alfr
hospit
allergi
immunolog
respiratori
medicin
melbourn
australia
background
elev
level
total
ige
tige
serum
characterist
allerg
diseas
level
tige
influenc
genet
predisposit
age
sex
helminth
infect
howev
associ
tige
allerg
diseas
children
live
area
endem
helminth
infect
clear
aim
studi
assess
relationship
tige
allerg
diseas
geohelminth
infect
children
method
total
schoolchildren
year
age
select
stratifi
random
sampl
data
regard
allerg
diseas
asthma
rhiniti
eczema
collect
standard
questionnair
given
parent
guardian
screen
helminth
infect
done
examin
fresh
stool
sampl
modifi
katokatz
techniqu
serum
tige
measur
fluoroenzymeimmunoassay
geohelminthposit
subject
compar
group
geohelminthneg
subject
result
mean
age
studi
popul
year
preval
geohelminth
infect
trichuri
trichiura
common
follow
ascari
lumbricoid
hookworm
mix
infect
detect
infect
children
infect
intens
light
infect
children
show
moder
heavi
infect
respect
cumul
preval
allerg
diseas
preval
asthma
rhiniti
eczema
respect
serum
tige
concentr
show
posit
skew
distribut
geometr
mean
gm
tige
geohelminth
infect
group
significantli
higher
noninfect
group
p
also
higher
allerg
group
nonallerg
group
differ
statist
signific
p
gm
tige
nonallerg
children
studi
popul
much
higher
seen
nonallerg
children
develop
countri
conclus
serum
tige
concentr
strongli
associ
presenc
geohelminth
infect
children
serum
tige
may
use
marker
allerg
diseas
children
live
area
endem
geohelminth
infect
evid
eosinophil
activ
adenoid
tonsil
tissu
atop
children
seungyoup
shin
changki
hong
sungjin
choi
kunhe
lee
joongsaeng
cho
haesim
park
kyunghe
univers
hospit
depart
otorhinolaryngolog
seoul
republ
korea
ajou
univers
hospit
depart
allergi
rheumatolog
suwon
republ
korea
background
adenoid
tonsil
consid
immun
organ
may
present
differ
cellular
cytokin
profil
accord
atop
statu
object
studi
find
statu
eosinophil
activ
compar
atop
nonatop
children
materi
method
adenoid
tonsil
tissu
obtain
children
atop
nonatop
enrol
seven
atop
nonatop
children
chronic
inflammatori
diseas
chronic
rhinosinus
cr
andor
otiti
media
effus
ome
atop
statu
classifi
posit
result
mast
test
common
inhal
allergen
serum
total
ige
eosinophil
count
measur
ecp
level
cellular
activ
marker
includ
within
supernat
adenoid
tonsil
tissu
measur
cap
system
pharmacia
sweden
elisa
result
ecp
level
adenoid
tonsil
tissu
atop
children
significantli
higher
nonatop
children
respect
ecp
level
adenoid
tonsil
tissu
atop
children
cr
show
highest
follow
nonatop
children
cr
atop
children
without
cr
nonatop
children
without
cr
ecp
level
adenoid
significantli
correl
local
produc
total
ige
cellular
activ
marker
includ
conclus
find
suggest
activ
eosinophil
could
involv
inflammatori
respons
occur
adenoid
tonsil
atop
nonatop
children
activ
eosinophil
cr
combin
activ
cell
especi
cell
could
lead
activ
eosinophil
adenoid
tonsil
tissu
plant
homeodomain
finger
protein
gene
polymorph
associ
plasma
total
ige
exhal
nitric
oxid
level
chines
children
hing
yee
sy
ting
fan
leung
chung
yi
li
iri
h
chan
edmund
yung
nelson
l
tang
christoph
w
k
lam
gari
w
k
wong
chines
univers
hong
kong
depart
paediatr
hong
kong
hong
kong
chines
univers
hong
kong
depart
chemic
patholog
hong
kong
hong
kong
background
singlenucleotid
polymorph
snp
gene
encod
plant
homeodomain
finger
protein
shown
posit
clone
associ
sever
asthma
elev
circul
total
ige
level
caucasian
snp
also
associ
childhood
atop
dermat
genet
associ
studi
chines
object
studi
investig
associ
snp
asthma
phenotyp
chines
children
method
asthmat
nonallerg
children
recruit
paediatr
clinic
lung
function
assess
spirometri
exhal
nitric
oxid
feno
level
measur
onlin
chemiluminesc
analys
expiratori
flow
rate
ml
plasma
total
specif
ige
quantifi
immunoassay
ten
snp
genotyp
multiplex
snapshoti
reaction
genet
analys
linkag
disequilibrium
ld
pattern
snp
analys
haploview
associ
asthma
trait
analys
multivari
regress
result
mean
sd
logtransform
plasma
total
ige
feno
level
case
control
ppb
ppb
respect
p
g
snp
follow
hardyweinberg
equilibrium
p
signific
interethn
variat
minor
allel
children
compar
caucasian
polymorph
associ
asthma
diagnosi
p
asthmat
fev
g
predict
p
atopi
p
multivari
linear
regress
show
associ
plasma
total
ige
p
respect
associ
feno
p
two
haplotyp
block
could
construct
one
three
major
haplotyp
snp
ctga
ct
ttat
tt
tcgt
tc
identifi
associ
asthma
diagnosi
conclus
result
suggest
polymorph
associ
plasma
total
ige
feno
level
asthma
diagnosi
chines
children
martin
mateo
montserrat
garriga
ana
plaza
martin
mait
giner
piquer
hospit
sant
joan
de
clinic
universidad
de
barcelona
barcelona
spain
altahia
hospit
de
manrresa
barcelona
spain
hospit
sant
joan
de
de
alergia
barcelona
spain
follow
bronchiol
caus
respiratori
syncyti
viru
rsv
later
recurr
wheez
common
object
aim
studi
establish
relationship
repiratori
syncyti
viru
modif
immun
caus
appear
childhood
asthma
patient
method
prospect
studi
two
group
studi
children
bronchiol
group
problem
group
children
origin
made
children
averag
age
month
day
month
admit
hospit
first
episod
vr
posit
bronchiol
decemb
februari
complet
followup
year
test
done
moment
admitt
hemogram
ig
g
ig
ig
ig
e
lymphocyt
count
eosinophil
cation
protein
ifng
month
month
adhes
molecul
count
request
slselectin
second
group
group
b
made
children
subdivid
group
accord
age
ifng
adhes
molecul
result
acut
stage
bronchiol
immunolog
respons
viral
infect
anomal
present
humor
immun
respons
increas
immunoglobulin
g
later
p
decreas
cellular
immun
immunololog
respons
viral
infect
must
cellular
predomin
order
effect
among
children
suffer
vr
bronchiol
found
statist
signific
increas
p
slselectin
month
age
comparison
healthi
children
age
conclus
characterist
pattern
lead
us
believ
child
suffer
bronchiol
develop
asthma
increas
humor
immun
respons
acut
stage
bronchiol
decreas
cellular
immun
respons
acut
vr
infect
month
age
increas
valu
mainli
month
age
decreas
infg
month
age
associ
polymorph
mast
cell
chymas
gene
promot
region
ga
tg
n
ga
repeat
downstream
gene
bronchial
asthma
children
elham
hossni
nermin
amr
shereen
elsay
rasha
nasr
eman
ibraheim
sham
univers
pediatr
cairo
egypt
sham
univers
microbiolog
immunolog
cairo
egypt
background
mast
cell
chymas
import
mediat
inflamm
remodel
asthmat
lung
variou
studi
examin
associ
ga
singl
nucleotid
polymorph
snp
mast
cell
chymas
gene
allerg
phenotyp
inconsist
result
tg
n
ga
repeat
polymorph
bp
downstream
chymas
gene
previous
found
associ
asthma
adult
sought
investig
associ
snp
well
tg
n
ga
repeat
polymorph
childhood
asthma
associ
trait
casecontrol
studi
aim
identifi
local
data
countri
method
studi
compris
children
year
old
bronchial
asthma
famili
histori
atopi
enrol
consecut
asthma
exacerb
age
sex
match
children
neg
person
famili
histori
allergi
control
group
subject
clinic
evalu
serum
total
ige
estim
well
search
polymorph
gene
promot
region
ga
use
pcr
restrict
fragment
length
polymorph
base
genotyp
relp
tg
n
ga
repeat
polymorph
bp
downstream
gene
result
investig
ga
snp
reveal
signific
differ
distribut
g
allel
patient
control
allel
g
detect
patient
compar
control
allel
overexpress
control
group
data
show
first
time
posit
associ
ga
snp
asthma
concern
tg
n
ga
repeat
signific
differ
obtain
allel
count
among
patient
control
current
studi
largest
differ
observ
allel
repres
asthmat
children
allel
overexpress
among
control
posit
associ
allel
tg
n
ga
repeat
serum
ige
level
also
detect
seri
find
limit
sampl
size
conclus
report
associ
ga
snp
tg
n
ga
repeat
polymorph
downstream
gene
bronchial
asthma
group
egyptian
children
find
suggest
allel
genotyp
haplotyp
investig
possibl
import
determin
asthma
suscept
probabl
involv
regul
ige
level
atop
asthma
efficaci
mometason
furoat
nasal
spraymfnsin
treatment
allerg
rhiniti
metaanalysi
random
control
trial
martin
penago
enrico
compalati
francesco
tarantini
giovanni
passalacqua
giorgio
walter
canonica
allergi
respiratori
diseas
clinic
genoa
univers
depart
intern
medicin
genoa
itali
object
assess
efficaci
mfn
treatment
allerg
rhiniti
studi
select
random
placebocontrol
doubl
blind
trial
studi
effect
mfn
patient
allerg
rhiniti
comprehens
search
embas
lilac
cochran
librari
medlin
databas
januari
refer
identifi
articl
review
outcom
differ
outcom
measur
activ
treatment
control
group
consid
review
manag
program
cochran
collabor
use
data
synthesi
outcom
extract
origin
articl
inform
avail
author
trial
contact
graphic
digit
analysi
includ
calcul
standard
mean
differ
smd
signific
heterogen
among
studi
result
differ
studi
methodolog
randomeffect
model
use
result
initi
scan
identifi
articl
potenti
relev
trial
use
mometason
treatment
allerg
rhiniti
studi
random
control
trial
met
inclus
criteria
metaanalysi
random
clinic
trial
includ
comparison
group
differ
outcom
individu
global
efficaci
assess
patient
analyz
receiv
mometason
placebo
mfn
associ
signific
reduct
total
symptom
score
smd
ci
p
g
heterogen
safeti
advers
event
report
patient
includ
receiv
mfn
placebo
signific
differ
mfn
placebo
reveal
smd
ci
p
heterogen
conclus
first
among
nasal
css
mfn
efficaci
achiev
evid
ia
treatment
allerg
rhinitisth
frequenc
advers
event
similar
group
compar
placebo
studi
role
tumor
necrosi
factor
alpha
gene
polymorph
therapeut
respons
intranas
uv
phototherapi
borosgyevi
edina
garaczi
andrea
koreck
lajo
univers
szege
dermatolog
allergolog
szege
hungari
tumor
necrosi
factor
alpha
tnf
one
key
cytokin
uvinduc
immunosuppress
shown
intranas
phototherapi
mix
uvauvbvis
light
muvvi
new
therapeut
tool
manag
allerg
rhiniti
aim
studi
investig
whether
effici
rhinophototherapi
relat
specif
tnf
polymorph
fiftynin
patient
histori
least
year
ragweedinduc
allerg
rhiniti
treat
ragwe
season
szege
hungari
rhinophototherapi
carri
time
week
week
continu
oneweek
follow
period
time
week
week
increas
dose
muvvi
total
dose
muvvi
therapi
end
studi
therapeut
regimen
patient
grade
follow
symptom
allerg
rhiniti
standard
sever
scale
nasal
itch
nasal
obstruct
rhinorrhea
sneez
refer
total
nasal
score
tn
averag
improv
tn
patient
evalu
use
repeat
measur
anova
patient
percent
decreas
averag
chang
tn
consid
respond
less
percent
decreas
nonrespond
accord
paramet
patient
consid
respond
patient
nonrespond
blood
sampl
taken
patient
singl
nucleotid
polymorph
snp
analysi
tnf
three
snp
promot
region
tnf
gene
select
polymeras
chain
reaction
restrict
fragment
length
polymorph
pcrrflp
analysi
genotyp
allel
frequenc
select
snp
compar
respond
nonrespond
rhinophototherapi
allerg
rhiniti
occurr
sinus
nd
andeep
sahay
danish
jamal
ashok
shah
vallabhbhai
patel
chest
institut
respiratori
medicin
delhi
india
background
patient
allerg
rhiniti
categor
bsneezersrunnersand
bblocker
presenc
sinus
often
overlook
patient
occurr
sinus
assess
two
clinic
present
allerg
rhiniti
method
consecut
patient
allerg
rhiniti
skin
allergi
test
posit
enrol
categor
bsneezersrunnersand
bblockersa
per
predomin
symptom
base
aria
guidelin
subject
comput
tomographi
ct
paranas
sinus
extent
sinus
stage
per
lund
kennedi
criteria
presenc
sinus
correl
clinic
symptom
result
patient
male
femal
bsneezersrunnersand
bblocker
sinus
present
bsneezersrunnerswhil
bblocker
sinus
significantli
higher
bblocker
vs
p
furthermor
occurr
sinus
signific
bblocker
vs
p
bsneezersrunn
vs
p
mean
sinu
ct
score
significantli
higher
bblockersa
compar
bsneezersrunn
vs
p
mean
number
sinus
involv
significantli
bblocker
vs
p
clinic
practic
care
patient
gener
mani
question
diagnosi
prognosi
treatment
challeng
health
profession
keep
date
medic
literatur
one
approach
meet
challeng
learn
practis
evid
base
medicin
ebm
accord
ebm
conclus
metaanalys
random
trial
repres
solid
evid
sourc
assess
efficaci
treatment
metaanalysi
statist
procedur
integr
result
differ
independ
studi
pool
togeth
thu
allow
object
apprais
evid
tradit
narr
review
metaanalysi
provid
quantit
estim
treatment
effect
pharmacolog
treatment
allerg
rhiniti
repres
bench
mark
therapeut
manag
practic
guidelin
need
high
qualiti
prove
evid
order
provid
reliabl
recommend
therapeut
manag
metaanalysi
may
repres
answer
need
sourc
solid
evid
cochran
collabor
recommend
quorom
statement
repres
gold
standard
qualiti
assess
present
systemat
review
high
methodolog
qualiti
avail
progress
evid
ia
efficaci
antihistamin
treatment
provid
desloratadin
patient
show
signific
reduct
total
symptom
score
total
nasal
symptom
score
nasal
blockag
relief
compar
placebo
metaanalysi
confirm
also
ebastin
induc
greater
decreas
baselin
mean
rhiniti
symptom
score
placebo
patient
mometason
furoat
present
one
nasal
steroid
may
benefit
evid
effect
ia
mean
inprogress
metaanalysi
whose
preliminari
result
show
patient
signific
reduct
total
symptom
score
accord
recent
systemat
review
pool
analysi
leukotrien
receptor
antagonist
produc
small
statist
signific
improv
nasal
symptom
compar
placebo
patient
drug
show
good
safeti
profil
antihistamin
nasal
steroid
antileukotrien
demonstr
evid
efficaci
treatment
allerg
rhiniti
tool
also
demonstr
good
benefitcost
ratio
order
satisfi
futur
methodolog
approach
guidelin
formul
grade
leukotrien
receptor
express
allerg
rhiniti
effect
allergen
exposur
treatment
teet
pullerit
carina
jan
lung
pharmacolog
group
depart
allergolog
lung
medicin
gothenburg
sweden
lung
pharmacolog
group
depart
allergolog
lung
medicin
gothenburg
sweden
background
cysteinyl
leukotrien
mediat
contribut
symptom
allerg
rhiniti
exert
effect
specif
receptor
aim
evalu
effect
natur
occur
grass
pollen
season
antirhin
treatment
express
cysteinyl
leukotrien
receptor
cyslt
r
nasal
mucosa
allerg
rhiniti
patient
method
doubleblind
randomis
studi
patient
allerg
rhiniti
receiv
treatment
either
nasal
steroid
fluticason
propion
fp
microgday
oral
antileukotrien
montelukast
ml
mgday
alon
combin
antihistamin
loratadin
lt
mgday
placebo
grass
pollen
season
nasal
biopsi
immunohistochem
cyslt
r
analysi
taken
peak
grass
pollen
season
result
grass
pollen
season
induc
signific
increas
cyslt
r
express
placebo
cell
field
ml
ml
lt
fp
treat
patient
fp
treat
patient
significantli
lower
pollenseason
induc
chang
cyslt
r
express
compar
group
also
ml
mllt
treatment
group
significantli
lower
increas
cyslt
r
express
compar
placebo
treatment
conclus
conclud
inhibitori
effect
cyslt
r
express
one
mechan
nasal
steroid
antileukotrien
alon
togeth
antihistamin
exert
antiinflammatori
effect
allerg
rhiniti
nasal
steroid
demonstr
strongest
inhibit
separ
protein
signatur
inflammatori
mediat
pair
serum
sampl
analyz
use
raybio
human
cytokin
antibodi
array
v
serum
level
leptin
differenti
express
umbil
cord
blood
ucb
matern
asthma
creactiv
protein
crp
measur
elisa
assay
respect
lower
detect
limit
marker
ngl
mgl
result
six
pregnant
mother
asthma
nonallerg
control
recruit
respect
mean
sd
age
year
year
five
ucb
sampl
newborn
matern
asthma
increas
leptin
level
compar
newborn
nonallerg
mother
mediat
alter
level
two
ucb
sampl
matern
asthma
includ
pdgfbb
gro
mig
serum
leptin
crp
level
asthmat
mother
significantli
higher
ucb
newborn
p
g
serum
crp
level
nonallerg
mother
compar
newborn
p
g
leptin
level
show
signific
posit
correl
crp
level
r
p
g
sera
asthmat
mother
hand
crp
detect
limit
ucb
serum
sampl
serum
leptin
level
ucb
differ
without
matern
asthma
background
cysteinyl
leukotrien
cyslt
potent
inflammatori
mediat
act
least
two
receptor
cysltr
cysltr
cysltr
mrna
protein
express
upregul
patient
sever
asthma
phenotyp
frequent
sever
exacerb
chronic
airflow
limit
steroidresist
asthma
chang
cysltr
promot
might
influenc
transcript
activ
therefor
might
modul
airway
inflamm
aim
investig
associ
polymorph
cysltr
gene
promot
sever
nonsever
asthma
phenotyp
method
studi
group
consist
patient
sever
asthma
patient
nonsever
asthma
diagnos
accord
gina
criteria
healthi
subject
genom
dna
isol
peripher
blood
leukocyt
fragment
cysltr
promot
region
amplifi
pcr
sequenc
directli
result
three
singl
nucleotid
polymorph
spss
tc
identifi
promot
region
cysltr
gene
snp
strong
linkag
disequilibrium
patient
control
group
two
common
haplotyp
identifi
caa
tcg
among
observ
male
patient
male
control
signific
differ
observ
allel
frequenc
male
subject
allel
occur
significantli
often
men
sever
asthma
compar
male
control
group
p
cor
ci
conclus
genet
variant
cysltr
gene
promot
might
associ
sever
asthma
phenotyp
male
asthmat
patient
elucid
associ
might
improv
understand
heterogen
condit
sever
asthma
tatjana
caparoska
biserka
kjaeva
jagoda
stojkov
olivera
caparoska
clinic
centerskopj
clinic
pulmolog
allergolog
skopj
macedonia
fyrom
univers
health
network
img
ontario
toronto
canada
background
patient
aspirinsensit
asthma
often
contini
inflamm
upper
sinus
complic
chronic
rhiniti
chronic
sinus
nasal
polyposi
frequent
lead
asthma
attack
patient
often
awar
problem
upper
respiratori
tract
goal
studi
evalu
inflammatori
chang
upper
respiratori
tract
patient
aspirin
sensit
asthma
asa
method
follow
patient
paranas
xray
ctscan
skin
prick
test
pulmonari
function
test
rhynomanometri
chest
xray
patient
divid
group
pt
nsaid
intoler
includ
first
group
mean
age
q
second
group
aspirin
intoler
asthma
pt
mean
age
q
diagnosi
asthma
made
base
clinic
evalu
skin
prick
test
pulmonari
function
test
includ
histamin
provoc
test
endoscop
method
use
asses
paranas
sinus
nasal
passag
result
endoscop
examin
show
group
nasal
polyposi
deviat
nasal
septum
hypertrophi
nasal
mucosa
chronic
tonsil
pt
pt
observ
chang
xray
paranas
sinus
chang
ctscan
pn
ptsrhynomanometr
evalu
show
decreas
nose
pathway
bacteriolog
analysi
nose
throat
show
predomin
bacteria
speci
moraxella
influenz
moraxella
catarali
stahylococcu
aureu
conclus
studi
result
confirm
coexist
chronic
inflam
upper
respiratori
tract
pt
bronchial
asthma
regardless
type
hopkin
allergi
baltimor
unit
state
nation
institut
age
immunolog
baltimor
unit
state
univers
missouricolumbia
surgeri
molecular
immunolog
columbia
missouri
unit
state
john
hopkin
univers
allergi
baltimor
unit
state
rational
posttranscript
regul
ptr
key
yet
illdefin
area
gene
express
cell
investig
ptr
interleukin
il
role
rnabind
protein
hur
play
process
hur
associ
adenylateuridylaterich
element
region
utr
mrna
promot
mrna
stabil
translat
method
mrna
decay
monitor
human
peripher
bloodderiv
cell
use
transcript
inhibitor
actinomycin
subclon
tetracyclin
tet
globin
report
construct
transient
express
absenc
presenc
overexpress
hur
cell
associ
hur
mrna
detect
immunoprecipit
ip
messeng
ribonucleoprotein
complex
mrnp
biotin
pulldown
result
mrna
halflif
increas
cell
treat
pma
ionomycin
compar
unstimul
cell
vs
p
g
n
decay
globin
transcript
faster
cell
transfect
compar
transfect
areless
ptetbbb
h
vs
h
p
g
n
overexpress
hur
increas
globin
mrna
halflif
cell
transfect
h
vs
h
p
g
n
enrich
mrna
detect
pcr
follow
ip
jurkat
cell
mrnp
antihur
vs
control
antibodi
hur
bind
confirm
pulldown
assay
use
biotinlabel
rna
probe
span
code
region
conclus
ptr
play
relev
role
express
hurmedi
stabil
mrna
could
relev
therapeut
target
asthma
function
studi
prostaglandin
receptor
chemoattract
receptor
molecul
express
cell
promot
polymorph
aspirinintoler
asthma
nami
palikh
seunghyun
kim
eunmi
yang
youngmin
ye
gyuyoung
hur
eunjoo
nam
haesim
park
ajou
univers
school
medicin
depart
allergi
suwon
republ
korea
yonsei
univers
school
medicin
depart
pharmacolog
seoul
republ
korea
background
object
prostaglandin
import
lipid
mediat
pathogenesi
eosinophil
airway
inflamm
via
receptor
human
gene
encod
g
proteincoupl
chemoattract
receptor
express
cell
eosinophil
basophil
monocyt
main
object
studi
investig
associ
promot
polymorph
patient
aspirin
intoler
asthma
aia
subject
method
case
control
studi
perform
three
group
patient
aia
aspirin
toler
asthma
ata
normal
control
nc
two
promot
polymorph
gene
genotyp
primer
extens
method
perform
snapshot
ddntp
primer
extens
kit
appli
biosystem
ca
usa
result
two
novel
singlenucleotid
polymorph
snp
identifi
promot
region
gene
among
two
snp
polymorph
posit
show
signific
differ
genotyp
frequenc
aia
ata
aia
patient
show
significantli
higher
frequenc
homozyg
tt
genotyp
combin
homozyg
cc
heterozyg
ct
genotyp
p
multipl
logist
regress
analysi
control
age
sex
recess
model
luciferas
report
assay
show
report
plasmid
carri
allel
show
significantli
higher
promot
activ
allel
human
monocyt
cell
line
human
mast
cell
line
p
g
p
g
respect
similarli
promot
activ
allel
cotransfect
found
increas
dose
depend
baselin
promot
activ
cell
conclus
result
suggest
may
directli
indirectli
associ
allel
stimul
mast
cell
activ
releas
cytokin
proinflammatori
mediat
contribut
increas
suscept
aia
promot
polymorph
relationship
earli
infect
due
rsv
specif
subsequ
develop
asthma
clinic
studi
rsvinfect
patient
indic
increas
level
cytokin
ige
suggest
allergylik
condit
develop
infect
skew
balanc
toward
compar
retrospect
analysi
children
admit
winter
season
first
attack
brochiol
age
month
perform
order
elabor
correl
possibl
specif
asthma
term
pathogenesi
naa
immun
respons
complianc
treatment
group
children
divid
basi
phenotyp
group
n
ige
associ
persist
wheezier
ii
group
n
nonatop
recurr
wheez
iii
n
viral
associ
wheez
rsv
infect
respons
first
attack
wheez
earli
adenoviru
infect
ii
group
famili
histori
asthma
multipl
asthma
trigger
perform
bilater
genet
risk
fund
compar
ii
group
opposit
mani
riskfactor
prenat
peripart
earli
neonat
period
life
present
seriou
anoth
ill
found
ii
group
p
g
oligohydramnion
placenta
abrupt
infarct
small
date
extremli
lbw
gigant
babi
extrem
higher
birth
weight
low
apgar
score
reanimationadapt
problem
birth
patient
group
demonstr
higher
level
neu
eo
moder
degre
diseas
recurr
wheez
andor
asthma
sever
ill
mani
immun
endocrin
metabol
genet
deregul
lycytosi
mocytosi
typic
ii
group
complianc
ic
significantli
better
group
basi
data
may
indirectli
conclud
implic
excess
type
andor
defici
type
immun
respons
pathogenesi
rsv
bronchiol
subsequ
asthma
develop
group
contrast
ii
group
probabl
higher
immun
respons
rsv
infect
basi
matern
intrauterin
factor
sever
diseas
shown
higher
percentag
immun
deregul
patient
ii
group
attribut
specif
naa
complex
immunoregulatori
pattern
follow
inappropri
respons
treatment
result
indic
immunolog
background
via
cell
may
play
import
role
regul
differenti
activ
rsv
infect
indoor
air
qualiti
dyspnea
mucos
dermal
gener
symptom
relat
room
temperatur
ventil
univers
comput
classroom
experiment
studi
dan
kla
uppsala
univers
dept
medic
scienc
uppsala
sweden
aim
studi
effect
increas
ventil
temperatur
chang
comput
classroom
measur
indoor
air
qualiti
medic
symptom
univers
student
technic
univers
student
four
classroom
particip
blind
studi
two
classroom
higher
air
exchang
ach
two
other
lower
air
exchang
ach
one
week
ventil
condit
shift
room
student
report
medic
symptom
last
hour
seven
step
rate
scale
room
temperatur
rh
ultra
fine
particl
measur
simultan
hour
addit
illumin
air
veloc
oper
temperatur
suppli
air
temperatur
formaldehyd
airborn
level
bacteria
mould
common
allergen
measur
total
student
particip
least
studi
two
week
particip
twice
longitudin
analysi
total
femal
smoker
asthma
pollen
allergi
hay
fever
furri
pet
allergi
mean
ppm
ppm
temperatur
c
c
rh
low
high
air
exchang
rate
correspond
person
outdoor
air
flow
ls
p
ls
p
respect
mean
low
high
ventil
flow
crude
analysi
ocular
nasal
throat
symptom
dermal
symptom
dyspnea
sinus
headach
tired
nausea
significantli
common
higher
level
higher
room
temperatur
higher
air
exchang
rate
dyspnea
dermal
symptom
significantli
less
common
similar
result
obtain
multivari
analysi
control
potenti
confound
gender
smoke
histori
atopi
longitudin
analysi
subset
particip
twice
increas
temperatur
significantli
relat
increas
tired
conclus
comput
classroom
may
level
current
ventil
standard
ppm
temperatur
c
due
crowded
high
thermal
load
increas
temperatur
may
affect
dermal
mucos
membran
symptom
well
headach
tird
recommend
person
ventil
flow
least
ls
allergen
recombin
nativ
blomia
tropicali
allergen
among
atop
subject
john
donni
ramo
nge
cheong
kaw
yan
chua
univers
santo
toma
research
center
natur
scienc
manila
philippin
nation
univers
singapor
depart
paediatr
singapor
singapor
background
blomia
tropicali
bt
predomin
hous
dust
mite
hdm
speci
tropic
subtrop
region
world
sourc
multipl
allergen
caus
allerg
sensit
among
atop
individu
isol
character
allergen
bt
allergen
essenti
evalu
clinic
relev
hdm
speci
method
eight
recombin
bt
allergen
express
gstfusion
allergen
e
coli
secret
allergen
p
pastori
two
nativ
bt
allergen
purifi
immunoaffin
chromatographi
specificig
reactiv
bt
allergen
determin
use
btallerg
nonatop
sera
panel
bt
allergen
likewis
use
skin
prick
test
spt
btallerg
pediatr
patient
abil
recombin
nativ
blo
allergen
inhibit
igebind
activ
bt
extract
determin
absorpt
studi
result
blo
blo
blo
blo
blo
blo
blo
express
solubl
gstrecombin
protein
e
coli
blo
express
p
pastori
nativ
blo
blo
purifi
bt
extract
use
monoclon
antibodi
btallerg
patient
sera
test
react
posit
recombin
blo
blo
respect
ige
reactiv
observ
recombin
bt
allergen
interestingli
ige
reactiv
recombin
blo
blo
compar
ige
reactiv
nativ
counterpart
respect
spt
result
show
compar
result
elisa
absorpt
assay
show
inhibit
ige
reactiv
bt
extract
obtain
differ
bt
allergen
conclus
result
obtain
studi
suggest
clinic
import
blomia
tropicali
major
sourc
allergen
caus
allerg
sensit
tropic
region
incorpor
bt
allergen
panel
diagnost
immunotherapeut
allergen
hdm
allergi
highli
recommend
phleum
pratens
alon
repres
pooidea
grass
pollen
speci
due
high
immunochem
similar
homolog
grass
pollen
allergen
jorgen
n
larsen
charlott
hejl
henrik
ipsen
peter
wurtzen
niel
johansen
alkabello
research
horsholm
denmark
background
pooidea
grass
constitut
larg
taxonom
subfamili
thousand
speci
worldwid
occurr
extens
homolog
amino
acid
sequenc
grass
pollen
allergen
occur
grass
pollen
count
publish
togeth
due
larg
immunochem
similar
grass
pollen
allergen
object
studi
immunochem
similar
grass
pollen
allergen
differ
pooidea
speci
method
amino
acid
sequenc
repres
grass
pollen
allergen
obtain
uniprot
databas
structur
similar
group
allergen
illustr
map
ident
amino
acid
surfac
xray
structur
phl
p
pdb
larg
number
data
point
grass
pollen
allerg
patient
ige
measur
magic
lite
solid
phase
immunoassay
eight
pooidea
grass
pollen
extract
respect
ige
eight
pooidea
grass
pollen
extract
measur
advia
centaur
solid
phase
immunoassay
without
inhibit
mg
phleum
pratens
pollen
extract
standard
cell
stimul
assay
use
cell
line
grass
pollen
allerg
donor
appli
assess
cell
crossreact
result
sequenc
align
pooidea
grass
pollen
allergen
show
high
homolog
map
ident
amino
acid
surfac
xray
structur
phl
p
clearli
show
presenc
ident
surfac
structur
larg
enough
harbor
ige
bind
epitop
high
correl
spearman
rank
correl
coeffici
observ
compar
level
ige
phleum
pratens
pollen
extract
individu
grass
speci
phleum
pratens
pollen
extract
inhibit
ige
grass
speci
patient
cell
line
specif
phl
p
phl
p
show
similar
stimul
indic
stimul
differ
grass
pollen
extract
indic
extens
cell
crossreact
individu
grass
speci
conclus
phleum
pratens
alon
cover
immunochem
reactiv
test
pooidea
grass
speci
respect
allerg
patient
ige
cell
line
specif
group
major
allergen
show
extens
crossreact
grass
speci
one
speci
alon
eg
phleum
pratens
therefor
seem
adequ
specif
manag
allergi
pooidea
grass
pollen
gradual
shift
aeroallergen
index
affect
allergi
patient
recent
year
texa
panhandl
nabarun
ghosh
mandi
whitesid
kyla
kersh
constantin
saadeh
michael
gaylor
w
smith
west
texa
univers
life
earth
environment
scienc
canyon
unit
state
allergi
aart
patholog
amarillo
unit
state
univers
north
texa
biolog
denton
unit
state
aeroallergen
caus
seriou
allerg
asthmat
reaction
analyz
aeroallergen
data
texa
panhandl
region
last
year
determin
aeroallergen
index
regularli
analyz
coat
melinex
tape
burkard
volumetr
spore
trap
sampl
examin
count
photograph
everi
hour
use
olympu
microscop
olympu
digit
camera
data
correl
daili
temperatur
precipit
peak
wind
speed
clinic
studi
establish
allergi
art
clinic
research
laboratori
effort
aid
diagnosi
mold
pollenrel
allergi
aeroallergen
record
alaternaria
conidia
pezizal
ascospor
curvularia
cladosporium
dreschlera
stachybotrysand
pollen
short
ragwe
ambrosia
artemisiifolia
grass
poacea
hairi
sunflow
helianthu
hirsutu
buffalo
bur
solanum
rostratum
purpl
nightshad
solanum
elaeagnifolium
lamb
quarter
chenopodium
album
due
sever
drought
condit
previou
year
pollen
concentr
significantli
low
reach
highest
peak
april
onward
year
plenti
rainfal
observ
pick
april
juli
last
year
notic
gradual
shift
aeroallergen
index
texa
panhandl
recent
year
global
warm
increas
concentr
exert
widespread
impact
biotic
system
mani
region
current
experienc
warm
effect
associ
global
climat
chang
includ
longer
grow
season
earli
arriv
spring
short
ragwe
ambrosia
artemisiifolia
releas
pollen
ambient
releas
roger
et
al
japan
studi
show
gradual
shift
cryptomeria
japonica
pollen
season
result
support
steadili
increas
number
report
indic
global
warm
trend
temperatur
chang
affect
start
date
c
japonica
pollen
season
particularli
relev
context
human
health
clinic
data
aart
clinic
clearli
evid
patient
suffer
allerg
rhiniti
month
march
june
year
back
peak
pollen
mold
season
may
septemb
ghosh
et
al
gradual
shift
marchjun
frequenc
patient
visit
allergi
clinic
background
glucan
proinflammatori
associ
airway
inflamm
respiratori
symptom
method
studi
assess
glucan
level
upper
bodi
cloth
jersey
subject
glucan
level
estim
modifi
limulu
amoebocyt
lysat
kinet
assay
result
glucan
level
rang
wide
ngg
glucan
level
significantli
lower
cotton
jersey
warm
water
wash
jersey
background
develop
natur
cacr
subject
expos
consist
level
fel
major
cat
allergen
natur
set
transient
exposur
disturb
reservoir
cat
allergen
object
develop
cacr
fel
level
rang
approxim
ngm
concentr
rang
fel
select
repres
higher
level
fel
home
cat
known
induc
allerg
andor
asthmat
respons
method
cacr
fulli
carpet
contain
couch
cover
cotton
sheet
chair
cacr
preload
fel
use
proprietari
aerosol
gener
maintain
allergen
two
cacr
inliv
cat
fel
level
transient
increas
vigor
shake
sheet
aerosol
fel
fel
airborn
concentr
measur
use
person
air
sampler
total
airborn
particul
collect
use
button
sampler
sampl
analyz
use
elisa
particl
size
independ
measur
laser
particl
counter
result
background
measur
indic
fel
undetect
cacr
aerosol
follow
one
hour
cat
allergen
aerosol
day
cat
hous
averag
maximum
total
particl
count
maintain
consecut
day
ppm
fel
concentr
ngm
addit
aerosol
fel
total
cat
hous
day
averag
maximum
total
particl
count
maintain
addit
consecut
day
ppm
averag
fel
concentr
ngm
follow
addit
two
day
concentr
fel
gm
overal
two
period
aerosol
fel
total
cat
hous
day
result
mean
concentr
fel
ngm
conclus
data
indic
aerosol
fel
effect
obtain
natur
allergen
level
rapidli
live
cat
maintain
level
time
within
target
rang
work
demonstr
develop
cacr
model
use
toward
studi
etiolog
put
therapeut
cat
allergi
asthma
fund
provid
alli
researchcetero
research
ca
druginduc
regulatori
cell
asthma
toll
like
receptor
repres
distinct
marker
glucocorticoid
versu
action
human
cell
alon
togeth
glucocorticoid
induc
secret
regulatori
phenotyp
human
cell
cell
inhibit
nabv
cell
respons
glucocorticoid
induc
product
defect
patient
clinic
insensit
asthma
either
vitro
follow
oral
ingest
patient
restor
impair
respons
aim
identifi
distinct
phenotyp
function
effect
two
drug
human
cell
method
vitro
base
tissu
cultur
quantit
rtpcr
flow
cytometri
antibodi
captur
assay
elisa
cytometr
bead
array
use
studi
human
cell
phenotyp
function
follow
polyclon
activ
anti
presenc
absenc
dexamethason
andor
cell
phenotyp
follow
ingest
also
analyz
result
show
alon
inhibit
cytokin
product
enhanc
gener
also
percentag
posit
cell
howev
express
appear
mutual
exclus
furthermor
optim
effect
effector
cytokin
product
observ
distinct
drug
concentr
dexamethason
select
induc
express
vitro
whilst
select
induc
express
cell
vitro
follow
patient
ingest
comparison
cell
popul
nabv
treg
ligat
tlr
druginduc
result
loss
treg
function
case
distinct
mechan
conclus
glucocorticoid
promot
product
regulatori
function
human
cell
alon
combin
use
distinguish
glucocorticoid
exposur
human
cell
ligat
receptor
downregul
treg
function
sublingu
immunotherapi
inhal
allergen
sensitis
effect
chitosan
p
cunningham
c
e
elliot
p
g
holt
wayn
r
thoma
telethon
institut
child
health
research
molecular
biotechnolog
perth
australia
background
immunotherapi
establish
form
treatment
necessari
develop
efficaci
method
develop
model
respiratori
sensitis
induc
intranas
administr
cystein
proteas
papain
without
adjuv
produc
high
boostabl
ige
titr
upon
challeng
pulomonari
eosinophilia
evid
releas
cytokin
bronchoalveolar
lavag
bal
fluid
model
use
optimis
sublingu
desensitis
mucos
sensitis
anim
previous
demonstr
abil
suppress
allergen
specif
ige
studi
lymph
node
examin
effect
excipi
chitosan
method
allerg
sensitis
achiev
administr
low
dose
papain
homologu
der
p
desensitis
examin
sublingu
administr
antigen
chitosan
antigen
alon
chitosan
alon
serum
antibodi
examin
high
dose
challeng
follow
bal
use
studi
cellular
infiltr
cytokin
product
lung
lymph
node
cultur
prolifer
cytokin
product
respons
allergen
stimul
measur
result
treatment
even
chitosan
alon
suppress
ige
antibodi
chitosan
deliveri
desensitis
result
signific
reduct
cell
infiltr
lung
seen
treatment
group
howev
chitosan
alon
chitosan
papain
significantli
suppress
neutrophilia
seen
cytokin
bal
fluid
reduc
treatment
group
although
group
receiv
chitosan
elev
level
ifn
cultur
lymph
node
cell
lower
level
prolifer
sublingu
therapi
solubl
antigen
chitosan
use
cell
prolifer
similar
level
control
cytokin
level
lymph
node
cell
supernat
show
significantli
increas
level
tgf
significantli
decreas
ifn
treatment
group
conclus
sublingu
immunotherapi
decreas
ige
igg
antibodi
lung
inflammatori
respons
howev
shown
lymph
node
prolifer
cytokin
product
decreas
could
longterm
effect
chitosan
caus
nonspecif
reduct
greater
allergen
alon
analysi
epitopespecif
immun
respons
induc
vaccin
structur
fold
unfold
recombin
bet
v
allergen
deriv
man
background
previous
construct
recombin
deriv
major
birch
pollen
allergen
bet
v
hundredfold
reduc
abil
induc
igemedi
allerg
reaction
deriv
differ
two
recombin
bet
v
fragment
repres
unfold
molecul
wherea
recombin
trimer
resembl
structur
fold
bet
v
allergen
method
analyz
antibodi
ige
igg
subclass
iga
igm
respons
bet
v
recombin
synthet
bet
v
peptid
birch
pollen
allerg
patient
vaccin
deriv
adjuv
alon
furthermor
studi
induct
igemedi
skin
respons
patient
use
bet
v
bet
v
fragment
result
type
vaccin
induc
compar
respons
new
sequenti
epitop
overlap
conform
ige
epitop
bet
v
respons
much
higher
induc
immunotherapi
birch
pollen
extract
trimer
fragment
induc
also
ige
respons
new
epitop
transient
increas
skin
sensit
fragment
begin
therapi
howev
skin
reaction
bet
v
reduc
one
year
treatment
activ
treat
group
conclus
demonstr
vaccin
fold
unfold
recombin
allergen
deriv
induc
igg
antibodi
new
epitop
data
may
import
develop
therapeut
well
prophylact
vaccin
base
recombin
allergen
materi
group
subject
includ
individu
allergi
grass
pollen
confirm
medic
histori
posit
skin
prick
test
spt
specif
ige
sige
min
class
treat
sit
pollen
season
gr
sex
age
match
control
subject
confirm
allergi
grass
pollen
untreat
sit
gr
b
control
healthi
nonallerg
grass
pollen
subject
gr
c
method
subcutan
sit
grass
pollen
allergen
extract
absorb
aluminum
hydroxid
accord
manufactur
quidlin
gr
ii
evalu
questionnair
clinic
rhinoconjunct
symptom
score
pollen
season
endpoint
group
b
iii
flow
cytometri
analysi
blood
sampl
perform
begin
sit
treatment
reach
mainten
dose
endpoint
gr
endpoint
gr
b
c
result
subject
gr
reach
end
point
phase
sit
without
signific
advers
event
reduct
symptom
score
subject
subject
subject
sit
treatment
shown
gr
b
symptom
score
grass
pollen
season
compar
group
sit
treatment
flow
cytometr
analysi
show
lower
percentag
regulatori
cell
allerg
patient
gr
gr
versu
control
gr
end
point
ii
statist
nonsignific
percentag
upward
trend
regulatori
cell
popul
cours
sit
treat
sit
group
conclus
lower
count
regulatori
cell
group
allerg
patient
suggest
dysfunct
within
popul
might
contribut
patholog
allergi
percentag
upward
trend
treg
popul
sit
treatment
accompani
improv
symptom
score
suggest
mainten
balanc
treg
popul
crucial
peripher
toler
project
continu
cover
broader
popul
investig
immunolog
paramet
earli
suppress
basophil
activ
allergenspecif
immunotherapi
upregul
histamin
receptor
wroclaw
univers
medic
faculti
wroclow
poland
background
primari
effect
allergen
specif
immunotherapi
sit
exert
effector
cell
howev
surprisingli
inform
mechan
sit
modifi
suppress
immun
respons
basophil
mast
cell
particular
repetit
administr
increas
allergen
dose
builtup
phase
one
main
mediat
releas
effector
cell
upon
allergen
challeng
histamin
divers
immunoregulatori
function
histamin
base
differenti
distribut
histamin
receptor
immunocompet
cell
histamin
receptor
hr
decreas
humor
immun
increas
cellular
immun
display
oppos
function
decreas
cellular
immun
mediat
tolerogen
immun
mechan
therefor
earli
desensit
effect
sit
due
reprogram
effector
cell
respons
histamin
via
modul
histamin
receptor
repertoir
repres
excit
plausibl
strategi
method
honey
bee
wasp
venom
sit
appli
patient
accord
rush
protocol
mrna
level
pbmc
isol
peripher
blood
patient
builtup
phase
sit
day
evalu
real
time
pcr
histamin
receptor
mrna
level
basophil
enrich
peripher
blood
trigger
via
ige
receptor
determin
addit
activ
state
basophil
ige
receptor
crosslink
treatment
ligand
select
well
camp
induc
forscolin
second
messeng
analys
flow
cytometri
sulfidoleukotrien
releas
assay
result
signific
increas
mrna
level
well
ratio
observ
pbmc
patient
day
sit
ige
receptor
crosslink
basophil
peripher
blood
increas
antiig
dose
led
upregul
select
trigger
specif
agonist
dimaprit
forscolin
strongli
suppress
igereceptorinduc
activ
basophil
dose
depend
fashion
conclus
mediat
immunosilenc
function
igereceptor
activ
basophil
upregul
express
basophil
respons
repetit
igereceptor
cross
link
well
allergen
challeng
builtup
phase
sit
might
repres
key
mechan
earli
desensit
effect
sit
level
effector
cell
author
contribut
equal
jeanpierr
allam
gligor
stojanovski
nikolau
friedrich
thoma
bieber
reinhard
natalija
novak
univers
hospit
bonn
dermatolog
bonn
germani
univers
hospit
bonn
patholog
bonn
germani
background
sublingu
immunotherapi
slit
proven
safe
effici
altern
subcutan
immunotherapi
scit
treatment
allerg
rhiniti
antigenpres
cell
langerhan
cell
lc
thought
play
major
role
effect
slit
mast
cell
mc
like
account
observ
advers
reaction
oral
itch
sublingu
edema
sinc
littl
known
lc
mc
within
oral
caviti
investig
distribut
search
altern
mucos
applic
area
highest
densiti
lc
lowest
presenc
mc
method
differ
biopsi
taken
simutan
mucos
tissu
vestibular
buccal
palatin
lingual
sublingu
gingiv
region
n
tissu
process
immunohistochemistri
flow
cytometri
mc
detect
chymas
lc
express
result
highest
densiti
mc
could
detect
within
gingiva
lowest
densiti
mc
found
within
palatinum
lingua
howev
sublingu
region
mc
locat
within
lobe
duct
sublingu
gland
substanti
number
individu
might
explain
swell
sublingu
caruncl
slit
patient
consid
lc
could
detect
highest
densiti
within
vestibular
region
follow
region
bucca
palatinum
lingua
interestingli
lowest
densiti
lc
locat
sublingu
region
flow
cytometri
investig
express
high
affin
receptor
ige
fc
ri
might
play
central
role
allergen
uptak
slit
therebi
could
detect
highest
express
fc
ri
lc
vestibular
region
conclus
view
data
differ
mucos
applic
site
vestibulum
might
repres
altern
region
potent
allergen
uptak
especi
slit
patient
suffer
sublingu
edema
furthermor
data
might
serv
basi
develop
new
applic
form
slit
tablet
stripe
probiot
propos
decreas
preval
allergi
suscept
individu
investig
whether
could
affect
igeinduc
mast
cell
secretori
respons
end
mous
bone
marrowderiv
mast
cell
bmmc
expos
lactic
acid
bacteria
bmmc
express
highaffin
receptor
ige
fc
ri
sensit
ige
antibodi
challeng
specif
antigen
releas
secret
varieti
inflammatori
molecul
includ
granular
mediat
enzym
among
hexosaminidas
lipid
mediat
cytokin
among
tnf
chemokin
check
first
none
bacteria
test
activ
mast
cell
inde
incub
bmmc
min
hr
bacteria
ratio
bacteriacel
induc
hexosaminidas
releas
tnf
secret
respect
investig
whether
previou
exposur
bmmc
bacteria
would
affect
subsequ
igeinduc
biolog
respons
mast
cell
found
overnight
incub
bmmc
one
strain
bacteria
ratio
bacteriacel
prior
sensit
ige
antibodi
inhibit
aginduc
hexosaminidas
releas
tnf
secret
live
gammairradi
bacteria
equal
inhibitori
bacteria
decreas
express
fc
ri
affect
sensit
bmmc
ige
inhibit
requir
direct
contact
cell
bacteria
inhibit
similar
bmmc
mice
bmmc
wt
mice
exclud
well
respons
receptor
preliminari
work
aim
analyz
bacteria
interfer
fc
ri
signal
indic
sever
intracellular
signal
molecul
reduc
express
earli
late
fc
ridepend
phosphoryl
event
decreas
ib
degrad
prevent
thu
interf
nuclear
transloc
nfb
igeinduc
increas
intracellular
concentr
profoundli
inhibit
altogeth
result
indic
probiot
especi
lactic
acid
bacteria
exert
direct
inhibitori
effect
mast
cell
activ
support
idea
probiot
protect
allergi
prevent
igeinduc
mast
cell
activ
induct
allerg
airway
inflamm
hous
dust
mite
allergen
specif
cell
mice
c
h
huang
l
liew
c
kuo
h
wen
l
goh
l
goh
b
w
lee
k
chua
nation
univers
singapor
paediatr
singapor
singapor
star
singapor
institut
clinic
scienc
singapor
singapor
background
known
allerg
inflammatori
diseas
asthma
cellsmedi
howev
pivot
role
allergenspecif
cell
induct
allerg
lung
inflamm
fulli
elucid
aim
elucid
imunopatholog
role
cell
allerg
airway
inflamm
method
mice
epicutan
sensit
major
dust
mite
allergen
blo
wellcharacter
blo
cell
line
subsequ
establish
splenocyt
sensit
mice
immunopatholog
role
cell
line
assess
vivo
adopt
cell
transfer
approach
nabv
mice
receiv
blo
cell
intraven
follow
intranas
challeng
blo
respons
recipi
mice
analys
immunolog
histochem
method
result
long
term
tcrv
blo
specif
cell
line
produc
high
level
ifn
establish
high
cell
show
upregul
ico
upon
stimul
blo
intranas
challeng
blo
cell
recipi
mice
develop
blo
ige
airway
eosinophilia
mucu
product
goblet
cell
addit
donor
cell
cellular
infiltr
consist
cell
nk
cell
recipi
mice
cellular
inflamm
could
suppress
dexamethason
intervent
patholog
result
observ
pb
challeng
recipi
mice
conclus
blo
cell
play
central
patholog
role
mediat
allerg
airway
inflammatori
respons
resembl
seen
human
anim
model
particularli
use
screen
novel
therapeut
asthma
allergi
differ
ratio
symptomat
atop
patient
asymptomat
atop
control
similar
level
marker
kanami
orihara
masami
narita
akira
akasawa
yukihiro
ohya
kenji
matsumoto
hirohisa
saito
nation
research
institut
child
health
develop
depart
allergi
immunolog
tokyo
japan
nation
center
child
health
develop
divis
allergi
tokyo
japan
nation
center
child
health
develop
depart
interdisciplinari
medicin
tokyo
japan
rational
respons
gene
ipex
syndrom
respons
hyperreact
known
master
gene
natur
occur
regulatori
cell
mayb
regulatori
cell
subset
therefor
regulatori
role
cell
allerg
disord
highli
expect
howev
precis
role
circul
cell
common
allerg
diseas
remain
unclear
order
evalu
diagnost
potenti
examin
intracellular
protein
express
circul
peripher
blood
cell
allerg
patient
healthi
control
singlecel
level
method
ratio
cell
cell
fraction
well
variou
laboratori
data
measur
donor
includ
patient
atop
dermat
andor
bronchial
asthma
none
subject
treat
oral
corticosteroid
patient
judg
posit
specif
ige
antibodi
least
one
dermatophagoid
pternyssinu
dermatophagoid
farina
japanes
cedar
pollen
use
pharmacia
cap
system
fluoresc
enzymelink
immunoassay
capfeia
twentythre
agematch
healthi
volunt
also
show
least
one
posit
reaction
allergen
capfeia
although
never
subject
symptom
relat
allerg
diseas
result
ratio
total
popul
correl
invers
level
total
serum
ige
p
eosinophil
count
p
serum
ifn
p
perform
casecontrol
studi
matchedpair
analysi
elimin
influenc
level
correl
total
ige
level
eosinophil
ratio
ratio
significantli
lower
activ
atop
patient
compar
asymptomat
donor
similar
level
ige
eosinophil
ifn
conclus
find
impli
circul
regul
respons
vivo
moreov
symptomat
atop
patient
lower
ratio
asymptomat
atop
control
similar
level
marker
measur
ratio
potenti
aid
evalu
presenc
activ
inflamm
patient
allerg
diseas
evalu
known
marker
patient
allerg
diseas
molecular
biomark
eosinophillineag
commit
multiplex
qpcr
analysi
mbp
receptor
mrna
express
kinet
peripher
umbil
cord
blood
background
examin
practic
physician
india
china
sri
lanka
australia
singapor
indonesia
philippin
taiwan
monitor
treat
childhood
asthma
method
standard
questionnair
sent
doctor
via
post
questionnair
made
question
method
monitor
childhood
asthma
b
practic
manag
acut
asthma
exacerb
c
choic
therapi
mainten
treatment
result
studi
reflect
mostli
practic
doctor
practic
urban
region
respond
gener
pediatrician
gener
practition
small
fraction
doctor
use
score
card
diari
monitor
asthma
rang
philippin
australia
india
sri
lanka
australia
use
either
peak
flow
meter
andor
spirometri
monitor
asthma
howev
frequenc
usag
china
indonesia
never
seldom
make
use
peak
flow
meter
china
indonesia
never
seldom
use
spirometri
monitor
nebulis
salbutamol
given
everi
minut
treatment
choic
treat
acut
asthma
attack
major
doctor
countri
rang
china
sri
lanka
minor
china
taiwan
administ
system
corticosteroid
outpati
set
er
polyclin
acut
asthma
india
sri
lanka
doctor
also
indic
durat
treatment
corticosteroid
would
day
dosag
throughout
durat
good
number
sri
lanka
taiwan
use
antibiot
treatment
acut
asthma
pneumonia
otiti
media
sinus
like
doctor
favour
highdos
inhal
corticosteroid
acut
manag
rang
indonesia
sri
lanka
philippin
mainten
treatment
signific
fraction
doctor
chose
longact
beta
agonist
laba
monotherapi
firstchoic
treatment
asthma
mainten
infant
percentag
rang
australia
indonesia
preschool
australia
china
older
children
philippin
china
conclus
much
room
improv
increas
doctor
awar
guidelin
effect
manag
paediatr
asthma
southeast
asia
especi
regard
use
laba
monotherapi
efficaci
inhal
heparin
effect
treatment
acut
exacerb
asthma
nanci
mahmoud
abdelati
mahmoud
elprinc
magdi
abd
elsalam
faculti
medicin
suez
canal
univers
chest
depart
ismailia
egypt
faculti
medicin
sham
univers
chest
depart
cairo
egypt
background
inhal
heparin
found
highli
protect
methacholin
induc
bronchospasm
bronchial
asthma
possibl
via
direct
effect
smooth
muscl
may
potenti
antiinflammatori
activ
object
aim
studi
determin
addit
therapeut
benefit
inhal
heparin
treatment
hospit
patient
acut
asthmat
exacerb
treat
inhal
bronchodil
glucocorticoid
therapi
method
thirti
patient
male
femal
mean
age
j
year
admit
acut
exacerb
asthma
particip
prospect
random
doubleblind
placebocontrol
studi
subject
receiv
hydrocortison
administ
intravenousl
nebul
salbutamol
treatment
group
receiv
inhal
heparin
therapi
u
ml
everi
hr
placebo
group
receiv
salin
solut
hour
baselin
respiratori
paramet
oxygen
satur
respiratori
rate
peak
background
aim
recent
could
demonstr
mucos
target
aleuria
aurantia
lectin
aal
coat
poli
llactidecoglycol
acid
plga
microspher
modul
specif
immun
respons
birch
pollen
allergi
use
grass
pollen
novel
allergen
encapsul
aalcoat
particl
aim
evalu
immun
modul
function
microspher
murin
asthma
model
method
balbc
mice
sensit
intraperiton
grass
pollen
extract
follow
aerosol
challeng
induc
acut
allerg
asthma
thereaft
anim
treat
repeatedli
grass
pollen
load
plga
microspher
coat
aal
mcell
target
mice
immun
microspher
coat
glycin
intraperiton
allergen
inject
nabv
anim
serv
control
outcom
treatment
evalu
measur
grass
pollen
specif
antibodi
ige
iga
sera
bronchioalveolar
lavag
bal
determin
cytokin
profil
tgf
spleen
supernat
result
anim
treat
aalcoat
mircrospher
allergenspecif
ige
level
unaffect
treatment
howev
allergenspecif
iga
level
increas
therapi
interestingli
cytokin
evalu
level
chang
wherea
reduc
amount
high
level
tgf
measur
mice
treat
aalfunction
microspher
compar
group
conclus
data
indic
murin
model
grass
pollen
allergi
benefici
influenc
target
mcell
via
aalcoat
allergenload
microspher
thu
potenti
function
microparticl
specif
immunotherapi
acut
respiratori
allergi
confirm
oral
sulforaphan
safe
effect
induc
antioxid
phase
ii
enzym
human
airway
substanti
evid
implic
particul
air
pollut
exposur
import
factor
asthma
exacerb
increas
preval
allerg
respiratori
diseas
inflammatori
effect
particul
air
pollut
mediat
induct
cellular
oxid
stress
strategi
reduc
oxid
stress
may
potenti
reduc
harm
effect
particul
air
pollut
endogen
phase
ii
enzym
abrog
oxid
stress
metabol
particulateassoci
reactiv
chemic
scaveng
reactiv
oxygen
speci
conduct
placebocontrol
dose
escal
trial
investig
vivo
effect
sulforaphan
natur
occur
potent
induc
phase
ii
enzym
express
upper
airway
human
subject
sixti
human
studi
subject
consum
oral
standard
broccoli
sprout
homogen
bsh
dose
contain
sulforaphan
daili
consecut
day
escal
block
design
use
gram
g
bsh
ensur
safeti
toler
addit
subject
subsequ
enrol
dose
g
examin
doserespons
effect
five
subject
complet
protocol
nonsulforaphan
contain
alfalfa
sprout
homogen
dose
g
control
group
rna
express
select
phase
ii
enzym
measur
nasal
lavag
cell
rtpcr
wilcoxon
nebul
singl
dose
formoterol
powder
mcg
effect
three
dose
albuterol
one
fifth
cost
children
acut
asthma
well
toler
patient
age
benefit
nebul
formoterol
singl
dose
non
inferior
three
dose
albuterol
underscor
mani
possibl
substanti
care
save
given
heavi
load
acut
asthma
care
repres
countri
mani
develop
nation
pari
nebul
pronet
turbo
bsh
dose
subject
toler
oral
bsh
dose
without
signific
advers
event
increas
phase
ii
enzym
express
nasal
lavag
cell
occur
dose
depend
manner
maxim
enzym
induct
observ
highest
dose
g
bsh
g
bsh
daili
express
baselin
express
respect
p
e
enzym
phase
ii
enzym
induct
seen
ingest
nonsulforaphan
contain
alfalfa
sprout
thu
oral
sulforaphan
safe
effect
induc
mucos
phase
ii
enzym
express
upper
airway
human
subject
base
work
previou
vitroanim
studi
sulforaphan
may
repres
novel
therapeut
strategi
treatment
allerg
respiratori
condit
addit
studi
underway
determin
whether
phase
ii
enzym
induct
effect
reduc
inflammatori
effect
particulateinduc
oxid
stress
human
airway
background
increas
incid
aspergillu
fumigausinduc
allerg
asthmat
world
necessit
identif
catalogu
allergen
clinic
import
present
studi
immunoproteom
approach
use
establish
set
candid
allergen
could
explor
diagnost
applic
allerg
aspergillosi
asthmat
includ
abpa
method
immunoproteom
combin
mass
spectrometr
analysi
use
identifi
protein
threeweek
cultur
filtrat
respons
induc
fumigatusspecif
ige
immunoreact
use
pool
sera
fumigatussensitis
asthmat
diagnost
potenti
also
examin
patient
allerg
bronchopulmonari
aspergillosi
abpa
immunoblot
individu
sera
patient
result
peptid
mass
fingerprint
pmf
use
matrixassist
laser
desorptionionizationtim
flightmass
spectrometri
malditofm
andor
de
novo
sequenc
msm
analysi
protein
spot
gel
led
identif
total
sixteen
allergen
fumigatu
eleven
report
allergen
first
time
five
report
earlier
put
isoform
protein
asp
f
chitosanas
observ
first
time
studi
immunoreact
protein
among
patient
abpa
use
individu
sera
patient
exhibit
sensitis
although
pattern
vari
taken
togeth
protein
could
thu
consid
potenti
allergen
even
among
patient
abpa
three
protein
viz
hypothet
protein
extracellular
arabinas
chitosanas
could
major
allergen
conclus
immunoproteom
approach
appli
analysi
cultur
filtrat
protein
result
identif
sever
candid
allergen
mani
novel
contribut
catalogu
fumigatu
allergen
protein
allergen
may
facilit
improv
serodiagnosi
allerg
aspergillosi
addit
immunoreact
protein
observ
among
patient
abpa
may
potenti
serodiagnosi
open
scope
evalu
develop
person
immunotherapeut
laboratori
test
evalu
oliv
pollen
allergi
cross
reactiv
jordan
hani
ababneh
hani
ababneh
ghada
maaytah
presid
jordanian
societi
allergi
immunolog
immunolog
queen
alia
hospit
amman
jordan
king
hussein
medic
center
immunolog
amman
jordan
background
extens
unorgan
plant
cultiv
holli
oliv
tree
countri
first
caus
allergi
oliv
tree
olea
europaea
pollen
major
caus
season
allergymak
first
outdoor
pollen
calendar
jordan
date
ten
allergen
name
ole
e
ole
e
isol
character
pollen
ole
e
small
protein
recent
describ
major
allergen
pollen
sinc
affect
allerg
patient
studi
regard
oliv
allergi
report
area
oliv
pollin
season
last
two
month
approxim
middl
may
middl
juli
object
main
aim
studi
address
perform
oliv
screen
test
total
specif
ige
cross
reaction
pollen
method
total
specif
serum
ige
oliv
pollen
test
evalu
allerg
patient
peak
pollen
season
use
immunoblot
allergi
screenrespiratori
pannel
result
patient
serum
specimen
allergi
ige
oliv
pollen
allerg
patient
elev
total
serum
ige
iuml
sampl
healthi
subject
use
neg
control
crossreact
orang
banana
grass
pollen
ambrosia
notic
case
conclus
oliv
tree
pollen
one
main
caus
allergi
mediterranean
region
includ
jordan
worth
mention
import
total
specif
ige
test
oliv
pollen
allergi
detect
crossreact
pollen
fruit
suggest
presenc
ole
e
protein
mani
sourc
may
relat
develop
exacerb
allerg
asthmat
process
result
could
interpret
caution
regard
clinic
symptom
sign
skin
prick
test
vivo
reactiv
grass
pollen
correl
specif
ige
antibodi
level
patient
allerg
rhinoconjunct
johann
hussmarp
ulf
darsow
florian
pfab
ingrid
weichenmei
carl
johan
petersson
magnu
borr
johann
ring
heidrun
behrendt
zaum
center
allergi
environ
gsftum
divis
environment
dermatolog
allergi
munich
germani
depart
dermatolog
allergi
biederstein
technic
univers
munich
munich
germani
phadia
ab
phadia
ab
uppsala
sweden
background
previou
investig
establish
doserespons
curv
sever
clinic
symptom
specif
ige
antibodi
level
indoor
food
allergen
allerg
individu
question
whether
also
hold
true
outdoor
allergen
eg
grass
pollen
allergen
method
patient
allerg
rhinoconjunct
arc
allergi
timothi
grass
pollen
well
healthi
control
recruit
grass
pollen
season
investig
correl
ige
antibodi
level
threshold
vivo
reactiv
determin
specif
serum
ige
antibodi
timothi
grass
pollen
immunocapi
phadia
ab
uppsala
three
time
point
one
year
junejuli
octob
decemb
perform
conjunctiv
nasal
provoc
test
grass
pollen
extract
differ
concentr
phleum
pratens
hal
allergi
duesseldorf
germani
addit
skin
prick
test
perform
investig
parallel
grass
pollen
count
use
burkard
trap
perform
univers
campu
biederstein
munich
distant
laboratori
ground
addit
patient
score
symptom
visual
analog
scale
exhal
nitric
oxid
analys
measur
inflammatori
lung
reaction
result
preliminari
result
patient
arc
reveal
signific
relationship
specif
ige
concentr
serum
titrat
level
skin
prick
test
p
g
jonckheereterpsta
trend
test
howev
correl
specif
serum
ige
timothi
grass
threshold
nasal
conjunctiv
provoc
test
found
conclus
measur
specif
serum
ige
level
seem
accur
predict
vivo
reactiv
regard
skin
prick
test
patient
arc
grass
pollen
allergen
preliminari
result
indic
good
correl
indic
sensit
serum
ige
level
threshold
allergen
concentr
induc
symptom
data
analysi
concern
conjunctiv
nasal
provoc
test
symptom
score
greater
number
patient
progress
diagnosi
pollenfood
syndrom
pf
use
structur
questionnair
pf
manifest
oral
allergi
syndrom
oa
common
food
allergi
characterist
symptom
speed
onset
typic
food
involv
suggest
pf
could
diagnos
though
clinic
histori
alon
subject
report
springtim
hay
fever
complet
pf
diagnost
questionnair
pfsdq
alloc
either
group
pf
group
pf
food
allergi
group
pf
food
allergi
subject
consult
allergi
specialist
made
provision
pf
diagnosi
follow
skin
prick
test
fresh
food
use
prick
prick
test
method
ppt
oral
food
challeng
ofc
pfsdq
measur
gold
standard
posit
ofc
second
standard
final
diagnosi
accord
subject
medic
allergi
specialist
use
ppt
ofc
result
modifi
origin
diagnosi
subject
complet
studi
alloc
group
pfsve
group
pfsve
subject
posit
ofc
group
although
signific
differ
pfsdq
ofc
result
p
g
case
pfsdq
compar
final
diagnosi
standard
p
sensit
specif
posit
neg
predict
valu
pfsdq
q
test
final
diagnosi
standard
reliabl
pfsdq
high
standardis
alpha
score
chronbach
alpha
test
factor
analysi
show
key
compon
pfsdq
symptom
type
raw
cook
food
speed
onset
symptom
number
report
symptom
varimix
rotat
logist
regress
analysi
show
predict
factor
pf
diagnosi
reaction
raw
plant
food
p
g
onset
symptom
within
minut
eat
p
g
number
report
symptom
food
p
g
diagnosi
pf
use
pfsdq
significantli
differ
made
specialist
allergist
use
clinic
histori
ppt
ofc
import
predict
variabl
pf
report
reaction
raw
plant
food
rapid
onset
symptom
multipl
symptom
pfsdq
could
use
diagnost
aid
work
primari
care
screen
adult
report
food
symptom
presenc
absenc
pf
laur
rouanetbousquet
philipp
jean
bousquet
bernard
arnoux
pascal
demoli
antonino
romano
univers
hospit
arnaud
de
villeneuv
explor
de
allergi
inserm
montpelli
franc
univers
hospit
de
l
inform
montpelli
franc
inserm
u
montpelli
franc
complesso
integrato
columbu
unita
di
allergologia
roma
itali
introduct
drug
hypersensit
betalactam
often
skin
test
use
benzylpenicillin
major
ppl
minor
mdm
penicillin
determin
amoxicillin
ampicillin
culprit
betalactam
howev
ppl
mdm
remov
mark
aim
studi
assess
import
benzylpenicillin
withdraw
method
use
drug
allergi
hypersensit
databas
dahd
data
come
italian
centr
conduct
historicoprospect
cohort
studi
patient
consult
suspect
betalactam
hypersensit
reaction
least
posit
skin
test
benzylpenicillin
includ
diagnosi
skin
test
follow
european
network
drug
allergi
enda
recommend
benzylpenicillin
ppl
mdm
ampicillin
amoxicillin
alway
skin
test
result
patient
men
asthmat
atop
includ
posit
benzylpenicillin
also
posit
ppl
mdm
without
skin
test
ppl
mdm
number
posit
benzylpenicillin
increas
differ
observ
asthma
atop
subject
posit
benzylpencillin
also
posit
anoth
penicillin
p
p
respect
anaphylaxi
anaphylact
shock
common
subject
posit
sever
penicillin
vs
p
convers
vs
present
urticaria
angiodema
conclus
sinc
withdraw
ppl
mdm
benzylpenicillin
skin
test
appear
mandatori
patient
posit
drug
significantli
reduc
oral
challeng
zenro
ikezawa
chieko
watanab
kazuko
nakamura
yumiko
yaman
yuki
shigehira
yuko
ikezawa
michiko
aihara
yokohama
citi
univers
graduat
school
medicin
enviroment
immunodermatolog
yokohama
japan
background
bdruginduc
hypersensit
syndrom
dih
uniqu
sever
advers
drug
reaction
well
known
accompani
reactiv
human
herpesviru
mani
case
week
develop
drug
reaction
clinic
featur
syndrom
acut
widespread
maculopapular
polymorph
eczemat
andor
erythroderm
erythema
fever
lymph
node
swell
liver
dysfunct
eosinophilia
leukocytosi
atyp
lymphocyt
first
report
dih
reactiv
japan
case
report
data
reactiv
method
retrospect
analyz
recent
report
suspect
advers
drug
reaction
submit
medic
journal
japan
order
defin
present
characterist
diseas
japan
result
age
rang
year
old
mean
year
old
ratio
mf
caus
drug
anticonvuls
carbamazepin
anticonvuls
drug
common
caus
drug
sulfonamid
mexilletin
antiarrhythm
drug
allopurinol
symptom
develop
week
begin
caus
drug
administr
patient
recurr
symptom
observ
patient
four
die
mortal
rate
reactiv
detect
patient
increas
igg
andor
increas
dna
peripher
blood
sera
hand
reactiv
cytomegaloviru
observ
patient
without
reactiv
treatment
patient
dih
steroid
without
pul
case
steroid
pul
mpsl
case
day
unclear
intraven
inject
high
dose
immunoglobulin
ivig
steroid
case
plasmaapheresi
pa
steroid
case
mortal
dih
unexpectedli
high
compar
sj
discuss
probabl
role
dih
discuss
comparison
epsteinbarr
eb
viru
infecti
mononucleosi
mosquito
bite
hypersensit
drug
provoc
test
patient
drug
hypersensit
reaction
background
bndeen
confirm
drug
hypersensit
common
life
threaten
diagnosi
vigor
base
clinic
histori
physic
examin
possibl
skin
test
drug
provoc
test
intend
describ
come
drug
provoc
test
analyz
patient
histori
suggest
drug
allergi
use
retrospect
analysi
clinic
case
seri
method
consecut
patient
suspect
immedi
drug
allergi
refer
hospit
januari
februari
patient
serv
skin
reaction
posit
result
skin
test
blactam
exclud
note
singleblind
administr
increas
dose
suspect
drug
usual
daili
dose
struck
hospit
surveil
result
drug
provoc
test
perform
use
variou
drug
includ
aspirin
nonsteroidel
antiinflammatori
drug
macrolid
paracetamol
nonsteroid
antiinflammatori
drug
posit
provoc
test
result
also
reproduc
symptom
albeit
milder
shorter
durat
follow
histori
anaphylact
shock
histori
anaphylaxi
without
shock
histori
urticaria
histori
maculopapular
erupt
reaction
complet
refer
prednison
epinephrin
howev
assum
accept
fals
neg
result
drug
provoc
test
may
occur
sanit
rare
cofactor
includ
diagnost
procedur
toler
introduct
provoc
conclus
certain
drug
provoc
test
individu
suspect
drug
allergi
perform
care
control
set
confirm
drug
hypersensit
antitubercul
drug
rechalleng
success
rate
among
patient
cutan
hypersensit
reaction
lara
theresa
aleta
univers
philippinesphilippin
gener
hospit
allergi
quezon
citi
philippin
background
first
studi
systemat
document
proport
cutan
hypersensit
reaction
chr
patient
advers
drug
reaction
adr
antitubercul
medic
excipi
object
determin
proport
chr
due
specif
antitubercul
medic
investig
success
rate
rechalleng
shift
differ
brand
antitubercul
medic
methodolog
patient
chr
antitubercul
medic
januari
august
includ
least
hour
antihistamin
patient
rechalleg
white
light
yellow
color
drug
minim
excipi
patient
may
sensit
rechalleng
consid
success
recurr
symptom
multipl
antitubercul
drug
regimen
result
sixtysix
patient
refer
adr
antitubercul
medic
fortyf
chr
fortytwo
patient
rechalleng
fourteen
success
sixteen
document
cutan
advers
reaction
one
drug
highest
incid
occur
ethambutol
pyrazinamid
success
rate
rechalleng
conclus
skin
allergi
common
first
line
antitb
drug
common
drug
associ
chr
ethambutol
pyrazinamid
success
rate
drug
rechalleng
shift
differ
brand
antitb
medic
metaanalysi
risk
angioedema
angiotensin
receptor
blocker
arb
patient
prior
angioedema
associ
angiotensin
convert
enzym
inhibitor
acei
bret
haymor
jiun
yoon
cecilia
mikita
kent
deze
walter
reed
armi
medic
center
allergyimmunolog
washington
dc
unit
state
william
beaumont
armi
medic
center
intern
medicin
el
paso
unit
state
background
patient
experi
angioedema
ae
take
acei
report
develop
ae
take
arb
studi
describ
risk
sought
answer
question
perform
systemat
review
medic
literatur
method
literatur
search
perform
medlin
embas
biosi
current
content
limit
jan
scisearch
also
use
identifi
addit
citat
key
articl
refer
list
retriev
studi
review
articl
evalu
addit
citat
two
author
independ
evalu
studi
inclus
abstract
relev
data
accord
predefin
paramet
articl
describ
cohort
patient
experienc
ae
take
acei
subsequ
expos
arb
follow
least
one
month
includ
percentag
patient
experienc
ae
abstract
articl
confid
interv
calcul
use
exact
binomi
method
pool
percentag
calcul
use
invers
varianc
method
result
uniqu
articl
initi
identifi
three
articl
describ
patient
met
inclus
criteria
one
random
control
trial
two
retrospect
cohort
mean
age
patient
year
male
femal
two
studi
predominantli
caucasian
subject
third
studi
africanamerican
mean
time
followup
month
articl
describ
confirm
possibl
case
ae
secondari
arb
possibl
case
risk
ae
ci
confirm
case
ci
fatal
event
statist
heterogen
trial
p
conclus
limit
evid
suggest
patient
develop
ae
take
acei
risk
develop
ae
take
arb
confirm
ae
risk
inform
aid
clinician
counsel
patient
regard
therapi
option
develop
ae
due
acei
nervou
system
well
immun
hematopoiet
system
secret
larger
amount
preferenti
cell
function
heterodimer
receptor
compos
osmr
express
constitut
epitheli
cell
keratinocyt
cell
like
involv
dermat
pruriti
patient
upregul
object
method
peripher
blood
mononuclear
cell
obtain
patient
atop
dermat
allerg
henegg
rang
year
age
well
healthi
individu
allerg
symptom
patient
recurr
eczema
pruriti
posit
skin
reaction
egg
white
patient
also
posit
respons
oral
provoc
test
raw
hen
egg
diagnost
criteria
atop
dermat
base
criteria
hanifin
rajk
evalu
express
cell
method
newli
develop
fca
analysi
result
discuss
preferenti
express
cla
skinhorm
cutan
lymphocyt
antigen
well
cell
atop
children
complain
skin
lesion
pruriti
compar
normal
subject
sever
symptom
correl
amount
cell
conclus
result
suggest
larger
amount
express
like
involv
pruriti
well
skin
lesion
atop
children
dysregul
induc
effect
monocyt
patient
atop
dermat
impact
polymorph
margaret
niebuhr
jen
langnickel
christian
dra
alexand
kapp
thoma
werfel
hannov
medic
school
depart
dermatolog
allergolog
hannov
germani
univers
konstanz
biochem
pharmacolog
depart
biolog
konstanz
germani
background
atop
dermat
ad
often
complic
enhanc
suscept
bacteri
skin
infect
especi
staphylococcu
aureu
aureu
tolllik
receptor
especi
tlr
recogn
cell
wall
compon
aureu
eg
lipoteicho
acid
lta
peptidoglycan
pgn
heterozyg
polymorph
occur
frequenc
adult
ad
patient
shown
associ
sever
phenotyp
object
method
aim
studi
investig
impact
agonist
lta
pgn
cytokin
product
cell
surfac
marker
express
human
monocyt
ad
patient
polymorph
compar
ad
patient
bwild
typet
control
individu
elucid
function
role
polymorph
result
could
show
ad
patient
mutat
produc
significantli
significantli
less
compar
ad
patient
nonmut
upon
stimul
agonist
express
significantli
higher
upon
stimul
polymorph
patient
express
unaffect
stimul
agonist
conclus
show
first
time
function
differ
respons
monocyt
ad
patient
mutat
compar
wild
type
ad
patient
ligand
depend
manner
clinic
implic
data
stratifi
emerg
concept
ad
patient
dysbal
innat
well
aquir
immun
might
essenti
pathogenesi
ad
involv
enhanc
suscept
skin
infect
aureu
higher
inflammatori
respons
patient
polymorph
impact
atop
dermat
qualiti
life
japanes
patient
yukihiro
ohya
yasuo
kubota
akira
hoshioka
ritsuko
hosoya
namiko
kojima
masami
narita
akiko
miyazaki
nahoko
sakamoto
nation
center
child
health
develop
divis
allergi
tokyo
japan
kagawa
univers
depart
dermatolog
kagawa
japan
chiba
children
hospit
divis
allergi
chiba
japan
hosoya
clinic
dermatolog
tokyo
japan
juntendo
univers
depart
public
health
tokyo
japan
background
preval
atop
dermat
ad
japanes
popul
rapidli
increas
decad
impact
ad
qualiti
life
qol
difficult
assess
use
translat
qol
scale
develop
western
nation
influenc
differ
cultur
aim
studi
develop
origin
qol
assess
scale
japanes
patient
atop
dermat
method
collect
data
patient
visit
japanes
hospit
clinic
use
anonym
open
questionnair
interview
one
hundr
eighti
item
extract
whole
data
base
secondari
questionnair
compris
item
made
expert
discuss
appli
patient
atop
dermat
psychometr
item
reduct
result
process
factor
analysi
item
analysi
sixti
eight
item
converg
item
compris
four
factor
influenc
daili
activ
burden
medic
itchi
gener
annoy
anxieti
futur
intern
consist
factor
excel
cronbach
factor
item
content
factor
load
score
item
weak
enthusiasm
influenc
sleep
disturb
burden
hous
keep
burden
topic
therapi
unwilling
topic
applic
annoy
itchi
annoy
scratch
anxieti
remiss
anxieti
fluctuat
symptom
conclus
studi
reveal
impact
atop
dermat
qol
patient
associ
dermatolog
symptom
also
adher
burden
anxieti
prognosi
compact
time
questionnair
develop
japan
time
would
use
detect
comprehens
qualiti
life
patient
atop
dermat
even
busi
situat
outpati
clinic
eosinophil
protein
serum
urin
children
atop
dermat
magdalena
czarneckaoperacz
dorota
jenerowicz
wojciech
silni
poznan
univers
medic
scienc
dermatolog
poznan
poland
atop
dermat
ad
inflammatori
skin
diseas
character
chronic
recurr
cours
begin
primarili
earli
childhood
aim
project
evalu
use
select
eosinophil
protein
serum
ecp
epx
urin
epx
children
suffer
ad
marker
diseas
sever
studi
also
aim
analyz
correl
level
examin
protein
paramet
skin
prick
test
spt
result
serum
concentr
total
ige
coexist
symptom
atop
diseas
examin
ad
children
attend
allerg
diseas
diagnost
center
hospit
depart
dermatolog
control
group
select
healthi
children
without
symptom
allerg
diseas
mean
level
eosinophil
protein
measur
serum
ecp
epx
urin
epx
children
suffer
ad
higher
control
statist
signific
differ
detect
serum
level
epx
patient
present
severesever
ad
higher
level
eosinophil
protein
patient
present
mildmoder
ad
although
signific
differ
found
ad
children
posit
spt
result
detect
serum
specif
ige
present
higher
mean
level
serum
urin
eosinophil
protein
compar
group
patient
neg
spt
result
undetect
serum
specif
ige
although
statist
signific
differ
total
ige
level
ad
children
repres
allerg
form
diseas
statist
significantli
higher
children
nonallerg
ad
children
severesever
ad
total
ige
level
significantli
higher
children
moderatemild
diseas
result
present
indic
singnific
role
eosinophil
etiopathogenesi
ad
measur
serum
urin
level
select
eosinophil
protein
may
consid
import
part
diagnost
approach
children
suffer
ad
especi
differenti
allerg
nonallerg
form
diseas
among
eosinophil
protein
epx
alway
subject
particularli
thorough
investig
easi
noninvas
way
measur
urin
import
featur
diagnost
children
epx
marker
significantli
better
differenti
ad
patient
healthi
individu
comparison
factor
ecp
peripher
blood
eosinophilia
quantit
analysi
nerv
growth
factor
ngf
horni
layer
atop
dermat
effect
treatment
ngf
zenro
ikezawa
junko
yamaguchi
michiko
aihara
takeshi
kambara
yusuk
kobayashi
yokohama
citi
univers
graduat
school
medicin
environment
immunodermatolog
yokohama
japan
shiseido
co
r
plan
divis
yokohama
japan
express
nerv
growth
factor
ngf
known
increas
skin
patient
atop
dermat
ad
relat
diseas
aggrav
present
studi
measur
skin
ngf
level
ad
patient
assess
possibl
relationship
ad
sever
well
effect
treatment
method
ngf
horni
layer
horn
ngf
skin
lesion
cubit
fossa
collect
via
tape
strip
measur
use
elisa
ad
patient
week
treatment
itch
erupt
whole
bodi
lesion
measur
ngf
evalu
peripher
blood
eosinophil
count
serum
ldh
level
serum
total
ige
level
also
examin
result
level
ngf
significantli
higher
ad
patient
healthi
control
correl
sever
itch
erythema
scale
xerosi
eosinophil
count
ldh
level
ngf
level
decreas
significantli
treatment
olopatadin
andor
topic
steroid
week
decreas
ngf
correl
decreas
sever
itch
sever
ad
whole
bodi
erythema
papul
scalexerosi
lichenif
lesion
eosinophil
count
ldh
level
conclus
level
horn
ngf
found
reflect
sever
itch
erupt
ad
therefor
measur
ngf
via
harmless
method
appear
use
assess
sever
therapeut
effect
ad
associ
allel
variant
delta
receptor
preval
urticaria
angioedema
atop
dermat
symptom
jorg
molina
rut
aguero
ledit
ardusso
cintia
crudelli
rodolfo
navarret
natalia
pujato
guillermo
mujica
nora
figueroa
rosario
nation
univers
human
physiolog
rosario
argentina
rosario
nation
univers
allergi
depart
rosario
argentina
introduct
cc
chemokin
includ
rant
specif
receptor
play
import
role
genesi
allerg
inflamm
presenc
homozygosi
polymorph
produc
absenc
receptor
cell
surfac
heterozygosi
promot
low
express
receptor
henc
reduc
avail
receptor
capabl
interact
chemokin
induc
inflammatori
respons
previous
inform
reduc
risk
develop
asthma
rhiniti
adult
present
allel
variant
could
find
report
relationship
atop
dermat
ad
urticaria
urt
angioedema
ang
object
evalu
associ
polymorph
ad
urt
ang
adult
rosario
citi
materi
method
caucasian
subject
male
femal
age
year
old
x
answer
questionnair
ad
isaac
urt
ang
dna
extract
blood
sampl
polymorph
determin
pcr
oligonucleotid
sequenc
sens
antisens
result
subject
present
heterozygot
polymorph
homozygot
polymorph
risk
suffer
ae
urt
ang
significantli
lower
subject
present
polymorph
among
subject
refer
ad
symptom
least
life
one
present
heterozygosi
homozygosi
subject
refer
symptom
frequenc
genotyp
rr
p
g
among
subject
refer
urt
symptom
least
life
present
heterozygosi
homozygosi
subject
refer
symptom
frequenc
genotyp
rr
p
g
similar
result
obtain
subject
refer
ang
symptom
least
life
sinc
one
present
heterozygosi
homozygosi
polymorph
individu
refer
symptom
frequenc
mention
allel
rr
p
g
conclus
result
obtain
studi
allow
us
suggest
reduc
risk
develop
ad
urt
ang
could
influenc
presenc
allel
variant
background
contrast
advanc
knowledg
pathogenesi
atop
dermat
ad
establish
intern
diagnost
criteria
standard
remain
challeng
criteria
hanifin
rajka
though
extens
mention
research
set
reli
featur
signific
variat
due
age
ethnic
factor
may
unsuit
epidemiolog
studi
clearcut
casecontrol
definit
need
valid
uk
work
parti
criteria
report
popul
hospitalbas
studi
mostli
children
data
concern
adult
howev
limit
object
aim
test
valid
uk
work
parti
criteria
adult
patient
refer
univers
hospit
bulgaria
also
test
relev
six
clinic
sign
commonli
associ
ad
without
criteria
name
fine
hair
periorbit
periauricular
dermat
infraauricular
fissur
cheiliti
angulari
hertogh
sign
method
patient
age
year
recruit
studi
patient
examin
independ
senior
dermatologist
resid
blind
studi
aim
result
evalu
third
independ
blind
observ
use
conting
tabl
result
found
higher
sensit
specif
posit
neg
predict
valu
uk
work
parti
diagnost
criteria
one
hanifin
rajka
respect
famili
histori
atopi
erythroderma
signific
factor
fals
posit
result
addit
examin
featur
highest
sensit
specif
found
binfraauricular
fissur
respect
conclus
result
confirm
valid
uk
work
parti
criteria
adult
hospit
popul
bulgaria
although
case
may
repres
sever
diseas
end
spectrum
systemat
public
ad
featur
adulthood
studi
provid
valuabl
data
perform
diagnost
criteria
relev
individu
clinic
sign
age
group
atop
dermat
realli
atop
mariana
mandazhievapepelanova
nevena
berova
militari
medic
academi
depart
dermatolog
allergolog
sofia
bulgaria
background
littl
data
correl
atop
dermat
atop
diseas
asthma
rhiniti
atopi
marker
posit
skin
prick
test
specif
ige
dermatophagoid
pteronissinu
dpt
comorbid
atop
dermat
allerg
rhiniti
bronchial
asthma
presenc
atopi
marker
investig
well
correl
posit
atopi
marker
posit
patch
test
dpt
method
correl
patchtest
skin
prick
test
dpt
specif
ige
evalu
patient
men
atop
dermat
rhiniti
concomit
diseas
allerg
rhiniti
bronchial
asthma
test
specif
ige
skin
prick
test
patch
test
dpt
perform
result
patient
posit
patch
test
dpt
posit
specif
ige
antibodi
dpt
posit
skin
prick
test
dpt
conclus
case
posit
patch
test
prevail
compar
posit
skin
prick
test
specif
ige
posit
patch
test
alway
correl
atopi
evalu
posit
skin
prick
test
specif
ige
dpt
patch
test
could
use
routin
reliabl
method
practic
evalu
role
dpt
pathogenesi
atop
dermat
viktoriia
klymenko
kharkiv
state
medic
univers
depart
propedeut
pediatr
kharkiv
ukrain
background
immun
cell
play
main
role
develop
atop
dermat
ad
howev
far
limit
data
document
distribut
cell
skin
cutan
inflamm
object
gain
better
insight
number
phenotyp
immun
cell
lesion
skin
ad
patient
method
lesion
skin
biopsi
patient
differ
form
atop
dermat
exud
erytematosquamous
lichenoid
investig
carri
skin
biopsi
children
age
year
biopsi
made
needl
diamet
avidinbiotin
immunoperoxidas
stain
paraffinembed
skin
section
quantit
count
cell
label
antihladr
human
leukocyt
antigen
antiig
monoclon
antibodi
use
result
result
immunomorphologyc
analysi
show
great
infiltr
tlymphocyt
high
intraepiderm
express
ige
amount
main
immun
cell
per
cell
hladr
conclus
immunophenotyp
found
use
diagnost
method
ad
patient
data
help
elucid
pathogenesi
ad
undiagnos
alllerg
dermat
prospect
studi
vipul
shah
tripathi
allergi
clinic
allergi
surat
india
bombay
hospit
allergi
mumbai
india
introduct
undiagnos
case
dermat
refer
clinic
treat
number
dermatologist
citi
case
treat
differ
type
symptomat
drug
last
yr
yield
signific
result
label
difficult
dermat
materi
method
ten
patient
refer
clinic
subject
detail
medic
histori
clinic
examin
decid
perform
skin
prick
test
modifi
spt
determin
possibl
role
airborn
allergen
patient
show
posit
skin
prick
test
reaction
mani
allergen
asp
flavu
asptarmar
alt
alternaria
farina
dpter
hous
dust
hay
dust
parthenium
paltophorm
among
airborn
allergen
reaction
observ
significantli
posit
certain
food
allergen
also
milk
almond
yeast
hazel
nut
sinc
patient
show
strong
reactiv
certain
allergen
ige
mediat
hypersensit
attempt
made
administ
allergen
immunotherapi
cours
allergen
strongli
posit
show
airborn
domin
vicin
patient
select
allergen
immunotherapi
mixtur
allergen
immunotherapi
initi
subject
per
guidelin
laid
result
discuss
improv
observ
symptomat
relief
record
within
month
initi
allergen
immunotherapi
conclus
allergen
immunotherapi
could
play
major
role
treatment
airborn
contact
dermat
prognosi
allerg
contact
dermat
patient
patch
test
univers
hospit
beij
linfeng
li
peke
univers
third
hospit
dermatolog
beij
china
background
although
believ
prognosi
allerg
contact
dermat
acd
good
longterm
prognosi
acd
report
object
investig
outcom
acd
univers
dermatolog
set
patient
method
twoyear
period
consecut
patient
patch
test
peke
univers
third
hospit
suspect
acd
one
year
patch
test
patient
ask
revisit
prognosi
acd
evalu
rate
clearanc
complet
free
dermat
without
recurr
month
final
evalu
result
patient
finish
studi
case
acd
rate
clearanc
relaps
respect
concurr
atop
diathesi
ichthyosi
histori
drug
allergi
well
diseas
locat
effect
clearanc
rate
signific
lower
clearanc
rate
found
patient
longer
diseas
durat
month
diagnosi
clearanc
rate
patient
noncontinu
acd
also
lower
continu
acd
vs
chi
squar
test
ignor
reexposur
contact
allergen
mean
reason
relaps
conclus
outcom
acd
good
expect
longer
diseas
durat
diagnosi
noncontinu
acd
main
risk
factor
poor
prognosi
patient
suspect
acd
patch
test
earli
possibl
mandatori
ingredi
label
suffici
patient
educ
necessari
improv
prognosi
acd
fish
allergen
hide
prohapten
cinnam
aldehyd
cinnam
alcohol
identifi
potent
sensit
skin
major
target
organ
allerg
reaction
small
molecular
weight
compound
allerg
contact
dermat
allerg
drug
allergi
gener
accept
small
molecular
weight
compound
must
bound
high
molecular
weight
compound
order
becom
immunogen
bind
hapten
protein
hapten
must
highli
reactiv
chemic
intermedi
metabolit
cytochrom
cyp
depend
metabol
prohapten
recent
demonstr
use
organotyp
cyp
cocktail
identifi
prohapten
combin
cyp
cocktail
dendrit
cellbas
vitro
model
identifi
sensit
small
molecular
weight
compound
et
al
jid
mukhtar
et
al
jid
cinnam
alcohol
oxidis
cinnam
aldehyd
cypdepend
metabol
therefor
interest
whether
cinnam
aldehyd
nomin
antigen
allerg
reaction
cinnam
alcohol
gener
immatur
dc
human
peripher
blood
monocyt
deplet
posit
leukocyt
consecut
incub
gmcsf
least
million
cell
stimul
follow
test
compound
hour
respect
sulfon
acid
tnb
mgml
sodium
dodecyl
sulfat
sd
mgml
dimethyl
sulfoxid
dmso
cald
mm
calc
mm
rna
isol
treat
cell
revers
transcriptasepcr
analysi
perform
use
primerprob
set
specif
detect
mrna
express
sensit
effect
cald
could
shown
donor
indic
median
upregul
fold
normal
rel
mediumtr
control
contrast
median
enhanc
mrna
express
significantli
greater
incub
calc
stimul
sd
dmso
conclus
cinnam
aldehyd
possess
stronger
allergen
activ
cinnam
alcohol
cypdepend
metabolis
cinnam
aldehyd
result
support
concept
combin
prohapten
modifi
organotyp
cyp
cocktail
dendrit
cellbas
vitro
model
contact
allergen
may
streamlin
increas
predict
effici
current
safeti
test
method
allerg
contact
dermat
profil
patch
test
reaction
common
contact
allergen
relat
sex
jochen
brasch
axel
schnuch
wolfgang
uter
univers
clinic
schleswigholstein
campu
kiel
depart
dermatolog
kiel
germani
institut
univers
inform
network
depart
dermatolog
germani
univers
dept
med
informat
biometri
epidemiol
erlangen
germani
background
worldwid
observ
patient
expos
diagnost
patch
test
predominantli
women
commonli
explain
distinct
sexrel
pattern
allergen
exposur
caus
differ
pattern
sensit
men
women
higher
health
awar
women
nevertheless
addit
sexrel
differ
respons
contact
allergen
taken
consider
method
sexrel
reaction
profil
common
patch
test
allergen
use
standard
patch
test
seri
retrospect
analys
base
data
patient
file
inform
network
depart
dermatolog
germani
within
period
year
patch
test
done
use
ident
method
patient
suspect
contact
allergi
histori
atop
dermat
proport
weak
posit
reaction
question
irrit
reaction
evalu
calcul
posit
ratio
reaction
index
separ
men
women
allergen
result
allergen
evalu
slightli
higher
posit
ratio
slightli
higher
reaction
index
women
men
allergen
lower
posit
ratio
anoth
lower
reaction
index
women
men
allergen
lower
posit
ratio
plu
lower
reaction
index
women
men
particular
allergen
similar
rate
posit
reaction
men
women
femal
sex
significantli
relat
higher
posit
ratio
reaction
index
conclus
small
statist
signific
dispar
reactiv
men
women
common
patch
test
allergen
women
gener
higher
rate
weak
posit
reaction
less
question
irrit
reaction
allergen
men
margin
differ
probabl
relev
patch
test
add
new
element
pathogenet
puzzl
contact
allergi
reduc
allergi
rate
contact
allergenshapten
oral
cutan
exposur
atop
eczema
subject
atopi
hapten
hypothesi
background
whilst
allergi
food
protein
almost
exclus
seen
atop
impress
hold
true
hapten
contact
allergen
present
diet
diallyl
disulfid
major
hapten
allergen
garlic
allerg
contact
dermat
observ
peopl
handl
garlic
whilst
prepar
food
paraben
lanolin
contact
allergen
commonli
use
mani
cosmet
medica
cream
howev
unlik
lanolin
preserv
paraben
use
process
food
retrospect
review
data
patch
test
clinic
compar
frequenc
allergi
rate
patch
test
posit
pt
hapten
atop
eczemadermat
ad
nonad
dermat
patient
result
total
popul
patient
eczemadermat
patch
test
ad
contrast
patient
pt
diallyl
disulfidegarl
ad
adtot
popul
vs
addiallyl
disulfid
pt
p
paraben
pt
ad
whilst
lanolin
pt
ad
pg
discuss
frequenc
contact
allergi
hapten
oral
skin
exposur
reduc
ad
patient
compar
nonad
patient
direct
contrast
food
protein
allergi
decreas
observ
lanolin
use
skin
possibl
reason
result
could
confound
factor
eg
ad
patient
handl
garlic
less
nonad
patient
ad
patient
effici
toleris
hapten
way
secondari
atop
statu
oral
toler
hapten
may
way
antagonis
toler
protein
contribut
develop
atopi
hapten
hypothesi
note
increas
atopi
last
year
also
coincid
period
process
food
milk
chemicalhapten
content
use
western
diet
incid
preval
paraphenylenediamin
allergi
adult
thai
popul
public
health
problem
kirikkal
univers
hospit
patholog
kirikkal
turkey
hypersensit
sex
hormon
long
recogn
cyclic
recurr
rush
progesteron
sensit
term
autoimmun
progesteron
dermat
apd
shown
posit
skin
test
patient
femal
present
cyclic
skin
erupt
two
yearsdur
right
deliv
babi
begin
fix
singl
maculopapular
itchi
skin
lesion
cm
occur
two
day
prior
monthli
cycl
resolv
begin
men
howev
new
lesion
occur
finger
late
prior
exogen
hormon
use
menstruel
cycl
irregular
sinc
year
old
progesteron
level
found
high
pregnanc
wasnt
treat
possibl
apd
suspect
cyclic
natur
lesion
serum
level
sex
hormon
normal
well
gonadotrophin
prolactin
skin
biopsi
show
nonspesif
dermat
moder
perivascul
infiltr
lenfocyt
cell
upper
dermi
direct
immunofluoresc
studi
neg
challeng
test
aqueou
progesteron
perform
prick
patch
test
neg
wherea
intraderm
test
mgml
progesteron
posit
confirm
diagnosi
apd
despit
mani
local
report
wasnt
case
appear
finger
seen
caseexposur
exogen
progesteron
oral
contracept
oc
suggest
stimulu
product
autoantibodi
react
endogen
progesteron
apd
howev
case
oc
use
isnt
necessari
observ
patient
possibl
autoimmun
damag
progesteron
contain
ovarian
tissu
could
result
prematur
ovarian
failur
patient
evid
ovarian
disfunct
child
case
apd
diagnos
patient
typic
histori
recurr
lesion
luteal
phase
menstrual
cycl
confirm
intraderm
test
progesteron
endogen
progesteron
produc
ovulatori
cyclu
goal
therapi
suppress
ovul
combin
oc
ineffect
danazol
gonadotropin
releas
hormon
analog
tamoxifen
oophorectomi
may
tri
patient
didnt
accept
treatment
want
anoth
babi
analysi
discoidin
domain
express
tissueinfiltr
eosinophil
allerg
skin
diseas
yukari
nishimura
hiroyuki
murota
norihisa
kotobuki
shun
kitaba
mika
terao
ichiro
katayama
cours
integr
medicin
graduat
school
medicin
osaka
univers
dermatolog
oasaka
japan
background
discoidin
domain
receptor
receptor
tyrosin
kinas
activ
bind
ligandcollagen
compon
extracellular
matrix
ecm
organ
known
constitut
express
normal
tissu
lung
kidney
colon
brain
report
tissueinfiltr
eosinophil
express
interact
endogen
eosinophil
collagen
ecm
might
affect
eosinophil
surviv
tissu
microenviron
nfkb
activ
churgstrauss
syndrom
css
character
necrot
granulomat
angiti
massiv
eosinophil
infiltr
asthma
hypereosinophilia
patient
method
express
peripher
blood
eosinophil
asthma
patient
healthi
volunt
report
significantli
lower
css
patient
howev
littl
known
express
signific
tissu
infiltr
eosinophil
allerg
diseas
therefor
analys
express
tissueinfiltr
eosinophil
allerg
skin
diseas
atop
dermat
drug
erupt
kimura
diseas
eosinophil
infiltr
result
conclus
significantli
express
eosinophil
lesion
skin
css
atop
dermat
drug
erupt
kimura
diseas
current
result
indic
express
eosinophil
local
inflammatori
site
specif
css
could
diseas
marker
allerg
skin
diseas
eosinophil
infiltrationmechan
eosinophil
surviv
activ
might
differ
css
allerg
skin
diseas
atop
dermat
genegen
interact
receptor
associ
total
ige
korean
children
atop
dermat
object
evalu
serum
ige
level
correl
symptomatolog
plasma
chemokin
level
children
ad
method
ad
patient
younger
year
old
recruit
paediatr
dermatolog
clinic
univers
teach
hospit
ad
sever
evalu
score
atop
dermat
scorad
index
concentr
serum
total
ige
eosinophil
count
plasma
adassoci
chemokin
cutan
cell
attract
cytokin
ctack
thymu
activ
regul
chemokin
tarc
measur
result
one
hundr
seventeen
chines
children
ad
boy
girl
mean
sd
age
year
recruit
mean
sd
overal
scorad
defin
total
serum
ige
level
divid
agespecif
upper
limit
correl
well
extent
intens
ad
except
oozingcrust
signific
male
signific
correl
pruritu
sleep
loss
femal
patient
report
histori
allerg
rhiniti
report
histori
asthma
hyperact
airway
diseas
subgroup
patient
never
allerg
rhiniti
asthma
urticaria
n
logtransform
correl
well
object
scorad
spearman
rho
p
level
ige
ctack
tarc
eosinophil
count
differ
significantli
among
patient
mild
moder
sever
diseas
correl
well
tarc
r
p
g
eosinophil
count
r
p
g
ctack
r
p
predict
moderatetosever
eczema
gave
area
receiveroper
characterist
curv
ci
p
optimum
posit
predict
valu
achiev
cutoff
point
sensit
specif
conclus
correl
well
object
clinic
serum
tarc
level
may
serv
overal
marker
diseas
sever
furthermor
predict
moderatetosever
diseas
unlik
chemokin
serum
ige
measur
inexpens
readili
avail
clinic
servic
ige
laboratori
marker
atopi
also
paramet
diseas
sever
soy
intak
reduc
preval
skin
allerg
deseas
symptom
jorg
molina
ledit
ardusso
cecilia
torrent
paula
daneri
sara
molina
latinoamerican
center
univers
physiopatolog
rosario
argentina
centenari
hospit
allergi
depart
rosario
argentina
introduct
soy
one
food
contain
import
level
linol
acid
polyunsatur
fatti
acid
known
reduc
product
arachidon
acid
deriv
abl
reduc
chronic
inflammatori
respons
object
evalu
associ
dietari
soy
intak
presenc
skin
allerg
symptom
adult
materi
method
conduct
crosssect
studi
student
centro
educativo
latinoamericano
univers
rosario
randomli
chosen
femal
male
age
year
old
x
answer
questionnair
urticariaangioedema
contact
dermat
atop
dermat
frequenc
soyfood
intak
result
differ
found
food
intak
classifi
two
group
never
less
month
b
month
week
day
soybas
mayonnais
margarin
intak
subject
found
group
b
preval
skin
diseas
within
group
significantli
lower
group
exampl
atop
dermat
group
preval
angioedema
symptom
lower
rest
group
soyfood
ingest
significantli
higher
male
men
present
significantli
less
preval
symptom
studi
statist
signific
remain
adjust
sex
ingest
histaminereleas
food
differ
found
soy
intak
urticaria
symptom
conclus
result
obtain
allow
us
estim
intak
soy
rich
food
least
month
could
protect
skin
disord
hous
dust
mite
sensit
factor
chronic
urticaria
mojgan
safari
hamedan
univers
medic
scienc
pediatr
ward
hamedan
islam
republ
iran
introduct
chronic
urticaria
common
cutan
disord
seen
outpati
allergi
clinic
report
associ
hous
dust
mite
sensit
chronic
urticaria
studi
investig
possibl
associ
hous
dust
mite
sensit
chronic
urticaria
method
studi
four
group
patient
enrol
group
chronic
urticaria
subject
group
ii
allerg
rhiniti
subject
group
iii
asthmat
patient
subject
group
allerg
rhiniti
asthma
subject
group
ii
iii
iv
consid
posit
control
patient
underw
skin
prick
test
antigen
hous
dust
mite
dermatophagoid
pteronyssinu
dp
dermatophagoid
farina
df
posit
neg
control
result
group
group
ii
group
iii
group
iv
patient
skin
sensit
hous
dust
mite
statist
differ
preval
posit
skin
test
mite
four
group
conclus
suggest
possibl
associ
hous
dust
mite
sensit
chronic
urticaria
sensitis
colonis
statu
malassezia
patient
atop
dermat
frequenc
select
mrsastrain
composit
microbiocenosi
skin
patient
atop
dermat
yuriy
turin
dmitri
dolbin
sergey
kulikov
olga
tupkina
kazan
scientif
research
institut
epidemiolog
microbiolog
rospotrebnadzor
kazan
russian
feder
background
defin
share
alloc
mrsastrain
structur
microbiocenosi
skin
patient
atop
dermat
defin
properti
staphylococcu
skin
patient
method
patient
atop
dermat
examin
age
till
year
degre
graviti
patient
defin
use
intern
standard
index
scorad
score
atop
dermat
research
microbiocenosi
skin
carri
bacteriolog
method
strain
staphylococcu
skin
patient
investig
check
stabil
antibiot
method
disk
cup
petri
activ
catalas
lysat
staphylococcu
colorimetr
method
sinha
k
statist
analysi
result
execut
mean
statist
program
microsoft
excel
statistica
statsoft
result
part
skin
microbiocenosi
staphylococcu
aureu
coagulas
neg
staphylococcu
high
frequenc
occurr
mrsastrain
structur
microbiocenosi
skin
patient
reveal
high
frequenc
found
among
mrsa
repeatedli
steadi
pressur
antibiot
conclus
part
microbiocenosi
skin
patient
sick
atop
dermat
domin
mrsastrain
level
activ
pressur
mrsa
correl
catalas
abil
surviv
organ
poison
mrsa
also
often
alloc
patient
heavi
degre
scorad
phenotyp
featur
coccal
microflora
skin
norm
atop
dermat
sergey
kulikov
yuriy
turin
lira
bayazitova
dmitriy
dolbin
rustem
fassakhov
elena
sukmanskaya
kazan
scientif
research
institut
epidemiolog
microbiolog
rospotrebnadzor
kazan
russian
feder
background
phenotyp
featur
coccal
microflora
skin
diseas
sever
correl
children
atop
dermat
ad
method
forti
eight
ad
patient
age
year
recruit
score
atop
dermat
scoard
use
clinic
score
assess
ad
symptomatolog
skin
analyz
staphylococcu
aureu
coagulaseneg
staphylococci
detect
igproteas
collagenas
lysozym
dnaas
activ
staphylococc
isol
studi
methicillinresist
staphylococcu
aureu
isol
determin
disk
diffus
method
result
saureu
colon
increas
skin
ad
increas
scorad
scorad
scorad
staphylococc
isol
skin
moder
ad
scorad
isol
skin
sever
ad
scorad
dnaas
activ
also
igproteas
collagenas
activ
staphylococc
isol
skin
atop
dermat
higher
skin
norm
conclus
virul
factor
staphylococc
isol
correl
scoard
index
diseas
sever
staphylococc
isol
skin
ad
essenti
aggress
comparison
isol
healthi
skin
role
fecal
microflora
children
allerg
eczemadermat
syndrom
alla
nakonechna
tatiana
umanetz
nation
medic
univers
clinic
immunolog
allergolog
kiev
ukrain
institut
pediatri
obstetr
gynaecolog
pulmonolog
kiev
ukrain
rational
role
intestin
microflora
children
allerg
eczema
dermat
syndrom
a
still
disput
although
benefici
influenc
a
cours
certain
intestin
bacteria
administ
probiot
describ
intervent
studi
purpos
investig
relationship
gut
microbiota
sensit
cytokin
product
children
a
materi
method
casecontrol
studi
children
year
a
agematch
healthi
control
subject
conduct
differenti
diagnosi
use
skin
prick
test
spt
common
allergen
total
specif
ige
ifn
level
assess
elisa
patient
investig
gut
microflora
result
children
a
found
significantli
low
count
bifidobacterium
compar
healthi
control
subject
vs
cfug
well
lactobacillu
vs
cfug
time
atop
children
present
high
level
escherichia
coli
staphylococcu
aureu
clostridium
dificil
candida
albican
investig
microflora
profil
furthermor
a
children
demonstr
posit
spt
common
allergen
especi
food
allergen
increas
level
total
food
specif
ige
mostli
egg
milk
peanut
hazelnut
group
shown
increas
product
pkgml
n
pkgml
pkgml
n
pkgml
decreas
product
ifn
pkgml
n
pkgml
p
conclus
investig
demonstr
relationship
perturb
intestin
microbiota
ige
sensit
children
a
augment
type
lymphocyt
function
reflect
increas
product
a
children
disord
intestin
microflora
might
play
role
onset
atop
eczema
selfheal
blister
disord
skin
caus
small
insect
belong
genu
paederu
famili
staphylinida
order
coleoptera
appear
skin
hemolymph
paederu
beetl
studi
undertaken
identifi
domin
speci
paederu
beetl
report
expos
part
bodi
studi
area
method
peaderu
beetl
collect
hand
uv
black
ray
everi
month
entomolog
studi
medic
studi
questionnair
complet
physician
health
center
studi
area
result
investig
reveal
paederu
ilsa
bernhauer
paederu
iliensi
coiffait
two
speci
identifi
first
time
studi
area
research
reveal
case
linear
dermat
occur
face
neck
eye
hand
leg
respect
kazeron
area
furthermor
case
also
secondari
infect
later
conclus
public
awar
avoid
contact
adult
beetl
consid
best
way
reduc
case
linear
dermat
new
caus
facial
eczema
ferret
barthelemi
splingard
jean
pol
dumur
jeanluc
schmutz
annick
barbaud
nanci
barbaud
chu
nanci
dermatolog
nanci
franc
observ
year
old
patient
one
year
face
eczema
mainli
eyelid
lip
histori
allergi
medic
beautician
suspect
profession
sensit
eczema
persist
holiday
expos
numer
perfum
product
institut
six
year
mani
year
hors
pet
dog
cat
two
year
ferret
patchtest
standard
cosmet
product
methacryl
fragranc
seri
product
brought
patient
cream
perfum
household
profession
product
neg
hour
pricktest
aeroallergen
mold
latex
foodstuff
neg
specif
ige
ferret
undetect
normal
total
ige
ferret
given
one
friend
two
month
eczema
dramat
improv
short
new
contact
ferret
eczema
relaps
conclus
case
asthma
urticaria
caus
ferret
report
former
case
eczema
ferret
belong
fissip
famili
mink
marten
ermin
polecat
theoric
cross
reactiv
could
occur
case
yet
report
culprit
allergen
well
known
albumin
ferret
like
felid
lick
salivari
protein
could
allergen
protein
contact
dermat
emphas
sensit
ferret
new
pet
evok
case
eczema
asthma
even
specif
allergolog
test
neg
allerg
contact
dermat
due
propoli
alejandro
joral
jose
antonio
navarro
jose
francisco
garmendia
olga
villarr
aranzab
susana
lizarza
hospit
donostia
allergi
section
san
sebastian
spain
hospit
de
mendaro
allergi
unit
mendaro
spain
hospit
de
allergi
unit
spain
propoli
product
made
bee
variou
veget
sourc
mainli
resin
poplar
well
known
induc
occup
dermat
apicultor
use
natur
cosmet
widespread
given
antiinflammatori
antisept
properti
present
case
year
old
woman
without
atop
background
present
eczemat
itchi
rash
area
use
cosmet
propoli
among
ingredi
patch
test
perform
true
test
seri
cosmet
seri
propoli
test
posit
propoli
neg
contact
allergen
includ
balsam
peru
sensit
capac
propoli
mainli
attribut
methylbutenil
cafet
phenylethil
cafet
mainli
crossreact
balsam
peru
share
least
compon
therefor
present
allerg
contact
dermat
propoli
natur
cosmet
patient
apicultor
relationship
hobbi
advers
reaction
dark
chocol
case
report
christina
oberhub
sonja
gaier
eva
untersmayrelsenhub
karin
hoffmannsommergrub
biomay
vienna
austria
medic
univers
vienna
depart
pathophysiolog
vienna
austria
background
atop
dermat
ad
chronic
inflammatori
skin
disord
character
pruritu
inflamm
lichenif
typic
distribut
eczemat
lesion
environment
factor
well
allergen
variou
sourc
may
trigger
skin
inflamm
exact
caus
ad
unknown
immunolog
psycholog
factor
taken
account
report
case
old
femal
suffer
atop
dermat
histori
recurr
episod
pruritu
urticaria
facial
angioedema
start
hour
eat
dark
chocol
pralin
elimin
milk
chocol
dark
chocol
diet
episod
occur
white
chocol
well
toler
consum
frequent
method
skin
prick
test
commerci
extract
common
aeroallergen
food
allergen
perform
furthermor
prick
prick
test
use
white
chocol
milk
chocol
dark
chocol
cocoa
powder
cocoa
powder
cocoa
powder
carri
specif
ige
level
larg
panel
purifi
food
allergen
milk
egg
peanut
hazelnut
soy
peach
appl
celeri
chocol
extract
determin
elisa
experi
result
skin
prick
test
commerci
extract
neg
ige
level
variou
food
allergen
chocol
extract
increas
compar
non
atop
individu
wherea
level
test
allergen
chocol
extract
significantli
higher
control
sera
prick
prick
test
chocol
brand
reveal
erythema
increas
intens
accord
higher
content
cocoa
powder
white
chocol
without
cocoa
powder
elicit
skin
reaction
conclus
case
report
illustr
complex
diagnos
advers
reaction
food
ingest
dark
chocol
elicit
angioedema
ad
white
chocol
toler
even
absenc
allergenspecif
ige
allergenspecif
reactiv
high
level
observ
case
reportcontact
dermat
perfum
nicoleta
cimpean
cristina
barbinta
adriana
bujor
diana
dumitrascu
medcial
clinic
clujnapoca
allergolog
clujnapoca
romania
background
dermat
inflamm
skin
contact
dermat
local
rash
irrit
skin
caus
contact
foreign
substanc
substanc
caus
contact
dermat
mani
peopl
includ
poison
plant
poison
ivi
certain
food
metal
clean
solut
deterg
cosmet
perfum
industri
chemic
latex
rubber
allerg
contact
dermat
type
tcellmedi
hypersensit
case
report
femal
clinic
sign
persist
allerg
rhiniti
sneez
itch
rhinorrhea
present
sever
erupt
intens
itch
use
new
perfum
clinic
aspect
skin
lesion
erythema
papul
vesicl
neck
chest
augment
symptom
solar
exposur
manifest
begun
hour
exposur
new
perfum
result
skin
prick
test
reveal
atop
patient
sensit
alternaria
skin
patch
test
european
standard
cosmet
fragranc
fragranc
mix
balsam
peru
cosmet
preserv
paraben
mix
quaternium
cosmet
ingredi
colophoni
thiomerosol
ethylenediamin
formaldehyd
perfum
reveal
late
sensit
hour
perfum
fragranc
mix
recomand
avoid
contact
known
allergen
treatment
anihistamin
topic
steroid
conclus
patient
contact
dermat
may
uncomfort
poor
qualiti
life
best
treatment
identifi
avoid
substanc
may
caus
allerg
reaction
influenc
psidium
guajava
tea
atop
dermat
itsuo
suzuki
masaru
kisida
intern
univers
health
welfar
pediatr
tokyo
japan
previous
report
antihistamin
effect
antileukotrien
effect
psidium
guajava
pg
nativ
plant
north
america
thu
made
pg
tea
perview
effect
atop
dermat
method
seventyf
patient
atop
dermat
treat
sanno
hospit
enrol
studi
age
year
old
pg
tea
made
hot
water
drank
three
time
per
day
one
week
observ
without
treatment
use
pg
tea
four
week
skin
condit
measur
eosinophil
cation
protein
ecp
valu
histamin
level
blood
result
fortytwo
improv
itch
skin
thirti
improv
skin
condit
ecp
valu
serum
decreas
histamin
level
serum
decreas
conclus
investig
effect
pg
tea
atop
dermat
studi
show
abl
improv
clinic
featur
diseas
significantli
furthermor
ecp
valu
histamin
level
serum
index
allerg
inflamm
decreas
conclud
result
pg
tea
effect
method
treatment
atop
dermat
role
contact
sensit
contact
dermat
patient
among
seawe
farmer
bantaeng
south
sulawesi
indonesia
atop
dermat
remain
one
seriou
problem
pediatr
preval
diseas
among
children
quit
high
accord
data
differ
countri
increas
tendenc
aim
studi
assess
effect
probiot
clinic
cours
atop
dermat
children
studi
patient
age
year
admit
guramishvili
pediatr
clinic
patient
fulfil
criteria
least
major
minor
diagnosi
atop
dermat
hannifin
rajka
children
divid
group
first
group
children
week
receiv
probiot
lactobacterin
contain
lactobacillu
acidophilu
bifidumbacterin
contain
bifidumbacterin
emolli
ointment
second
group
children
emolli
ointment
scorad
index
use
evalu
sever
extent
ad
end
studi
diseas
object
sign
spread
lesion
intens
erythema
edema
ooz
excori
lichenif
xerosi
subject
sign
pruritu
sleep
disord
assess
mean
scorad
index
treatment
week
well
week
treatment
found
improv
clinic
scorad
index
decreas
group
time
reduct
scorad
index
signific
probiot
group
week
studi
children
better
scorad
index
baselin
compar
second
group
improv
conclud
supplement
probiot
benefici
improv
sever
ad
children
influenc
peel
procedur
allerg
contact
dermati
jun
young
lee
jung
eun
kim
st
mari
hospit
cathol
univers
korea
dermatolog
seoul
republ
korea
background
preval
allerg
contact
dermat
acd
patient
previous
undergon
peel
rare
studi
object
compar
frequenc
posit
patch
test
pt
reaction
patient
group
histori
peel
control
group
histori
peel
patient
method
korean
standard
seri
cosmet
seri
perform
total
patient
sixtytwo
patient
previous
undergon
peel
patient
result
frequenc
posit
pt
reaction
korean
standard
seri
significantli
higher
peel
group
compar
control
group
p
chisquar
test
howev
commonli
identifi
allergen
mostli
cosmeticunrel
allergen
frequenc
posit
pt
reaction
cosmet
seri
peel
group
higher
control
group
lack
statist
signific
relationship
frequenc
peel
frequenc
posit
pt
reaction
total
number
posit
pt
result
conclus
appear
peel
may
gener
affect
develop
contact
sensit
work
requir
focus
larg
scale
prospect
studi
perform
pt
peel
therapeut
efficaci
safeti
profil
allergen
extract
ea
treat
patient
labial
lichen
planu
ishaq
khan
sameera
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
introduct
lichen
planu
uncommon
skin
complaint
thought
due
abnorm
immun
reaction
provok
viral
infect
hepat
c
drug
inflammatori
cell
seem
mistak
skin
cell
foreign
attack
case
clear
skin
surfac
within
month
affect
mouth
may
persist
longer
method
classic
lichen
planu
character
shini
flattop
firm
papul
vari
pin
point
size
eggutt
larger
centimet
lesion
shinni
flattop
firm
papul
vari
pinpoint
much
larger
size
lesion
studi
concern
individu
includ
medic
differ
empir
therapi
remit
relaps
cours
patient
treat
combin
regimen
anti
histamin
gradual
lower
dilut
dust
mite
therapeut
extract
period
month
remiss
lesion
evid
form
reduct
intens
itchi
ooz
red
final
outcom
evid
form
scar
format
result
ongo
trial
therapeut
respons
dramat
femal
male
patient
conclus
lichen
planu
chronic
intract
condit
multipl
caus
time
diagnost
dilemma
detail
drugsdietari
histori
supplement
immunolog
assess
provid
diagnost
clue
prick
test
profil
treatment
present
tacrolimu
ointment
effect
well
toler
treatment
atop
dermat
asian
countri
changi
gener
hospit
dermatolog
singapor
singapor
astella
pharma
inc
depart
asia
intern
tokyo
japan
background
tacrolimu
ointment
use
treatment
atop
dermat
ad
adult
pediatr
patient
worldwid
howev
studi
report
efficaci
safeti
larg
popul
asian
patient
ad
aim
overview
survey
assess
efficaci
safeti
conduct
patient
across
asian
area
china
indonesia
korea
malaysia
philippin
singapor
taiwan
thailand
method
analyz
combin
data
patient
ad
studi
conduct
asian
area
adult
pediatr
patient
moder
sever
ad
enrol
adult
patient
appli
tacrolimu
ointment
pediatr
patient
appli
twice
daili
week
primari
efficaci
end
point
physician
global
evalu
clinic
respons
pge
evalu
includ
eczema
area
sever
index
easi
percent
bodi
surfac
area
affect
bsa
patient
assess
itch
patient
assess
overal
respons
categori
dermatolog
life
qualiti
index
dlqi
children
dlqi
cdlqi
result
patient
includ
asian
studi
success
base
pge
observ
patient
improv
patient
assess
overal
respons
similar
pge
percent
bsa
affect
easi
patient
assess
itch
improv
week
end
treatment
decreas
patient
assess
itch
greatest
compar
decreas
bsa
affect
easi
dlqi
subscal
symptom
feel
daili
activ
leisur
work
school
person
relationship
treatment
improv
also
subscal
cdlqi
symptom
feel
leisur
school
holiday
person
relationship
sleep
treatment
improv
end
treatment
particular
symptom
feel
show
mark
decreas
age
group
subscal
cdlqi
sleep
also
mark
improv
improv
pge
associ
decreas
bsa
easi
patient
assess
itch
also
dlqicdlqi
advers
event
frequent
report
skin
burn
pruritu
applic
site
incid
skin
burn
lower
pediatr
patient
adult
seriou
advers
event
report
studi
conclus
tacrolimu
ointment
effect
well
toler
treatment
patient
ad
asian
countri
downmodulatori
effect
epinastin
chemokin
product
epiderm
langerhan
cell
kazunari
sugita
miwa
kobayashi
tomoko
mori
kenji
kabashima
yoshiki
tokura
univers
occup
environment
health
depart
dermatolog
kitakyushu
japan
background
epinastin
belong
second
gener
antihistamin
also
possess
antiinflammatori
antiallerg
properti
cutan
well
system
allergi
includ
mast
cell
stabil
suppress
costimulatori
molecul
express
inhibit
eosinophil
chemotaxi
granulocyt
accumul
suppress
cytokin
chemokin
product
japan
system
prepar
epinastin
approv
atop
dermat
also
prurit
psoriasi
vulgari
skin
wellorchestr
immun
organ
epiderm
langerhan
cell
lc
function
antigenpres
cell
keratinocyt
serv
produc
variou
cytokin
chemokin
previous
report
epinastin
suppress
product
chemokin
keratinocyt
sinc
keratinocyt
lc
main
epiderm
sourc
chemokin
respect
effect
epinastin
chemokin
product
lc
issu
clarifi
method
prepar
epiderm
cell
suspens
balbc
mice
enrich
lc
lcenrich
epiderm
cell
cultur
epinastin
h
express
level
chemokin
tarc
assess
realtim
pcr
analysi
result
express
depress
epnastin
low
express
also
inhibit
epinastin
dosedepend
manner
conclus
studi
suggest
epinastin
exert
antihistamin
action
also
downmodulatori
effect
cell
migrat
toward
epidermi
inhibit
lc
product
chemokin
taken
togeth
previou
find
epinastin
downregul
chemokin
product
keratinocyt
conclud
antihistam
drug
inhibitori
potenti
migrat
cell
skin
studi
efficaci
epinastin
hydrochlorid
patient
prurit
dermatosi
chronic
urticaria
effect
qol
patient
akiko
miyata
mika
yamamoto
yoshiaki
hayashi
mariko
nanbu
noboru
nakagawa
tatsuya
tsuda
shoichiro
minami
kiyofumi
yamanishi
hyogo
colleg
medicin
dermatolog
nishinomiya
japan
epinastin
hydrochlorid
ales
nippon
boehring
ingelheim
co
ltd
mg
daili
administ
patient
age
year
older
prurit
dermatosi
chronic
urticaria
week
efficaci
effect
patient
qol
assess
studi
enrol
patient
total
patient
eczemadermat
patient
cutan
pruritu
patient
urticaria
patient
prurit
dermatosi
mean
age
endpoint
sever
pruritu
sever
skin
erupt
visual
analog
scale
va
pruritu
qol
patient
symptom
emot
statu
daili
live
leisur
workschool
treatment
concern
gener
improv
remark
moder
improv
achiev
patient
respect
sever
pruritu
indic
va
significantli
decreas
qol
patient
also
improv
possibl
advers
drug
reaction
increas
ast
observ
patient
result
show
oral
epinastin
hydrochlorid
daili
appear
safe
benefici
symptom
qol
patient
prurit
dermatosi
chronic
urticaria
randomis
doubleblind
placebocontrol
studi
efficaci
toler
chines
herbal
medicin
concoct
atop
dermat
background
consider
interest
tradit
chines
herbal
medicin
tchm
treatment
atop
dermat
ad
twicedaili
concoct
ancestr
formula
contain
five
herb
found
benefici
open
studi
five
herb
includ
flo
lonicera
jinyinhua
herba
mentha
bohe
cortex
moutan
danpi
rhizoma
atractylodi
cangzhu
cortex
phellodendri
huangbai
demonstr
corticosteroid
cs
cs
relat
compound
formul
object
assess
efficaci
toler
concoct
children
ad
method
follow
runin
period
children
longstand
moderatetosever
ad
randomis
receiv
treatment
twice
daili
dose
three
capsul
either
tchm
placebo
score
atop
dermat
scorad
score
children
dermatolog
life
qualiti
index
cdlqi
allerg
rhiniti
score
requir
topic
corticosteroid
oral
antihistamin
assess
week
treatment
advers
event
toler
haematolog
biochem
paramet
monitor
studi
result
eightyf
children
ad
recruit
week
mean
scorad
fell
tchm
group
n
p
placebo
group
n
p
howev
signific
differ
score
correspond
time
point
two
group
cdlqi
tchm
treat
patient
significantli
improv
compar
patient
receiv
placebo
end
treatment
week
stop
therapi
p
respect
total
amount
topic
corticosteroid
use
also
significantli
reduc
onethird
tchm
group
seriou
advers
effect
observ
group
analysi
biochem
data
also
reveal
signific
chang
ige
level
haematolog
complet
blood
count
eosinophil
count
biochem
electrolyt
renal
liver
function
paramet
monitor
patient
complain
capsul
unpalat
conclus
tchm
concoct
efficaci
improv
qualiti
life
reduc
topic
corticosteroid
usag
children
moderatetosever
ad
formul
palat
well
toler
probabl
use
adjunct
treatment
children
refractori
ad
histamin
blocker
inhibit
histamineinduc
collagen
synthesi
dermal
fibroblast
shun
kitaba
hiroyuki
murota
ichiro
katayama
cours
integr
medicin
graduat
school
medicin
osaka
univers
dermatolog
osaka
japan
background
mast
cellderiv
histamin
known
act
dermal
fibroblast
contribut
format
intract
chronic
allerg
dermat
although
fibrot
event
may
also
occur
organ
nasal
mucosa
direct
evid
report
whether
respons
histamin
fibroblast
deriv
differ
organ
intens
furthermor
histamin
blocker
prove
effect
allevi
symptom
allerg
diseas
abil
affect
histamineinduc
tissu
remodel
yet
clarifi
object
aim
studi
effect
histamineinduc
tissu
remodel
method
macro
array
assay
use
comprehens
analysi
histamineinduc
gene
express
normal
human
fibroblast
fibroblast
deriv
skin
nasal
mucosa
cultur
presenc
variou
concentr
histamin
synthesi
type
collagen
measur
mean
semiquantit
rtpcr
elisa
assay
determin
effect
blocker
diphenhydramin
hydrochlorid
emedastin
difumar
investig
assay
result
histamin
induc
variou
kind
fibrogen
molecul
fibroblast
increas
type
collagen
express
observ
fibroblast
treat
highdos
logm
lowdos
histamin
histamineinduc
type
collagen
synthesi
effect
diminish
emedastin
difumar
conclus
found
express
fibroblastderiv
gene
regul
differ
differ
concentr
histamin
robust
inhibitori
action
blocker
differ
skinderiv
nasal
mucosaderiv
fibroblast
believ
find
may
contribut
better
understand
mechan
histamineinduc
tissu
remodel
provid
inform
use
manag
refractori
allerg
dermat
attenu
effect
fexofenadin
hydrochlorid
develop
cutan
inflammatori
respons
inhibit
substanc
p
product
mice
kazuhito
asano
kenichi
kanai
atsuko
furuta
harumi
suzaki
showa
univers
school
nr
divis
physiolog
yokohama
japan
showa
univers
school
medicin
depart
otolaryngolog
hatanodai
shinagawaku
tokyo
japan
background
purpos
fexofenadin
hydrochlorid
fex
secondgener
antihistamin
use
treatment
allerg
diseas
inflammatori
skin
reaction
success
result
report
primarili
therapeut
mode
action
fex
gener
believ
owe
suppress
effect
effector
cell
activ
respons
develop
allerg
inflamm
recent
neuropeptid
substanc
p
sp
attract
attent
essenti
factor
trigger
exacerb
modul
allerg
skin
reaction
howev
influenc
fex
neuropeptideinduc
inflammatori
skin
reaction
fulli
understood
method
ncnga
mice
age
femal
receiv
repeat
local
applic
tncb
provok
chronic
cutan
inflamm
fex
singl
dose
mgkg
oral
administ
mice
day
week
either
day
week
applic
tncb
number
scratch
min
count
min
final
fex
administr
count
number
scratch
sp
content
skin
tissu
serum
ige
level
examin
elisa
result
repeat
local
applic
tncb
induc
itch
skin
lesion
togeth
increas
level
sp
ige
treatment
mice
fex
caus
signific
decreas
level
sp
ige
scratch
behavior
also
decreas
significantli
treatment
mice
fex
number
scratch
nontreat
mice
fextreat
mice
conclus
result
may
suggest
fex
inhibit
scratch
behavior
observ
chronic
cutan
inflamm
suppress
sp
product
skin
lesion
efficaci
safeti
levocetirizin
vs
cetirizin
patient
dermat
eczema
pruritu
multicent
doubleblind
doubledummi
radom
activecontrol
studi
background
levocetirizin
late
develop
select
antagonist
purpos
studi
assess
efficaci
safeti
levocetirizin
mg
compar
cetirizin
mg
patient
suffer
dermat
eczema
pruritu
moderatesever
method
studi
conduct
random
center
parallel
doubleblind
doubledummi
screen
day
subject
randomli
assign
either
levocetirizin
cetirizin
treatment
group
administ
week
topic
hydrocortison
patient
visit
screen
visit
random
visit
day
random
visit
day
visit
pruritu
sever
score
assess
patient
use
score
scale
none
mild
moder
sever
respond
defin
patient
report
post
treatment
score
rate
none
mild
visit
studi
complet
visit
result
patient
screen
patient
random
patient
complet
studi
patient
adequ
efficaci
evalu
proport
respond
levocetirizin
treat
group
cetirizin
treat
group
three
patient
levocetirizin
treat
group
six
patient
cetirizin
treat
group
drug
relat
advers
event
unexpect
advers
drug
reaction
report
group
conclus
levocetirizin
noninferior
cetirizin
improv
pruritu
patient
dermat
eczema
pruritu
levocetirizin
safe
effici
treatment
patient
dermat
eczema
pruritu
background
aim
studi
investig
sensit
hous
dust
mite
hdm
aureu
atop
dermat
patient
recurr
pyoderma
ad
rp
patient
investig
efficaci
safeti
specif
immunotherapi
staphylococc
hdm
allergovaccin
patient
materi
method
group
patient
consist
ad
rp
patient
intraderm
test
staphylococc
allergen
prick
test
der
pteronissinu
der
farina
allergen
carri
ad
rp
patient
skin
test
carri
ad
rp
patient
remiss
period
specif
ige
level
staphylococc
enterotoxin
b
well
der
pteronissinu
der
farina
sera
ad
rp
patient
measur
unicap
system
phadia
ad
rp
patient
posit
skin
test
posit
specif
ige
hdm
staphylococc
enterotoxin
b
receiv
specif
immunotherapi
sit
staphylococc
hdm
allergovaccin
subcutan
inject
allergen
vaccin
made
daili
increas
dose
durat
main
cours
specif
immunotherapi
day
one
mainten
dosag
everi
week
observ
period
last
month
result
observ
sensit
hdm
ad
rp
patient
aureu
patient
hdm
aureu
patient
posit
effect
sit
hdm
staphylococc
vaccin
month
observ
period
index
scorad
decreas
accordingli
exacerb
rp
patient
topic
corticosteroid
antibiot
decreas
significantli
index
respiratori
symptom
decreas
significantli
treatment
mild
local
reaction
red
edema
flare
observ
patient
exacerb
ad
rp
patient
observ
inspit
advers
event
none
patient
exclud
studi
level
specif
sera
hdm
saureu
increas
significantli
level
specif
ige
sera
hdm
saureu
chang
conclus
accord
data
hdm
aureu
common
offend
allergen
ad
rp
patient
thu
sit
applic
patient
need
sit
ad
rp
patient
hdm
staphylococc
vaccin
effect
safe
topic
applic
improv
prolong
atop
dermat
suppress
macrophag
migrat
inhibitori
factor
background
grow
evid
egcg
exert
antiinflammatori
effect
chronic
inflammatori
skin
condit
atop
dermat
ad
macrophag
migrat
inhibitori
factor
mif
recent
suggest
one
crucial
immunoregulatori
cytokin
imbal
ad
studi
assess
antiinflammatori
effect
egcg
topic
applic
ad
skin
lesion
ncnga
mous
model
determin
whether
effect
egcg
mediat
immunoregulatori
cytokin
includ
mif
method
induct
ad
skin
lesion
made
paint
dermatophagoid
pteronissinu
extract
dpe
onto
surfac
ear
ncnga
mice
one
group
treat
egcg
solut
anoth
group
vehicl
group
shamtreat
week
compar
clinic
sign
group
measur
ear
thick
everi
week
last
day
ear
excis
prepar
follow
procedur
hematoxylin
eosin
stain
immunohistochemistri
mif
tnf
ifn
quantit
revers
transcript
polymeras
chain
reaction
mif
tnf
ifn
blood
sampl
also
perform
enzymelink
immunosorb
assay
mif
total
ige
serum
result
compar
vehicl
treatment
topic
applic
egcg
significantli
reduc
ear
thick
likewis
histolog
grade
chronic
inflamm
includ
epiderm
hyperplasia
mononuclear
cell
infiltr
dermi
also
significantli
decreas
skin
lesion
egcg
group
immunohistochem
stain
comparison
vehicl
treatment
egcg
treatment
significantli
diminish
express
tnf
ifn
well
mif
lesion
p
g
similarli
mrna
express
mif
tnf
ifn
lesion
significantli
downregul
egcg
treatment
p
g
serum
mif
total
ige
product
also
significantli
reduc
egcg
treatment
p
g
conclus
result
demonstr
topic
applic
egcg
could
reduc
chronic
inflamm
ad
lesion
suppress
seri
immunoregulatori
cytokin
includ
mif
taken
togeth
suggest
topic
applic
egcg
potenti
therapeut
modal
ad
antiig
treatment
patient
hyperig
syndrom
hepat
c
viru
infect
n
paravisini
r
avil
aldegu
e
fernandezcruz
hospit
gener
universitario
gregorio
immunolog
madrid
spain
background
hyperig
syndrom
hie
primari
immunodefici
character
recurr
infect
dermat
elev
serum
ige
underli
caus
hie
unknown
manag
patient
difficult
gener
goal
control
pruritu
eczema
prevent
infect
report
patient
typic
featur
hie
hepat
c
viru
hcv
infect
antiig
monoclon
therapi
allerg
manifest
could
effect
therapeut
altern
method
woman
nonconsanguin
parentag
present
moder
asthma
sever
atop
dermat
sinc
earli
infanc
histori
recurr
respiratori
infect
delay
shed
primari
teeth
slight
facial
dysmorphia
persist
elev
serum
ige
level
kul
suffer
relaps
multipl
discret
confluent
erythemat
scali
papul
plaqu
follicular
promin
face
trunk
limb
lichenif
warm
hypersensit
skin
limit
activ
daili
live
diagnos
hcv
infect
later
develop
unusu
autoimmun
associ
haemolit
anaemia
alopecia
universali
autoinmun
hypothyroid
rash
treat
antihistamin
drug
topic
steroid
poor
respons
given
high
level
serum
ige
given
omalizumab
therapi
high
dose
mg
sc
everi
day
schedul
monitor
ige
level
hemogram
biochem
analys
result
patient
improv
current
symptom
asthma
sinc
first
dose
omalizumab
two
month
eczema
sever
decreas
mild
form
patient
clear
almost
skin
lesion
although
light
lichenif
area
persist
flexur
improv
xerosi
lower
itch
suffer
relaps
serum
ige
level
persist
elev
chang
biochem
analys
present
side
effect
conclus
therapi
antiig
monoclon
antibodi
found
welltoler
effect
although
current
knowledg
therapeut
option
hie
limit
variabl
success
antiig
monoclon
therapi
allerg
manifest
seem
effect
safe
therapeut
altern
even
steroid
spare
agent
consid
hcv
infect
efficaci
omalizumab
treatment
patient
sever
refractori
atop
dermat
paravisini
r
suarez
j
gil
e
fernandezcruz
hospit
gener
universitario
gregorio
immunolog
madrid
spain
hospit
gener
universitario
gregorio
dermatolog
madrid
spain
background
atop
dermat
chronic
cutan
inflammatori
diseas
mediat
type
hypersensit
reaction
high
ige
serum
level
commonli
found
correl
sever
ad
treatment
moderatesever
case
includ
phototherapi
cyclosporin
azathioprin
mycophenol
mofetil
intraven
immunoglobulin
variabl
result
omalizumab
human
monoclon
antibodi
bind
free
serum
ige
decreas
level
high
affin
receptor
success
use
allergi
asthma
rhiniti
allerg
reaction
certain
food
drug
latex
insect
bite
experi
treatment
ad
limit
controversi
report
preliminari
result
ad
patient
receiv
antiig
treatment
method
adult
patient
age
sever
refractori
ad
high
ige
treat
omalizumab
xolair
subcutan
everi
week
patient
month
one
patient
third
month
treatment
patient
allerg
rhiniti
one
current
symptom
asthma
one
histori
asthma
previous
treat
topic
system
steroid
topic
calcineurin
inhibitor
cyclosporin
partial
control
symptom
patient
inform
offlabel
use
side
effect
profil
result
patient
experienc
improv
treatment
two
month
eczema
sever
decreas
sever
moderatemild
form
two
patient
stop
medic
either
antihistamin
drug
one
continu
take
cyclosporin
one
patient
obtain
partial
respons
clear
lesion
lower
itch
abl
restart
sport
patient
suffer
autolimit
relaps
requir
therapi
final
reach
complet
clearanc
last
one
improv
skin
lesion
asthma
symptom
later
patient
diminish
dose
cyclosporin
mgday
biochem
analys
remain
normal
none
suffer
advers
reaction
conclus
omalizumab
systemat
diminish
serum
ige
level
achiev
significantli
clinic
improv
even
monotherapi
month
hand
omalizumab
show
safe
profil
might
promis
treatment
patient
system
therapi
success
atop
dermat
ad
chronic
inflammatori
skin
diseas
whose
pathophysiolog
product
complex
interact
suscept
gene
host
environ
infecti
agent
defect
skin
barrier
immunolog
respons
basic
treatment
ad
consist
topic
emolli
topic
system
cs
immunosuppress
drug
antihistamin
phototherapi
adjunct
hdivig
resist
ad
may
offer
use
approach
suggest
small
number
uncontrol
trial
case
report
via
number
immunomodulatori
effect
patient
ad
colon
aureu
experi
exacerb
infect
organ
case
treatment
antibiot
result
reduct
skin
diseas
signal
case
man
affect
pollensmitesallerg
rhiniti
adolesc
suffer
sever
ad
year
typic
sign
lesion
chronic
lichenifi
plaqu
fissur
face
neck
upper
arm
back
palm
dorsa
hand
attent
typic
phenomena
microbi
colon
evid
subject
confirm
high
sensit
mite
grass
total
ige
sum
kul
neg
celiac
diseas
food
allergi
normal
common
haematobiochem
paramet
cultur
microbiolog
lesion
demonstr
aureu
sensibl
common
antibiot
first
line
treatment
result
efficaci
short
cours
oral
antibiot
cs
associ
topic
antibiot
obtain
decreas
flare
week
relaps
occur
frequent
justifi
respond
diseas
common
treatment
analysi
demonstr
total
gammaglobulin
reduct
relat
select
decreas
igg
class
mgdl
normal
lymphocyt
fenotip
prolif
respons
common
antigen
mild
deficit
granulocyt
chemotaxi
diagnosi
common
variabl
immunodefici
formul
hdivig
instaur
first
administr
mgkg
sever
lesion
ad
significantli
improv
evid
resolut
infect
first
line
treatment
alon
result
effici
control
diseas
follow
month
subject
affect
sever
respond
convent
therapi
ad
especi
evid
infect
may
reason
investig
possibl
immunodefici
case
hdivig
treatment
may
use
support
immunomodulatori
effect
neutral
cutan
pathogen
influenc
laser
therapi
function
activ
nuetrophil
carri
nbttest
found
patient
atop
dermat
origin
state
number
spontan
activ
neutrophil
consider
higher
healthi
peopl
studi
neutrophil
activ
index
reflect
reactiv
extrins
stimul
found
studi
group
gener
drop
index
time
larger
compar
norm
along
patient
atop
dermat
also
regist
consider
decreas
phagocyt
activ
nuetrophil
amount
compar
norm
examin
patient
divid
group
compar
criteria
group
patient
treat
laser
tradit
therapi
control
group
patient
treat
tradit
drug
therapi
posit
dynam
studi
paramet
regist
applic
differ
treatment
method
howev
highest
influenc
laser
therapi
thu
main
group
content
neutrophil
leucocyt
recov
normal
quantiti
dynam
mention
paramet
averag
higher
control
group
henc
newli
develop
combin
method
treat
atop
dermat
proven
desensit
antiallerg
effect
indic
recoveri
function
activ
neutrophil
background
chronic
cours
highli
disfigur
skin
lesion
atop
dermat
ad
substanti
impact
qualiti
life
qol
moreov
previou
studi
assess
financi
cost
ad
shown
repres
notabl
econom
burden
howev
littl
known
qol
econom
burden
korean
patient
ad
method
questionnair
specif
design
clinic
experi
use
determin
ad
affect
live
patient
andor
parent
parent
complet
selfadministr
questionnair
includ
question
multidimension
aspect
qol
also
survey
find
much
money
spent
treatment
ad
last
month
qol
score
linearli
transform
scale
indic
worst
qol
favor
addit
patient
diseas
sever
evalu
use
scorad
index
result
qol
data
reveal
ad
significantli
neg
effect
qol
aspect
life
includ
daili
live
activ
psycholog
statu
social
function
averag
total
qol
score
qol
score
significantli
increas
proport
increas
sever
ad
regard
daili
live
activ
major
stresscaus
factor
restrict
cosmet
use
choic
food
cloth
well
concern
exposur
skin
psycholog
statu
patient
report
feel
deepli
nervou
likelihood
offspr
ad
futur
regard
social
function
told
ad
patient
difficulti
make
relationship
someon
less
interest
opposit
sex
ad
parent
also
high
level
stress
associ
modifi
lifestyl
keep
children
scratch
estim
cost
relat
ad
posit
correl
sever
ad
wide
rang
per
patient
month
import
averag
direct
medic
cost
correspond
total
indirect
cost
repres
total
averag
cost
conclus
result
suggest
ad
signific
impact
variou
compon
qol
well
econom
burden
korean
patient
parent
background
extens
evid
accumul
role
nerv
growth
factor
ngf
allerg
diseas
although
physic
exercis
associ
anim
model
increas
ngf
express
data
avail
effect
ngf
human
aim
studi
ngf
serum
level
top
athlet
popul
sampl
allerg
diseas
neuroimmun
disord
amyotroph
later
sclerosi
al
yare
report
signific
increas
preval
method
male
soccer
player
mean
age
five
first
divis
team
studi
allerg
diseas
trough
origin
specif
questionnair
histori
physic
examin
skin
prick
test
andor
phadiatop
sera
taken
athlet
differ
time
period
store
ngf
determin
trough
doubleantibodi
elisa
data
pilot
sampl
athlet
nonallerg
sedentari
match
control
present
result
preval
allergi
soccer
player
spite
high
intraand
interindividu
variabl
valu
possibl
due
differ
train
load
soccer
season
mean
ngf
serum
level
significantli
higher
soccer
player
control
ngml
j
ngml
vs
ngml
j
ngml
p
ngf
serum
level
athlet
increas
independ
presenc
allergi
conclus
studi
confirm
high
preval
allerg
diseas
athlet
increas
ngf
serum
level
allerg
soccer
player
consist
role
neurotrophin
allerg
inflamm
first
report
increas
serum
level
ngf
relat
intens
physic
activ
human
special
featur
allergi
test
elit
sportsmen
nataliya
shartanova
institut
immunolog
asthma
moscow
russian
feder
sport
inevit
part
modern
societi
howev
today
precis
convinc
data
preval
featur
current
allerg
diseas
elit
russian
sportsmen
absent
purpos
present
research
studi
preval
featur
allergen
spectrum
structur
allerg
diseas
elit
sportsmen
skin
pricktest
differ
group
allergen
estim
total
ige
end
iga
igm
igg
blood
serum
challeng
bronchial
test
physic
exercis
use
modern
clinic
laboratori
allerg
research
method
includ
gather
allerg
pharmacolog
food
anamnesi
screen
elit
sportsmen
carri
fenc
sport
art
gymnast
dzudo
softbal
water
polo
volleybal
figur
skate
hockey
grass
row
cano
freestyl
biathlon
youth
soccer
team
footbal
analysi
carri
research
shown
follow
sportsmen
clinic
attribut
allerg
diseas
allerg
dermat
allerg
urticaria
allerg
rhiniti
pollenallerg
rhiniti
bronchial
asthma
drug
allergi
food
allergi
increas
total
ige
level
blood
serum
reveal
sportsmen
allerg
diseas
meml
immun
statu
analysi
demonstr
decreas
igg
iga
level
increas
igm
level
elit
sportsmen
without
connect
atopi
sportsmen
allergi
diagnos
first
time
obtain
data
testifi
widespread
allerg
diseas
among
elit
sportsmen
allerg
diseas
hypodiagnost
hypodiagnost
allerg
diseas
result
late
prescript
adequ
therapi
restrict
sport
achiev
chang
immun
statu
index
requir
investig
antiprolif
anti
remodel
effect
beclomethason
dipropion
formoterol
salbutamol
alon
combin
primari
human
bronchial
fibroblast
desideria
descalzi
chiara
folli
gabriel
nicolini
anna
maria
riccio
cinzia
gamalero
francesca
scordamaglia
giorgio
walter
canonica
background
bronchial
asthma
character
lower
airway
inflamm
remodel
antiinflammatori
treatment
inhal
corticosteroid
provid
mainstay
asthma
therapi
togeth
bronchodil
induc
short
longact
inhal
lower
airway
fibroblast
may
play
critic
role
airway
inflamm
remodel
suggest
might
repres
import
target
major
antiasthmat
drug
aim
studi
investig
effect
beclomethason
dipropion
salbutamol
formoterol
either
alon
combin
vitro
cultur
human
bronchial
fibroblast
method
fibroblast
cultur
presenc
proinflammatori
prolif
stimuli
beclomethason
dipropion
salbutamol
formoterol
effect
drug
cell
prolifer
ascertain
incorpor
express
detect
flow
cytometri
fibronectin
secret
use
elisa
techniqu
result
studi
show
beclomethason
dipropion
alon
signific
antiprolif
effect
lung
fibroblast
treat
bfgf
laba
saba
show
signific
effect
differ
cultur
combin
bdp
formoterol
salbutamol
strengthen
effect
express
fibronectin
product
modul
proinflammatori
prolif
stimuli
addit
drug
brought
back
near
basal
level
conclus
vitro
studi
conclud
beclomethason
dipropion
combin
salbutamol
formoterol
exhibit
enhanc
anti
remodel
activ
bronchial
fibroblast
provid
new
insight
addit
effect
inhal
corticosteroid
asthma
therapi
inhibit
interact
suppress
mirin
model
allerg
asthma
shigeki
katoh
akira
yamauchi
mitsuomi
hirashima
faculti
medicin
kagawa
univers
depart
cell
regul
kagawa
japan
faculti
medicin
kagawa
univers
depart
immunolog
immunopatholog
kagawa
japan
background
belong
galectin
famili
exhibit
affin
galactosid
varieti
biolog
activ
howev
role
allerg
inflamm
unknown
evalu
effect
stabl
form
human
protein
allerg
airway
inflamm
mite
allergeninduc
asthma
model
method
human
stabl
given
intraven
inject
mice
antigen
challeng
effect
airway
inflamm
airway
hyperrespons
ahr
evalu
result
reduc
ahr
well
helper
type
associ
airway
inflamm
furthermor
administr
well
monoclon
antibodi
inhibit
infiltr
peripher
blood
cell
airway
interestingli
directli
bound
adhes
molecul
inhibit
interact
hyaluronan
ha
consist
concept
interact
mediat
migrat
cell
lung
block
adhes
mous
cell
ha
conclus
conclud
inhibit
allerg
inflamm
airway
ahr
modul
depend
leukocyt
recognit
extracellular
matrix
suppress
effect
watersolubl
fraction
artemisia
capillari
ovalbumininduc
allerg
asthma
model
background
asthma
chronic
inflammatori
diseas
airway
character
revers
airway
obstruct
hyperreact
remodel
airway
even
though
number
medic
treatment
diseas
avail
demand
rather
mild
prevent
medic
use
natur
product
chines
tradit
medicin
increas
especi
number
asian
countri
artemisia
carpillari
perenni
herb
easili
found
around
temper
asian
region
includ
entir
korean
peninsula
call
binjin
korea
byin
chin
byin
chen
hao
china
tradit
use
treatment
liver
diseas
also
appli
allerg
symptom
hive
rash
order
identifi
antiallerg
principl
plant
isol
watersolubl
glycosid
fraction
smaller
determin
biolog
activ
allerg
asthma
model
anim
method
investig
suppress
effect
fraction
ovalbumininduc
allerg
asthma
balbc
mice
studi
cellular
molecular
mechan
antiallerg
activ
result
watersolubl
fraction
artemisia
carpillari
significantli
reduc
pulmonari
eosinophilia
cytokin
express
lung
well
serum
ige
level
surfac
express
class
ii
mhc
lung
dendrit
cell
also
reduc
treatment
fraction
indic
fraction
also
modul
dendrit
cell
develop
lung
tissu
conclus
consid
pulmonari
dendrit
cell
crucial
differenti
cell
product
lung
tissu
cytokin
import
ige
antibodi
product
eosinophil
infiltr
fraction
appear
includ
antiallerg
principl
modul
differenti
result
allerg
asthma
develop
protect
effect
allel
receptor
gene
thai
asthmat
patient
background
genet
polymorph
involv
variat
argi
gli
glni
glu
amino
acid
posit
adrenerg
receptor
possibl
associ
variou
asthma
relat
phenotyp
includ
advers
effect
lung
function
regular
use
albuterol
asthmat
patient
homozyg
protect
effect
homozyg
asthma
sever
object
determin
associ
polymorph
asthma
phenotyp
thai
patient
method
materi
one
hundr
thirti
asthmat
patient
genotyp
polymorph
patient
demograph
diseas
sever
pulmonari
function
test
result
medic
use
collect
haplotyp
unknown
phase
infer
use
em
algorithm
method
anova
appli
compar
mean
among
group
result
preval
allel
respect
linkag
disequilibrium
coeffici
two
snp
three
haplotyp
infer
arggln
glygln
glyglu
frequenc
mean
percentag
predict
correspond
haplotyp
sd
sd
respect
although
mean
statist
differ
p
predict
glyglu
higher
rest
haplotyp
number
hospit
emerg
visit
also
lower
genotyp
ie
versu
p
hospit
versu
p
visit
emerg
final
inhal
corticosteroidlongact
icslaba
usag
significantli
lower
patient
patient
ie
versu
p
conclus
presenc
allel
thai
asthmat
patient
associ
better
paramet
asthma
sever
includ
higher
percentag
predict
less
hospit
emerg
depart
visit
past
year
signific
lower
amount
icslaba
usag
clinic
implic
vascular
endotheli
growth
factor
children
asthma
eosinophil
bronchiti
kyuearn
kim
kyung
kim
hye
mi
jee
myung
hyun
sohn
yonsei
univers
colleg
medicin
pediatr
seoul
republ
korea
background
eosinophil
bronchiti
eb
condit
character
corticosteroid
respons
cough
sputum
eosinophilia
without
bronchial
hyperrespons
vascular
endotheli
growth
factor
vegf
import
mediat
airway
inflamm
remodel
asthma
aim
explor
whether
vegf
express
elev
level
airway
asthma
eb
associ
pulmonari
function
bronchial
hyperrespons
children
method
one
hundr
seventeen
asthmat
children
children
eb
healthi
control
mean
age
year
enrol
studi
sputum
supernat
collect
vegf
eosinophil
cation
protein
ecp
level
measur
perform
pulmonari
function
test
methacholin
challeng
test
measur
total
eosinophil
count
serum
total
ige
ecp
subject
result
asthmat
children
significantli
higher
level
vegf
induc
sputum
log
pgml
compar
children
eb
log
pgml
p
healthi
control
log
pgml
p
posit
signific
correl
found
sputum
vegf
r
p
wherea
signific
correl
found
sputum
vegf
bronchial
hyperrespons
sputum
eosinophil
count
sputum
ecp
sputum
eosinophil
count
show
higher
level
children
asthma
eb
control
p
g
sputum
ecp
also
demonstr
higher
level
children
asthma
eb
control
p
p
respect
conclus
find
suggest
sputum
vegf
might
valuabl
marker
distinguish
asthma
eb
children
chronic
cough
also
suggest
vegf
would
affect
airway
inflamm
contribut
airway
remodel
may
reflect
proport
eosinophil
noneosinophil
inflamm
phenotyp
patient
mild
sever
bronchial
asthma
influenc
main
clinic
function
outcom
efficaci
inhal
steroid
treatment
mari
bukovski
normund
jurka
immanuel
taivan
background
bronchial
asthma
probabl
singl
diseas
complex
separ
syndrom
one
method
standardis
asthma
phenotyp
identif
inflammatori
pattern
inflamm
subtyp
may
influenc
treatment
efficaci
ic
object
studi
determin
percentag
patient
eosinophil
noneosinophil
asthma
phenotyp
sputum
inflammatori
cell
spectrum
patient
group
influenc
main
asthma
control
paramet
ic
treatment
efficaci
method
lung
function
mch
induc
sputum
cell
count
asthma
symptom
score
use
investig
nonsmok
steroid
naiv
ic
treat
patient
mild
sever
persist
bronchial
asthma
cutoff
point
patient
group
defin
sputum
eosinophilia
steroid
naiv
patient
alloc
treatment
fp
twice
daili
week
treatment
efficaci
previous
mention
paramet
evalu
result
steroid
naiv
patient
previous
treat
ic
includ
studi
steroid
naiv
patient
group
patient
classifi
asthmat
eosinophil
phenotyp
noneosinophil
phenotyp
ic
treatment
group
classifi
eosinophil
noneosinophil
asthmat
patient
demograph
data
ic
dose
similar
patient
noneosinophil
asthma
found
significantli
higher
rel
absolut
sputum
neutrophil
count
asthma
symptom
score
use
p
g
signific
differ
vs
vs
steroid
naiv
ic
treat
patient
respect
mch
j
vs
j
mg
j
vs
j
mg
steroid
naiv
ic
treat
patient
respect
patient
eosinophil
noneosinophil
asthma
treat
fp
observ
statist
signific
better
improv
morn
pef
patient
initi
airway
eosinophilia
compar
noneosinophil
asthma
p
g
chang
mch
asthma
symptom
score
use
similar
patient
group
conclus
noneosinophil
asthma
phenotyp
associ
increas
sputum
neutrophilia
sever
symptom
higher
rescu
medic
use
less
effect
ic
treatment
lung
function
influenc
antiig
antibodi
omalizumab
airway
remodel
express
interleukin
asthma
oleksii
korzh
sergiy
krasnokutskiy
elizaveta
lavrova
kharkov
medic
academi
postgradu
educ
intern
diseas
clinic
pharmacolog
kharkov
ukrain
background
studi
relat
transform
growth
factorbeta
tgfbeta
airway
remodel
investig
effect
omalizumab
airway
inflamm
airway
remodel
asthma
method
thirti
five
femal
balbc
mice
randomli
divid
remodel
group
treatment
group
omalizumab
group
balb
c
mice
group
mice
sensit
ovalbumin
ova
omalizumab
group
treat
omalizumab
number
total
cell
eosinophil
bronchoalveolar
lavag
fluid
balf
count
light
electron
microscop
use
detect
patholog
histolog
morpholog
chang
situ
hybrid
revers
transcriptionpolymeras
chain
reaction
rtpcr
use
measur
tgfbeta
mrna
lung
result
number
total
cell
eosinophil
balf
remodel
group
x
ml
treatment
group
x
ml
respect
differ
signific
p
g
histolog
electron
microscop
examin
show
extens
airway
inflamm
notabl
accumul
signific
number
eosinophil
lymphocyt
remodel
group
featur
includ
promin
prolifer
airway
epitheli
cell
protrud
like
finger
increas
thick
smooth
muscl
hyperplasia
connect
tissu
goblet
cell
hyperplasia
mark
increas
airway
mucu
secret
mucu
plug
extens
collagen
deposit
around
airway
also
note
remodel
group
treatment
group
inflamm
significantli
decreas
decreas
product
mucu
decreas
collagen
granul
mucu
around
airway
less
prolifer
airway
epithelium
smooth
muscl
hypertrophi
airway
spasm
situ
hybrid
show
express
mrna
tgfbeta
mrna
lung
oqf
remodel
group
respect
treatment
group
conclus
omalizumab
could
effect
inhibit
airway
remodel
decreas
express
mrna
tgfbeta
mrna
well
mrna
mrna
lung
asthma
ige
autoreact
bronchial
asthma
anna
konischeva
valentina
gervasieva
mechnickov
research
institut
vaccin
sera
ram
moscow
russian
feder
current
pay
much
attent
phenomenon
autoreact
immunopathogenesi
allerg
diseas
chronic
allerg
inflamm
bronchial
tree
lead
tissu
injuri
result
modif
structur
releas
intracellular
autoantigen
discov
igg
autoantibodi
dna
bronchial
endothelium
cell
antigen
patient
bronchial
asthma
ba
goal
determin
content
ige
ab
tissu
antigen
patient
atop
ba
differ
degre
sever
materi
method
identifi
igeautoab
elisa
follow
tissu
antigen
epitheli
keratin
iii
vi
collagen
type
myelin
basic
protein
mbp
elastin
myosin
sigma
usa
use
specif
ige
refer
set
bdr
fook
germani
studi
serum
sampl
adult
asthmat
patient
healthi
individu
age
result
level
igeautoab
determin
control
subject
taken
us
averag
homeostat
norm
iuml
compar
patient
easi
middl
ba
note
reliabl
elev
igeautoab
keratin
iuml
collagen
iii
vi
type
iuml
iuml
elastin
iuml
myosin
iuml
patient
sever
asthma
rais
autoab
elastin
iuml
collagen
type
iii
iuml
myosin
iu
ml
time
increas
total
ige
correl
igeautoab
elastin
myosin
r
r
respect
autoab
also
determin
serum
sampl
sever
middl
asthmat
subject
serum
healthi
peopl
normal
averag
valu
ngml
level
tissu
antigen
asthmat
patient
time
higher
healthi
control
also
reveal
signific
neg
correl
igeautoab
elastin
r
iii
collagen
type
r
mbp
r
data
indic
ige
contribut
develop
chronic
inflamm
patient
atop
ba
need
investig
chang
intern
diamet
larg
airway
exacerb
bronchial
asthma
sanghoon
kim
byoung
hoon
lee
jae
hyoung
lee
eulji
hospit
intern
medicin
seoul
republ
korea
background
exacerb
bronchial
asthma
character
increas
airway
respons
induc
lower
airway
inflamm
result
airway
obstruct
small
airway
known
main
area
obstruct
caus
limit
airflow
inflammatori
chang
exacerb
occur
entir
airway
includ
larg
airway
evalu
chang
intern
diamet
larg
airway
exacerb
method
high
resolut
comput
tomographi
hrct
pulmonari
function
test
done
soon
possibl
admiss
patient
exacerb
asthma
follow
studi
done
improv
symptom
discharg
hrct
scan
imag
exacerb
intern
diamet
larg
airway
measur
consecut
right
main
right
subsegment
bronchu
measur
repeat
discharg
level
angl
scan
bronchu
result
ten
patient
male
mean
age
rang
complet
studi
pulmonari
function
markedli
improv
treatment
exacerb
mean
fvc
l
l
p
mean
l
l
p
mean
intern
diamet
hrct
exacerb
mm
treatment
mm
p
one
patient
signific
increas
intern
diamet
decreas
patient
improv
associ
chang
intern
diamet
hrct
r
p
conclus
treatment
asthma
exacerb
mark
improv
pulmonari
function
chang
intern
diamet
measur
hrct
consist
tnf
import
proinflammatori
cytokin
also
well
known
induc
inflammatori
respons
regul
immun
strong
argument
exist
tnf
critic
cytokin
pathogenesi
chronic
inflammatori
disord
airway
releas
airway
tnf
act
induc
gener
inflammatori
respons
mainli
enhanc
releas
proinflammatorychemotact
mediat
upregul
adhes
molecul
eselectin
thu
facilit
migrat
neutrophil
eosinophil
date
limit
inform
use
tnf
block
agent
asthma
present
studi
investig
effect
solubl
tnf
receptor
airway
inflamm
mice
model
bronchial
asthma
mice
treat
intraperiton
solubl
tnf
receptor
ova
challeng
mice
expos
ova
develop
sustain
eosinophil
airway
inflamm
sustain
ahr
methacholin
compar
control
mice
intraperiton
administr
solubl
tnf
receptor
inhibit
develop
ahr
eosinophil
inflamm
moreov
solubl
tnf
receptor
treatment
reduc
level
bronchoalveolar
lavag
fluid
result
suggest
solubl
tnf
receptor
modul
airway
inflamm
ahr
via
inhibit
inflammatori
cytokin
product
detect
multilocu
genet
interact
aspirinintoler
asthma
multifactordimension
reduct
analysi
background
object
aspirinintoler
asthma
aia
common
phenotyp
aspirin
hypersensit
affect
asthmat
patient
recent
singl
gene
polymorph
associ
aia
suscept
investig
identif
multilocu
singl
nucleotid
polymorph
snp
set
associ
suscept
investig
subject
method
studi
select
snp
candid
gene
asthmat
aspirin
hypersensit
aia
asthmat
without
aspirin
hypersensit
aspirintoler
asthma
ata
genotyp
snp
primer
extens
method
multilocu
genet
interact
examin
multifactordimension
reduct
mdr
test
multilocu
snp
combin
effici
predict
aia
result
mdr
analysi
identifi
fourlocu
genegen
interact
model
predict
aia
diseas
risk
among
asthmat
patient
balanc
accuraci
conclus
result
suggest
signific
epistat
effect
fourlocu
genet
interact
may
exist
suscept
aia
asthmat
patient
may
use
vitro
method
diagnos
aia
accept
sensit
product
respons
candida
albican
secretori
aspart
proteas
marker
isol
latephas
bronchial
respons
upon
inhal
challeng
nonatop
asthma
delin
mechan
nonatop
asthma
peripher
blood
mononuclear
cell
pbmc
obtain
atop
asthmat
nonatop
asthmat
healthi
control
incub
variou
allergen
molecul
ifn
product
measur
specif
elisa
cell
prolifer
assess
uptak
ige
igg
antibodi
assay
rast
elisa
respect
intraderm
bronchial
inhal
challeng
antigen
perform
accord
standard
procedur
histamin
releas
test
hrt
perform
use
peripher
blood
leucocyt
prolif
respons
crude
candida
albican
ca
extract
statist
differ
among
three
group
indic
common
sensit
ca
antigen
signific
amount
produc
pbmc
obtain
sever
nonatop
asthmat
upon
incub
crude
ca
extract
purifi
antigen
secretori
aspart
proteinas
product
undetect
pbmc
obtain
healthi
control
subject
respons
upon
intraderm
bronchial
challeng
late
immedi
skin
bronchial
respons
observ
asthmat
respect
neither
iar
lar
detect
asthmat
indic
specif
respons
lar
induc
asthmat
igedepend
mechan
rule
neg
rast
hrt
immedi
skin
reaction
igg
antibodi
precipitin
detect
serum
either
asthmat
control
subject
nonatop
asthma
may
caus
igeindepend
celldepend
immunerecognit
vitro
cytokin
synthesi
becom
reliabl
diagnost
test
bt
cell
allergen
correl
serum
immun
marker
bronchial
hyperreact
background
asthma
characteris
underli
allerg
inflamm
result
bronchial
hyperreact
aim
examin
studi
correl
serum
biolog
marker
rant
total
ige
bronchial
hyperreact
symptomfre
adult
childhood
bronchial
asthma
symptomfre
children
studi
method
bronchial
hyperreact
prove
metacholin
airway
provoc
symptomfre
patient
adult
children
patient
children
serum
rant
ige
detect
perfom
elisa
result
signific
higher
pgml
vs
pgml
rant
pgml
vs
pg
ml
ige
x
kul
vs
kul
concentr
prove
symptomfre
patient
bronchial
hyperreact
compar
nonhyperreact
symptomfre
patient
bronchial
hyperreact
signific
posit
linear
correl
prove
serum
level
rant
ige
conclus
serum
level
correl
ige
concentr
nonhyperreact
patient
well
bronchial
hyperreact
show
correl
chemokin
rant
total
ige
persist
inflamm
detect
bronchial
hyperrect
even
symptomfre
patient
local
serum
level
solubl
receptor
teenag
bronchial
asthma
analysi
dynam
system
local
content
teenag
variou
clinic
form
allerg
diseas
reveal
higher
level
system
content
comparison
local
mainten
nasal
lavag
despit
differ
level
correl
marker
found
studi
biolog
liquid
estim
result
research
bronchial
asthma
ba
level
ngml
serum
blood
ngml
local
howev
research
reveal
opposit
direct
present
group
patient
higher
level
nasal
lavag
comparison
serum
pgml
pgml
accordingli
combin
level
serum
blood
ba
atop
dermat
ad
patient
tend
increas
comparison
group
patient
ba
made
ngml
level
nasal
secret
ba
ngml
research
ba
patient
combin
ad
reveal
authent
increas
serum
level
present
cytokin
pg
ml
decreas
local
one
pgml
content
practic
differ
compar
ba
atop
rhiniti
ar
patient
ba
patient
make
ngml
serum
blood
ngml
nasal
secret
howev
quantiti
present
group
highest
serum
blood
nasal
secret
pgml
pgml
accordingli
combin
clinic
form
ar
ad
level
cytokin
least
studi
clinic
variant
atop
march
make
pgml
serum
pgml
local
ngml
ngml
accordingli
thu
greatest
increas
level
serum
blood
nasal
secret
occur
combin
ba
r
children
teenag
form
atop
march
level
solubl
receptor
children
also
increas
combin
ba
r
wherea
teenag
clinic
evid
ba
ad
essenti
zinc
iron
ratio
allerg
asthma
allerg
rhiniti
vojislav
djuric
institut
allergolog
immunolog
function
diagnost
unit
belgrad
serbia
montenegro
background
zinc
shown
protect
effect
respiratori
system
expos
oxid
stress
soit
may
play
role
allerg
airway
diseas
iron
role
oxid
stress
allerg
respiratori
diseas
iron
well
copper
transfer
electron
produc
reactiv
oxygen
speci
damag
epithelium
allerg
diseas
trace
element
also
signific
influenc
immun
system
method
use
atom
absorpt
spectrophotometri
measur
concentr
zinc
iron
serum
supernat
induc
sputum
patient
allerg
asthma
patient
allerg
rhiniti
control
subject
result
postivi
corel
found
serum
zinc
iron
concentr
patient
allerg
asthma
correl
zinc
iron
concentr
sputum
conclus
zinc
iron
trace
element
antagonist
action
respiratori
epithelium
posit
correl
serum
alerg
asthmat
immunohistochem
coloc
transient
receptor
potenti
trachea
use
guineapig
asthma
model
aim
investig
distribut
transient
receptor
potenti
airway
guineapig
studi
compar
chang
trachea
use
guineapig
asthma
model
method
creat
asthma
model
guineapig
administr
ovalbumin
oa
control
sham
accord
doubl
blind
studi
trachea
remov
section
cryostat
slidemount
section
incub
normal
donkey
serum
hr
follow
minut
addit
block
avidinbiotin
block
kit
subsequ
section
incub
polyclon
antibodi
hr
next
incub
biotinyl
donkey
antirabbit
immunoglobulin
g
minut
incub
streptavidin
biotinperoxidas
complex
hr
follow
fluorescein
tyramid
min
final
observ
activ
section
confoc
microscopi
compar
result
result
immunoreact
axon
local
fine
axon
within
epithelium
around
smooth
muscl
area
axon
found
stronger
frequent
oa
group
sham
group
conclus
find
suggest
immunoreact
axon
trachea
increas
number
allerg
inflammatori
condit
water
solubl
chitosan
attenu
mite
allergeninduc
macrophag
activ
allerg
asthmat
patient
chitin
chitosan
versatil
antitumor
antifung
antimicrobi
biolog
properti
oral
intak
intranas
administr
chitin
attenu
allergeninduc
airway
inflamm
sensit
mice
may
due
adjuv
properti
howev
detail
mechan
action
clear
report
demonstr
water
solubl
chitosan
specif
immunomodulatori
effect
dust
mite
allergen
dermatophagoid
farina
der
f
stimul
monocytederiv
macrophag
mdm
shift
cytokin
polar
decreas
inflammatori
cytokin
product
tnf
downregul
receptor
express
inhibit
tcell
prolifer
presenc
allergenstimul
mdm
scan
electron
microscop
sem
examin
chitosan
reduc
cellular
chang
pseudopodia
format
der
fstimul
mdm
allerg
asthma
patient
effect
chitosan
allergenstimul
mdm
may
occur
inhibit
pkcua
phosphoryl
nfkb
pathway
activ
murin
model
asthma
found
intranas
applic
chitosan
attenu
der
finduc
lung
inflamm
reduc
infiltr
inflammatori
cell
epithli
damag
goblet
cell
hyperplasia
product
ino
thymic
stromal
lymphopoietin
tslp
bronchial
epithelium
allergenchalleng
sensit
mice
markedli
decreas
chitosantr
mice
therefor
believ
result
examin
antiallerg
effect
chitosan
may
provid
new
therapeut
modal
allerg
asthma
basic
play
key
role
allerg
sensit
airway
pathogenesi
asthma
background
asthma
character
chronic
inflammatori
disord
airway
associ
airway
hyperrespons
ahr
mucu
product
airway
remodel
smooth
muscl
hypertrophi
subepitheli
fibrosi
basic
fgf
member
larg
fgf
famili
play
role
prolifer
fibroblast
migrat
prolifer
airway
epitheli
cell
wound
heal
howev
role
allerg
sensit
total
unknown
although
level
thought
elev
patient
asthma
object
evalu
immunolog
role
airway
allergen
sensit
pathogenesi
asthma
method
femal
balbc
mice
sensit
intranas
lpsdeplet
ovalbumin
ova
presenc
absenc
day
challeng
intranas
ova
day
ahr
measur
whole
plethysmographi
hour
last
challeng
mice
sacrif
day
bal
cellular
lung
histolog
sever
immunolog
paramet
assess
evalu
effect
cotreat
result
ahr
methacholin
challeng
significantli
increas
mice
sensit
ova
plu
compar
group
number
total
cell
macrophag
eosinophil
lymphocyt
bal
fluid
also
makedli
increas
rfgf
treat
mice
accompani
sever
peribronchi
perivascular
eosinophil
inflamm
histolog
find
mucu
secret
subepitheli
fibrosi
also
increas
mice
respect
tgf
level
bal
fluid
markedli
enhanc
mice
sensit
ova
plu
conclus
find
suggest
play
import
role
pathogenesi
allerg
asthma
especi
promot
allerg
sensit
via
product
inflammatori
cytokin
tgf
role
vegf
receptor
airway
allerg
sensit
pathogenesi
asthma
diseas
asthma
chronic
bronchiti
report
level
vegf
tissu
biolog
sampl
increas
patient
asthma
vegf
assum
contribut
asthmat
tissu
edema
effect
vascular
permeabl
recent
studi
use
lung
specif
vegf
overexpress
transgen
mice
show
vegf
induc
lung
inflamm
howev
still
remain
whether
vegf
affect
allergen
sensit
adapt
immun
respons
allergen
specif
cell
object
assess
role
vegf
receptor
allerg
sensit
airway
method
wild
type
mice
sensit
intranas
lp
deplet
ovalbumin
ova
presenc
lp
day
challeng
intranas
ova
day
sensit
mice
intraperiton
inject
inhibitor
sensit
period
proper
time
day
sacrif
mice
analyz
phenotyp
includ
bal
cellular
lung
histolog
evalu
immunolog
paramet
product
cytokin
bal
fluid
result
day
number
total
cell
macrophag
lymphocyt
neutrophil
increas
bal
fluid
mice
sensit
ova
presenc
lp
compar
ova
treat
mice
interestingli
block
recruit
inflammatori
cell
sensit
period
time
product
tnf
also
decreas
bal
fluid
treat
mice
ova
challeng
day
number
total
cell
decreas
bal
mice
treat
sensit
period
histolog
find
show
infiltr
inflammatori
cell
also
significantli
decreas
treat
mice
conclus
vegf
induc
allerg
sensit
signal
pathway
play
key
role
allergen
specif
cell
prime
cytokin
respons
exacerb
compar
stabl
phase
asthmat
children
background
bronchial
asthma
chronic
inflammatori
disord
airway
lymphocyt
crucial
initi
mainten
allerg
inflammatori
respons
particularli
helper
cell
balanc
respons
target
treatment
recent
studi
show
import
role
regul
allerg
respons
decreas
asthmat
patient
object
examin
cytokin
respons
includ
interferongamma
ifn
asthmat
children
acut
exacerb
method
fourteen
asthmat
children
includ
studi
fresh
whole
blood
obtain
patient
two
phase
exacerb
stabl
phase
separ
peripher
blood
mononuclear
cell
stimul
phytohemagglutinin
pha
mite
allergen
der
hour
elisa
assay
appli
measur
cytokin
concentr
ifn
supernat
level
phastimul
significantli
decreas
acut
asthma
exacerb
pgml
compar
stabl
phase
pgml
p
ifn
level
cytokin
ratio
stimul
significantli
differ
among
episod
pbmc
phastimul
level
slightli
decreas
moder
persist
asthma
compar
mild
persist
asthma
vs
p
correl
sever
exacerb
asthma
score
size
skin
prick
test
cytokin
level
conclus
decreas
product
asthmat
children
acut
exacerb
may
role
asthma
exacerb
decreas
product
sever
asthma
moder
persist
support
idea
defect
immun
regul
studi
produc
cell
treatment
enhanc
respons
might
use
prevent
treatment
asthma
altern
transcript
cysteinyl
leukotrien
receptor
cysltr
patient
bronchial
asthma
introduct
cysteinyl
leukotrien
lipid
mediat
implic
pathogenesi
sever
inflammatori
process
includ
asthma
caus
bronchoconstrict
mucou
hypersecret
increas
microvascular
permabl
bronchial
hyperrespons
eosinophil
infiltr
biolog
action
cyslt
mediat
via
cyslt
cyslt
receptor
human
cysltr
gene
consist
five
exon
variabl
splice
transcript
compos
exon
major
transcript
present
human
leukocyt
smooth
muscl
transcript
ii
compos
exon
less
abund
find
blood
leukocyt
smooth
muscl
hart
brain
role
altern
transcript
asthma
pathogenesi
still
known
aim
goal
studi
investig
differ
express
cysltr
altern
transcript
ii
patient
bronchial
asthma
healthi
control
group
method
pbmc
obtain
peripher
blood
patient
sever
nonsever
asthma
healthi
volunt
total
rna
obtain
mononuclear
cell
use
totalrna
cdna
synthes
use
revers
transcriptas
design
specif
primer
span
exonexon
junction
transcript
exon
transcript
ii
exon
common
primer
cysltr
code
region
accord
publish
cysltr
transcript
sequenc
realtim
pcr
reaction
perform
rotorgen
use
evagreen
dye
result
found
cysltr
transcript
ii
present
patient
asthma
control
group
cysltr
transcript
iii
ratio
patient
sever
asthma
moder
asthma
mild
asthma
control
group
addit
found
signific
differ
cysltr
transcript
iii
ratio
sever
asthmat
subgroup
comparison
control
p
sever
asthmat
comparison
mild
p
cysltr
transcript
iii
ratio
moder
asthmat
comparison
control
group
p
mild
asthmat
comparison
control
group
p
conclus
differ
cysltr
altern
transcript
express
might
possibl
contribut
airway
inflamm
patient
bronchial
asthma
prostaglandin
product
differ
asthma
patient
valeriya
nemtsova
inga
fedotova
volodimir
fedotov
kharkov
allergolog
center
allergolog
kharkov
ukrain
background
special
regulatori
role
prostaglandin
postul
aspirininduc
asthma
aim
studi
investig
effect
aspirin
system
product
prostaglandin
cysteinyl
leukotrien
patient
asthma
method
determin
urinari
concentr
two
main
prostaglandin
metabolit
use
commerci
enzym
immunoassay
acid
use
ga
chromatographymass
spectrometri
leukotrien
use
immunoassay
determin
perform
baselin
follow
oral
aspirin
celecoxib
challeng
two
welldefin
asthma
phenotyp
aspirinsensit
aspirintoler
patient
result
aspirin
precipit
bronchial
reaction
aspirinsensit
none
aspirintoler
patient
celecoxib
mg
well
toler
patient
except
one
aspirininduc
asthma
baselin
mean
prostaglandin
metabolit
valu
differ
group
follow
differ
aspirin
provoc
dose
two
main
prostaglandin
metabolit
decreas
aspirintoler
group
mean
level
remain
unchang
aspirinsensit
group
dose
aspirin
effect
magnitud
respons
prostaglandin
metabolit
durat
group
urinari
prostaglandin
metabolit
decreas
follow
celecoxib
challeng
correl
found
prostaglandin
metabolit
leukotrien
conclus
aspirinprecipit
asthmat
attack
associ
chang
system
prostaglandin
product
contrast
prostaglandin
system
product
becom
depress
aspirin
nonsensit
patient
differ
respons
might
indic
depend
prostaglandin
control
inflammatori
cell
aia
thu
releas
clinic
reaction
aspirin
altern
pathway
clinic
implic
find
line
current
observ
good
toler
select
inhibitor
sensit
patient
mastcel
activ
aspirininduc
asthma
inga
fedotova
irina
feclina
irina
tikhonova
kharkov
allergolog
centr
allergolog
kharkov
ukrain
background
increas
evid
import
cysteinyl
leukotrien
lt
mediat
aspirininduc
bronchoconstrict
aspirinsensit
asthma
cellular
origin
lt
yet
clear
method
urinari
concentr
leukotrien
ntaumethylhistamin
measur
h
follow
cumul
intraven
administr
increas
dose
lysin
aspirin
asthmat
patient
addit
urinari
concentr
metabolit
measur
consecut
day
patient
suffer
asthma
attack
percutan
administr
nonsteroid
antiinflammatori
drug
result
aspirininduc
asthma
patient
aia
n
basal
concentr
urinari
metabolit
significantli
higher
aspirintoler
asthma
patient
ata
n
intraven
aspirin
provoc
aia
group
show
geometr
mean
increas
excret
first
h
also
increas
aia
group
first
h
h
collect
period
ntaumethylhistamin
excret
also
increas
lesser
degre
administr
aspirin
caus
signific
suppress
excret
aia
ata
group
percentag
maximum
increas
metabolit
baselin
concentr
compar
aia
group
ata
group
significantli
higher
increas
excret
ntaumethylhistamin
observ
aia
group
ata
group
increas
excret
detect
patient
suffer
asthma
attack
percutan
administr
nonsteroid
antiinflammatori
drug
conclus
consid
human
lung
mast
cell
capabl
produc
prostaglandin
histamin
result
studi
support
concept
mast
cell
least
may
particip
develop
aspirininduc
asthma
zlatica
goseva
angelko
gjorcev
dejan
dokic
tatjana
caparoska
zoran
arsovski
clinic
pulmolog
allergi
depart
allergi
skopj
macedonia
fyrom
background
bronchial
asthma
character
airway
inflamm
hiperrespons
varieti
stimuli
airway
obstruct
revers
differ
cell
involv
pathogenesi
asthma
like
tlymphocyt
mast
cell
eosinophil
macrophag
etc
number
differ
inflammatori
cell
infiltr
airway
trigger
caus
releas
inflammatori
mediat
cell
could
marker
inflamm
method
investig
role
import
inflammatori
cell
mediat
like
eosinophil
ecp
studi
subject
divid
three
group
follow
asthma
patient
patient
obstruct
bronchiti
control
group
result
number
eosinophil
significantli
increas
group
asthma
patient
versu
second
third
group
eosinophil
import
role
allerg
inflamm
found
presenc
ecp
demonstr
ongo
inflamm
without
clinic
symptom
asthma
patient
signific
differ
valu
ecp
asthma
patient
versu
second
group
bronchiti
healthi
control
valu
significantli
increas
group
found
explan
fact
marker
earli
allerg
inflamm
result
shown
involv
pathophysiolog
asthma
valu
significantli
increas
versu
second
group
control
also
found
decreas
valu
inflammatori
marker
treatment
corticosteroid
conclus
conclud
eosinophil
ecp
could
use
marker
select
allerg
patient
could
use
togeth
examin
marker
inflamm
could
import
role
measur
allerg
inflamm
could
monitor
treatment
effect
mucos
immunotherapi
cpg
oligodeoxynucleotid
increas
local
concentr
murin
model
chronic
asthma
tahereh
mousavi
alireza
salek
moghadam
reza
falak
iran
univers
immunolog
tehran
islam
republ
iran
examin
cpg
motif
effect
previous
develop
murin
model
asthma
chronic
airway
inflamm
induc
repeat
allergen
chenopodium
album
cha
inhal
use
model
examin
respons
mucos
administr
cpg
dna
oligonucleotid
specif
antigen
immunotherapi
cpgbase
immunotherapi
significantli
revers
acut
chronic
marker
inflamm
compar
specif
ag
immunotherapi
level
also
measur
splenocyt
lung
cultur
supernat
result
show
antigen
recal
respons
lung
cultur
mucos
treat
mice
demonstr
antigenspecif
enhanc
releas
concentr
regulatori
cytokin
signific
chang
splenocyt
cultur
medium
result
suggest
mucos
immunotherapi
cpg
dna
may
induc
local
product
cytokin
without
system
effect
th
respons
suggest
mucos
coadministr
cpg
ag
may
provid
basi
effici
form
immunotherapi
allerg
asthma
inde
local
induct
cytokin
procedur
may
diminish
potenti
toxic
system
antigen
administr
assess
airway
remodel
hrct
asthmat
correl
age
smoke
diseas
durat
sever
alia
mohamedhussein
w
hasan
g
agmi
abdel
aziz
e
abou
elhamd
assiut
univers
hospit
assiut
egypt
chest
assiut
egypt
assiut
univers
hospit
assiut
egypt
radiolog
assiut
egypt
background
date
airway
remodel
usual
assess
use
histolog
examin
airway
howev
possibl
assess
quantifi
extent
airway
remodel
vivo
use
highresolut
ct
hrct
aim
studi
prospect
evalu
airway
wall
thick
indic
remodel
use
thin
section
hrct
asthmat
correl
find
pulmonari
function
test
pft
result
clinic
indic
asthmat
method
patient
asthma
healthi
control
particip
studi
remodel
measur
whole
airway
wall
thick
assess
hrct
thicknessto
diamet
ratio
tdr
percentag
wall
area
pwa
determin
spirometr
test
also
perform
result
tdr
pwa
significantli
higher
asthmat
control
tdr
pwa
strongli
correl
diseas
sever
durat
also
tdr
pwa
invers
correl
percentag
predict
forc
vital
capac
fvc
forc
expiratori
volum
second
postbronchodil
revers
asthmat
conclus
find
indic
hrct
use
noninvas
method
assess
airway
wall
thick
airway
wall
thicken
occur
patient
moder
sever
asthma
degre
relat
durat
sever
asthma
degre
airflow
obstruct
clinic
immunolog
find
methylen
diphenyl
diisocyan
induc
occup
asthma
singl
car
upholsteri
gyuyoung
hur
donghe
koh
gilsoon
choi
hanjung
park
sungjin
choi
youngmin
ye
kyoosang
kim
haesim
park
ajou
univers
school
medicin
allergi
rheumatolog
suwon
republ
korea
korea
occup
safeti
health
research
institut
incheon
republ
korea
background
although
methylen
diphenyl
diisocyan
mdi
wide
use
mani
industri
studi
mdiinduc
occup
asthma
object
investig
present
clinic
immunolog
find
methylen
diphenyl
diisocyanateexpos
worker
singl
industri
car
upholsteri
method
fiftyeight
expos
worker
singl
industri
enrol
work
relat
respiratori
symptom
screen
use
respiratori
questionnair
serum
specif
ige
igg
antibodi
mdihuman
serum
albumin
conjug
measur
elisa
atopi
statu
evalu
use
allergi
skin
prick
test
confirm
mdiinduc
occup
asthma
methacholin
bronchial
challeng
test
mdispecif
inhal
test
chang
sputum
eosinophil
count
perform
symptomat
worker
result
thirteen
subject
complain
respiratori
workrel
symptom
preval
mdioccup
asthma
note
worker
occup
eosinophil
bronchiti
note
worker
preval
specif
igg
higher
specif
ige
preval
mdioccup
asthma
eosinophil
bronchiti
strongli
associ
presenc
workrel
respiratori
symptom
mdispecif
igg
antibodi
p
g
p
g
respect
conclus
mdi
may
caus
agent
occup
asthma
among
mdiexpos
worker
preval
mdioccup
asthma
mdieosinophil
bronchiti
confirm
worker
presenc
workrel
lower
respiratori
symptom
serum
specif
igg
mdihuman
serum
albumin
conjug
may
use
predict
mdioccup
asthmaeosinophil
bronchiti
mdi
expos
worker
result
averag
durat
employ
worker
year
pesticid
crop
sprayer
workrel
wheez
ocularnas
urticariaskin
symptom
preval
orchard
preval
sensit
spt
highest
tu
follow
hous
dust
mite
atop
preval
allergi
tu
skin
reactiv
workrel
symptom
respiratori
common
skin
allergi
workrel
ocularnas
skin
symptom
commonli
report
pesticid
crop
sprayer
worker
tuallerg
rhinoconjunct
probabl
asthma
like
atop
spray
pesticid
low
ug
hgb
ach
level
background
toluen
diisocyan
tdi
highli
reactiv
industri
chemic
one
lead
caus
occupationrel
asthma
industri
countri
pathogenesi
tdiinduc
asthma
remain
fulli
understood
part
due
lack
appropri
anim
model
studi
establish
novel
tdi
asthma
mous
model
epicutan
sensit
intranas
challeng
method
thirti
two
week
balbc
mice
randomli
divid
four
group
n
tdi
aceton
oliv
oil
aoo
ovalbumin
ova
salin
sal
day
mice
epicutan
sensit
tdi
aceton
oliv
oil
aoo
aoo
ova
sal
sal
respect
everi
allergen
solvent
place
patch
steril
gauz
cm
tape
skin
shave
mous
back
kept
day
per
sensit
day
mice
challeng
intranas
ident
allergen
solvent
respect
day
mice
sacrif
day
hour
first
intranas
challeng
last
intranas
challeng
airway
respons
methacholin
mch
measur
unrestrain
whole
bodi
plethysmogragh
express
enhanc
paus
penh
mice
expos
nebul
phosphatebuff
salin
baselin
increas
dose
mch
name
follow
measur
penh
valu
minut
tdiand
ovaspecif
ige
sera
measur
elisa
express
optic
densiti
od
mean
valu
result
histolog
tdiexpos
mice
exhibit
neutrophildomin
pulmonari
inflamm
peribronchi
perivascular
region
lung
tissu
haematoxylin
eosin
stain
increas
mucu
secret
pa
stain
ovatr
mice
exhibit
eosinophildomin
inflamm
mucu
product
challeng
tditreat
mice
airway
respons
significantli
augment
ovaand
solventtr
mice
signific
increas
product
sera
tdispecif
ige
tditreat
mice
observ
well
increas
ovaspecif
ige
ova
mice
conclus
studi
show
allerg
asthmat
respons
chemic
sensit
tdi
may
occur
dermal
sensit
airway
challeng
via
igemedi
mechan
remei
bori
cinta
valldeperez
miquel
baltasar
drago
hospit
tortosa
verg
de
la
cinta
unit
allergi
tortosa
spain
hospit
tortosa
verg
de
la
cinta
intern
medicin
tortosa
spain
report
case
patient
male
year
old
recurr
symptom
rhiniti
conjunct
dermat
relat
job
hasnt
famili
person
anteced
atopi
symptom
recurr
prurigin
eczema
locat
bodi
leg
accompani
rhiniti
conjunct
without
symptom
bronchial
reactiv
symptom
appear
place
work
improv
weekend
holiday
work
eighteen
month
pipe
factori
support
agent
use
polyvinyl
made
pipe
contact
resin
cobalt
styren
glass
fibr
factori
preform
skin
prick
test
batteri
common
aeroallergen
standard
patch
test
true
test
neg
result
basal
espirometri
perform
normal
pattern
bronchodilat
test
neg
blood
analysi
show
normal
biochem
level
normal
haematolog
valu
antinuclear
antitissu
antibodi
neg
specif
ige
determin
anhydrid
phthalic
kul
formaldehyd
diagnosi
suspicion
sensit
anhydrid
phthalic
caus
symptom
present
patient
evolut
job
chang
favour
remain
asymptomat
nowaday
specif
ige
level
anhydrid
phthalic
gone
lower
kul
eighteen
moth
later
use
anhydrid
phthalic
harden
epoxi
resin
form
polym
use
make
materi
glass
fibr
sometim
mani
substanc
occup
environ
difficult
causal
diagnosi
acid
anhydrid
substanc
low
molecular
weight
caus
rhiniti
asthma
contact
dermat
associ
ige
mediat
mechan
airborn
exposit
anhydrid
phthalic
happen
frequent
plastic
industri
predictor
workrel
symptom
allerg
sensitis
occup
asthma
among
supermarket
bakeri
worker
south
africa
background
recent
studi
report
high
risk
develop
workrel
asthma
among
supermarket
baker
studi
aim
determin
predictor
workrel
symptom
allerg
sensitis
nonspecif
bronchial
hyperrespons
nsbh
baker
asthma
small
bakeri
supermarket
chain
store
south
africa
method
crosssect
studi
current
previous
employ
baker
conduct
cape
town
bakeri
use
modifi
european
commun
respiratori
health
survey
ecrh
questionnair
skin
prick
test
common
aeroallergen
cereal
flour
well
serum
specif
ige
wheat
flour
rye
flour
fungal
alpha
amylas
immunocapsystem
phadia
sweden
nsbh
assess
use
medic
aid
pro
nebul
dosimet
method
exposurerespons
model
conduct
identifi
signific
determin
result
mean
age
baker
year
current
smoker
preval
atopi
posit
spt
common
aeroallergen
common
workrel
symptom
ocularnas
chest
tight
wheez
one
third
baker
sensitis
bakeri
allergen
sensitis
cereal
flour
wheat
rye
worker
demonstr
evid
bronchial
respons
airway
obstruct
doubl
employ
durat
associ
increas
odd
specif
ige
reactiv
wheat
background
occup
allergi
cutler
strang
phenomena
even
though
handl
lot
potenci
allergen
substanc
case
report
man
cutler
sinc
activ
smoker
cigarettesday
refer
depar
present
last
month
daili
dysnea
wheez
cough
thorac
oppress
accompani
rhiniti
conjunct
diurnal
predomin
clearli
relat
work
place
treat
formoterol
mcg
budesonida
mcg
everi
hour
sinc
day
visit
got
wors
throughout
week
special
friday
swept
floor
factori
forc
fact
go
emerg
depar
occas
improv
weekend
refer
work
metal
wood
oliv
tree
oak
bwith
resin
artifici
wood
although
worker
next
handl
deer
antler
sinc
year
bull
horn
previou
work
cutleri
year
use
work
deer
antler
wood
last
three
month
work
present
daili
cough
dysnea
wheez
relat
wood
dust
chang
compani
present
one
remain
asymptomat
year
result
skin
prick
test
spt
standard
batteri
inhal
epitheli
allergen
batteri
wood
mite
neg
sptwith
extract
deer
antler
gave
posit
result
mm
neg
control
atop
patient
spt
bull
horn
neg
respiratori
function
test
remain
hour
without
treatment
forc
spirometri
mild
obstruct
pattern
fvc
posit
bronchodil
test
total
ige
uiml
specif
ige
measur
east
method
enzym
allergosorb
test
obtain
follow
result
deer
antler
kul
class
fur
dander
cow
kul
class
epithelium
dog
cat
hors
less
kul
class
serum
specif
ige
level
serum
albumin
bovin
cat
chicken
alpha
livetin
also
measur
kul
class
molecular
mass
ige
bind
protein
determin
sdspage
inmunoblot
two
band
kda
detect
deer
antler
extract
conclus
report
first
case
literatur
allerg
rhiniti
conjunct
asthma
caus
deer
antler
acut
allerg
reaction
chronic
pulmonari
effect
occup
inhal
exposur
talc
dust
main
purpos
studi
assess
character
pulmonari
reaction
associ
occup
exposur
talc
dust
method
ninetyseven
talc
worker
unexpos
employe
refer
group
randomli
select
local
rubber
industri
standard
respiratori
questionnair
administ
subject
underw
chest
xray
examin
specialist
possibl
respiratori
abnorm
diagnos
furthermor
pulmonari
function
test
pft
measur
work
shift
moreov
assess
extent
worker
expos
talc
dust
use
standard
method
inhal
respir
dust
concentr
measur
differ
dusti
worksit
result
averag
mean
sd
age
year
weight
kg
height
cm
durat
exposur
talc
dust
year
expos
group
respect
correspond
valu
nonexpos
group
respect
atmospher
concentr
inhal
respir
talc
dust
estim
mean
sd
respect
talc
expos
subject
significantli
higher
preval
respiratori
symptom
similarli
pft
reveal
exposur
lubric
agent
associ
signific
decreas
mean
percentag
predict
vital
capac
vc
forc
vital
capac
fvc
forc
expiratori
volum
first
second
likewis
gener
tendenc
vc
fvc
decreas
estim
cumul
exposur
year
work
increas
moreov
acut
reduct
paramet
pulmonari
function
vc
fvc
work
shift
chest
radiograph
expos
worker
show
pneumoconiosi
profus
p
p
accord
ilo
chest
xray
classif
conclus
result
support
notion
occup
inhal
exposur
talc
associ
chronic
respiratori
disord
induc
bronchiti
interstiti
lung
diseas
addit
support
hypothesi
inhal
exposur
talc
dust
induc
acut
aalerg
revers
advers
effect
pft
chang
lung
function
airway
hyperrespons
occup
asthma
exposur
caus
agent
signific
improv
disappear
symptom
ahr
follow
period
frequent
use
paramet
oa
outcom
measur
howev
studi
longitudin
evalu
chang
lung
function
ahr
serial
measur
evalu
signific
lung
function
ahr
outcom
paramet
serial
measur
compar
chang
clinic
condit
oa
method
pulmonari
function
test
methacholin
bronchial
provoc
test
asthma
symptom
medic
score
evalu
regular
interv
patient
oa
confirm
specif
challeng
test
result
ahr
continu
resolv
followup
period
mean
year
rang
year
patient
ahr
transient
disappear
howev
subsequ
redevelop
addit
patient
level
ahr
improv
increas
methacholin
patient
fluctuat
remain
patient
level
fluctuat
along
sever
asthma
symptom
proport
level
ahr
patient
reduc
lung
function
initi
examin
lung
function
recov
follow
period
signific
improv
symptom
mainten
nearli
asymptomat
state
achiev
patient
three
disappear
ahr
patient
show
fluctuat
level
ahr
lung
function
sever
asthma
diagnosi
interv
develop
oa
symptom
avoid
associ
function
impair
conclus
spite
medic
treatment
avoid
mani
patient
oa
persist
fluctuat
ahr
lung
function
impair
even
absenc
respiratori
symptom
intermitt
singl
assess
lung
function
ahr
outcom
measur
might
lead
incorrect
clinic
evalu
comprehens
approach
requir
background
allerg
diseas
constitut
global
health
problem
increas
econom
social
impact
especi
deepli
interfer
patient
daili
life
caus
physic
emot
discomfort
health
relat
qualiti
life
hrqol
becom
increasingli
import
healthcar
research
aim
examin
scientif
literatur
last
three
year
deal
impact
allerg
rhiniti
ar
treatment
suggest
aria
guidelin
patient
hrqol
identifi
unexplor
fulli
investig
area
concern
issu
method
studi
sought
medlin
januari
decemb
use
key
word
aria
suggest
drug
allerg
rhiniti
qualiti
life
random
dbc
trial
publish
peerreview
journal
use
valid
questionnair
select
result
research
lead
select
dbpc
trial
paediatr
adult
popul
hrqol
assess
total
patient
rqlq
questionnair
use
studi
rhinasthma
appli
one
studi
involv
patient
rhiniti
asthma
use
togeth
specif
questionnair
trial
paper
sublingu
immunotherapi
slit
evalu
health
statu
mean
subject
satisfact
mean
satisfact
profil
satp
durat
studi
vari
day
year
studi
sar
par
season
perenni
rhiniti
studi
investig
rhiniti
accord
aria
classif
persist
allerg
rhiniti
consid
persist
allerg
rhiniti
comorbid
asthma
studi
investig
rhiniti
without
provid
classif
diseas
trial
evalu
possibl
presenc
comorbid
asthma
discuss
basi
research
possibl
identifi
unexplor
area
hrqol
patient
affect
allerg
rhiniti
new
aria
classif
intermitt
persist
rhiniti
carri
treatment
order
fulli
appreci
effect
drug
use
ar
aldult
children
patient
hrqol
effect
comorbid
hrqol
extens
investig
hrqol
studi
includ
aspect
patient
perspect
life
ie
satisfact
adher
disturb
nocturn
sleep
excess
daytim
sleepi
sleepspecif
qualiti
life
impair
patient
allerg
rhiniti
danish
jamal
ashok
shah
vallabhbhai
patel
chest
institut
respiratori
medicin
delhi
india
background
nocturn
sleep
disturb
excess
daytim
sleepi
impair
qualiti
life
qol
allerg
rhiniti
often
overlook
patient
physician
alik
method
consecut
skin
allergi
test
posit
patient
allerg
rhiniti
match
control
subject
comput
tomographi
paranas
sinus
ctpn
patient
categor
allerg
rhiniti
group
allerg
rhiniti
sinus
group
control
group
evalu
nocturn
sleep
excess
daytim
sleepi
sleep
specif
qol
disturb
use
pittsburgh
sleep
qualiti
index
psqi
epsworth
sleepi
score
ess
nocturn
rhinoconjunct
qualiti
life
questionnair
nrqlq
respect
also
categor
bsneezerrunn
bblocker
result
patient
male
femal
group
group
group
patient
group
significantli
higher
mean
score
psqi
ess
nrqlq
questionnair
compar
group
season
allerg
rhiniti
sar
hypersensit
immun
respons
allergen
caus
nasal
ocular
symptom
lead
signific
declin
suffer
qualiti
life
qol
environment
exposur
chamber
eec
model
allergen
exposur
relationship
sar
score
qol
investig
end
special
rhinoconjunct
qol
eecrqol
questionnair
develop
evalu
qol
problem
experienc
patient
chamber
questionnair
contain
question
domain
nonnoseey
symptom
nne
practic
problem
pp
emot
problem
ep
global
assess
ga
aim
examin
whether
correl
exist
qol
instantan
score
sar
symptom
studi
subject
eec
secondli
determin
effect
sequenti
eec
visit
qol
method
group
ragweedsensit
studi
subject
expos
ragwe
pollen
eec
record
instantan
tss
everi
halfhour
consecut
day
relationship
eecrqol
score
tss
visit
examin
use
pearson
correl
linear
regress
result
four
visit
individu
domain
well
total
eecrqol
score
significantli
correl
symptom
score
see
tabl
subject
particip
subsequ
eec
visit
line
linear
regress
visit
show
clear
rightward
shift
gradual
increas
slope
conclus
qol
measur
eec
use
eecrqol
questionnair
significantli
correl
sar
symptom
subject
visit
day
chang
linear
regress
four
visit
indic
increas
sar
sever
accompani
subsequ
declin
qol
moreov
subject
appear
experi
greater
deterior
qol
visit
rate
declin
faster
worsen
sar
symptom
find
suggest
neg
effect
qol
associ
eec
confin
thu
confirm
import
develop
eecspecif
rqol
questionnair
furthermor
demonstr
crosssect
construct
valid
qualityassess
diseasespecif
qualiti
life
questionnair
rhiniti
rhinosinus
systemat
review
carolin
van
oen
ellen
v
reij
mirjam
spranger
wytsk
fokken
academ
medic
centr
ent
amsterdam
netherland
academ
medic
centr
medic
psycholog
amsterdam
netherland
background
recent
year
multipl
hrql
questionnair
develop
specif
rhiniti
rhinosinus
sever
review
describ
hrql
questionnair
concern
rhiniti
andor
rhino
sinus
howev
littl
attent
paid
qualiti
psychometr
properti
questionnair
object
aim
systemat
review
give
qualityassess
review
exist
diseasespecif
health
relat
qualiti
life
questionnair
concern
rhiniti
rhinosinus
adult
method
review
literatur
may
pubm
embas
medlin
identifi
studi
interest
addit
databas
aaaai
qualiti
life
resourc
patientreport
outcom
qol
instrument
databas
search
qualiti
assess
defin
characterist
qualiti
life
questionnair
assess
criteria
result
result
construct
descript
feasibl
psychometr
perform
instrument
provid
final
provid
clinician
guid
choos
questionnair
base
measur
goal
discrimin
valid
respons
point
obtain
qualiti
assess
top
score
instrument
regard
overal
qualiti
assess
health
relat
qualiti
life
caus
disord
ventil
drainag
middl
ear
mainli
disord
open
mechan
eustachian
tubeth
purpos
studi
evalu
persist
symptom
serou
otiti
media
children
adenoid
hypertrophi
allerg
rhiniti
materi
method
group
studi
made
patient
adenoid
hyperplasia
serou
otiti
media
examin
treat
pediatr
hospit
oradea
patient
diagnos
allerg
rhiniti
object
endocavitari
ent
examin
systemat
perform
patient
evalu
criteria
degre
hear
loss
serou
rhinorrhea
nasal
obstruct
sneez
perform
adenoidectomi
gener
anesthesia
patient
second
phase
month
later
patient
reevalu
clinic
audiolog
result
case
patient
group
adenoid
hypertrophi
serou
otiti
media
remit
case
month
reevalu
case
patient
allerg
rhiniti
adenoid
hypertrophi
serou
otiti
media
remit
case
fluctuant
evolut
month
reevalu
treatment
desloratadin
mucolit
agent
serou
otiti
media
remit
complet
second
evalu
case
first
group
studi
show
reduct
nasal
obstruct
patient
compar
second
group
recoveri
present
patient
certifi
hear
test
clinic
aspect
tympan
membran
otoscopi
conclus
result
adenoidectomi
improv
permeabl
eustachian
tube
diminish
effus
middl
ear
persist
case
patient
associ
allerg
rhiniti
antihistamin
drug
desloratadin
import
role
prevent
recurr
attack
serou
otiti
media
children
allerg
rhiniti
asthma
survey
clinic
psycholog
perspect
fulvio
braido
ilaria
baiardini
silvia
brandi
anna
porcu
giorgio
walter
canonica
univers
genoa
allergi
respiratori
diseas
genova
itali
background
exist
close
link
asthma
rhiniti
bring
consequ
therapi
diseas
manag
demonstr
mani
studi
object
trial
perform
follow
aim
assess
physician
knowledg
rhinitisasthma
comorbid
evalu
patient
manag
behaviour
experi
symptom
expect
investig
clinic
psycholog
mean
gp
patient
knowledg
method
gener
practition
asthmat
patient
involv
studi
ask
fill
two
differ
multiplechoic
questionnair
associ
asthma
rhiniti
impact
result
gener
practition
awar
asthmarhin
link
assum
comorbid
basi
clinic
experi
physician
make
diagnosi
autonom
asthmat
patient
experi
three
less
rhinit
symptom
symptom
symptom
symptom
deep
impact
daili
life
caus
sleep
problem
lack
concentr
difficulti
spare
time
sport
rhiniti
symptom
respons
worsen
asthma
increas
dyspnoea
cough
wheez
patient
state
interest
combin
therapi
approach
clinic
efficiaci
antileukotrien
threapi
allerg
rhiniti
chang
subject
object
paramet
qualiti
life
measur
cemal
cingi
kivanc
gunhan
eskisehir
osmangazi
univers
ent
eskisehir
turkey
celal
bayar
univers
ent
manisa
turkey
background
leukotrien
histamin
thought
quantit
promin
mediat
final
pathway
allerg
rhiniti
ar
intranas
corticosteroid
oral
antihistamin
cornerston
therapi
antileukotrien
therapi
combin
antihistamin
show
synergist
effect
treat
ar
howev
littl
data
object
paramet
qualiti
life
measur
method
multicent
prospect
random
plabebo
control
studi
random
patient
mild
moder
intermit
ar
three
group
fexofenadin
mgday
fexofenadin
plu
montelukast
mgday
fexofenadin
plu
placebo
nasal
endoscop
examin
object
upper
airway
measur
anterior
rhinomanometri
evalu
end
day
treatment
period
daili
symptom
score
standard
visual
analog
scale
va
daili
diari
qualiti
life
measur
result
nasal
endoscop
examin
show
addit
effect
turbin
congest
combin
therapi
object
nasal
airway
assess
reveal
total
nasal
resist
decreas
monotherapi
combin
therapi
p
g
averag
mean
symtom
score
nasal
congest
nasal
itch
sneez
point
signific
declin
first
three
day
howev
nasal
congest
score
better
antileukotrien
addon
therapi
posit
effect
qualiti
life
measur
mainli
sleep
daili
life
activ
perform
increas
combin
therapi
reveal
significantli
better
result
end
day
significantli
effect
placebo
side
effect
encount
conclus
data
provid
basi
optim
control
ar
antileukotrieneantihistamin
combin
therapi
control
nasal
congest
pronounc
subject
object
compar
antihistamin
alon
effect
might
due
addit
antiinflammatori
activ
provid
reduct
inflammatori
infiltr
cytokin
level
longterm
studi
need
evalu
clinic
effect
antileukotrien
especi
addon
therapi
avail
data
suggest
reason
safe
add
agent
standard
therapi
nasal
symptomatolog
remain
unresolv
role
montelukast
perenni
allerg
rhiniti
associ
sleep
disturb
daytim
somnol
background
one
main
manifest
perenni
allerg
rhiniti
congest
nasal
congest
predispos
sleep
apnea
microarous
sleep
disturb
result
daytim
somnol
fatigu
use
montelukast
may
effect
reduc
congest
object
subject
studi
lack
demonstr
reduct
congest
result
improv
sleep
reduc
somnol
purpos
research
determin
montelukast
effect
improv
sleep
daytim
somnol
patient
perenni
allerg
rhiniti
method
studi
crossov
doubleblind
placebocontrol
studi
use
montelukast
mg
tablet
match
placebo
approv
irb
activ
phase
studi
includ
runin
follow
treatment
period
week
wash
week
subject
cross
altern
arm
studi
week
subject
instrument
assess
sleep
daytim
somnol
util
sa
use
statist
assess
result
montelukast
mg
compar
placebo
statist
improv
daytim
sleepi
p
daytim
fatigu
small
cohort
unabl
significantli
demonstr
decreas
congest
howev
congest
reduc
scale
placebo
reduc
congest
conclus
montelukast
reduc
daytim
somnol
fatigu
may
suitabl
altern
topic
nasal
corticosteroid
unwil
use
intoler
nasal
steroid
daytim
impair
perenni
allerg
rhiniti
intranas
phototherapi
effect
fexofenadin
hydrochlorid
treatment
season
allerg
rhiniti
edina
garaczi
zsolt
bella
borosgyevi
emes
zsanett
csoma
lajo
andrea
koreck
univers
szege
dermatolog
allergolog
szege
hungari
univers
szege
otolaryngolog
head
neck
surgeri
szege
hungari
recent
show
intranas
phototherapi
repres
effici
therapeut
modal
treatment
allerg
rhiniti
aim
studi
compar
efficaci
intranas
phototherapi
second
gener
antihistamin
fexofenadin
hcl
allerg
rhiniti
random
open
studi
conduct
patient
histori
moder
sever
ragweedinduc
allerg
rhiniti
thirtyon
patient
randomli
assign
receiv
either
intranas
irradi
low
dose
uvb
uva
visibl
light
refer
muvvi
time
week
week
n
mg
fexofenadin
hcl
per
day
week
n
patient
kept
diari
symptom
nasal
obstruct
nasal
itch
rhinorrhea
sneez
palat
itch
treatment
total
nasal
score
tn
sum
score
nasal
symptom
also
calcul
muv
vi
group
individu
score
significantli
decreas
compar
baselin
paramet
sneez
p
rhinorrhea
p
nasal
itch
p
nasal
obstruct
p
palat
itch
p
fexofenadin
hcl
group
none
score
improv
significantli
end
treatment
except
sneez
p
tn
significantli
decreas
muvvi
group
p
signific
chang
observ
fexofenadin
hcl
group
conclus
found
intranas
phototherapi
effici
therapeut
tool
fexofenadin
hcl
reduc
clinic
symptom
allerg
rhiniti
burden
ill
allerg
rhiniti
canada
background
object
assess
burden
symptom
canadian
adult
allerg
rhiniti
ar
method
crosssect
randomdigitdi
telephon
survey
canadian
household
conduct
juli
identifi
adult
ar
patient
screen
adult
structur
interview
done
respond
patient
diagnos
physician
ar
take
medic
ar
result
canadian
adult
report
suffer
nasal
symptom
due
allergi
unrel
cold
less
half
diagnos
physician
half
season
symptom
spring
summer
worst
season
ar
asthma
chronic
recurr
sinus
nasal
polyp
onequart
toler
symptom
without
treatment
sought
medic
attent
symptom
one
time
onequart
done
past
year
bothersom
symptom
includ
stuffi
nose
runni
nose
repeat
sneez
water
eye
worst
month
twothird
patient
report
stuf
nose
either
daili
sever
day
per
week
almost
onequart
report
headach
sleep
loss
onefifth
describ
symptom
poorli
control
control
worst
month
year
onehalf
use
otc
product
use
prescript
onequart
use
conclus
despit
treatment
mani
canadian
experi
allerg
rhiniti
symptom
could
better
evalu
control
asthma
sinus
nasal
polyposi
common
concomit
condit
radiofrequ
tissu
ablat
treatment
persist
allerg
rhiniti
effect
qualiti
life
object
paramet
kivanc
gunhan
hali
unlu
ali
vefa
yuceturk
murat
songu
celal
bayar
univers
otorhinolaryngolog
headneck
surgeri
manisa
turkey
background
patient
suffer
persist
allerg
rhiniti
par
sever
drugresist
hypertrophi
increas
glandular
structur
inferior
turbin
may
develop
lead
constant
nasal
obstruct
rhinorea
radiofrequ
tissu
ablat
turbin
reduc
nasal
obstruct
secret
method
prospect
singlesit
studi
random
patient
mild
moder
par
substanti
bilater
hypertrophi
inferior
turbin
mometason
furoat
monohydr
nasal
spray
mfmn
spray
per
nostril
total
dose
daili
radiofrequ
inferior
turbin
ablat
rifa
punctur
site
total
dose
joul
plateau
temperatur
energi
watt
treatment
group
object
outcom
evalu
total
nasal
resist
anterior
rhinomanometri
subject
outcom
assess
qualiti
life
questionnair
analyz
least
month
treatment
result
median
total
nasal
resist
patient
treat
mfmn
decreas
pacm
pacm
p
pacm
pacm
patient
rifa
p
year
postop
compar
preoper
score
postop
score
patient
significantli
improv
separ
domain
score
overal
qualiti
life
questionnair
score
p
nasal
symptomatolog
markedli
reduc
month
radiofrequ
applic
advers
reaction
includ
bleed
infect
adhes
worsen
allerg
symptom
encount
patient
experienc
last
benefit
procedur
conclus
result
suggest
topic
mometason
reduc
volum
inferior
turbin
point
improv
qualiti
life
patient
par
radiofrequ
inferior
turbinoplasti
also
improv
qualiti
life
effect
decreas
nasal
resist
patient
par
substanti
nasal
congest
effect
might
due
switch
inflammatori
cell
fibrot
tissu
histopatholog
longer
term
studi
requir
enlighten
potenti
rifa
manag
allerg
rhiniti
role
allerg
rhiniti
suppur
chronic
otiti
media
prelaminari
report
background
eustachian
tube
dysfunct
signific
effect
pathogenesi
ear
diseas
especi
chronic
otiti
media
com
hand
allerg
rhiniti
preval
diseas
wellknown
condit
effect
eustachian
tube
function
role
serou
otiti
media
studi
sever
aspect
effect
chronic
suppur
otiti
media
without
cholesteatoma
studi
yet
method
prospect
case
control
studi
patient
suppur
chronic
otiti
media
candid
surgeri
healthi
sex
agematch
person
evalu
allergi
use
standard
questionnair
prick
test
serum
ige
result
fifteen
patient
six
control
allerg
rhiniti
result
show
higher
incid
allergi
patient
group
p
g
conclus
author
knowledg
first
document
survey
show
correl
allergi
chronic
otiti
media
extens
studi
effect
allergi
especi
allerg
rhiniti
chronic
otiti
media
even
postsurg
prognosi
strongli
recommend
nasal
mucosa
remodel
reactiv
epitheli
mesenchym
trophic
unit
human
allerg
rhiniti
tong
wang
tongren
hispit
beij
china
ent
depart
beij
china
object
investig
histopatholog
characterist
mark
chronic
inflammatori
reaction
remodel
role
reactiv
epitheli
mesenchym
trophic
unit
mark
structur
chang
nasal
mucosa
allerg
rhiniti
method
studi
divid
two
part
first
part
investig
whether
remodel
airway
mucosa
present
nasal
mucosa
allerg
rhiniti
second
part
investig
possibl
role
epitheli
mesenchym
trophic
unit
pathogenesi
inflamm
remodel
allerg
rhiniti
tissu
block
embed
paraffin
stain
hematoxylin
eosin
alcian
blue
period
acidschiff
abpa
masson
trichrom
mt
immunohistochem
stain
infiltr
eosinophil
nasal
mucosa
examin
abpasposit
cell
surfac
epithelium
nasal
mucosa
count
percentag
area
mt
stain
extracellular
matrix
mucosa
concha
damag
epithelium
determin
imag
analyz
immunohistochem
stain
reveal
egf
egfr
tgf
sma
immunoreact
nasal
mucosa
result
epitheli
damag
shed
basement
membran
thicken
submucosa
fibrosi
mucos
goblet
cell
hyperplasia
submuc
gland
hyperplasia
strikingli
eosinophil
infiltr
lymphocyt
infiltr
promin
patient
ar
compar
nonar
group
p
compar
control
group
immunohistochem
stain
reveal
egf
egfr
immunoreact
damag
epithelium
decreas
allerg
rhiniti
howev
stronger
tgf
sma
immunoreact
observ
allerg
rhiniti
mucosa
compar
normal
nasal
mucosa
conclus
histopatholog
find
asthma
epitheli
damag
goblet
cell
hyperplasia
extracellular
matrix
deposit
name
inflamm
featur
airway
remodel
also
present
allerg
rhiniti
mayb
result
activ
epithelialmesenchym
unit
lead
myofibroblast
activ
propag
remodel
respons
submucosa
concept
epithelialmesenchym
unit
mayb
contribut
understand
pathogenesi
allerg
rhiniti
may
provid
potenti
target
novel
therapi
allerg
rhiniti
zsolt
bella
edit
kadocsa
laszlo
szeke
jozsef
jori
univers
szege
ent
szege
hungari
medicent
medic
institut
ent
szege
hungari
object
previou
randomis
doubl
blind
clinic
studi
prove
intranas
phototherapi
use
combin
uvb
uva
visibl
light
muvvi
rhinolight
effect
modal
treat
allerg
rhiniti
ar
aim
studi
show
clinic
experi
grass
pollen
sensit
allerg
patient
method
treat
ar
patient
n
intranas
muvvi
patient
moderatesev
intermitt
grass
pollen
induc
ar
pollen
count
continu
rhinophototherapi
perform
monotherapi
combin
oral
antihistamin
day
orwith
nasal
steroid
maximum
intranas
caviti
irradi
time
week
week
muvvi
dose
irradi
rais
step
step
caviti
nasal
symptom
patient
regist
treatment
day
scale
total
symptom
visual
analog
scale
va
result
patient
drop
final
patient
got
full
therapi
monotherapi
muvvi
got
wors
patient
nt
chang
improv
va
muvvisdrug
got
wors
nt
chang
improv
nasal
symptom
significantli
improv
group
rhinophototherapi
toler
well
use
vitamin
oil
time
day
develop
pain
xeromucosa
could
avoid
patient
need
extra
one
brake
day
two
treatment
occas
conclus
result
suggest
intranas
phototherapi
alon
drug
combin
effect
modal
treat
grass
pollen
induc
ar
clinic
characterist
children
allerg
rhiniti
ar
vs
nonallerg
rhiniti
nar
univers
pediatr
allergi
clinic
chanthana
suratannon
nualanong
visitsunthorn
piyarat
lerdbannapong
mahidol
univers
siriraj
hosit
pediatr
bangkok
thailand
background
proper
differenti
chronic
rhiniti
ar
nar
essenti
sinc
avoid
offend
allergen
ar
could
rapidli
lead
allevi
symptom
wherea
nar
usual
chronic
nonremit
condit
unfortun
allergi
skin
test
feasibl
gener
practic
sever
countri
around
world
aim
studi
determin
specif
characterist
among
pediatr
patient
ar
nar
method
three
hundr
two
children
symptom
chronic
rhiniti
present
pediatr
allergi
clinic
januari
decemb
categor
group
ie
allerg
rhiniti
ar
nonallerg
rhiniti
nar
accord
skin
prick
test
result
nasal
cytolog
perform
subcategor
nar
nonallerg
rhiniti
eosinophilia
syndrom
nare
result
patient
ar
nar
nineteen
nar
patient
nare
median
age
onset
patient
ar
nar
year
old
respect
symptom
rhinorrhea
postnas
drip
nasal
congest
differenti
two
group
apart
interestingli
nasal
itch
sneez
eye
symptom
common
among
ar
nar
group
p
g
snore
sinus
common
nar
ar
group
p
g
season
sever
symptom
proport
asthma
differ
group
preval
food
allergi
common
ar
nar
group
p
g
conclus
ar
threefold
preval
nar
among
children
present
allergi
clinic
chronic
rhiniti
nasal
itch
sneez
common
ar
nar
group
p
g
snore
sinus
common
nar
ar
group
p
g
eye
symptom
histori
food
allergi
common
ar
nar
group
p
g
p
g
allerg
diseas
increas
global
health
problem
either
world
hungari
incid
allerg
rhiniti
new
case
oo
preval
oo
incid
allerg
asthma
oo
preval
oo
basic
treatment
allerg
diseas
receptor
antagonist
levocetirizin
new
oral
nonsed
antihistamin
shown
effect
allerg
symptom
offer
good
toler
object
collect
data
concern
treatment
allerg
diseas
gener
practic
measur
effect
levocetirizin
allerg
diseas
report
side
effect
levocetirizin
therapi
method
nationwid
survey
organ
hungari
use
questionnair
fill
two
time
start
end
treatment
period
inth
patient
particip
survey
allerg
diseas
treat
levocetirizin
monthsdata
questionnair
analys
patient
femal
male
p
g
patient
age
younger
result
patient
allerg
rhiniti
urticaria
allerg
asthma
atop
dermat
food
allergi
patient
symptom
allerg
diseas
longer
year
cutan
test
perform
diagnos
allerg
diseas
patient
posit
allerg
diseas
influenc
way
life
patient
patient
clinic
import
symptom
seriou
intermedi
end
survey
patient
clinic
signific
symptom
patientss
symptom
improv
allerg
rhiniti
persist
rhiniti
patient
becom
symptomless
ratio
symptom
free
case
allerg
asthma
atop
dermat
food
allergi
urticaria
patient
treat
combin
therapi
side
effect
occur
patient
treatment
period
summari
accord
result
month
treatment
allerg
diseas
levocetirizin
establish
levocetirizin
effect
decreas
clinic
symptom
allerg
diseas
well
toler
without
import
side
effect
frequenc
adenoid
hypertrophi
atopi
childhood
elena
korovkina
mechnikov
research
institut
vaccin
sera
allergolog
depart
moscow
russian
feder
background
adenoid
part
waldey
ring
basic
function
antibodi
format
react
later
great
varieti
antigen
pediatr
adenoid
obstruct
nasal
airway
associ
signific
morbid
frequent
indic
surgeri
relationship
allergi
often
studi
method
examin
influenc
atopi
adenoid
hypertrophi
studi
children
year
old
analys
group
children
suffer
difficulti
nose
breath
rhinorrhea
recurr
upper
respiratori
tract
infect
hear
disord
sleep
disturb
diagnost
adenoid
hypertrophi
use
anamnesi
anterior
rhinoscopi
endoscopi
rhinoscopi
patient
consult
allergistimmunologist
diagnosi
allerg
rhinti
use
interview
skin
pricktest
presenc
sige
rast
serum
nasal
provoc
test
dust
polen
allergen
result
children
adenoid
hypertrophi
degre
got
relaps
adenoid
surgeri
analis
group
children
posit
skin
pricktest
andor
posit
reaction
specif
ige
mostli
differ
kind
pollen
hous
dust
mite
eosiniphil
nasal
secret
posit
nasal
provoc
test
group
patient
bronchial
asthma
children
atop
dermat
patient
adenoid
allerg
rhiniti
got
complex
therapi
topic
nasal
steroid
antihistamin
age
dose
children
brochial
asthma
atop
dermat
also
receiv
pharmacolog
treatment
week
observ
signific
decreas
clinic
symptom
endoscop
adenoid
size
conclus
studi
show
allergi
sensit
differ
kind
allergen
import
risk
factor
greater
degre
adenoid
hypertrophi
children
chronic
allerg
inflamm
upper
airway
caus
lymphoid
hypertrophi
promin
adenoid
tonsillar
tissu
patient
difficulti
nase
breath
reccur
upper
respiratori
tract
infect
need
consult
allergistimmunologist
except
alleg
diseas
qualiti
life
patient
atop
asthma
associ
allerg
rhiniti
ion
gabriel
stoica
spitalul
de
pneumologi
ambulatoriul
tbc
sector
bucharest
romania
object
aim
studi
assess
effect
allerg
rhiniti
qualiti
life
patient
atop
asthma
method
examin
atop
asthmat
patient
persist
allerg
rhiniti
patient
atop
asthma
without
allerg
rhiniti
qualiti
life
measur
asthma
qualiti
life
questionnair
aqlq
clinic
symptom
score
use
rescu
medic
record
diari
week
assess
qualiti
life
lung
function
measur
day
studi
qualiti
life
result
clinic
symptom
score
use
shortyact
similar
group
differ
vs
p
asthma
symptom
score
activ
limit
within
aqlq
significantli
lower
patient
asthma
allerg
rhiniti
compar
asthma
patient
without
allerg
rhiniti
p
g
conclus
persist
allerg
rhiniti
may
neg
effect
asthma
symptom
qualiti
life
patient
atop
asthma
background
allerg
rhiniti
common
caus
rhiniti
affect
approxim
popul
allerg
rhiniti
lifethreaten
condit
complic
occur
condit
significantli
impair
qualiti
life
lead
number
indirect
cost
suscept
individu
exposur
certain
foreign
protein
lead
allerg
sensit
character
product
specif
ige
direct
protein
specif
ige
track
standard
skin
prick
test
method
materi
month
studi
case
allerg
disord
refer
allergi
clinic
among
allerg
rhiniti
standard
skin
prick
test
alust
prick
allergen
aeroallergen
food
allergen
perform
compar
neg
posit
standard
control
wheal
flare
larger
neg
control
regard
posit
test
result
analyz
spss
preval
allergen
calcul
differ
group
patient
regard
age
sex
type
allerg
rhiniti
perenni
season
result
male
mean
age
year
sd
femal
mean
age
sd
studi
among
patient
season
allerg
rhiniti
sar
patient
perenni
allerg
rhiniti
par
patient
par
season
aggrav
patient
episod
symptom
patient
less
year
patient
year
patient
year
histori
rhiniti
aeroallergen
sensit
detect
patient
botan
allergen
sensit
shown
present
patient
chenopodiacea
includ
chenopodium
alba
rough
pigwe
tree
especi
ash
platanu
willow
birch
grass
includ
artemisia
ryegrass
timothi
among
preval
botan
allergen
conclus
allerg
rhiniti
preval
allergi
caus
sign
symptom
genet
suscept
patient
confront
environment
allergen
studi
aeroallergen
studi
studi
aeroallergen
especi
botan
allergen
shown
common
allergen
season
perenni
allerg
rhiniti
sensit
one
aeroallergen
sensit
one
botan
allergen
rhiniti
allerg
azita
hekmatdoost
nader
h
rad
meran
ghoreishi
tehran
univers
medic
scienc
faculti
health
tehran
islam
republ
iran
introduct
accept
criteria
distinguish
allerg
nonallerg
rhiniti
aim
studi
compar
clinic
paraclin
featur
allerg
nonallerg
rhiniti
method
retrospect
studi
compar
clinic
paraclin
featur
allerg
non
allerg
rhiniti
patient
yearold
evalu
includ
respiratori
sign
symptom
lab
test
respiratori
function
test
result
patient
allerg
rhiniti
sign
symptom
within
season
term
cough
sneez
nasal
congest
rhinorrhea
itchi
eye
nose
respiratori
function
test
p
g
wherea
nonallerg
rhiniti
persist
symptom
headach
p
g
food
allergi
p
g
serum
ig
e
p
g
airway
hyperrespons
p
g
common
patient
allerg
rhiniti
conclus
result
indic
sign
symptom
fluctuat
allerg
rhiniti
sever
within
season
studi
respect
adult
children
rhiniti
recommend
allerg
nonallerg
rhiniti
adolesc
adult
levan
bolokadz
eugeniya
bolokadz
volodimir
fedotov
kharkov
allergolog
centr
allergolog
kharkov
ukrain
background
aim
studi
describ
differ
allerg
rhiniti
ar
nonallerg
rhiniti
nar
larg
communitybas
sampl
adolesc
adult
method
total
subject
year
age
screen
questionnair
report
histori
airway
symptom
suggest
asthma
andor
allergi
take
medic
condit
clinic
examin
particip
interview
respiratori
symptom
furthermor
skin
test
reactiv
lung
function
airway
respons
measur
use
standard
techniqu
result
total
subject
rhiniti
ar
wherea
nar
subject
nar
like
femal
p
persist
symptom
within
last
week
p
recur
headach
p
hand
subject
nar
less
like
airway
hyperrespons
p
g
food
allergi
p
treat
antihistamin
last
week
p
g
compar
subject
ar
subject
ar
symptomat
wors
within
season
term
sneez
p
g
itchi
eye
p
g
compar
subject
nar
wherea
nasal
congest
rhinorrhea
equal
frequent
two
group
p
p
respect
conclus
proport
subject
nar
adolesc
adult
popul
rhiniti
around
onefourth
women
nar
twice
often
men
gener
subject
nar
persist
equal
sever
symptom
compar
subject
ar
howev
subject
allerg
rhiniti
sneez
itchi
eye
within
particular
season
allergi
compar
subject
nonallerg
rhiniti
relationship
histamin
receptor
occup
ro
reduct
symptom
season
allerg
rhiniti
sar
levocetirizin
l
subject
expos
pollen
environment
exposur
unit
eeu
background
estim
vivo
ro
take
account
affin
antihistamin
histamin
receptor
free
plasma
concentr
far
better
predictor
human
pharmacodynam
evalu
inhibit
histamin
allergeninduc
wheal
flare
consid
vitro
affin
plasmat
halflif
gillard
et
al
inflamm
re
frossard
et
al
br
j
clin
pharm
purpos
studi
assess
whether
valid
also
pharmacodynam
model
score
symptom
sar
ragwe
sensit
subject
expos
ragwe
pollen
eeu
method
subject
mean
age
yr
mean
bodyweight
kg
expos
pollen
eeu
day
receiv
singl
dose
l
remain
eeu
pm
day
subject
expos
pollen
eeu
noon
primari
efficaci
variabl
reduct
baselin
major
symptom
complex
msc
score
calcul
sum
follow
symptom
runni
nose
itchi
nose
sniffl
nose
blow
sneez
wateri
eye
baselin
valu
msc
score
drug
administr
day
msc
score
evalu
differ
time
l
administr
see
tabl
plasma
concentr
differ
time
administr
singl
dose
mg
l
obtain
studi
healthi
volunt
mean
age
yr
mean
bodyweight
kg
balt
et
al
fund
clin
pharm
normal
therapeut
dose
mg
see
tabl
plasma
protein
bind
data
l
come
bree
et
al
fund
clin
pharm
ro
calcul
describ
gillard
et
al
inflamm
re
result
kinet
chang
baselin
msc
score
fit
much
better
ro
free
plasma
concentr
see
tabl
possibl
howev
free
plasma
concentr
l
repres
receptor
short
time
ro
valu
calcul
overestim
time
also
possibl
lag
time
ro
relief
symptom
conclus
eeu
model
confirm
previou
result
kinet
ro
l
better
predictor
efficaci
drug
plasma
pharmacokinet
express
matrix
metalloproteinas
timp
allerg
nasal
mucosa
inhibitor
mmp
known
timp
regul
mmp
function
allerg
rhiniti
ar
asthma
share
mani
similar
inflammatori
respons
epitheli
shed
basement
membran
thicken
fibrosi
seen
ar
contrast
nasal
polyp
share
featur
asthma
asthma
demonstr
increas
express
low
timp
nasal
polyp
hypothes
differenti
express
mmp
may
least
part
contribut
differ
ar
asthma
method
perform
nasal
allergen
challeng
nac
ar
patient
mite
allergen
disk
control
disk
analyz
number
mmp
timp
nasal
biopsi
min
hr
hr
post
challeng
elisa
examin
level
nasal
mucosa
ar
patient
result
min
post
nac
increas
hr
post
nac
hour
post
nac
significantli
increas
increas
min
min
hr
post
nac
mmp
ratio
high
level
high
allerg
nasal
mucosa
conclus
result
suggest
may
play
import
role
pathomechan
allerg
rhiniti
differenti
express
mmp
may
contribut
least
part
contribut
differ
ar
asthma
play
essenti
role
pathophysiolog
cri
j
pollinosi
mice
tokyo
medic
dental
univers
human
gene
scienc
center
tokyo
japan
background
prostaglandin
pg
major
prostanoid
produc
acut
phase
allerg
reaction
two
receptor
isol
dp
whether
particip
pathophysiolog
allerg
diseas
remain
unclear
investig
role
initi
allerg
rhiniti
mice
method
first
develop
novel
murin
model
pollinosi
type
season
allerg
rhiniti
pathophysiolog
differ
pollinosi
compar
wildtyp
defici
mice
effect
treatment
ramatroban
dual
antagonist
also
determin
result
repeat
intranas
sensit
cri
j
major
allergen
cryptomeria
japonica
pollen
absenc
adjuv
significantli
exacerb
nasal
symptom
cri
j
ige
product
nasal
eosinophilia
cri
j
vitro
product
submandibular
lymph
node
cell
addit
mrna
nasal
mucosa
significantli
elev
cri
j
mice
follow
repeat
intranas
sensit
cri
j
defici
mice
significantli
weaker
cri
j
product
nasal
eosinophilia
product
submandibular
lymph
node
cell
wildtyp
mice
similar
result
found
mice
treat
ramatroban
conclus
result
suggest
interact
elev
follow
sensit
play
proinflammatori
role
pathophysiolog
allerg
rhiniti
especi
pollinosi
mice
clinic
cours
allerg
rhiniti
asthma
chang
skin
prick
test
spirometri
aftermath
hurrican
katrina
prem
kumar
annett
fiorillo
sandhya
mani
dougla
barstow
lsu
allergyimmunolog
new
orlean
la
unit
state
background
allerg
rhiniti
asthma
preval
diseas
seen
everyday
practic
aftermath
hurrican
katrina
sever
patient
report
exacerb
allerg
rhiniti
allerg
conjunct
either
exacerb
develop
asthma
result
katrina
mani
home
flood
caus
signific
increas
mold
level
sought
investig
chang
report
symptom
correl
chang
skin
prick
test
spt
reactiv
andor
chang
spirometri
method
start
studi
look
patient
report
increas
allerg
symptom
previous
perform
spt
repeat
spt
compar
result
earlier
find
addit
patient
histori
asthma
complain
respiratori
symptom
spirometri
done
result
compar
done
katrina
result
four
five
patient
reactiv
mani
antigen
previous
anerg
reactiv
mold
increas
commonli
alternaria
aspergilu
fumigatu
cladosporium
addit
chang
spirometri
also
note
one
patient
initi
normal
spirometri
neg
methalcholin
challeng
develop
abnorm
spirometri
patient
markedli
decreas
improv
bronchodil
conclus
much
concern
effect
katrina
may
patient
health
mani
patient
demonstr
increas
symptom
relat
allerg
rhiniti
asthma
case
demonstr
atop
patient
new
orlean
sensit
new
allergen
patient
experienc
increas
symptom
rhiniti
conjunct
asthma
reevalu
spt
spirometri
thorough
histori
environment
exposur
larg
number
peopl
affect
katrina
studi
perform
patient
return
new
orlean
area
mechan
mast
cell
migrat
allerg
nasal
epithelium
chika
ozu
rubi
pawankar
takizawa
ryuta
nonaka
manabu
yagi
toshiaki
nippon
medic
school
departo
otorhinolaryngolog
tokyo
japan
object
mast
cell
increas
nasal
epithelium
patient
allerg
rhiniti
ar
yet
precis
mechan
increas
unclear
previous
report
nasal
mast
cell
express
exhibit
increas
chemotaxi
rant
suggest
role
rant
mast
cell
migrat
confirm
present
studi
examin
level
rant
eotaxin
scf
epithelium
lamina
propria
patient
ar
kinet
rant
tryptas
cell
epithelium
lamina
propria
nasal
allergen
challeng
method
elisa
examin
level
rant
eotaxin
scf
homogen
nasal
scrape
lamina
propria
ar
patient
ar
patient
perform
nasal
allergen
challeng
hous
dust
mite
took
biopsi
min
hr
hr
immunohistochemistri
examin
number
tryptas
rant
eotaxin
cell
compar
control
result
level
rant
eotaxin
scf
greater
epithelium
lamina
propria
minut
nasal
allergen
challeng
tryptas
rant
cell
increas
epithelium
six
hour
post
challeng
tryptas
rant
cell
increas
epithelium
hr
increas
tryptas
cell
detect
conclus
migrat
mast
cell
allerg
nasal
epithelium
occur
earli
min
parallel
increas
rant
cell
result
confirm
rant
one
critic
factor
regul
mast
cell
migrat
allerg
nasal
epithelium
explain
consequ
competit
two
drug
renal
excret
mediat
transport
protein
organ
cation
transport
pglycoprotein
effect
levocetirizin
dextrocetirizin
eutom
distom
cetirizin
respect
transport
substrat
tetraethylammonium
tea
investig
vitro
chines
hamster
ovari
cho
cell
stabli
transfect
method
cell
seed
well
plate
grown
confluenc
confluent
transport
experi
conduct
transport
buffer
contain
h
tea
levocetirizin
dextrocetirizin
posit
control
cimetidin
ad
well
interv
transport
buffer
remov
well
rins
three
time
ml
ice
cold
buffer
stop
transport
cell
solubil
aliquot
remov
scintil
count
result
levocetirizin
dextrocetirizin
inhibit
tea
uptak
cell
valu
respect
comparison
posit
control
cimetidin
inhibit
tea
uptak
ic
discuss
levocetirizin
weak
inhibitor
ic
valu
inhibit
tetraethylammonium
transport
levocetirizin
fold
c
max
steadi
state
follow
therapeut
dose
mg
unlik
levocetirizin
caus
drug
interact
interfer
renal
elimin
inhibit
renal
dextrocetirizin
weaker
inhibitor
levocetirizin
racem
cetirizin
also
unlik
caus
drug
interact
inhibit
express
glucocorticoid
receptor
glucocorticoidresist
allerg
rhiniti
akihiro
ishida
nobuo
ohta
masaru
aoyagi
yamagata
univ
school
medicin
depart
otolaryngolog
yamagata
japan
background
glucocorticoid
gc
commonli
use
antiinflammatori
reagent
treatment
chronic
allerg
diseas
includ
allerg
rhiniti
effect
gc
mediat
glucocorticoid
receptor
gr
upon
bind
gc
activ
gr
enhanc
transcript
antiinflammatori
gene
also
interact
protein
regul
inflamm
nuclear
howev
clinic
benefit
sometim
limit
patient
demonstr
persist
tissu
inflamm
despit
treatment
high
dose
gc
gener
consid
interfer
nonfunct
gr
variant
immun
cell
may
result
gcresist
gr
wellknown
natur
splice
variant
consist
amino
acid
includ
exon
part
code
region
bind
gc
report
increas
gr
express
patient
bronchial
asthma
ulcer
coliti
patient
respond
gc
administr
test
hypothesi
investig
correl
express
gr
gr
protein
patient
allerg
rhiniti
respons
gc
treatment
patient
group
consist
subject
allerg
rhiniti
show
persist
gcresist
result
requir
surgic
remov
gc
treatment
month
normal
control
nasal
tissu
obtain
subject
underw
maxillofaci
surgeri
expos
gc
treatment
perform
immunohistochem
analysi
detect
gr
gr
protein
nasal
tissu
result
conclus
compar
normal
subject
wherea
number
gr
posit
inflammatori
cell
decreas
number
gr
posit
cell
significantli
increas
nasal
tissu
patient
group
number
cell
similar
level
patient
normal
control
conclus
data
suggest
increas
express
gr
rel
gr
associ
gcresist
effect
azelastin
substanc
p
releas
nasal
lavag
nonallerg
rhiniti
patient
radoslaw
gawlik
barbara
jawor
lawrenc
dubusk
silesian
univers
school
medicin
allergi
immunolog
zabrz
poland
irin
allergi
immunolog
gardner
unit
state
introduct
nonallerg
rhiniti
condit
affect
patient
perenni
nasal
symptom
occur
either
alon
conjunct
allerg
rhiniti
neural
mechan
may
role
condit
studi
assess
impact
intranas
azelastin
concentr
substanc
p
sp
nasal
lavag
fluid
method
patient
defin
nonallerg
rhiniti
histori
examin
addit
presenc
neg
skin
prick
test
use
common
inhal
allergen
low
total
ige
use
phadia
cap
patient
treat
intranas
azelastin
two
spray
twice
daili
day
control
group
consist
patient
nonallerg
rhiniti
use
salin
nasal
spray
spray
twice
day
nasal
lavag
perform
day
treatment
period
intranas
azelastin
control
salin
nasal
spray
concentr
sp
nasal
lavag
fluid
determin
eia
assay
design
inc
usa
method
patient
record
nasal
symptom
daili
includ
rhinorrhea
sneez
pruritu
congest
use
visual
rate
scale
vr
baselin
concentr
sp
nasal
lavag
fluid
similar
azelastin
placebo
group
pgml
versu
pgml
significantli
lower
concentr
substanc
p
note
nasal
lavag
fluid
day
azelastin
treatment
pgml
compar
placebo
treatment
pgml
differ
azelastin
placebo
treat
group
vr
symptom
score
versu
also
statist
signific
demonstr
reduct
nasal
lavag
sp
level
occur
conjunct
improv
clinic
symptom
conclus
intranas
azelastin
reduc
substanc
p
releas
nasal
lavag
fluid
nonallerg
rhiniti
patient
associ
clinic
improv
day
treatment
period
efficaci
azelastin
perenni
nonallerg
rhiniti
may
relat
reduct
releas
sp
nonadrenerg
noncholinerg
neural
mediat
nasal
secret
doubl
blind
placebo
control
studi
clinic
efficaci
vivo
pharmacodynam
potassium
humat
treatment
hayfev
patient
inhal
allergi
sever
mechanist
studi
done
potassium
humat
deriv
bitumin
coal
last
year
establish
product
stimul
lymphocyt
prolifer
increas
product
growth
factor
howev
vivo
studi
done
antiinflammatori
effect
humat
deriv
coal
human
proven
humic
acid
extract
brown
coal
toxic
teratogen
effect
purpos
aim
studi
investig
potassium
humat
antiinflammatori
properti
patient
suffer
exacerb
hayfev
grass
pollen
season
south
africa
use
clinic
symptom
sign
well
establish
chang
inflammatori
marker
use
establish
new
laboratori
techniqu
total
symptom
score
hour
period
qualiti
life
questionnair
evalu
potassium
humat
daili
divid
dose
randomli
assign
atop
patient
present
acut
symptom
hayfev
patient
receiv
placebo
resembl
humat
treatment
period
one
month
preced
one
week
runin
period
symptom
score
scale
one
four
nasal
nonnas
symptom
global
clinic
impress
score
doctor
end
studi
measur
surfac
area
skin
prick
test
done
baselin
end
studi
restrict
inhal
indic
biggest
reaction
result
differ
presenc
improv
symptom
detect
group
result
qualiti
life
assess
also
group
flare
size
comparison
show
promis
result
signific
differ
p
g
observ
compar
result
treat
versu
placebo
group
respect
conclus
potassium
humat
show
promis
treatment
hayfev
allerg
rhiniti
studi
also
conduct
inflammatori
marker
show
posit
result
result
present
elsewher
durat
studi
one
month
might
influenc
result
evid
nasal
mucos
hyperreact
healthi
women
induc
high
level
estrogen
karin
toll
peter
graf
magnu
backheden
par
stjarn
karolinska
institutet
divis
otorhinolaryngolog
stockholm
sweden
karolinska
institutet
dept
women
child
health
stockholm
sweden
karolinska
institutet
lime
stockholm
sweden
background
pregnanc
rhiniti
common
condit
thought
affect
pregnant
women
annoy
mani
women
may
develop
time
pregnanc
usual
disappear
shortli
deliveri
caus
known
may
due
hormon
factor
data
shown
may
relat
high
estrogen
level
nasal
mucos
reactiv
knowledg
etiolog
condit
import
sinc
satisfactori
treatment
avail
aim
studi
determin
whether
nasal
mucos
reactiv
microcircul
chang
variou
level
estrogen
blood
constant
level
hormon
method
women
undergo
vitro
fertil
ivf
includ
examin
measur
nasal
mucosa
done
first
part
concentr
estrogen
blood
extrem
low
concentr
estrogen
high
nasal
mucosa
studi
combin
rhinostereometri
laserdoppl
flowmetri
challeng
histamin
swell
nasal
mucosa
record
rhinostereometri
optic
direct
noninvas
method
design
measur
nasal
mucos
swell
high
degre
accuraci
laserdoppl
flowmetri
noninvas
method
studi
microcircul
provid
continu
instantan
measur
nasal
mucos
blood
flow
combin
rhinostereometri
laserdoppl
flowmetri
advantag
use
two
noninvas
method
permit
direct
simultan
measur
congest
microcircul
result
rhinostereometri
found
increas
nasal
mucos
swell
histamin
challeng
estrogen
level
blood
high
laserdoppl
flowmetri
increas
microcirculatori
paramet
veloc
move
blood
cell
perfus
lower
estrogen
level
blood
high
conclus
high
level
estrogen
blood
ivf
treatment
healthi
women
may
induc
nasal
hyperreact
chang
microcircul
suggest
estrogen
play
role
pregnanc
rhiniti
effect
lactobacillu
paracasei
grass
pollen
allerg
rhiniti
sophi
nutten
jacquelin
wassenberg
audran
juli
moulin
annick
merceni
spertini
nestl
research
center
nutrit
health
depart
lausann
switzerland
chuv
servic
dimmunologi
et
dallergi
lausann
switzerland
background
lactobacillu
paracasei
strain
found
exert
antiallerg
effect
anim
model
aim
aim
present
studi
investig
effect
patient
allerg
rhiniti
grass
pollen
method
subject
yearsold
enrol
random
doubleblind
placebocontrol
crossov
studi
studi
consist
first
week
period
subject
consum
either
ferment
milk
contain
placebo
acidifi
milk
drink
washout
period
six
eight
week
final
week
period
crossov
first
treatment
phase
entir
studi
perform
pollen
season
clinic
symptom
analys
nasal
provoc
test
use
grass
pollen
allergen
immunolog
paramet
specif
immunoglobulin
serum
percentag
eosinophil
nasal
wash
cytokin
secret
restimul
pbmc
compar
two
treatment
period
result
trend
decreas
nasal
itch
favour
probiot
treatment
notic
signific
improv
nasal
blockag
favour
probiot
treatment
observ
howev
signific
chang
nasal
reaction
threshold
observ
end
first
second
treatment
period
whatev
sequenc
activ
product
placebo
product
consumpt
immunolog
paramet
analys
investig
side
effect
report
group
studi
period
conclus
decreas
nasal
blockag
observ
allerg
patient
nasal
challeng
grass
pollen
consumpt
ongo
analysi
immunolog
paramet
help
understand
mechan
lead
mitig
respiratori
allergi
symptom
fluticason
furoat
nasal
spray
demonstr
consist
efficaci
nasal
ocular
symptom
season
allerg
rhiniti
robert
naclerio
tom
toler
anna
ellsworth
univers
chicago
depart
surgeri
chicago
unit
state
glaxosmithklin
research
develop
research
triangl
park
nc
unit
state
background
fluticason
furoat
ff
novel
enhancedaffin
glucocorticoid
develop
topic
respiratori
use
data
four
randomis
studi
present
demonstr
consist
nasal
ocular
efficaci
ff
nasal
spray
ffn
adolesc
adult
patient
season
allerg
rhiniti
sar
method
patient
age
year
confirm
sar
enrol
four
studi
n
combin
total
receiv
oncedaili
doubleblind
treatment
ffn
n
combin
total
vehicl
placebo
spray
n
combin
total
week
individu
nasal
ocular
symptom
score
patient
categor
scale
none
sever
morn
even
nasal
ocular
efficaci
evalu
mean
chang
baselin
treatment
period
daili
reflect
total
nasal
symptom
score
rtnss
averag
pm
score
total
nasal
congest
nasal
itch
rhinorrhoea
sneez
daili
reflect
total
ocular
symptom
score
rtoss
averag
pm
score
total
eye
itchingburn
tearingwat
red
predos
instantan
total
nasal
symptom
score
itnss
total
ocular
symptom
score
itoss
also
assess
measur
symptom
control
result
signific
consist
greater
improv
rtnss
seen
ffn
placebo
across
four
studi
background
safeti
profil
novel
enhancedaffin
glucocorticoid
fluticason
furoat
ff
administ
use
uniqu
sideactu
devic
investig
children
perenni
par
andor
season
allerg
rhiniti
sar
method
safeti
evalu
integr
analysi
data
three
randomis
doubleblind
parallelgroup
studi
paediatr
patient
age
year
sar
par
patient
receiv
oncedaili
ff
nasal
spray
ffn
n
n
placebo
n
week
sar
studi
week
par
studi
assess
includ
evalu
advers
event
ae
clinic
laboratori
test
nasal
examin
ophthalm
examin
week
par
studi
electrocardiogram
ecg
studi
effect
oncedaili
ffn
serum
cortisol
sc
assess
domicil
set
patient
par
result
safeti
toler
issu
identifi
paediatr
patient
par
sar
integr
analysi
common
ae
incid
common
ffn
placebo
headach
nasopharyng
epistaxi
pyrexia
pharyngolaryng
pain
incid
drugrel
ae
similar
across
ffn
treatment
placebo
group
epistaxi
report
patient
respect
headach
patient
respect
data
par
studi
demonstr
sc
level
follow
administr
ffn
similar
follow
placebo
least
squar
mean
vs
treatment
ratio
confid
interv
suggest
ffn
associ
effect
hpa
axi
addit
plasma
level
ff
nonquantifi
conclus
oncedaili
ffn
favour
safeti
toler
profil
children
age
year
par
sar
furthermor
ffn
show
low
system
exposur
associ
hypothalamicpituitaryadren
axi
suppress
children
age
year
par
longterm
safeti
fluticason
furoat
nasal
spray
daili
adult
adolesc
perenni
allerg
rhiniti
background
fluticason
furoat
novel
enhancedaffin
glucocorticoid
uniqu
pharmacolog
properti
suitabl
topic
use
rhiniti
studi
investig
longterm
safeti
toler
fluticason
furoat
nasal
spray
ffn
month
adult
adolesc
perenni
allerg
rhiniti
par
method
follow
screen
period
patient
age
year
par
randomis
ratio
doubleblind
treatment
oncedaili
ffn
n
vehicl
placebo
nasal
spray
n
month
advers
event
ae
data
collect
use
diari
card
interview
studi
visit
investig
grade
ae
sever
mild
moder
sever
assess
relationship
ae
administr
studi
treatment
safeti
assess
urinari
cortisol
excret
nasal
ophthalm
examin
ecg
clinic
laboratori
test
plasma
level
ff
determin
blood
sampl
complianc
measur
use
diari
card
chang
bottl
weight
symptom
score
result
patient
complet
studi
demograph
characterist
similar
treatment
placebo
group
ffn
well
toler
incid
ae
ffn
group
similar
placebo
group
except
epistaxi
defin
observ
blood
nose
irrespect
quantiti
frequent
ffn
placebo
recipi
vs
clinic
meaning
differ
ffn
placebo
term
safeti
assess
includ
urin
cortisol
excret
mean
ophthalm
paramet
ecg
clinic
laboratori
test
plasma
level
ff
quantifi
major
patient
follow
administr
ffn
complianc
studi
treatment
high
base
diari
card
patient
complianc
bottl
weight
treatment
period
improv
reflect
total
nasal
symptom
score
greater
ffn
placebo
conclus
longterm
administr
ffn
daili
adult
adolesc
patient
par
reveal
safeti
profil
typic
intranas
corticosteroid
class
evid
clinic
relev
system
corticosteroid
exposur
preval
allerg
rhiniti
colleg
student
kenya
medic
train
collegenairobi
kenya
charl
gathiru
isaac
macharia
malindi
district
hospit
ear
nose
throat
depart
mombasa
kenya
univers
nairobi
depart
surgeryear
nose
throat
nairobi
kenya
background
allerg
rhiniti
one
commonest
atop
diseas
world
wide
yet
epidemiolog
kenya
remain
larg
unknown
current
one
questionnair
base
studi
intern
studi
asthma
allergiesisaac
children
document
kenya
object
primari
object
determin
preval
allerg
rhiniti
kenya
medic
train
colleg
student
age
year
object
determin
sever
pattern
symptomatolog
common
aeroallergen
involv
studi
group
method
studi
done
two
step
stage
use
stratifi
random
sampl
student
screen
symptom
allerg
rhiniti
base
intern
consesu
report
definit
rhiniti
stage
posit
respond
student
subject
physic
examin
skin
prick
test
confirm
presenc
allerg
rhiniti
result
point
preval
rate
found
sex
age
predilect
studi
group
averag
age
onset
year
season
peak
januari
juli
decemb
student
allerg
rhiniti
daili
activ
affect
certain
degre
sneez
commonest
smptom
hypertrophi
inferior
turbin
commonest
physic
find
patient
intermitt
diseas
student
allerg
rhiniti
famili
histori
atopi
commonest
aeroallergen
hous
dust
mite
least
aspergillu
niger
conclus
allerg
rhiniti
affect
signific
proport
colleg
student
symptom
impact
lifestyl
patient
common
aeroallergen
found
within
immedi
surround
eg
hous
dust
mite
control
patient
educ
proper
cheap
enviroment
control
measur
institut
eduard
semyatichko
valeriya
nemtsova
irina
tikhonova
kharkov
allergolog
center
allergolog
kharkov
ukrain
background
nasal
polyposi
np
often
coexist
asthma
rhiniti
polyp
histolog
typic
show
chronic
eosinophil
inflamm
includ
eosinophil
lymphocyt
plasma
cell
mast
cell
studi
mediat
level
leukocyt
valu
nasal
fluid
nf
eosinophil
cation
protein
ecp
total
ige
level
eosinophil
blood
allerg
nonallerg
patient
np
patient
allerg
rhiniti
ar
method
fortysix
patient
np
patient
ar
control
group
patient
season
ar
grass
pollen
ar
sensit
parietaria
ar
sensit
hous
dust
mite
hdm
enter
studi
twentyon
patient
np
also
allerg
patient
sensit
parietaria
hdm
wherea
nonallerg
patient
tryptas
histamin
valu
assay
nf
total
ige
determin
serum
ecp
valu
assay
nf
serum
eosinophil
quantifi
blood
nf
result
tryptas
level
significantli
higher
nf
patient
np
patient
without
np
vs
ul
p
g
correl
symptom
score
r
p
g
median
level
histamin
nf
patient
np
significantli
higher
patient
without
np
ngml
p
g
correl
symptom
score
median
level
ecp
nf
patient
np
significantli
higher
patient
without
np
vs
ngml
p
g
correl
symptom
score
r
p
g
regard
leukocyt
count
nf
signific
differ
rhiniti
patient
np
without
np
regard
serum
ecp
serum
total
ige
signific
differ
detect
two
group
blood
eosinophil
level
patient
np
significantli
higher
patient
without
np
vs
p
conclus
chronic
eosinophil
mucos
inflammatori
diseas
np
involv
selfsustain
mechan
independ
allergen
stimul
nasal
mucosa
increas
releas
inflammatori
mediat
contribut
develop
np
determin
oedema
increas
recruit
inflammatori
cell
eosinophil
mast
cell
also
play
key
role
process
physician
complianc
intern
guidelin
treatment
allerg
rhiniti
ralph
julian
univers
cologn
imsi
cologn
germani
background
allerg
rhiniti
ar
allergi
associ
high
burden
cost
diseas
also
consid
import
risk
factor
develop
asthma
within
time
slot
year
rhiniti
patient
develop
asthma
aria
guidelin
introduc
address
problem
make
treatment
recommend
allerg
rhiniti
base
concept
bone
airway
one
diseas
sever
studi
investig
implement
process
guidelin
stress
suitabl
daili
use
method
object
present
analysi
estim
complianc
accept
intern
guidelin
among
ent
specialist
gener
practition
treat
patient
allerg
rhiniti
purpos
examin
data
patient
use
ipd
metaanalysi
seven
postmarket
survey
collect
result
first
investig
data
pool
whole
result
show
patient
treat
ent
specialist
receiv
therapi
accord
intern
guidelin
contrast
gener
practition
heed
guidelin
recommend
next
examin
time
line
gener
regardless
physician
specialti
observ
rate
complianc
accept
higher
previou
year
moreov
case
patient
rhiniti
concomit
asthma
treat
ent
specialist
accord
aria
guidelin
conclus
result
evid
wellstructur
success
implement
process
aria
guidelin
ent
specialist
could
appli
recommend
practic
easili
compar
guidelin
howev
investig
also
show
aria
document
yet
found
way
daili
routin
gener
practition
find
thu
support
goal
set
bintern
primari
care
respiratori
group
implement
special
guidelin
gener
practition
primari
care
set
inhibit
nasal
reaction
secondgener
antihistamin
patient
japanes
cedar
pollinosi
artifici
pollen
exposur
chamber
ohio
chamber
kimihiro
okubo
minoru
gotoh
kazuhiro
hashiguchi
nippon
medic
school
depart
otolaryngolog
tokyo
japan
kitasato
institut
hospit
depart
otolaryngolog
tokyo
japan
background
pollinosi
season
allerg
rhiniti
due
pollen
antigen
preval
high
enough
call
nation
diseas
japan
among
mani
pollen
antigen
japanes
cedar
pollinosi
common
pollen
exposur
chamber
ohio
chamber
built
central
tokyo
japan
order
studi
season
allerg
rhiniti
sar
epinastin
hydrochlorid
epinastin
secondgener
antihistamin
larg
use
indic
allerg
rhiniti
japan
purpos
studi
investig
protect
efficaci
epinastin
patient
japanes
cedar
pollinosi
artifici
pollen
exposur
chamber
ohio
chamber
method
studi
design
doubleblind
studi
preliminari
studi
volunt
initi
expos
low
concentr
jc
hour
chamber
volunt
random
group
group
group
b
alloc
receiv
either
epinastin
mg
tablet
placebo
tablet
day
week
end
week
intervent
period
volunt
expos
low
concentr
jc
hour
end
anoth
week
intervent
period
volunt
expos
high
concentr
jc
hour
subject
nasal
ocular
symptom
record
minut
use
person
comput
system
amount
nasal
secret
measur
allergen
exposur
period
result
total
symptom
score
tss
epinastin
group
significantli
lower
placebo
group
low
concentr
jc
expos
howev
high
concentr
jc
expos
signific
differ
tss
observ
conclus
first
clinic
studi
use
japanes
cedar
pollen
wellcontrol
condit
ohio
chamber
studi
show
epinastin
daili
reduc
sever
allerg
symptom
compar
week
placebo
pollen
season
develop
nextgener
deliveri
system
allerg
rhiniti
fluticason
furoat
nasal
spray
jim
godfrey
glaxosmithklin
research
develop
ware
unit
kingdom
background
patient
allerg
rhiniti
ar
consid
eas
use
import
featur
prescript
nasal
spray
formulationrel
attribut
eg
medic
run
throatout
nose
bitter
tast
key
barrier
continu
use
thu
improv
deliveri
system
formul
may
help
improv
adher
nasal
spray
treatment
method
fluticason
furoat
nasal
spray
ffn
devic
design
optim
ergonom
follow
review
publish
data
key
dimens
oper
rang
requir
devic
oper
determin
devic
concept
model
evalu
user
group
whose
feedback
use
refin
finalis
design
reliabl
devic
test
vitro
eas
use
assess
phase
iii
clinic
studi
patient
ar
deliveri
system
develop
minim
step
use
suitabl
use
wide
patient
popul
easier
thirdparti
administr
allow
determin
medic
remain
pack
result
vitro
test
confirm
ffn
devic
robust
oper
reliabl
forc
appli
side
lever
deliv
consist
dose
even
left
unus
week
lowdos
volum
deliv
fine
mist
consist
deliv
minimis
amount
formul
avail
run
back
throat
drip
nostril
phase
iii
clinic
studi
patient
found
devic
easi
use
found
easi
carri
found
drug
product
comfort
use
addit
review
independ
ergonomist
conclud
ffn
devic
comfort
hold
easier
oper
current
btopdown
nasal
spray
devic
suitabl
use
children
young
year
uniqu
sideactu
deliveri
mechan
also
allow
easier
thirdparti
administr
conclus
novel
ffn
devic
easi
use
deliv
consist
dose
address
patientreport
barrier
use
exist
nasal
spray
method
total
patient
visit
us
ar
without
ba
enrol
review
clinic
data
follow
badetect
questionnair
base
intern
primari
care
respiratori
group
ipcrg
guidelin
result
statist
analyz
result
among
loss
fu
regular
visitor
respond
questionnair
phone
via
mail
respond
answer
ye
either
doctordiagnos
asthma
pivot
ipcrg
question
suspect
group
subsequ
develop
ba
ba
ba
show
higher
femal
rate
nonsuspect
group
nba
ba
male
younger
femal
higher
bmi
nba
p
g
respect
famili
allerg
diseas
nasal
polypsurgeri
frequent
ba
ba
longer
ar
durat
yr
nba
yr
accord
increas
ar
durat
ba
increas
linearli
p
current
ar
symptom
preval
ba
nba
atop
tendenc
skin
test
result
serum
total
ige
induc
sputum
eosinophil
differ
group
pulmonari
function
test
ba
male
show
lower
initi
l
fvc
l
p
g
respect
initi
methacholin
challeng
test
mtest
airway
hyperreact
ahr
g
mgml
common
ba
nba
conclus
ar
patient
mean
durat
year
suspect
develop
subsequ
ba
progress
might
suggest
femal
gender
younger
age
male
higher
bmi
femal
longer
ar
durat
frequent
ahr
posit
result
initi
mtest
ar
patient
without
lower
respiratori
symptom
follow
regularli
earli
diagnosi
subsequ
ba
possibl
roll
nitric
oxid
immun
marker
diagnosi
respiratori
patholog
venezuelan
scholar
children
background
propos
clear
associ
exhal
nitric
oxid
asthma
exacerb
evalu
nasal
mucu
sera
venezuelan
scholar
children
year
old
low
middl
socioeconom
background
cover
differ
area
caraca
venezuela
allerg
rhiniti
bronquial
asthma
method
children
evalu
valid
modifi
graffar
socioeconom
questionnair
allerg
rhiniti
asthma
atop
dermat
aria
gina
hannifin
criteria
skin
prick
test
alkabello
common
food
inhal
allergen
plu
total
ige
elisa
complet
blood
count
coulter
serial
fece
examin
ova
parasit
perform
children
pre
post
bronchodil
pef
spirometr
measur
valu
obtain
microloop
obtain
approv
ethic
committe
institut
biomedicin
ratifi
academ
council
medic
faculti
central
univers
venezuela
inform
consent
sign
parent
guardian
nasal
mucu
sera
children
detect
simpl
colorimetr
method
base
griess
methodolog
result
accord
clinic
evalu
children
classifi
four
group
healthi
children
children
rhiniti
without
asthma
children
asthma
without
rhiniti
children
asthma
plu
rhiniti
healthi
children
present
lower
valu
sera
x
nasal
mucu
x
rhiniti
children
higher
level
sera
nasal
mucu
find
statist
differ
nasal
mucu
level
compar
control
group
asthmat
children
level
lower
rhiniti
higher
healthi
control
group
conclus
nasal
mucu
studi
immun
paramet
nitric
oxid
rapid
simpl
methodolog
could
clarifi
local
inflammatori
process
relat
allerg
rhiniti
order
bring
better
strategi
diagnosi
also
evolut
treatment
induc
eosinophil
apoptosi
inject
steroid
nasal
polyp
kensuk
watanab
tomonori
eguti
sigenori
ohd
dokkyo
medic
univers
koshigaya
hospit
depart
otorhinolaryngolog
koshigaya
japan
background
wellknown
basic
protein
eosinophil
induc
respiratori
epitheri
disord
eosinophil
migrat
nasal
mucosa
return
circul
blood
stream
report
eosinophil
nasal
mucosa
mucu
degranul
cytolysi
prefer
treatment
allergi
eosinophil
promptli
exclud
nasal
mucosa
without
degranul
aspir
eosinophil
induc
apoptosi
necrosi
method
polyp
taken
right
nostril
patient
whose
mucu
mani
eosinophil
observ
corticosteroid
inject
polyp
left
nostril
two
day
steroid
injecion
polyp
left
nostril
taken
side
polyp
fix
glutaraldehyd
hour
postfix
osmic
acid
minut
embed
epon
ultrathin
cross
section
prepar
observ
transmiss
electron
microscop
total
number
eosinophil
macrophag
without
phagocytos
eosinophil
ulrathin
cross
section
localizaion
ssdnawa
examin
mark
apoptosi
result
nucleu
eosinophil
show
typic
characterist
apoptpsi
apopto
bodi
observ
steroid
inject
ssdna
admit
part
heterochromatin
nucleu
prove
apoptosi
caus
known
cell
phagocytos
macrophag
soon
induc
apoptosi
signific
differ
number
total
eosinophil
macrophag
polyp
steroid
administr
rate
eosinophil
phagocytosi
macrophag
significantli
increas
steroid
administr
conclus
clalifi
eosinophil
induc
apoptosi
steroid
administr
featur
nucleu
electron
microscop
proof
ssdna
eosinophil
induc
apoptosi
promptli
phagocytos
macrophag
acoust
rhinometri
children
allerg
rhiniti
fernando
de
la
torr
eva
perez
rodriguez
elena
rodriguez
plata
guacimara
hernandez
santana
victor
matheu
hospit
universitario
ns
candelaria
tenerif
spain
allergi
servic
santa
cruz
de
tenerif
spain
acoust
rinometri
ar
soundbas
techiniqu
reflect
wave
provid
inform
volum
area
nasal
caviti
ar
explor
abilitiy
assess
nasal
patenc
patient
suffer
nasal
obstruct
goal
studi
studi
basal
figur
endonas
measur
subject
allerg
rhiniti
dust
mite
winter
season
canari
island
subtrop
climat
high
humid
mild
temperatur
compar
subject
without
obstruct
method
patient
clinic
histori
rhiniti
assess
skin
prick
test
spt
mite
german
cockroach
perform
acoust
rinometri
perform
rinomet
rhinoscan
ser
modul
denmark
three
measur
made
nose
mean
area
distanc
curv
calcul
side
nose
curv
artifact
discard
patient
without
blockag
normal
minim
crosssect
area
mca
cnotch
valu
around
result
clinic
histori
rhiniti
posit
spt
mite
seen
patient
histori
mildsever
persist
rhiniti
patient
spt
neg
patient
patient
mca
locat
first
notch
inotch
correspond
itsmu
nasi
remaind
mca
locat
second
notch
cnotch
correspond
head
inferior
turbin
studi
averag
distanc
calcul
nostril
head
inferior
turbin
mm
averag
mca
allerg
patient
nonallerg
rhiniti
patient
signific
differ
group
conclus
measur
ar
similar
allerg
nonallerg
rhiniti
patient
patient
mca
locat
first
notch
inotch
correspond
itsmu
nasi
ar
major
advantag
method
assess
nasal
patenc
sinc
simpl
method
requir
minim
cooper
clinic
therapeut
aspect
moderatesever
allerg
rhiniti
transylvania
ioana
adriana
bujor
diana
dumitrascu
luis
horvath
univers
medicin
pharmaci
biuliu
hasieganu
medic
clinic
allergolog
cluj
napoca
romania
background
moderatesever
allerg
rhiniti
msar
affect
nasal
mucosa
induc
allergen
exposur
produc
specif
ige
mediat
chronic
inflamm
symptom
present
day
week
week
aria
guid
symptom
interf
activ
sleep
relat
msar
incid
allerg
rhiniti
frequent
adolesc
young
peopl
usual
financi
resourc
therapi
topic
corticosteroid
immunotherapi
smar
patient
reduc
qualiti
life
absente
cost
seem
import
health
problem
method
aim
studi
evalu
patient
smar
last
year
month
age
year
medium
age
patient
complet
questionnair
nasal
symptom
effect
treatment
antihistamin
topic
corticosteroid
immunotherapi
evalu
skin
prick
test
inhal
allergen
rhinoscopi
nasal
mucosa
questionnair
symptom
score
result
major
msar
polisensit
dust
mite
cat
pollen
cockroach
mould
dog
patient
monosensit
hous
dust
mite
score
symptom
highov
day
day
last
daysw
evalu
nasal
congest
rhinoreea
nasal
itch
sneez
antihystamin
therapi
lower
efficiencyto
one
patient
polisensit
patient
sever
congest
practic
effect
patient
none
feel
better
therapeut
method
higher
effici
topic
corticosteroid
witch
make
obviou
amelior
score
symptom
decreas
day
day
financi
aspect
patient
msar
show
could
provid
topic
corticosteroid
least
month
patient
conclus
msar
hard
treat
control
without
topic
corticosteroid
effect
olopatadin
hydrochlorid
rhiniti
induc
intranas
instil
rat
tadafumi
tamura
masato
komai
kyowa
hakko
kogyo
co
ltd
pharmaceut
research
center
shizuoka
japan
background
main
symptom
allerg
rhiniti
sneez
rhinorrhea
nasal
obstruct
patient
ar
level
neurotrophin
nerv
growth
factor
ngf
neuropeptid
substanc
p
sp
increas
therefor
consid
import
modul
develop
ar
olopatadin
hydrochlorid
olopatadin
antiallerg
agent
histamin
receptor
antagonist
action
report
olopatadin
inhibit
elev
level
ngf
sp
mous
model
chronic
inflammatori
dermat
object
investig
whether
olopatadin
effect
product
ngf
sp
use
tdisensit
rat
anim
model
nasal
allergi
method
intranas
challeng
tdi
number
sneez
count
blind
way
determin
ngf
sp
product
nasal
lavag
fluid
nalf
rat
anesthet
nasal
lavag
done
olopatadin
oral
administ
oral
nasal
instil
tdi
result
tdichalleng
rat
nasal
allergylik
behavior
sneez
rhinorrhea
inflamm
provok
tdi
challeng
amount
ngf
sp
nalf
increas
olopatadin
reduc
nasal
allergylik
behavior
moreov
olopatadin
inhibit
increas
ngf
sp
product
conclus
find
suggest
increas
ngf
sp
product
one
mechan
respons
nasal
allergylik
behavior
tdichalleng
rat
result
suggest
suppress
neurogen
inflammatori
reaction
might
partial
involv
improv
allergylik
behavior
treatment
olopatadin
topic
steroid
reduc
subject
object
measur
nasal
congest
persist
allerg
rhiniti
kivanc
gunhan
hali
unlu
ali
vefa
yuceturk
murat
songu
celal
bayar
univers
otorhinolaryngolog
headneck
surgeri
manisa
turkey
background
nasal
breath
essenti
maintain
physiolog
function
upper
lower
airway
predomin
symptom
allerg
rhiniti
nasal
congest
also
signific
impact
qualiti
life
work
product
patient
suffer
persist
allerg
rhiniti
par
sever
drugresist
hypertrophi
increas
glandular
structur
inferior
turbin
may
develop
lead
constant
nasal
obstruct
object
method
strongli
recommend
use
evalu
pharmacolog
agent
expect
improv
nasal
airflow
method
prospect
singlesit
studi
random
patient
mild
moder
par
substanti
bilater
hypertrophi
inferior
turbin
desloratadin
mgday
addit
mometason
furoat
monohydr
nasal
spray
mfmn
spray
per
nostril
total
dose
daili
treatment
group
patient
previou
treatment
concomit
sinonas
disord
system
diseas
exclud
object
outcom
evalu
total
nasal
resist
anterior
rhinomanometri
subject
outcom
assess
endoscop
nasal
examin
qualiti
life
questionnair
analyz
least
month
treatment
result
median
total
nasal
resist
patient
treat
mfmn
decreas
p
least
month
later
compar
pretreat
score
post
treatment
score
patient
significantli
improv
separ
domain
score
overal
rhinoconjunct
qualiti
life
questionnair
score
p
nasal
symptomatolog
reduc
month
mfmn
applic
advers
reaction
includ
bleed
infect
hormon
disord
encount
patient
experienc
last
benefit
treatment
conclus
nasal
congest
affect
individu
allerg
rhiniti
notabl
impact
qualiti
life
emot
function
product
abil
perform
daili
activ
result
suggest
topic
mometason
reduc
volum
inferior
turbin
point
significantli
improv
qualiti
life
patient
par
histopatholog
longer
term
studi
larger
group
enlighten
potenti
mechan
efficaci
topic
steroid
manag
inferior
turbin
hypertrophi
patient
par
topic
treatment
perenni
allerg
rhiniti
children
felicia
manol
faculti
medicin
oradea
otorhinolaryngolog
oradea
romania
background
topic
corticosteroid
accept
safe
effect
control
symptom
allerg
nonallerg
rhiniti
mometason
furoat
monohydr
nasal
spray
daili
topic
corticosteroid
prepar
object
evalu
efficaci
safeti
mometason
furoat
monohydr
nasal
spray
children
year
age
perenni
allerg
rhiniti
method
doubleblind
placebocontrol
parallel
group
recruit
patient
evalu
treatment
daili
mometason
furoat
monohydr
nasal
spray
mcg
daili
placebo
week
follow
followup
period
fortyeight
patient
group
treat
mometason
furoat
monohydr
nasal
spray
placebo
random
assign
result
statist
signific
sex
mean
age
weight
height
two
group
patient
treat
mometason
furoat
monohydr
nasal
spray
show
signific
decreas
total
symptom
score
rate
physician
week
week
respect
p
g
p
g
rhiniti
symptom
score
treatment
group
rate
patient
nasal
blockag
sneez
wateri
rhinorrhea
significantli
decreas
week
p
g
p
g
nasal
symptom
assess
doctor
turbin
swell
color
nasal
mucosa
secret
postnas
drip
also
decreas
week
statist
signific
except
secret
week
postnas
drip
week
p
g
evid
effect
adren
function
morn
plasma
cortisol
concentr
two
group
conclus
mometason
furoat
monohydr
nasal
spray
safe
effect
well
toler
children
age
year
perenni
allerg
rhiniti
incid
advers
event
compar
placebo
effect
season
allerg
rhiniti
fatigu
level
mood
ziad
adwan
saha
allergi
reo
de
janero
brazil
object
mani
allergi
patient
complain
fatigu
moodi
dysphoria
allergi
season
studi
evalu
effect
symptomat
allerg
rhiniti
fatigu
level
mood
method
symptomat
ragwe
allerg
rhiniti
patient
medic
healthi
control
subject
complet
multidimension
fatigu
inventori
posit
affectneg
affect
mood
rate
scale
inoutin
ragwe
season
research
design
result
ragwe
season
allerg
patient
report
higher
level
gener
fatigu
mental
fatigu
physic
fatigu
well
reduc
motiv
patient
describ
experienc
feel
greater
sad
reduc
pleasur
engag
increas
anxieti
emot
distress
report
conclus
find
suggest
allerg
reaction
ragwe
pollen
caus
signific
fatigu
mood
chang
least
subgroup
patient
psychoneuroimmunolog
medic
genet
research
suggest
allerg
reaction
engend
biochem
chang
directli
affect
central
nervou
system
sheenyi
fang
nation
cheng
kung
univers
hospit
dept
otolaryngolog
tainan
taiwan
background
levocetirizin
levo
potent
latestgener
nonsed
oral
data
taiwanes
popul
yet
publish
object
primari
patient
percept
levo
treatment
allerg
rhiniti
ar
secondari
advers
event
ae
incid
intermitt
iar
persist
per
ar
defin
aria
taiwan
method
multicent
observ
studi
medic
center
conduct
may
march
taiwan
assess
treatment
percept
ar
patient
levo
runni
nose
nasal
ocular
pruritu
sneez
nasal
obstruct
measur
absent
sever
total
symptom
score
sum
symptom
rang
asthma
symptom
per
gina
mild
moder
daili
sever
continu
determin
observ
period
week
onset
action
rate
rapid
rapid
moder
visual
analogu
scale
va
use
evalu
global
satisfact
patient
physician
rang
result
patient
includ
complet
studi
patient
lost
followup
due
ae
none
seriou
patient
concomit
asthma
per
diagnos
iar
patient
improv
baselin
end
treatment
overal
efficaci
toler
assess
bgood
excel
patient
respect
least
patient
bmoderateseveresymptom
report
complet
recoveri
mark
improv
individu
symptom
subject
report
onset
action
rapid
rapid
levo
report
better
previou
therapi
patient
bgood
excellentimprov
qualiti
sleep
daili
activ
report
result
season
intermitt
allerg
rhiniti
treatment
mild
form
rhiniti
episod
symptom
treatment
begun
per
oral
topic
administr
antihistamin
nonsed
drug
variant
treatment
topic
decongest
longer
day
per
oral
decongest
recommend
children
eye
symptom
prevail
rhiniti
symptom
stop
administr
per
oral
antihistamin
prepar
prepar
may
addit
use
eye
drop
case
moder
sever
sever
form
episod
symptom
treatment
includ
per
oral
antihistamin
prepar
decongest
topic
glucocorticoid
alltheyearround
persist
allerg
rhiniti
case
light
clinic
cours
symptom
diseas
requir
special
treatment
measur
elimin
allergen
may
perform
variant
medicament
therapi
includ
per
oral
topic
antihistamin
prepar
per
oral
antihistamin
prepar
decongest
topic
glucocorticosteroid
efficaci
therapi
perform
must
evalu
week
moder
sever
sever
form
rhiniti
prepar
first
line
topic
glucocorticosteroid
sharp
disturb
nasal
breath
treatment
may
ad
short
cours
system
steroid
therapi
effect
therapi
evalu
week
conclus
caus
insuffici
efficaci
topic
glucocorticosteroid
may
irregular
dose
prepar
physician
patient
insuffici
administr
prepar
nasal
caviti
sharp
edema
mucou
membran
presenc
concomit
patholog
deform
nasal
septum
chronic
rhinosinus
other
power
effect
unremov
allergen
irregularli
establish
diagnosi
impact
flixonas
qualiti
life
paediatr
patient
season
allerg
rhiniti
maia
kherkheulidz
nani
kavlashvili
nino
adamia
eka
kandelaki
state
medic
univers
pediatr
tbilisi
georgia
aim
studi
investig
efficaci
flixonas
children
season
allerg
rhiniti
evalu
impact
treatment
qualiti
life
year
old
outpati
children
season
allerg
rhiniti
enrol
clinic
studi
evalu
histori
clinic
symptom
sever
nasal
symptom
sever
sneez
runni
nose
itch
stuffi
nonnas
symptom
sever
eye
ear
throat
symptom
chronic
cough
headach
rhinoscopi
swell
hyperemia
mucou
evalu
allerg
marker
eosinophyl
nasal
lavag
detect
diagnosi
rhiniti
studi
blood
immun
data
ige
assess
qualiti
life
use
junip
rinoconiuct
qualiti
life
pediatr
adolesc
scale
baselin
result
show
eosinophilia
peripher
blood
observ
patient
ige
hyper
product
determin
correl
link
ige
hyper
product
sever
diseas
eosinophil
count
nasal
lavag
flixonaz
administ
mcg
day
treatment
flixonas
time
treatment
day
show
signific
improv
clinic
symptom
patient
condit
reduct
nasal
well
nonnas
sever
symptom
medic
assess
averag
score
time
observ
decreas
eosinophil
count
nasal
lavag
two
week
trial
period
overal
rqlq
score
treat
patient
improv
baselin
conclud
use
flixonazein
paediatr
patient
season
allerg
rhiniti
improv
patient
condit
well
qualiti
life
allerg
rhiniti
especi
nasal
microflora
children
background
staphylococcu
aureu
prove
play
unduestion
role
develop
atop
dermat
connect
investig
bacteria
role
dermat
pathogenesi
consider
interest
aim
present
studi
investig
microbi
microflora
nasal
caviti
patient
persist
allerg
rhiniti
par
method
total
par
suffer
age
year
investig
bacteriolog
studi
nasal
secret
carri
result
staphylococcu
haemolyticu
diagnosticali
insignific
titer
isol
everi
second
person
group
par
patient
n
staphylococcu
aureu
diagnosticali
insignific
titer
isol
patient
high
level
dissemin
koeml
note
patient
staphylococcu
n
staphylococcu
n
par
patient
along
atop
bronchial
asthma
n
rise
staphylococcu
haemolyticu
n
staphylococcu
n
observ
patient
isol
staphylococcu
ureu
strain
combin
klebsiella
escherichia
coli
citrobact
spp
isol
permiss
normal
microflora
valu
equal
staphylococcu
haemolyticu
n
n
staphylococcu
aureu
streptococcu
haemolyticu
isol
patient
group
par
patient
along
atop
dermat
n
staphylococcu
aureu
patient
studi
main
repres
nasal
caviti
microbiocenosi
conclus
preval
staphylococc
found
cours
studi
nasal
caviti
par
patient
may
suqgest
abil
microorgan
support
allerg
inflamm
efficaci
topic
desensit
chronic
rhinosinus
nasal
polyposi
associ
nonsteroid
antiinflammatori
drug
hypersensit
background
subject
suffer
aspirin
nonsteroid
antiinflammatori
drug
nsaid
hypersensit
frequent
develop
chronic
rhinosinus
cr
nasal
polyposi
np
previou
studi
show
aspirinlysin
topic
desensit
may
effect
cr
np
treatment
prevent
recurr
np
aim
studi
evalu
efficaci
topic
desensit
sodium
diclofenac
patient
sd
nsaid
hypersensit
chronic
rhinosinus
nasal
polyposi
method
ten
subject
male
femal
mean
age
year
intranas
polypotomi
posit
result
nasal
challeng
sd
underw
topic
sd
desensit
daili
treatment
sd
mg
year
addit
patient
receiv
intranas
corticosteroid
stabl
dose
result
signific
reduct
total
endoscop
count
p
g
nasal
symptom
score
p
g
subgroup
combin
desensit
topic
corticosteroid
therapi
subgroup
improv
nasal
inspiratori
peak
flow
lmin
lmin
p
g
pulmonari
function
use
inhal
corticosteroid
decreas
recurr
nasal
polyposi
patient
one
year
observ
conclus
topic
sodium
diclofenac
desensit
effect
treatment
chronic
rhinosinus
nasal
polyposi
associ
nsaidshypersensit
influenc
allerg
rhiniti
outcom
function
endoscop
sinu
surgeri
sylvi
meuret
heidrun
mueller
gero
strauss
andrea
dietz
univers
clinic
leipzig
ent
depart
leipzig
germani
background
exact
pathogenesi
nasal
poyposi
np
still
unknown
empir
data
show
patient
suffer
np
allerg
rhiniti
ar
benefit
much
function
endoscop
sinu
surgeri
fess
patient
without
ar
method
studi
want
present
expiri
fess
patient
ar
patient
includ
devid
three
group
patient
ar
without
np
without
fess
patient
ar
np
fess
patient
sit
b
patient
without
sit
patient
np
without
ar
protocol
includ
score
symptom
endoscopi
find
cct
sinus
result
gener
patient
group
better
outcom
fess
patient
group
group
benefit
fess
group
conclus
investig
show
tendenc
patient
np
ar
treat
sit
better
outcom
fess
patient
without
ar
express
mammaglobin
b
differ
nasal
polyp
without
allerg
rhiniti
supinda
saengpanich
chuntima
phannaso
siraprapa
tongkobpetch
songklot
aeumjaturapat
yong
poovorawan
kanya
suphapeetiporn
vorasuk
shotelersuk
chulalongkorn
univers
depart
otolaryngolog
bangkok
thailand
king
chulalongkorn
memori
hospit
depart
otolaryngolog
bangkok
thailand
chulalongkorn
univers
depart
pediatr
bangkok
thailand
background
nasal
polyposi
chronic
diseas
nose
sinus
actual
caus
remain
unclear
mammaglobin
implic
pathogenesi
nasal
polyp
howev
associ
occurr
nasal
polyp
presenc
allerg
rhiniti
explor
object
aim
studi
compar
express
level
mammaglobin
b
nasal
polyp
allerg
rhiniti
without
allerg
rhiniti
method
patient
bilater
nasal
polyposi
underw
skin
prick
test
specif
aeroallergen
nasal
polyp
tissu
obtain
patient
divid
group
nasal
polyp
allerg
rhiniti
nasal
polyp
without
allerg
rhiniti
depend
skin
prick
test
result
polyp
tissu
analyz
level
mammaglobin
mammaglobin
b
use
realtim
quantit
polymeras
chain
reaction
techniqu
rtqpcr
result
sampl
patient
nasal
polyp
allerg
rhiniti
one
express
detect
level
mammaglobin
detect
express
mammaglobin
tissu
group
nasal
polyp
without
allerg
rhiniti
express
mammaglobin
b
detect
nasal
polyp
tissu
group
mean
express
mammaglobin
b
significantli
differ
nasal
polyp
allerg
rhiniti
rang
nasal
polyp
without
allerg
rhiniti
rang
conclus
express
mammaglobin
b
differ
nasal
polyp
without
allerg
rhiniti
find
suggest
mammaglobin
implic
pathogenesi
nasal
polyp
independ
underli
allerg
rhiniti
characterist
associ
condit
acut
sinus
thai
children
prospect
evalu
patient
maleewan
kitcharoensakkul
orapan
poachanukoon
faculti
medicin
thammasat
univers
depart
pediatr
pathumthani
thailand
backgroud
sinus
common
diseas
children
even
though
new
research
find
continu
publish
variou
aspect
diseas
report
clinic
characterist
associ
condit
still
limit
object
describ
characterist
associ
condit
acut
sinus
thai
children
materi
method
studi
consist
acut
sinus
patient
present
thammasat
univers
hospit
acut
sinus
diagnos
basi
clinic
present
includ
persist
sever
worsen
nasal
symptom
inform
consent
form
obtain
patient
studi
radiographi
use
aid
diagnosi
acut
sinus
allerg
skin
prick
test
also
perform
studi
result
age
rang
patient
year
mean
sd
year
histori
allerg
rhiniti
confirm
posit
skin
prick
test
nasal
cytolog
found
parent
histori
atopi
found
posit
histori
tobacco
smoke
found
famili
member
diagnosi
cold
sinu
infect
time
found
patient
attend
day
care
school
five
day
per
week
patient
histori
swim
dive
past
month
patient
past
histori
sinu
diseas
four
common
symptom
nasal
blockag
rhinorrhea
nighttim
cough
snore
three
common
sign
swell
turbin
erythema
turbin
tonsillar
enlag
paranas
sinus
xray
abnorm
maxillari
sinu
commonli
involv
sinu
follow
ethmoid
sinu
patient
involv
one
sinu
adenoid
hypertrophi
posit
patient
skin
prick
test
posit
patient
test
perform
conclus
nasal
blockag
rhinorrhea
nighttim
cough
snore
common
acut
sinus
present
studi
demonstr
allerg
rhiniti
recurr
sinus
common
patient
alter
paranas
sinu
mucosa
children
allerg
rhiniti
felicia
manol
faculti
medicin
oradea
otorhinolaryngolog
oradea
romania
purpos
studi
determin
alter
paranas
sinus
pediatr
patient
diagnos
allerg
rhiniti
studi
patient
age
diagnos
allerg
rhiniti
period
associ
diseas
establish
asthma
sinus
serou
otiti
media
hypertroph
chronic
pharyng
allerg
rhiniti
found
perenni
case
season
case
associ
sinus
diagnos
patient
high
level
ig
e
patient
season
rhiniti
main
clinic
symptom
nasal
discharg
nasal
obstruct
sneez
headach
eye
itch
cough
postnas
drip
clinic
radiolog
examin
xray
paranas
sinus
shown
alter
maxillari
ethmoid
frontal
sinu
mucosa
mucosa
swollen
serou
effus
result
studi
demonstr
maxillari
ethmoid
sinus
predomin
affect
patient
season
allerg
rhiniti
radiolog
examin
shown
predomin
lesion
type
sinus
swollen
mucosa
postnas
drip
cough
associ
allerg
rhiniti
indirect
symptom
alter
paranas
sinus
allerg
rhiniti
children
must
consid
isol
disord
must
consid
context
system
allerg
disord
sinu
disord
children
often
misdiagnos
nasal
mucos
edema
level
middl
meatu
favor
associ
sinu
disord
presenc
eosinophil
inflamm
airway
remodel
sign
sinu
tissu
patient
asthma
chronic
rhinosinus
dilek
saka
cem
saka
filiz
cimen
sema
canbakan
stemihan
ak
n
funda
demirag
nermin
capan
ataturk
chest
diseas
chest
surgeri
educ
research
hospit
respiratori
medicin
ankara
turkey
diskapi
yildirim
beyazit
educ
research
hospit
otorhinolaryngologyhead
neck
surgeri
ankara
turkey
ataturk
chest
diseas
chest
surgeri
educ
research
hospit
patholog
ankara
turkey
background
chronic
rhinosinus
exist
high
amount
asthma
patient
still
unknown
whether
caus
effect
relationship
present
two
diseas
manifest
underli
diseas
process
affect
whole
respiratori
tract
object
aim
studi
find
sinu
tissu
chronic
rhinosinus
asthma
relat
histolog
featur
eosinophil
inflam
airway
remodel
method
sinu
tissu
taken
asthmat
patient
chronic
rhinosinus
ungergon
function
endoscop
sinu
surgeri
examin
histolog
patient
nasal
polyposi
hematoxylin
eosin
stain
use
detect
epitheli
damag
basement
membran
thicken
airway
mucosa
evalu
pa
stain
two
sign
accept
sign
airway
remodel
eosinophil
semiquantit
score
system
use
detect
presenc
amount
eosinophil
result
patint
mean
age
year
includ
studi
patient
femal
male
patient
found
atop
skin
prick
test
patient
epitheli
damag
sever
damag
patient
basement
membran
thicken
patient
eosinophil
sinu
tissu
patient
allerg
rate
allergi
patient
eosinophil
sinu
tissu
conclus
patient
asthma
chronic
rhinosinus
without
nasal
polyposi
histopatholog
sign
asthma
also
seen
sinu
tissu
patient
taken
function
endoscop
sinu
surgeri
clue
pathogenet
event
whole
respiratori
tract
alveolar
concentr
bronchial
output
exhal
nitric
oxid
chronic
rhinosinus
enrico
heffler
iuliana
badiu
giusepp
guida
luisa
bommarito
pietro
marsico
giovanni
rolla
univers
torino
aso
ordin
mauriziano
allergi
clinic
immunolog
torino
itali
background
rhiniti
chronic
rhinosinus
cr
particularli
nasal
polyp
strong
risk
factor
asthma
exhal
nitric
oxid
feno
reliabl
noninvas
marker
airway
inflamm
known
elev
patient
asthma
rhiniti
studi
investig
inflammatori
function
airway
involv
patient
cr
method
recruit
patient
cr
respiratori
questionnair
spirometri
feno
measur
constant
flow
mlsec
obtain
alveolar
concentr
fano
maxim
bronchial
output
qbrmaxno
nitric
oxid
calcul
patient
use
nonlinear
model
describ
silkoff
et
al
patient
asthmalik
symptom
investig
methacholin
inhal
challeng
andor
bronchodil
test
result
patient
met
function
clinic
criteria
asthma
nasal
polyp
among
patient
without
asthma
complain
asthmalik
symptom
feno
higher
patient
asthma
ic
ppb
asthmalik
symptom
normal
lung
function
ic
ppb
compar
without
asthmat
symptom
ic
ppb
three
group
patient
feno
higher
healthi
control
ic
ppb
qbrmaxno
elev
patient
asthmat
symptom
without
lung
function
criteria
asthma
ic
ic
nl
respect
compar
patient
without
asthmalik
symptom
nl
p
g
fano
higher
patient
asthmalik
symptom
normal
lung
function
ic
ppb
compar
asthma
ic
ppb
without
asthmat
symptom
ic
ppb
conclus
patient
cr
show
higher
level
feno
compar
normal
control
suggest
diffus
airway
inflamm
feno
valu
particularli
elev
increas
maxim
bronchial
output
nitric
oxid
patient
asthmat
symptom
irrespect
lung
function
asthmat
alveolar
concentr
nitric
oxid
significantli
higher
patient
asthmat
symptom
normal
lung
function
suggest
peripher
inflamm
patient
patient
asthma
microbiolog
patient
clinic
diagnosi
sinus
diagnosi
acut
bacteri
rhinosinus
abr
involv
clinic
symptom
sign
without
use
plain
sinu
radiograph
wish
determin
microbiolog
sinus
use
criteria
compar
endoscop
cultur
result
without
plain
sinu
film
method
patient
diagnos
acut
sinus
clinic
criteria
studi
clinic
criteria
includ
biphas
ill
sign
symptom
sinus
purul
sinonas
drainag
entri
patient
endoscop
ostiomeat
cultur
water
view
plain
radiograph
result
pathogen
identifi
descend
order
staphylococcu
aureu
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
enterococcu
haemophilu
influenza
proteu
mirabili
strep
speci
also
found
methicillin
resist
staphylococcu
aureu
mrsa
aspergillu
niger
symptom
best
combin
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
coloredpurul
nasal
drainag
congest
facial
pain
ad
posit
xray
produc
specif
npv
reduc
sensit
ppv
respect
util
clinic
criteria
color
nasal
drainag
congest
facial
pain
togeth
without
xray
provid
best
combin
sensit
specif
ppv
npv
mometason
furoat
nasal
spray
season
allerg
rhiniti
ziad
adwan
saha
allergi
swaida
syrian
arab
republ
background
mometason
furoat
nasal
spray
mfn
effect
prevent
treat
nasal
symptom
season
allerg
rhiniti
sar
effect
ocular
symptom
investig
retrospect
analysi
examin
effect
mfn
ocular
symptom
subject
sar
method
ocular
symptom
data
pool
analyz
four
random
doubleblind
studi
compar
mfn
mcg
daili
n
placebo
n
subjectreport
ocular
itch
red
tear
record
baselin
twice
daili
throughout
treatment
scale
none
sever
total
ocular
symptom
score
toss
defin
combin
averag
symptom
score
result
mfn
produc
statist
greater
reduct
toss
baselin
compar
placebo
vs
p
g
likewis
mean
reduct
individu
symptom
significantli
improv
mfn
p
g
symptom
subject
toss
baselin
mfn
recipi
n
report
significantli
greater
reduct
toss
compar
placebo
recipi
n
vs
p
g
statist
signific
benefit
also
observ
individu
ocular
symptom
p
g
symptom
conclus
mfn
benefici
effect
ocular
symptom
addit
establish
effect
nasal
symptom
subject
sar
background
royal
jelli
health
supplement
wide
consum
commun
perceiv
benefit
rang
includ
boost
immun
system
howev
royal
jelli
consumpt
link
contact
dermat
acut
asthma
anaphylaxi
death
case
report
allergi
royal
jelli
report
among
atop
previou
studi
among
local
allerg
patient
demonstr
royal
jelli
sensit
found
present
countri
sever
major
allergen
rang
kd
detect
thu
aim
studi
identifi
major
allergen
royal
jelli
use
electrophoresi
massspectrometri
analysi
method
extract
royal
jelli
fraction
charg
molecular
weight
use
electrophoresi
immunoblot
profil
perform
identifi
allergen
spot
major
allergen
use
sera
royal
jelli
allerg
patient
spot
excis
gel
digest
trypsin
analyz
malditof
ms
qtof
msm
protein
identif
mass
obtain
use
search
databas
identifi
protein
result
gel
fraction
royal
jelli
protein
differ
protein
spot
spot
demonstr
specif
ige
sera
test
digest
peptid
allergen
spot
compar
amino
acid
sequenc
databas
identifi
fragment
royal
jelli
homologu
major
royal
jelli
protein
major
royal
jelli
protein
result
confirm
major
allergen
spot
royal
jelli
identif
igebind
protein
thunnu
tonggol
tongkol
mass
spectrometri
analysi
background
fish
one
frequent
caus
food
allergi
parvalbumin
repres
main
major
allergen
respons
ige
crossreact
variou
speci
fish
tongkol
belong
genu
thunnu
includ
sever
speci
tuna
wide
consum
worldwid
also
belong
genu
aim
studi
character
igebind
compon
thunnu
tonggol
tongkol
northern
bluefin
tuna
method
uncook
cook
extract
fish
prepar
fish
meat
protein
profil
ige
bind
pattern
demonstr
sodium
dodecyl
polyacrylamid
gel
electrophoresi
sdspage
immunoblot
use
sera
subject
fish
allergi
major
allergen
fish
identifi
twodimension
electrophoresi
follow
mass
spectrometri
analysi
peptid
digest
result
sdspage
raw
extract
reveal
protein
fraction
wide
molecular
weight
rang
cook
extract
demonstr
nine
protein
fraction
immunoblot
detect
igebind
protein
rang
molecular
weight
kd
two
protein
fraction
molecular
weight
kd
identifi
major
allergen
fish
protein
sensit
heat
gel
profil
raw
extract
demonstr
distinct
protein
spot
immunoblot
detect
least
differ
major
ige
reactiv
spot
molecular
mass
expect
isoelectr
point
pi
valu
rang
comparison
major
allergen
spot
sequenc
kd
protein
known
protein
sequenc
databas
reveal
extens
similar
fish
enolas
trios
phosphat
isomeras
respect
conclus
studi
demonstr
enolas
trios
phosphat
isomeras
major
allergen
compon
speci
fish
interestingli
studi
also
detect
heat
resist
protein
kd
parvalbumin
similar
sal
howev
protein
seen
minor
allergen
fish
analysi
mite
cockroach
allergen
vitro
test
allerg
diseas
baoq
sun
lili
wei
hongyu
wang
chunq
zhang
jing
li
nanshan
zhong
guangzhou
institut
respiratori
diseas
allergi
dept
guangzhou
china
object
investig
level
specif
ige
sige
mite
cockroach
allergi
patient
blood
serum
studi
correl
method
elisa
test
examin
mite
cockroach
allergen
sige
blood
serum
outpati
recruit
oct
oct
respiratori
depart
allergi
depart
result
mite
dermatophagoid
pteronyssinu
dermatophagoid
farina
blomia
tropicali
allerg
group
children
show
higher
proport
posit
result
adult
group
strong
posit
result
record
children
cockroach
allerg
patient
posit
result
class
iv
level
patient
allerg
mite
cockroach
mite
allergen
sige
blood
significantli
higher
cockroach
allergen
p
g
conclus
mite
cockroach
import
allergen
allerg
diseas
mite
play
domin
role
patient
allerg
mite
cockroach
prove
sensit
mite
allergen
background
american
cockroach
cr
periplaneta
americana
import
sourc
indoor
allergen
among
thai
current
screen
monitor
allerg
statu
allerg
patient
perform
skin
prick
test
use
crude
cr
extract
vari
allergen
composit
batchtobatch
thu
recombin
cr
allergen
may
better
standard
altern
thu
studi
produc
recombin
tropomyosin
per
one
p
americana
major
allergen
protein
test
abil
bind
ige
sera
cr
allerg
thai
patient
object
produc
recombin
tropomyosin
american
cockroach
determin
ige
bind
abil
recombin
allergen
materi
method
sera
patient
cr
allergi
gave
posit
skin
prick
test
cr
extract
sera
nonallerg
counterpart
collect
total
rna
extract
adult
p
americana
first
strand
cdna
produc
rtpcr
gene
encod
tropomyosin
amplifi
use
oligonucleotid
primer
cdna
templat
amplifi
sequenc
clone
clone
vector
protein
express
vector
latter
use
transfect
escherichia
coli
host
e
coli
transform
grown
product
tropomyosin
protein
induc
iptg
protein
extract
purifi
bacteri
lysat
result
gene
encod
american
cockroach
tropomyosin
bp
amplifi
clone
clone
vector
ie
pgem
protein
express
vector
ie
pet
b
amplifi
sequenc
show
homolog
tropomyosin
gene
sequenc
databas
recombin
tropomyosin
produc
purifi
whole
cell
lysi
e
coli
transform
grown
iptg
inducedcondit
protein
kda
found
bind
ige
sera
allerg
thai
patient
conclus
clinic
relev
recombin
tropomyosin
p
americana
success
produc
pure
form
protein
bind
ige
sera
cr
allerg
thai
patient
thu
protein
may
use
standard
reagent
screen
monitor
allerg
statu
patient
serum
allergen
profil
relat
moth
hous
dust
mite
cockroachallerg
patient
invitro
assay
correl
analysi
baoq
sun
nili
wei
jing
li
mei
jiang
nanshan
zhong
guangzhou
institut
respiratori
diseas
dept
medicin
guangzhou
china
object
look
serum
profil
specif
immunoglobin
e
sige
relat
moth
hous
dust
mite
allergen
cockroachallerg
patient
provid
evid
research
insect
hypersensit
method
thirtythre
patient
present
respiratori
allergi
clinic
octob
may
test
posit
blattella
germanica
allergen
skin
prick
test
sige
test
evalu
allergen
relat
periplaneta
americana
moth
hous
dust
mite
use
fluoresc
enzymelink
immunosorb
assay
result
patient
show
concurr
hypersensit
studi
allergen
respons
cockroach
moth
weakposit
grade
iv
significantli
lower
sige
level
found
hous
dust
mite
p
g
linear
regress
show
posit
correl
allergen
two
speci
cockroach
moth
p
g
hous
dust
mite
moth
cockroach
conclus
high
respons
hous
dust
mite
demonstr
patient
multipl
allergi
allergen
blattella
germanica
periplaneta
americana
moth
appear
share
ige
bind
site
common
product
identif
major
allergen
two
speci
local
crab
blue
swim
crab
portunu
pelagicu
red
crab
charybdi
japonica
rosmilah
misnan
shahnaz
murad
noormalin
abdullah
siti
masitah
jamaluddin
yuslina
yusoff
amir
shahmi
md
ali
institut
medic
research
allergi
immunolog
research
centr
kuala
lumpur
malaysia
background
crab
recogn
sourc
potent
allergen
especi
countri
seafood
form
larg
portion
diet
commun
blue
swim
crab
portunu
pelagicu
red
crab
charybdi
japonica
famili
portunida
among
commonli
consum
crab
malaysia
object
studi
character
igebind
protein
major
allergen
speci
crab
method
cook
uncook
extract
crab
prepar
fraction
sodium
dodecyl
polyacrylamid
gel
electrophoresi
sdspage
igebind
protein
demonstr
immunoblot
test
use
sera
patient
posit
skin
prick
test
spt
blue
red
crab
extract
respect
result
speci
crab
similar
protein
profil
uncook
extract
crab
produc
protein
band
rang
kd
sever
protein
band
kd
kd
present
uncook
extract
appear
denatur
cook
extract
immunoblot
blue
red
crab
reveal
variou
igebind
protein
rang
kd
respect
common
igebind
protein
identifi
rang
kd
kd
protein
identifi
major
allergen
crab
kd
protein
also
demonstr
major
allergen
red
crab
two
protein
kd
also
seen
major
allergen
blue
crab
interestingli
major
allergen
kd
similar
size
tropomyosin
main
major
allergen
respons
major
allerg
reaction
variou
seafood
speci
includ
crab
skin
prick
test
reactiv
peanut
tree
nut
adult
children
atopi
noormalin
abdullah
shahnaz
murad
rosmilah
misnan
institut
medic
research
allergi
immunolog
research
centr
kuala
lumpur
malaysia
background
nut
allergi
peanut
tree
nut
common
caus
allergi
even
caus
sever
anaphylact
reaction
peanut
allergi
common
tree
nut
allergi
mani
subject
develop
hypersensit
peanut
tree
nut
peanut
known
ground
nut
earth
nut
monkey
nut
tree
nut
refer
nut
brazil
nut
hazel
nut
almond
walnut
cashew
nut
peanut
plant
arachi
hypogaea
belong
botan
famili
leguminos
relat
botan
nut
brazil
nut
hazel
nut
almond
report
preval
peanut
tree
nut
allergi
malaysia
neither
report
fatal
anaphylaxi
due
nut
allergi
method
total
children
adult
histori
atopi
asthma
allerg
rhiniti
hive
food
allergi
skin
test
panel
peanut
tree
nut
commerci
inhous
extract
result
found
children
higher
skin
test
posit
peanut
tree
nut
compar
adult
children
skin
prick
test
show
posit
raw
peanut
walnut
big
peanut
almond
cashew
nut
extract
whilst
skin
prick
test
posit
hazel
nut
walnut
lower
respect
adult
common
skin
test
reactiv
peanut
cashew
nut
conclus
appear
skin
test
reactiv
nut
exist
subject
clinic
present
nut
allergi
larg
number
individu
skin
test
reactiv
multipl
nut
probabl
due
crossreact
allergenspecif
igevalu
inhal
food
allergen
china
comparison
two
commerci
immunoassay
baoq
sun
jing
li
nanshan
zhong
guangzhou
institut
respiratori
diseas
dept
medicin
guangzhou
china
purpos
studi
comparison
two
vitro
assay
detect
allergenspecif
ige
sige
total
ige
tige
dr
fook
allergoliq
neuss
germani
wwwfookelabsd
pharmacia
capsystem
upsala
sweden
wwwpharmaciacom
reanalyz
sera
sige
common
inhalatan
food
allergen
tige
materi
method
allergen
inhal
housedust
mite
pter
dfarina
blomia
tropicali
cat
epithelia
dog
epithelia
german
cockroach
aspergillu
fumigatu
food
allergen
fa
hen
egg
cow
milk
crab
shrimp
patient
sera
sera
allerg
patient
bronchu
asthma
allerg
rhiniti
chronic
cough
collect
oct
may
guangzhou
institut
respiratori
diseas
patient
depart
clinic
data
evalu
perform
sige
measur
singl
run
accord
recommend
manufactur
assay
featur
methodolog
differ
list
tabl
calcul
associ
quantit
sigelevel
differ
assay
calcul
use
nonparametr
spearmanranktest
depict
log
scale
sensit
specif
agreement
per
allergen
calcul
use
follow
formula
sensit
liq
result
cap
result
per
allergen
specif
liqresult
capresult
per
allergen
background
autism
neuropsychiatr
condit
present
abnorm
bizarr
behaviour
pattern
accompani
learn
difficulti
peptid
known
casamorphin
milk
protein
gliadinomorphin
gluten
protein
absorb
gut
blood
stream
lead
theori
bleaki
gut
syndrom
method
eightyfour
autism
children
divid
group
younger
age
less
year
older
age
group
year
skin
prick
test
spt
panel
food
allergen
blood
test
specif
immunoglobulin
e
ige
cow
milk
wheat
soya
oat
specif
immunoglobulin
g
igg
immunoglobulin
iga
alphalactalbumin
betalactoglobulin
casein
gliadin
carri
questionnair
behaviour
pattern
children
fill
parent
result
major
autism
children
chines
male
younger
group
found
spt
soya
wheat
cow
milk
specif
ige
cow
milk
wheat
soya
detect
level
igg
alphalactalbumin
igg
betalactoglobulin
iga
betalactoglobulin
igg
casein
iga
alphalactalbumin
igg
casein
igg
gliadin
iga
casein
iga
gliadin
detect
group
children
older
children
posit
spt
wheat
soya
cow
milk
specif
ige
cow
milk
wheat
wherea
soya
detect
igg
alphalactalbumin
igg
betalactoglobulin
igg
gliadin
detect
level
igg
casein
iga
alphalactalbumin
betalactoglobulin
gliadin
iga
casein
behaviour
pattern
studi
show
younger
group
older
group
present
unawar
world
younger
group
poor
eye
contact
compar
older
group
much
differ
gener
learn
abil
antisoci
behaviour
observ
group
conclus
studi
show
children
year
higher
spt
posit
wheat
cow
milk
casein
found
low
age
group
gliadin
detect
younger
group
behaviour
pattern
seem
improv
becam
older
correl
cow
milk
gluten
allergi
background
order
diagnos
allerg
patient
relev
allergen
speci
directli
expos
indigen
speci
collect
prepar
commerci
along
allergen
collabor
project
ms
inmunotek
madrid
spain
allergen
test
allerg
patient
region
evalu
efficaci
reactiv
method
total
allergen
extract
indigen
speci
includ
diagnost
panel
allergen
speci
select
comprehens
aerobiolog
studi
mani
part
countri
growth
avail
region
glycerin
extract
prepar
inmunotek
brand
name
allergotek
standard
prick
test
histamin
salin
control
conduct
allerg
individu
middl
east
africa
method
consid
conveni
econom
provid
natur
sensit
allergen
opportun
possibl
success
immunotherapi
maximum
combin
reactiv
pollen
allergen
site
record
cynodon
dactylon
chenopodium
mural
phoenix
dactylifera
salsola
imbricata
prosopi
juliflora
lolium
perenn
maximum
indoor
allergen
reactiv
record
farina
pteronyssinu
feli
domesticu
periplaneta
americana
blatella
germanica
blatta
orietali
result
efficaci
trial
indigen
allergen
reveal
major
allergen
effect
moder
sever
reaction
asthmat
allerg
individu
found
compar
sensit
indoor
allergen
speci
outdoor
allergen
cultur
habit
climat
appear
play
role
socioeconom
condit
influenc
overal
sensit
pattern
suggest
possibl
region
speci
allergen
materi
includ
diagnost
test
panel
preval
sensit
weed
pollen
saudi
arabia
method
spt
individu
asthma
allerg
manifest
attend
allergi
clinic
six
differ
region
conduct
use
commerci
extract
select
allergen
made
extens
nation
wide
aerobiolog
survey
use
burkard
volumetr
spore
trap
major
pollen
compon
kingdom
environ
identifi
amaranthu
viridi
atriplex
polycarpa
chenopodium
album
cyperu
rotundu
rumex
crispu
plantago
spp
result
spt
data
reveal
compar
higher
degre
sensit
weed
pollen
south
mountain
region
abha
agricultur
set
gassim
patient
react
weed
pollen
anoth
locat
eastern
region
hofuf
patient
close
red
sea
region
gizan
patient
react
posit
variou
weed
pollen
includ
atriplex
polycarpa
chenopodium
album
salsola
tennifolia
rumex
crispu
individu
pollen
releav
chenopodium
album
maximum
reactiv
agricultur
set
gassim
follow
salsola
tennifolia
alhofuf
rumex
crispu
gassim
gizan
apart
cynodon
dactylon
grass
pollen
prosopi
juliflora
tree
pollen
highest
skin
reactiv
record
member
chenopodiac
weed
region
studi
indic
sensit
exacerb
symptom
patient
pollin
season
may
caus
desert
weed
grow
kingdom
may
possibl
major
contributor
respiratori
allergi
saudi
arabia
specif
igg
antibodi
total
subclass
saffron
studi
correl
specif
ige
immedi
skin
reaction
saffron
crocu
sativu
cultiv
one
agricultur
product
iran
saffron
contain
aeroallergen
caus
reactiv
respiratori
allerg
reaction
expos
subject
investig
role
specif
ige
igg
type
allerg
reaction
saffron
specif
ige
igg
subclass
determin
sera
expos
subject
test
group
normal
subject
control
group
elisa
immedi
skin
reaction
assess
expos
subject
mean
optic
densiti
saffronspecif
total
igg
ige
antibodi
significantli
higher
test
group
control
group
specif
antibodi
lower
test
group
igg
subclass
signific
differ
two
group
immedi
skin
reaction
posit
test
group
specif
ige
antibodi
level
correl
specif
total
igg
antibodi
level
posit
skin
reaction
r
r
respect
revers
correl
found
specif
ige
antibodi
level
specif
antibodi
level
r
specif
ige
test
primari
care
cost
save
background
allergi
reduc
qualiti
life
place
consider
burden
societi
specif
immunoglobulin
e
sige
test
improv
manag
potenti
reduc
cost
purpos
studi
assess
costeffect
allergi
test
patient
respiratori
andor
skin
problem
primari
care
itali
method
costminim
analysi
carri
cost
two
treatment
altern
compar
assess
use
decis
model
includ
cost
pharmaceut
physician
visit
primari
care
cost
allergi
test
noteststrategi
part
patient
classifi
allerg
nonallerg
uncertain
basi
clinic
judgment
without
test
teststrategi
part
classif
patient
also
base
sige
result
result
agreement
physician
classif
test
result
substanti
elev
teststrategi
part
vs
noteststrategi
part
cost
per
patient
year
decreas
notest
strategi
test
strategi
owe
mostli
reduc
medic
cost
sensit
preval
allergi
price
medic
demonstr
conclus
allergi
test
primari
care
costsav
compar
test
decreas
falseposit
uncertain
diagnos
main
compon
cost
reduct
enabl
appropri
patient
manag
studi
clinic
cohort
patient
test
allergi
diagnosit
immunolocgi
clinic
heidemari
saxarra
glenn
reev
karla
lemmert
john
hunter
hospit
hap
immunolog
hap
newcastl
australia
larg
number
patient
studi
allergi
resut
collat
specif
allergen
test
dust
mite
grass
mix
food
mix
anim
epitheli
mix
weed
mix
latex
peanut
tabul
group
patient
analys
trend
follow
paramet
clinic
note
medic
record
use
age
sex
medic
gener
health
symptom
allergi
sever
symptom
studi
limit
paramet
avail
cohort
studi
signific
trend
note
howev
use
guidelin
establish
futur
review
larg
patient
cohort
diagnosit
laboratori
royal
colleg
pathologist
australasia
immunolog
qap
help
laboratori
robert
heddl
sue
jovanovich
peter
robertsthomson
flinder
medic
centr
depart
respiratori
medicin
adelaid
australia
flinder
medic
centr
rcpa
immunolog
qap
adelaid
australia
vitro
allergi
test
surviv
despit
gener
less
sensit
slower
expens
skin
test
applic
skin
disord
eg
eczema
dermatograph
medic
eg
antihistamin
tricycl
antidepress
risk
anaphylaxi
eg
initi
test
drug
allergi
extrem
nut
allergi
would
prevent
inhibit
skin
test
requir
clinician
carri
expens
rang
allergen
lend
qualiti
control
standardis
region
collabor
qualiti
control
vitro
allergi
test
error
clinic
crucial
eg
fals
neg
result
nut
allergi
credibl
laboratori
reagent
equip
perform
depend
satisfactori
perform
qc
understand
discrep
enhanc
product
appropri
reduc
number
pollen
allergen
three
karuna
keat
karen
byth
conni
katelari
westmead
hospit
immunolog
depart
westmead
australia
westmead
hospit
westmead
millenium
institut
westmead
australia
background
skin
prick
test
spt
essenti
tool
diagnosi
allerg
disord
optim
number
type
allergen
use
differ
set
remain
undefin
aim
describ
spt
clinic
practic
propos
appropri
reduc
number
pollen
allergen
three
aim
improv
costeffect
reduc
time
spent
allergen
test
particularli
commun
set
method
consecut
patient
attend
privat
room
immunologist
allergyimmunolog
clinic
tertiari
referr
hospit
requir
skin
prick
test
evalu
june
novemb
statist
analysi
undertaken
use
pearson
chisquar
fisher
exact
test
assess
signific
multivari
analysi
also
perform
result
total
skin
prick
test
set
perform
signific
differ
rate
spt
posit
common
pollen
allergen
two
clinic
posit
spt
perenni
ryegass
lolium
perenn
timothi
phleum
patens
bermuda
grass
cynodon
dactylon
sensit
bent
orchard
grass
dactyli
glomer
sensit
english
plantain
plantago
lanceolata
bahia
grass
paspalum
notatum
docksorrel
rumex
sp
respect
use
perenni
ryegrass
timothi
bermuda
grass
also
detect
tree
pollen
sensit
sensit
birch
mix
betula
sp
acacia
casuarina
platanu
sp
privet
ligustrum
sp
conclus
use
common
grass
pollen
allergen
spt
lolium
perenn
phleum
pratens
cynodon
dactylon
detect
atop
individu
sensit
mani
pollen
type
inform
may
use
defin
appropri
allergen
determin
pollen
hypersensit
commun
set
clinic
evalu
new
allergi
later
flow
assay
profession
home
use
michael
mahler
lorenz
christin
ralf
lucassen
margrit
fook
kleinetebb
dr
fook
laboratorien
develop
neuss
germani
allergi
asthma
center
westend
allergi
unit
berlin
germani
dr
fook
laboratorien
gener
manag
neuss
germani
background
specif
immunoglobulin
e
sige
hallmark
diagnosi
type
allerg
reaction
atop
diseas
new
allergi
screen
test
allergi
later
flow
assay
alfa
tm
qualit
detect
sige
human
whole
blood
serum
plasma
base
test
devic
allow
linkag
varieti
allergen
object
studi
evalu
alfa
tm
profession
home
use
aspergillu
niger
capillari
blood
serum
test
specif
ige
singl
allergen
contain
alfa
tm
test
allergoliq
furthermor
skin
prick
test
spt
allergopharma
perform
volunt
defin
allerg
patient
histori
concord
spt
sige
invitro
result
alfa
tm
result
patient
diagnos
analyz
kappa
agreement
chisquar
test
posit
ppv
neg
predict
valu
npv
diagnost
effici
de
result
alfa
tm
result
obtain
volunt
p
sensit
five
common
aeroallergen
children
suffer
atop
eczema
examin
atopi
patch
test
skin
pricktest
specif
ige
martin
liska
petr
panzner
vladimir
hrasko
vaclava
gutova
faculti
hospit
pilsen
institut
immunolog
allergolog
pilsen
czech
republ
background
although
role
allergi
atop
eczema
ae
still
controversi
patient
atop
eczema
suffer
exacerb
skin
lesion
contact
inhal
aeroallergen
histolog
examin
skin
contact
aeroallergen
known
delayedtyp
hypersensit
reaction
mediat
allergenspecif
cell
take
part
pathogenesi
atop
eczema
atopi
patch
test
apt
repres
use
tool
detect
hypersensit
method
examin
hypersensit
common
aeroallergen
birch
pollen
grass
pollen
cat
dander
housedust
mite
use
apt
skin
pricktest
spt
specif
ige
children
suffer
atop
eczema
result
method
compar
result
delayedtyp
hypersensit
found
use
apt
patient
immedi
type
hypersensit
found
use
spt
patient
use
specif
ige
patient
immedi
type
hypersensit
prove
patient
delayedtyp
hypersensit
patient
type
hypersensit
occur
concomitantli
patient
case
type
hypersensit
differ
allergen
signific
pg
posit
correl
found
spt
specif
ige
correl
clinic
symptom
ae
posit
test
patient
ige
mediat
hypersensit
patient
delayedtyp
hypersensit
conclus
variou
aeroallergen
influenc
substanti
cours
atop
eczema
via
specif
ige
well
specif
cellmedi
reaction
therefor
test
hypersensit
aeroallergen
use
spt
andor
specif
ige
atopi
patch
test
could
use
bogdan
petrunov
georgi
nikolov
antoaneta
michova
tzveti
ivanova
julia
radenkovasaeva
hristo
taskov
nation
center
infecti
parasit
diseas
allergolog
immunolog
sofia
bulgaria
emerg
hospit
bpirogov
toxicolog
depart
sofia
bulgaria
background
aim
studi
assess
diagnost
potenti
two
vitro
method
ige
diagnosi
compar
skinprick
test
spt
gold
standard
method
patient
posit
case
histori
spt
grass
pollen
hous
dust
mite
mould
bee
wasp
venom
suffer
bronchial
asthma
allerg
rhiniti
hay
fever
clinic
health
control
studi
vitro
quantiti
serum
allergenspecif
ige
unicap
pharmacia
percentag
allergenspecif
basophil
degranul
fasimmun
bd
evalu
correl
percent
coincid
result
three
method
analys
statistica
result
signific
statist
correl
resul
three
method
patient
sensit
grass
pollen
hous
dust
mite
found
strong
posit
correl
spearman
spt
quantiti
specif
vivo
test
fasimmun
vitro
method
determin
data
patient
allerg
insect
venom
show
high
percent
coincid
three
method
respect
cincid
spt
quantiti
specif
ige
group
sensit
mould
establish
conclus
result
invitro
method
repres
posit
correl
coincid
spt
especi
allergen
grass
pollen
hous
dust
mite
bee
wasp
venom
applic
ensur
preceis
diagnosi
patient
contribut
complex
assess
ige
mediat
allergi
rawil
fakhrullin
rustem
fassakhov
victor
vinter
elena
sukmanskaya
olga
konovalova
kazan
state
univers
depart
biochemistri
kazan
russian
feder
kazan
reseach
institut
epidemiolog
microbiolog
depart
allergolog
immunolog
kazan
russian
feder
background
allerg
diseas
signific
impact
clinic
practic
due
high
preval
total
ige
quantif
one
import
step
classic
atop
diseas
diagnosticsth
wide
use
method
ige
detect
timeconsum
complex
biosensor
interest
tool
offer
certain
oper
advantag
standard
photometr
method
notabl
respect
rapid
easeofus
cost
simplic
portabl
eas
mass
manufactur
method
qcm
work
sensor
base
relationship
frequenc
chang
mass
load
surfac
crystal
accord
sauerbrey
equat
sauerbrey
j
phi
antigen
react
coat
antibodi
surfac
frequenc
shift
occur
chang
proport
mass
load
result
monoclon
antiig
success
immobil
nafion
polymer
matrix
silver
electrod
piezoelectr
quartz
reson
optim
condit
antiig
immobil
procedur
piezoelectr
immunoassay
determin
microlitr
serum
minut
reaction
time
requir
measur
total
ige
found
biosensor
capabl
differenti
blood
serum
patient
low
intermedi
high
level
ige
conclus
quartz
crystal
microbal
immunosensor
offer
number
signific
advantag
currentlu
avail
vitro
techniqu
detect
total
ige
suppos
biosensor
use
laboratori
practic
ige
determin
background
purpos
studi
determin
month
rate
sr
p
id
st
symptom
report
respons
immedi
treatment
epinephrin
im
method
retrospect
review
one
year
period
conduct
evalu
sr
p
id
st
allergen
tree
grass
weed
anim
mold
food
medic
hymenoptera
subject
standard
form
use
record
symptom
sign
treatment
vasovag
reaction
includ
nurs
instruct
attend
physician
administ
epinephrin
vv
im
soon
sign
symptom
anaphylaxi
occur
result
patient
sr
femal
male
averag
age
patient
sr
year
rang
median
year
asthma
symptom
report
prurit
eye
nose
pharynx
worsen
cough
sensat
difficulti
swallow
worsen
nasal
congest
rhinorrhea
chest
tight
andor
short
breath
gener
pruritu
sneez
urticaria
wheez
sever
asthma
shock
hypotens
unconsci
late
phase
respons
occur
treatment
patient
receiv
epinephrin
averag
dose
cc
im
oral
prednison
oral
prednison
take
hour
reaction
oral
antihistamin
nebul
beta
agonist
conclus
sr
occur
patient
skin
test
readili
respond
earli
intervent
epinephrin
earli
administr
epinephrin
nurs
appear
prevent
seriou
late
phase
reaction
clara
cell
protein
irrit
sensit
effect
inhal
benzalkonium
chlorid
rat
background
benzalkonium
chlorid
bac
bacteriostat
agent
use
pharmaceut
industri
preserv
known
caus
bronchoconstrict
asthmat
subject
aim
studi
qualif
result
inhal
exposur
bac
rat
particular
refer
effect
remodel
respiratori
system
condit
allerg
reaction
impair
lung
function
allerg
asthma
evalu
specif
lung
biomark
known
irrit
fume
affect
noncili
epitheli
clara
cell
releas
antiinflammatori
immunosuppress
clara
cell
protein
respiratori
tract
materi
method
femal
wistar
rat
expos
bac
aerosol
day
day
reexpos
bac
h
exposur
bronchoalveolar
lavag
fluid
balf
collect
balf
concentr
total
protein
ige
hyaluron
acid
ha
tnf
activ
lactat
dehydrogenas
ldh
determin
marker
bronchiolar
epithelium
assess
latex
immunoassay
lung
histolog
examin
done
activ
glutathion
stransferas
gst
determin
additionali
total
differenti
cell
number
lymphocyt
neutrophil
macrophag
measur
result
benzalkonium
exposur
challeng
induc
statist
signific
increas
balf
cytokin
ldh
ige
balf
serum
level
balf
significantli
reduc
signific
neg
correl
concentr
balf
mediat
inflammatori
process
seen
huge
increas
ldh
correl
level
total
protein
ige
serum
neg
relationship
shown
occur
ldh
ige
serum
balf
correl
histopatholog
examin
focal
agglomer
alveolar
macrophag
note
well
prolifer
peribronchi
lymphat
tissu
conclus
play
protect
role
allerg
inflamm
take
part
remodel
effect
low
molecular
weight
sensit
use
diagnost
marker
earli
detect
impair
respiratori
function
pulmonari
irrit
inhal
exposur
benzalkonium
chlorid
rat
radoslaw
swiercz
tadeusz
halatek
wojciech
wasowicz
barbara
kur
zofia
grzelinska
wanda
majcherek
nofer
institut
occup
medicin
depart
toxicolog
carcinogenesi
lodz
poland
nofer
institut
occup
medicin
depart
immunotoxicolog
lodz
poland
background
benzalkonium
chlorid
bac
quaternari
ammonium
compound
alkyl
group
chain
length
bac
exert
toxic
effect
microorgan
properti
util
cosmet
industri
medicin
use
effect
germicid
preserv
agent
variou
baccontain
prepar
use
peopl
may
produc
number
advers
effect
human
bodi
bear
mind
bac
wide
use
differ
branch
nation
economi
toxic
effect
may
constitut
major
health
problem
materi
method
femal
wistar
rat
imp
wist
bodi
weight
g
expos
bac
aerosol
target
concentr
dynam
inhal
chamber
h
day
h
day
exposur
h
termin
exposur
bac
aerosol
bronchoalveolar
lavag
fluid
balf
collect
anim
balf
concentr
total
protein
clara
cell
protein
matrix
hyalurn
acid
ha
immunoglobulin
e
ige
cytokin
tnf
activ
lactat
dehydrogenas
ldh
gshstransferas
gst
determin
result
rat
surviv
inhal
exposur
bac
signific
reduct
bodi
weight
note
anim
expos
repeatedli
inhal
bac
lung
weight
total
protein
ha
level
ldh
activ
balf
higher
rat
singl
repeat
exposur
bac
compar
control
decreas
concentr
balf
rat
observ
singl
repeat
inhal
exposur
significantli
higher
level
ige
note
balf
anim
expos
singl
repeat
dose
concentr
tnf
balf
rat
expos
bac
similar
found
control
anim
conclus
bac
show
strong
inflammatori
irrit
activ
lung
rat
alreadi
hour
inhal
exposur
bac
stimul
dynam
pattern
ige
product
infiltr
protein
blood
circul
system
balf
continu
exposur
result
chang
involv
cellular
destruct
statist
increas
ldh
activ
continu
reduct
concentr
balf
allerg
bronchopulmonari
aspergillosi
asthma
clinic
use
essenti
minim
criteria
sookeol
lee
dookyung
yang
choonhe
son
kinam
kim
kinam
lee
donga
univers
intern
medicin
busan
republ
korea
donga
univers
diagnost
radiolog
busan
republ
korea
object
allerg
bronchopulmonari
aspergillosi
abpa
occur
case
atop
asthma
may
result
import
lung
diseas
earli
diagnosi
essenti
diseas
respons
corticosteroid
howev
still
consensu
diagnost
criteria
patient
differ
stage
abpa
may
fulfil
criteria
studi
evalu
preval
abpa
abpalik
diseas
asthma
clinic
use
essenti
minim
diagnost
criteria
method
prospect
evalu
patient
bronchial
asthma
abpa
juli
onward
abpa
diagnos
use
essenti
minim
criteria
asthma
skin
prick
test
spt
posit
aspergillu
fumigatu
af
elev
serum
total
ige
cap
elev
serum
afspecif
ige
cap
central
bronchiectasi
ct
scan
result
nineti
consecut
patient
bronchial
asthma
enrol
fortyfour
patient
atop
posit
spt
af
five
patient
show
elev
serum
afspecif
ige
without
posit
respons
af
spt
secur
diagnosi
abpa
satisfi
essenti
minim
criteria
evid
patient
conclus
high
preval
abpa
asthmat
patient
present
hospit
evalu
requir
differenti
abpa
asthma
patient
sensit
af
without
abpa
role
serum
afspecif
ige
screen
tool
diagnosi
abpa
redefin
clinic
present
patint
allerg
bronchopulmonari
aspergillosi
abdelmonem
sharara
manaf
hijazi
hythem
elkhushman
jafer
momani
moham
enjada
king
hussein
medic
center
depart
chest
diseas
amman
jordan
purpos
allerg
bronchopulmonari
aspergillosi
abpa
immunolog
mediat
lung
diseas
charecteris
complex
hypersensit
reaction
patient
asthma
occur
bronchi
becom
colon
aspergillu
repeat
episod
bronchial
obstruct
inflamm
mucoid
impact
lead
bronchiectasi
fibrosi
chronic
lung
diseas
aim
studi
increas
awar
diseas
method
describ
studi
case
allerg
bronchopulmonari
aspergillosi
twelv
patient
men
women
diagnos
chest
depart
king
hussien
hospit
main
criteria
diagnosi
histori
asthma
immedi
skin
test
reactiv
aspergillu
antigen
serum
total
ige
concentr
greater
ngml
peripher
blood
eosinophilia
lung
infiltr
proxim
bronchiectasi
result
demograph
data
patient
allerg
bronchopulmonari
aspergillosi
conclus
abpa
rare
diseas
diagnosi
depend
upon
certain
criteria
clinic
implic
think
diagnosi
abpa
patient
histori
asthma
lung
infiltr
peripher
blood
eosinophilia
signific
diagnost
profil
ophthalm
allergi
exclud
mimick
clinic
condit
mc
may
pose
therapeut
difficulti
ishaq
khan
sameera
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
introduct
patient
ac
withwithout
concomit
allergi
case
therapeut
dilemma
method
seri
patient
age
year
usual
intermitt
red
eye
shot
red
intract
itch
eye
tear
stringi
discharg
withwithout
season
associ
laboratori
investig
found
rais
tear
blood
eosinophil
count
total
eosinophil
count
total
serum
ige
measur
case
higher
kul
support
rise
titer
allergenspecif
ige
radioallergosorb
test
rast
method
skin
prick
test
mixtur
allergen
extract
conclus
evid
allergi
caus
red
eye
ophthalmoscop
examin
found
pinkish
papilla
central
vessel
characterist
serou
wateri
conjunctiv
secret
conjunctiv
scrape
tear
cytolog
perform
topic
ocular
allergen
challeng
sensit
subject
shown
signific
increas
neutrophil
eosinophil
presenc
evidenc
posit
diagnost
criterion
result
confirm
suspect
allerg
sensit
skin
prick
test
diagnosi
immedi
hypersensit
sensit
fastest
cheapest
method
confirm
allerg
sensit
howev
carri
small
signific
risk
system
anaphylaxi
conclus
challeng
test
way
relat
specif
allergen
trigger
ocular
symptom
variabl
degre
system
anaphylaxi
bacteri
chlamydi
viral
conjunct
superior
limbic
phlyctenular
conjunct
keratoconjunct
rosaceaassoci
conjunct
erythema
multiform
eoiscleritisscler
ocular
cicatrici
pemphigoid
electrodiagnost
studi
phrenic
nerv
function
patient
system
lupu
erythematosu
nanci
mahmoud
abdelati
mahmoud
el
princ
smaher
labib
moham
hefni
faculti
medicin
suez
canal
univers
chest
depart
ismailia
egypt
faculti
medicin
suez
canal
univers
medicin
depart
ismailia
egypt
faculti
medicin
suez
canal
univers
physic
medicin
depart
ismailia
egypt
object
patient
sle
screen
presenc
phrenic
nerv
neuropathi
determin
whether
neurophysiolog
find
correl
clinic
respiratori
sign
spirometr
abnorm
serolog
examin
patient
system
lupu
erythematosu
method
total
patient
femal
male
system
lupu
erythematosu
sle
age
rang
yr
includ
studi
physic
pulmonari
examin
chest
radiographi
respiratori
function
test
well
serolog
examin
bilater
transcutan
phrenic
nerv
conduct
studi
result
patient
complain
dyspnea
one
patient
show
paradox
abdomin
movement
pulmonari
function
test
show
proport
reduct
forc
vital
capac
fvc
forc
expiratori
volum
second
suggest
restrict
process
sever
patient
patient
corticosteroid
patient
immunosuppress
medic
includ
methotrex
cyclophosphamid
phrenic
nerv
evalu
use
transcutan
stimul
studi
show
delay
latenc
rt
lt
phrenic
nerv
patient
respect
confirm
demyelin
neuropathi
also
phrenic
nerv
stimul
evok
lowamplitud
respons
right
left
patient
respect
confirm
axon
neuropathi
signific
correl
electr
phrenic
nerv
stimul
serum
immun
marker
except
decreas
action
potenti
amplitud
sle
group
posit
result
anti
dna
patient
anti
dna
show
reduc
amplitud
rt
phrenic
nerv
show
reduc
amplitud
lt
phrenic
nerv
fourteen
patient
present
dyspnea
show
abnorm
phrenic
nerv
conduct
studi
patient
show
abnorm
cxr
small
clear
lung
field
evid
major
parenchym
lung
pleural
diseas
found
signific
correl
electr
phrenic
nerv
stimul
cxr
abnorm
conclus
diaphragmat
weak
patient
sle
common
like
caus
phrenic
neuropathi
evid
bilater
involv
search
engin
diagnost
tool
complex
immunolog
allerg
case
report
googl
use
object
evalu
util
search
clinic
inform
googl
order
obtain
correct
diagnosi
complex
immunolog
allerg
cia
case
report
studi
design
compar
crosssect
studi
method
firtyf
cia
case
report
randomli
select
independ
investig
peerview
medic
journal
clinic
data
present
separ
three
observ
blind
final
diagnosi
observ
consult
intern
medicin
allergi
expert
knowledg
field
basic
comput
skill
observ
b
registrar
intern
medicin
allergi
observ
c
research
nurs
observ
b
c
familiar
knowledg
regular
use
comput
search
engin
internetbas
search
use
googl
conduct
order
perform
observ
individu
studi
text
independ
select
five
search
term
choos
case
record
enter
standard
googl
search
engin
observ
record
case
singl
promin
diagnosi
evid
within
first
three
result
page
conduct
googl
search
sinc
googl
necessarili
includ
diagnos
within
search
result
page
observ
permit
select
diagnosi
best
fit
case
record
inform
open
direct
result
link
independ
investig
compar
diagnos
obtain
observ
definit
diagnos
publish
journal
main
outcom
measur
studi
percentag
correctli
obtain
diagnos
achiev
observ
result
observ
identifi
definit
diagnosi
case
ci
observ
b
ci
observ
c
ci
diagnost
inaccuraci
observ
relat
primari
immunodefici
pediatr
case
conclus
googlebas
search
use
achiev
appropri
diagnosi
cia
case
comput
internetbas
search
skill
could
influenc
result
antiallerg
properti
potassium
humat
johanna
meed
gandi
justin
constanc
medlen
jacqu
snyman
univers
pretoria
pharmacolog
pretoria
south
africa
background
although
antiinflammatori
properti
humat
deriv
peat
sapropel
mumi
describ
clinic
studi
done
antiinflammatori
effect
humat
deriv
coal
leonardit
humat
compar
favour
prednisolon
suppress
contact
hypersensit
rat
model
accord
report
european
agenc
evalu
medicin
product
toxic
studi
feb
humic
acid
extract
brown
coal
toxic
effect
rat
chronic
studi
oral
dosag
high
bw
wherea
rat
oral
administr
humic
acid
report
greater
bw
report
recent
confirm
separ
studi
object
studi
establish
safeti
therapeut
efficaci
oral
potassium
humat
reduc
sign
symptom
hay
fever
atop
patient
grass
pollen
season
method
parallel
doubleblind
placebo
control
phase
ii
studi
potassium
humat
randomli
assign
dosag
divid
dosesday
atop
patient
n
present
acut
symptom
hay
fever
blood
nasal
sampl
use
determin
safeti
effect
potassium
humat
basophil
activ
cytokin
level
eosinophil
migrat
skin
prick
test
use
determin
antiallerg
effect
vitro
neutrophil
adhes
test
use
determin
effect
product
adhes
human
neutrophil
babi
hamster
kidney
cell
result
signific
decreas
skin
prick
test
result
present
elsewher
eosinophil
count
observ
signific
differ
observ
regard
neutrophil
adhes
differ
observ
regard
stimul
basophil
howev
decreas
observ
express
treatment
although
reach
statist
signific
product
effect
neutrophil
adhes
conclus
studi
confirm
without
doubt
product
possess
antiinflammatori
well
antiallerg
properti
possibl
due
decreas
recruit
eosinopil
site
inflamm
antiinflammatori
effect
therapeut
intervent
intract
skin
ulcer
yorihisa
kotobuki
hiroyuki
murota
ichiro
katayama
cours
integr
medicin
graduat
school
medicin
osaka
univers
dermatolog
osaka
japan
background
intract
skin
ulcer
common
daili
practic
although
patient
qol
sever
impair
skin
lesion
effect
treatment
protocol
establish
wound
heal
process
separ
inflammatori
phase
prolifer
phase
remodel
phase
recent
review
describ
prolong
inflammatori
phase
might
partli
affect
pathogen
mechan
intract
skin
ulcer
inflammatori
phase
variou
kind
inflammatori
cell
infiltr
ware
observ
affect
area
recruit
macrophag
secret
inflammatori
cytokin
includ
vegf
prostaglandin
treatment
believ
one
promis
treatment
skin
ulcer
also
demonstr
improv
drug
deliveri
system
note
report
infiltr
macrophag
uptak
taken
result
togeth
hypothes
might
antiinflammatori
effect
thu
contribut
improv
intract
skin
ulcer
method
patient
variou
kind
intract
skin
ulcer
administ
intraven
inject
microgramday
palxu
two
week
size
ulcer
area
serum
concentr
crp
vegf
measur
treatment
result
effect
reduc
size
ulcer
area
serum
inflammatori
marker
two
week
conclus
result
indic
antiinflammatori
effect
might
contribut
improv
intract
skin
ulcer
compar
efficaci
levocetirizin
desloratadin
clemastin
kvifenadin
sekvifenadin
histamin
prick
test
induc
weal
reaction
blood
perfus
evalu
laser
doppler
flowmetri
random
doubleblind
placebocontrol
crossov
design
studi
background
evalu
weal
reaction
laser
doppler
flowmetri
valuabl
method
evalu
efficaci
differ
pharmacolog
agent
aim
studi
compar
influenc
differ
histamin
induc
weal
reaction
increas
skin
blood
perfus
sedat
method
histamin
prick
test
induc
weal
area
percentag
blood
perfus
chang
area
curv
peak
perfus
period
aucmax
measur
periflux
system
perim
ab
sweden
hour
intak
mg
levocetirizin
mg
desloratadin
mg
clemastin
mg
kvifenadin
mg
sekvifenadin
placebo
sed
effect
measur
mm
visual
analogu
scale
va
result
result
express
mean
ci
mean
weal
reaction
area
respect
statist
signific
differ
observ
activ
treatment
placebo
levocetirizin
increas
blood
perfus
respect
signific
decreas
augment
blood
perfus
observ
pretreat
levocetirizin
desloratadin
vs
placebo
levocetirizin
vs
kvifenadin
sekvifenadin
clemastin
aucmax
u
aucmax
significantli
lower
pretreat
levocetirizin
vs
placebo
antihistamin
sed
effect
mm
va
signific
differ
sedat
observ
levocetirizin
vs
sekvifenadin
clemastin
vs
kvifenadin
sekvifenadin
placebo
conclus
levocetirizin
induc
signific
decreas
weal
flare
reaction
skin
blood
perfus
compar
placebo
influenc
kvifenadin
sekvifenadin
weal
reaction
area
similar
desloratadin
clemastin
sed
effect
clemastin
pronounc
kvifenadin
sekvifenadin
characteris
pharmacolog
properti
fluticason
furoat
novel
enhancedaffin
glucocorticoid
method
bind
affin
ff
human
lung
glucocorticoid
receptor
gr
determin
elucid
associ
dissoci
rate
constant
molecular
interact
ff
gr
identifi
xray
crystallographi
gr
ligandbind
domain
cellular
onset
action
determin
measur
nuclear
transloc
human
lung
epitheli
cell
measur
human
progesteron
pr
mineralocorticoid
mr
androgen
ar
oestrogen
receptor
er
activ
use
assess
steroid
hormon
select
ff
cellular
protect
ff
elastas
mechan
wound
determin
human
lung
epitheli
cell
antiinflammatori
effect
ff
lung
determin
use
brown
norway
ovalbumin
rat
model
result
ff
fast
associ
slow
dissoci
gr
rel
receptor
affin
rra
refer
dexamethason
rra
higher
current
avail
clinic
glucocorticoid
mometason
furoat
mf
fluticason
propion
fp
ciclesonid
activ
principl
budesonid
ff
hydrogen
bond
interact
gr
hydroxi
group
fluoromethylthioest
group
also
form
favour
electrostat
interact
ff
induc
rapid
transloc
gr
nucleu
minut
maximum
effect
high
select
gr
versu
pr
mr
ar
er
respect
ff
confer
substanti
protect
elastaseand
mechan
induc
damag
potent
protect
budesonid
fp
mf
ff
complet
prevent
lung
eosinophilia
effect
greater
fp
conclus
ff
enhanc
affin
gr
compar
avail
glucocorticoid
translat
potent
protect
cellular
damag
lung
inflamm
coupl
fast
cellular
onset
action
high
select
gr
properti
may
contribut
favour
clinic
efficaci
safeti
profil
ff
downmodulatori
effect
cetirizin
levocetirizin
cytokinechemokin
product
express
keratinocyt
miwa
kobayashi
kenji
kabashima
yoshiki
tokura
univers
occup
environment
health
japan
dermatolog
kitakyushu
japan
cetirizin
antihistam
drug
second
gener
besid
antihistam
activ
variou
action
report
antihistam
epiderm
keratinocyt
cetirizin
inhibit
express
costimulatori
molecul
mhc
class
ii
molecul
hladr
moreov
exert
antiinflamm
action
suppress
product
cytokin
chemokin
variou
immunocompet
cell
levocetirizin
lcetirizin
optic
isom
cetirizin
wide
use
treatment
allerg
disord
european
countri
studi
investig
whether
differ
cetirizin
levocetirizin
cytokin
chemokin
product
normal
human
epiderm
keratinocyt
nhek
nhek
stimul
interferon
ifn
tumor
necrosi
factor
tnf
cetirizin
levocetirizin
ad
experiment
cultur
three
daycultur
supernat
measur
concentr
rant
mig
itac
mdc
ifn
tnf
augment
level
itack
significantli
suppress
addit
either
cetirizin
levocetirizin
cultur
dosedepend
manner
rant
mig
mdc
suppress
cetirizin
examin
effect
two
reagent
express
molecul
nhek
incub
ifn
without
cetirizin
levocetirizin
hr
cetirizin
levocetirizin
downmodul
express
molecul
similar
level
otherthi
studi
demonstr
cetirizin
levocetirizin
compar
effect
immunolog
function
keratinocyt
note
levocetirizin
slightli
significantli
stronger
effect
cetirizin
product
rant
mig
efficaci
safeti
levocetirizin
continu
ondemand
treatment
persist
allerg
rhiniti
month
giorgio
walter
canonica
enrico
compalati
laura
guerra
anthi
rogkak
cinzia
gamalero
pierangela
massacan
federica
fumag
christian
zanella
ilaria
baiardini
univers
genoa
allergi
respiratori
diseas
depart
genoa
itali
background
aim
document
efficaci
safeti
levocetirizin
continu
ct
ondemand
treatment
ond
persist
allerg
rhiniti
per
defin
aria
method
singlecent
randomis
openlabel
studi
compar
ct
vs
ond
treatment
per
patient
levocetirizin
daili
month
patient
allow
mild
asthma
treat
shortact
betaagonist
sneez
rhinorrhea
nasal
ocular
pruritu
symptom
nasal
congest
measur
daili
absent
sever
scale
rhinasthma
questionnair
rq
use
assess
subject
qualiti
life
rang
item
questionnair
bother
much
qualiti
sleep
report
va
scale
result
patient
enrol
per
group
ond
ct
group
complet
studi
patient
discontinu
drugrel
seriou
advers
event
ae
improv
baselin
significantli
higher
favour
ct
month
maxim
improv
ond
ct
maxim
improv
nasal
congest
ond
ct
qualiti
sleep
consider
improv
end
studi
baselin
ond
ct
ond
ct
seriou
ae
observ
subject
ct
ond
group
report
drugrel
treatmentemerg
ae
conclus
studi
confirm
previou
data
take
potent
antihistamin
like
levocetirizin
per
symptom
includ
nasal
congest
effect
control
treatment
period
addit
individu
symptom
control
significantli
better
treat
continu
regardless
regimen
levocetirizin
improv
patientsq
ualiti
life
sleep
well
toler
fewer
patient
report
ae
ct
group
result
support
longterm
continu
treatment
per
potent
welltoler
antihistamin
oxatomidetr
children
atop
dermat
complic
food
allergi
prevent
asthma
develop
norifumi
ogawa
toshiaki
saeki
kawano
yutaka
takeshi
noma
kitasato
univers
school
medicin
pediatr
depart
sagamihara
kanagawa
japan
background
recent
epidemiolog
suggest
increas
preval
allerg
diseas
industri
countri
includ
japan
necessit
analysi
mechan
allerg
diseas
develop
effect
treatment
oxatomid
oxm
antihistamin
drug
shown
clinic
effect
treatment
hypersensit
childhood
asthma
mode
action
elucid
increas
ifng
activ
well
antihistamin
reaction
object
method
peripher
blood
mononuclear
cell
obtain
patient
atop
dermat
allerg
henegg
rang
month
year
month
age
patient
recurr
eczema
pruritu
posit
skin
reaction
egg
white
andor
cow
milk
patient
also
posit
respons
oral
provoc
test
raw
hen
egg
cow
milk
diagnost
criteria
atop
dermat
base
criteria
hanifin
rajk
clarifi
mode
action
wherebi
oxm
amelior
condit
children
food
allergycompl
atop
dermat
whether
develop
bronchial
asthma
prevent
oxmrel
alter
clinic
symptom
examin
seen
patient
cours
month
year
month
treatment
evalu
result
discuss
score
itch
sleep
disturb
skin
lesion
inflamm
lichenif
crack
improv
mean
cours
week
treatment
oxm
addit
elimin
diet
treatment
skin
care
shower
isodin
r
nonsteroid
ointment
administr
hydroxyzin
andor
oral
sodium
cromogl
studi
oxm
effici
suppress
incid
asthma
approxim
patient
total
ige
valu
peripher
eosinophil
count
elev
oxmtreat
lower
agematch
asthma
patient
untreat
oxm
conclus
oxm
signific
candid
one
therapeut
modal
children
food
allergyinduc
atop
dermat
base
clinic
studi
also
found
effect
prophylaxi
develop
childhood
asthma
comparison
intramuscular
dexamethason
fluticason
propion
inhal
treatment
croup
jamal
faghihinia
isfahan
univerc
pediatr
isfahan
islam
republ
iran
introduct
croup
common
viral
diseas
children
year
old
incid
rate
mainstay
treatment
airway
manag
treatment
focus
respiratori
distress
use
cold
mist
epinephrin
heliox
corticosteroid
studi
tri
compar
effect
fluticason
spray
intramuscular
dexamethason
materi
method
clinic
trial
children
croup
randomli
assign
two
group
studi
group
treat
fluticason
propion
control
group
treat
intramuscular
dexamethason
croup
score
perform
hour
initi
administr
accord
westley
croup
score
result
improv
observ
studi
group
control
group
hour
initi
treatment
group
patient
respond
treatment
p
hour
treatment
studi
group
respons
control
group
respons
p
rhiniti
chronic
idiopath
urticaria
pediatr
adult
popul
clinic
pharmacolog
profil
dl
extens
investig
dl
avail
number
formul
includ
tablet
syrup
bioequival
dl
tablet
syrup
studi
date
chines
popul
random
openlabel
singl
dose
crossov
trial
studi
pharmacokinet
dl
administ
tablet
ml
mg
ml
syrup
healthi
adult
male
chines
subject
provid
written
inform
consent
undergo
screen
subject
admit
clinic
baselin
assess
subject
random
receiv
one
two
dl
formul
fast
state
blood
test
pharmacokinet
taken
day
subject
remain
clinic
first
hour
day
washout
period
subject
cross
dl
formul
underw
ident
pharmacokinet
analys
main
pharmacokinet
variabl
two
formul
logtransform
auc
cmax
dl
biochem
hematolog
test
ecg
data
vital
sign
also
assess
studi
advers
event
ae
report
collect
result
dl
safe
well
toler
administ
tablet
syrup
formul
ae
report
tmax
cmax
auc
valu
dl
similar
formul
statist
signific
differ
tablet
syrup
dl
formul
basi
logtransform
cmax
auc
valu
dl
ci
auc
cmax
respect
dl
respect
rel
bioavailbl
dl
syrup
dl
met
criteria
bioequival
two
formul
conclus
syrup
tablet
formul
dl
safe
well
toler
administ
syrup
formul
dl
bioequival
tablet
form
dl
healthi
chines
subject
pharmacokinet
safeti
profil
desloratadin
healthi
korean
volunt
background
desloratadin
dl
nonsed
select
potent
antagonist
effect
well
toler
treatment
subject
allerg
rhiniti
chronic
idiopath
urticaria
pharmacokinet
pk
dl
studi
korean
popul
date
method
doubleblind
dose
escal
studi
pk
toler
singl
dose
dl
healthi
male
korean
subject
dose
group
subject
receiv
dl
receiv
placebo
safeti
demonstr
dl
dose
escal
next
dose
group
subject
screen
elig
week
prebaselin
period
subject
confin
day
baselin
bloodurin
test
ecg
perform
dl
administ
fast
day
subject
remain
confin
day
blood
sampl
perform
biochemistri
hematolog
pk
dl
administr
day
tmax
termin
cmax
auclast
desloratadin
metabolit
calcul
vital
sign
physic
examin
ecg
perform
regularli
advers
event
ae
report
collect
background
elderli
patient
allerg
rhiniti
secondgener
adequ
studi
although
wide
use
assum
safe
object
evalu
cardiac
safeti
loratadin
treatment
allerg
rhiniti
elderli
patient
method
total
patient
perenni
allerg
rhiniti
enrol
studi
male
femal
age
year
mean
case
histori
cardiovascular
diseas
present
abnorm
ecg
paramet
prolong
qtinterv
subject
receiv
loratadin
oncedaili
day
seri
baselin
ecg
record
obtain
treatment
ecg
effect
treatment
compar
baselin
ecg
result
chang
sinu
rhythm
patient
day
treatment
loratadin
statist
signific
differ
found
heart
rate
p
durat
pr
qr
interv
baselin
endpoint
ecg
p
signific
prolong
qt
well
qtc
correct
heart
rate
use
bazett
formula
result
suggest
cardiotox
loratadin
usual
recommend
dose
longterm
treatment
allerg
rhiniti
elderli
propranolol
cytotox
human
leukem
cell
line
background
propranolol
betaadrenerg
blocker
use
treatment
larg
number
cardiovascular
diseas
drug
also
inhibitor
phosphatid
acid
pa
phosphohydrolas
phosphatid
acid
biosynthesi
phosphatid
acid
growth
factor
tumor
cell
addit
inhibitori
effect
propranolol
develop
tobaccoinduc
pulmonari
adenocarcinoma
also
cytotox
rat
human
lung
macrophag
human
lung
tumor
cell
line
report
widespread
longterm
use
propranolol
lot
heart
diseas
well
cytotox
tumor
cell
prompt
us
investig
cytotox
effect
human
leukem
cell
line
method
cell
cultur
complet
rpmi
medium
incub
differ
concentr
propranolol
mm
hour
cytotox
assess
mtt
reduct
also
trypan
blue
dye
exclus
method
result
propranolol
induc
signific
dose
depend
cytotox
effect
human
cell
line
less
hour
compar
untreat
control
cell
result
show
human
leukem
cell
line
dose
depend
sensit
propranolol
studi
investig
vivo
effect
propranolol
leukem
patient
also
leukem
cell
warrant
clinic
featur
diagnos
laboratori
investig
subject
prospect
collect
laboratori
staff
blind
detail
perform
lowstring
revers
transcriptionpolymeras
chain
reaction
rtpcr
assay
use
pair
primer
detect
constant
region
hcov
ie
pancoronaviru
result
subject
male
recruit
mean
sd
age
year
main
discharg
diagnos
pneumonia
upper
respiratori
infect
uri
asthma
seizur
bronchiol
roseola
infantum
croup
other
twentyeight
npa
sampl
posit
hcov
clinic
diagnos
associ
hcov
isol
includ
asthma
seizur
uri
bronchiol
pneumonia
tonsil
roseola
infantum
croup
otiti
media
hcov
infect
relat
age
highest
respiratori
rate
maxim
temperatur
hcov
infect
associ
wheez
ill
defin
fasthma
fbronchiti
fbronchiol
versu
lower
respiratori
infect
three
plu
fpneumonia
p
hcov
case
like
suffer
seizur
versu
complet
blood
count
creactiv
protein
relat
hcov
infect
conclus
hcov
uncommon
yet
import
pathogen
caus
seizur
disord
local
hospitalis
children
hand
hcov
infect
associ
wheez
ill
hong
kong
children
predomin
strain
staphylococcu
aureu
atop
dermat
patient
genotyp
character
staphylococcu
aureu
isol
adolesc
adult
patient
atop
dermat
nizat
aureu
clinic
sever
skin
barrier
function
demonstr
qualit
analysi
especi
genotyp
character
aureu
isol
atop
patient
howev
rare
report
method
studi
aim
find
genotyp
character
aureu
atop
dermat
patient
perform
newlydevelop
type
method
spa
type
multilocu
sequenc
type
mlst
toxin
gene
assay
multiplex
polymeras
chain
reaction
isol
staphylococcu
result
show
predomin
clone
aureu
high
heterogen
spa
type
mlst
toxin
gene
assay
show
interest
result
aureu
strain
least
two
kind
toxin
gene
sea
preval
role
primari
secondari
lowgrad
rhinoviru
infect
allerg
airway
inflamm
murin
model
allerg
asthma
mykola
korzh
kharkov
nation
univers
fundament
medicin
kharkov
ukrain
background
rhinoviru
respiratori
syncyti
viru
rsv
infect
known
develop
exacerb
asthma
young
children
adult
rsv
caus
recurr
asymptomat
infect
howev
impact
asymptomat
rsv
infect
adult
asthma
yet
determin
aim
studi
determin
effect
primari
secondari
lowgrad
rhinoviru
infect
allerg
airway
inflamm
murin
model
allerg
asthma
method
lowgrad
rhinoviru
x
plaqueform
unitsmous
inocul
caus
neither
pulmonari
inflamm
symptom
induc
signific
ifngamma
product
thorac
lymph
node
investig
interact
lowgrad
viru
dermatophagoid
farina
df
airway
hyperrespons
lung
inflamm
cytokin
product
thorac
lymph
node
compar
primari
secondari
lowgrad
rhinoviru
infect
four
group
mice
control
df
allergensensit
rhinovirusinfect
dfsensit
rhinovirusinfect
mice
direct
comparison
lowand
highgrad
rhinoviru
infect
also
perform
primari
infect
investig
role
secondari
rhinoviru
infect
monoclon
antibodi
mab
inject
mice
similar
paramet
compar
four
group
mice
result
primari
highgrad
rhinoviru
infect
increas
allergeninduc
airway
inflamm
primari
lowgrad
rhinoviru
infect
attenu
allergeninduc
airway
inflamm
concomit
signific
ifngamma
product
lungdrain
lymph
node
mark
contrast
secondari
lowgrad
rhinoviru
infect
increas
ifngamma
product
result
exacerb
allergeninduc
airway
inflamm
mab
treatment
secondari
lowgrad
rhinoviru
infect
df
allergensensit
mice
attenu
viru
allergeninduc
airway
inflamm
conclus
lowgrad
rhinoviru
infect
per
se
caus
pulmonari
inflamm
wherea
induc
signific
immunolog
respons
allergensensit
host
result
indic
subclin
recurr
rhinoviru
infect
may
play
import
role
exacerb
mainten
asthma
adult
wherein
critic
involv
hai
lee
chung
sang
mi
kwon
school
medicin
cathol
univers
taegu
pediatr
taegu
republ
korea
background
zinc
one
dietari
antioxid
previou
studi
shown
zinc
crucial
normal
develop
function
cell
mediat
nonspecif
immun
recent
zinc
supplement
report
reduc
acut
lower
respiratori
infect
prevent
sever
pneumonia
children
purpos
examin
zinc
level
serum
young
children
recurr
earli
wheez
evalu
clinic
laboratori
find
relat
zinc
statu
method
seventythre
patient
age
month
yr
admit
acut
respiratori
infect
wheez
enrol
children
experienc
episod
wheez
admiss
zinc
level
measur
serum
sampl
collect
admiss
use
induct
coupl
plasmaopt
emiss
spectrometri
icpo
valu
g
mgdl
defin
zinc
defici
clinic
laboratori
find
children
zinc
defici
examin
compar
children
normal
valu
zinc
level
sixteen
agematch
control
also
studi
result
median
valu
zinc
level
patient
significantli
lower
control
patient
found
zinc
defici
significantli
higher
control
zinc
defici
observ
patient
yr
age
yr
age
signific
differ
total
wbc
count
lymphocyt
count
atop
statu
relat
zinc
statu
patient
ratio
significantli
lower
patient
zinc
defici
howev
immun
profil
within
normal
limit
conclus
studi
show
median
valu
zinc
level
significantli
lower
zinc
defici
frequent
found
patient
recurr
earli
wheez
compar
agematch
control
result
suggest
zinc
defici
may
associ
frequent
respiratori
viral
infect
like
trigger
recurr
earli
wheez
young
children
aurora
losada
pena
luz
aythami
santana
emma
gonzalez
seco
hospit
ramon
cajal
allergi
depart
madrid
spain
aim
mycobacterium
avium
intracellular
mav
atyp
mycobacterium
commonli
associ
human
diseas
pulmonari
diseas
frequent
clinic
present
appear
higher
preval
immunosuppress
patient
present
case
year
old
woman
nurs
profess
cough
dysnea
period
nine
year
wheez
fever
constitut
syndrom
refer
skin
prick
test
common
aeroallergen
latex
spirometri
bronchodilat
test
perform
total
ige
complement
studi
protein
electrophoresi
immunoglobulin
determin
cellular
immun
studi
hiv
xray
studi
thorac
ctscan
mantoux
zielh
sputum
cultur
done
result
posit
skin
prick
test
pollen
dog
cat
epithelia
obtain
patient
normal
spirometri
valu
neg
bronchodilat
test
laboratori
test
normal
level
determin
total
ige
kul
chest
xray
show
caviti
lung
interstiti
infiltr
ctscan
confirm
find
mantoux
zielh
baarfield
mav
cultur
posit
mycobacterium
tuberculosi
exclud
crp
cellular
immun
complement
protein
electrophoresi
immunoglobulin
determin
normal
rang
hiv
test
neg
conclus
present
case
patient
rhinoconjunt
due
pollen
hypersensit
persist
cough
pulmonari
infect
mycobacteium
avium
associ
mycobacterium
avium
describ
human
pathogen
mani
seri
describ
pulmonari
infect
mav
mycobacterium
mainli
attack
immunosuppress
patient
infect
less
frequent
patient
normal
immun
patient
immunosuppress
risk
factor
present
time
treat
antibiot
ethambutol
claritromicin
good
gener
condit
need
hospitalis
chronic
granulomat
diseas
cgd
inherit
phagocyt
disord
caus
mutat
nadph
oxidas
subunit
patient
cgd
lifethreaten
bacteri
fungal
infect
children
medic
center
tehran
univers
referr
center
immunodefici
iran
two
year
studi
forti
five
famili
clinic
diagnos
cgd
refer
center
neutrophil
function
assay
perform
affect
children
mother
activ
residu
activ
detect
affect
neutrophil
pmn
poli
morpho
nuclear
oxid
burst
reveal
mosaic
pattern
mother
western
blot
analysi
reveal
son
mutat
screen
cybb
gene
use
sscp
analysi
follow
sequenc
show
differ
mutat
includ
one
novel
mutat
western
immunoblot
subtyp
patient
whose
mother
show
mosaic
pattern
reveal
patient
null
express
patient
defect
respect
gt
screen
gene
reveal
patient
mutat
mutat
analysi
rest
gene
patient
understudi
cyba
mutat
analysi
reveal
differ
mutat
includ
three
novel
mutat
overal
number
autosom
recess
patient
cgd
iran
high
seem
consanguin
marriag
one
caus
factor
appropri
paper
inform
present
volunt
motiv
understand
vaccin
properti
trial
procedur
risk
behavior
abil
perform
trial
protocol
estim
volunt
enrol
trial
confidenti
medic
investig
inform
consent
undersign
result
person
enquiri
screen
potenti
volunt
main
reason
particip
help
hivinfect
peopl
includ
person
nearest
surround
wife
husband
friend
child
contribut
develop
hivaid
vaccin
possibl
immun
protect
hiv
free
insur
andor
medic
care
person
refus
particip
trial
reason
refus
doubt
vaccin
safeti
fear
receiv
hivinfect
fear
side
effect
fear
vaccineinduc
hiv
seroposit
imposs
perform
trial
protocol
low
compens
unexplain
person
refus
particip
clinic
trial
decid
futur
clinic
trial
phase
ii
reason
plan
pregnanc
tempor
imposs
perform
trial
protocol
volunt
men
woman
age
enrol
trial
leav
trial
vaccin
unexplain
reason
success
pass
trial
protocol
final
step
trial
conclus
first
cohort
clinic
trial
prevent
hivaid
vaccin
creat
russia
partial
enrol
clinic
trial
vichrepol
vaccin
cohort
stabl
expand
may
includ
intern
multicent
trial
novel
mutat
within
exon
cybb
gene
result
sever
form
xlink
chronic
granulomat
diseas
chronic
granulomat
diseas
cgd
primari
phagocyt
disord
defect
superoxid
format
intracellular
kill
common
form
xlink
cgd
xcgd
result
mutat
cybb
gene
chromosom
evalu
thai
boy
multipl
salmonella
septicemia
aspergillu
pneumonia
brain
abscess
nitroblu
tetrazolium
nbt
test
reportedli
abnorm
dihydrorhodamin
dhr
flow
cytometri
assay
perform
fluoresc
pattern
upon
stimul
compat
typic
xcgd
cybb
analysi
reveal
novel
complex
mutat
atggacgi
ttca
exon
base
pair
result
amino
acid
tyr
gli
arg
delet
replac
amino
acid
phe
gln
dhr
mutat
analysi
mother
show
normal
dhr
pattern
mutat
exon
cybb
gene
cybb
mutat
regist
intern
maintain
xcgd
databas
mutat
distribut
throughout
exon
exonintron
boundari
almost
mutat
uniqu
report
novel
mutat
within
exon
cybb
gene
nicotinamid
adenin
dinucleotid
phosphat
nadph
bind
domain
cgd
patient
function
defect
demonstr
almost
absenc
fluoresc
upon
stimul
granulocyt
dhr
histogram
defect
lead
sever
form
xcgd
background
nutrit
import
factor
influenc
immun
nutrit
defici
impair
resist
infectionsmalnutrit
common
caus
immunodefici
worldwid
trace
element
zinc
selenium
iron
copper
influenc
sever
compon
immun
primmari
antibodi
defici
disord
group
disord
character
unusu
suscept
infect
malnutrit
impair
nutrit
statu
report
immunodefici
patient
aim
studi
determin
anthropometr
indic
trace
element
statu
patient
method
thirtyeight
children
male
femal
age
year
primari
antibodi
defici
refer
children
medic
center
tehran
univers
medic
scienc
enrol
research
primari
immunodefici
disord
consist
cvid
xla
iga
defici
igg
subclass
defici
hyper
igm
assess
anthropometr
indic
compris
height
weight
measur
bodi
mass
index
bmi
calcul
heightforag
haz
weightforheight
whz
weightforag
waz
determin
accord
zscore
studi
mild
moder
sever
malnutrit
serum
copper
zinc
selenium
iron
level
measur
atom
absorpt
spectromet
result
common
disord
cvid
xlink
agammaglobulinemia
base
bmi
measured
patient
malnutrit
accord
haz
sever
moder
mild
malnutrit
respect
accord
waz
sever
moder
mild
malnutrit
respect
regard
whz
moder
mild
malnutrit
respectivelylow
selenium
level
high
copper
level
obsevd
respect
conclus
anthropometr
data
show
frequenc
malnutrit
patient
higher
cdc
standard
low
serum
selenium
level
high
serum
copper
level
observ
suggest
research
need
paramet
patient
serum
zinc
iron
level
within
normal
rang
recommend
clinic
immunologist
nutritionist
make
collect
effort
provid
patient
standard
special
diet
decreas
risk
infect
registri
primari
immunodefici
univers
hospit
thailand
yearreview
patchane
benjasupattananan
nualanong
visitsunthorn
pakit
vichyanond
voravich
luangwedchakarn
orathai
jirapongsananuruk
mahidol
univers
siriraj
hospit
pediatr
bangkok
thailand
mahidol
univers
siriraj
hospit
immunolog
bangkok
thailand
background
primari
immunodefici
group
rare
diseas
difficult
diagnos
manag
present
symptom
infect
uncommon
organ
lead
high
morbid
mortal
object
evalu
clinic
characterist
pediatr
patient
primari
immunodefici
thailand
method
medic
record
patient
diagnos
treat
primari
immunodefici
past
year
siriraj
hospit
bangkok
thailand
review
patient
secondari
immunodefici
chromosom
abnorm
exclud
result
total
pediatr
patient
male
femal
regist
earliest
onset
symptom
newborn
period
igg
subclasss
defici
common
primari
immunodefici
diseas
follow
sever
combin
imuunodefici
specif
antibodi
defici
agammaglobulinemia
common
variabl
immunodefici
chronic
granulomat
diseas
common
present
symptom
antibodi
defici
upper
respiratori
tract
infect
patient
tcell
immunodefici
common
present
pcp
pneumonia
septicemia
common
present
among
patient
phagocyt
defect
increas
trend
earli
detect
primari
immunodefici
decreas
diagnost
lag
month
past
year
histori
death
famili
import
inform
rapid
diagnosi
conclus
establish
registri
primari
immunodefici
may
provid
inform
earli
detect
proper
treatment
improv
prognosi
patient
thailand
pauciti
advers
event
associ
administr
ivig
constanc
katelari
marjori
bennett
univers
western
sydney
immunolog
an
allergi
sydney
australia
westmead
hospit
immunolog
allergi
sydney
australia
introduct
intraven
immunoglobulin
ivig
valuabl
treatment
mani
immunemedi
disord
vital
manag
humor
immunodefici
individu
receiv
regular
longterm
therapi
ivig
advers
event
associ
administr
ivig
report
specialist
unit
westmead
hospit
sydney
approxim
cours
ivig
administ
annual
aim
larg
experi
ivig
administr
perform
retrospect
analysi
advers
event
ae
experienc
patient
attend
unit
method
retrospect
chart
review
ivig
infus
deliv
last
four
year
perform
factor
examin
patient
demograph
diagnosi
previou
administr
ivig
infus
symptom
ae
ivig
product
util
intragamp
csl
bioplasma
melbourn
australia
sandoglobulin
zlb
bioplasma
g
bern
switzerland
octagam
octapharma
ag
lachen
switzerland
patient
receiv
ivig
routin
premed
either
antihistamin
steroid
result
centr
infus
ivig
given
year
period
patient
male
femal
patient
pid
variou
autoimmun
condit
treatment
induc
hypogammaglobulinemia
patient
long
stand
recipi
ivig
nabv
ivig
product
year
ae
observ
patient
nabv
ivig
product
longterm
recipi
patient
pid
remaind
autoimmun
condit
discuss
review
show
incid
ae
associ
ivig
infus
low
infus
similar
figur
report
elsewher
ae
may
prevent
three
patient
nabv
ivig
may
benefit
premed
three
reaction
occur
recommend
maximum
infus
rate
exceed
reaction
occur
due
patient
delay
infus
patient
experienc
ae
continu
ivig
without
reoccurr
ae
one
routin
premed
therefor
conclus
due
regard
infus
rate
time
infus
use
premed
ivig
safe
treatment
humer
immunodefici
autoimmun
disord
lilian
varga
zsuzsanna
kelemen
va
judit
georg
visi
henriett
farka
semmelwei
univers
depart
intern
medicin
budapest
hungari
heim
children
hospit
depart
intern
medicin
budapest
hungari
diagnosi
hereditari
angioedema
hae
base
complement
test
howev
relationship
clinic
symptom
complement
level
poorli
studi
studi
compar
complement
valu
patient
hae
patient
angioedema
unknown
origin
addit
complement
paramet
antigen
function
test
time
diagnosi
correl
age
sex
sever
diseas
patient
hae
type
patient
type
ii
unlik
previou
find
found
complement
paramet
test
function
highest
specif
lowest
sensit
diagnosi
hae
highest
specif
observ
antigen
assay
find
correl
complement
level
age
time
diagnosi
associ
found
complement
level
sex
hae
type
found
signific
associ
baselin
function
level
sever
diseas
conclus
demonstr
antigen
function
requir
correct
diagnosi
hae
test
highli
valid
result
determin
funcion
may
clinic
signific
regular
evalu
paramet
use
tool
strategi
long
term
prophylaxi
howev
studi
requir
confirm
associ
henriett
farka
lilian
varga
gabor
szeplaki
temesszentandrasi
laszlo
jakab
bela
feket
georg
fust
istvan
karadi
semmelwei
univers
depart
intern
medicin
budapest
hungari
background
hae
character
recurr
edemat
swell
subcutan
submucos
tissu
bradykinin
play
essenti
role
develop
angioedema
studi
conduct
investig
effect
select
icatib
treatment
attack
patient
hae
due
defici
openlabel
extens
phase
random
doubl
blind
control
phase
iii
studi
patient
cutan
andor
abdomin
attack
hereditari
angioedema
treat
icatib
within
hour
onset
moderatesever
attack
receiv
singl
inject
mg
icatib
subcutan
symptom
assess
patient
va
symptom
score
physician
symptom
score
global
assess
clinic
global
impress
result
angioedema
attack
patient
hae
treat
icatib
affect
site
twice
extrem
genitalia
patient
patient
experienc
two
abdomin
attack
anoth
attack
affect
gastrointestin
tract
one
extrem
clinic
symptom
attack
improv
quickli
time
first
improv
symptom
minut
durat
complet
resolut
symptom
shorter
abdomin
attack
compar
attack
involv
subcutan
tissu
min
versu
min
drug
relat
advers
event
relaps
experienc
local
skin
reaction
inject
site
toler
resolv
within
hour
conclus
icatibantywhich
differ
earlier
drug
concern
mode
action
method
administr
wellyha
found
effect
safe
treatment
angioedema
attack
patient
hae
possibl
subcutan
administr
icatib
may
improv
daili
life
patient
suffer
hae
present
case
repeat
use
icatib
result
reduc
efficaci
potenti
icatib
treatment
bradykinin
mediat
angioedema
test
studi
leukocyt
adhes
genet
immunodefici
diseas
character
lifethreaten
infect
result
mutat
leukocyt
integrin
molecul
sever
moder
phenotyp
report
case
sever
lad
occur
month
old
girl
case
moder
lad
present
aggress
periodont
case
clinic
featur
includ
delay
separ
umbil
cord
omphal
sever
bullos
ulcer
skin
erupt
mimic
pictur
staphylocol
scale
skin
syndrom
neonat
period
persist
leukocytosi
immunolog
workup
show
patholog
valu
respect
patient
wait
bmt
case
year
old
boy
aggress
periodont
primari
dentit
patholog
examin
show
actinomycosi
ginigivit
normal
separ
umbil
cord
peripher
blood
flowcytometeri
compat
moder
phenotyp
receiv
antibiot
prophylaxi
conclus
although
lda
rare
form
congenit
immuno
defici
sever
consid
delay
wound
heal
recurr
bacteri
skin
infect
present
newborn
moder
aggress
periodont
normal
wound
heal
clinic
molecular
characterist
thai
famili
xlink
chronic
granulomat
diseas
prapaporn
vilaiphan
pantipa
chatchate
jarungchit
ngamphaiboon
siraprapa
tongkobpetch
kanya
suphapeetiporn
vorasuk
shotelersuk
chulalongkorn
univers
depart
pediatr
divis
allergi
immunolog
bangkok
thailand
chulalongkorn
univers
depart
pediatr
divis
medic
genet
metabol
bangkok
thailand
rational
xlink
chronic
granulomat
diseas
xcgd
immunodefici
disord
character
defect
intracellular
kill
microorgan
due
neutrophil
inabl
gener
superoxid
ion
although
caus
mutat
cybb
gene
clinic
molecular
characterist
vari
among
differ
ethnic
background
materi
method
two
unrel
thai
boy
present
sever
persist
pulmonari
infect
age
two
month
abnorm
dhr
assay
support
diagnosi
xcgd
mutat
analysi
perform
polymeras
chain
reaction
pcr
amplif
sequenc
entir
code
region
cybb
mutat
identifi
confirm
restrict
enzym
analys
result
pcrsequenc
entir
code
region
cybb
identifi
nonsens
mutat
exon
exon
proband
famili
proband
mother
found
carrier
conclus
observ
support
cybb
gene
respons
xcgd
across
differ
popul
nonsens
mutat
associ
sever
phenotyp
background
inflammatori
respons
prior
infect
due
improv
immun
respons
latent
pathogen
paradox
clinic
worsen
observ
hivinfect
patient
initi
potent
antiretrovir
therapi
case
report
cytomegaloviru
cmv
associ
cn
iri
children
method
report
case
seriou
atyp
advers
event
initi
arv
result
year
old
thai
girl
cdc
c
due
wast
syndrom
present
histori
fever
oral
candidiasi
count
cellsml
viral
load
copiesml
week
cotrimoxazol
pcp
prophylaxi
start
antiretrovir
therapi
arv
stavudin
lamivudun
nevirapin
chulalongkorn
hospit
one
week
later
develop
right
side
hemiparesi
without
histori
headach
vomit
loss
conscious
neurolog
exam
reveal
right
side
weak
motor
power
grade
iv
upper
lower
extrem
normal
reflex
clonu
differenti
diagnos
cerebr
toxoplasmosi
brain
abscess
tumor
ct
brain
contrast
media
reveal
gener
brain
atrophi
without
mass
ring
enhanc
lumbar
punctur
perform
cerebrospin
fluid
csf
colorless
clear
wbc
rbc
protein
mgdl
csf
sugar
plasma
sugar
mgdl
respect
csf
bacteri
cultur
growth
csf
cytomegaloviru
cmv
posit
pcr
method
mri
brain
shown
hypodens
lesion
right
cerebellum
ophthalmolog
examin
normalaft
week
arv
count
viral
load
cellsml
copiesml
respect
diagnosi
immun
reconstitut
inflammatori
syndrom
iri
howev
prescrib
steroid
bacteremia
period
continu
take
arv
usual
one
month
hospit
reexamin
fine
full
motor
power
total
month
arv
fine
count
cellsml
viral
load
copiesml
conclus
report
cmv
iri
right
hemiparesi
week
initi
antiretrovir
therapi
hiv
infect
girl
sever
immunosuppress
diagnosi
atyp
cn
symptom
initi
arv
rapidli
increas
decreas
viral
load
consid
iri
use
quantif
creactiv
protein
crp
diagnosi
bacteri
infect
febril
neutropen
child
martin
penago
fortino
solorzano
miguel
villasi
andrea
tapia
hugo
rivera
roberto
bernaldez
pediatr
hospit
cmn
pediatr
section
mexico
citi
mexico
pediatr
hospit
cmn
bsiglo
xxi
imss
pediatr
section
mexico
citi
mexico
background
diagnosi
bacteri
infect
neutropen
child
fever
becom
difficult
due
poor
inflammatori
respons
current
method
reliabl
fast
identifi
patient
bacteri
infect
avail
crp
evalu
patient
controversi
result
object
determin
sensit
specif
predict
valu
likelihood
ratio
crp
diagnosi
bacteri
infect
neutropen
children
fever
design
crosssect
studi
method
includ
patient
less
year
age
fever
sever
neutropenia
blood
cultur
crp
taken
initi
evalu
empir
antimicrobi
treatment
evolut
follow
discharg
blood
cultur
process
autom
system
bactalert
crp
nephelometri
patient
classifi
group
group
clinic
bacteriolog
infect
group
ii
infect
clinic
defin
group
iii
fever
due
caus
infect
group
iv
patient
cancer
neutropenia
without
fever
diagnost
test
analysi
receiv
oper
curv
roc
likelihood
ratio
perform
result
one
hundr
twenti
seven
episod
includ
subject
leukemia
frequent
diseas
twenti
nine
episod
includ
group
ii
iii
iv
respect
found
microbiolog
isol
episod
staphylococcu
aureu
escherichia
coli
common
isol
germ
median
crp
level
iqr
mgl
group
mgl
group
ii
mgl
group
iii
mgl
group
iv
cor
curv
crp
level
higher
mgl
show
sensit
specif
e
posit
pv
ppv
neg
pv
vpn
compar
group
ii
vs
iii
cut
level
likelihood
ratio
posit
result
neg
result
among
patient
diagnosi
solid
tumor
e
ppv
npv
found
none
patient
neutropenia
fever
neg
blood
cultur
without
focal
infect
crp
level
lower
mgl
bacteri
infect
patient
crp
level
higher
mgl
infect
conclus
crp
use
fast
econom
test
identifi
bacteri
infect
neutropen
patient
cancer
fever
method
patient
observ
tradit
clinic
paraclin
method
investig
result
clinic
sign
recurr
furunculosi
episod
skin
cold
staphylococc
abscess
onset
streptostaphylodermia
month
age
first
clinic
manifest
diseas
frequenc
exacerb
time
per
year
recurr
bronchiti
sinc
month
recurr
pneumonia
complic
pleuriti
pneumatocel
sinc
year
old
child
pneumonia
per
year
child
oper
age
yearlobectomi
upper
right
lung
lobe
age
year
lobectomi
upper
left
lung
lobe
age
year
toracotomi
sew
bronchopleura
fistula
left
lung
recurr
abscess
abdomin
caviti
sinc
year
child
oper
mani
time
year
due
acut
append
complic
periton
year
huge
abscess
big
omentum
year
abscess
region
afteroper
scar
month
abscess
left
underdiaphragm
region
abscess
upper
pole
spleen
presenc
atop
dermat
sinc
month
eczemat
skin
erupt
season
variat
present
degre
time
presenc
skeleton
anomali
scoliosi
gener
hyperextens
joint
facial
abnorm
retent
primari
teeth
unresorb
root
absent
lower
premolari
upper
premolari
lower
upper
molari
lab
find
high
eosinophilia
lymphocytosi
till
thanneutrophilia
till
shift
left
band
neutrophil
elevet
esr
mmhour
high
level
ige
iu
ml
imag
studi
dental
abnorm
delay
primari
teeth
shed
owe
lack
root
resorpt
absent
perman
teeth
xray
thinwal
cyst
lung
xray
cyst
liver
lung
ultrason
comput
tomographi
patient
treat
prolong
cours
antibacteri
therapi
fluconazol
mucocutan
candidiasi
onychomycosi
topic
steroid
eczemat
dermat
conclus
clinic
case
give
us
experi
observ
treatment
children
suffer
rare
primari
immunodefici
disord
evalu
clinic
paraclin
twenti
cvid
patient
detect
signific
cellular
function
invitro
way
marzieh
heidarzadeh
arani
abolhassan
farhoudi
asghar
aghamohammadi
gholamreza
ghasemiyeh
shahid
behashti
pediatr
kashan
islam
republ
iran
children
medic
center
immunolog
allergi
tehran
islam
republ
iran
shahid
behashti
farmacolog
kashan
islam
republ
iran
subject
common
variabl
immunodefici
primari
immunodefici
diseas
cvid
heterogen
group
immunolog
disord
un
known
etiolog
character
impair
antibodi
respons
associ
number
function
cell
defect
includ
lymphopenia
anergi
impair
lymphocyt
prolifer
deficit
cytokin
secret
import
preval
object
goal
studi
evalu
clinic
paraclin
character
cvid
patient
interlukin
product
compair
healthi
control
group
method
materi
done
random
cross
section
studi
cvid
patient
depart
immunolog
allergi
children
medic
center
healthi
control
evalu
patient
done
question
peripher
blood
mononuclear
cell
twp
group
cultur
pha
supernat
collect
quantit
elisa
result
mean
age
patient
distribut
gender
femal
male
high
frequenc
hospit
case
two
time
frequent
infect
respiratori
tract
infect
opportunist
infect
autoimmun
case
un
respons
dth
case
product
zero
patient
patient
level
lower
correspond
level
healthi
control
p
conclus
studi
patient
show
cell
exhibit
defici
product
manifest
defici
high
frequenc
autoimmun
granolumatos
diseas
bronchectasia
recurr
infect
spite
given
monthli
ivig
patient
year
old
femal
scid
j
b
j
nk
treat
halogen
bone
marrow
transplant
case
report
horacio
del
olmo
tellez
francisco
espinosa
rosal
nation
institut
pediatr
mexico
allergi
immunolog
mexico
citi
mexico
year
old
femal
second
two
children
born
nonconsanguin
mexican
parent
uncompl
term
pregnanc
birth
weight
g
length
cm
breast
feed
month
age
nt
receiv
immun
histori
year
old
brother
suffer
totipot
cell
transplant
sever
immunodefici
curs
neurolog
infect
die
age
day
abund
liquid
blood
stool
receiv
ceftriaxon
treatment
partial
improv
stool
cultiv
test
posit
campylobact
yeyuni
treat
claritromicyn
day
also
oral
esophag
candidiasi
treat
miconazol
brother
immunodefici
arriv
hospit
follow
studi
done
cd
cd
igm
mgdl
igg
mgdl
iga
mgdl
sever
combin
immunodefici
diagnosi
made
j
b
j
nk
featur
suppos
defici
enzim
receptor
recombin
restitut
totipot
cell
halogen
bone
marrow
transplant
hla
compat
patient
dr
patient
father
homozig
dr
high
resolut
studi
dr
patient
patient
father
decid
admist
partial
hidrol
formula
posibl
risk
adquir
infect
breast
feed
treat
immunosupresor
acondicion
treatment
busulfan
mgkgday
day
day
cyclophosphamid
mgkgday
day
septemb
patient
receiv
hallogen
bone
marrow
trasplant
prior
medic
blocker
steroid
adminit
ml
aferesi
product
total
count
mononuclear
patient
present
host
againt
diseas
papul
petechia
abdomen
treat
metotrex
ciclosphorin
methilprednisolon
citomegaloviru
blood
cultur
test
posit
treat
succes
ganciclovir
nowaday
normal
blood
citolog
immunoglobulin
level
lymphocyt
subpopul
complet
immun
schedul
two
half
year
stem
cell
transfus
berufsgenossenschaftlich
unfallkrankenhau
boberg
depart
dermatolog
hamberg
germani
univers
erlangen
med
informat
biometri
epidemiolog
erlangen
germani
background
staphylococcu
aureu
aureu
well
known
trigger
factor
atop
dermat
ad
besid
staphylococc
superantigen
alphatoxin
produc
one
third
skincolon
aureu
strain
ad
may
influenc
cutan
inflamm
detect
upper
epidermi
dermi
ad
patient
sublyt
concentr
shown
induc
tcell
prolifer
secret
tcell
cytokin
object
explor
associ
sensit
inhal
allergen
produc
skin
colon
aureu
ad
method
investig
adult
patient
ad
accord
skin
colon
treatment
antiinflammatori
antisept
substanc
medic
histori
sever
ad
sensit
differ
allergen
result
patient
colon
aureu
aureu
colon
patient
suffer
sever
ad
scorad
aureu
posit
patient
aureu
neg
patient
show
higher
sensit
level
differ
inhal
allergen
surprisingli
also
suffer
frequent
allerg
asthma
aureu
posit
patient
aureu
neg
patient
aureu
skincolon
strain
produc
sever
ad
similar
patient
colon
neg
aureu
tpt
compar
patient
produc
pt
pt
signif
higher
specif
ige
birch
pollen
median
pt
tpt
trend
higher
total
ige
valu
median
pt
tpt
specif
ige
timothi
grass
pollen
median
pt
tpt
conclus
follow
topic
treatment
colon
rate
lower
expect
high
rate
patient
skin
colon
produc
aureu
colon
aureu
associ
higher
sever
atop
dermat
higher
sensit
higher
frequenc
allerg
asthma
cutan
colon
produc
aureu
associ
higher
sensit
saison
inhal
allergen
ad
consequ
direct
chronic
cutan
tcell
stimul
sublyt
dose
toxin
penetr
constantli
skin
need
investig
trichophyton
allergi
review
case
ag
palmacarlo
ml
palmacarlo
clinic
allergi
immunolog
center
caic
allergolog
lisbon
portug
background
associ
mycosi
onicomycosi
dermatophyt
fungi
allerg
diseas
includ
urticariaangioedema
rhiniti
asthma
describ
year
larg
seri
confirm
case
publish
method
patient
seen
last
year
male
femal
clinic
histori
previou
actual
visibl
skin
nail
infect
posit
test
tricophyton
skin
test
done
patient
prick
first
step
intraderm
dilut
second
step
specif
ige
look
unicap
tricophyton
rubrum
case
treatment
antifung
itraconazol
tri
first
option
patient
allerg
symptom
subsist
specif
immunotherapi
parenter
rout
start
slow
releas
vaccin
minim
period
year
result
fungal
infect
present
tinea
pedi
patient
onicomycosi
tinea
cruri
remain
pruritu
clear
infect
dual
infect
present
patient
total
clinic
mycosi
allerg
diseas
urticaria
angioedema
patient
rhiniti
asthma
plu
rhiniti
eczema
conjunct
fifteen
patient
rhinit
also
posit
skin
test
hous
dust
mite
prick
test
tricophyton
posit
patient
intraderm
test
alway
posit
specif
ige
posit
case
rang
kul
treatment
antifung
clear
allerg
diseas
specif
immunotherapi
tri
patient
good
result
complet
clear
good
moder
nil
conclus
tricophyton
ige
mediat
allergi
play
role
pathogenesi
urticariaangioedena
asthma
rhiniti
patient
fungal
skin
nail
infect
must
search
skin
test
specif
ige
use
diagnosi
sensit
specif
skin
prick
test
specif
ige
roughli
compar
specif
immunotherapi
must
tri
anti
fungal
therapi
fail
good
result
case
profil
inflammatori
cell
erythema
nodosum
leprosum
patient
treat
minocyclineprednison
combin
drug
prednison
background
clinic
trial
studi
conduct
b
prepost
treatmentd
esign
know
effect
minocyclineprednison
combin
drug
prednison
erythema
nodosum
leprosum
enl
patient
profil
cell
inflamm
method
sixti
enl
patient
releas
treatment
rft
includ
studi
devid
group
patient
treat
minocyclineprednison
combin
drug
group
patient
treat
prednisoneplacebo
group
b
evalu
result
studi
perform
histopatholog
examin
skin
biopsi
haematolog
test
peripher
blood
sampl
obtain
cubit
venou
punctur
chang
clinic
featur
result
result
enl
patient
group
shown
improv
histopatholog
haematolog
find
show
differ
group
improv
chang
clinic
featur
patient
get
combin
therapi
conclus
combin
therapi
prednisoneminocyclin
better
prednison
enl
patient
may
altern
drug
reduc
steroid
depend
enl
patient
multipl
sclerosi
one
demyelin
diseas
base
pathophysiolog
chang
vasculomyelin
system
immunolog
basi
diseas
failur
immunolog
toler
brain
antigen
develop
autoimmun
cellular
reaction
import
role
failur
develop
demyelin
process
attribut
bacteria
possess
antigen
determin
common
myelin
basic
protein
mbp
molecul
therefor
perform
multipl
sclerosi
patient
studi
igg
igm
antibodi
clebsiella
pneumonia
e
coli
st
aureu
h
influenza
pertussi
anatoxin
studi
perform
serum
patient
differ
type
multipl
sclerosi
titer
antibodi
clebsiella
pneumonia
e
coli
st
aureu
h
influenza
pertussi
anatoxin
detect
enzym
immunoassay
result
express
class
reaction
studi
show
recurr
type
multipl
sclerosi
exacerb
accompani
increas
igm
antibodi
level
class
abovement
bacteria
remiss
mark
lower
igm
level
compar
exacerb
one
class
increas
igg
level
class
progress
type
multipl
sclerosi
level
igg
well
igm
antibodi
increas
progress
class
cours
multipl
sclerosi
last
year
level
igg
igm
antibodi
highest
mostli
class
base
data
obtain
conclud
degre
manifest
antibacteri
immun
reflect
sever
multipl
sclerosi
consid
neg
prognost
factor
local
cytokin
statu
clinic
morpholog
paramet
chronic
viral
c
hepat
current
research
aim
investig
level
local
cytokin
liver
histolog
examin
sampl
cch
patient
take
account
clinic
morpholog
paramet
well
biochemistri
virolog
investig
cytokin
investig
homogen
liver
histolog
examin
sampl
perform
period
cch
clinic
manifest
accompani
cytolysi
tool
control
sampl
hepat
tissu
belong
donor
chronic
diseas
marker
infect
virus
parenter
hepat
use
investig
cytokin
level
homogen
liver
histolog
examin
sampl
process
investig
liver
histolog
examin
sampl
homogen
cch
patient
establish
authent
increas
tnf
proport
decreas
ifn
proport
consider
fluctuat
proport
level
minim
maxim
indic
note
total
distribut
differ
normal
one
hamper
adequ
assess
investig
indic
patient
divid
two
group
differ
median
low
upper
percentil
quantit
content
local
cytokin
level
first
group
whose
level
practic
investig
cytokin
liver
histolog
examin
sampl
authent
differ
second
group
proport
second
group
nearli
twice
exceed
index
first
group
increas
tnf
level
liver
histolog
examin
sampl
cch
patient
second
group
six
time
high
first
group
note
consider
decreas
local
proport
second
group
pgml
versu
pgml
p
g
pgml
versu
pgml
p
g
correspondingli
note
differ
level
investig
group
note
p
accord
local
cytokin
level
along
median
extrem
percentil
two
cvh
patient
group
singl
group
authent
differ
clinic
biochem
morpholog
paramet
hfr
one
clinic
form
hantaviru
infect
wide
spread
eurasian
contin
europ
hfr
predominantli
associ
puumala
dobrava
belgrad
hantavirus
hv
asiawith
hantaan
amur
seoul
anoth
clinic
form
common
american
contin
hantaviru
pulmonari
syndrom
hp
associ
sin
nombr
and
serotyp
south
far
east
region
three
serotyp
hv
collect
similar
main
pathogen
clinic
aspect
hfr
hp
reveal
establish
pathogenesi
import
role
play
either
hv
initi
process
reaction
cellular
immun
virul
hv
sin
nombr
and
hantaan
amur
lass
virul
puumala
seoul
known
studi
immunopathogenesi
hfr
patient
reveal
depend
characterist
immun
respons
serotyp
hv
onset
diseas
level
misbal
serum
cytokin
high
level
ifn
il
low
level
ifn
also
number
cytotox
lymphocyt
correl
sever
clinic
symptom
serotyp
hv
hfr
associ
hantaan
amur
serotyp
sever
complic
manifest
hemorrhag
syndrom
hyperhydr
kidney
respiratori
tract
liver
tissu
multiorgan
insuffici
sever
form
seoul
infect
less
common
characterist
immun
cytokin
statu
chang
lot
studi
level
cytokin
metabolit
nitric
oxid
urin
exhal
air
condens
show
absenc
correl
product
local
system
fact
reveal
independ
synthesi
immun
respons
mediat
allow
suppos
respiratori
tract
kidney
target
organ
hv
viremia
begin
respiratori
infect
alveolar
macrophag
central
cell
pathogenesi
endotheli
cell
lung
kidney
organ
result
studi
cytokin
differ
biolog
substrat
serum
urin
exhal
air
condens
onset
diseas
show
preval
immun
reaction
pathogenesi
hfr
without
depend
hantaviru
serotyp
comparison
allergen
cytokin
product
profil
experiment
infect
rat
anisaki
simplex
ju
hyeon
lee
haneul
nari
lee
sunga
cho
hangyum
kim
kyungwhan
joo
joonsang
lee
guan
gyu
song
sungweon
cho
background
anisaki
simplex
marin
parasit
belong
ascaroidea
worm
normal
live
within
marin
mammal
howev
frequent
induc
allergi
infect
mammal
land
third
stage
larva
carri
marin
fish
infect
mammal
worm
develop
fourth
stage
larva
state
larva
produc
differ
excretorysecretori
product
esp
main
protein
constitu
investig
compar
esp
antigen
allergen
develop
effici
method
diagnos
allergi
analyz
cytokin
profil
reinfect
critic
period
allergi
develop
method
kinet
specif
antibodi
product
sera
harvest
rat
infect
analyz
indirect
elisa
use
either
antigen
immobil
elisa
plate
cytokin
kinet
ifnr
analyz
rat
sera
harvest
reinfect
result
kinet
antibodi
product
show
specif
antibodi
level
higher
antigen
level
igm
similar
howev
latter
evid
higher
allergen
former
specif
ige
level
reinfect
sera
level
rel
constantli
maintain
contrast
ifni
j
decreas
continu
conclus
result
indic
better
allerg
state
analysi
cytokin
compar
domin
anisaki
simplex
larva
reinfect
miki
fukuda
kengo
kobayashi
yuriko
hirono
hisa
ishikawa
emenik
c
ejiogu
masaharu
sawai
minoru
takeuchi
kyoto
sangyo
univers
biotechnolog
kyoto
japan
origin
japan
co
ltd
ceo
kyoto
japan
takara
shuzo
co
ltd
develop
kyoto
japan
introduct
jungl
honey
jh
collect
timber
blossom
wild
honey
bee
live
tropic
forest
nigeria
use
tradit
medicin
cold
skin
inflamm
burn
wound
well
health
care
howev
effect
jungl
honey
immunomodulatori
activ
yet
clearli
investig
effect
jungl
honey
immun
system
antitumor
activ
mice
method
jh
provid
nihon
origin
jh
dissolv
distil
water
freez
dri
adjust
pb
concentr
jh
fraction
fraction
fr
hplc
size
chromatographi
femal
mice
inject
jh
dose
time
intraperiton
time
inject
periton
cell
pc
obtain
periton
lavag
pb
total
number
pc
count
homocytometor
cell
differenti
observ
microscop
giemsa
stain
express
surfac
antigen
nk
pc
analyz
fac
h
product
pc
assay
fac
use
dcfhda
chemotact
assay
analyz
taxiscantm
use
neutrophil
peripher
blood
human
guinea
pig
mrna
express
pc
analyz
rtpcr
antitumor
activ
assay
use
lewi
lung
result
total
number
pc
increas
jhinject
mice
compar
control
mice
dot
plot
analysi
fac
neutrophil
increas
jhinject
mice
percent
surfac
antigen
posit
cell
intens
antigen
express
also
increas
h
product
pc
increas
jh
chemotact
activ
neutrophil
human
guinea
pig
express
concentr
jh
mrna
express
pc
increas
jh
molecular
weight
approxim
inhibitor
tumor
growth
show
jh
conclus
chemotact
activ
neutrophil
increas
neutrophil
count
h
product
pc
jh
may
prevent
bacteri
viral
infect
case
report
boy
infant
toxocara
cani
eosinophil
mening
nuntiya
pitaksit
pantipa
chatchate
jarungchit
ngamphaiboon
king
chulalongkorn
memori
hospit
pediatr
bangkok
thailand
boy
infant
refer
due
prolong
fever
week
drowsi
bulg
anterior
fontanel
clinic
respons
high
dose
cefotaxim
week
treat
bacteri
mening
neurolog
examin
reveal
mening
irrit
bulg
anterior
fontanel
mark
increas
absolut
eosinophil
count
present
lumbar
punctur
show
leukocytesmicrolit
eosinophil
protein
mgdl
csf
cultur
growth
neg
pcr
tb
immunoblot
assay
posit
toxocara
cani
serum
csf
ct
scan
brain
show
commun
hydrocephalu
patient
close
contact
cat
poor
sanit
diagnosi
eosinophil
mening
due
toxocara
cani
made
start
treatment
albendazol
oral
twice
day
week
prednisolon
mgkgday
tape
within
week
clinic
improv
discharg
day
start
medic
follow
monthli
clinic
symptom
monitor
absolut
eosinophil
count
abnorm
neurolog
symptom
detect
parent
got
rid
cat
household
area
serum
absolut
eosinophil
count
lumbar
punctur
result
turn
normal
within
month
treatment
serolog
follow
week
treatment
toxocara
cani
posit
serum
csf
use
immunoblot
assay
decreas
intens
normal
growth
develop
long
term
follow
done
awar
reinfect
patient
reinvestig
immunoblot
assay
follow
titer
toxocara
cani
done
activ
allium
ascalonicum
shallot
myrtu
communi
extract
two
novel
antibacteri
agent
acn
vulgari
ahmad
farajzadeh
sheikh
mohammad
ali
mashhdizad
mohammad
radmanesh
school
medicin
jondishapor
univers
medic
scienc
ahwaz
iran
microbiolog
ahwaz
islam
republ
iran
background
acn
vulgari
common
skin
diseas
etiolog
pathogenesi
well
known
treatment
satisfactori
therefor
studi
novel
drug
replac
common
drug
necessari
method
patient
suffer
acn
lesion
swab
obtain
swab
cultur
blood
agar
plate
store
aerob
anaerob
condit
sensit
test
herbal
extract
bacteri
isol
done
disk
diffus
method
compar
tetracyclin
disk
result
bacteri
strain
isol
coagulas
neg
staphylococci
con
strain
propionibacteria
spp
strain
diphtheroid
strain
e
coli
strain
streptococci
spp
isol
con
propionibacterium
isol
resist
tetracyclin
wherea
con
resist
shallot
myrtu
communi
water
extract
respect
propionibacterium
strain
propionibacterium
resist
shallot
myrtu
communi
water
extract
respect
also
con
isol
resist
shallot
alcohol
extract
resist
myrtu
communi
alcohol
extract
two
percent
propionibacterium
strain
resist
shallot
alcohol
extract
resist
mmyrtu
communi
alcohol
extract
conclus
find
reveal
bacteri
agent
acn
vulgari
highli
resist
tetracyclin
antibiot
effici
treatment
diseas
suggest
herbal
extract
may
potenti
acn
treatment
galactomannan
antigen
detect
diagnosi
invas
pulmonari
aspergillu
object
invas
aspergillu
occur
almost
exclus
immunocompromis
host
aspergillu
fumigatu
lead
caus
infecti
mortal
mani
hematolog
bone
marrow
allograft
transplant
galactomannan
hetropolysaccharid
present
cell
wall
aspergillu
speci
rapid
import
method
invas
aspergillu
diagnost
could
circul
galactomannan
aspergillu
gm
measur
serum
bal
bronchoalveolar
lavag
sampl
patient
aim
studi
determin
valu
galactomannan
detect
serum
diagnosi
invas
aspergillu
method
patient
fifti
three
patient
recurr
pulmonari
infect
suspect
aspergillu
includ
studi
group
none
select
patient
receiv
anti
fungal
therapi
prior
studi
direct
microscopi
fungal
cultur
bal
bronchoalveolar
lavag
done
galactomannan
estim
serum
bal
measur
result
patient
consid
galactomannan
test
posit
total
case
male
femal
patient
isol
aspergillu
microscopi
cultur
conclus
gm
eia
assay
greater
sensit
cultur
microcopi
detect
aspergillu
spp
bal
fluid
experiment
induc
invas
pulmonari
aspergillu
gm
posit
also
allow
anticip
invas
aspergillu
diagnosi
day
mycolog
cultur
revisit
hygien
hypothesi
crossreact
studi
hous
dust
mite
ascari
lumbricoid
background
causal
relationship
allergi
ascariasi
remain
matter
controversi
despit
grow
evid
protect
immun
exert
helminth
infect
allerg
diseas
molecular
immunolog
mechan
involv
need
elucid
studi
crossreact
allergen
hous
dust
mite
hdm
blomia
tropicali
blo
dermatophagoid
pteronyssinu
der
p
farina
der
f
antigen
ascari
lumbricoid
asc
l
determin
method
enzymelink
immunosorb
assay
perform
determin
allergen
hdm
extract
antigen
asc
l
extract
allerg
ascariasi
healthi
control
patient
inhibit
assay
western
blot
analys
done
use
posit
sera
allerg
ascariasi
specif
ige
level
allerg
ascariasi
patient
recombin
paramyosin
peptid
blo
determin
result
allergen
hdm
extract
significantli
higher
among
allerg
patient
blo
der
der
posit
reaction
ascariasi
patient
respect
antigen
asc
l
extract
among
allerg
patient
significantli
lower
ascariasi
patient
crossinhibit
assay
show
asc
l
antigen
inhibit
ige
reactiv
allerg
patient
hdm
allergen
ige
reactiv
ascariasi
patient
asc
l
antigen
inhibit
hdm
allergen
western
blot
analysi
show
multipl
sensit
allerg
patient
hdm
allergen
molecular
weight
rang
kda
ascariasi
patient
asc
l
antigen
rang
kda
posit
reaction
rblo
observ
among
allerg
ascariasi
patient
conclus
multipl
crossreact
antigen
present
hdm
al
extract
may
play
role
complex
immunolog
relationship
allergi
ascariasi
antigen
might
share
homolog
similar
epitop
recognit
site
must
identifi
futur
studi
potenti
role
paramyosin
specif
crossreact
allergen
present
hdm
lumbricoid
describ
find
provid
support
hygien
hypothesi
may
serv
basi
novel
form
treatment
diagnosi
allerg
diseas
helminth
infect
model
allow
us
defin
basic
principl
pathogenesi
infect
cellular
level
abl
defin
precaus
effect
macrophag
activ
lead
subsequ
infect
elimin
method
follow
express
specif
macrophag
surfac
marker
cd
cd
cd
fcgiiiiir
cd
includ
specif
isotyp
control
phenotyp
chang
express
mean
fluoresc
intens
mfi
percentag
posit
respect
evalu
flow
cytometri
morpholog
chang
document
immunofluoresc
microscopi
murin
macrophagelik
cell
incub
cultiv
flask
medium
dulbecco
mem
bsa
cell
activ
ng
lp
per
medium
iu
ifn
per
medium
respect
infect
f
tularensi
lv
multipl
infect
particular
time
scheme
result
infect
f
tularensi
result
activ
host
cell
seen
stabl
phenotyp
profil
infect
cell
time
contrari
stimul
cell
ifn
lp
result
predict
time
dose
depend
phenotyp
chang
phenotyp
profil
ifn
activ
cell
characterist
cell
display
harmon
increas
surfac
express
time
contrari
activ
lp
result
isol
express
elev
without
increas
express
moreov
prior
f
tularensi
infect
macrophag
prevent
subsequ
activ
especi
lp
demonstr
essenti
role
ifn
infect
control
minim
concentr
ifn
result
activ
infect
elimin
iuml
conclus
assum
f
tularensi
infect
abl
interfer
intracellular
signal
trigger
especi
lp
less
significantli
ifn
interfer
lead
immunosupress
seem
effici
escap
mechan
f
tularensi
effect
cigarett
smoke
exposur
immun
function
alveolar
macrophag
report
inhibit
antibodi
product
alveolar
macrophag
cigarett
smoke
cs
expos
mice
howev
mechan
immun
suppress
cs
function
clearli
understood
therefor
investig
effect
cs
phagocytosi
antibodi
product
express
surfac
antigen
mrna
associ
immun
function
method
femal
mice
expos
cigarett
day
day
day
obtain
bronchoalveolar
lavag
bal
phagocytosi
activ
analyz
fac
use
fitc
label
seep
red
blood
cell
srbc
express
surfac
antigen
class
ii
analyz
fac
mrna
express
analyz
rtpcr
antibodi
product
analyz
plaqu
form
cell
pfc
assay
use
srbc
antigen
result
phagocytosi
significantli
decreas
smoke
mice
sm
compar
nonsmok
mice
nsm
surfac
antigen
posit
cell
decreas
sm
compar
nsm
mrna
express
lp
nonstimul
increas
case
lp
stimul
decreas
sm
compar
nsm
antibodi
product
significantli
decreas
induct
phase
express
phase
sm
compar
nsm
conclus
result
suggest
inhibit
antibodi
product
caus
inhibit
phagocytosi
express
surfac
antigen
inhibit
function
may
increas
risk
bacteri
viru
infect
katsuhiko
matsui
akemi
nishikawa
meiji
pharmaceut
univers
depart
immunobiolog
tokyo
japan
background
atop
dermat
ad
chronic
inflammatori
skin
diseas
immunopatholog
featur
vari
depend
durat
lesion
lesion
skin
ad
patient
show
increas
number
eosinophil
dermi
superfici
staphylococcu
aureu
colon
previou
studi
show
percutan
applic
peptidoglycan
peg
aureu
induc
eosinophil
infiltr
murin
skin
rant
product
epiderm
langerhan
cell
lc
although
well
known
peg
agonist
tolllik
receptor
tlr
unclear
whether
tlr
agonist
abl
induc
rant
product
lc
studi
therefor
rant
product
murin
lc
respons
differ
tlr
stimuli
signal
pathway
involv
investig
method
peg
appli
barrierdisrupt
abdomin
skin
mice
everi
day
twenti
day
later
eosinophil
abdomin
skin
detect
lc
purifi
epiderm
cell
pan
method
use
antiia
monoclon
antibodi
rant
product
skin
cultur
lc
investig
rtpcr
immunohistolog
analysi
elisa
analysi
signal
pathway
respons
rant
product
lc
perform
elisa
use
nacetyllcystein
specif
inhibitor
nfe
b
activ
jnk
erk
mapk
respect
final
confirm
western
blot
analysi
result
result
rtpcr
elisa
show
peg
poli
c
lp
cpg
dna
whose
signal
transduc
respect
strongli
induc
product
rant
although
treatment
inhibitor
nfe
b
activ
inhibit
peg
poli
c
lpsand
cpg
dnainduc
rant
product
treatment
jnk
inhibitor
inhibit
cpg
dnainduc
rant
product
furthermor
treatment
mapk
inhibitor
affect
pegand
lpsinduc
rant
product
inhibit
rant
product
correl
mapk
phosphoryl
conclus
result
suggest
signal
pathway
involv
rant
product
murin
epiderm
lc
respons
differ
tlr
stimuli
necessarili
inhibit
mapk
may
specif
therapeut
strategi
eosinophil
inflamm
ad
patient
aureu
colon
mansour
amin
balo
p
kapadni
dept
microbiolog
school
medicin
ahwaz
jondishapor
univers
medic
scienc
ahwaz
iran
microbiolog
ahwaz
islam
republ
iran
pune
univers
microbiolog
pune
india
background
studi
past
decad
confirm
growth
gram
posit
gram
neg
bacteria
yeast
mold
inhibit
garlic
onion
cinnamon
clove
thyme
sage
spice
latin
name
shallot
allium
ascalonicum
shallot
belong
lili
famili
name
allium
known
deriv
celtic
word
allium
pungent
wherea
name
ascalonicum
could
either
deriv
origin
site
cultiv
ascalon
old
palestinian
town
french
name
echalogn
method
studi
extract
shallot
extract
organ
solvent
purifi
help
column
chromatographi
tlc
pure
compound
name
shallomin
antimicrobi
activ
compound
test
strain
includ
pathogen
non
pathogen
microb
use
modifi
e
test
broth
dilut
techniqu
fungi
bacteria
test
sensit
shallomin
mic
valu
shallomin
microorgan
test
rang
fungi
sensit
bacteria
novel
antimicrobi
compound
mlc
valu
slightli
greater
mic
indic
cidal
natur
antimicrobi
low
concentr
conclus
shallot
commonli
use
folklor
medicin
use
cure
earach
fever
antidot
snake
venom
also
aphrodisiac
studi
antimicrobi
properti
shallot
investig
discoveri
new
antibiot
base
shallomin
effect
medicin
treatment
dermatomycosi
infecti
diseas
hydatid
diseas
lung
nemeth
agn
banfi
andrea
peterffi
erzsebet
baktai
kosa
lajo
goschler
adam
kurti
sandor
feket
semmelwei
univers
faculti
medicin
depart
pediatr
budapest
hungari
pediatr
institut
svabhegi
broncholog
depart
budapest
hungari
counti
hospit
pediatr
depart
szolnok
hungari
human
hydatid
diseas
caus
metacestod
echinococcu
granulosi
hydatid
diseas
lung
appear
frequent
childhood
infect
may
result
asymptomat
sever
diseas
may
fatal
convent
treatment
hydatid
diseas
surgic
intervent
sever
report
prove
patient
widespread
diseas
surgic
resect
possibl
medic
treatment
remain
oportun
percutan
aspir
treatment
hydatid
cyst
believ
contraind
due
anaphylaxi
spillag
scolic
howev
sever
investig
report
neither
anaphylaxi
dissemin
author
present
success
treatment
pulmonari
hydatid
diseas
bronchoscop
investig
combin
mabendazolealbendazol
therapi
nine
year
old
boy
admit
counti
hospit
intens
black
vomit
without
sever
diseas
previou
medic
histori
lost
kg
within
month
bloodi
split
earlier
chest
xray
show
decreas
left
side
basal
transpar
ct
scan
suggest
tumor
refer
depart
pediatr
semmelwei
univers
laboratori
data
indic
possibl
lung
infect
start
antibiot
therapi
patient
improv
day
bloodi
vomit
stop
repeat
ct
scan
prove
improv
bronchoscopi
requir
cyst
found
sampl
remov
cours
bronchoscopi
histolog
serolog
investig
confirm
diagnosi
pulmonari
hydatid
diseas
repeat
bronchoscopi
lavag
mg
bwkgday
mabendazol
mgbwkgday
albendazol
therapi
continu
month
combin
therapi
patient
good
medic
condit
gain
weight
regulari
perform
physic
activ
control
bronchoscopi
ct
scan
show
mild
bronchiectasi
left
side
segment
one
year
begin
hydatid
diseas
patient
recov
nearli
complet
conclus
author
demonstr
safeti
efficaci
combin
medic
bronchoscop
treatment
pulmonari
hydatid
diseas
preval
clinic
characterist
recurr
wheez
infant
south
brazil
herberto
jose
chong
neto
nelson
rosario
dirceu
javier
mallol
univers
parana
pediatr
curitiba
brazil
univers
sao
paulo
pediatr
sao
paulo
brazil
univers
santiago
pediatr
santiago
chile
background
data
regard
recurr
wheez
infant
around
world
aim
studi
verifi
preval
recurr
wheez
infant
south
brazil
method
crosssect
studi
standard
questionnair
appli
parent
infant
monthsold
attend
health
center
regular
immun
instrument
previous
valid
question
clinic
characterist
wheez
respiratori
infect
risk
factor
among
immun
center
randomli
select
order
maintain
homogen
select
popul
sampl
result
three
thousand
three
parent
answer
survey
fourti
five
percent
least
one
wheez
episod
first
twelv
month
life
start
month
age
wheez
episod
group
use
agonist
inhal
steroid
oral
steriod
antagonist
leukotrien
receptor
respect
nighttim
symptom
breathless
emerg
room
visit
frequent
wheez
infant
hospit
asthma
asthma
diagnos
nighttim
symptom
emerg
room
visit
sever
symptom
asthma
hospit
diagnosi
asthma
frequent
among
wheezer
equal
episod
p
g
conclus
preval
recurr
wheez
infant
south
brazil
high
start
earli
carrier
great
morbid
infant
possibl
repres
high
number
persist
asthmat
pediatr
asthma
sever
score
bpassand
pulmonari
score
bpsa
clinic
tool
compar
other
instrument
measur
acut
asthmat
children
khale
taman
malak
shaheen
lammia
mokhtar
sham
pediatr
cairo
egypt
background
intern
guidelin
treatment
acut
asthma
call
measur
peak
expiratori
flow
rate
pefr
object
test
pulmonari
function
measur
howev
frequent
difficult
obtain
young
children
unfamiliar
techniqu
pefr
therefor
varieti
clinic
score
system
develop
evalu
sever
acut
exacerb
asthma
children
aim
cmopar
pediatr
asthma
sever
score
bpass
pulmonari
score
bp
clinic
tool
other
instrument
measur
peak
flow
meter
puls
oximetri
arteri
blood
gase
assess
sever
acut
asthmat
attack
children
also
aim
find
clinic
assess
tool
valu
rapid
intervent
treatment
acut
asthma
compar
laboratori
measur
patient
method
clinic
studi
done
ashtmat
children
attend
er
acut
attack
asthma
age
rang
year
period
januari
januari
clinic
assess
sever
done
use
bpass
bp
result
assess
compar
bpefr
oxygen
satur
arteri
blood
gase
result
signific
associ
bpass
bpefr
treatment
minut
hour
treatmentther
also
signific
associ
bp
bpefr
treatment
minut
hour
treatment
signific
associ
bpass
bp
score
oxygen
satur
hour
treatment
conclus
bpassand
bpsare
clinic
util
assess
sever
asthmat
attack
especiali
patiant
unabl
use
peak
flow
meter
puls
oximetri
peak
flow
meter
avail
key
word
acut
asthma
assess
pediatr
asthma
sever
score
pulmonari
score
peak
flow
meter
puls
oximetri
arteri
blood
gase
clinic
immunologic
characterist
children
patholog
biliari
system
proceed
background
allerg
diseas
shahla
rustamova
sanubar
rustamova
aslan
qasanov
azerbaijan
state
advanc
train
institut
doctor
depart
pediatr
baku
azerbaijan
background
studi
featur
immun
infring
children
patholog
biliar
system
proceed
background
allerg
diseas
method
supervis
children
bronchial
asthma
ba
children
determin
level
gener
ige
absolut
quantiti
basofil
peripher
blood
result
survey
children
deform
biliou
bubbl
sfigur
prezens
excess
field
bodi
bottom
cervix
reveal
thu
similar
featur
structur
biliou
bubbl
frequent
found
parent
survey
children
clinic
display
character
abund
polymorph
complaint
incident
nausea
vomit
observ
survey
ba
dispepsia
frustrat
observ
lock
meteor
abdomin
pain
syndrom
survey
children
major
patient
complaint
veget
charact
mark
increas
local
gener
sweat
establish
patient
patient
complaint
undu
fatig
emot
labil
sleepless
headach
dizzi
disturb
thermoregul
manifest
chill
fall
temperatur
distal
part
extrem
signific
meteotrop
discov
children
ba
caus
aggrav
gener
condit
chang
weather
children
express
clinic
display
patholog
biliar
system
tendenc
higher
paramet
gener
ige
iuml
children
asymptomat
current
ill
iuml
mark
children
ige
within
limit
norm
correl
analys
level
gener
ige
quantiti
basofil
show
posit
correl
one
children
level
gener
ige
limit
norm
observ
increas
quantiti
basofil
peripher
blood
may
suppos
children
happen
igeindepend
degranul
fat
cell
connect
possibl
breach
veget
innerv
conclus
thu
lead
research
dictat
necess
profound
inspect
immunologic
paramet
given
conting
children
prognost
import
ige
evolut
recurr
wheez
bronchial
asthma
children
recurr
wheez
associ
childhood
evalu
bronchial
asthma
aim
studi
perform
determin
potenti
forecast
ige
develop
recurr
wheez
bronchial
asthma
method
children
age
year
old
recurr
wheez
includ
studi
studi
done
part
detail
medic
cheek
followup
period
year
use
stepwis
select
student
criterion
statist
analysi
coeffici
conting
ufish
f
criterion
select
forecast
paramet
develop
asthma
childhood
result
statist
discrimin
bstepwis
analysi
identif
level
ige
paramet
potenti
inform
prognost
select
children
risk
asthma
prognosi
asthma
risk
children
hiperimmunoglobulinemia
e
iuml
specif
sensit
prognosi
index
favor
evolut
complet
recoveri
children
wheez
determin
ige
increas
iuml
potenti
prognosi
knowledg
bronchial
asthma
risk
need
elabor
program
effect
measur
prevent
asthma
children
recurr
wheez
conclus
level
hiperimmunoglobulinemia
e
child
recurr
wheez
permit
prognosi
risk
develop
bronchial
asthma
thalassotherapi
seasidetreat
allerg
children
jaroslava
simonickova
gabriela
polakova
vit
petru
na
homolc
hospit
ctr
allergol
clin
immunol
pragu
czech
republ
background
gener
held
comprehens
therapi
allerg
children
includ
thalassotherapi
ie
seasid
treatment
attempt
objectifi
effect
therapi
two
group
children
one
diagnosi
bronchial
asthma
atop
eczema
method
effect
three
week
seasid
stay
evalu
group
asthmat
children
compar
asthmat
children
control
group
evalu
base
follow
criteria
chang
activ
score
pulmonari
function
price
antiasthmat
pharmacotherapi
number
school
absenc
parent
questionnair
second
group
includ
children
atop
eczema
effect
evalu
basi
extent
skin
afflict
intens
symptom
scorad
index
parent
questionnair
result
group
asthmat
children
score
fell
chang
control
group
difficulti
becam
less
frequent
dyspnea
exert
allevi
drug
consumpt
fell
school
absenc
price
antiasthmat
therapi
reduc
pulmonari
function
remain
unchang
group
eczemat
children
extent
skin
afflict
fell
averag
score
reflect
intens
difficulti
fell
averag
point
child
averag
valu
scorad
index
whole
group
treatment
treatment
chang
evalu
paramet
statist
signific
conclus
three
week
therapeut
seasid
treatment
reduc
activ
bronchial
asthma
atop
eczema
markedli
improv
allerg
patient
qualiti
life
abstract
withdrawn
readytous
hdm
atopi
patch
test
apt
diagnosi
sensit
hdm
children
christoph
dupont
pascal
soulain
nathali
donn
pierr
henri
benham
nicola
kalach
hopit
saint
vincent
de
paul
pediatr
pari
franc
dbv
technolog
dbv
technolog
boulogn
billancourt
franc
background
sensit
allergen
deriv
hous
dust
mite
hdm
strongli
associ
asthma
perenni
rhiniti
atop
dermat
diagnosi
consid
crucial
allerg
work
condit
increas
number
report
demonstr
accuraci
atopi
patch
test
apt
diagnosi
hdm
allergi
aim
aim
studi
assess
accuraci
new
readytous
hdm
atopi
patch
test
apt
diallertest
diagnosi
sensit
hdm
children
method
prospect
studi
carri
children
age
mean
sd
rang
mo
girl
patient
exhibit
isol
combin
atop
dermat
ad
children
test
specif
hdmige
pteronyssinu
dpt
farina
df
skin
test
base
hdm
dpt
df
skin
prick
test
spt
atp
use
hdmdiallertest
result
among
enrol
children
case
exhibit
sensit
posit
specif
hmdige
titer
dpt
df
posit
spt
dpt
df
respect
hdmdiallertest
posit
among
posit
hdmdiallertest
exhibit
eczemat
reaction
show
excel
concord
dpt
dfspt
specif
ige
dpt
df
respect
conclus
diagnost
techniqu
exhibit
compar
level
accuraci
diagnosi
hdm
allergen
sensit
excel
concord
techniqu
hdmdiallertest
eczemat
reaction
strongli
support
use
reliabl
non
invas
diagnost
tool
hdm
sensit
preval
asthma
allerg
rinoconjunct
atop
dermat
southwest
mexico
citi
isaac
model
studi
alvaro
pedroza
jose
huerta
lopez
francisco
espinosa
gabriela
trevino
francisco
riva
cintia
ramo
nadia
ramirez
horacio
del
olmo
instituto
nacion
de
pediatria
pediatr
allergi
immunolog
mexico
citi
mexico
introduct
allerg
diseas
frequent
chronic
entiti
childhood
time
preval
increas
last
three
decad
deasign
task
forc
call
intern
studi
asthma
allergi
childhood
isaac
promot
epidemiolog
research
asthma
allerg
diseas
object
approach
preval
sever
asthma
allerg
rhinoconjunct
atop
dermat
children
year
year
old
southwest
mexico
citi
method
materi
observ
transvers
descript
prospect
studi
includ
student
first
second
grade
primari
school
whit
age
year
old
junior
high
school
student
year
old
studi
author
public
educ
institut
school
princip
parent
statist
analysi
made
epi
info
version
whit
signif
valu
p
e
result
school
enrol
student
wouthwest
mexico
citi
primari
school
girl
boy
junior
high
school
includ
student
school
girl
boy
scholast
popul
anteced
one
wheez
episod
present
proport
patient
sever
asthma
data
asthma
diagnosd
teenag
diagnost
sever
rhinoconjunct
present
kid
teenag
major
part
student
kid
adolesc
give
correctli
inform
atop
dermat
join
pet
cat
dog
discuss
similar
studi
made
around
world
reveal
asthma
allerg
diseas
public
health
problem
implic
qualiti
life
may
lead
tempor
perman
incapac
diagnos
treat
earli
approach
variat
preval
expect
variou
factor
import
divers
zone
risk
factor
fact
result
compar
differ
popul
use
epidemiolog
knowledg
zone
bronchial
asthma
child
physic
activ
lithuania
egl
vaitkaitien
kauna
medic
univers
institut
biomed
research
social
pediatr
kauna
lithuania
background
studi
preval
child
asthma
lithuania
asthma
clinic
social
problem
also
aim
studi
evalu
physic
activ
limit
asthmat
children
method
use
studi
group
includ
children
suffer
asthma
age
sever
asthma
assess
grade
asthma
mild
moder
sever
use
standard
diseasespecif
paql
questionnair
nation
version
respons
asthmat
children
analyz
result
obtain
one
third
respond
involv
extra
activ
sport
danc
sing
parent
notic
children
extra
activ
children
asthma
attend
sport
school
ask
children
name
three
activ
bother
asthma
respond
indic
three
daili
activ
restrict
asthma
asthma
boy
disturb
run
play
pet
play
ball
sleep
girl
mark
differ
activ
run
housekeep
school
sport
asthma
bother
boy
run
play
ball
often
girl
girl
bother
asthma
often
boy
chore
sing
statist
signific
differ
found
compar
three
main
activ
boy
girl
first
activ
df
p
g
second
activ
df
p
third
activ
df
p
conclus
reach
asthma
limit
factor
childrenf
level
physic
activ
prevent
children
variou
activ
due
asthma
children
abl
run
play
ball
chore
play
pet
boy
often
complain
thet
asthma
limit
physic
activ
run
play
game
wherea
girl
indic
diseas
limit
physic
activ
run
well
passiv
activ
chore
addit
danc
sing
analysi
allergenspecif
serum
ige
children
asthma
cough
variant
asthma
xin
song
jing
zhao
capit
institut
pediatr
asthma
center
beij
china
object
investig
posit
rate
food
allergen
mix
mold
phadiatop
hous
dust
mite
allergenspecif
serum
ige
sige
children
age
month
year
diagnos
asthma
cough
variant
asthma
cva
age
distribut
characterist
also
compar
analyz
method
blood
sampl
asthmat
children
appli
phadiatop
test
use
fluoroenzymeimmunometricassay
posit
rate
phadiatop
compar
age
distribut
characterist
children
posit
sige
analyz
result
posit
rate
phadiatop
respect
highest
posit
rate
phadiatop
highest
children
age
group
posit
rate
peak
children
year
year
separ
among
children
posit
case
manifest
phadiatop
neg
children
clinic
diagnos
asthma
cva
present
posit
test
phadiatop
least
conclus
twothird
asthma
cva
patient
exist
sige
asthmat
infant
mainli
manifest
food
allergen
sensit
posit
phadiatop
increas
age
posit
increas
age
children
e
year
decreas
older
children
q
year
one
main
allergen
asthmat
children
observ
studi
effect
montelukast
children
chronic
rhiniti
background
impact
chronic
rhiniti
children
especi
nasal
congest
includ
learn
disord
impair
school
perform
qualiti
life
intranas
corticosteroid
effect
medic
chronic
rhiniti
treatment
recent
leukotrien
receptor
antagonist
ad
mode
therapi
approv
us
food
drug
administr
allerg
rhiniti
object
assess
effect
addon
montelukast
intranas
corticosteroid
children
chronic
persist
rhiniti
method
enrol
children
attend
allergi
clinic
depart
pediatr
faculti
medicin
chulalongkorn
univers
poorli
control
rhiniti
period
april
decemb
diagnosi
allerg
rhiniti
made
posit
prick
skin
test
least
one
aeroallergen
intranas
corticosteroid
firstlin
medic
treatment
persist
symptom
montelukast
ad
case
respons
intranas
corticosteroid
mostli
due
nasal
congest
efficaci
assess
symptom
improv
nasal
congest
rhinorrhea
itch
sneez
report
patient
physic
examin
allergist
result
boy
girl
averag
age
mean
durat
symptom
diagnosi
year
twelv
children
diagnos
allerg
rhiniti
children
nonallerg
rhiniti
prick
skin
test
mean
durat
intranas
steroid
use
year
children
allerg
rhiniti
year
children
nonallerg
rhiniti
symptom
improv
especi
nasal
congest
report
allerg
rhiniti
subject
nonallerg
rhiniti
subject
addon
mg
montelukast
daili
montelukast
overal
well
toler
mean
durat
montelukast
therapi
year
group
intranas
corticosteroid
abl
stop
children
nonallerg
rhiniti
unabl
stop
children
allerg
rhiniti
patient
satisfi
treatment
conclus
montelukast
advantag
addit
treatment
either
allerg
nonallerg
rhiniti
children
particularli
benefit
children
nonallerg
rhiniti
sputum
eosinophil
childhood
asthma
correl
pefr
control
asthmat
exacerb
maria
cristina
edquilag
agn
andaya
univers
santo
toma
hospit
depart
pediatr
section
allergi
manila
philippin
background
sputum
eosinophilia
noninvas
airway
inflammatori
marker
airway
inflamm
characterist
function
abnorm
peculiar
asthma
lead
variabl
airflow
limit
signific
correl
pefr
absolut
eosinophil
count
observ
among
patient
asthma
howev
studi
limit
other
show
conflict
result
object
determin
correl
sputum
eosinophilia
pefr
among
patient
asthma
methodolog
follow
clinic
assess
peak
flow
determin
sputum
eosinophil
count
determin
among
patient
stabl
asthma
acut
exacerb
patient
classifi
intermitt
persist
asthmat
age
sex
atop
statu
asthma
durat
obtain
sputum
eosinophil
count
consid
signific
result
patient
sputum
eosinophilia
lower
pefr
compar
without
sputum
eosinophilia
p
patient
sputum
eosinophilia
like
abnorm
pefr
compar
normal
pefr
ci
patient
persist
asthma
like
sputum
eosinophilia
compar
intermitt
asthma
ci
similarli
patient
acut
exacerb
like
sputum
eosinophilia
compar
stabl
asthma
ci
conclus
studi
demonstr
direct
correl
sputum
eosinophilia
pefr
among
patient
acut
exacerb
howev
correl
could
made
among
patient
stabl
asthma
sinc
patient
normal
pefr
serum
level
vegf
tgf
ecp
children
acut
astma
bronchiol
kadir
kocak
bilal
yildiz
yesim
kural
omer
colak
eskisehir
osmangazi
univers
faculti
medicin
pediatr
allergi
eskisehir
turkey
eskisehir
osmangazi
univers
faculti
medicin
pediatr
eskisehir
turkey
eskisehir
osmangazi
univers
faculti
medicin
biochemistri
eskisehir
turkey
background
asthma
lead
caus
chronic
ill
increas
vascular
vascular
permeabl
airway
lung
tissu
remodel
although
variou
growth
factor
cytokin
implic
modul
process
role
factor
cytokin
known
well
asthmat
children
aim
studi
determin
serum
level
vascular
endotheli
growth
factor
vegf
transform
growth
factor
tgf
eosinophil
cation
protein
ecp
acut
astmat
children
aac
compar
acut
bronchiol
healthi
subject
assess
chang
treatment
method
paramet
measur
elisa
techniqu
aac
bronchiol
patient
inhal
system
steroid
ss
result
serum
vegf
tgf
level
increas
patient
aac
bronchiol
control
therapi
paramet
higher
aac
bronchiol
except
tablei
serum
vegf
ecp
level
higher
aac
control
treatment
steroid
therapi
vegf
ecp
level
higher
aac
bronchiol
level
higher
patient
bronchiol
serum
level
bronchiol
similar
control
treatment
sever
diseas
vegf
level
increas
modar
aac
bronchiol
higher
mild
patient
p
g
vegf
level
lower
aac
treat
prophylact
drug
aac
without
prophylact
treatment
p
g
accord
modal
steroid
treatment
vegf
level
lower
aac
treat
inhal
steroid
compar
ss
p
g
aac
vegf
ecp
level
higher
control
treatment
ss
p
g
aac
treat
inhal
steroid
vegf
level
similar
control
treatment
p
conclus
vegf
tgf
may
play
role
pathogenesi
asthma
bronchiol
paramet
nt
use
distinguish
asthma
bronchiol
vegf
could
use
paramet
distinguish
mild
moder
diseas
asthma
bronchiol
accord
find
inhal
ss
could
combin
appropri
treatment
moder
aac
also
antivegf
therapi
may
use
aac
effect
selfmanag
educ
asthma
complic
pulmonari
function
iranian
children
asthma
background
despit
global
effort
manag
asthma
advers
outcom
diseas
increas
effect
selfmanag
treatment
complianc
import
achiev
good
symptom
control
asthma
aim
studi
determin
whether
asthma
nurs
intervent
clinic
period
could
increas
knowledg
improv
selfmanag
whether
would
influenc
frequenc
sever
symptom
pulmonari
function
test
set
univers
hospit
pediatr
outpati
clinic
method
random
control
trial
children
intermitt
mild
moder
persist
asthma
assess
indic
whether
educ
selfmanag
intervent
would
improv
lung
function
use
inhal
spacer
score
increas
feel
control
asthma
decreas
use
health
care
servic
children
asthma
categor
base
diseas
sever
durat
diseas
age
randomli
assign
experiment
group
receiv
educ
program
comparison
group
receiv
common
educ
educ
program
consist
group
session
focus
improv
patient
parent
selfmanag
skill
background
chronic
cough
last
week
often
seem
intract
problem
childhood
toxocara
infest
associ
increas
preval
airway
symptom
may
possibl
etiolog
agent
chronic
cough
method
spirometri
bronchial
revers
test
nonspecif
bronchu
provoc
test
carri
patient
could
cooper
test
measur
made
peripher
blood
eosinophil
count
serum
total
ige
level
serum
total
magnesium
mg
concentr
serolog
examin
toxocara
cani
base
wide
use
enzymelink
immunosorb
assay
igg
toxocara
cani
igg
elisa
novatec
germani
sensit
western
blot
toxocara
western
blot
igg
ldbio
franc
method
perform
patient
posit
serolog
cani
index
posit
treat
albendazol
dose
mgkgday
patient
weigh
kg
receiv
mg
albendazol
day
day
patient
bronchial
asthma
cva
treat
inhal
corticosteroid
ic
shortterm
could
administ
case
dyspnoea
ba
need
result
onehundr
thirtysix
children
age
year
seroposit
cani
antigen
ninetythre
children
adequ
assess
diagnos
follow
year
bronchial
asthma
diagnos
cough
variant
asthma
cva
nonasthmat
eosinophil
bronchiti
naeb
children
chronic
cough
eosinophil
cell
count
toxocara
cani
igg
total
ige
level
total
mg
concentr
serum
predictor
improv
declin
patient
condit
could
significantli
decreas
dose
ic
children
bronchial
asthma
anthelminth
avoid
suffici
children
naeb
none
need
ic
ic
therapi
could
stop
month
later
patient
cva
found
patient
cva
present
asthmat
symptom
end
period
conclus
hungari
cani
may
potenti
sensit
chronic
cough
seroposit
children
deworm
therapi
allevi
airway
symptom
without
exacerb
patient
bronchial
asthma
definit
treat
children
naeb
major
children
cva
suppos
prenat
polar
immun
respons
possibl
marker
polar
trustworthi
associ
atopi
form
known
aim
evalu
connect
ige
level
express
intracellular
interferon
ifn
product
cord
blood
mononuclear
cell
cbmc
risk
infant
atop
dermat
ad
form
method
defin
per
cent
content
cbmc
use
flow
cytometri
well
concentr
total
ige
fullterm
newborn
simultan
intracellular
ifn
express
well
earli
activ
marker
separ
total
mononuclear
cell
popul
examin
newborn
estim
ad
presenc
enrol
newborn
age
one
year
medic
diagnos
ad
mark
data
shown
median
quartil
absolut
cell
count
statist
analysi
perform
use
mannwhitney
test
rel
risk
rr
present
ci
result
nonactiv
cbmc
produc
ifn
subtyp
ifn
associ
ad
form
found
number
cbmc
ad
infant
oppos
infant
without
ad
p
rel
risk
ad
form
newborn
low
g
median
cohort
signific
differ
number
cbmc
kept
adjust
factor
famili
atop
histori
place
live
cityvillag
birth
order
firstsecond
later
number
famili
member
live
togeth
bedshar
smoke
pet
owe
newborn
genderw
reveal
neg
concentr
total
ige
cord
blood
ratio
r
p
find
associ
express
ratio
well
level
total
ige
ad
form
infant
median
chosen
cut
point
rr
respect
conclus
thu
decreas
intracellular
ifn
product
nonactiv
cbmc
prove
prenat
displac
balanc
strong
predictor
infant
ad
form
howev
decreas
ratio
well
level
total
ige
cord
blood
predictor
atop
phenotyp
form
infant
sputum
eosinophil
level
children
mild
moder
sever
exacerb
stabl
asthma
maria
cristina
edquilag
agn
andaya
univers
santo
toma
hospit
depart
pediatr
section
allergi
manila
philippin
background
sputum
eosinophilia
noninvas
marker
evalu
airway
inflamm
well
asthma
control
increas
proport
sputum
eosinophil
observ
among
subject
asthma
especi
among
exacerb
howev
also
studi
show
airway
eosinophilia
among
patient
control
asthma
object
determin
sputum
eosinophil
level
among
asthmat
patient
exacerb
stabl
asthma
determin
associ
sever
diseas
methodolog
follow
clinic
assess
peak
flow
determin
sputum
eosinophil
level
determin
among
patient
stabl
asthma
n
mild
n
moder
sever
n
asthma
exacerb
age
sex
atop
statu
asthma
durat
medic
obtain
sputum
eosinophil
count
q
consid
signific
result
mean
eosinophil
count
children
stabl
asthma
mild
exacerb
moder
sever
exacerb
respect
sputum
eosinophil
significantli
higher
children
moder
sever
exacerb
mild
exacerb
stabl
asthma
p
percentag
patient
signific
sputum
eosinophilia
higher
among
moder
sever
exacerb
mild
exacerb
stabl
asthma
statist
signific
differ
seen
among
three
popul
p
logist
regress
show
wheez
p
g
peak
expiratori
flow
rate
p
sex
p
asthma
durat
significantli
associ
sputum
eosinophilia
p
statist
signific
differ
seen
respect
long
term
asthma
sever
classif
p
conclus
studi
demonstr
signific
sputum
eosinophilia
seen
among
patient
moder
sever
asthma
exacerb
compar
mild
exacerb
stabl
asthma
sputum
eosinophilia
also
significantli
associ
wheez
lower
peak
expiratori
flow
rate
male
sex
longer
asthma
durat
longterm
asthma
sever
defin
factor
evalu
sputum
eosinophilia
among
asthmat
sever
exacerb
allergi
children
manag
patient
risk
anaphylaxi
sriniva
bandi
colin
macdougal
birmingham
heartland
hospit
paediatr
birmingham
unit
kingdom
univers
hospit
paediatr
coventri
unit
kingdom
aim
report
manag
children
allergi
district
gener
hospit
particular
review
prescrib
practic
epinephrin
auto
injector
epipen
compar
manag
children
seen
allergi
clinic
seen
gener
paediatr
clinic
clinic
record
children
prescrib
epipen
epipen
junior
novemb
octob
retrospect
review
patient
includ
seen
allergi
clinic
seen
gener
paediatr
clinic
age
rang
month
year
median
year
result
common
allergen
nutsse
follow
egg
milk
fish
children
posit
skin
prick
test
posit
rast
total
posit
test
inform
treatment
epipen
provid
children
seen
allergi
clinic
compar
children
seen
gener
clinic
practic
instruct
epipen
administr
provid
compar
gener
paediatr
clinic
metabol
respons
treatment
salbutamol
theophyllin
asthmat
children
moham
ragab
alexandria
univers
faculti
medicin
alexandria
egypt
drug
therapi
abus
incrimin
main
contribut
factor
asthma
mortal
effect
treat
asthmat
salbutamol
inhal
mgkg
bodi
weight
mgdose
group
theophyllin
bodi
weight
group
c
drug
group
b
investig
asthmat
children
ten
healthi
children
match
age
sex
also
includ
serv
control
serum
glucos
increas
significantli
group
b
chang
significantli
group
c
compar
pretreat
level
serum
inorgan
phosphat
decreas
significantli
group
b
c
signific
chang
group
serum
sodium
level
significantli
decreas
asthmat
children
treatment
group
b
c
show
signific
reduct
serum
sodium
level
compar
pretreat
valu
serum
sodium
level
chang
significantli
group
serum
potassium
decreas
significantli
three
studi
group
compar
pretreat
valu
metabol
chang
could
possibl
help
explain
observ
increas
case
fatal
asthma
use
combin
inhal
betaagonist
oral
theophyllin
prepar
multymeasur
phenotyp
autom
prevent
system
bronchial
asthma
children
tbilisi
state
univers
stomatolog
depart
tbilisi
georgia
background
prevent
earli
age
period
significantli
decreas
morbid
allerg
diseas
improv
qualiti
life
sometim
doctor
unabl
manag
well
patholog
neglect
earli
diagnost
accord
actual
perspect
direct
nowaday
allergolog
work
new
scientif
approach
resolut
bronchial
asthma
ba
problem
young
popul
hereditari
predisposit
play
import
role
develop
diseas
everyth
recogniz
may
demonstr
clinic
symptom
parent
close
rel
affect
individu
aim
elabor
new
autom
assess
costeffect
system
would
allow
earli
diagnost
prevent
ba
use
bformal
cardsbi
provid
multymesur
phenotyp
georgian
children
popul
system
base
primari
secondari
prognosi
ba
method
choos
marker
hlamark
terrasaki
micro
lymphocytetox
test
type
perform
class
dr
dq
class
b
c
antigen
locu
erythrocyt
marker
abo
rhesu
mn
system
clinicalgenealog
method
falcon
studi
genealog
tree
investig
famili
geneticstatist
analysi
inform
criteria
differ
sign
ontogeni
phenotyp
environment
factor
kulback
goubler
eb
method
multidimension
phenotyp
agglomerativehierarch
cluster
analys
chosen
system
sign
analys
perform
interact
order
result
multidimension
phenotyp
shove
phenotyp
class
class
basic
predisposit
includ
individu
manifest
asthma
class
rel
predisposit
includ
less
individu
manifest
asthma
phenotyp
class
includ
patient
phenotyp
class
predispos
ba
basic
includ
healthi
person
conclus
elabor
comput
tabl
enough
simpl
opportun
comprehens
use
propos
primari
prognost
ba
practic
doctor
work
outpati
clinic
dispensari
well
militari
doctor
work
enlist
committe
militari
unit
method
give
possibl
prognosi
predisposit
bronchial
asthma
young
popul
gene
polymorph
pharmacogenet
effect
leukotrien
receptor
antagonist
children
asthma
background
thromboxan
receptor
gene
polymorph
associ
atopi
asthma
howev
role
children
defin
investigate
associ
asthmarel
phenotyp
polymorph
also
analyz
whether
polymorph
effect
efficaci
leukotrien
receptor
antagonist
ltra
montelukast
asthmat
children
exerciseinduc
bronchoconstrict
eib
method
asthmat
children
n
control
children
n
evalu
asthmarel
phenotyp
includ
total
ige
pulmonari
function
test
bhr
methacholin
exercis
genotyp
detect
pcrrflp
montelukast
studi
exercis
challeng
perform
montelukast
treatment
result
polymorph
associ
asthma
suscept
clinic
paramet
asthma
howev
asthmat
children
combin
c
c
risk
allel
significantli
higher
total
ige
level
p
total
eosinophil
count
p
g
lower
p
fef
p
carri
common
allel
compar
individu
common
allel
patient
c
tt
homozygot
c
heteroor
homozygot
ct
cc
poor
respons
montelukast
treatment
regard
maximum
percent
fall
exercis
odd
ratio
ci
conclus
combin
effect
c
c
risk
allel
may
link
ige
product
eosinophil
inflamm
sever
asthma
addit
combin
genotyp
may
predict
marker
clinic
respons
ltra
korean
asthmat
children
eib
random
prospect
doubl
blind
control
trial
effect
longterm
consumpt
ferment
milk
contain
lactobacillu
casei
preschool
children
allerg
asthma
andor
rhiniti
institut
cattolica
del
sacro
cuor
piacenza
itali
univers
milansan
paolo
hospit
paediatr
depart
milan
itali
background
aim
probiot
may
immunomodulatori
function
exert
benefici
effect
allerg
diseas
investig
whether
prolong
daili
consumpt
lactobacillu
casei
ferment
milk
improv
health
statu
children
age
year
allerg
inhal
method
randomis
prospect
doubl
blind
control
trial
patient
randomli
assign
receiv
one
year
ml
per
day
l
casei
ferment
milk
cellsml
probiot
control
clinic
evalu
occur
everi
month
faecal
flora
composit
assess
everi
month
treat
control
outcom
measur
time
free
number
episod
asthmarhin
number
fever
diarrhoea
episod
igega
serolog
level
month
vs
baselin
result
particip
treat
similar
regard
gestat
age
breastfeed
famili
smoker
pet
sibl
daycar
admiss
statist
differ
intervent
control
group
occur
asthmat
children
children
rhiniti
annual
number
rhiniti
episod
lower
intervent
group
mean
differ
ci
mean
durat
episod
diarrhoea
lower
intervent
group
mean
differ
day
faecal
analysi
show
lactobacillu
casei
gut
flora
supplement
children
studi
period
conclus
longterm
daili
consumpt
lactobacillu
casei
ferment
milk
may
posit
influenc
clinic
immunolog
statu
allerg
children
preval
pediatr
allerg
diseas
first
three
year
life
chizuko
sugizaki
motohiro
ebisawa
sagamihara
nation
hospit
clinic
research
center
depart
allergi
sagamiharac
kanagawa
japan
background
maintain
birth
cohort
studi
sagamiharac
sinc
clarifi
preval
atop
dermat
ad
food
allergi
fa
bronchial
asthma
ba
japanes
cedar
pollinosi
jcp
infanc
childhood
method
use
mass
medic
examin
system
age
month
mo
old
first
obtain
inform
eczema
nutrit
method
famili
histori
allerg
diseas
result
allergi
examin
questionnair
follow
subject
whose
parent
agre
particip
studi
age
mo
mo
year
old
use
questionnair
mail
furthermor
risk
factor
subject
develop
ba
age
analyz
inform
obtain
studi
result
inform
consent
obtain
parent
mo
infant
parent
could
follow
infant
age
mo
infant
age
mo
children
age
incid
chronic
eczema
suspect
ad
mo
mo
respect
incid
food
elimin
due
fa
report
parent
mo
mo
respect
interestingli
incid
doctordiagnos
fa
mo
mo
respect
confus
relat
fa
ad
infanc
seem
exist
parent
doctor
preval
ba
mo
respect
risk
factor
infant
develop
ba
relat
possess
ad
fa
mo
mo
famili
histori
allerg
diseas
histori
indirect
cigarett
exposur
incid
jcp
even
conclus
sinc
popul
children
sagamiharac
repres
japan
estim
preval
allerg
diseas
infanc
childhood
data
obtain
studi
howev
difficult
estim
preval
fa
especi
infanc
due
underevalu
doctor
overreact
parent
import
doctor
parent
fix
confus
societi
data
make
us
possibl
clarifi
preval
pediatr
allerg
diseas
reveal
transit
diseas
updat
guidelin
allergi
prevent
torsten
cathleen
borowskimuch
abap
consensu
group
medic
univers
luebeck
institut
social
medicin
luebeck
germani
background
prevent
crucial
counteract
rise
trend
allergi
publish
evidencebas
consent
guidelin
primari
secondari
prevent
asthma
allerg
rhiniti
atop
eczema
order
updat
guidelin
repeat
systemat
literatur
search
present
result
method
literatur
search
perform
medlin
year
april
use
meshterm
group
follow
endpoint
asthma
allergi
allerg
atop
hay
fever
dermat
eczema
rhiniti
intervent
prevent
risk
factor
epidemiolog
studi
type
random
control
trial
clinic
trial
control
studi
systemat
review
meta
analysi
case
control
studi
cohort
studi
term
combin
band
within
group
bor
group
includ
studi
human
publish
english
german
languag
exclud
therapeut
drug
trial
first
select
process
perform
basi
titl
abstract
result
obtain
hit
potenti
relev
studi
identifi
later
consist
review
rct
cohortand
casecontrolstudi
initi
review
studi
could
alloc
area
breast
feed
hypoallergen
formula
introduct
solid
food
diet
mother
child
smoke
mould
damp
vaccin
recommend
guidelin
area
support
actual
evid
new
evid
allow
specif
current
recommend
topic
bodi
mass
index
exhaust
indic
recommend
hous
dust
mite
pet
keep
unspecif
immun
modul
need
revis
conclus
literatur
search
possibl
updat
current
evidencebas
recommend
allergi
prevent
adapt
recommend
accord
current
literatur
c
borowski
tl
diepgen
hellermann
piechotowski
rees
roo
schmidt
h
sitter
werfel
u
gieler
und
die
konsensusgrupp
de
evidenzbasiert
und
konsentiert
leitlini
allergo
j
specif
mixtur
short
chain
galactooligosaccharid
long
chain
fructooligosaccharid
induc
antiallerg
immunoglobulin
profil
infant
risk
allergi
background
prospect
studi
infant
famili
histori
atopi
specif
prebiot
oligosaccharid
mixtur
short
chain
galactooligosaccharid
long
chain
fructooligosaccharid
gosfo
immunoforti
reduc
cumul
incid
atop
dermat
six
month
age
subgroup
infant
possibl
obtain
blood
sampl
six
month
age
analys
potenti
effect
dietari
oligosaccharid
immunoglobulin
profil
method
prospect
doubleblind
random
placebo
control
studi
infant
receiv
hypoallergen
formula
either
gosfo
gl
maltodextrin
placebo
six
month
three
month
age
children
vaccin
diphteria
tetanu
ad
polio
dtp
six
month
age
total
plasma
level
ige
well
cow
milk
protein
cmp
dtp
specif
immunoglobulin
measur
result
supplement
gosfo
lead
signific
reduct
plasma
level
total
ige
p
p
p
p
immunoglobulin
wherea
signific
effect
observ
plasma
level
cmp
specif
significantli
decreas
p
gosfo
group
level
cmp
specif
ige
low
effect
gosfo
supplement
could
observ
cmp
specif
detect
sampl
influenc
go
fo
supplement
found
vaccin
specif
antibodi
isotyp
level
conclus
evid
gosfo
supplement
induc
antiallerg
immunoglobulin
profil
infant
high
risk
allerg
diseas
wherea
desir
specif
immun
respons
affect
indic
potenti
role
oral
gosfo
exposur
primari
prevent
allergi
background
alter
microbi
exposur
may
underli
increas
allerg
diseas
affluent
societi
earli
colonis
bifidobacterium
b
lactobacilli
l
postul
prevent
children
develop
allergi
clostridium
c
difficil
colonis
associ
allerg
diseas
previou
studi
mainli
perform
cultur
depend
techniqu
howev
late
sequenc
bacteri
genom
made
possibl
studi
gut
flora
molecular
techniqu
realtim
pcr
techniqu
use
primer
target
conserv
gene
bacteria
lead
effici
qualit
quantit
analysi
bacteri
dna
faecal
sampl
method
presenc
amount
bacteri
dna
infant
faecal
sampl
collect
week
month
month
measur
realtim
pcr
relat
allergi
develop
swedish
children
follow
prospect
month
age
children
regard
allerg
develop
allerg
symptom
sensitis
food
andor
inhal
allergen
first
five
year
life
nonallerg
children
nonsensitis
without
symptom
primer
bind
c
difficil
b
bifidum
b
longuminfanti
b
adolescenti
b
breve
bacteroid
fragili
lactobacilli
group
l
rhamnosu
l
paracasei
l
casei
lactobacilli
group
ii
l
gasseri
l
johnsonii
group
use
result
abund
bacteria
b
longuminfanti
children
colonis
c
difficil
one
week
age
none
allerg
children
colonis
lactobacilli
group
compar
children
remain
nonallerg
also
month
age
b
adolescenti
common
nonallerg
allerg
children
furthermor
persist
colonis
bacteria
common
among
nonallerg
children
respect
conclus
divers
gut
flora
might
prevent
allergi
develop
earli
colonis
might
major
import
aim
evalu
efficac
educ
activ
school
asthma
children
asthma
andor
famili
method
materi
school
asthma
children
specialist
perform
educ
activ
children
differ
form
asthma
parent
educ
seminar
consist
session
approach
follow
subject
trigger
asthma
symptom
prophylaxi
asthma
medicin
session
also
includ
individu
interrog
train
estim
knowledg
asthma
educ
session
accord
theme
work
day
qualiti
knowledg
children
asthma
andor
parent
also
test
month
afterward
visit
result
found
knowledgeof
children
parent
train
school
asthma
children
incomplet
incorrect
children
sever
asthma
wrong
knowledg
trigger
prophylaxi
compar
suffer
mild
asthma
respect
moder
respect
knowledg
children
mild
asthma
refer
trigger
grown
children
moder
asthma
sever
asthma
also
establish
growth
knowledg
prophylaxi
group
children
mild
moder
asthma
sever
asthma
knowledg
children
regard
clinic
manifest
constitut
mild
asthma
moder
asthma
sever
asthma
knowledg
level
subject
treatment
incomplet
group
question
person
mild
asthma
moder
asthma
sever
asthma
toward
end
cours
appreci
follow
mild
asthma
moder
asthma
sever
asthma
averag
knowledg
group
children
month
refer
trigger
prophylaxi
regard
clinic
manifest
refer
treatment
compar
averag
knowledg
educ
activ
refer
trigger
prophylact
measur
clinic
manifest
treatment
conclus
knowledg
question
littl
decreas
month
remain
net
superior
level
seminar
usag
paracetamol
subsequ
develop
allergi
asthma
studi
match
patientss
background
mani
studi
field
come
suggest
intak
paracetamol
pregnanc
first
month
life
riski
increas
risk
childhood
asthma
aim
deter
asoci
paracetamol
usag
pregnanc
first
ten
moth
life
childhood
allergi
allergi
asthma
asthma
match
patientss
studi
compar
patient
allerg
asthma
healthi
sibl
without
symptom
allerg
diseas
allerg
patient
sibl
determin
skin
prick
test
assum
children
one
posit
skin
prick
test
consid
allerg
intak
paracetamol
assess
standard
interview
yadminist
questionnair
pair
allergi
asthma
patient
vs
nonallerg
sibl
compar
determin
risk
factor
allerg
asthma
pair
allerg
asthma
patient
vs
allerg
sibl
compar
determin
risk
factor
asthma
howev
pair
allerg
asthma
patient
vs
nonasthmat
sibl
without
allergi
compar
determin
risk
factor
asthma
also
allerg
sibl
compar
nonallerg
sibl
asthma
determin
risk
factor
allergi
result
intak
paracetamol
pregnanc
associ
allerg
asthma
p
intak
paracetamol
birth
ten
month
age
four
seven
moth
age
also
found
associ
nonallerg
asthma
p
p
respect
usag
paracetamol
pregnanc
earli
month
life
may
play
role
develop
allerg
non
yallerg
children
conclus
intak
paracetamol
pregnanc
first
month
life
associ
increas
risk
childhood
asthma
cow
milk
allergi
prematur
infant
readytous
cow
milk
atopi
patch
test
start
aminoacid
formula
christoph
dupont
lapillon
pascal
soulainesv
pierr
henri
benhamouv
nathali
donn
hopit
saint
vincent
de
paul
pediatr
pari
franc
dbv
technolog
dbv
technolog
boulogn
bllancourt
franc
background
cow
milk
cm
allergi
cma
infantil
diseas
usual
appear
first
month
life
case
report
prematur
infant
studi
design
detect
cma
prematur
infant
digest
symptom
base
readytous
atopi
patch
test
apt
diallertest
method
year
prematur
infant
week
girl
age
receiv
formula
prematur
cm
present
digest
symptom
rectal
bleed
diarrhea
sever
reflux
other
test
cma
diallertest
whatev
result
children
receiv
aminoacid
formula
neocat
outcom
symptom
evalu
one
month
later
result
among
prematur
infant
test
digest
symptom
disappear
aminoacid
formula
diallertest
posit
case
infant
posit
diallertest
improv
aminoacid
formula
fals
posit
child
neg
diallertest
improv
diet
fals
neg
conclus
cma
frequent
mostli
underestim
caus
digest
symptom
prematur
infant
mostli
fed
cm
base
formula
apt
seem
appropri
method
diagnos
cma
age
rang
diallertest
might
thu
use
tool
neonat
ward
import
regard
psycholog
consequ
level
asthma
control
overal
diseas
sever
paediatr
asthma
alexandra
mezei
endr
semmelwei
univers
first
depart
pediatr
budapest
hungari
aim
studi
object
examin
consequ
overal
asthma
sever
current
asthma
control
regard
psycholog
symptom
paediatr
asthma
method
patient
age
meantsd
year
boy
year
girl
year
complet
child
depress
inventori
cdi
state
trait
anxieti
inventori
children
hstaic
pediatr
asthma
qualiti
life
questionnair
paqlq
symptom
score
also
measur
result
mean
twentythre
patient
intermitt
asthma
patient
mild
persist
patient
moder
persist
patient
sever
persist
asthma
factor
associ
depress
less
factor
associ
anxieti
night
symptom
asthma
control
factor
associ
qualiti
life
age
begin
asthma
asthma
durat
current
symptom
night
symptom
day
symptom
factor
associ
diseas
sever
allergi
skin
test
posit
conclus
overal
diseas
sever
allerg
comorbid
current
asthma
statu
level
control
alter
psycholog
statu
asthmat
child
distinguish
small
chang
level
control
thu
profession
asthma
care
focu
achiev
best
possibl
asthma
control
time
chang
induc
sputum
cytolog
leukotrien
antagonist
tetsuya
takamasu
yukinori
enomoto
naoka
ito
chisato
inuo
kazuyuki
kurihara
kanagawa
children
medic
center
depart
allergi
yokohama
japan
inhal
corticosteroid
b
j
bic
b
k
b
leukotrien
receptor
antagonist
b
j
bltra
b
k
bare
major
control
bronchial
asthma
previou
observ
ic
decreas
eosionophil
increas
neutrophil
induc
sputum
studi
examin
chang
induc
sputum
cytolog
start
ltra
method
subject
patient
mean
age
year
boy
girl
prescrib
ltra
asthma
control
month
start
ltra
pranlukast
case
montelukast
case
obtain
sputa
inhal
salin
sampl
treat
cell
count
differenti
cell
eosin
stain
result
cell
number
start
ltra
cell
ml
cellsml
respect
ns
percentag
eosinophil
neutrophil
ns
conclus
ltra
decreas
sputum
eosinophil
well
ic
howev
increas
neutrophil
abnorm
lung
function
bronchial
hyperreact
earli
infanc
predictor
sever
respiratori
syncyti
viru
infect
porntiva
poorisrisak
lott
loland
han
bisgaard
gentoft
hospit
danish
pediatr
asthma
centr
hellerup
copenhagen
denmark
background
twothre
percent
infant
react
sever
bronchiol
infect
respiratori
syncyti
viru
rsv
caus
exagger
respons
common
infect
unknown
suggest
may
associ
preexist
abnorm
pulmonari
function
aim
compar
lung
function
bronchial
hyperrespons
newborn
later
develop
sever
rsv
bronchiol
infant
develop
sever
infect
method
prospect
birth
cohort
studi
copenhagen
studi
asthma
childhood
conduct
infant
asthmat
mother
lung
function
schedul
month
age
mean
rais
volum
rapid
thoracoabdomin
compress
techniqu
sedat
measur
forc
expiratori
volum
bronchial
respons
determin
metacholin
challeng
use
transcutan
oxygen
endpoint
defin
sever
rsv
bronchiol
child
admit
hospit
requir
medic
highdos
inhal
budesonid
oral
prednisolon
rsvverifi
bronchiol
result
prospect
cohort
studi
children
develop
sever
rsv
infect
age
mean
age
month
complet
baselin
lung
function
measur
subsequ
rsv
infect
children
sever
rsv
infect
control
never
present
sever
rsv
bronchiol
differ
significantli
baselin
lung
function
metacholin
challeng
log
comparison
conclus
sever
rsv
infect
infanc
associ
preexist
abnorm
lung
function
bronchial
hyperreact
background
sever
studi
explor
role
probiot
treatment
prevent
atop
diseas
find
howev
inconclus
object
assess
effect
bifidobacterium
longum
lactobacillu
rhamnosu
gg
supplement
first
month
life
incid
eczema
allergen
sensit
first
year
high
risk
asian
infant
materi
method
infant
n
first
degre
rel
famili
histori
allerg
diseas
sensit
dust
mite
random
doubl
blind
placebocontrol
manner
receiv
cow
milk
base
infant
formula
without
probiot
daili
dose
colonyform
unit
cfu
bifidobacterium
longum
lactobacillu
rhamnosu
gg
first
month
life
subject
assess
month
atop
diseas
skin
prick
test
conduct
month
visit
result
subject
followedup
month
drop
rate
subject
two
treatment
group
compar
term
demograph
birth
characterist
except
gender
birth
order
incid
eczema
probiot
n
group
found
similar
placebo
n
ci
differ
rate
sensit
common
allergen
probiot
vs
placebo
ci
sensit
dust
mite
allergen
dermatophagoid
pteronyssinu
blomia
tropicali
common
probiot
vs
control
follow
egg
probiot
vs
control
none
subject
sensit
cow
milk
soy
potenti
confound
factor
includ
birth
order
household
size
smoke
exposur
presenc
pet
breastfeed
affect
outcom
measur
adjust
imbal
gender
birth
order
treatment
group
affect
find
significantli
conclus
studi
show
protect
effect
probiot
supplement
first
month
life
eczema
allergen
sensit
high
risk
asian
infant
year
age
preval
eczema
cohort
also
lower
report
studi
detect
fecal
bifidobacterium
infanti
first
year
life
infant
risk
atopi
supplement
lactobacillu
rhamnosu
gg
bifidobacterium
longum
birth
till
month
old
gc
yap
kw
mah
c
lay
lpc
shek
aw
ky
chua
gw
tannock
bw
lee
nation
univers
singapor
depart
paediatr
faculti
medicin
singapor
singapor
star
institut
microelectron
singapor
singapor
univers
otago
depart
microbiolog
immunolog
dunedin
new
zealand
background
studi
suggest
oral
administr
probiot
bacteria
earli
life
may
posit
modul
immun
system
infant
risk
atopi
toward
nonallerg
state
aim
studi
aim
monitor
intestin
transit
probiot
supplement
lactobacillu
rhamnosu
gg
bifidobacterium
longum
first
month
life
risk
infant
first
degre
rel
allerg
diseas
particip
ongo
random
doubleblind
placebo
control
trial
effect
supplement
bifidobacterium
infanti
preval
also
investig
particular
bifidobacteri
speci
implic
potenti
signatur
infant
low
preval
atopi
method
newborn
risk
allergi
receiv
either
probiot
prepar
n
placebo
n
daili
first
month
life
analysi
fecal
bacteria
clinic
examin
conduct
serial
birth
month
bacteri
dna
extract
fecal
sampl
evalu
nucleic
acid
amplif
approach
use
specif
pcr
primer
target
lactobacillu
rhamnosu
gg
bifidobacterium
infanti
result
extract
dna
sampl
amplifi
univers
primer
target
conserv
region
rrna
ensur
extract
intact
dna
lactobacillu
rhamnosu
gg
commonli
detect
probiot
group
compar
placebo
group
day
vs
vs
vs
respect
significantli
old
vs
infant
supplement
probiot
also
like
harbour
bifidobacterium
infanti
month
n
compar
placebo
n
group
p
conclus
data
suggest
probiot
supplement
birth
may
modul
intestin
bifidobacteri
speci
composit
effect
allergi
outcom
remain
examin
object
main
object
studi
establish
allergen
sensit
larg
proport
children
requir
hospitalis
sever
exacerb
asthma
materi
method
patient
hospitalis
victor
fouch
hospit
monitor
patient
contact
phone
leav
hospit
afterward
skin
test
common
aeroallergen
includ
mite
speci
cockroach
cat
dog
grass
food
detail
questionnair
concern
environment
social
risk
factor
answer
parent
result
total
hospitalis
count
period
time
total
children
boy
girl
mean
age
year
hospitalis
mean
number
hospitalis
per
child
time
mean
day
admiss
per
patient
number
hospitalis
total
patient
boy
girl
agre
undergo
skin
test
group
skin
test
prior
entri
studi
start
abandon
immunotherapi
one
hundr
nineti
six
children
least
posit
skin
test
sensitis
least
allergen
posit
least
mite
speci
least
cockroach
speci
least
one
food
among
sensitis
shrimp
sensitis
cat
dog
grass
pollen
conclus
identifi
high
rate
sensit
aeroallergen
larg
cohort
young
paediatr
patient
sever
asthma
requir
hospitalis
martiniqu
mite
cockroach
shrimp
account
largest
number
sensitis
result
similar
obtain
control
group
allerg
children
evalu
allerg
respiratori
diseas
period
time
background
tropic
region
larg
proport
popul
contact
intestin
parasit
includ
roundworm
ascari
spp
conflict
report
protect
effect
harm
influenc
sensit
ascari
spp
patient
allerg
respiratori
diseas
allerg
asthma
object
investig
specif
ige
level
children
hospitalis
sever
asthma
tropic
island
martiniqu
materi
method
investig
specif
ige
level
serum
children
hospitalis
sever
asthma
fort
de
franc
martiniqu
control
use
group
children
mean
age
evalu
allerg
respiratori
diseas
outpati
clinic
specif
ige
ascari
spp
measur
cap
system
phadia
result
total
children
boy
girl
mean
age
investig
mean
number
hospitalis
day
stay
hospit
day
respect
total
children
posit
determin
mean
valu
kul
mean
number
hospitalis
posit
group
mean
day
stay
hospit
day
children
stay
day
hospit
group
ascari
spp
neg
ascari
spp
posit
children
ns
neg
group
mean
number
hospitalis
time
mean
day
stay
hospit
day
control
group
posit
specif
ige
determin
ascari
spp
conclus
contrast
propos
tropic
countri
sensit
ascari
spp
seem
influenc
sever
asthma
martiniqu
similar
rate
sensit
ascari
spp
detect
allerg
children
requir
hospitalis
allerg
asthma
demograph
monitor
treatment
childhood
asthma
surakarta
central
java
indonesia
johann
ridwan
sugiarto
prof
hugo
van
bever
phd
dr
oen
hospit
pediatr
surakarta
indonesia
nation
univers
hospit
pediatr
singapor
singapor
background
surakarta
one
district
central
java
indonesia
popul
around
one
million
mani
area
hous
industri
compani
lead
high
pollut
trigger
childhood
asthma
common
chronic
ill
children
childhood
asthma
caus
school
absenc
limit
children
activ
make
asthma
especi
seriou
method
standard
questionnair
distribut
randomli
doctor
surakarta
gener
physician
gener
pediatrician
pediatr
pulmonologist
result
questionnair
return
gener
physician
pediatrician
doctor
never
use
score
card
monitor
childhood
asthma
never
use
spirometri
never
use
peak
flow
meter
treatment
acut
asthma
methylprednisolon
first
choic
use
dexamethason
mainten
treatment
childhood
asthma
physician
use
montelukast
drug
avail
surakarta
howev
first
choic
mainten
treatment
physician
use
longact
betaagonist
laba
combin
inhal
corticosteroid
infant
preschool
older
children
conclus
strike
result
low
usag
score
card
lung
function
test
monitor
childhood
asthma
high
usag
laba
combin
inhal
corticosteroid
first
choic
mainten
treatment
suggest
guidelin
asthma
monitor
treatment
strictli
follow
surakarta
frequenc
infect
atop
eczema
asthma
outcom
infanc
john
warner
augustin
huret
marieetienn
pinelli
imperi
colleg
paediatr
london
unit
kingdom
busi
effisci
scienc
strategi
pari
franc
ucb
pharma
global
medic
affairsallergi
brussel
belgium
studi
associ
frequent
earli
infect
allerg
diseas
outcom
produc
diametr
oppos
result
associ
reduc
frequenc
other
increas
frequenc
infect
allerg
diseas
employ
uniqu
algorithm
busi
effisci
analysi
larg
databas
earli
prevent
atop
asthma
children
epaac
trial
infant
year
age
atop
eczema
enter
studi
complet
month
follow
differ
activ
placebo
intervent
subject
merg
purpos
analysi
establish
factor
recruit
either
singli
combin
greatest
impact
subsequ
develop
asthma
defin
greater
equal
three
episod
wheez
andor
paroxysm
cough
disturb
sleep
least
three
consecut
night
analyz
impact
earli
infect
asthma
analys
effect
number
infect
per
year
infant
birth
asthma
onset
end
studi
asthma
observ
bell
shape
curv
identifi
infant
less
often
develop
asthma
less
infect
per
year
often
asthma
infect
per
year
less
often
asthma
infect
per
year
interact
proxim
factori
surrog
pollut
exposur
increas
risk
asthma
frequenc
infect
two
five
per
year
thu
combin
atop
eczema
rais
ige
proxim
factori
associ
uplift
frequenc
develop
asthma
frequenc
infect
per
year
bell
shape
curv
frequenc
infect
relat
asthma
risk
may
well
explain
discrep
result
variou
studi
low
frequenc
infect
occur
infant
effect
respons
therefor
reduc
probabl
develop
allerg
diseas
high
frequenc
infect
greater
probabl
induc
respons
normal
rate
infect
atop
predispos
individu
modifi
outcom
challeng
fpeanut
challeng
riniva
bandi
scott
hackett
birmingham
heartland
hospit
paediatr
birmingham
unit
kingdom
background
diagnosi
peanut
allergi
import
consequ
patient
famili
accur
diagnosi
peanut
allergi
essenti
usual
life
long
potenti
fatal
cornerston
diagnosi
detail
histori
skin
prick
test
spt
ige
estim
without
oral
peanut
challeng
object
demonstr
import
peanut
challeng
diagnos
children
peanut
allergi
see
whether
predict
children
like
outgrow
peanut
allergi
assess
safeti
peanut
challeng
method
retrospect
studi
peanut
challeng
perform
tertiari
care
paediatr
hospit
allergi
clinic
januari
decemb
result
peanut
challeng
perform
data
avail
posit
children
histori
suggest
peanut
allergi
skin
prick
test
spt
ige
rast
perform
prior
challeng
spt
result
spttige
rast
neg
either
posit
rast
spt
posit
challeng
neg
challeng
mm
mm
mm
neg
child
neg
spt
develop
posit
challeng
wherea
children
posit
spt
rast
neg
challeng
analysi
children
neg
challeng
show
major
spt
e
mm
spt
spt
q
posit
ige
rast
spt
ige
rast
posit
spt
e
mm
strongli
associ
neg
peanut
challeng
fisher
exact
test
p
advers
clinic
effect
posit
peanut
challeng
includ
urticaria
lip
swell
vomit
one
anaphylaxi
requir
medic
treatment
conclus
major
children
diagnosi
peanut
allergi
base
histori
skin
prick
antibodi
test
neg
challeng
peanut
challeng
warrant
patient
definit
histori
peanut
anaphylaxi
posit
spt
recommend
histori
suggest
spt
neg
borderlin
posit
ie
e
mm
peanut
challeng
necessari
confirm
diagnosi
plan
spt
rast
test
patient
peanut
challeng
see
improv
sensit
specif
challeng
effect
lyse
enterococcu
faecali
lfk
intestin
microflora
antibiot
treat
mice
takashi
shimada
tadao
enomoto
lei
cheng
nichinichi
pharmaceut
co
ltd
central
research
laboratori
igac
mie
japan
japanes
red
cross
societi
wakayama
medic
center
depart
otolaryngolog
wakayama
japan
nanj
medic
univers
intern
centr
allergu
research
nanj
china
background
antibiot
use
infanc
may
associ
increas
risk
develop
allerg
diseas
lyse
enterococcu
faecali
lfk
could
suppress
allerg
respons
howev
mechan
respons
phenomenon
remain
unclear
object
evalu
effect
lfk
intestin
microflora
antibiot
treat
wean
mice
method
threeweekold
balbc
mice
sensit
cedar
pollen
allergen
establish
experiment
model
oral
administ
erythromycin
one
kind
macrolid
antibiot
use
experi
intestin
microbiota
allergeninduc
accumul
eosinophil
ige
level
sera
determin
control
antibiot
lfk
antibioticlfk
group
n
respect
result
total
aerob
total
anaerob
enterococcu
intestin
microflora
significantli
differ
among
group
lactobacillu
distinctli
elimin
mice
expos
erythromycin
day
total
recov
erythromycintr
mice
lfk
intervent
day
could
recov
erythromycintr
mice
without
lfk
intervent
conclus
lfk
improv
intestin
ecosystem
disturb
antibiot
use
may
prevent
subsequ
develop
allergi
background
mycobacteri
tuberculosi
major
caus
mortal
morbid
worldwideinfect
bacteria
known
induc
develop
autoantibodi
antibodi
also
known
diagnost
marker
diseas
anca
one
autoantibodi
use
clinic
set
diagnos
system
vasculit
syndrom
studi
investig
anca
posit
diseas
small
vessel
vascul
studi
undertaken
determin
preval
anca
pulmonari
tuberculosi
tb
could
lead
fals
diagnosi
wegner
granulomatosi
vice
versa
materi
method
caseycontrol
studi
consecut
smear
posit
pulmonari
tb
patient
normal
individu
studi
case
control
screen
anca
indirect
immunoflurec
iif
also
myeloperoxidas
antibodi
antimpo
proteinas
antibodi
test
elisa
result
perinuclear
pattern
panca
detect
case
control
cytoplasm
pattern
canca
case
control
iif
assay
anca
specif
elisa
case
reveal
antimyleperoxidas
antiproteinas
control
antimpo
person
anti
posit
anca
significantli
correl
tuberculosi
p
also
posit
antimpo
significantli
correl
tb
p
conclus
autoantibodi
especi
anca
may
present
diseas
wegner
granulomatosi
tuberculosi
presenc
autoantibodi
tb
patient
could
multifactori
etiolog
presenc
human
lymphocyt
reactiv
heat
stress
protein
may
import
target
immun
respons
certain
intracellular
autoantigen
antimpo
pmn
ad
mechan
molecular
mimicri
would
explain
associ
anca
tb
cell
psoriat
skin
rational
psoriasi
autoimmun
diseas
signific
role
immun
system
method
investig
group
patient
activ
form
chronic
psoriasi
vulgari
treatment
cyclosporin
result
compar
control
group
patient
without
skin
diseas
sampl
skin
tissu
detect
cell
surfac
marker
hladr
use
monoclon
antibodi
immunotech
bectondickinson
result
lymphocyt
repres
sampl
skin
patient
activ
state
psoriasi
control
group
patient
treatment
cytotox
tcell
repres
sampl
skin
tissu
psoriat
patient
control
group
treatment
cytotox
tcell
express
hladr
psoriat
patient
treatment
treatment
control
group
found
lymphocyt
skin
patient
treatment
treatment
control
group
express
surfac
marker
lower
activ
stage
comparison
control
group
vs
express
increas
treatment
introduct
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
autoimmun
diseas
respect
cell
mediat
b
cell
mediat
mechan
endotoxin
et
gram
neg
flora
rapidli
induc
reactiv
experiment
arthriti
probabl
stimul
secret
inflammatori
cytokin
et
potent
polyclon
blymphocyt
activ
studi
investig
antiendotoxin
humor
immun
patient
ra
sle
method
patient
studi
includ
group
patient
ra
group
patient
sle
age
rang
year
diseas
durat
month
year
diseas
statu
base
clinic
includ
joint
involv
laboratori
data
less
equal
class
ii
degre
activ
peripher
blood
obtain
serum
analyz
quantif
iga
igm
igg
antiet
antibodi
done
elisa
et
esherichia
coli
k
employ
antigen
control
group
includ
healthi
donor
result
patient
ra
level
iga
antiet
igm
antiet
fold
less
averag
healthi
control
level
igg
antiet
antibodi
differ
healthi
control
group
patient
sle
level
igg
antiet
antibodi
fold
greater
normal
control
sle
patient
level
iga
antiet
igm
antiet
respect
fold
less
healthi
control
group
reduc
iga
antiet
level
occur
reduc
igm
antiet
level
occur
sle
patient
reduc
iga
antiet
level
occur
reduc
igm
antiet
level
occur
ra
patient
conclus
antiet
igg
level
ra
patient
demonstr
normal
level
respons
sle
patient
greater
normal
respons
et
occur
dysfunct
antiet
immun
respons
occur
respect
reduc
igm
iga
antiet
antibodi
sle
ra
patient
may
role
gut
flora
immun
respons
et
factor
modul
immun
respons
ra
sle
patient
activ
system
lupu
erythematosu
mexican
children
correl
medic
clinic
evalu
evalu
base
use
five
indic
activ
rosa
maria
cort
grimaldo
francisco
espinosa
rosal
marcia
del
carmen
perez
ruiz
martin
j
penago
paniagua
daniel
garcia
imperi
instituto
nacion
de
pediatria
allergi
immunolog
mexico
mexico
comput
program
develop
evalu
five
import
sle
ai
sledai
slam
bilag
lai
eclam
indic
close
correl
case
adult
patient
also
compar
expert
opinion
contrari
spars
inform
use
indic
children
sle
object
determin
whether
correl
differ
sle
ai
children
assess
correl
clinic
evalu
activ
physician
depart
immunolog
provid
use
five
ai
sle
materi
method
transvers
analyt
studi
undertaken
patient
year
age
diagnos
sle
nation
institut
pediatr
mexico
citi
questionnair
use
contain
everi
variabl
includ
five
indic
sle
activ
statist
analysi
median
interquartil
limit
use
descript
ststistic
variabl
show
normal
distribut
kolmogorovsmirnov
test
ascertain
degre
associ
among
quantit
variabl
correl
test
spearman
use
sensibl
specif
predict
valu
estim
differ
cutoff
level
select
best
one
use
receptor
oper
curv
roc
result
includ
patient
sle
femal
two
male
median
age
year
liq
median
time
evolut
time
diagnosi
month
liq
accord
expert
patient
activ
sle
accord
sledai
patient
activ
sle
p
conclus
indic
greater
correl
sledai
opinion
expert
si
best
correl
apprais
clinician
sledai
si
sensibl
specif
one
expert
si
sledai
respect
valu
corticosteroid
csp
counter
residua
protract
tubercul
infectioninflamm
ti
khan
sameera
munir
imran
khan
ali
iftikhar
ishaq
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
purpos
cs
bthe
doubl
edg
swordin
function
favor
therapeut
advantag
disadvantag
weigh
indic
aris
method
ti
linger
process
associ
enhanc
degre
exud
caseat
fibrogenesi
etcther
may
bind
obstructionconstrictoion
compress
surround
inflam
surfac
also
constitut
symptom
consequ
releas
inflammatori
productsexud
chang
cerebrospin
fluid
pathway
associ
featur
space
occupi
lesion
ti
pleural
pericardi
periton
effus
associ
fibrou
band
format
also
exud
chang
around
inflam
joint
space
may
lead
interfer
function
structur
case
corticosteroid
therapeut
dose
associ
remark
degre
improv
without
fibrou
residua
prodrom
manifest
reliev
favour
rel
serious
ill
patient
also
patient
termin
stage
ill
verg
death
advanc
tuberculosi
inanit
corticosteroid
may
indic
pure
humanitarian
ground
cs
detox
patient
allow
chemotherapeut
agent
take
princip
effect
dosag
regimen
adult
divid
dose
first
day
divid
dose
taper
day
intervalsfor
children
less
year
less
year
age
result
patient
reason
certain
degre
diagnosi
ti
cs
concomit
antituberculosi
drug
remark
therapeut
respons
evidenc
fall
temperatur
improv
appetit
vigor
conclus
uncertain
diagnosi
ti
cs
may
mask
untoward
effect
chemotherapeut
agent
creat
fals
sens
improv
may
precipit
steroid
depend
clinic
implic
safeti
cs
question
indic
shortest
possibl
time
tail
step
ladder
pattern
prednisolon
sulphat
prophylact
valu
low
dose
intraven
immunoglobulin
ivig
reduc
incid
infect
chronic
lymphat
leukemia
cll
secondari
hypogammaglobulinaemia
ishaq
khan
sameera
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
object
studi
conceren
low
dose
ivig
effect
high
dose
reduc
risk
infect
patient
chronic
lymphat
leukemia
cll
secondari
hypogammaglobulinaemia
without
inclus
control
group
behind
idea
assess
ivig
superior
empir
therapi
materi
method
patient
cll
background
hypogammaglobulinaemia
histori
infect
episod
almost
month
includ
randomli
alloc
receiv
regularli
infus
ivig
everi
week
month
financi
reason
could
afford
expens
continu
ongo
ivig
schedul
result
respons
ivig
immedi
accumul
increas
serum
igg
level
associ
decreas
total
seriou
infect
month
studi
incid
infect
sever
neutropenia
observ
four
patient
complet
ivig
overal
reduct
incid
infect
patient
month
ivig
reduct
incid
infect
conclus
infect
main
caus
morbid
mortal
consequ
upon
hypogammaglobulinaemia
background
cell
mediat
immun
associ
protract
cytotox
drug
therapi
trial
conceren
protect
valu
ivig
time
relat
dose
relat
longer
period
ivig
therapi
le
incid
infect
bear
mind
cost
ivig
advis
pateint
life
threaten
infect
lower
dose
reduc
expens
incur
upon
treatment
khan
et
al
aljh
nsr
nwfp
pk
six
year
old
girl
recurr
varicella
infect
associ
mutat
fcyriiia
suthida
kankirawatana
yule
dai
prescott
atkinson
univers
alabama
birmingham
divis
allergi
immunolog
depart
birmingham
unit
state
background
natur
killer
nk
cell
subset
lymphocyt
play
pivot
role
innat
immun
nk
cell
recogn
antibodyco
target
cell
use
fcyriiia
kill
target
cell
process
call
antibodydepend
cellmedi
cytotox
quantit
qualit
defect
nk
cell
function
result
suscept
intracellular
microb
method
lymphocyt
subpopul
peripher
blood
determin
use
flow
cytometri
nk
cell
surfac
express
intracellular
express
level
perforin
granzym
b
analyz
flow
cytometri
patient
cdna
sequenc
screen
mutat
within
code
region
result
patient
yearold
girl
suffer
recurr
upper
lower
respiratori
tract
infect
experienc
two
episod
varicella
despit
receiv
vaccin
despit
varicella
antibodi
neg
also
numer
wart
finger
immunolog
studi
reveal
low
serum
immunoglobulin
igg
iga
igm
mgdl
year
exuber
antibodi
product
respons
pneumococc
vaccin
peripher
blood
lymphocyt
phenotyp
reveal
slightli
low
cell
number
age
preserv
ratio
b
cell
normal
percentag
number
nk
cell
lymphocyt
gate
express
less
use
howev
analysi
nk
cell
use
differ
antibodi
reveal
normal
surfac
express
sequenc
peripher
blood
cdna
demonstr
homozyg
ta
transvers
base
pair
mrna
sequenc
produc
leu
substitut
residu
peptid
sequenc
mutat
previous
describ
patient
recurr
orolabi
hsv
exacerb
respiratori
infect
jawahar
et
al
clin
exp
immunol
background
cicatrici
pemphigoid
cp
rare
autoimmun
subepitheli
blister
disord
character
predomin
involv
mucou
membran
occasion
skin
chronic
cours
tendenc
toward
scar
affect
area
common
site
involv
oral
mucosa
conjunctiva
hospit
second
case
cp
first
case
skin
involv
last
five
year
case
year
old
male
undergon
dysphagia
blister
disord
skin
six
month
clinic
manifest
erythemat
eros
oral
mucou
tongu
crust
lip
skin
lesion
tens
hemorrhag
blister
neg
nikolski
sign
eros
crust
chest
axila
abdomen
left
lower
arm
slight
atroph
scar
also
found
pharyngoscopi
show
erythemat
brittl
pharynx
soft
palat
tongu
histopatholog
examin
show
subepiderm
bulla
epiderm
atrophi
spars
perivascular
periappendag
inflammatori
infiltr
consist
mostli
lymphocyt
polymorphonuclear
leukocyt
eosinophil
fibrosi
dermi
patient
favor
respond
oral
steroid
prednison
mg
daili
combin
dapson
mg
daili
improv
seven
week
discuss
cp
rare
autoimmun
subephiteli
blister
disord
character
predomin
involv
mucou
membran
accord
literatur
skin
involv
cp
occur
onefourth
case
diagnosi
case
suggest
presenc
scar
lesion
pharyng
mucou
membran
dysphagia
slight
atroph
scar
skin
confirm
histopatholog
prednison
dapson
use
due
sever
diseas
prevent
potenti
sever
complic
conclus
cp
skin
involv
uncommon
diagnosi
base
clinic
manifest
confirm
histopatholog
therapi
prednison
dapson
show
good
result
cp
introduct
iga
defici
igad
common
immunoglobulin
defici
one
frequent
primari
immunodefici
preval
igad
iceland
blood
donor
recent
estim
correl
igad
variou
autoimmun
diseas
includ
autoimmun
thyroid
diseas
aitd
rapport
materi
method
iga
measur
serum
patient
thyrotoxicosi
patient
dm
ti
comparison
iga
level
blood
donor
evalu
iga
measur
beckman
array
system
nephelometri
iga
level
also
studi
relat
titer
tsh
receptor
antibodi
trab
thyroid
peroxidas
antibodi
anti
tpo
trab
measur
elisa
anti
tpo
measur
use
feia
result
none
thyrotoxicosi
patient
igad
iga
serum
g
gl
women
thyrotoxicosi
significantli
lower
level
serum
iga
compar
men
thyrotoxicosi
iga
male
gl
vs
iga
femal
gl
howev
similar
gender
differ
also
found
blood
donor
iga
level
increas
significantli
age
patient
thyrotoxicosi
similar
correl
found
blood
donor
group
neg
correl
found
level
iga
serum
trab
correl
p
also
level
iga
antitpo
correl
p
one
individu
dm
ti
hypogammaglobulinemia
none
select
igad
cohort
interestingli
men
dm
ti
lower
serum
iga
women
conclus
result
strong
indic
preval
igad
increas
amont
patient
thyrotoxicosi
dm
ti
iceland
neg
correl
iga
level
thyroid
autoantibodi
suggest
possibl
role
iga
pathogenesi
autoimmun
thyroid
diseas
iga
might
protect
role
format
autoantibodi
thyroid
structur
mutual
autoimmun
mechan
might
caus
brakedown
iga
format
thyroid
autoantibodi
allerg
immunolog
mechan
background
asthma
chronic
inflammatori
disord
airway
associ
revers
airway
obstruct
airway
hyperrespons
thought
respons
play
critic
role
pathogenesi
asthma
howev
recent
report
respons
also
play
import
role
pathogenesi
asthma
immun
respons
key
molecul
play
import
role
develop
promot
respons
product
interferongamma
believ
also
play
import
role
immun
rspons
still
remain
unclear
whether
molecul
play
key
role
asthma
develop
vivo
method
evalu
role
murin
model
asthma
receptor
jj
jj
null
mutant
litterm
wild
type
control
mice
use
respect
mice
sensit
four
time
ova
day
presenc
absenc
lp
challeng
time
intranas
ova
day
jj
wild
type
control
mice
sensit
challeng
manner
challeng
test
airway
hyperrespons
ahr
methacholin
challeng
mice
sacrif
hour
last
allergen
challeng
variou
immunolog
paramet
evalu
bal
fluid
cellular
result
total
cell
number
bal
fluid
increas
mice
sensit
lp
ova
compar
mice
sensit
ova
bal
fluid
flammatori
cell
similar
receptor
l
knockout
mice
wild
type
mice
significantli
decreas
null
mutant
mice
interestingli
level
bal
fluid
partial
decreas
jj
mice
markedli
decreas
jj
mice
conclus
experiment
asthma
airway
inflammatori
respons
partial
depend
depend
signal
pathway
role
sensit
alveolar
macrophag
cell
prolifer
bo
ram
bang
eunyoung
chun
heungwoo
park
yoonseok
chang
sunsin
kim
sangheon
cho
kyungup
min
youyoung
kim
seoul
nation
univers
colleg
medicin
institut
allergi
clinic
immunolog
seoul
republ
korea
background
well
known
alveolar
macrophag
compos
bronchial
alveolar
cell
first
barrier
protect
lung
harm
antigen
howev
differ
studi
suggest
sensit
alveolar
macrophag
could
exacerb
asthma
phenotyp
airwayhyperrespons
ahr
exact
role
alveolar
macrophag
asthma
unknown
thu
undertook
determin
whether
sensit
alveolar
macrophag
could
induc
cell
prolifer
asthma
anim
model
balbc
mice
intraperiton
sensit
ovalbumin
alum
follow
challeng
ovalbumin
day
lung
cell
isol
analys
fac
analysi
cell
isol
bronchial
lymph
node
bronchial
alveolar
lavag
bal
cell
cocultur
without
ovalbumin
vitro
order
determin
abil
sensit
alveolar
macrophag
induc
cell
prolifer
result
challeng
percent
lung
cell
alveolar
macrophag
chang
mhc
ii
express
lung
cell
increas
compar
pb
group
prolifer
cell
increas
time
ip
group
group
without
stimul
ovalbumin
furthermor
bal
cell
ip
group
stimul
ovalbumin
induc
time
increas
cell
prolifer
compar
group
conclus
suggest
sensit
alveolar
macrophag
bal
could
facilit
prolifer
cell
asthma
anim
model
tolllik
receptor
express
function
peripher
blood
mononuclear
cell
asthma
patient
background
asthma
chronic
inflammatori
lung
diseas
caus
impair
adapt
immun
system
like
mani
immunolog
diseas
howev
pathogenesi
unwant
respons
well
determin
tolllik
receptor
shown
play
pivot
role
innat
adapt
immun
respons
recent
mani
research
group
hypothes
tlr
like
play
import
role
asthma
pathogenesi
studi
focus
effect
tlr
polymorph
therefor
investig
whether
express
sever
tlr
differ
asthma
patient
compar
normal
subject
whether
function
receptor
could
relat
chang
method
express
peripher
blood
mononuclear
cell
pbmc
asthma
patient
normal
subject
analyz
flow
cytometri
studi
function
respons
receptor
pbmc
stimul
pgn
ligand
lp
ligand
ligand
hour
amount
tnf
determin
elisa
result
express
upregul
pbmc
asthma
patient
compar
normal
subject
upon
stimul
pgn
tnf
product
significantli
increas
asthma
patient
contrast
respons
lp
ligand
stimul
pbmc
higher
normal
subject
asthma
patient
although
express
significantli
differ
asthma
patient
normal
subject
case
surfac
express
significantli
reduc
asthma
patient
howev
differ
observ
amount
tnf
secret
pbmc
treat
conclus
data
suggest
differ
phonotyp
express
function
respons
tlr
might
relat
pathogenesi
asthma
influenc
antiig
antibodi
omalizumab
allergeninduc
airway
inflamm
bronchial
hyperrespons
murin
model
asthma
background
aim
studi
examin
effect
treatment
omalizumab
antiimmunoglobulin
e
antibodi
allergicairway
respons
mice
inhal
natur
occur
aeroallergen
aspergillu
fumigatu
af
examin
effect
omalizumab
specif
immun
respons
defin
protein
antigen
use
ovalbumin
ova
model
asthma
method
mice
subject
either
repeat
intranas
applic
af
extract
intraperiton
immun
ova
follow
inhal
challeng
omalizumab
control
fluid
given
daili
throughout
sensit
process
immunoglobulin
e
ige
level
bronchoalveolar
lavagefluid
cytokin
cytolog
lung
histolog
physiolog
respons
methacholin
assess
allergentr
mice
antiova
ige
respons
ovadriven
tcell
cytokin
product
examin
result
treatment
omalizumab
inhibit
bronchial
inflamm
bronchial
hyperrespons
afand
ovatr
mice
inhibit
requir
omalizumab
administ
concurr
allergen
sensit
indic
attenu
bronchial
hyperrespons
inflamm
caus
anticholinerg
receptor
effect
ovarespons
cell
omalizumabtr
mice
exhibit
depress
product
normal
amount
interferongamma
amount
also
diminish
bronchoalveolar
lavag
fluid
conclus
omalizumab
given
time
exposur
allergen
inhibit
induct
allerg
pulmonari
inflamm
bronchial
hyperrespons
result
suggest
omalizumab
similar
agent
given
time
antigen
exposur
might
alter
diseas
progress
patient
respiratori
allergi
nonproteolyt
major
hous
dust
mite
allergen
der
p
induc
proasthmat
respons
bronchial
epitheli
cell
partli
mapk
pathway
camilla
osterlund
han
gronlund
sofia
sundstrom
guro
gafvelin
ander
bucht
foi
cbrn
defenc
secur
resp
medicin
allergi
univers
hospit
sweden
karolinska
institut
dep
medicin
clinic
immunolog
allergi
stockholm
sweden
background
hous
dust
mite
hdm
belong
common
sourc
airborn
allergen
worldwid
sensit
strongli
associ
develop
allerg
airway
diseas
mani
proteolyt
hdm
allergen
activ
respiratori
epitheli
cell
produc
proinflammatori
mediat
contrast
limit
knowledg
regard
potenti
similar
effect
nonproteolyt
allergen
although
includ
mani
major
allergen
one
der
p
dermatophagoid
pteronyssinu
investig
whether
der
p
activ
respiratori
epitheli
cell
produc
mediat
involv
pathogenesi
allerg
asthma
elucid
mechan
activ
expos
human
bronchial
epitheli
cell
line
allergen
method
bronchial
cell
expos
recombin
der
p
hour
mrna
level
secret
amount
solubl
mediat
well
express
cell
adhes
receptor
involv
recruit
surviv
bind
inflammatori
cell
instanc
gmcsf
analyz
exposur
adhes
leukocyt
cell
epitheli
cell
also
studi
order
studi
activ
depend
signal
map
kinas
jnk
specif
inhibitor
use
result
der
p
induc
dosedepend
upregul
gene
express
protein
secret
granulocytemacrophag
colonystimul
factor
gmcsf
express
also
upregul
associ
subsequ
increas
adhes
leukocyt
epitheli
cell
respons
partli
depend
mapk
activ
sinc
specif
inhibitor
reduc
activ
conclus
taken
togeth
result
impli
der
p
may
potenti
asthmat
respons
airway
direct
activ
lung
epitheli
cell
proteaseindepend
manner
human
eosinophil
play
import
role
pathogenesi
allerg
diseas
specif
asthma
interleukin
monocyt
chemotact
protein
play
pivot
role
mediat
infiltr
activ
immun
cell
pathogen
lesion
includ
lung
skin
aim
studi
examin
whether
hous
dust
mite
dermatophagoid
pteronissinu
extract
dpe
affect
mrna
protein
express
human
eosinophil
cell
line
perform
rtpcr
elisa
dpe
increas
mrna
protein
express
cell
increas
express
inhibit
inhibitor
src
rottlerin
inhibitor
protein
kinas
c
pkc
upstream
inhibitor
extracellularsignalregul
kinas
erk
indic
dpe
increas
express
src
pkc
erk
also
found
express
due
dpe
relat
src
pkc
mitogenactiv
protein
kinas
mapk
earli
signal
pathway
express
regul
src
famili
tyrosin
kinas
pkc
pathway
activ
dpe
find
may
contribut
elucid
pathogen
mechan
trigger
dpe
perturb
nk
cell
regulatori
function
respiratori
allerg
diseas
background
allerg
diseas
character
abnorm
respons
allergen
favor
inappropri
regul
polar
nk
cell
give
rise
complex
nkdc
crosstalk
would
help
respons
analyz
peripher
blood
nk
cell
patient
suffer
either
allerg
rhiniti
rhiniti
intermitt
asthma
evalu
whether
cell
impair
abil
interact
dc
method
differ
circul
nk
cell
subset
analyz
flow
cytofluorimetri
mix
nkdc
cultur
perform
assess
reciproc
function
interact
nk
cell
analyz
abil
induc
dc
matur
cytokin
product
kill
immatur
dc
addit
dc
assess
abil
induc
cytokin
product
nk
cell
result
first
analyz
subset
circul
nk
cell
abl
respond
dc
prolifer
produc
ifn
analysi
reveal
nk
cell
subpopul
sharpli
reduc
patient
reflect
reduc
nk
cellmedi
ifn
product
respons
dc
also
capabl
promot
dc
matur
andor
kill
immatur
dc
function
sustain
cell
reduc
patient
conclus
suggest
allerg
diseas
accompani
partial
impair
nk
cell
capabl
promot
maintain
appropri
respons
humor
cellular
immun
respons
blomia
tropicali
concanavalin
abind
fraction
atop
patient
ernesto
taketomi
ronaldo
alv
deis
silva
jorg
fernand
karin
almeida
leandro
ynoue
cristian
bernard
priscila
moreira
sopelet
margareth
gennaricardoso
sunsang
sung
feder
univers
laboratori
allergi
clinic
immunolog
brazil
state
univers
santa
cruz
immunolog
brazil
univers
virginia
rheumatolog
immunolog
charlottesvil
unit
state
background
blomia
tropicali
bt
dermatophagoid
pteronyssinu
dp
farina
df
preval
hous
dust
mite
hdm
concanavalin
abind
compon
deriv
b
tropicali
btcona
extract
shown
highli
immunogen
allerg
diseas
studi
aim
evalu
humor
cellular
immun
respons
b
tropicali
sensit
patient
method
total
patient
allerg
rhiniti
withwithout
asthma
nonatop
subject
select
analyz
skin
reactiv
spt
total
serum
ige
specif
ige
level
bttotal
btcona
extract
prolif
respons
cytokin
ifn
product
peripher
blood
mononuclear
cell
stimul
extract
result
spt
show
patient
sensit
bt
bt
patient
monosensit
bt
similar
level
specif
ige
bttotal
btcona
extract
found
btpatient
higher
level
total
serum
ige
found
atop
nonatop
subject
signific
pbmc
prolifer
observ
respons
bttotal
extract
btsensit
btnonsensit
patient
nonatop
subject
btcona
extract
abl
induc
increas
prolif
respons
patient
group
signific
ifn
product
observ
btcona
stimul
btpatient
bttotal
extract
show
chang
product
consist
seen
btpatient
allergenspecif
stimul
even
stimulu
conclus
conclud
btcona
extract
may
contain
relev
antigen
involv
humor
cellular
immun
respons
potenti
use
diagnost
procedur
kenichi
kanai
watanab
atsuko
furuta
kazuhito
asano
harumi
suzaki
showa
univers
otorhinolaryngolog
tokyo
japan
showa
univers
school
nr
divis
physiolog
tokyo
japan
background
purpos
eosinophil
well
accept
import
cell
develop
mainten
clinic
condit
allerg
diseas
allerg
rhiniti
asthma
also
accept
nasal
mucos
epitheli
cell
secret
sever
type
cytokin
chemokin
affect
eosinophil
accumul
site
diseas
cell
surviv
howev
influenc
secondgener
antihistamin
use
treatment
prevent
allerg
diseas
well
understood
present
studi
therefor
undertaken
evalu
influenc
epinastin
hydrochlorid
ep
famou
secondgener
antihistamin
japan
cytokin
secret
eosinophil
surviv
materi
method
epitheli
cell
nasal
polyp
stimul
ngml
tnf
without
ep
h
cytokin
level
cultur
supernat
examin
elisa
human
peripher
blood
eosinophil
cultur
epitheli
cell
condit
medium
cm
ep
eosinophil
surviv
assess
trypan
blue
dye
exclus
test
result
express
mean
se
cytokin
concentr
pgml
eosinophil
surviv
index
result
addit
ep
cell
cultur
dosedepend
inhibit
abil
cell
produc
granulocytemacrophag
coloni
stimul
factor
gmcsf
vascular
endotheli
growth
factor
vegf
increas
tnf
stimul
ep
also
could
inhibit
eosinophil
surviv
induc
cm
minimum
concentr
ep
caus
signific
suppress
surviv
ngml
conclus
inhibitori
effect
ep
inflammatori
cytokin
product
epitheli
cell
eosinophil
surviv
contribut
therapeut
effect
allerg
airway
diseas
includ
allerg
rhiniti
inhibitori
action
epinastin
hydrochrolid
product
antiangiogenesi
factor
mous
periton
mast
cell
vitro
atsuko
furuta
kenichi
kanai
kazuhito
asano
harumi
suzaki
showa
univers
otorhinolaryngolog
tokyo
japan
showa
univers
divis
physiolog
school
nr
tokyo
japan
background
receptor
antagonist
call
antihistamin
accept
antiangiogenesi
properti
addit
antagonist
epinastin
hydrochlorid
ep
famou
receptor
antagonist
japan
use
treatment
allerg
upper
airway
inflammatori
diseas
pollinosi
remark
success
howev
influenc
ep
proangiogenesi
factor
product
well
understood
present
studi
therefor
investig
influenc
ep
product
angiogenesi
factor
vascular
endotheli
growth
factor
vegf
keratinocytederiv
chemokin
kc
murin
mast
cell
vitro
materi
method
murin
mast
cell
stimul
ovalbumin
presenc
variou
dose
ep
h
level
vascular
endotheli
growth
factor
vegf
keratinocytederiv
chemokin
kc
tumor
necrosi
factor
tnf
level
cultur
supernat
examin
elisa
mrna
express
factor
also
examin
semiquantit
rtpcr
hcultur
mast
cell
result
ep
could
suppress
product
vegf
kc
tnf
induc
ige
dependentmechan
dosedepend
manner
minimum
concentr
agent
caus
signific
suppress
ep
also
suppress
mrna
express
examin
agent
ad
cell
cultur
dose
ngml
conclus
find
strongli
suggest
antiangiogenesi
activ
ep
may
confer
attenu
effect
agent
allerg
diseas
includ
allerg
pollinosi
reduc
level
total
serum
ige
fcri
express
releas
nonreleas
basophil
fcri
mediat
signal
pathway
basophil
mast
cell
lead
releas
histamin
mediat
invitro
invivo
system
interestingli
basophil
popul
releas
histamin
mediat
activ
ige
signal
transduct
pathway
attribut
absenc
tyrosin
kinas
lyn
syk
present
work
deal
histamin
releas
indian
subject
assess
relationship
releas
non
releas
basophil
express
fcri
total
serum
ige
levelsbasophil
peripher
blood
healthi
adult
purifi
densiti
gradient
centrifug
neg
immunoselect
techniqu
histamin
releas
assay
perform
flourometr
assess
ige
receptor
express
carri
flowcytometri
total
serum
ige
estim
elisa
methodhistamin
releas
cona
challeng
vari
indian
subject
eighteen
percent
subject
show
less
histamin
releas
consid
nonreleas
consid
releas
flowcytometr
analysi
reveal
significantli
reduc
express
fcri
non
releas
basophil
p
g
interestingli
total
serum
ige
level
also
significantli
p
g
reduc
nonreleas
suggest
common
regul
phenotyp
depth
evalu
could
lead
identif
potenti
target
develop
therapeut
allerg
patient
investig
interact
ige
truncat
recombin
fragment
naser
nazari
kermanshah
univers
medic
scienc
depart
parasitolog
medic
school
kermanshah
islam
republ
iran
lowaffin
receptor
ige
wide
implic
synthesi
ige
well
igemedi
immun
inflammatori
function
two
form
cell
express
function
activ
differ
structur
present
singl
membranespan
domain
follow
extracellular
domain
consist
three
region
coil
coil
stalk
region
mediat
format
trimer
follow
lectin
head
bind
ige
c
terminu
short
tail
contain
invers
rgd
argglyasp
sequenc
aim
project
express
defin
truncat
fragment
assess
physic
biolog
properti
truncat
fragment
regard
ige
independ
mast
cell
basophil
secretayogu
activ
obtain
necessari
inform
concern
differ
gener
fragment
well
vector
piresegfp
appropri
primer
design
primer
essenti
pcr
amplif
desir
sequenc
subsequ
clone
pire
vector
b
yrgd
sequenc
also
whole
thing
b
clone
pire
vector
transfect
subsequ
evalu
ige
function
assay
overlap
pcr
use
produc
differ
truncat
fragment
molecul
consist
b
minu
rgd
sequenc
adhes
part
meantim
plasmid
vector
pire
introduc
cell
order
obtain
use
mini
midi
prep
protocol
gene
transfect
dna
protein
purifi
obtain
characteris
electrophoresi
brgd
sequenc
whole
thing
transfect
mous
myeloma
cell
order
studi
express
egfp
biolog
activ
fac
fluoresc
activ
cell
sort
fac
analysi
investig
interact
ige
differ
express
bind
igefc
fragment
cell
surfac
express
human
assess
use
flow
cytometri
detect
bind
ige
cell
surfac
receptor
use
biotinyl
antiig
follow
streptavidin
phycoerythrin
conjug
result
show
express
argd
sequenc
cell
cell
express
brgd
sequenc
stabl
allergen
hypoallergen
isoform
major
birch
pollen
allergen
bet
v
differenti
uptaken
dc
allerg
healthi
individu
background
major
birch
pollen
allergen
bet
v
present
structur
slightli
differ
isoform
vari
allergen
properti
wherea
bet
v
repres
potent
allergen
natur
occur
isoform
bet
v
engin
bet
v
display
strongli
reduc
allergen
activ
although
biolog
cell
allergi
well
understood
littl
known
mechan
control
initi
cell
polar
dc
respons
allergen
object
present
studi
investig
differ
properti
bet
v
isoform
uptaken
human
monocytederiv
dc
modc
birch
pollen
allerg
healthi
individu
method
eight
birch
pollen
allerg
healthi
donor
includ
studi
modc
gener
peripher
blood
taken
day
differenti
incub
variou
concentr
fluorescein
isothiocyan
fitc
label
recombin
bet
v
bet
v
bet
v
minut
studi
mean
flow
cytometri
mechan
antigen
intern
investig
experiment
setup
presenc
inhibitor
pinocytosi
endocytosi
receptor
intern
result
fitclabel
protein
taken
modc
doseand
time
depend
manner
percentag
fitc
posit
cell
increas
label
protein
wherea
cell
intern
protein
minut
lowest
concentr
uptak
bet
v
lower
compar
uptak
bet
v
bet
v
dc
studi
group
fact
chang
healthi
individu
higher
concentr
protein
use
wherea
allerg
individu
bet
v
uptak
higher
concentr
similar
two
isoform
inhibit
uptak
gener
lower
use
dc
allerg
compar
healthi
individu
conclus
differ
agent
show
inhibit
indic
uptak
bet
v
isoform
mediat
via
one
pathway
interplay
mechan
like
receptormedi
intern
endocyt
process
macropinocytosi
observ
implic
differ
mechan
involv
bet
v
uptak
allerg
individu
possibl
lead
induct
signal
polar
studi
support
sfb
austria
scienc
fund
austrian
academi
scienc
polymorph
atop
dermat
egg
white
allergi
korean
children
purpos
known
polymorph
human
leukocyt
antigen
hla
class
ii
restrict
specif
ige
respons
investig
whether
particular
polymorph
contribut
develop
ad
ew
sensit
korean
children
ad
method
total
patient
ad
normal
control
nc
person
famili
histori
allergi
includ
type
done
use
pcrsso
sequenc
specif
oligonucleotid
pcrsscp
singl
strand
conform
polymorph
method
phenotyp
frequenc
allel
ad
patient
compar
nc
ad
patient
allergi
ew
defin
group
patient
whose
ew
specif
ige
kul
less
year
old
age
kul
greater
year
old
age
group
b
patient
defin
ew
specif
ige
neg
among
ad
patient
phenotyp
frequenc
allel
group
group
b
compar
nc
allel
classifi
function
group
de
dr
e
q
r
frequenc
function
group
group
group
b
compar
nc
result
present
significantli
higher
frequenc
ad
patient
compar
nc
vs
ci
regard
factor
associ
ad
suscept
result
signific
bonferroni
correct
frequenc
vs
decreas
ad
compar
nc
show
weak
protect
effect
develop
ad
decreas
group
compar
group
b
vs
regard
weak
protect
factor
develop
egg
allergi
ad
increas
group
compar
group
b
vs
regard
weak
suscept
factor
associ
develop
egg
allergi
ad
function
group
includ
also
weakli
associ
develop
egg
allergi
ad
howev
none
these
result
remain
signific
bonferroni
correct
conclus
signific
associ
ad
weak
associ
suscept
protect
develop
ew
allergi
ad
observ
maria
background
food
allergi
abnorm
respons
immunolog
system
especi
mucosa
immunolog
system
antigen
suppli
per
os
complic
still
unexplain
end
immunolog
mechan
lead
hypersensit
reaction
often
food
hypersensit
identifi
effect
atopi
connect
humor
respons
specif
ige
antibodi
contrari
cell
immunolog
respons
less
investig
howev
import
especi
signific
factor
initi
patholog
allerg
process
aim
studi
concern
use
flow
cytometri
estim
specif
sensit
subpopul
lymphocyt
food
allergen
allergi
diagnosi
method
investig
perform
children
sinc
month
year
old
children
cma
ige
depend
cma
ige
independ
healthi
children
ige
total
sige
igg
iga
igm
basic
immunolog
panel
cd
pcna
measur
result
notic
decreas
express
ii
examin
iii
decreas
express
iii
test
decreas
express
ii
examin
type
hypersensit
observ
decreas
express
iii
examin
decreas
express
iii
examin
iv
type
hypersensit
express
decreas
diet
allergi
ige
depend
valu
express
pcna
similar
iv
type
hypersensit
children
cma
decreas
express
pcna
ii
examin
observ
case
allergen
reintroduc
caus
increas
express
pcna
type
allergi
conclus
recent
research
confirm
chang
express
lymphocyt
activ
marker
connect
vivo
stimul
allergen
allergen
elimin
studi
express
activ
marker
use
flow
cytometri
food
allergi
children
help
observ
dynam
progress
process
use
singl
diagnosi
test
background
probiot
defin
live
nonpathogen
microorgan
benefici
affect
host
suggest
administr
probiot
may
therapeut
andor
prevent
benefit
improv
respons
atop
dermat
ad
aim
investig
possibl
skin
use
target
prevent
ad
lactobacillu
rhamnosu
one
commonli
use
therapeut
intestin
probiot
induc
respons
keratinocyt
method
keratinocyt
treat
l
rhamnosu
hour
cultur
new
media
hour
supernat
kcm
l
rhamnosustr
keratinocyt
collect
use
matur
immatur
dendrit
cell
normal
ad
individu
cell
naiv
cell
isol
peripher
blood
normal
ad
individu
use
isol
kit
differenti
immatur
dendrit
cell
idc
gmcsf
ngml
ng
ml
day
idc
activ
kcm
lp
lipopolysaccharid
lp
posit
control
hour
cocultur
naiv
cell
day
result
could
confirm
matur
idc
kcm
lp
morpholog
chang
express
matur
dc
specif
marker
normal
ad
individu
elisa
analysi
show
matur
dc
activ
kcm
could
induc
repons
ifn
significantli
increas
cocultur
supernat
matur
dc
naiv
cell
level
almost
base
furthemor
found
highli
increas
keratinocyt
l
rhamnosu
treatment
conclus
probiot
l
rhamnosu
improv
respons
keratinocyt
effect
probiot
mediat
secret
keratinocyt
howev
differ
effect
probiot
normal
ad
individu
interact
aeroallergen
respiratori
interphas
degrad
process
transmiss
via
epitheli
barrier
research
center
borstel
biolog
chemistri
borstel
germani
background
antigen
present
cell
consid
import
immun
cell
give
rise
allergi
toler
develop
apc
alreadi
embed
cytokin
milieu
part
predict
immun
respons
epitheli
cell
form
barrier
environ
activ
upon
contact
molecul
eg
allergen
therefor
might
play
pivot
role
sensit
process
studi
fate
major
grass
pollen
allergen
phl
p
molecular
modif
contact
respiratori
interfac
method
influenc
mucos
secret
nasal
secret
bronchial
lavag
fluid
investig
immunoblot
zymographi
uptak
transmiss
allergen
epitheli
cell
cell
line
nasal
lung
biopsi
studi
fac
analysi
determin
cytokin
releas
immunohistolog
result
nasal
secret
individu
suffer
bronchial
inflamm
allergi
aeroallergen
show
proteolyt
activ
experi
use
supernat
mast
cell
neutrophil
similar
acut
inflamm
result
partial
cleavag
allergen
investig
allergen
uptak
two
epitheli
cell
line
use
mimic
differ
section
lung
deriv
alveolar
pneumocyt
upper
respiratori
epithelium
cell
line
activ
phl
p
demonstr
releas
cell
contrast
cell
express
mhcii
prerequisit
antigen
process
present
cell
hand
take
allergen
macropinocytosi
probabl
perform
transcytosi
first
result
human
lung
slice
incub
phl
p
show
faint
allergen
uptak
macrophag
alveolar
space
show
consider
uptak
whether
macrophag
allergen
uptak
enter
interstitium
andor
whether
epitheli
cell
transfer
allergen
fragment
profession
apc
interstitium
still
investig
conclus
secret
respiratori
tract
caus
less
incomplet
fragment
allergen
may
facilit
allergen
uptak
epitheli
cell
result
reveal
differ
uptak
transmiss
allergen
upper
lower
airway
epitheli
cell
upper
part
probabl
degrad
process
allergen
cell
lower
part
seem
transmit
unprocess
allergen
estim
influenc
variou
program
therapi
system
local
level
made
develop
atop
march
teenag
patient
research
allow
reveal
therapi
help
topic
steroid
practic
influenc
level
serum
blood
led
decreas
level
patient
ba
pgml
combin
r
pgml
combin
r
simultan
decreas
establish
use
topic
steroid
contrari
clinic
ad
evid
steroid
therapi
led
onestag
increas
cytokin
level
receptor
thu
research
nasal
lavag
offer
nonivas
method
control
effici
therapi
patient
combin
r
use
topic
steroid
therapi
topic
steroid
patient
combin
r
r
ad
provid
decreas
level
lead
chang
level
serum
blood
therapi
topic
steroid
lead
decreas
content
serum
nasal
secret
group
patient
combin
ad
previou
work
typei
pollen
allergi
focus
lymphocyt
immun
respons
begin
analys
system
biolog
topdown
view
differ
nasal
epithelium
obtain
healthi
allerg
subject
light
immunoelectron
microscop
analysi
show
birch
pollen
bet
v
allergen
bound
epitheli
cell
surfac
within
minut
even
nonsymptomat
winter
season
allerg
healthi
individu
bet
v
also
travel
epithelium
togeth
lipid
raftscaveola
reach
mast
cell
allerg
healthi
individu
within
minut
put
viral
entri
protein
ubiquitinprotein
ligas
three
enzym
involv
lipid
raftscaveola
metabol
among
bet
v
bind
protein
found
allerg
subject
affin
chromatographi
nasal
epitheli
cell
transcriptom
nonsymptomat
winter
season
identifi
list
put
receptor
bet
v
might
recogn
also
suggest
defenc
mechan
express
histatin
could
impair
allerg
patient
compar
nasal
epitheli
transcriptom
taken
winter
symptomat
summer
season
provid
hint
cellular
perturb
enabl
bet
traffic
nasal
epitheli
cell
tissu
thu
applic
discoveri
hypothesi
driven
methodolog
human
nasal
epitheli
tissu
could
provid
new
hypothesi
worth
analysi
underli
molecular
mechan
signific
aspect
topdown
explor
studi
use
whole
genom
largescal
analysi
provid
truli
new
hypothesi
work
would
argu
nasal
epithelium
markedli
differ
healthi
compar
allerg
subject
alreadi
nonsymptomat
winter
session
base
valid
result
mechan
bet
v
pollen
allergen
bind
traffic
epithelium
explor
analys
furthermor
must
note
singl
data
domain
whether
would
microscopi
proteom
transcriptom
etc
would
alon
point
abovedescrib
phenomenon
thu
system
level
understand
complex
pathophysiolog
phenomena
need
possibl
wet
lab
techniqu
combin
comput
scienc
biolog
transform
computerread
format
matern
toler
achiev
pregnanc
transfer
offspr
prevent
asthma
develop
next
gener
tobia
polt
christian
hennig
gesin
hansen
martin
luther
univers
hallewittenberg
depart
pediatr
hall
germani
hanov
medic
school
depart
pediatr
hanov
germani
studi
hypothes
immunolog
toler
acquir
concept
transfer
dam
pup
murin
model
induc
toler
concept
oral
applic
antigen
immun
offspr
toler
dam
antigen
offspr
nabv
dam
develop
asthmalik
phenotyp
airway
hyperreact
inflamm
product
immun
offspr
toler
dam
protect
even
immun
late
month
birth
critic
involv
toler
transfer
allergenspecif
igg
increas
pregnanc
toler
mous
fetu
newborn
fcrn
jj
mice
transport
igg
via
placenta
transfer
toler
offspr
miss
diaplacent
igg
transfer
compens
igg
transfer
via
breast
milk
toler
dam
offspr
crossfost
nabv
mice
inhibit
ifn
produc
memori
b
cell
offspr
abrog
protect
effect
matern
toler
demonstr
crucial
memori
role
maternofet
toler
transfer
data
show
matern
immunolog
memori
signific
persist
impact
immun
respons
offspr
indic
eg
allergi
prevent
strategi
might
effect
one
gener
medit
suggest
allergi
autoimmun
diseas
parisa
karimi
alireza
salekmoghaddam
immunolog
asthma
allergi
research
institut
medicin
tehran
islam
republ
iran
iran
univers
medic
scienc
medicin
tehran
islam
republ
iran
object
aim
present
studi
analyz
effect
medit
program
complet
blood
cell
count
cbc
igg
marker
specif
nonspecif
humor
immun
method
subject
age
year
male
femal
undergo
period
one
month
medit
exclud
experienc
medit
first
time
start
medit
train
volunt
visit
physician
healthi
subject
subject
take
type
drug
regular
life
habit
chosen
clinic
trial
blood
sampl
taken
subject
day
studi
commenc
one
month
later
end
studi
blood
paramet
investig
includ
number
leukocyt
total
leukocyt
monocyt
neutrophil
eosinophil
basophil
lymphocyt
red
cell
count
rbc
hemoglobin
hb
hematocrit
hct
mean
cell
volum
mcv
mean
cell
hemoglobin
mch
mean
cell
hemoglobin
concentr
mchc
red
cell
distribut
width
rdw
platelet
count
well
concentr
immunoglobulin
igg
complement
volunt
exclud
research
plan
sick
period
result
statist
signific
differ
found
first
second
blood
sampl
volunt
show
lower
number
total
leukocyt
eosinophil
number
percentag
monocyt
well
complement
concentr
conclus
find
demonstr
one
month
practic
medit
decreas
immunolog
paramet
accord
result
medit
suggest
hypersensit
allergi
autoimmun
diseas
although
studi
seem
need
key
word
medit
complet
blood
cell
count
cbc
igg
random
doubleblind
placebo
control
trial
effect
zinc
supplement
bronchial
asthma
measur
sputum
eosinophil
count
asthma
control
test
act
children
felix
bernard
cepeda
agn
andaya
univers
santo
toma
section
allergi
asthma
immunolog
manila
philippin
backround
zinc
major
dietari
antioxid
protect
role
airway
epithelium
may
therefor
import
implic
asthma
physic
barrier
vulner
compromis
object
investig
effect
zinc
supplement
bronchial
asthma
measur
sputum
eosinophil
level
asthma
control
test
act
children
methodolog
sixtysix
asthmat
subject
age
rang
year
old
random
receiv
zinc
placebo
sputum
eosinophil
count
check
supplement
week
later
likewis
asthma
control
test
act
score
obtain
supplement
week
week
week
thereaft
result
week
supplement
sputum
eosinophil
count
decreas
group
zinc
group
signific
chang
eosinophil
compar
placebo
respect
howev
act
score
week
week
show
differ
zinc
placebo
group
conclus
dietari
zinc
supplement
significantli
reduc
sputum
eosinophil
count
compar
placebo
howev
declin
sputum
eosinophil
count
associ
improv
asthma
control
zinc
consid
decreas
airway
inflamm
asthma
control
document
rel
efficaci
safeti
profil
salbutamol
deliveri
slow
infus
si
vs
inhal
patient
acut
sever
bronchial
asthma
khan
sameera
ishaq
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
purpos
patient
acut
sever
bronchial
asthma
moribund
posit
art
devis
effect
deliveri
system
may
follow
optim
relief
degre
bronchospam
goal
resolv
immin
urgenc
acut
sever
bronchial
asthma
method
patient
sex
year
histori
acut
sever
bronchial
asthma
includ
studi
group
medic
prednisolon
mg
immedi
follow
mg
day
along
salbutamol
bodi
weight
slow
infus
group
b
medic
prednisolon
group
along
inhal
deliveri
salbutamol
dilut
adult
childhood
bronchial
asthma
respect
therapeut
respons
observ
result
group
b
follow
optim
bronchodil
minut
group
minut
conclus
group
b
therapeut
advantag
vs
eg
optim
bronchodil
rel
shorter
period
hazard
parent
administr
simpl
techniqu
deliveri
manag
even
one
preval
asthma
increas
worldwid
sinc
incid
asthma
high
among
children
howev
rel
high
annual
incid
also
estim
adult
studi
risk
factor
mainli
analyz
crosssect
design
data
base
preval
case
asthma
studi
may
determin
either
caus
consequ
incid
studi
mostli
focus
occup
asthma
smoke
habit
sinc
late
obes
report
associ
asthma
increas
preval
obes
report
along
parallel
increas
asthma
preval
howev
convinc
relationship
asthma
obes
establish
accordingli
studi
carri
aim
demonstr
effect
weight
reduct
clinic
function
serolog
paramet
obes
asthmat
studi
obes
asthmat
patient
show
mark
improv
clinic
function
mark
decreas
number
exacerb
medic
use
feasibl
applic
secondari
prevent
asthma
allergi
practic
mahesh
padukudru
anand
amrutha
holla
devida
ak
prabhakar
biliger
jayaraj
cp
chathura
rao
b
chaitra
pudupakkam
k
vedanthan
jss
medic
colleg
depart
pulmonari
medicin
mysor
india
allergi
asthma
chest
center
depart
allergi
mysor
india
univers
colorado
health
scienc
depart
allergi
colorado
unit
state
background
possibl
secondari
prevent
asthma
highlight
prevent
asthma
studi
demonstr
immunotherapi
patient
allerg
rhiniti
could
prevent
asthma
patient
feasibl
secondari
prevent
asthma
proport
patient
like
benefit
need
demonstr
immunotherapi
requir
time
exert
benefici
effect
methodolog
patient
underw
detail
evalu
includ
allergi
test
period
includ
studi
structur
questionnair
appli
collect
data
demographi
detail
clinic
histori
durat
asthma
allerg
rhiniti
proport
patient
whose
rhiniti
preced
asthma
time
interv
develop
rhiniti
asthma
result
total
case
includ
studi
patient
allerg
rhiniti
vari
interv
develop
asthma
patient
continu
rhiniti
year
without
develop
asthma
patient
asthma
without
rhiniti
patient
develop
asthma
develop
rhiniti
develop
asthma
within
year
develop
rhiniti
develop
asthma
within
month
month
patient
develop
asthma
year
onset
rhiniti
frequenc
gradual
decreas
increas
durat
rhiniti
conclus
major
patient
rhiniti
develop
asthma
nearli
patient
preced
rhiniti
develop
asthma
within
one
year
may
amen
secondari
prevent
immunotherapi
due
delay
referr
allergist
time
requir
obtain
necessari
benefit
immunotherapi
patient
develop
asthma
alon
develop
rhiniti
onset
asthma
candid
secondari
prevent
total
case
studi
less
undergo
intervent
target
toward
secondari
prevent
asthma
intens
educ
famili
physician
ent
specialist
need
ensur
prompt
referr
allergist
help
patient
aim
assess
relationship
act
differ
marker
airway
inflamm
asthmat
subject
method
crossov
design
studi
patient
suffer
mild
moder
asthma
median
age
iqr
fifti
five
percent
treat
short
beta
agonist
demand
visit
patient
fullfil
act
questionnair
exhal
nitric
oxid
eno
niox
mini
measur
bronchial
challeng
hyperton
salin
sputum
induct
perform
result
whole
sampl
act
modestli
correl
eno
r
pg
eosinophil
induc
sputum
pg
slope
hyperton
salin
bronchial
challeng
r
pg
patient
good
control
act
significantli
lower
level
eno
vs
ppb
eosinophil
vs
pg
correl
variabl
improv
patient
treat
beta
agonist
demand
includ
eno
pg
eosinophil
induc
sputum
p
slope
hyperton
salin
bronchial
challeng
r
pg
act
correl
conclus
asthma
control
assess
asthma
control
test
correl
direct
indirect
marker
airway
inflamm
act
pulmonari
function
variabl
correl
salbutamol
metereddos
inhal
effect
nebulis
manag
acut
asthma
exacerb
hospit
children
accord
asthma
pathway
ann
goh
oh
moh
chay
jenni
tang
ling
ho
oon
hoe
teoh
kee
chong
ng
kk
women
children
hospit
depart
paediatr
medicin
singapor
singapor
kk
women
children
hospit
children
emerg
singapor
singapor
background
acut
asthma
exacerb
tradit
manag
nebulis
bronchodil
emerg
room
well
inpati
singapor
hit
sar
fear
use
nebulis
could
caus
spread
viru
prompt
develop
asthma
pathway
use
mdi
aim
compar
length
stay
children
admit
asthma
exacerb
introduct
asthma
pathway
manag
acut
exacerb
salbutamol
metereddos
inhal
mdi
instead
nebulis
method
children
present
children
emerg
admit
ward
asthma
exacerb
manag
accord
asthma
pathway
result
increas
admiss
emerg
depart
high
depend
intens
care
implement
asthma
pathway
use
salbutamol
mdi
instead
nebulis
averag
length
stay
decreas
high
day
preimplement
pathway
low
day
postimplement
averag
cost
per
patient
decreas
post
pathway
implement
conclus
asthma
pathway
shown
use
salbutamol
mdi
effect
nebulis
manag
acut
asthma
exacerb
led
decreas
averag
length
hospitalis
well
decreas
cost
per
patient
pierangela
massacan
anthi
rogkak
laura
guerra
enrico
compalati
antonio
scordamaglia
giorgio
walter
canonica
univers
genoa
allergi
respiratori
diseas
genoa
itali
case
report
asiat
man
admit
emerg
room
hospit
fever
wheez
dyspnea
arthralgia
past
histori
remark
allergi
rhiniti
recurr
episod
asthma
sinc
arriv
itali
age
patient
treat
cours
system
corticosteroid
daili
prednisolon
theophyllin
inhal
budesonid
formoterol
mcg
twice
day
montelukast
mg
chest
radiograph
full
blood
count
includ
eosinophil
count
normal
spirometr
test
show
fvc
pef
lmin
one
month
later
seen
outpati
depart
note
gener
unwel
wheezi
day
visit
notic
comparison
hemoptysi
chest
radiograph
full
blood
count
includ
eosinophil
count
normal
antinuclear
antibodi
antineuthrophil
cytoplasm
antibodi
anca
neg
sputum
cultur
urin
microscopi
unremark
aspergillu
precipitin
radioallergosorb
test
rast
aspergillu
neg
cultur
mycobacteria
neg
electrocardiogram
echocardiogram
normal
comput
tomographi
paranas
sinus
dimostr
neartot
opac
materi
soft
part
normal
sinu
right
sphenoid
sinu
well
ethmoid
cell
right
maxillari
sinu
nasal
caviti
thorax
comput
tomografi
reveal
gener
enlarg
mediastin
lymph
node
treatment
montelukast
stop
high
dose
oral
prednisolon
commenc
patient
elect
discontinu
inhal
treatment
three
month
later
symptom
asthma
return
chestxray
show
patchi
bilater
infiltr
lung
mark
hypereosinophilia
elev
serum
ige
level
iuml
antineuthrophil
cytoplasm
antibodi
anca
posit
spirometr
test
show
fvc
pef
lmin
requir
short
cours
oral
coricosteroid
symptom
remain
troublesom
treatment
chang
cyclosporin
mg
kg
condit
show
mark
clinic
well
radiolog
improv
discuss
must
care
diagnos
treat
patient
middleag
onset
sever
asthma
symptom
may
lung
manifest
css
variou
organ
involv
result
system
necrot
vascul
educ
cours
improv
asthma
manag
treatment
angelko
gjorcev
zlatica
goseva
marija
zdraveska
deska
dimitrievska
dejan
todevski
clinic
pulmolog
allergi
asthma
depart
skopj
macedonia
fyrom
background
educ
patient
one
first
goal
asthma
manag
intern
treatment
protocol
made
studi
order
estim
need
effect
educ
program
prepar
macedonian
asthma
center
method
studi
asthmat
prepar
pilot
educ
cours
cover
import
hot
subject
concern
asthma
follow
guidelin
global
strategi
asthma
manag
prevent
may
questionnair
question
treat
problem
concern
treatment
problem
asthma
manag
question
group
part
gener
knowledg
asthma
medic
necess
adequ
continu
antiinflammatori
treatment
ii
accent
emerg
intervent
action
acut
exacerb
questionnair
complet
patient
attend
educ
cours
result
visit
cours
answer
correctli
questionnair
correct
answer
part
part
ii
result
impli
test
asthmat
popul
realiz
need
prevent
medic
would
fact
take
wrong
medic
worsen
diseas
visit
educ
cours
result
follow
overal
correct
answer
nonsignificantn
result
part
show
ns
patient
gave
correct
answer
signific
answer
ii
part
correctli
conclus
conclud
patient
willingli
accept
advic
emerg
self
manag
acut
asthma
exacerb
difficult
overcom
fear
prevent
treatment
chang
dogmat
opinion
therapeut
issu
asthma
manag
studi
show
necess
organ
continu
asthma
educ
program
level
health
care
clinic
evalu
sever
asthma
attack
requir
tracheal
intub
respir
manag
kiyoshi
sekiya
masami
taniguchi
keishi
sugino
hidenori
tanimoto
yuuma
fukutomi
emiko
ono
chiyako
oshikata
takako
hojyo
kazuo
akiyama
saka
honma
nation
hospit
organ
sagamihara
nation
hospit
clinic
research
center
allergi
kanagawa
japan
toho
univers
medic
center
depart
respiratori
medicin
tokyo
japan
background
recent
number
patient
requir
hospit
asthma
attack
decreas
howev
still
patient
requir
hospit
tracheal
intub
respir
manag
sever
asthma
attack
therefor
evalu
background
featur
asthmat
patient
requir
tracheal
intub
respir
manag
hospit
method
evalu
asthmat
patient
visit
hospit
januari
decemb
requir
tracheal
intub
respir
manag
patient
sever
exacerb
asthma
determin
basi
guidelin
global
initi
asthma
gina
requir
tracheal
intub
respir
manag
evalu
histori
smoke
day
asthma
attack
onset
visit
hospit
level
asthma
control
determin
gina
guidelin
treatment
taken
patient
visit
hospit
frequenc
visit
hospit
reason
tracheal
intub
respir
manag
base
asthma
prevent
manag
japanes
guidelin
prognosi
result
patient
requir
tracheal
intub
respir
manag
follow
smoker
patient
take
irregularli
take
treatment
patient
use
inhal
shortact
agonist
time
asthma
attack
patient
use
inhal
glucocorticosteroid
reason
tracheal
intub
respir
manag
follow
less
despit
maximum
oxygen
administr
patient
sudden
increas
lead
unconsci
less
despit
maximum
oxygen
administr
sudden
increas
lead
unconsci
sever
ventilatori
cardiorespiratori
disturb
conclus
observ
thorough
educ
patient
treatment
mainli
use
inhal
glucocorticosteroid
import
prevent
sever
asthma
attack
requir
tracheal
intub
respir
manag
assess
qualiti
life
caregiv
asthmat
children
shima
sayanjali
fariborz
zandieh
tehran
univers
medic
scienc
asthma
allergi
immunolog
tehran
islam
republ
iran
background
interest
impact
ill
day
day
function
lead
investig
includ
diseas
specif
gener
health
relat
qualiti
life
hr
qol
questionnair
broad
rang
clinic
studi
gain
full
pictur
impact
asthma
live
caregiv
asthmat
children
necessari
make
direct
measur
health
relat
qualiti
life
method
respons
need
use
junip
pediatr
asthma
caregiv
qualiti
life
questionnair
pacqlq
develop
base
guidelin
construct
dozen
valid
diseas
specif
qualiti
life
instrumentsth
pacqlq
contain
item
two
domain
emot
activ
disturb
studi
design
consist
month
singl
cohort
studi
patient
particip
studi
children
year
age
wide
rang
asthma
sever
caregiv
caregiv
pacqlq
complet
one
week
visit
patient
record
morn
peak
flow
rate
medic
use
symptom
diari
complet
physic
examin
determin
asthma
sever
spirometri
perform
result
questionnair
static
analysi
show
good
level
longitudin
cross
section
correl
convent
asthma
indic
gener
qualiti
life
conclus
found
good
relev
sever
asthma
qol
score
disturb
qol
caregiv
male
asthmat
patient
caregiv
femal
asthmat
patient
bronchial
asthma
chronic
devast
diseas
affect
life
style
patient
also
caregiv
increment
knowledg
disturb
help
physician
better
understand
burden
patient
unifi
treatment
school
children
allerg
rhiniti
asthma
jelena
moskovljev
emerg
center
immunolog
ni
serbia
montenegro
aim
verifi
efficaci
beclomethason
dipropion
bdp
administ
nasal
inhal
simultan
treatment
asthma
allerg
rhiniti
ar
method
patient
asthma
ar
age
year
randomli
alloc
eight
week
receiv
bdpcfc
least
mcgday
inhal
exclus
nose
mouth
close
use
largevolum
ml
spacer
attach
facemask
control
group
subject
receiv
convent
treatment
ie
bdp
dual
administr
aqueou
intranas
oral
inhal
mouthpiec
spacer
devic
everi
two
week
clinic
score
ar
peak
expiratori
flow
pef
assess
independ
observ
spirometri
perform
admiss
end
follow
minimum
decreas
clinic
score
consid
therapeut
success
result
therapeut
success
rate
experiment
group
control
group
pef
statist
differ
two
group
neither
admiss
end
treatment
p
conclus
result
suggest
altern
treatment
could
recommend
simultan
treatment
ar
asthma
special
develop
world
advantag
higher
complianc
lower
cost
fewer
side
effect
influenc
topic
intranas
steroid
improv
ventil
capabl
lung
patient
bronchial
asthma
tair
nurpeissov
rimma
akpeissova
bibigul
ilyasova
institut
intern
diseas
republican
allergolog
center
almati
kazakhstan
background
treatment
bronchial
asthma
ba
often
conduct
without
allow
concomit
allerg
rhiniti
ar
reason
unsuccess
result
achiev
maxim
therapeut
effect
research
interact
ba
ar
conduct
republican
allerg
center
scientif
research
institut
cardiolog
intern
diseas
ministri
public
health
republ
kazakhstan
aim
determin
degre
influenc
allerg
inflamm
upper
respiratori
tract
ventil
capabl
lung
patient
bronchial
asthma
materi
method
thirti
patient
sever
ba
concomit
ar
prescrib
intranas
mometazon
spray
dose
microgram
two
time
day
one
month
treatment
follow
two
week
cours
standard
hospit
therapi
includ
steroid
intraven
inhal
etc
age
patient
rang
year
old
therapi
effect
control
clinic
laboratori
method
spirographi
daili
pickflowmetri
determin
resist
bronchial
tree
rhinomanometri
identif
ecp
result
patient
end
first
month
treatment
mention
stabl
improv
nasal
breath
sleep
recoveri
also
valid
reduct
resist
nasal
apertur
discov
major
patient
improv
clinic
pictur
ba
confin
less
amount
asthma
attack
also
improv
function
laboratori
measur
pef
growth
decreas
variabl
reduct
resist
bronhial
tree
normal
ecp
conclus
conduct
research
prove
valid
increas
effect
support
therapi
ba
combin
activ
treatment
ar
becom
appar
besid
clinic
improv
addit
growth
measur
ventil
capabl
lung
level
resist
bronchial
tree
nasal
apertur
normal
ecp
content
cardiff
unit
kingdom
univers
wale
institut
cardiff
statist
cardiff
unit
kingdom
audit
secondari
care
offer
acut
asthmat
patient
admit
hospit
wale
uk
februari
audit
analys
referr
sourc
care
deliv
ambul
servic
emerg
unit
medic
admiss
unit
inpati
unit
case
asthma
age
year
greater
data
extract
qualifi
medic
personnel
result
show
patient
admit
month
patient
exclud
asthma
acut
severesever
moder
mild
sever
document
ambul
transfer
use
case
patient
call
ambul
directli
overal
ambul
staff
measur
vital
sign
well
peak
flow
pfr
measur
case
patient
receiv
nebulis
bronchodilatorshigh
flow
oxygen
transfer
process
steroid
use
rare
observ
repeat
case
emerg
unit
primari
site
acut
care
pfr
measur
case
compar
oxygen
satur
measur
case
record
steroid
administr
reassess
admit
specialist
care
treat
specialist
respiratori
ward
overal
discharg
plan
emerg
inpati
unit
disappoint
inpati
written
manag
plan
patient
discharg
directli
emerg
unit
offer
review
secondari
care
acut
asthma
wale
confirm
nation
guidelin
accept
level
care
chunmei
zhu
yuzhi
chen
capit
institut
pediatr
asthma
clinic
educ
center
beij
china
object
investig
approach
monitor
treatment
pediatrician
gener
physician
childhood
asthma
china
method
standard
questionnair
survey
construc
apapari
monitor
treat
childhood
asthma
send
physician
provinc
citi
china
result
questionnair
receiv
complet
doctor
gener
pediatrician
pediatr
pulmonologist
pediatr
allergist
adult
pulmonologist
allergist
also
treatment
children
other
nonspecifi
work
place
tertiari
hospit
secondari
hospit
work
first
grade
hospitalmost
doctor
use
peak
flow
meter
spirometri
monitor
childhood
asthma
use
diari
card
treat
acut
asthma
exacerb
first
choic
treatment
nebul
salbutamolterbutalin
everi
min
second
choic
salbutamol
inhal
spacer
third
choic
system
corticosteroid
pediatr
pulmonologist
pulmonologist
tend
use
ic
acut
asthma
frequent
use
system
corticosteroid
acut
asthma
treatment
dexamethason
methylprednisolon
hydrocortison
criteria
appli
doctor
start
mainten
therapi
asthmat
children
frequenc
symptom
sever
symptom
whether
sever
disturb
lung
function
test
select
drug
doctor
tend
choos
ic
gener
first
choic
drug
use
mainten
treatment
asthma
young
children
ic
second
montelukast
third
ic
oral
laba
slow
releas
sulbutamol
preschool
school
children
first
choic
laba
ic
second
ic
third
montelukast
moder
sever
asthma
first
choic
ic
laba
awar
recognit
childhood
asthma
use
peak
flow
meter
implement
gina
guidelin
use
ic
improv
among
doctor
citi
china
nevertheless
dissemin
gina
program
among
nonspecialist
doctor
countri
commun
must
continu
reenforc
impact
patient
educ
knowledg
attitud
practic
selfefficaci
patient
asthma
india
mahesh
padukudru
anand
sabin
thoma
parthasarathi
gurumurthi
jss
medic
colleg
depart
pulmonari
medicin
mysor
india
jss
colleg
pharmaci
depart
clinic
pharmaci
mysor
india
background
patient
relat
factor
like
poor
knowledg
individu
belief
attitud
patient
influenc
control
asthma
lead
nonadher
studi
conduct
develop
valid
kaps
questionnair
indian
popul
assess
knowledg
attitud
practic
selfefficaci
kaps
patient
mysor
regard
asthma
impact
patient
educ
kaps
patient
methodolog
total
adult
patient
particip
kaps
studi
part
studi
compar
efficaci
qualiti
life
patient
receiv
beclomethason
budesonid
fluticason
questionnair
item
select
knowledg
attitud
selfefficaci
kase
valid
instrument
asthma
suitabl
modifi
suit
cultur
educ
level
popul
two
medic
expert
perform
content
valid
item
content
valid
index
retain
cognit
debrief
patient
confirm
suitabl
accept
questionnair
patient
counsel
individu
group
inform
leaflet
patholog
asthma
drug
deliveri
system
conduct
everi
visit
occas
month
kaps
assess
baselin
educ
end
studi
result
patient
educ
significantli
improv
question
assess
knowledg
attitud
practic
selfefficaci
compar
baselin
subgroup
analysi
reveal
kaps
baselin
influenc
age
gender
durat
diseas
relat
educ
level
area
resid
follow
patient
educ
kaps
patient
improv
significantli
p
differ
patient
differ
area
resid
conclus
studi
demonstr
regular
patient
educ
significantli
improv
differ
aspect
knowledg
attitud
practic
selfefficaci
patient
regardless
age
gender
educ
place
resid
could
posit
influenc
patient
medic
adher
asthma
curabl
diseas
sivanandhan
kasimalliah
sri
ragavendra
clinic
paediatr
pollachi
india
background
normal
individu
serum
histamin
bind
capac
shbc
wherea
allerg
patient
shbc
rais
histaglobulin
hg
given
prepar
patient
properli
drug
like
mast
cell
stabilis
bronchodil
antihistamin
antiinflammatori
drug
given
along
hg
therapi
allerg
patient
serum
ige
level
high
come
hg
therapi
medicin
patient
becom
symptom
free
cure
method
observ
studi
year
patient
regist
differ
period
outpati
consist
agegroup
sex
urban
rural
area
immunoglobulin
e
ige
level
estim
routin
test
done
start
treatment
patient
prepar
hg
therapi
hg
given
two
phase
phase
primari
dose
phase
ii
booster
dose
along
hg
therapi
drug
like
mastcel
stabilis
receptorspecif
histamin
antagonist
loratadin
rupatadin
cromolyn
etc
bronchodil
theophyllin
antihistamin
cetirizin
levocetirizin
antiinflammatori
drug
monteleukast
given
month
booster
dose
ige
level
estim
patient
patient
examin
period
assess
clinic
improv
result
patient
patient
free
asthma
allerg
rhiniti
symptom
among
patient
free
year
patient
respond
satisfactorili
patient
patient
show
reduct
ige
level
clinic
free
asthma
patient
show
rais
ige
level
correspondingli
clinic
improv
also
found
allerg
manifest
lowest
year
age
yr
increas
male
affect
occurr
rate
came
age
group
yr
sex
occurr
rate
rais
femal
affect
conclus
thu
studi
compris
patient
complaint
allerg
asthma
without
allerg
rhiniti
hg
therapi
given
prepar
patient
continu
abovement
drug
hg
therapi
found
effect
cure
allerg
asthma
hg
effect
rais
shbc
therebi
improv
immun
patient
also
reduc
serum
ige
level
flavonoid
relat
compound
antiallerg
substanc
toshio
tanaka
toru
hirano
mari
kawai
shinji
higa
junsuk
arimitsu
yusuk
kuwahara
tomoharu
ohkawara
kaori
nakanishi
keisuk
hagihara
yoshihito
shima
atsushi
ogata
ichiro
kawas
osaka
univers
medic
school
respiratori
med
allergi
rheumat
diseas
suita
citi
osaka
japan
tondabayashi
hospit
intern
medicin
tondabayashi
citi
osaka
japan
preval
allerg
diseas
increas
world
last
two
decad
dietari
chang
consid
one
environment
factor
caus
increas
worsen
allerg
symptom
case
appropri
intak
food
beverag
antiallerg
activ
expect
prevent
onset
allerg
diseas
amelior
allerg
symptom
flavonoid
ubiquit
present
veget
fruit
tea
possess
antiallerg
activ
flavonoid
inhibit
histamin
releas
synthesi
ligand
express
basophil
analys
structureact
relationship
flavon
flavonol
relat
compound
show
luteolin
ayanin
apigenin
fisetin
strongest
inhibitor
product
valu
mm
determin
fundament
structur
inhibitori
activ
inhibitori
activ
flavonoid
ligand
express
possibl
mediat
inhibitori
action
activ
nuclear
factor
activ
cell
administr
flavonoid
atop
dermatitispron
mice
show
prevent
amelior
effect
recent
epidemiolog
studi
report
low
incid
asthma
significantli
observ
popul
high
intak
flavonoid
thu
evid
help
develop
low
molecular
compound
allerg
diseas
expect
dietari
menu
includ
appropri
intak
flavonoid
may
provid
form
complementari
altern
medicin
prevent
strategi
allerg
diseas
clinic
studi
verifi
point
progress
present
result
congress
sublingu
progesteron
dilut
bronchodil
asthmat
femal
background
asthma
associ
hormon
increas
asthma
symptom
associ
menstrual
varianc
premenstru
asthma
note
literatur
studi
earli
suggest
allerg
reaction
hormon
bronchial
asthma
femal
patient
could
due
allergi
selfhormon
particularli
progesteron
interestingli
progesteron
also
potent
respiratori
stimul
present
studi
aim
evalu
efficaci
sublingu
progesteron
dilut
bronchodil
method
studi
approv
ethic
committe
austin
texa
sixteen
femal
previou
diagnosi
sever
asthma
nebul
depend
select
studi
obtain
written
inform
consent
patient
spirometr
studi
perform
subject
use
sublingu
progesteron
bronchodil
analyz
chang
time
forc
expiratori
volum
one
second
fev
forc
vital
capac
fvc
peak
expiratori
flow
pef
patient
measur
lung
function
three
time
treatment
sublingu
normal
salin
treatment
sublingu
progesteron
treatment
result
treatment
sublingu
progesteron
twelv
sixteen
patient
experienc
signific
bronchodil
effect
greater
increas
either
fev
fvc
eight
experienc
signific
increas
fev
fvc
eight
increas
greater
pef
conclus
progesteron
dilut
candid
drug
treatment
bronchial
asthma
possibl
dilut
progesteron
act
progesteron
antagonist
bronchial
smooth
muscl
may
sensit
dilut
progesteron
due
activ
largininenitr
oxid
pathway
interest
close
relationship
immun
neuroendocrin
system
studi
might
import
implic
develop
novel
safe
noninvas
treatment
strategi
bronchial
asthma
due
hormon
allergi
random
doubleblind
placebo
control
trial
effect
zinc
supplement
bronchial
asthma
measur
sputum
eosinophil
level
asthma
control
test
act
children
age
yo
kristin
mari
gutierrez
world
citi
medic
center
pediatr
quezon
citi
philippin
zinc
may
role
bronchial
asthma
regul
airway
inflamm
subsequ
prevent
asthma
exacerb
object
determin
effect
zinc
supplement
bronchial
asthma
measur
sputum
eosinophil
level
asthma
control
test
act
children
age
yo
method
consent
obtain
children
local
commun
age
year
old
diagnos
intermitt
mildmoder
persist
asthma
randomli
alloc
receiv
zinc
supplement
mgday
placebo
thirti
day
chang
sputum
eosinophil
level
act
score
obtain
intervent
result
fifteen
subject
includ
zinc
group
subject
placebo
group
differ
demograph
profil
two
group
term
age
sever
asthma
atopi
use
mainten
medic
infect
studi
period
intragroup
statist
show
statist
signific
zinc
group
sputum
eosinophil
act
score
placebo
group
show
statist
signific
sputum
eosinophil
statist
signific
act
score
mean
differ
sputum
eosinophil
zinc
placebo
show
signific
differ
two
group
mean
chang
act
score
zinc
placebo
group
show
signific
differ
group
conclus
supplement
zinc
sulfat
improv
bronchial
asthma
term
act
score
sputum
eosinophil
count
children
age
year
old
applic
small
dose
human
recombin
interferon
oromucos
patient
season
atopi
bronchial
asthma
allerg
rhinoconjunct
veronica
osipova
seda
grigorian
alexandr
g
chuchalin
immuneyenzym
method
commerci
test
system
immuno
cap
pharmaci
sweden
use
determin
ecp
result
analisi
journal
patient
show
comparison
three
previou
year
intens
stuffi
nose
rhinorrea
owe
prevent
therapi
authent
lower
comparison
group
control
group
control
necess
authent
two
time
lower
analyz
group
patient
group
control
analyz
group
day
control
group
day
level
ecp
medic
treatment
higher
analyz
group
mkgl
norm
till
mkgl
control
group
mkgl
medic
treatment
level
ecp
authent
becam
lower
analyz
group
mkgl
howev
season
blossom
tree
unauthent
increas
registr
till
mkgl
level
ecp
control
group
unauthent
increas
medic
treatment
till
mkgl
howev
level
ecp
group
authent
increas
season
blossom
tree
till
mkgl
conclus
assert
prevent
usag
small
dose
guarante
posit
clinic
effect
pollinosi
bronchial
asthma
allerg
rhinoconjunct
provid
lower
level
ecp
therefor
decreas
inflamm
process
windpip
recommend
modern
medicin
prevent
theraphi
patient
season
atopi
polyprenol
possibl
supplement
treatment
steroid
resist
patient
asthma
galina
kuznecova
ines
joksta
klara
jegina
prevent
medicin
research
laboratori
allergi
unit
riga
latvia
background
plant
polyprenol
pp
approv
substitut
dolichyl
phosphat
dp
decreas
pglycoprotein
enhanc
synthesi
alpha
gp
isoform
express
vitro
proof
previou
studi
effect
oral
administr
pp
investig
steroid
resist
asthma
sra
patient
method
sampl
obtain
patient
asthma
patient
sra
patient
steroid
sensit
astma
ssa
donor
patient
forc
expiratori
volum
one
second
forc
vital
capac
fvc
measur
microspiromet
follow
recommend
procedur
standard
pulmonari
function
measur
patient
forc
expiratori
volum
g
predict
studi
ssa
patient
increas
cours
oral
prednison
mg
twice
daili
sra
fail
increas
dolichol
dol
blood
urin
assay
hplc
method
dolichyl
phosphat
alphaand
betagr
isoform
express
measur
tcell
result
blood
dol
concentr
person
ssa
ngml
urinari
dol
concentr
mgmmol
blood
dol
patient
sra
increas
six
time
make
ngml
urinari
dol
concentr
increas
make
mgmmol
normal
level
dol
donor
mgmmol
urin
ngml
blood
synthesi
dolp
decreas
tlymphocyt
patient
sra
day
cours
pp
mg
supplement
sra
patient
return
dolp
concentr
blood
urin
tcell
normal
level
sra
patient
demonstr
significantli
increas
fev
cours
oral
prednison
mg
twice
daili
mg
pp
conclus
dolichyl
posphat
cycl
dpc
disord
rate
limit
mechan
steroid
resist
asthma
associ
mark
defect
glucocorticoid
receptor
gr
nglycosyl
tcell
present
find
provid
evid
pp
supplement
patient
sra
enhanc
express
alpha
gp
isoform
restor
possibl
induc
synthesi
made
tcell
respons
steroid
plant
polyprenol
prednison
increas
fev
fvc
sra
patient
preliminari
result
may
import
implic
design
altern
treatment
approach
steroid
resist
asthma
uncontrol
sever
asthmat
patient
clearli
improv
antiig
omalizumab
treatment
case
report
beatriz
huerta
miguel
hinojosa
jesu
gonzalezcervera
belen
de
la
hoz
luz
diezgomez
mois
sanchezcano
adalberto
pacheco
cajal
hospit
allergolog
madrid
spain
ramon
cajal
hospit
pneumolog
madrid
spain
background
antiig
monoclon
antibodi
omalizumab
recent
introduc
treatment
bronchial
asthma
last
octob
emea
author
drug
european
union
allerg
sever
asthmat
patient
addon
therapi
experi
patienttreat
report
method
patient
femal
male
studi
age
averag
year
suffer
sever
allerg
asthma
step
v
present
gina
guidelin
last
yr
averag
yr
posit
skin
prick
test
andor
specif
ige
antibodi
varieti
common
aeroallergen
observ
patient
ige
sera
level
rang
iuml
overag
iuml
predict
patient
overag
predict
patient
treatment
high
dose
inhal
corticosteroid
long
act
inhal
betaagonist
leukotrien
modifi
eleven
also
treatment
oral
corticosteroid
prednison
rang
mg
omalizumab
mg
per
month
subcutan
administr
patient
twice
monthli
depend
ige
level
bodi
weight
everi
month
onset
treatment
follow
paramet
evalu
asthma
qualiti
life
questionnair
aqlq
e
junip
asthma
control
questionnair
acq
e
junip
physician
overal
assess
possibl
side
effect
patient
follow
two
ten
month
result
mark
improv
aqlq
acq
could
observ
patient
physician
overal
assess
also
improv
patient
improv
moder
remain
patient
respons
treatment
appreci
first
two
month
patient
also
improv
patient
rang
predict
one
patient
develop
mark
edema
leg
wk
anoth
acut
otalgia
erythema
nodosum
leg
wk
treatment
patient
withdrew
omalizumab
treatment
oral
corticosteroid
withdrawn
two
patient
low
four
conclus
omalizumab
treatment
prove
effect
patient
uncontrol
sever
allerg
asthma
total
control
shown
half
patient
enough
control
got
remain
patient
exacerb
observ
patient
omalizumab
treatment
advers
reaction
possibl
sure
relat
omalizumab
shown
two
patient
efficaci
budesonideformoterol
treatment
children
moderatesever
asthma
lina
chen
yuzhi
chen
chunmei
zhu
shuo
li
west
china
women
children
hospit
sichuan
univers
pediatr
chengdu
china
capit
institut
pediatr
asthma
clinic
educ
center
beij
china
background
previou
survey
indic
chines
pediatrician
tend
choos
iv
corticosteroid
treat
moderatesever
childhood
asthma
gina
recommend
combin
inhal
corticosteroid
ic
longact
agonist
laba
treatment
persist
asthma
order
evalu
one
combin
product
budesonideformoterol
treatment
moderatesever
childhood
asthma
investig
efficaci
safeti
method
studi
children
moderatesever
asthma
male
femal
mean
age
receiv
system
corticosteroid
week
prior
studi
laba
saba
week
studi
given
nebul
budesonid
suspens
salbutamol
plu
ipratropium
bromid
reliev
acut
exacerb
clinic
given
budesonideformoterol
one
inhal
morn
two
even
week
one
inhal
twice
daili
afterward
till
end
week
oral
prednison
day
slow
releas
salbutamol
day
prescrib
sever
asthmat
children
lung
function
symptom
improv
advers
effect
mornitor
inhal
therapi
result
lung
function
variabl
fvc
fvc
pef
pef
mmef
mmef
statist
improv
week
month
post
treatment
mean
time
relief
day
inhal
therapi
children
gain
complet
asthma
control
week
children
gain
complet
control
week
week
week
post
treatment
child
emerg
treatment
shortact
agonist
inhal
period
side
effect
hoars
pharyng
discomfort
observ
conclus
budesonideformoterol
effect
safe
treatment
option
children
moderatesever
asthma
treatment
regimen
may
reduc
intraven
infus
simplifi
therapi
improv
patient
adher
treatment
abstract
withdrawn
therapi
chronic
airway
diseas
nucleic
acid
stefani
thiel
andrea
pahl
univers
erlangen
depart
pharmacolog
erlangen
germani
background
rna
interfer
rnai
hold
consider
promis
therapeut
approach
silenc
gene
involv
inflammatori
pathway
report
intranas
administr
small
interf
rna
sirna
abl
downregul
protein
express
aim
project
develop
nucleic
acid
base
therapi
asthma
chronic
airway
diseas
method
differ
knockdown
strategi
evalu
vitro
variou
cell
line
transfect
sirna
short
hairpin
rna
shrna
use
differ
transfect
reagent
furthermor
optim
rout
applic
vivo
investig
intranas
administr
intratrach
administr
rnai
agent
investig
studi
constitut
gfpexpress
transgen
mice
use
allow
monitor
cell
specif
knockdown
effect
final
gene
relev
chronic
airway
diseas
knock
vivo
result
comparison
transfect
reagent
cation
lipid
show
highest
transfect
effici
along
lowest
toxic
vitro
well
vivo
use
reagent
vivo
uptak
shrna
lung
cell
could
detect
comparison
downregul
gfp
cultur
lung
cell
transgen
gfpmice
analys
sirna
direct
gfp
silenc
gfp
express
conclus
cation
lipid
transfect
reagent
suitabl
rnai
vitro
vivo
lung
cell
amen
rnai
agent
shown
intranas
applic
shrna
vector
effect
immunotherapi
issodn
allergen
anim
model
mugwort
allergi
junwoo
kim
bin
zhou
univers
tennesse
depart
medicin
memphi
unit
state
background
despit
number
effect
pharmacolog
option
prevent
treatment
pathophysiolog
respons
occur
sensit
patient
allergen
exposur
termin
allerg
hypersensit
remain
elus
therapeut
goal
specif
immunotherapi
sit
allergen
extract
allergi
cure
howev
limit
scope
efficaci
immunostimulatori
sequenc
oligodeoxynucleotid
issodn
known
provid
potent
allergenindepend
immun
redirect
object
investig
anim
model
mugwort
allergi
allerg
inflamm
control
issodn
mechan
immun
redirect
also
investig
issodn
allergen
model
potenti
sit
could
better
antiallergi
effect
allerg
inflamm
induc
specif
allergen
issond
alon
method
experi
perform
four
group
mice
design
develop
mugwort
allergi
sensit
aerosol
challeng
mugwort
extract
group
receiv
mg
issodn
mg
mugwort
allergen
therapeut
group
group
issodn
bovin
serum
albumin
group
codn
control
odn
mugwort
allergen
group
issodn
alon
cytokin
profil
ifn
degre
inflamm
lung
histolog
differenti
count
bronchoalveolar
lavag
cell
measur
result
signific
decreas
allerg
inflamm
lung
observ
issodn
allergn
group
issodn
alon
group
compar
neg
control
group
ifn
significantli
increas
issodn
allergen
group
issodn
alon
group
compar
control
group
conclus
allerg
inflamm
control
issodn
allergen
could
new
treatment
human
allerg
diseas
estrogen
exert
protect
effect
murin
model
asthma
method
mous
model
asthma
establish
sensit
challeng
femal
balbc
mice
ovalbumin
ova
addit
mice
given
intranas
induc
asthmalik
diseas
includ
airway
inflamm
airway
hyperrespons
vivo
studi
effect
treatment
methacholin
mch
induc
bronchoconstrict
analyz
use
buxco
system
airway
respons
record
penh
valu
increas
bronchoconstrict
reflect
increas
penh
valu
penh
express
mean
sem
vitro
studi
lung
ovasensit
femal
balbc
mice
section
mount
perfus
chamber
observ
microscop
imag
select
airway
captur
preand
posttreat
acetylcholin
ach
result
vivo
mchinduc
penh
ovasensit
mice
treatment
group
mice
treat
nm
prior
mch
challeng
penh
lower
ovasensit
mice
pretreat
pb
hand
display
chang
penh
preliminari
studi
also
suppress
airway
respons
mice
penh
versu
control
mice
respect
vitro
achinduc
airway
contract
lumen
area
measur
ach
compar
baselin
revers
treat
pretreat
airway
pretreat
block
achinduc
contract
lumen
area
measur
ach
compar
baselin
conclus
data
suggest
estradiol
inhibit
prevent
ahr
associ
antigen
murin
model
asthma
thu
estrogen
analogu
might
play
therapeut
role
manag
asthma
allergen
rhinoviru
infect
among
common
elicitor
asthma
sever
disabl
diseas
affect
million
peopl
worldwid
report
construct
recombin
combin
vaccin
allergenand
rhinovirusinduc
asthma
use
peptid
one
frequent
respiratori
allergen
major
timothi
grass
pollen
allergen
phl
p
human
rhinovirusderiv
coat
protein
requir
infect
respiratori
cell
recombin
fusion
protein
produc
immun
fusion
protein
induc
mice
rabbit
protect
igg
antibodi
recogn
allergen
neutral
infect
cell
express
receptor
human
rhinovirus
vaccin
exhibit
neither
ige
cellmedi
allergen
activ
describ
principl
may
use
combin
vaccin
allerg
infecti
asthma
internetbas
questionnair
studi
conduct
patient
asthma
chronic
obstruct
pulmonari
diseas
copd
parent
children
asthma
evalu
adher
regimen
treatment
conveni
use
inhal
transderm
prepar
valid
respons
obtain
patient
among
asthmat
patient
percentag
select
btake
prescrib
inhal
user
transderm
user
among
patient
copd
correspond
valu
signific
differ
percentag
inhal
transderm
prepar
airway
diseas
common
reason
poor
adher
bfrequenc
administr
high
proport
patient
prefer
oncedaili
administr
addit
patient
use
prepar
prefer
transderm
inhal
drug
signific
extent
conclus
health
care
profession
educ
patient
import
treatment
inhal
sinc
poor
adher
treatment
inhal
agent
significantli
hinder
achiev
optim
efficaci
addit
transderm
tulobuterol
patch
administ
daili
longact
appear
use
longterm
control
asthma
copd
aerosol
characterist
admixtur
budesonid
inhal
solut
procaterol
toshiko
itazawa
yuichi
adachi
hiroyuki
mochizuki
naoki
shimojo
toshishig
inou
toshiyuki
nishimuta
akihiro
morikawa
sankei
nishima
univers
toyama
pediatr
toyama
japan
gunma
univers
graduat
school
medicin
pediatr
maebashi
japan
chiba
univers
pediatr
chiba
japan
sumitomo
hospit
pediatr
osaka
japan
shimoshizu
nation
hospit
pediatr
shimoshizu
japan
fukuoka
nation
hospit
pediatr
fukuoka
japan
background
nebul
solut
asthma
medic
often
mix
togeth
order
simplifi
inhal
regimen
although
recommend
therefor
evalu
effect
admixtur
aerosol
characterist
method
cascad
impactor
use
measur
particl
size
distribut
admixtur
pulmicort
respul
budesonid
meptin
inhal
solut
unit
procaterol
hydrochlorid
jet
nebul
pari
lc
plu
concentr
drug
assay
hplc
physicochem
compat
also
assess
hour
mix
result
impact
analysi
reveal
differ
aerodynam
size
output
drug
admixtur
singledrug
solut
mass
median
aerodynam
diamet
mmad
budesonid
admixtur
procaterol
singledrug
solut
respir
mass
budesonid
admixtur
compar
singl
solut
respect
signific
chang
ph
visual
identif
precipit
admixtur
recoveri
rate
drug
kept
initi
valu
observ
period
conclus
studi
demonstr
compat
coadministr
budesonid
procaterol
aspect
aerodynam
characterist
physicochem
stabil
vivo
data
need
clinic
implic
find
efficaci
sublingu
immunotherapi
asthma
control
sylvia
novakova
rositsa
dimitrova
ivth
outpati
clinic
allergolog
plovdiv
bulgaria
region
hospit
pulmonari
diseas
allergolog
veliko
tarnovo
bulgaria
background
great
interest
evalu
clinic
efficaci
sublingu
immunotherapi
slit
achiev
asthma
control
interest
justifi
recent
gina
guidelin
put
emphasi
control
asthma
baselin
asthma
manag
furthermor
first
studi
slit
bulgaria
sinc
rout
administr
immunotherapi
avail
two
year
countri
copyright
world
allergi
organ
unauthor
reproduct
articl
prohibit
aim
studi
investig
potenti
effect
one
year
slit
dustmit
asthma
control
method
patient
asthma
allergi
dust
mite
dermatophagoid
pternyssinu
andor
dermatophagoid
farina
includ
studi
femal
age
year
mean
slit
prescrib
men
one
year
along
antiasthma
therapi
control
group
patient
men
maintain
medic
therapi
alon
asthma
control
test
act
perform
ass
level
control
last
four
week
basi
number
score
asthma
control
estim
control
partial
control
complet
control
assess
fvc
perform
result
group
patient
subject
slit
medic
treatment
complet
control
partial
control
control
last
four
week
studi
medic
treatment
alon
complet
control
partial
control
control
past
four
week
fvc
differ
group
patient
slit
better
control
first
year
treatment
conclus
result
studi
suggest
slit
afford
addit
benefit
medic
treatment
patient
asthma
allergi
dust
mite
result
suggest
slit
ad
medic
treatment
advantag
achiev
asthma
control
background
depig
polymeris
allergen
vaccin
shown
efficaci
use
object
subject
outcom
recogn
treatment
evalu
enabl
patient
feel
better
daytoday
life
activ
object
evalu
impact
qualiti
life
group
asthmat
patient
sensitis
hous
dust
mite
materi
method
studi
doubleblind
placebocontrol
sixtyfour
patient
randomli
alloc
either
receiv
activ
treatment
placebo
activ
treatment
therapeut
vaccin
contain
mixtur
depig
glutaraldehyd
polymer
mixtur
allergen
extract
pteronyssinu
farina
asthma
qualiti
life
questionnair
develop
mark
use
conduct
baselin
administr
allergen
vaccin
time
self
administ
questionnair
develop
measur
qualiti
life
adult
subject
asthma
measur
total
scale
score
togeth
subscal
score
breathless
mood
disturb
social
disrupt
concern
health
result
express
mean
measur
mannwhitney
test
use
evalu
statist
differ
group
hodgeslehmann
effect
size
differ
result
aqlq
overal
score
sum
individu
score
valu
mean
score
ci
activ
group
ci
placebo
differ
group
signific
mannwhitney
test
relev
hodgeslehmann
test
cl
activ
group
show
improv
placebo
conclus
result
clinic
trial
show
immunotherapytr
patient
contrast
untreat
experi
signific
improv
overal
qualiti
life
relat
asthma
statist
signific
well
improv
activ
group
compar
placebo
occur
also
domain
breathless
social
disrupt
concern
health
except
mood
disturb
leukotrien
receptor
antagonist
pranlukast
improv
qualiti
life
poorli
control
asthmat
patient
hiroko
arioka
intern
medic
center
japan
pulmonolog
tokyo
japan
background
asthma
chronic
inflammatori
diseas
inhal
corticosteroid
shown
effect
control
symptom
howev
import
minim
dosag
corticosteroid
use
local
system
advers
effect
import
leukotrien
pathogenesi
asthma
establish
mani
studi
shown
leukotrien
receptor
antagonist
improv
asthma
control
patient
poorli
control
asthma
despit
use
inhal
corticosteroid
object
aim
studi
assess
effect
week
pranlukast
treatment
qualiti
life
pulmonari
function
patient
inadequ
control
asthma
method
studi
conduct
hospit
clinic
japan
octob
march
recruit
outpati
mean
age
year
mildtosever
asthma
defin
japanes
societi
allergolog
well
control
daili
antiasthmat
treatment
treatment
period
patient
receiv
pranlukast
twice
day
addit
previou
treatment
patient
requir
complet
symptom
diari
record
peak
expiratori
flow
pef
daili
basi
qualiti
life
qol
assess
use
asthma
health
questionnair
ahq
result
total
asthmat
patient
enrol
signific
improv
observ
ahq
total
score
subscal
score
patient
classifi
accord
baselin
diseas
sever
mild
moder
sever
improv
baselin
remain
signific
ahq
subscal
score
econom
subscal
patient
group
patient
also
demonstr
signific
improv
baselin
pef
lmin
p
g
forc
vital
capac
forc
expiratori
volum
second
p
g
conclus
leukotrien
receptor
antagonist
pranlukast
improv
qol
pulmonari
function
asthmat
patient
inadequ
control
antiasthmat
therapi
effect
shortterm
oral
corticosteroid
prevent
relaps
follow
emerg
treatment
acut
asthma
tomoyuki
serizawa
shoji
yoshida
itsuo
iwamoto
asahi
gener
hospit
research
center
allergi
clinic
immunolog
asahi
citi
japan
background
acut
asthma
respons
mani
emerg
depart
ed
visit
shown
highdos
intraven
methylprednisolon
addit
standard
emerg
treatment
acut
asthma
induc
earli
termin
asthmat
attack
reduc
number
hospit
addit
report
asthmat
patient
treat
ed
relaps
requir
addit
intervent
within
week
ed
discharg
howev
littl
known
efficaci
oral
corticosteroid
reduc
relaps
asthmat
patient
discharg
ed
treatment
acut
asthma
purpos
studi
determin
effect
oral
corticosteroid
reduc
relaps
follow
emerg
treatment
acut
asthma
method
patient
acut
asthma
treat
nebul
salbutamol
intraven
mg
methylprednisolon
mg
theophyllin
discharg
ed
upon
discharg
patient
given
oral
mgday
prednisolon
day
result
asthmat
patient
receiv
oral
prednisolon
signific
decreas
need
repeat
emerg
care
patient
within
week
compar
patient
mean
dose
prednisolon
mg
day
mean
durat
day
conclus
conclud
cours
mediumdos
oral
prednisolon
mgkgday
outpati
prevent
relaps
follow
emerg
treatment
acut
asthma
manag
childhood
asthma
eastjava
indonesia
sulistiowati
santosa
handoko
tanuwidjaja
hugo
van
bever
adi
husada
hospit
paediatr
surabaya
indonesia
dr
ramelan
navi
hospit
pulmonari
allergi
surabaya
indonesia
nation
univers
hospit
paediatr
singapor
singapor
background
treatment
guidelin
childhood
asthma
avail
import
know
whether
guidelin
use
east
java
method
use
standard
questionnair
monitor
treatment
childhood
asthma
distribut
doctor
treat
childhood
asthma
east
java
result
doctor
particip
questionnair
studi
gener
practition
paediatrician
pulmonologist
work
policlin
privat
hospit
work
univers
hospit
symptom
score
peak
flow
meter
spirometri
never
seldom
use
monitor
childhood
asthma
nebulis
salbutamolterbutalin
first
drug
choic
treat
acut
asthma
attack
follow
iv
im
corticosteroid
iv
aminophyllin
three
main
criteria
admit
acut
attack
base
person
clinic
judgement
improv
dose
salbutamol
inhal
factor
home
distanc
travel
time
iv
aminophyllin
seldom
use
system
inhal
corticosteroid
seldom
use
outpati
set
corticosteroid
use
admit
patient
corticosteroid
choic
dexamethason
methylprednisolon
use
dose
day
oxygen
therapi
base
puls
oximetri
read
use
sever
asthma
antibiot
use
case
pneumonia
otiti
media
sinus
drug
choic
mainten
treatment
asthma
age
laba
first
choic
follow
laba
inhal
corticosteroid
inhal
corticosteroid
mainten
treatment
seldom
use
age
main
criterium
start
mainten
treatment
sever
symptom
specif
immunotherapi
never
use
conclus
although
treatment
guidelin
asthma
children
avail
daili
practic
still
find
mani
modif
includ
usag
laba
first
choic
mainten
treatment
effort
social
guidelin
provid
tool
monitor
treatment
asthma
children
need
use
yoga
adjuv
therapi
manag
bronchial
asthma
base
random
control
trail
ramaprabhu
vempati
deepak
kk
india
institut
medic
scienc
physiolog
new
delhi
india
background
complementari
altern
medicin
cam
therapi
herbal
therapi
acupunctur
yoga
chiropract
relax
techniqu
nutrit
dietari
supplement
continu
gain
popular
modal
manag
asthma
howev
dearth
qualit
research
strong
methodolog
understand
plausibl
mechan
action
therapi
asthma
present
random
control
trial
rct
examin
use
yoga
adjuv
therapi
manag
bronchial
asthma
method
studi
conduct
adult
patient
mild
moder
bronchial
asthma
alloc
randomli
either
yoga
group
n
waitlist
control
group
n
control
group
receiv
convent
treatment
wherea
yoga
group
receiv
addit
convent
treatment
also
intervent
base
certain
yogic
practic
outcom
measur
assess
group
wk
baselin
wk
wk
wk
result
yoga
group
steadi
progress
improv
pulmonari
function
also
trend
toward
reduct
exerciseinduc
fall
time
vital
capac
exercisesensit
exercis
induc
asthma
subgroup
subject
yoga
group
howev
correspond
reduct
excret
urinari
prostaglandin
metabolit
respons
exercis
challeng
indic
mast
cell
activ
also
signific
chan
signific
reduct
serum
solubl
receptor
level
wk
yoga
group
alon
nnt
qualiti
life
indic
work
qol
symptom
qol
activ
limit
qol
emot
function
qol
environment
stimuli
total
qualiti
life
result
indic
yoga
addit
convent
treatment
adjuv
therapi
asthmat
patient
result
improv
pulmonari
function
qualiti
life
reduct
tcell
activ
respons
exercis
stimuli
find
provid
yet
anoth
substanti
evid
toward
use
yoga
adjuv
therapi
manag
bronchial
asthma
background
effect
inhal
steroid
oxid
stress
asthmat
unclear
studi
level
lipid
peroxid
serum
asthmat
patient
whose
symptom
control
inhal
corticosteroid
longact
beta
agonist
measur
method
twentyfour
asthmat
patient
match
healthi
control
recruit
oxid
stress
level
quantifi
measur
thiobarbitur
acid
reactiv
substanc
result
month
treatment
mean
lipid
peroxid
concentr
significantli
higher
asthmat
patient
healthi
control
j
micromolml
vs
j
micromolml
respect
conclus
paramet
oxid
stress
higher
patient
asthma
healthi
control
even
asthma
well
control
month
treatment
effect
thalidomid
murin
model
asthma
background
tumor
necrosi
factoralpha
tnfalpha
identifi
proinflammatori
cytokin
might
import
airway
hyperrespons
ahr
thalidomid
exhibit
divers
action
antiinflamm
immunomodul
includ
attenu
tnfalpha
product
object
evalu
role
thalidomid
murin
model
asthma
method
sixweekold
femal
mice
sensit
lp
mgml
ovalbumin
ova
via
intranas
rout
expos
ova
via
intranas
rout
day
thalidomid
given
via
gavag
twice
day
day
challeng
airway
respons
inflammatori
cell
cytokin
bronchoalveolar
lavag
fluid
balf
serum
ovaspecif
ige
histolog
examin
carri
result
airway
hyperrespons
decreas
significantli
mice
treat
thalidomid
differ
ifngamma
eotaxin
level
balf
conclus
thalidomid
decreas
ahr
murin
model
asthma
therapeut
comparison
lowdos
sustainedreleas
theophyllin
dri
syrup
capsul
children
mild
persist
asthma
theophyllin
recent
report
concurr
antiinflammatori
effect
low
therapeut
plasma
concentr
dose
signific
clinic
use
bronchodilat
evid
sustainedreleas
formul
capsul
dri
syrup
form
develop
reduc
advers
effect
improv
clinic
effect
compar
therapeut
effect
theophyllin
dri
syrup
capsul
children
mild
asthma
method
nineti
children
mild
asthma
random
receiv
either
theophyllin
dri
syrup
n
theophyllin
capsul
n
mg
per
kilogram
bodi
weight
twice
day
week
baselin
serial
measur
daytim
nighttim
asthma
symptom
score
perform
complianc
score
drug
swallow
score
drug
usabl
score
measur
everi
week
score
rate
scale
serum
theophyllin
concentr
mesur
week
examin
antiinflammatori
effect
theophyllin
asthma
serum
eosinophil
cation
protein
marker
airway
inflamm
caus
eosinophil
measur
week
preand
postadministr
result
daytim
nighttim
asthma
symptom
score
two
group
week
significantli
improv
baselin
score
daytim
nighttim
asthma
symptom
score
dri
syrup
group
statist
lower
time
point
except
nighttim
symptom
score
week
complianc
score
drug
swallow
score
drug
usabl
score
dri
syrup
group
significantli
higher
end
time
point
dri
syrup
group
serum
ecp
end
time
point
statist
lower
baselin
conclus
lowdos
sustainedreleas
theophyllin
may
safe
effect
bronchial
asthma
effect
may
mediat
antiinflammatori
action
mechan
especi
use
children
asthma
dri
syrup
formul
recommend
higher
complianc
capsul
formul
steroiddepend
bronchial
asthma
reduc
dose
oral
glucocorticosteroid
improv
asthma
control
rustem
fassakhov
irina
reshetnikova
kazan
scientif
research
institut
epidemiolog
microbiolog
attach
rospotrebnadzor
allergolog
immunolog
depart
kazan
russian
feder
background
patient
chronic
sever
asthma
often
depend
long
term
prescript
oral
glucocorticosteroid
use
steroid
associ
seriou
side
effect
physician
treat
patient
continu
search
altern
therapi
reduc
need
chronic
dose
oral
steroid
aim
assess
efficaci
safeti
treatment
salmeterol
fluticason
propion
mcg
daili
fluticason
propion
mcg
daili
steroiddepend
bronchial
asthma
patient
age
year
receiv
oral
glucocorticosteroid
predisolon
equival
less
mg
daili
mg
daili
least
month
year
method
compar
random
multicentr
open
studi
parallel
group
visit
week
interv
oral
glucocorticosteroid
dose
reduct
phase
start
visit
result
inspit
continu
treatment
oral
glucocorticosteroid
patient
reach
asthma
control
treatment
mainten
dose
prednisolon
time
lower
comparison
baselin
moreov
oral
glucocorticosteroid
abolish
second
patient
recev
salmeterol
fluticason
propion
third
patient
receiv
fluticason
propion
time
asthma
control
qualiti
life
significantli
increas
administr
high
dose
fluticason
propion
decreas
dose
oral
glucocorticosteroid
lead
reliabl
increas
morn
level
serum
cortisol
sixth
month
treatment
group
patient
conclus
treatment
fluticason
propion
salmeterol
fluticason
propion
allow
reduc
dose
oral
glucocorticosteroid
moreov
caus
patient
abolish
oral
glucocorticosteroid
maintain
good
asthma
control
tatiana
ospelnikova
gamaleya
institut
epiremiolog
microbiolog
ram
gamaleya
institut
epiremiolog
microbiolog
moscow
russian
feder
respiratori
infect
viral
bacteri
may
trigger
atop
bronchial
asthma
aba
exacerb
reveal
iiiii
degre
interferon
ifn
ifng
product
defici
leukocyt
patient
moder
mild
aba
unstabl
remiss
phase
also
acut
mix
viral
bacteri
respiratori
infect
purpos
studi
use
low
molecular
ifn
induc
cycloferon
improv
ifn
system
indic
reduc
aba
exacerb
rate
known
low
molecular
ifn
induc
cycloferon
antivir
immunomodul
activ
success
use
acut
respiratori
viral
diseas
cycloferon
affin
alveolar
macrophag
receptor
induc
ifn
lung
administr
cycloferon
ifna
ifng
produc
capac
leukocyt
higher
comparison
treatment
patient
aim
aim
studi
compar
two
differ
topic
corticosteroid
treatment
asthmat
patient
materi
method
naiv
asthmat
patient
baselin
valu
divid
two
group
first
group
receiv
bdp
second
receiv
b
aerosol
total
week
short
act
agonist
salbutamol
use
need
clinic
symptom
fvc
perf
usag
agonist
record
local
advers
effect
also
document
result
indic
dynam
show
increas
valu
fvc
four
week
therapi
b
bdp
averag
respect
patient
took
b
increas
averag
patient
took
bdp
differ
proport
statist
signific
accident
sampl
patient
took
b
fvc
increas
averag
patient
took
bdp
differ
proport
statist
signific
accident
sampl
b
minim
increas
maxim
baselin
valu
minim
increas
fvc
maxim
increas
valu
therapi
b
bdp
minim
increas
maxim
baselin
valu
minim
increas
fvc
maxim
increas
valu
therapi
bdp
differ
morn
even
valu
pefr
influenc
b
becam
reduc
influenc
bdp
differ
proport
statist
signific
patient
compli
sore
throat
hoars
candida
albican
isol
therapi
topic
corticosteroid
improv
clinic
symptom
valu
fvc
perf
studi
group
differ
statist
signific
fluticason
propionatesalmeterol
combin
compar
fluticason
propion
alon
asthma
experi
gorica
breskovska
biserka
kaeva
gencijana
stevcevska
jagoda
stojkov
pulmolog
allergolog
clinic
medic
faculti
pulmolog
allergolog
skopj
macedonia
fyrom
background
rate
morbid
mortal
associ
asthma
increasingasthma
chronic
inflammatori
diseas
character
recurr
attack
dyspnea
associ
wheez
inhal
corticosteroid
effect
control
medic
current
availabl
may
provid
optim
control
asthma
taken
alon
addit
therapi
necessari
object
object
research
work
identifi
effici
fluticasonesalmeterol
discu
inhal
tvice
dauli
compar
fluticason
twice
dauli
patient
asthma
analyz
group
asthmat
age
sensit
allergen
dermatophagoid
pt
grass
pollen
split
two
group
group
consist
patient
undergon
fpsal
group
ii
patient
treat
fluticason
alon
given
skin
sensit
test
dermatophagoid
pt
symptom
score
morn
even
expiratori
flow
result
result
nvestig
show
statist
signific
improv
thr
score
symptom
first
group
reduct
number
asthmat
approach
increas
cough
prevent
follow
week
patient
first
group
patient
second
group
shown
side
effect
treatment
periodw
notic
significantli
greater
improv
morn
even
peak
expiratori
flow
patient
first
grouppati
second
group
need
addit
therapi
short
act
conclus
patient
fpsal
significantli
greater
improv
asthma
control
patient
fluticason
allon
studi
inhal
therapi
special
refer
inhal
techniqu
patient
percept
suresh
koolwal
sawai
mansingh
medic
colleg
jaipur
respiratori
diseas
jaipur
india
drug
deliveri
aerosol
rout
often
regard
twentieth
centuri
innov
fact
record
inhal
therapi
found
writ
ancient
cultur
notabl
china
india
greec
rome
middl
east
modern
era
inhal
date
back
year
ago
one
major
problem
manag
bronchial
asthma
copd
lie
airway
prescript
techniqu
inhal
crucial
manag
diseas
background
present
studi
design
find
patient
use
inhal
devic
patient
educ
affect
inhal
techniqu
view
apprehens
regard
inhal
therapi
problem
face
mode
therapi
studi
undertaken
patient
use
dri
powder
inhal
use
mdi
result
evalu
found
half
patient
use
devic
correctli
among
incorrect
user
major
mdi
among
correct
user
major
patient
educ
techniqu
physician
paramed
one
fourth
patient
wrong
prepar
inhal
incorrect
user
breath
inhal
half
patient
inhal
drug
inadequ
effort
hold
breath
inhal
cough
sudden
spasm
dysphonia
face
fear
addict
common
apprehens
use
inhal
detail
studi
present
psychosoci
perspect
asthma
third
world
portrait
societi
maladi
arnaldo
capril
hulett
hospit
san
juan
de
dio
unidad
de
alergologia
caraca
venezuela
asthma
latin
america
press
grow
health
problem
affect
young
mostli
impoverish
urban
popul
across
contin
venezuela
oil
rich
countri
popul
live
variabl
condit
poverti
acut
asthma
morbid
rank
ahead
diarrhea
second
bviral
syndrom
thu
repres
one
million
visit
per
year
ambulatori
health
servic
ministri
health
care
major
popul
tendenc
constantli
rise
roughli
million
inhabit
effort
year
exist
nation
asthma
program
dissemin
gina
similar
guidelin
unabl
revers
trend
prevail
asthma
approach
center
around
pervers
paradigm
viciou
cycl
consist
repeat
acut
asthma
care
boldli
denot
morbidli
persist
lack
awar
mind
physician
health
system
patient
lay
public
larg
uniqu
trait
valid
alik
upper
rich
well
venezuela
poor
margin
class
acknowledg
mani
year
psychotherapeut
practic
tendenc
sort
live
bstate
emerg
lack
futur
provis
kind
attitud
strong
accent
immediaci
life
along
risk
prevent
poverti
understood
bprecari
condit
daili
life
lie
beneath
set
highli
complex
issu
asthma
abound
attribut
part
consid
psychosomat
express
maladi
ie
bif
next
asthma
attack
crisi
come
see
repres
overwhelm
histor
challeng
heavili
pound
individu
mind
societi
undermin
much
need
reflect
make
surg
proper
respons
easi
task
implement
process
asthma
guidelin
primari
health
care
eeva
ahonen
risto
makinen
espoo
health
care
centr
finland
espoo
finland
background
aim
improv
clinic
practic
known
challeng
process
describ
implement
asthma
guidelin
develop
hous
rule
patient
self
manag
protocol
set
health
care
centr
six
gpnurs
team
provid
primari
care
inhabit
nation
asthma
programm
deleg
respons
prevent
treat
asthma
primari
health
care
evid
base
guidelin
publish
updat
give
gener
outlin
asthma
treatment
materi
method
participatori
observ
document
analysi
use
qualit
method
result
two
gp
two
nurs
nomin
asthma
coordin
act
intern
consult
organ
mani
workshop
introduc
guidelin
develop
asthma
manag
government
centr
pharmacotherapi
develop
join
implement
activ
provid
train
trainer
materi
tutori
support
therefor
workshop
year
problembas
multiprofession
use
ebm
feedback
prescript
practis
case
report
learn
method
health
centr
team
produc
written
agreement
interprofession
collabor
asthma
manag
process
hous
rule
asthma
care
workshop
arrang
new
workshop
assess
chang
asthma
care
multiprofession
group
develop
written
self
manag
protocol
patient
team
renew
hous
rule
workshop
accord
updat
nation
asthma
guidelin
discuss
evid
base
asthma
guidelin
valuabl
bgolden
refer
implement
interact
multiprofession
workshop
use
develop
hous
rule
method
seem
support
profession
commit
true
team
work
jointli
agre
practic
implement
necessari
process
continu
support
give
feedback
evalu
evalu
profession
attitud
toward
use
hous
rule
rate
admiss
secondari
care
chang
prescript
pattern
produc
guidelin
enough
improv
clinic
practic
demand
interest
use
implement
process
everi
day
work
exerciseinduc
bronchospasm
eib
wide
preval
asthmat
individu
particularli
children
vari
variou
report
howev
studi
address
effect
asthma
sever
airway
respons
exercis
india
aim
examin
mechan
exerciseinduc
bronchospasm
eib
import
determin
factor
mainli
affect
sever
eib
report
factor
patient
asthma
stepwis
multipleregress
analysi
method
sixti
five
asthmat
children
age
rang
year
adult
year
old
select
randomli
repres
person
live
citi
mumbai
subject
fill
questionnair
respiratori
symptom
bronchodil
therapi
withheld
three
day
studi
exposur
hous
dust
mite
allergen
estim
dust
sampl
obtain
subject
home
eosinophil
count
done
peripher
blood
serum
estim
adult
asthmat
elisa
method
atop
statu
label
basi
total
serum
ige
modifi
skin
prick
test
subject
exercis
challeng
assess
atopi
exercis
challeng
test
done
min
bout
cycleergomet
exercis
decreas
pefr
consid
posit
eib
result
atop
adult
show
significantli
higher
sensit
hous
dust
mite
compar
children
p
g
signific
rise
incid
eib
observ
adult
children
p
g
show
direct
relationship
hous
dust
mite
sensit
group
adult
correl
coeffici
r
p
g
children
r
p
rel
risk
develop
eib
associ
hdm
sensit
higher
adult
ci
regress
analysi
show
direct
relationship
sever
eib
serum
level
p
rais
eosinophil
well
correl
serum
level
conclus
find
suggest
though
eib
common
children
adult
significantli
affect
allergen
specif
ige
hous
dust
mite
serum
eosinophilia
major
associ
contribut
factor
develop
eib
asthmat
patient
clinic
implic
patient
exercis
induc
bronchospasm
may
benefit
novel
tharapi
special
design
target
specfic
mechan
underli
airway
inflamm
valeria
ghiglion
sara
balestracci
fulvio
braido
sara
cauglia
ilaria
baiardini
giorgio
walter
canonica
univers
genoa
depart
intern
medicin
genoa
itali
background
indic
asthma
guidelin
treatment
goal
total
control
asthma
consequ
minim
impact
asthma
patient
life
aim
aim
studi
investig
relationship
control
asthma
qualiti
life
real
life
method
month
period
asthmat
patient
enrol
consecut
routin
control
visit
spirometri
perform
everi
patient
patient
ask
complet
differ
questionnair
asthma
control
test
act
brief
instrument
develop
assess
asthma
control
patient
clinic
set
rhinasthma
item
tool
aim
evalu
impact
respiratori
allergi
qualiti
life
provid
differ
score
upper
airway
ua
lower
airway
la
respiratori
allergi
impact
rai
global
summari
gs
result
seventyfour
asthmat
outpati
men
women
mean
age
enrol
concomit
rhiniti
patient
control
asthma
achiev
obtain
asthma
control
valu
mean
correl
act
rhinasthma
la
rai
act
significantli
correl
four
rhinasthma
score
subdivid
patient
accord
score
optim
good
control
vs
non
control
compar
level
control
measur
mean
act
obtain
signific
correl
act
la
p
rai
p
gs
correl
rhinasthma
ua
score
p
analysi
patient
popul
show
well
total
control
achiev
patient
asthma
patient
asthma
rhinti
subanalysi
patient
concomit
rhiniti
show
wors
rhinasthma
score
domain
compar
patient
asthma
alon
p
g
discuss
result
show
asthma
control
relat
improv
qualiti
life
nevertheless
asthmat
patient
often
refer
also
symptom
due
rhiniti
import
impact
qualiti
life
order
improv
qualiti
life
asthmat
patient
treatment
patient
rhiniti
asthma
includ
lower
upper
airway
treatment
relationship
qualiti
life
relat
chronic
cough
asthma
level
control
pilot
studi
sara
balestracci
fulvio
braido
valeria
ghiglion
silvia
brandi
ilaria
baiardini
giorgio
walter
canonica
univers
genoa
depart
intern
medicin
genoa
itali
background
antiasthmat
treatment
nowaday
avail
induc
good
total
diseas
control
recent
evid
also
shown
level
control
strongli
relat
health
relat
qualiti
life
hrql
aim
aim
real
life
observ
studi
evalu
relationship
hrql
relat
chronic
cough
asthma
level
control
defin
accord
asthma
control
test
score
act
method
period
asthmat
patient
consecut
enrol
schedul
visit
patient
ask
complet
differ
questionnair
act
brief
instrument
develop
assess
asthma
control
patient
clinic
set
chronic
cough
impact
questionnair
cciq
item
valid
questionnair
divid
area
sleep
concentr
social
relationship
mood
daili
life
impact
result
seventyfour
asthmat
outpati
men
women
mean
age
sd
enrol
concomit
rhiniti
patient
total
well
control
asthma
act
score
non
control
asthma
act
score
g
act
correl
significantli
cciq
domain
sleepconcentr
p
social
relationship
p
mood
p
daili
life
impact
p
take
consider
concomit
rhiniti
could
induc
post
nasal
drip
relat
cough
subanalysi
patient
asthma
rhiniti
show
correl
cciq
act
discuss
previou
studi
show
signific
correl
asthma
level
control
hrql
despit
evid
analys
hrql
relat
specif
symptom
cough
occur
asthma
correl
lack
pilot
observ
seem
demonstr
act
use
tool
specif
instrument
amelior
patient
evalu
moreov
presenc
caus
cough
investig
well
control
asthmat
patient
persist
cough
clinic
effect
clean
air
administ
directli
breath
zone
airsonett
airshow
perenni
allerg
asthma
background
studi
previous
made
air
clean
shown
littl
effect
patient
perenni
allerg
asthma
examin
novel
treatment
airsonett
airshow
use
laminar
airflow
direct
breath
zone
patient
night
teenag
young
adult
moder
sever
allerg
asthma
hypothesis
direct
treatment
would
effect
bronchial
inflamm
consequ
qualiti
life
method
patient
year
age
mean
yr
random
doubleblind
week
activ
treatment
respect
week
placebo
treatment
patient
receiv
activ
placebo
treatment
crossov
week
washout
period
treatment
mainten
treatment
inhal
corticosteroid
unalt
budesonidday
equival
trial
period
health
relat
qualiti
life
miniaqlq
primari
effect
measur
exhal
nitric
oxid
feno
lung
function
also
investig
result
activ
treatment
result
improv
qualiti
life
compar
placebo
mean
score
p
g
n
also
effect
bronchial
inflamm
detect
significantli
lower
feno
valu
activ
treatment
period
mean
ppb
p
g
n
anxieti
symptom
allerg
patient
identif
risk
factor
ziad
adwan
saha
allergi
rio
de
janeiro
brazil
object
multipl
relationship
anxieti
allerg
symptom
treatment
difficulti
observ
aim
present
studi
estim
preval
anxieti
disord
outpati
variou
allerg
diseas
identifi
diagnost
cue
possibl
risk
factor
test
use
selfadminist
questionnair
screen
allergi
clinic
method
six
hundr
fortysix
consecut
patient
rhinoconjunct
asthma
bother
allergi
age
year
complet
selfadminist
questionnair
six
outpati
allergi
clinic
respond
also
particip
structur
psychiatr
interview
anxieti
measur
spielberg
statetrait
anxieti
result
accord
interview
stait
predict
accuraci
current
psychiatr
diagnosi
without
differenti
anxieti
depress
use
threshold
rate
anxieti
andor
depress
disord
estim
ci
unselect
allerg
outpati
sampl
patient
never
receiv
psychopharmacolog
treatment
indic
anxieti
relat
disord
underdiagnos
undertr
risk
indic
femal
gender
asthma
perenni
symptom
sleep
problem
nonspecif
allergi
trigger
like
strong
emot
stress
situat
consider
limit
everyday
activ
attribut
allerg
symptom
conclus
find
confirm
high
rate
anxieti
andor
depress
disord
patient
visit
allergi
clinic
selfadminist
questionnair
stait
provid
reliabl
help
identif
frequent
psychiatr
problem
key
word
anxieti
allergi
rhiniti
asthma
spielberg
statetrait
anxieti
inventori
depress
issu
health
care
assess
system
nepal
still
take
long
time
high
cost
collect
data
priorit
commun
health
problem
commun
essenti
plan
monitor
program
intervent
improv
commun
health
statu
scientif
rapid
commun
health
assess
methodolog
need
valid
rural
commun
develop
countri
like
nepal
econom
less
time
consum
object
valid
rapid
commun
health
assess
methodolog
rcha
priorit
commun
health
problem
rural
commun
studi
area
villag
rural
area
studi
popul
primari
school
teacher
randomli
select
primari
school
villag
one
teacher
class
v
school
valid
head
household
household
per
villag
systemat
sampl
data
collect
techniqu
selfadminist
questionnair
teacher
interview
schedul
head
household
data
analysi
help
epi
info
program
result
signific
correl
respons
school
teacher
head
household
commun
health
problem
viz
priorit
ten
villag
problem
r
p
g
b
priorit
util
servic
variou
health
functionari
treatment
advic
children
ill
r
p
g
c
priorit
household
use
water
differ
sourc
r
p
g
method
also
found
rapid
time
less
costli
time
compar
tradit
household
survey
method
conclus
rapid
commun
health
assess
methodolog
rcha
priorit
commun
health
problem
rural
commun
valid
inform
thu
obtain
util
purpos
health
polici
program
plan
monitor
evalu
especi
relev
micro
plan
child
health
servic
develop
countri
repeat
use
questionnair
monitor
diseas
control
program
must
care
consid
studi
confirm
reconfirm
result
studi
may
done
wider
applic
methodolog
aim
assess
tempor
chang
medicin
consumpt
relat
risk
factor
respiratori
symptomsdiseas
subsampl
gener
popul
italian
adult
method
within
po
delta
pisa
epidemiolog
survey
subject
habitu
use
medicin
baselin
select
case
control
nondrug
consum
subject
randomli
drawn
match
gender
age
group
subject
invit
particip
telephon
interview
followup
year
question
current
drug
consumpt
respiratori
health
statu
life
habit
comorbid
besid
sociodemograph
characterist
main
characterist
male
mean
age
case
use
logist
regress
model
account
smoke
habit
gender
age
comorbid
respiratori
symptom
occupationalpass
smokingenvironment
exposur
result
non
signific
increas
baselin
followup
preval
asthma
vs
rhiniti
vs
preval
rate
habitu
use
medicin
followup
vs
baselin
p
g
among
user
found
higher
preval
bronchopulmonari
vs
significantli
antiallerg
drug
vs
non
significantli
followup
new
regular
use
medicin
followup
persist
cessat
respect
asthma
result
significantli
relat
use
medicin
baselin
ci
followup
relat
signific
asthma
rhiniti
associ
use
specif
medicin
brochopulmonari
antiallergiccardiovasculardiuret
vs
medicineno
use
signific
asthma
baselin
roya
sherkat
alzahra
univers
hospit
infectious
diseas
isfahan
islam
republ
iran
introduct
chronic
urticariaangiooedema
tradit
defin
daili
almost
daili
symptom
last
week
chronic
urticaria
affect
individu
lifetim
preval
significantli
reduc
qualiti
life
optim
manag
chronic
acut
intermitt
urticaria
depend
thorough
understand
clinic
present
etiolog
trigger
aggrav
factor
underli
extran
caus
chronic
urticaria
identifi
patient
infect
may
play
caus
role
case
present
chronic
infect
dental
sepsi
sinus
urinari
tract
infect
cutan
fungal
infect
treat
howev
exhaust
investig
search
underli
infect
indic
infect
helicobact
pylori
hp
propos
possibl
caus
associ
unlik
causal
particularli
otherwis
asymptomat
children
background
preval
hp
infect
high
also
complement
activ
mediat
augment
histamin
releas
mast
cell
via
anaphylatoxin
inflammatori
pathway
trigger
antibodi
antigen
interact
form
immun
complexassoci
urticaria
eg
hepat
c
hepat
b
ebv
viral
possibl
parasit
infect
howev
common
trigger
episod
chronic
urticaria
intercurr
viral
infect
possibl
stress
human
brucellosi
infecti
diseas
produc
brucella
speci
small
coccoid
rodlik
aerob
gramneg
bacteria
everi
organ
system
human
bodi
affect
brucellosi
fact
underscor
import
includ
brucellosi
differenti
diagnosi
area
endem
diseas
even
clinic
featur
entir
compat
infect
also
affect
skin
present
case
chronic
urticaria
also
fever
chill
present
week
urticarialik
papul
plaqu
red
rais
itchi
rash
especi
face
continu
fever
stop
vast
array
laboratori
investig
brucella
serolog
use
eliza
serum
agglutin
method
posit
treatment
underli
infect
lead
resolut
symptom
bronchial
hyperrespons
patient
chronic
urticaria
zikica
jovic
mirjana
bogic
sanvila
raskov
aleksandra
peric
popad
ljiljana
stefanov
institut
allergolog
immunolog
cc
depart
allergolog
belgrad
serbia
montenegro
background
involv
respiratori
system
patient
chronic
urticaria
still
controversi
subject
larg
number
patient
report
dyspnea
aim
studi
investig
present
bronchial
hyper
respons
patient
chronic
urticaria
method
total
patient
women
men
age
rang
year
urticaria
least
week
without
known
caus
urticaria
enrol
studi
diagnost
programm
urticaria
includ
eosinophil
count
skin
prick
test
inhal
nutrit
allergen
test
nsaid
intoler
pulmonari
function
test
methacholin
provoc
patient
investig
phase
remiss
result
three
patient
abnorm
pulmonari
function
test
ten
patient
show
signific
bronchial
hyperrespons
methacholin
provoc
three
elev
eosinophil
count
four
posit
skin
prick
test
inhal
andor
nutrit
allergen
twelv
nsaid
intoler
airway
hyperrespons
associ
eosinophil
count
skin
prick
test
inhal
nutrit
allergen
nsaid
intoler
conclus
signific
number
patient
chronic
urticaria
show
bronchial
hyperrespons
perform
test
reason
patient
chronic
urticaria
audit
referr
public
sector
primari
care
physician
allergi
clinic
singapor
bernard
thong
khaipang
leong
chweey
tang
yewkuang
cheng
faith
chia
justina
tan
hiokhe
chng
tan
tock
seng
hospit
singapor
rheumatolog
allergi
immunolog
singapor
singapor
background
electron
registri
new
referr
new
case
registri
adult
allergi
clinic
set
juli
determin
sourc
referr
refer
diagnos
final
diagnos
sourc
referr
includ
primari
care
physician
public
privat
sector
specialist
nation
dermatolog
centr
militari
servic
self
referr
aim
describ
pattern
referr
primari
care
physician
public
sector
allergi
clinic
singapor
method
new
referr
prospect
captur
new
case
registri
studi
period
juli
decemb
result
referr
public
sector
primari
care
physician
compris
referr
half
femal
mean
age
year
major
chines
common
refer
diagnos
drug
allergi
da
urticaria
angioedema
food
allergi
fa
contrast
final
diagnosi
attend
allergist
da
nsaid
intoler
fa
respect
among
case
primari
care
physician
diagnos
da
allergist
diagnosi
da
nsaid
intoler
da
among
case
primari
care
physician
diagnos
fa
allergist
diagnosi
fa
chronic
idiopath
urticaria
compris
case
urticariaangioedema
follow
condit
underdiagnos
famili
physician
compar
allergist
anaphylaxi
versu
asthma
versu
atop
eczema
versu
allerg
rhiniti
versu
among
referr
suspect
allergi
deem
allerg
disord
upon
complet
evalu
conclus
da
urticariaangioedema
fa
common
reason
referr
nsaid
intoler
account
major
case
fdrug
allergi
refer
primari
care
physician
allerg
rhiniti
asthma
atop
eczema
anaphylaxi
underdiagnos
potenti
lead
patient
depriv
appropri
therapi
allerg
airway
diseas
lifesav
epinephrin
autoinjector
increas
awar
educ
may
use
improv
diagnosi
treatment
allerg
diseas
commun
chronic
urticaria
altern
treatment
betaagonist
summit
shah
lekha
nair
jonathan
bayuk
tuftsnew
england
medic
center
allergi
depart
boston
unit
state
tuftsnew
england
medic
center
pharmaci
boston
unit
state
hampden
counti
physician
allergi
springfield
unit
state
background
describ
year
old
patient
chronic
urticaria
unrespons
standard
therapi
respond
oral
beta
agonist
propos
possibl
mechan
action
method
perform
basic
bloodwork
check
eosinophil
level
ana
esr
cbc
cmp
antithyroid
antibodi
tsh
complement
level
skin
biopsi
perform
well
result
patient
histori
diabet
mellitu
present
treatment
chronic
urticaria
x
year
initi
patient
respond
corticosteroid
sinc
medic
help
includ
allegra
doxepin
periactin
test
result
reveal
normal
eosinophil
level
neg
ana
normal
esr
cbc
cmp
antithyroid
antibodi
tsh
complement
level
patient
unrespons
medic
requir
frequent
oral
corticosteroid
albuterol
sulfat
mg
tablet
given
patient
took
approxim
mg
albuterol
oral
day
approxim
day
addit
antihistamin
return
visit
patient
symptom
resolv
complet
conclus
beta
agonist
good
side
effect
profil
compar
oral
corticosteroid
may
great
benefit
reduc
urticari
symptom
possibl
mechan
action
includ
inhibit
antiig
induc
histamin
releas
thru
desensit
beta
adrenoceptor
may
promis
pharmacotherapi
treatment
chronic
urticaria
background
chronic
idiopath
urticaria
ciu
rel
common
diseas
yet
much
known
caus
factor
pathomechan
make
difficult
cure
due
chronic
natur
mani
patient
suffer
signific
detriment
effect
qualiti
life
qol
purpos
studi
assess
impact
ciu
qol
korean
patient
determin
whether
relationship
exist
qol
sever
diseas
method
one
hundr
twenti
four
patient
ciu
first
visit
outpati
clinic
august
juli
ask
complet
questionnair
design
assess
effect
ciu
daili
live
patient
qol
divid
six
differ
categori
mental
statu
ms
daili
live
activ
dla
leisur
activ
la
selfpercept
sp
treatmentinduc
restrict
tir
social
restrict
sr
qol
score
recalibr
scale
indic
worst
qol
favor
pearson
spearman
correl
coeffici
use
analyz
relationship
six
differ
qol
categori
well
associ
diseas
durat
qol
one
way
anova
use
analyz
relationship
diseas
sever
qol
p
valu
less
consid
signific
result
averag
qol
score
obtain
questionnair
follow
ms
dla
la
sp
tir
sr
result
show
patient
affect
mental
social
restrict
least
signific
six
differ
categori
show
posit
correl
amongst
demonstr
ciu
exert
influenc
one
mani
aspect
qol
la
tir
significantli
affect
longer
term
ciu
case
p
g
sp
ms
dla
sr
show
signific
relationship
diseas
durat
diseas
sever
found
signific
effect
sr
la
tir
categori
p
g
conclus
base
result
suggest
ciu
neg
impact
qol
korean
patient
therefor
import
recogn
effect
ciu
qol
consid
candid
treatment
well
neutrophil
activ
find
note
patient
asa
induc
urticaria
sungjin
choi
gyuyoung
hur
seungyoup
shin
seunghyun
kim
ajou
univers
school
medicin
allergi
rheumatolog
suwon
republ
korea
background
object
asa
ingest
could
induc
acut
chronic
urticaria
howev
pathogen
mechan
understood
compar
level
neutorphil
activ
relat
cytokin
asa
intoler
acut
urticaria
aiau
asa
intoler
chronic
urticaria
aicu
method
patient
aicu
patient
aiau
patient
normal
control
nc
enrol
clinic
laboratori
find
includ
serum
myeloperoxidas
mpo
level
level
compar
among
aiau
aicu
nc
group
correl
mpo
observ
result
level
serum
mpo
significantli
higher
aiau
aicu
nc
respect
level
significantli
higher
aiau
nc
signific
differ
note
level
within
aiau
patient
signific
correl
note
mpo
known
peopl
develop
urticaria
least
live
chronic
idiopath
urticaria
affect
popul
incid
acut
urticaria
higher
peopl
atopi
incid
chronic
urticaria
increas
peopl
atopi
studi
show
case
urticaria
relat
gastointestin
disord
activ
gastriti
esophag
peptic
ulcer
one
interest
thing
urticaria
like
singl
symptom
sever
mayb
lifethreaten
gastrointestin
disord
method
patient
acut
chronic
urticaria
pass
gastroscopi
day
onset
urticaria
addit
urticaria
angioedema
suffer
sever
pruritu
desquam
develop
palmar
eczema
result
patient
show
differ
gastrointestin
problem
correl
well
anamnesi
data
gastric
eros
among
esophag
esophag
atroph
gastriti
esophag
alon
patient
sever
gener
urticaria
big
cm
duoden
ulcer
patient
concomit
pruritu
lot
sever
gastric
esophag
duoden
eros
patient
suffer
ocasion
epigastr
pain
heartburn
none
said
symptom
sever
gastrointestin
caus
suspect
episod
urticaria
develop
increas
irrit
acid
food
spice
citrus
strawberri
drink
alcohol
soda
drug
nsaid
acetylcysteinum
ascorbin
acid
trigger
factor
alway
differ
dosedepend
patient
underw
antireflux
antacid
antisecretori
antibiot
therapi
along
symptomat
antihistamin
drug
recov
show
much
relief
patient
sever
pruritu
nt
pass
prescrib
treatment
chose
usual
intramuscular
inject
diprospan
instead
alway
report
short
relief
symptom
conclus
data
show
urticaria
alon
angioedema
often
occur
symptom
gastrointestin
disord
import
prescrib
gastroscopi
adequ
treatment
stop
urticaria
moreov
prevent
gastrointestin
bleed
perfor
genlti
oper
steroid
especi
oral
patient
etiolog
prognosi
acut
urticaria
univers
dermatolog
clinic
china
followup
studi
linfeng
li
yuan
cao
peke
univers
third
hospit
dermatolog
beij
china
background
etiolog
prognosi
acut
urticaria
report
china
object
investig
etiolog
outcom
acut
urticaria
univers
dermatolog
set
method
prospect
follow
studi
perform
patient
acut
urticaria
seen
author
march
juli
depart
dermatolog
peke
univers
third
hospit
ask
particip
etiolog
agent
trigger
evalu
comprehens
detail
histori
physic
examin
supplement
select
laboratori
test
follow
prognosi
assess
month
first
visit
cure
defin
complet
free
symptom
month
without
relaps
cessat
treatment
result
patient
particip
male
femal
age
rang
year
year
histori
acut
urticaria
childhood
atop
etiolog
agent
trigger
could
identifi
patient
includ
medic
infect
food
physic
stimuli
insect
bite
contact
patient
finish
follow
case
cure
patient
etiolog
trigger
unidentifi
progress
chronic
urticaria
free
symptom
end
evalu
overal
cure
rate
patient
diseas
durat
less
one
week
much
higher
patient
longer
durat
p
g
chisquar
test
sex
age
sever
diseas
effect
prognosi
conclus
etiolog
trigger
identifi
half
acut
urticaria
patient
medica
infect
food
common
trigger
outcom
acut
urticaria
favor
longer
diseas
durat
week
import
risk
poor
prognosi
result
among
patient
remit
evalu
allergi
penicillin
angioedema
penicillin
exclud
caus
exclus
control
administr
penicillin
stryptas
aspirin
nonsteroid
antiinflammatori
drug
ace
inhibitor
drug
seen
caus
mediat
leukotrien
bradykinin
direct
mast
cell
degranul
food
suspect
insect
sting
caus
honeybe
wasp
occup
agent
latex
nurs
fish
protein
flour
dye
nikel
one
inhibitor
slight
reduc
angioedema
associ
allerg
rhinoconjunct
asthma
infect
physic
stimuli
well
known
induc
rather
patient
nondrug
induc
angioedema
prophylact
anaphylact
medic
corticosteroid
antihistamin
home
epinephrin
epipen
autoinjector
conclus
urticaria
angioedema
frequent
manifest
sever
allerg
reaction
anaphylaxi
mani
differ
caus
may
induc
angioedema
howev
igemedi
mechan
frequent
suspect
caus
angioedema
depart
medicin
success
treatment
chronic
urticaria
low
molecular
weight
heparin
background
autolog
serum
skin
test
asst
use
detect
circul
vasoact
histaminereleas
factor
patient
chronic
urticaria
cu
recent
observ
autolog
plasma
skin
test
apst
score
posit
frequent
asst
cu
patient
posit
associ
activ
coagul
cascad
aim
report
case
chronic
urticaria
success
treat
anticoagul
therapi
use
low
molecular
weight
heparin
lmwh
see
whether
symptom
control
associ
reduct
coagul
activ
method
woman
histori
unremit
cu
evalu
outpati
allergi
clinic
diseas
present
clinic
histori
cu
improv
prednisolon
mgkgday
plu
antihistamin
therapi
taper
led
symptom
recurr
known
caus
cu
rule
laboratori
instrument
examin
asst
apst
neg
control
salin
solut
posit
control
histamin
perform
discontinu
steroid
therapi
repeat
day
lmwh
therapi
prothrombin
fragment
marker
coagul
activ
ddimer
marker
fibrinolysi
measur
elisa
start
lmwh
therapi
day
later
result
baselin
aspt
gave
unequivoc
posit
respons
mm
mean
wheal
diamet
wherea
asst
neg
prothrombin
fragment
valu
pmoll
normal
rang
pmoll
ddimer
valu
nmoll
normal
rang
nmoll
confirm
activ
coagul
cascad
fibrinolysi
lmwh
therapi
enoxaparin
ui
twice
day
sc
start
day
cu
improv
patient
stop
steroid
therapi
without
recurr
cu
fifteen
day
later
patient
still
asymptomat
receiv
lmwh
therapi
apst
becam
neg
observ
mark
reduct
prothrombin
fragment
pmoll
ddimer
nmoll
background
angiotensin
convert
enzym
inhibitor
acei
known
caus
angioedema
incid
clinic
relev
due
risk
lifethreaten
involv
upper
respiratori
tract
present
studi
report
clinic
featur
patient
complain
aceisangioedema
refer
unit
year
period
subgroup
studi
potenti
mastcel
involv
measur
serum
tryptas
method
descript
observ
aceisinduc
angioedema
period
januari
decemb
serum
tryptas
level
evalu
elisa
assay
angioedema
attack
baselin
condit
three
differ
group
group
patient
complain
previou
acei
angioedema
group
patient
previou
nonacei
angioedema
group
patient
treat
acei
without
angioedema
result
observ
patient
male
mean
age
yr
rang
yr
ascertain
aceiinduc
angioedema
one
patient
african
wherea
white
patient
report
averag
attack
angioedema
rang
upper
respiratori
tract
involv
observ
subject
eleven
patient
report
concomit
use
nsaid
aspirin
five
low
dosag
one
patient
report
previou
cough
due
acei
drug
respons
lisinopril
fosinopril
enalapril
quinalapril
rampril
captopril
period
time
begin
acei
therapi
first
angioedema
attack
rang
day
year
mean
year
patient
isol
angioedema
lip
face
tongu
two
patient
admit
medic
intens
care
unit
one
intub
followup
inform
avail
subject
relaps
stop
acei
treatment
attack
one
patient
show
slight
increas
serum
tryptas
ngml
wherea
signific
chang
observ
baselin
condit
three
group
group
ngml
group
b
ngml
group
c
ngml
serum
tryptas
conclus
acei
relev
caus
angioedema
mainli
adult
elderli
popul
physician
awar
potenti
risk
upper
airway
involv
mastcel
seem
involv
pathogenesi
keyword
angiotensin
convert
enzym
inhibitor
angioedema
tryptas
christian
bull
susann
haug
peter
schmidgrendelmei
univers
hospit
zurich
allergi
unit
dep
dermatolog
zurich
switzerland
rational
hereditari
angioedema
hae
characteris
skin
swell
variou
part
bodi
laryng
edema
abdomin
pain
besid
defici
malfunct
plasma
caus
hae
bradykinin
consid
key
mediat
symptom
hae
attack
new
treatment
acut
hae
attack
might
icatib
synthet
highli
select
antagonist
administ
subcutan
report
effect
icatib
treat
acut
attack
one
patient
hospit
openlabel
extens
phase
phase
iii
doubl
blind
random
multicent
trial
compar
icatib
versu
tranexam
acid
patient
abdomin
cutan
attack
treat
icatib
mg
sc
symptom
score
patient
document
time
onset
symptom
relief
measur
visual
analog
scale
time
complet
resolut
symptom
main
assess
result
patient
treat
hospit
year
old
otherwis
healthi
male
known
hae
sinc
age
month
frequent
attack
twice
per
month
usual
treat
tranexam
acid
patient
experienc
total
attack
abdomin
cutan
laryng
averag
durat
day
last
month
patient
came
clinic
sever
cutan
edema
genit
receiv
one
singl
inject
mg
icatib
sc
onset
symptom
relief
reach
rapidli
approxim
minut
complet
resolut
symptom
occur
within
hour
patient
could
leav
hospit
icatib
well
toler
mild
inject
site
reaction
pruritu
observ
system
advers
event
observ
conclus
present
case
icatib
provid
fast
complet
resolut
sever
cutan
hae
symptom
well
toler
treatment
cours
hae
attack
case
compli
result
doubl
blind
phase
trial
time
first
improv
hour
icatib
vs
hour
tranexam
acid
p
g
primari
endpoint
median
time
onset
symptom
relief
met
hour
icatib
compar
hour
tranexam
acid
p
g
end
attack
almost
complet
symptom
relief
reach
hour
treatment
icatib
compar
hour
tranexam
acid
p
g
evalu
receptor
occup
desloratadin
levocetirizin
allerg
subject
conclus
spite
higher
affin
ki
longer
compar
l
higher
free
plasma
concentr
l
h
postdos
produc
higher
percentag
ro
probabl
account
statist
signific
higher
inhibit
allergeninduc
wheal
flare
induc
l
impact
hereditari
defici
develop
atherosclerosi
method
crosssect
prospect
studi
includ
adult
patient
age
sex
match
healthi
individu
preval
cardioand
cerebrovascular
atherosclerot
diseas
well
distinct
atherosclerot
risk
profil
determin
addit
thick
intimamedia
imt
common
carotid
arteri
also
determin
sever
hae
patient
receiv
longterm
danazol
prophylaxi
yan
attenu
androgen
patient
divid
two
subgroup
accord
prophylact
treatment
result
low
preval
atherosclerosi
found
hae
patient
subject
affect
danazol
treat
treat
group
respect
accord
medic
histori
patient
longterm
danazol
prophylaxi
increas
risk
profil
atherosclerosi
significantli
higher
bodymass
index
ldlhdl
ratio
creatin
kinas
activ
creatinin
gpt
hemoglobin
level
found
compar
hae
patient
healthi
control
well
howev
carotid
imt
differ
relevantli
studi
subgroup
conclus
longterm
danazol
use
result
highli
proatherogen
risk
profil
patient
hae
howev
seem
lead
earli
atherosclerosi
preval
cardioor
cerebrovascular
diseas
low
hae
patient
irrespect
prophylact
treatment
carotid
imt
compar
healthi
control
hypothes
function
defici
might
protect
factor
patient
atherosclerosi
outlin
import
plasma
enzym
system
process
regul
patient
percept
levocetirizin
urticaria
multicent
studi
taiwan
chronic
urticaria
use
concomit
antihistamin
reduc
baselin
end
treatment
conclus
result
confirm
western
studi
levocetirizin
potent
effect
well
toler
also
taiwanes
patient
urticaria
patient
consid
better
previou
treatment
levocetirizin
better
overal
efficaci
desloratadin
chronic
idiopath
urticaria
doubleblind
random
clinic
trial
annick
barbaud
behalf
cute
studi
group
pital
fournier
servic
de
dermatologi
nanci
franc
background
levocetirizin
levo
desloratadin
deslo
latest
gener
levo
shown
significantli
potent
deslo
either
histamin
allergeninduc
wheal
flare
studi
far
headtohead
clinic
studi
chronic
idiopath
urticaria
ciu
corrobor
find
method
multicent
doubleblind
group
adult
levo
deslo
randomis
trial
week
w
treatment
compar
clinic
efficaci
safeti
levo
vs
deslo
daili
primari
endpoint
pruritu
sever
score
absent
sever
assess
daili
first
week
treatment
secondari
endpoint
pruritu
sever
studi
week
pruritu
durat
number
size
wheal
scale
global
satisfact
treatment
dissatisfi
satisfi
safeti
ciu
composit
score
repres
drug
overal
efficaci
also
assess
conclus
first
headtohead
comparison
levo
deslo
ciu
patient
satisfact
levo
significantli
higher
onset
action
levo
faster
overal
efficaci
levo
significantli
better
deslo
reliev
ciu
symptom
urticaria
angiooedema
due
daili
mg
dose
acetylsalicyl
acid
hong
oei
wilsa
l
kartanegara
richard
l
oei
albert
schweitzer
hospit
allergolog
dordrecht
netherland
background
low
dose
acetylsalicyl
acid
wide
prescrib
prevent
reduc
risk
stroke
heart
attack
mani
report
concern
known
side
effect
acut
urticaria
howev
report
intermitt
urticaria
angiooedema
due
daili
mg
intak
acetylsalicyl
acid
common
method
seen
patient
old
man
old
man
old
woman
old
woman
use
daili
dose
mg
acetylsalicyl
acid
week
complain
multipl
episod
swell
tongu
cheek
urticaria
frequenc
vari
week
week
within
period
month
patient
consult
dermatologist
anoth
physician
without
result
routin
screen
investig
neg
result
symptom
disappear
week
stop
take
acetylsalicyl
acid
take
clopidogrel
instead
urticaria
angiooedema
reappear
within
week
patient
continu
take
daili
dose
acetylsalicyl
acid
instead
replac
clopidogrel
overal
efficaci
toler
assess
bgoodexcel
patient
respect
least
patient
moderatesever
symptom
report
complet
recoveri
mark
improv
individu
allerg
symptom
subject
report
onset
action
rapid
rapid
levo
report
better
previou
therapi
patient
good
excel
improv
qualiti
sleep
daili
activ
report
patient
without
concomit
medic
respect
global
satisfact
levo
high
physician
patient
frequent
report
ae
somnol
fatigu
conclus
conclud
intak
low
dose
acetylsalicyl
acid
may
caus
urticaria
angiooedema
patient
reason
behind
attack
urticaria
angiooedema
happen
week
week
still
unclear
intermitt
natur
urticaria
angiooedema
attack
may
also
reason
mani
physician
awar
daili
mg
dose
acetylsalicyc
acid
may
caus
problem
suggest
replac
daili
mg
use
acetylsalicyl
acid
clopidogrel
patient
urticaria
angiooedema
possibl
caus
acetylsalicyl
acid
studi
need
investig
mechan
disord
distribut
hla
specif
patient
chronic
urticaria
gruzdeva
maria
inna
danilycheva
margarita
boldyreva
institut
immunolog
basic
allergolog
immunetherapi
moscow
russian
feder
nrc
institut
imunolog
fmba
rf
immunegenet
moscow
russian
feder
background
patient
chronic
urticaria
cu
origin
diseas
unknown
cu
case
autoimmun
mechan
involv
cu
patient
auto
antibodi
adna
panca
anf
rf
often
detect
along
clinic
manifest
autoimmun
patholog
arthralgia
myalgia
photodermat
sub
febril
bodi
temperatur
predisposit
autoimmun
diseas
connect
certain
variant
hla
gene
rel
risk
index
demonstr
individu
bear
hla
gene
variant
higher
risk
autoimmun
patholog
develop
individu
goal
studi
investig
associ
certain
hla
specif
cu
develop
method
studi
patient
divid
group
first
grouppati
acut
atop
urticaria
n
second
group
patient
cu
clinic
manifest
autoimmun
patholog
n
third
groupnorm
individu
n
hlagenotyp
perform
sspvariant
pcr
result
first
group
half
chronic
cu
case
reveal
childhood
weal
persist
less
hour
case
atop
background
case
efficaci
ah
drug
applic
second
group
urticaria
debut
age
urticaria
persist
year
averag
exist
autoimmun
patholog
manifest
reumotest
second
group
statist
signific
increas
autoantibodi
found
comparison
first
group
accord
hlagenotyp
data
patient
cu
demonstr
statist
signific
increas
level
hla
comparison
normal
individu
demonstr
rel
risk
patient
cu
specif
data
obtain
point
possibl
autoimmun
mechan
urticaria
develop
desloratadin
reduc
symptom
improv
qualiti
life
patient
chronic
idiopath
urticaria
multicent
practicebas
studi
china
zheng
wang
schere
plough
china
ltd
shanghai
schere
plough
pharmaceut
co
ltd
shanghai
china
background
chronic
idiopath
urticaria
ciu
associ
heavi
symptom
burden
translat
signific
impair
qualiti
life
qol
nonsed
antihistamin
firstlin
therapi
ciu
desloratadin
dl
nonsed
select
receptor
antagonist
shown
multipl
placebocontrol
studi
europ
unit
state
effect
reduc
sever
pruritu
wheal
ciu
improv
qol
measur
impact
dl
ciu
studi
chines
popul
method
openlabel
multicent
studi
evalu
efficaci
safeti
dl
qd
administ
day
patient
ciu
treat
everyday
practic
china
patient
age
yr
either
gender
week
histori
ciu
elig
patient
wheal
present
daysweek
pruritu
wheal
overal
ciu
sever
score
sever
baselin
day
patient
rate
sever
pruritu
wheal
sizenumb
total
ciu
symptom
interfer
sleep
daili
activ
overal
ciu
condit
use
scale
qol
assess
timepoint
use
dermatolog
life
qualiti
index
dlqi
day
global
respons
therapi
rate
relief
treatment
failur
advers
event
ae
occur
trial
collect
rate
severityrel
studi
drug
result
studi
includ
subject
femal
mean
age
year
mean
durat
diagnos
ciu
month
pruritu
wheal
size
wheal
number
total
ciu
score
interfer
sleep
daili
activ
overal
condit
ciu
significantli
improv
baselin
day
p
g
dlqi
also
improv
significantli
baselin
cours
studi
p
g
percentag
patient
complet
mark
relief
ciu
rose
day
day
day
dl
well
toler
seriou
ae
observ
frequent
ae
rate
possiblyprob
relat
treatment
drowsi
fatigu
headach
thirst
dizzi
conclus
practicebas
studi
chines
subject
confirm
dl
effect
well
toler
treatment
ciu
associ
improv
qol
fresh
frozen
plasma
treatment
acut
hereditari
angioedema
djahna
thoma
huamin
li
natali
ball
mark
scarupa
washington
hospit
center
intern
medicin
washington
dc
unit
state
institut
asthma
allergi
allergi
immunolog
wheaton
unit
state
background
chronic
prophylact
therapi
hereditari
angioedema
hae
exist
time
unit
state
acut
therapi
lack
fresh
frozen
plasma
ffp
use
treat
acut
attack
use
controversi
report
ffp
worsen
hae
symptom
exist
method
twentythre
patient
hae
answer
survey
question
regard
past
experi
ffp
purpos
survey
determin
whether
ffp
administr
acut
hae
attack
ever
lead
worsen
symptom
addit
patient
ask
whether
ffp
perceiv
benefici
demograph
data
data
type
attack
treat
also
collect
result
six
patient
receiv
ffp
acut
attack
addit
three
patient
receiv
ffp
surgic
dental
prophylaxi
greater
acut
attack
treat
ffp
one
individu
account
approxim
treatment
attack
locat
includ
abdomin
peripher
facial
genit
laryng
episod
acut
worsen
administr
ffp
spread
larynx
perceiv
benefit
ffp
five
instanc
conclus
specif
therapi
acut
treatment
hae
wide
avail
ffp
consid
treatment
option
particularli
nonlaryng
attack
hereditari
angioedema
prognosi
non
treat
algerian
patient
kamel
djenouhat
hassen
messaoudi
moham
cherif
abbadi
institut
pasteur
depart
immunolog
algier
algeria
chu
mustapha
hospit
intern
medecin
depart
algier
algeria
background
hereditari
angioedema
hae
autosom
domin
diseas
character
quantit
qualit
defici
plasma
protein
call
esteras
inhibitor
diseas
manifest
episod
attack
nonpit
nonprurit
local
oedema
progress
rapidli
without
urticaria
erythema
swell
intestin
caus
intens
abdomin
cramp
associ
vomit
diarrhoea
laryng
oedema
may
prove
fatal
main
present
retrospect
studi
report
followup
care
hae
non
treat
symptomat
patient
patient
method
patient
clinic
score
establish
complement
system
investig
includ
antigen
quantif
inh
nephelometri
dade
behr
germani
determin
inhibitor
function
chromogen
assay
inh
immuno
ag
vienna
austria
perform
result
two
strike
matter
hae
spontan
cours
patient
compar
literatur
data
androgen
therapi
firstli
low
mortal
rate
versu
secondli
less
develop
moder
attack
follow
dental
care
even
without
prevent
drug
conclus
popul
seem
resist
inhibitor
defici
european
american
patient
suppos
treat
patient
would
becom
sensit
minor
disord
non
treat
one
also
differ
could
due
environment
factor
microb
effect
cetirinax
skin
reactiv
patient
chronic
urticaria
sonya
genova
vania
tzvetkova
hristina
dardanova
desislava
yolcheva
ludmil
terziev
temenuga
yosifova
medic
univers
pleven
clinic
allergi
pleven
bulgaria
background
cetirinax
actavi
deriv
piperazin
belong
famili
secondgener
antihistamin
fundament
pharmacolog
activ
metabol
product
hydrazin
firstgener
antihistamin
besid
antihistamin
activ
cetirinax
posses
also
vari
qualiti
augment
antiallerg
properti
suppress
erythema
papula
tradit
pharmacodinam
mechan
use
determin
activ
receptor
antagonist
purpos
survey
get
touch
suppress
effect
cetirinax
erythema
papula
caus
histamin
patient
chronic
urticaria
aim
put
survey
suprress
effect
accord
time
clinic
condit
patient
sex
age
method
studi
involv
twenti
patient
chronic
urticaria
year
age
histamin
sensit
patient
given
pricktest
mgml
histamin
minut
treatment
cetirinax
sensibl
determin
minut
hour
result
suppress
effect
cetirinax
set
minut
highest
mark
hour
erythema
hour
papula
differ
statist
import
compar
basic
size
papula
erythema
depress
erythema
equal
like
papula
variou
hour
depress
effect
mark
clearli
hourw
determin
histamin
papula
erythema
similar
patient
independ
age
sex
clinic
condit
clinic
effect
correl
excel
suppress
function
conclus
cetirinax
medicin
excel
qualiti
skin
reactiv
background
impact
childhood
asthma
health
care
system
consider
one
chronic
diseas
children
asthma
frequent
caus
emerg
room
visit
hospit
admiss
clinic
observ
indic
atop
diseas
particularli
bronchial
asthma
allerg
rhiniti
also
common
saudi
arabia
howev
formal
studi
recent
preval
etiolog
childhood
asthma
countri
method
preval
bronchial
asthma
school
children
studi
differ
part
countri
use
standard
protocol
questionnair
questionnair
design
committe
intern
expert
first
use
isaac
launch
first
phase
limit
age
preval
studi
questionnair
howev
similar
isaac
questionnair
includ
children
year
age
compar
purpos
continu
use
protocol
part
countri
questionnair
translat
local
languag
distribut
ministri
primari
educ
differ
urban
school
kingdom
result
studi
complet
differ
interv
within
past
sever
year
combin
data
reveal
vari
preval
asthma
highest
coastal
citi
border
yemen
call
gizan
n
follow
taif
n
hail
n
agricultur
citi
preval
rate
asthma
place
algazim
n
abha
n
dammam
n
hofuf
n
jeddah
n
riyadh
n
preval
allerg
rhiniti
much
higher
asthma
conclus
bronchial
asthma
emerg
one
preval
diseas
saudi
arabia
show
region
divers
socioeconom
differ
asthmat
non
asthmat
children
none
strike
environment
geograph
influenc
consid
reason
variat
rate
preval
aim
neg
associ
number
sibl
older
sibl
especi
allerg
diseas
symptom
impact
infect
immun
respons
suggest
studi
aim
examin
influenc
presenc
sibl
presenc
older
sibl
asthma
young
adolesc
materi
method
selfreport
data
adolesc
age
year
citi
republ
macedonia
obtain
isaac
phase
questionnair
asthma
environment
risk
factor
analys
presenc
sibl
older
sibl
separ
adjust
sex
passiv
smoke
exposur
home
gaswood
cook
home
woodcoaloil
heat
home
durat
tv
watch
daili
cat
ownership
correl
wheez
ever
current
wheez
current
speechlimit
wheez
exerciseinduc
wheez
everdiagnos
asthma
odd
ratio
ci
binari
logist
regress
perform
statist
analysi
data
result
signific
associ
presenc
sibl
gener
presenc
older
sibl
especi
asthma
symptom
found
p
paramet
conclus
seem
presenc
sibl
older
sibl
influenc
asthma
young
adolesc
environment
tobacco
smoke
risk
bronchial
hyperreact
pediatr
asthma
mona
elganzouri
tharwat
deraz
karima
abd
el
mona
elganzouri
sham
univers
pediatr
cairo
egypt
sham
univers
pediatr
pulmonolog
cairo
egypt
background
fifti
passiv
smoke
chiidren
least
one
parent
chronic
smoker
includ
present
studi
age
rang
year
oldexposur
cigrett
smoke
recogn
person
histori
confirm
measur
urinari
cotinin
major
metabolit
nicotin
urin
aim
evalu
effect
household
environment
tabacco
smoke
bronchial
reactiv
subsequ
lung
function
passiv
smoke
children
also
aim
correl
pulmonari
function
passiv
smoker
children
number
smoke
cigarett
thier
parent
well
durat
thier
exposur
cigrarett
smoke
urinari
cotinin
studi
mirror
imag
number
smoke
cigarett
level
also
correl
bronchial
hyperreact
lung
function
studi
children
method
ass
bronic
hyperreact
metacholin
challeng
test
mch
done
use
dosimet
pulmonari
function
test
perform
metacholin
challeng
test
challang
test
stop
reduct
forc
expiratori
volum
second
base
line
maximum
concentr
metacholin
reach
pulmonari
function
test
perform
med
graphic
tm
spirometeri
seri
hard
disc
comput
system
urinari
cotinin
measur
high
perform
liqui
tomographi
result
children
found
bronchial
children
perform
challang
test
basel
bronchial
hyperreact
chidren
show
postiv
metacholin
challang
test
variou
concentr
signific
relat
bronchial
hyperreact
bhr
number
smoke
cigrattesalso
signific
relaton
mean
forc
expiratori
volumm
one
second
reduct
well
cumul
dose
cd
mch
number
smoke
cigarett
parentsdur
tabacco
smoke
found
great
influenc
chiidren
pulmonari
function
test
conclus
passiv
smoke
children
subclin
bronchial
hyperreact
variou
degre
may
turn
asthmat
pulmonari
function
children
depend
multifactor
particular
number
smoke
cigarett
durat
exposur
tobacco
smoke
health
educ
program
explain
hazard
effect
passiv
smoke
recommend
associ
skin
allergi
test
bronchial
asthma
patient
md
shakur
khan
nidch
mohakhali
dhaka
nation
asthma
center
dhaka
bangladesh
purpos
asthma
major
public
health
problem
bangladesh
allergi
play
import
role
asthma
asthmat
tend
atop
thu
allerg
skin
test
reactiv
nonasthmat
henc
skin
prick
test
may
serv
use
adjunct
diagnosi
manag
bronchial
asthma
result
skin
prick
test
import
compon
formul
prevent
plan
manag
bronchial
asthma
method
prospect
case
control
studi
carri
asthma
centr
nation
institut
diseas
chest
hospit
dhaka
bangladesh
bronchial
asthma
patient
taken
case
subject
histori
asthma
allergi
taken
control
mean
age
case
male
femal
ratio
control
male
femal
ratio
posit
skin
test
detect
mite
hous
dust
cockroach
mosquito
ladi
finger
tomato
chicken
egg
white
prawn
control
nonallerg
subject
show
posit
skin
test
result
caus
posit
reaction
nonallerg
control
may
due
differ
select
subject
standard
extract
record
result
conclus
skin
allergi
test
sensit
method
detect
specif
ige
antibodi
posit
skin
test
along
clinic
relev
determin
consider
asthmat
patient
immunotherapi
high
preval
posit
immedi
hypersensit
skin
test
reaction
asthmat
popul
strong
argument
includ
initi
evalu
patient
asthma
identif
allergen
posit
skin
test
may
help
prevent
plan
manag
bronchial
asthma
patient
addit
reason
cardiovascular
risk
increas
asthma
exacerb
tatyana
brodskaya
vera
nevzorova
bori
geltser
vladivostok
state
medic
univers
depart
therapi
vladivostok
russian
feder
vascular
disturb
great
import
asthma
pathogenesi
research
mechan
properti
vessel
particular
arteri
stiff
special
interest
estim
cardiovascular
system
function
clear
whether
increas
arteri
stiff
observ
patient
asthma
method
examin
patient
sever
moder
asthma
noninvas
arteriographi
arteriograph
tensioclin
tensiom
hungari
control
group
includ
ageand
sexmatch
healthi
volunt
result
aortal
stiff
asthma
exacerb
signific
healthi
person
express
increas
aortic
puls
wave
veloc
apwv
augment
index
ia
apwv
patient
sever
asthma
two
fold
surpass
apwv
healthi
person
ia
patient
fold
surpass
control
level
signific
rais
g
arteri
stiff
take
part
increas
cardiovascular
risk
asthma
exacerb
independ
increas
arteri
stiff
asthma
exacerb
apwv
ia
essenti
improv
came
nearer
control
level
asthma
remiss
suggest
function
charact
chang
augment
arteri
stiff
asthma
correl
lung
ventil
dysfunct
hypoxia
diseas
durat
sever
conclus
describ
chang
explain
cardiovascular
event
rise
patient
exacerb
asthma
data
suggest
transitori
charact
arteri
stiff
increas
asthma
exacerb
tatyana
brodskaya
vera
nevzorova
bori
geltser
elena
motkina
vladivostok
state
medic
univers
depart
therapi
vladivostok
russian
feder
arteri
stiff
independ
factor
cardiovascular
risk
exacerb
asthma
associ
increas
arteri
stiff
mechan
respons
associ
clear
method
examin
patient
exacerb
sever
moder
asthma
ageand
sexmatch
healthi
volunt
arteri
stiff
estim
noninvas
arteriographi
arteriograph
tensioclin
tensiom
hungari
plasma
tnfa
level
determin
immuneenzym
analysi
inflamm
index
calcul
ratio
tnfa
system
oxid
disbal
estim
ratio
oxid
antioxid
plasma
activ
assess
spectrophotometri
hypoxemia
assess
digit
pulsoximetri
nonplasma
level
determin
greiss
method
result
central
arteri
stiff
higher
patient
exacerb
asthma
healthi
person
express
increas
aortic
puls
wave
veloc
apwv
augment
index
ia
assess
correl
analysi
apwv
ia
strongli
correl
hypoxemia
r
r
g
inflamm
index
r
r
g
less
strongli
clearli
apwv
ia
correl
nonlevel
r
r
g
system
oxid
disbal
r
r
g
conclus
result
suggest
hypoxemia
system
inflamm
hyponitrooxidemia
oxid
disbal
involv
rais
arteri
stiff
asthma
exacerb
question
requir
futur
research
mojgan
safari
reza
amin
hamedan
univers
medic
scienc
pediatr
ward
hamedan
islam
republ
iran
shiraz
univers
medic
scienc
pediatr
ward
shiraz
islam
republ
iran
background
exposur
cockroach
report
caus
asthma
mani
part
world
object
determin
preval
cockroach
sensit
asthmat
children
less
year
age
iranian
children
asthma
method
nineti
two
femal
male
patient
ask
complet
questionnair
cover
demograph
characterist
subject
skin
prick
test
cockroach
allergen
blood
sampl
also
withdrawn
assess
total
serum
ige
eosinophilia
result
twenti
seven
percent
n
subject
posit
skin
test
result
cockroach
allergen
signific
correl
preval
cockroach
skin
test
posit
male
femal
children
rural
urban
area
infant
year
older
age
youngest
subject
posit
skin
test
cockroach
month
parent
level
educ
type
age
children
resid
effect
preval
cockroach
skin
test
posit
also
signific
correl
total
serum
ige
eosinophilia
preval
cockroach
skin
test
posit
conclus
cockroach
import
sourc
domest
infest
citi
shiraz
sensit
cockroach
allergen
may
develop
earli
life
skin
test
cockroach
allergen
children
infantil
asthma
may
provid
use
inform
institut
environment
control
relationship
sensit
durat
asthma
associ
allerg
rhiniti
ion
gabriel
stoica
spitalul
de
pneumologi
amabulatoriul
tbc
sector
bucharest
romania
object
aim
studi
assess
sensit
common
inhal
allergen
among
adult
patient
asthma
associ
allerg
rhiniti
ar
find
relationship
medic
durat
asthmaar
method
screen
survey
questionnair
includ
question
assess
preval
symptom
asthma
month
question
relat
month
preval
ar
symptom
distribut
year
old
median
age
yr
patient
present
outpati
depart
year
respons
rate
asthmat
patient
diagnos
accord
gina
definit
asthma
ar
diagnos
due
clinic
symptom
sneez
itch
rhinorhoea
nasal
congest
sensit
allergen
result
hypersensit
inhal
allergen
hous
dust
mite
anim
dander
pollen
assess
skin
prick
test
posit
mm
respond
clinic
histori
patient
asthma
ar
sensit
hous
dust
mite
dpteronyssinu
dfarina
hypersensit
document
posit
skin
prick
test
patient
asthma
ar
note
pollen
cat
dog
dander
respect
conclus
signific
correl
r
p
g
frequenc
sensit
hous
dust
mite
durat
asthma
hous
dust
mite
sensit
preval
allergen
sensit
adult
patient
asthma
ar
establish
control
allergen
critic
optim
treatment
svetlana
mazurina
valeri
kaznacheev
yuri
gervaziev
mechnickov
research
institut
vaccin
sera
ram
moscow
russian
feder
background
bronchial
asthma
ba
chronic
diseas
associ
elev
ige
level
demonstr
well
play
crucial
role
regul
ige
product
aim
studi
reveal
associ
g
gene
polymorph
level
total
ige
ba
patient
method
polymorph
gene
analyz
pcrrflp
asthma
patient
healthi
control
subject
result
total
ige
level
measur
elisa
total
serum
ige
level
found
elev
ba
patient
group
kul
within
normal
rang
control
group
kul
level
total
ige
ba
patient
healthi
donor
differ
significantli
p
g
frequenc
allel
combin
reliabl
differ
control
group
p
studi
influenc
polymorph
total
ige
level
reveal
level
consider
elev
kul
among
patient
allel
compar
group
allel
group
allel
total
ige
level
group
kul
kul
respect
patient
allel
identifi
link
diseas
studi
trait
determin
wolf
coeffici
associ
conclus
thu
studi
reveal
associ
gene
polymorph
total
ige
level
atopi
data
present
interquartil
rang
median
quartil
quartil
background
despit
high
preval
elderli
asthma
remain
unrecogn
misunderstood
symptom
may
typic
young
patient
cardiac
respiratori
diseas
may
frequent
associ
studi
clinic
characterist
elderli
asthma
report
till
method
investig
whether
characterist
elderli
asthma
differ
accord
onset
asthma
one
hundr
eighti
asthmat
patient
age
enrol
attend
asthma
allergi
clinic
seoul
nation
univers
bundang
hospit
result
patient
ninti
nine
patient
develop
asthma
age
group
lateonset
asthma
loa
mean
durat
diseas
yr
remain
group
earli
onset
asthma
eoa
mean
durat
ill
yr
group
indistinguish
symptom
medic
requir
serum
level
total
ige
eoa
greater
degre
airway
obstruct
predict
valu
p
g
greater
likelihood
neutrophil
induc
sputum
moreov
novel
indic
name
neutrophileosinophil
ratio
induc
sputum
invers
relat
sever
pft
indic
includ
fevfvc
fvc
find
suggest
eosionphil
also
neutrophil
could
play
import
role
airway
inflamm
airflow
limit
conclus
studi
sggest
cellular
composit
airway
inflamm
lung
function
depend
onset
possibl
durat
diseas
elderli
asthmat
find
suggest
earli
onset
longstand
asthma
may
lead
chronic
persist
airway
obstruct
therebi
mimic
chronic
obstruct
lung
diseas
apapari
questionnair
base
assess
monitor
treatment
asthma
physician
infant
preschool
older
children
krishan
chugh
sir
ganga
ram
hospit
pediatr
delhi
india
background
apapari
questionnair
design
assess
treatment
pattern
childhood
asthma
asiapacif
region
method
total
doctor
treat
asthma
invit
respond
apapari
questionnair
evalu
treatment
pattern
childhood
asthma
result
doctor
complet
questionnair
complet
treat
children
pediatrician
pediatr
pulmonologist
allergist
pulmonologist
belong
specialti
privat
practic
hospit
teach
hospit
work
set
respons
use
symptom
card
monitor
asthma
follow
respons
criteria
monitor
childhood
asthma
tabul
treat
acut
attack
use
nebulis
salbutamol
terbutalin
use
inhal
salbutamolterbutalin
spacer
use
oral
corticosteroid
criterion
use
hospit
admiss
acut
attack
asthma
given
puls
oximetri
basi
oxygen
therapi
use
patient
use
oximetri
sever
asthma
puls
oximetri
facil
favour
outcom
report
doctor
report
unfavor
result
sever
acut
asthma
ventilatori
support
compar
treat
tertiaryunivers
hospit
access
ventilatori
icu
facil
treat
sever
acut
attack
mainten
therapi
asthmat
infant
alway
use
frequent
use
choic
mainten
therapi
asthma
among
infant
preschool
older
children
follow
respond
knew
never
use
form
immunotherapi
occasion
use
knowledg
regard
avail
immunotherapi
conclus
signific
segment
doctor
follow
current
manag
guidelin
childhood
asthma
expect
bronchial
hyperreact
bhr
children
simpli
use
short
questionnair
anxhela
qirko
gurakuqi
sokol
agolli
uhc
allergi
depart
tirana
albania
background
provoc
test
asses
bhr
time
consum
sometim
imposs
perform
questionnair
offer
high
expect
bhr
questionnair
practic
valu
avoid
provoc
test
certain
case
method
children
year
old
tirana
perform
bronchial
provoc
test
salin
accord
isaac
protocol
children
answer
day
short
origin
questionnair
question
ever
short
breath
cough
situat
physic
effort
gym
hour
go
stair
etc
exposur
tobacco
smoke
exposur
car
eman
heat
cook
gase
laugh
loudli
everi
posit
answer
code
score
score
posit
answer
score
posit
answer
result
subject
posit
result
salin
provoc
chang
prepost
provoc
divid
accord
score
done
subject
neg
bhr
surprisingli
subject
neg
result
salin
provoc
score
compar
subject
posit
salin
also
subject
neg
salin
result
score
subject
posit
react
salin
provoc
score
subject
neg
result
salin
regardless
result
score
questionnair
nr
compar
subcategori
subject
besid
neg
salin
also
score
nr
found
last
group
higher
rate
person
familiar
histori
asthma
allergi
sensibl
specif
posit
predict
valu
neg
predict
valu
questionnair
forecast
bhr
calcul
score
presenc
symptom
score
absenc
symptom
conclus
short
questionnair
abl
forecast
neg
bhr
case
symptom
miss
score
score
regardless
provoc
result
intrigu
clinic
profil
posit
person
familiar
histori
allergi
requir
attent
doctor
deeper
investig
futur
ask
simpl
question
time
consum
bronchial
provoc
test
could
avoid
everyday
medic
practic
case
answer
neg
gabriella
galffi
lilla
tamasi
marta
orosz
gyorgi
losonczi
semmelwei
univers
dept
pulmonolog
budapest
hungari
global
initi
asthma
gina
report
provid
new
asthma
classif
base
sever
also
level
asthma
control
bronchial
asthma
wordwid
problem
estim
million
affect
individu
asthmat
patient
countri
classif
asthma
sever
use
doctor
made
decis
manag
treatment
patient
goal
asthma
treatment
achiev
maintain
clinic
control
asthma
control
test
one
valid
measur
analyz
control
partli
control
uncontrol
level
asthma
aim
aim
studi
investig
level
asthma
control
countri
method
outpati
clinic
studi
group
patient
femal
male
mean
age
bronchial
asthma
asthma
control
test
done
patient
also
eleven
question
regard
smoke
habit
asthma
medic
side
effect
exacerb
exercis
induc
dyspno
result
patient
n
pt
control
partli
control
asthma
level
n
pt
uncontrol
asthma
base
asthma
control
test
total
control
level
achiev
n
patient
unabl
work
job
patient
abl
work
even
household
suffer
asthma
seventi
eight
patient
reduc
qualiti
life
howev
pt
believ
felt
total
asthma
control
pt
subject
opinion
uncontrol
asthma
conclus
studi
found
patient
opinion
condit
asthma
correl
object
test
asthma
control
test
show
us
realiti
level
bronchial
asthma
test
easi
use
even
alon
patient
asthma
control
test
help
achiev
maintain
clinic
control
asthma
level
obes
risk
factor
asthma
sever
recent
obes
reach
epidem
proport
mani
countri
evid
mount
obes
also
risk
factor
asthma
aim
studi
assess
relat
obes
asthma
sever
children
conduct
crosssect
studi
outpati
depart
guramishvili
pediatr
clinic
studi
enrol
children
age
mean
age
boy
girl
use
bodi
mass
index
bmi
detect
overweight
obes
weight
categori
defin
bmi
number
posit
bmiag
growth
chartrisk
overweight
less
percentil
obes
equal
greater
percentil
asthma
sever
definit
base
patient
clinic
andor
spirometer
paramet
accord
gina
guidelin
children
histori
lung
diseas
exclud
preval
obes
studi
popul
among
girl
among
boy
obes
mean
bmi
femal
asthma
significantli
higher
male
p
g
obes
children
differ
baselin
asthma
classif
like
persist
asthma
despit
similar
sever
ill
admiss
longer
length
stay
hospit
j
vs
j
day
p
g
conclud
relationship
bodi
weight
asthma
sever
obes
may
potenti
modifi
risk
factor
asthma
asthma
exacerb
background
recent
data
anim
studi
indic
fat
tissu
sourc
eotaxin
may
play
import
role
asthma
howev
link
obes
airway
inflamm
asthma
well
understood
object
aim
investig
impact
obes
eotaxin
level
patient
stabl
mildmoder
asthma
method
steroidna
asthmat
mean
age
yr
control
subject
without
lung
diseas
mean
age
yr
investig
accord
bodi
mass
index
bmi
subject
divid
group
subject
normal
weight
bmi
g
subject
overweight
bmi
q
kgm
spirometri
bronchial
provoc
test
methacholin
pd
sputum
induct
bronchoscopi
perform
concentr
serum
sputum
supernat
bal
fluid
measur
use
commerci
elisa
kit
result
asthma
patient
overweight
concentr
induc
sputum
significantli
higher
compar
asthma
patient
normal
weight
vs
pgml
control
subject
vs
pgml
p
g
wherea
significantli
differ
studi
group
correl
eotaxin
level
number
eosinophil
induc
sputum
bal
fluid
conclus
elev
sputum
concentr
asthmat
overweight
let
suggest
increas
bodi
mass
may
upregul
inflammatori
marker
asthma
patient
fariborz
zandieh
isfahan
univers
medic
scienc
asthma
allergi
immuolog
isfahan
islam
republ
iran
background
interest
impact
ill
day
day
function
lead
investig
includ
diseas
specif
gener
health
relat
qualiti
life
hr
qol
questionnair
broad
rang
clinic
studi
gain
full
pictur
impact
asthma
live
children
condit
necessari
make
direct
measur
health
relat
qualiti
life
method
respons
need
use
junip
pediatr
asthma
qualiti
life
questionnair
paqlq
junip
pediatr
asthma
caregiv
qualiti
life
questionnair
pacqlq
develop
base
guidelin
construct
dozen
valid
diseas
specif
qualiti
life
instrument
paqlq
consist
item
children
asthma
identifi
troublesom
daili
live
pacqlq
contain
item
two
domain
emot
activ
disturb
studi
design
consist
month
singl
cohort
studi
patient
particip
studi
children
year
age
wide
rang
asthma
sever
caregiv
patient
paqlq
caregiv
pacqlq
complet
one
week
visit
patient
record
morn
peak
flow
rate
medic
use
symptom
diari
complet
physic
examin
determin
asthma
sever
spirometri
perform
result
questionnair
static
analysi
show
good
level
longitudin
cross
section
correl
convent
asthma
indic
gener
qualiti
life
found
consist
qol
boy
disturb
femal
good
relev
sever
asthma
qol
score
disturb
qol
caregiv
male
asthmat
patient
caregiv
femal
asthmat
patient
could
find
signific
relev
percentag
predict
overal
score
qol
conclus
smaller
airway
higher
airway
resist
activ
male
femal
may
explain
boy
disturb
life
style
femal
shadan
pedram
thehran
univers
medic
scienc
medicalsurgicalnurs
thehran
islam
republ
iran
asthma
qualiti
life
iranian
asthmat
patient
asthma
chronic
diseas
make
mani
health
problem
everi
world
aspect
qualiti
life
iranian
asthmat
patient
variabl
object
determin
factor
influenc
qualiti
life
patient
asthma
reffer
lung
clinic
gener
hospit
tehran
methodolog
research
descript
studyth
subject
consist
patientssampl
select
sampl
randomizedth
method
collect
data
questionnaireth
data
collect
one
stage
analyz
descript
inferenti
method
spss
soft
ware
find
result
show
qualiti
life
inpati
physic
aspect
inappropriateand
social
econom
aspect
rare
appropri
patient
mental
sleep
aspect
inappropri
neither
sex
overweight
risk
factor
asthma
symptom
adolesc
popul
argentina
background
posit
associ
bodi
mass
index
bmi
asthma
recent
suggest
howev
sexdepend
associ
remain
controversi
aim
present
studi
explor
relationship
bmi
asthma
well
sexdepend
young
adolesc
method
selfreport
data
obtain
standard
intern
studi
asthma
allergi
childhood
isaac
phase
three
written
questionnair
young
adolesc
age
year
old
randomli
select
privat
public
school
salta
cordoba
argentina
use
bmi
individu
calcul
intern
cutoff
point
bmi
overweight
obes
sex
age
use
normal
overweight
obes
kg
low
preval
obes
includ
overweight
group
variabl
ecolog
questionnair
consid
probabl
confound
confront
tabl
wheez
last
month
bmi
variabl
found
significantli
associ
includ
final
analysi
data
statist
analyz
chisquar
test
p
odd
ratio
ci
binari
logist
regress
result
respond
male
boy
associ
overweight
ci
p
exercis
one
less
week
associ
obes
ci
p
adjust
one
significantli
associ
increas
bmi
p
respect
watch
tv
one
less
hourday
relat
lower
bmi
ci
p
exercis
less
per
week
factor
associ
wheez
adjust
bmi
sex
p
conclus
popul
neither
sex
overweight
associ
wheez
symptom
howev
sex
significantli
associ
overweight
mayb
scarc
obes
popul
citi
contribut
find
howev
sedentari
profil
contribut
increas
bmi
wheez
symptom
also
expect
abstract
withdrawn
abstract
withdrawn
threeyear
followup
studi
asthma
airway
symptom
selfreport
allergi
among
pilot
cabin
crew
commerci
aircraft
gunilla
wiesland
torsten
lindgren
dan
norback
dep
medic
scienc
occup
env
med
uppsala
sweden
depart
medic
scienc
occup
environment
medicin
uppsala
sweden
background
cabin
air
qualiti
import
especi
employe
sensit
airway
studi
incid
asthma
allergi
pilot
cabin
crew
aim
studi
studi
relat
occup
factor
person
factor
age
gender
atopi
smoke
habit
incid
asthma
allergi
method
standard
questionnair
rebro
na
answer
pilot
n
cabin
attend
n
three
year
later
questionnair
sent
pilot
n
cabin
attend
n
duti
new
onset
asthma
allergi
three
year
incid
calcul
logist
regress
relat
person
factor
logist
regress
result
preval
airway
symptom
asthma
two
three
time
lower
pilot
cabin
attend
three
year
incid
doctor
diagnos
asthma
among
pilot
among
cabin
attend
incid
airway
symptom
wheez
attack
breathless
among
pilot
among
cabin
attend
incid
chronic
bronchiti
daili
product
cough
among
pilot
among
cabin
attend
incid
pollen
allergi
furri
pet
allergi
respect
among
pilot
respect
among
cabin
attend
incid
food
allergi
intoler
among
pilot
among
cabin
attend
incid
airway
symptom
lower
pilot
p
g
incid
doctor
diagnos
asthma
food
allergi
higher
atop
p
g
younger
cabin
crew
purser
higher
incid
pollen
furri
pet
allergi
p
g
relat
seen
gender
tobacco
smoke
conclus
age
atopi
type
occup
relat
incid
asthma
selfreport
allergi
incid
doctor
diagnos
asthma
among
pilot
year
somewhat
higher
expect
airway
symptom
genral
two
three
time
common
among
cabin
attend
studi
start
stop
smoke
intercontin
flight
result
indic
parietaria
pollinosi
frequent
greec
among
patient
sara
parietaria
pollinosi
appear
increas
problem
last
year
greec
phenomenon
may
repres
influenc
environment
factor
preval
asthma
rhiniti
eczema
among
brazilian
japanes
adolesc
ad
citi
paulo
brazil
camelonun
ricardo
yamada
lui
guilherm
pimentel
thale
shibata
sano
dirceu
charl
naspitz
feder
univers
paulo
divis
allergi
clinic
immunolog
paulo
brazil
hospit
nipobrasileiro
divis
pediatr
allergi
paulo
brazil
object
evalu
import
genet
background
preval
asthma
rhinoconjunct
r
atop
eczema
ae
among
ad
born
brazil
differ
genet
background
method
written
questionnair
appli
two
group
ad
similar
socioeconom
statu
live
citi
paulo
brazilian
n
japanes
third
gener
born
brazil
famili
without
mix
marriag
n
affirm
respons
bhave
wheez
last
yearidentifi
ad
bnasal
ocular
symptom
last
yearthos
r
beczema
last
year
evidenc
flexur
areasthos
ae
questionsspeech
problem
last
month
acut
attack
bnasal
symptom
interf
daili
activ
bkept
awak
night
itchi
rash
last
haracter
sever
r
ae
respect
result
differ
accord
gender
group
except
preval
r
higher
among
brazilian
femal
preval
x
p
g
preval
r
x
p
g
higher
brazilian
ad
compar
japanes
ad
respect
differ
sever
x
r
sever
significantli
higher
brazilian
ad
x
p
g
preval
ae
higher
japanes
ad
x
p
g
without
differ
sever
x
p
preval
diseas
differ
observ
japan
paulo
isaac
phase
conclus
preval
observ
among
third
gener
japanes
ad
without
miscegen
born
brazil
show
similar
result
obtain
isaac
phase
recent
publish
japan
consid
ad
group
evalu
expos
environ
might
specul
genet
background
japanes
popul
import
environment
influenc
develop
asthma
allerg
diseas
asthma
korea
corea
larg
multicent
longterm
cohort
studi
whole
spectrum
asthma
clinic
characterist
accord
sever
asthma
diseas
mani
research
use
recogn
spectrum
chronic
obstruct
airway
disord
coad
accordingli
import
reveal
prognost
factor
influenc
natur
cours
asthma
prohibit
progress
sever
irrevers
uncontrol
asthma
thought
possibl
case
asthmat
patient
observ
long
term
follow
cohort
studi
object
defin
import
prognost
factor
contribut
asthma
sever
suggest
new
clinic
understand
paradigm
coad
method
research
univers
hospit
establish
asthma
cohort
name
cohort
realiti
evolut
adult
asthma
korea
corea
sinc
year
korea
continu
collect
patient
chronic
persist
respiratori
symptom
dyspnea
cough
sputum
wheez
month
airflow
limit
less
ahr
confirm
methacholin
bronchial
provoc
test
mbpt
first
studi
cohort
analyz
variou
clinic
factor
influenc
sever
asthma
regist
patient
time
firstvisit
sever
assess
special
allergist
definit
gina
guidelin
result
sever
asthma
associ
skin
prick
test
posit
p
g
histori
hospit
visit
due
asthma
exacerb
p
symptom
onset
p
durat
diagnosi
p
sever
also
significantli
correl
fvc
bronchodil
respons
p
g
howev
smoke
nt
affect
sever
asthma
even
case
passiv
smoke
venezuela
asthma
caus
one
million
crise
per
year
rather
signific
impact
health
system
compar
usa
report
demograph
situat
similar
rest
latin
america
young
mostli
urban
popul
live
variabl
condit
poverti
applic
massiv
vaccin
program
public
health
measur
ensu
noncommunic
diseas
occupi
major
role
near
futur
venezuela
isaac
data
show
eighteen
percent
wheez
past
year
overal
preval
thirti
two
percent
report
method
order
explor
previou
high
preval
carri
multidisciplinari
ongo
studi
approv
ethic
committe
institut
biomedicin
ratifi
academ
council
medic
faculti
central
univers
venezuela
unselect
school
children
year
old
low
middl
socioeconom
background
cover
differ
area
caraca
venezuela
inform
consent
sign
parent
guardian
children
randomli
select
school
evalu
valid
modifi
graffar
socioeconom
questionnair
allerg
rhiniti
asthma
atop
dermat
valid
questionnair
aria
gina
hannifin
criteria
skin
prick
test
alkabello
common
food
inhal
allergen
plu
total
ige
elisa
complet
blood
count
coulter
serial
fece
examin
ova
parasit
perform
children
pre
post
bronchodil
pef
spirometr
measur
valu
obtain
microloop
includ
data
analysi
result
found
child
evalu
allerg
rhiniti
asthma
atop
dermat
without
allerg
patholog
also
found
child
evalu
parasit
respiratori
infecti
diseas
associ
conclus
data
confirm
high
preval
allerg
diseas
venezuela
employ
questionnair
clinic
exam
immun
diagnost
evalu
methodolog
henc
health
system
medic
faculti
highli
awar
similar
find
establish
proper
educ
program
primari
health
care
personnel
also
commun
develop
nation
wait
simpler
effect
approach
manag
public
health
problem
time
come
herberto
jose
chong
neto
nelson
rosario
ana
carolina
dela
bianca
dirceu
javier
mallol
univers
parana
pediatr
curitiba
brazil
univers
sao
paulo
pediatr
sao
paulo
brazil
univers
santiago
pediatr
santiago
chile
background
larg
intern
studi
asthma
allergi
childhood
found
notori
variat
preval
tempor
trend
among
countri
howev
intern
studi
epidemiolog
characterist
wheez
first
year
life
aim
studi
valid
questionnair
assess
preval
recurr
wheez
infant
method
studi
undertaken
pediatr
emerg
room
per
random
sampl
parent
visit
per
lower
respiratori
ill
answer
questionnair
wheez
develop
intern
studi
wheez
infant
eisl
spanish
estudio
internacion
de
sibilancia
en
lactant
visit
infant
examin
one
author
blind
report
presenc
wheez
chest
auscult
sensit
specif
predict
posit
valu
predict
neg
valu
concord
level
calcul
parent
physician
report
result
two
hundr
nine
infant
age
month
particip
studi
fifti
six
parent
report
current
wheez
confirm
physician
parent
report
current
wheez
wheez
physic
examin
ci
questionnair
show
high
sensit
specif
posit
predict
valu
predict
neg
valu
conclus
regardless
previou
experi
wheez
episod
parent
reliabl
inform
infant
current
wheez
simpl
conveni
questionnair
confirm
physic
examin
produc
accur
tool
ass
preval
asthma
symptom
infant
differ
season
monthli
variat
asthma
exacerb
patient
allerg
non
allerg
asthma
christo
grigorea
dimitrio
vourda
konstantino
petala
air
forc
hospit
allergolog
depart
athen
greec
background
recognit
clear
season
monthli
pattern
asthma
exacerb
ae
particular
area
may
allow
prevent
strategi
develop
object
aim
studi
determin
season
monthli
variat
ae
patient
allerg
nonallerg
asthma
method
data
obtain
depart
athen
octob
septemb
month
evalu
ae
occur
period
patient
allerg
asthma
aa
nonallerg
asthma
naa
diagnosi
classif
aa
naa
made
accord
result
skin
prick
test
spt
common
aeroallergen
patient
aa
defin
posit
sptand
patient
naa
defin
neg
spt
posit
sptwa
defin
wheal
size
least
mm
greater
neg
control
ae
defin
deterior
asthma
result
unschedul
visit
ie
patientiniti
lead
chang
asthma
treatment
need
oral
steroid
day
andor
emerg
room
visithospit
data
present
monthli
averag
year
combin
data
percent
j
averag
monthli
valu
month
studi
result
ae
male
femal
patient
aa
male
femal
also
ae
male
femal
patient
naa
male
femal
percent
averag
monthli
valu
conclus
find
suggest
ae
differ
clear
season
monthli
variat
patient
aa
naa
patient
aa
show
increas
ae
april
may
june
spring
earli
summer
especi
may
occur
great
increas
peak
ae
patient
naa
increas
ae
januari
april
winter
spring
septemb
novemb
autumn
result
may
offer
signific
opportun
improv
diseas
manag
season
defin
wheal
size
least
mm
greater
neg
control
ae
defin
deterior
asthma
result
unschedul
visit
ie
patientiniti
lead
chang
asthma
treatment
need
oral
steroid
day
andor
emerg
room
visithospit
data
present
monthli
averag
year
combin
data
percent
j
averag
monthli
valu
month
studi
result
ae
male
femal
asthmat
patient
male
femal
ae
identifi
patient
year
patient
year
patient
year
patient
year
conclus
find
suggest
ae
athen
region
season
monthli
variat
patient
allerg
mite
pteronyssinu
farina
greec
increas
ae
occur
spring
month
march
april
may
june
peak
may
also
autumn
month
septemb
octob
novemb
peak
septemb
decreas
ae
occur
rest
month
nadir
august
although
ae
may
trigger
number
factor
ie
respiratori
viral
infect
studi
suggest
asthmat
patient
allerg
mite
repres
season
monthli
variat
ae
greec
result
may
offer
signific
opportun
improv
diseas
manag
conclus
sverdlovsk
region
ba
spread
urban
area
wider
rural
region
ba
atop
form
prevail
urban
rural
area
citi
import
asthma
rf
bad
factor
product
facil
presenc
cockroach
bird
asthma
rf
common
urban
rural
area
allerg
rhiniti
strain
asthma
allergi
presenc
fish
aquarium
live
hous
apart
outcom
childhood
asthma
asthmat
children
moham
herrag
mustapha
iraqui
ibn
sina
univers
hospit
pulmonologyallergolog
rabat
morocco
aim
studi
investig
outcom
childhood
asthma
asthmat
children
age
year
seen
year
follow
prospect
till
sever
asthma
classifi
mild
moder
sever
sever
evalu
everi
three
year
chang
respiratori
symptom
spirometri
initi
children
mild
asthma
moder
asthma
ware
consid
sever
asthma
children
initi
mild
asthma
sever
ten
year
later
moder
asthma
sever
asthma
children
mild
asthma
mild
asthma
ten
year
later
children
sever
asthma
consid
sever
ten
year
later
final
prognosi
influenc
initi
sever
asthma
presenc
associ
atop
diseas
effect
nitric
oxid
synthas
inhibitor
airway
hyperrespons
inflamm
murin
asthma
model
introduct
excess
airway
product
nitric
oxid
suggest
play
role
bronchial
asthma
still
clear
ino
isoform
involv
eosinophil
airway
inflamm
object
select
induc
nitric
oxid
synthas
ino
inhibitor
aminomethyl
benzyl
acetamidin
nonselect
no
inhibitor
lname
nnitrolarginin
methyl
ester
test
murin
acut
asthma
model
method
six
weekold
femal
balbc
mice
sensit
expos
aerosol
ovalbumin
ova
balbc
mice
group
n
treat
indic
dose
mgkg
mgkg
mgkg
intraperiton
lname
intraperiton
five
time
allergen
challeng
methacholin
bronchoprovoc
test
bronchoalveolar
lavag
bal
fluid
analys
perform
result
airway
inflamm
decreas
group
bal
fluid
total
cell
count
posit
control
x
mgkg
mgkg
mgkg
x
p
p
g
p
g
eosinophil
count
posit
control
mgkg
x
mgkg
mgkg
p
p
p
decreas
group
compar
posit
control
group
signific
differ
airway
hyperrespons
log
p
regardless
treatment
result
demonstr
select
ino
inhibitor
effect
improv
airway
inflamm
reduc
total
inflammatori
cell
count
ovasensit
balbc
mice
levan
bolokadz
inga
fedotova
volodimir
fedotov
kharkov
allergolog
centr
allergolog
kharkov
ukrain
background
assess
relationship
among
sexual
psycholog
hormon
physic
statu
women
bronchial
asthma
ba
method
twentynin
women
ba
healthi
women
control
group
enrol
studi
patient
ask
complet
femal
sexual
function
index
gener
health
questionnair
medic
outcom
studi
short
form
health
survey
mental
physic
compon
summari
score
calcul
use
answer
questionnair
given
group
well
statist
analysi
perform
use
mannwhitney
u
test
pearson
correl
test
result
statist
signific
differ
observ
questionnair
score
p
common
femal
sexual
dysfunct
diminish
arous
n
women
ba
correl
analysi
total
femal
sexual
function
index
score
statist
signific
posit
correl
mental
compon
summari
score
r
p
neg
correl
gener
health
questionnair
score
r
p
conclus
result
studi
shown
bronchial
asthma
caus
femal
sexual
dysfunct
mental
psychiatr
mechan
ekaterin
karseladz
maia
davituri
rusudan
karseladz
tinatin
bigvava
tbilisi
state
univers
stomatolog
depart
tbilisi
georgia
tbilisi
children
hospit
allergolog
depart
tbilisi
georgia
tbilisi
state
univers
pediatr
depart
tbilisi
georgia
institut
pediatr
neonatolog
depart
tbilisi
georgia
difficult
pathogenesi
bronchial
asthma
import
nerv
inflammatori
mechan
unbal
variou
group
autonom
nervou
system
process
made
bronchial
asthma
caus
lipid
phase
cell
membran
chang
import
oxid
process
reinforc
develop
antioxid
syndrom
studi
aim
ass
last
product
lipid
peroxid
oxid
lpo
enzym
malon
dealdehyd
mda
ceruloplasmin
cp
superoxidismuta
sod
function
autonom
nervou
system
situat
person
nervou
statu
fulfil
diagnosi
test
c
spilberg
emot
statu
studi
lusher
color
test
investig
index
oxid
stress
psychosomat
characterist
children
bronchial
asthma
patient
median
age
patient
year
bronchial
asthma
practic
healthi
children
investig
mathemat
treatment
date
made
program
packag
spss
result
blood
serum
patient
contemt
mda
high
control
group
p
g
mda
level
patient
eyton
type
veget
regul
lower
vagotonyc
patient
p
g
especi
import
coeffici
date
lpo
product
quantiti
patient
g
vagotonyc
tape
straight
contact
emot
stress
r
p
end
studi
carri
bronchial
asthma
conduct
high
level
lpo
product
blood
serum
lpo
activ
shown
almost
everytim
year
result
investig
show
us
lpo
prosess
activ
time
bronchial
asthma
establish
coordib
lpo
level
blood
serum
sever
diseas
patient
bronchial
asthma
confirm
antioxid
decreas
patient
low
antioxid
guard
patient
eyton
type
vegetat
regul
give
us
chanc
seper
biochem
nontrustworthi
x
lipid
peroxid
oxid
system
relat
bcgscar
diamet
asthma
children
conflict
idea
invers
relationship
delay
type
hypersensit
reaction
bcg
atop
state
stronger
respons
ppd
test
indic
potent
respons
suppos
influenc
allerg
reaction
still
doubt
whether
scar
bcg
vaccin
also
suppos
indic
respons
previou
studi
ppd
test
respons
significantli
smaller
asthmat
patient
studi
relationship
bcg
scar
asthma
investig
method
patient
younger
year
old
vaccin
birth
variabl
sever
asthma
compar
number
ageadjust
healthi
control
group
casecontrol
studi
mean
vertic
longitudin
diamet
determin
time
sever
asthma
case
group
evalu
accord
classif
nation
institut
health
nation
institut
heart
lung
blood
ask
mother
frequenc
night
day
symptom
interv
attack
patient
divid
three
group
mild
moder
sever
group
mild
intermitt
mild
persist
group
classifi
one
group
result
case
group
mean
size
bcg
scar
control
group
mean
size
p
conclus
result
previou
research
show
signific
revers
relat
ppdskin
test
respons
asthma
signific
relat
found
bcg
scar
asthma
may
indic
bcgscar
good
indic
respons
probabl
relat
mechan
wound
heal
bilun
gemicioglu
imran
ozdemir
bilg
ozgur
yuksel
istanbul
univers
faculti
medicin
cerrahpasa
depart
pulmonari
diseas
istanbul
turkey
backround
act
valid
questionnair
total
score
rang
poor
control
total
control
nathan
ra
et
al
jaci
aim
correl
act
feno
evalu
well
control
asthma
patient
three
month
followup
period
method
act
feno
measur
femal
male
persist
asthma
patient
follow
outpati
clinic
asthma
andor
feno
andor
addon
therapi
given
month
paramet
remeasur
correl
paramet
addon
therapi
evalu
result
mean
act
score
feno
period
period
addon
therapi
femal
male
asthma
patient
mean
age
tabl
patient
three
paramet
feno
act
feno
act
normal
valu
remain
patient
comorbid
diseas
found
reason
uncontrol
asthma
result
increas
three
paramet
significantli
well
correl
conclus
conclud
three
paramet
well
correl
act
may
suffici
observ
patient
alon
although
would
best
measur
paramet
avail
global
approach
psycholog
aspect
child
asthma
anselmo
sanchez
palacio
hospit
universitari
insular
gran
canaria
allergolog
unit
la
palma
gc
canari
island
spain
background
although
signific
incid
variou
psycholog
variabl
recogn
long
time
asthmat
children
true
role
subject
strong
controversi
stress
suggest
extern
condit
affect
respiratori
tract
chronic
aspect
diseas
disrupt
effect
qualiti
life
sensat
threat
life
condit
appear
differ
psychosoci
alter
patient
immedi
famili
environ
experiment
test
shown
sever
diseas
multipl
hospit
absenc
specif
ige
mediat
symptom
upon
exposur
allergen
could
contribut
increas
emot
disord
children
object
search
effici
intervent
procedur
includ
improv
children
school
person
famili
social
adapt
help
modifi
inadequ
attribut
attitud
toward
diseas
materi
method
random
stratifi
prospect
studi
includ
popul
pediatr
patient
age
compris
year
age
boy
girl
asthma
rhiniti
asthma
rhiniti
patient
divid
activ
control
group
follow
test
use
multifactori
autoevalu
test
infantil
adapt
tama
questionnair
attribut
attitud
toward
diseas
atac
questionnair
evalu
physic
aspect
diseas
eveo
program
appli
case
group
consist
emotionalinstruct
program
pieasa
result
psychotherapeut
approach
treatment
asthmat
children
use
program
pieasa
achiev
global
improv
children
fulfil
object
program
modif
neg
attribut
attitud
toward
diseas
accomplish
chang
attitud
increas
food
intak
complianc
medic
obtain
better
result
obtain
boy
girl
regard
social
school
adapt
aspect
howev
girl
show
reduct
number
emerg
room
visit
conclus
believ
use
type
evalu
en
asthmat
children
recommend
sinc
contribut
overal
improv
asthmat
symptom
children
autoimmunt
uveiti
year
experi
posterior
uveiti
patient
process
bilater
unilater
right
eye
affect
establish
patient
unilater
left
eye
affect
patient
familiar
histori
present
uveiti
associ
system
diseas
nonassoci
system
diseas
patient
system
diseas
juvenil
chronic
arthriti
spondyl
vogt
kayanagi
harada
diseas
nodosa
poliarter
wegen
granulomatosi
sarcoidosi
infecti
etiolog
agent
identifi
patient
clinic
sign
describ
diminut
visual
sharp
ocular
pain
fotofobia
red
eye
found
antibodi
antinuclear
posit
patient
weak
pattern
immunosupresor
treatment
use
cyclophosphamid
patient
azatyoprin
patient
methotrex
use
children
complic
includ
synechia
cataract
keratopathi
patient
patient
left
treatment
conculs
clinic
demograph
characterist
present
diseas
latin
children
hospit
third
referr
hospit
describ
respiratori
allerg
diseas
italian
monitor
studi
gina
aria
guidelin
arga
maio
baldacci
borbotti
angino
f
martini
b
piegaia
p
silvi
simoni
f
di
pede
g
viegi
cnr
institut
clinic
physiolog
pulmonari
environment
epidemiolog
unit
pisa
itali
background
asthma
chronic
inflammatori
airway
diseas
close
associ
atop
diseas
like
allerg
rhiniti
diseas
increas
epidem
proport
increas
medic
cost
reduc
patient
qualiti
life
qol
lower
product
correct
manag
asthmat
rhinit
patient
would
ensur
use
intern
world
health
organ
guidelin
gina
global
initi
asthma
aria
allerg
rhiniti
impact
asthma
mani
studi
prove
guidelin
recommend
partial
appli
within
clinic
practic
object
evalu
applic
gina
aria
guidelin
impact
patient
qol
gener
practic
evalu
short
long
term
efficaci
continu
medic
educ
cme
intervent
gener
practition
gp
itali
method
prospect
observ
studi
differ
italian
area
north
centr
southisland
gp
attend
educ
intervent
didnt
attend
enrol
patient
diagnosi
asthmarhin
prescript
antiasthmat
antirhinit
drug
asthmat
rhiniticlik
symptom
previou
month
gp
patient
fill
questionnair
respiratori
allerg
diseas
advers
drug
event
patient
fill
also
rhinasthma
questionnair
qol
asthma
control
test
followup
done
month
expect
result
epidemiolog
data
asthma
rhiniti
burden
evalu
applic
util
adher
gina
aria
guidelin
gp
patient
short
term
long
term
efficaci
cme
intervent
evalu
prescript
appropri
treatment
costefficaci
ratio
respiratori
psychiatr
comorbid
italian
primari
care
popul
epidea
studi
baldacci
borbotti
maio
angino
f
martino
f
di
pede
balestrieri
bellomo
nardini
g
viegi
cnr
institut
clinic
physiolog
pulmonari
environment
epidemiolog
unit
pisa
itali
epidemiolog
research
primari
care
epim
pisa
itali
aim
evalu
relationship
psychiatr
disord
respiratori
diseas
chronic
obstruct
pulmonari
diseas
copd
asthma
italian
primari
care
popul
method
crosssect
survey
carri
italian
geograph
area
subject
expect
sampl
mean
age
yr
randomli
select
gener
practition
particip
studi
subject
answer
physicianadminist
interview
base
standard
nation
research
council
questionnair
detect
psychiatr
disturb
respiratori
diseas
symptom
rel
risk
factor
pharmacolog
treatment
fill
gener
health
questionnair
ghq
result
preval
current
lifetim
psychiatr
disturb
affect
disord
anxieti
respect
copd
asthma
significantli
associ
presenc
anxieti
alon
copres
anxieti
depress
logist
regress
model
adjust
independ
effect
age
area
smoke
educ
work
posit
ghq
score
sex
copd
result
associ
anxieti
depress
combin
ci
anxieti
alon
ci
asthma
also
associ
copres
anxieti
depress
ci
anxieti
alon
ci
conclus
epidea
studi
confirm
larg
diffus
psychiatr
disord
italian
primari
care
popul
associ
respiratori
diseas
affect
anxieti
disord
suggest
take
account
aspect
clinic
practic
pneumologist
allergologist
psychiatrist
exerciseinduc
anaphylaxi
relat
cannabi
sativa
smoke
exposur
antonio
navarro
olga
villarr
natividad
longo
alejandro
joral
jose
francisco
garmendia
susana
lizarza
ascens
aranzab
hospit
donostia
allergi
section
san
sebastian
spain
hospit
de
mendaro
allergi
unit
mendaro
spain
hospit
de
santiago
servicio
de
alergia
e
inmunologia
vitoria
spain
hospit
de
zumarraga
allergi
unit
zumarraga
spain
background
exerciseinduc
anaphylaxi
lifethreaten
condit
fooddepend
specif
nonspecif
drugdepend
sometim
trigger
exercis
report
case
trigger
episod
previou
smoke
marijuana
cannabi
sativa
cigarett
patient
yearsoldman
previosli
diagnos
cerealdepend
exerciseinduc
anaphylaxi
spite
strict
avoid
food
recurr
episod
anaphylaxi
exercis
jog
reevalu
recogn
use
smoke
marijuana
cigarett
often
sometim
exercis
year
evalu
begun
present
sudden
onset
rhinoconjuct
time
smoke
marijuana
cigarett
gave
marijuana
smoke
sinc
anaphylact
reaction
jog
eat
cereal
exercis
without
problem
one
year
method
skin
test
prickprick
test
fresh
cannabi
sativa
leav
skin
test
leav
extract
ige
immunoblot
cannabi
sativa
leav
extract
result
skin
test
posit
neg
control
immunoblot
patient
ige
recogn
kd
band
conclus
report
first
case
exerciseinduc
anaphylaxi
trigger
inhal
cannabi
sativa
smoke
skin
test
vitro
result
well
clinic
pictur
evolut
smoke
cessat
consist
bcannabi
sativa
smoke
depend
exerciseinduc
anaphylaxi
patient
also
ige
mediat
immedi
rhinoconjuct
due
marijuana
smoke
mechan
anaphylact
reaction
obscur
previou
report
confirm
cannabi
sativa
smoke
caus
immedi
hypersensit
symptom
like
bronchospasm
rhinoconjuct
gener
itch
sensit
individu
knowledg
previou
report
exerciseinduc
reaction
appear
depend
marijuana
smoke
use
serum
tryptas
diagnosi
shrimp
anaphylaxi
children
patcharaporn
wongkaewpothong
punchama
pajarn
chaweewan
sripramong
siriporn
boonchoo
nualanong
visitsunthorn
pakit
vichyanond
orathai
jirapongsananuruk
siriraj
hospit
allergi
immunolog
pediatr
depart
bangkok
thailand
background
anaphylaxi
lifethreaten
allerg
reaction
food
one
common
culprit
serum
tryptas
marker
mast
cell
activ
could
use
confirm
anaphylaxi
shrimp
object
determin
util
serum
tryptas
diagnosi
shrimpinduc
anaphylaxi
method
twentyon
patient
previou
allerg
reaction
shrimp
recruit
prospect
studi
shrimp
challeng
twelv
patient
develop
mild
allerg
reaction
nine
patient
develop
anaphylaxi
serum
tryptas
obtain
shrimp
challeng
hour
onset
symptom
result
group
patient
median
tryptas
level
significantli
elev
onset
shrimp
challeng
compar
baselin
baselin
tryptas
peak
tryptas
anaphylaxi
group
baselin
tryptas
peak
tryptas
nonanaphylaxi
group
p
g
delta
tryptas
peak
minu
baselin
valu
anaphylaxi
group
significantli
higher
nonanaphylaxi
group
vs
p
tryptas
ratio
peak
divid
baselin
valu
anaphylaxi
group
also
significantli
higher
nonanaphylaxi
group
vs
p
use
recommend
cutoff
rang
peak
tryptas
g
sensit
cutoff
specif
conclus
recommend
use
serial
tryptas
valu
includ
tryptas
ratio
andor
delta
tryptas
valu
diagnosi
foodinduc
anaphylaxi
latter
two
valu
may
help
peak
serum
tryptas
suleiman
eisa
alhammadi
uae
univers
pediatr
alain
unit
arab
emir
food
consid
common
caus
anaphylaxi
children
common
caus
food
allergi
anaphylaxi
cow
milk
hen
egg
white
wheat
peanut
tree
nut
fish
shellfish
soya
fresh
fruit
also
common
especi
peach
prunu
persica
case
year
old
boy
present
emerg
room
gener
itchi
erythemat
skin
rash
bodi
min
eat
peach
histori
medic
new
food
insect
bite
histori
short
breath
wheez
stridor
abdomin
pain
vomit
swell
tongu
mucu
membran
loss
conscious
signific
hypotens
notic
obtain
vital
sign
low
mmhg
last
hr
instead
appropri
dose
og
adrenalin
inject
chlorpheneramin
maleat
iv
intraven
fluid
histori
atop
dermat
allerg
rhiniti
asthma
breastfed
year
reciev
goat
milk
child
mother
allerg
rhiniti
father
sibl
healthi
child
continu
oral
allergi
symptom
accident
peach
ingest
small
amount
anaphylaxi
incid
never
anaphylaxi
peach
fruit
highli
allergen
food
conclus
rosacea
fruit
allergi
typic
peach
true
fruit
allergi
spectrum
symptom
rang
oral
allergi
syndrom
rare
anaphylaxi
case
patient
anaphylaxi
initi
present
fresh
fruit
allergi
even
consum
avoid
epinephrin
autoinjector
appropri
manag
background
wheat
uncommon
caus
fooddepend
exerciseinduc
anaphylaxi
aim
studi
describ
common
clinic
characterist
laboratori
manifest
natur
histori
diseas
method
children
histori
wheatdepend
exerciseinduc
anaphylaxi
identifi
skin
prick
test
specif
ige
wheat
done
threeday
challeng
program
includ
open
challeng
wheat
exercis
exercis
challeng
test
meal
contain
wheat
perform
result
five
children
age
year
mean
year
evalu
atop
histori
found
patient
patient
symptom
involv
skin
respiratori
system
two
hypotens
sera
specif
ige
wheat
determin
patient
among
two
posit
three
patient
complet
threeday
protocol
anaphylaxi
occur
patient
amount
wheat
consum
prior
exercis
gram
conclus
wheatdepend
exerciseinduc
anaphylaxi
common
male
skin
respiratori
symptom
major
manifest
threeday
wheat
challeng
protocol
definit
diagnost
tool
howev
amount
wheat
requir
challeng
high
kazuki
sato
tomoko
numata
yoko
nezu
takayasu
arima
yuzaboro
inou
minako
tomiita
naoki
shimojo
yoichi
kohno
nation
shimoshizu
hospit
depart
pediatr
chiba
japan
chiba
univers
graduat
school
medicin
depart
pediatr
chiba
japan
two
case
anaphylaxi
exclus
breastfeed
report
boy
exclus
breastfeed
suffer
eczema
sinc
mother
restrict
intak
egg
cow
milk
sinc
month
hospit
tarri
stool
month
age
within
hour
breastfeed
mother
taken
raw
fish
develop
wholebodi
rash
three
time
skin
prick
test
posit
hors
mackerel
mackerel
salmon
codfish
mother
restrict
fish
ingest
symptom
observ
breast
feed
continu
boy
exclus
breastfeed
present
sever
eczema
month
age
thereaft
mother
avoid
egg
cow
milk
soy
fish
month
fed
almost
breastf
ate
littl
solid
food
one
day
develop
rash
cough
soon
mother
fed
breast
milk
breastf
hour
later
present
vomit
rash
whole
bodi
hospit
blood
examin
reveal
high
titer
specif
ige
egg
cow
milk
sardin
codfish
serum
skin
prick
test
also
posit
sardin
egg
small
amount
allergen
detect
breast
milk
although
food
mother
took
determin
anaphylaxi
due
food
allergen
breast
milk
suspect
system
immedi
type
food
allergi
due
small
amount
food
allergen
includ
breast
milk
rare
far
case
report
carolina
jessica
salina
antonieta
paola
toch
angelica
marinov
univers
chile
clinic
hospit
allergi
immunolog
unit
santiago
chile
background
anaphylaxi
sever
acut
allerg
reaction
quickli
progress
potenti
fatal
trigger
mainli
food
antigen
drug
preval
studi
condit
conduct
countri
neither
clinic
present
andor
etiolog
object
determin
clinic
characterist
patient
anaphylact
reaction
seen
clinic
hospit
univers
chile
patient
method
retrospect
review
medic
record
span
year
may
allow
us
obtain
data
patient
deriv
allergi
immunolog
depart
clinic
hospit
univers
chile
diagnosi
anaphylaxi
unknown
origin
three
patient
exclud
studi
two
diagnosi
system
mastocytosi
hereditari
angioedema
evalu
sex
age
number
episod
consult
interv
first
last
episod
histori
atopi
time
elaps
exposur
suspect
trigger
factor
appear
symptom
form
present
sever
reaction
treatment
receiv
clinicallaboratori
work
result
patient
men
women
includ
age
rang
month
year
mean
year
atop
averag
delay
consult
year
median
number
previou
episod
etiolog
identifi
case
main
caus
drug
follow
food
hymenoptera
sting
averag
time
onset
symptom
minut
postexposur
nineti
six
percent
patient
present
urticaria
andor
angioedema
sever
manifest
grade
iii
iv
seen
individu
individu
indic
manag
epinephrin
receiv
emerg
room
conclus
clinic
characterist
chilean
patient
anaphylaxi
similar
report
countri
relev
emphas
great
percentag
atop
patient
seri
well
delay
consult
anaphylaxi
singapor
children
smi
wong
wk
liew
wc
chiang
kidon
goh
kk
women
children
hospit
paediatr
allergi
immunolog
rheumatolog
singapor
singapor
background
studi
epidemiolog
review
treatment
anaphylaxi
asian
singapor
children
method
retrospect
studi
includ
patient
anaphylaxi
seen
kk
children
hospit
singapor
case
identifi
relev
discharg
code
children
emerg
ce
hospit
inpati
record
crosscheck
referr
allergi
clinic
result
children
anaphylaxi
identifi
male
less
year
old
time
present
age
year
race
distribut
correspond
popul
demograph
featur
atopi
food
trigger
report
food
specif
ige
sensit
demonstr
children
egg
peanut
cow
milk
clam
chines
pear
case
secondari
drug
nsaid
paracetamol
tradit
chines
medic
asparaginas
desferrioxamin
blood
product
two
patient
identifi
trigger
diagnos
idiopath
anaphylaxi
patient
present
dermatolog
respiratori
featur
children
vomit
abdomin
pain
hypotens
fatal
studi
patient
present
ce
admit
observ
patient
requir
admiss
intens
care
unit
hypotens
requir
fluid
resuscit
present
children
treat
epinephrin
administ
mostli
subcutan
rout
given
antihistamin
steroid
bronchodil
therapi
intraven
fluid
bolus
children
equip
selfinject
epinephrin
receiv
selfinject
epinephrin
includ
case
drug
trigger
patient
default
parent
refus
due
anxieti
selfinject
cost
concern
anaphylaxi
predominantli
food
trigger
singapor
children
notic
increas
peanut
food
allergi
also
signific
number
case
attribut
ibuprofen
paracetamol
whilst
epinephrin
cornerston
therapi
anaphylaxi
case
receiv
treatment
urgent
need
improv
awar
treatment
anaphylaxi
popul
angiotensin
convert
enzym
activ
patient
anaphylact
reaction
hymenoptera
sting
event
renin
angiotensin
system
seem
play
signific
role
respons
anaphylact
reaction
aim
studi
evalu
serum
activ
angiotensin
convert
enzym
ace
patient
anaphylaxi
hymenoptera
sting
event
depend
polymorph
ace
gene
specif
ige
materi
studi
group
consist
patient
mean
age
year
patient
specif
ige
wasp
venom
bee
venom
venom
method
ace
activ
measur
accord
method
describ
liberman
id
ace
polymorph
determin
base
pcr
techniqu
employ
insert
specificprim
specif
ige
measur
allergopharma
specif
ige
elisa
kit
germani
result
ace
activ
studi
group
iu
tabl
contain
ace
activ
depend
ace
gene
polymorph
p
g
tabl
contain
ace
activ
depend
specif
ige
hymenoptera
p
conclus
serum
activ
ace
patient
anaphylact
reaction
hymenoptera
gener
popul
signific
statist
differ
ace
activ
group
accord
ace
gene
polymorph
specif
ige
influenc
ace
activ
andrzej
dbrowski
renata
rubinsztajn
jaro
aw
renata
walkiewicz
zbigniew
gaciong
ryszarda
chazan
medic
univers
dept
pneumonolog
allergolog
warsaw
poland
medic
univers
dep
intern
medicin
hypertens
angiolog
warsaw
poland
activ
ace
may
play
import
role
anaphylactiv
reaction
ace
activ
genet
determin
dd
genotyp
correl
arteri
hypertens
vascular
disord
id
polymorph
caucasian
popul
aim
studi
analyz
frequenc
angiotensin
convert
enzym
gene
polymorph
patient
document
histori
anaphylact
reaction
hymenoptera
sting
materi
studi
group
consist
patient
mean
age
year
patient
specif
ige
wasp
venom
bee
venom
venom
control
group
healthi
person
mean
age
year
method
id
ace
polymorph
determin
base
pcr
techniqu
employ
inserspecif
primer
specif
ige
measur
allergopharma
specif
ige
elisa
germani
result
ace
gene
polymorph
control
group
dd
id
ii
ace
gene
polymorph
studi
group
dd
id
ii
conclus
group
patient
document
anaphylact
reaction
hymenoptera
sting
differ
ace
gene
polymorph
gener
popul
observ
differ
polymorph
wasp
bee
group
waspbe
one
allel
frequent
therefor
larger
group
seem
justifi
milk
wheat
common
caus
anaphylaxi
children
zahra
pourpak
rosita
akramian
raheleh
shokouhi
shoormasti
leyla
ghojezadeh
hasan
bemanian
mostafa
moin
immunolog
asthma
allergi
research
institut
immunolog
depart
tehran
islam
republ
iran
background
anaphylaxi
medic
emerg
requir
immedi
recognit
treatment
report
common
find
first
case
seri
anaphylaxi
iran
carri
children
refer
center
immunolog
asthma
allergi
materi
method
children
refer
clinic
allergi
previou
diagnosi
anaphylaxi
consid
studi
specif
questionnair
complet
patient
detail
clinic
histori
demograph
data
record
patient
skin
prick
test
specif
ige
measur
perform
suspect
allergen
determin
caus
allergen
base
patient
histori
ige
mediat
test
challeng
test
perform
patient
result
children
age
rang
year
old
previou
diagnosi
anaphylaxi
refer
clinic
allergi
year
male
femal
respect
skin
prick
test
posit
specif
ige
posit
probabl
caus
agent
popul
food
milk
wheat
frequent
caus
anaphylaxi
children
episod
anaphylaxi
life
also
case
multifactori
food
anaphylaxi
identifi
first
time
common
caus
allergen
recurr
anaphylaxi
milk
patient
dermatolog
sign
symptom
common
vs
respiratori
gastrointestin
neurolog
cardiovascular
sign
symptom
respect
flush
seen
pruriti
urticaria
preorbit
edema
patient
rash
erythema
angioedema
conclus
data
confirm
food
special
milk
wheat
common
caus
anaphylaxi
children
dermatolog
sign
symptom
common
find
thu
parent
physician
educ
recogn
common
caus
allergen
common
present
clinic
manifest
diseas
avoid
progress
life
threaten
syndrom
abl
manag
anaphylact
patient
food
anaphylaxi
clinic
studi
isabel
carrapatoso
alexandra
santo
faria
celso
pereira
carlo
loureiro
celso
chieira
coimbra
univers
hospit
immunoallergolog
depart
coimbra
portug
background
food
allergi
one
common
caus
anaphylaxi
object
aim
studi
character
group
patient
food
anaphylaxi
followedup
food
allergi
outpati
depart
oneyear
period
method
twentytwo
consecut
patient
observ
depart
june
may
suggest
clinic
histori
food
anaphylaxi
select
food
involv
sever
system
reaction
identifi
atop
comorbid
occurr
anaphylaxi
studi
period
medic
use
investig
standard
questionnair
skin
prick
test
airborn
allergen
mite
mould
cockroach
cat
dog
dander
pollen
feather
latex
food
allergen
egg
milk
seafood
mammal
bird
meat
fruit
nut
cereal
legum
spice
veget
perform
serum
specif
ige
airborn
food
allergen
andor
pricktoprick
natur
food
extract
done
select
case
evid
clinic
reactiv
result
patient
select
past
histori
immedi
sever
system
reaction
ingest
food
mean
age
popul
studi
year
fourteen
patient
femal
mean
age
first
anaphylaxi
episod
year
food
involv
fruit
patient
crustacean
patient
cow
milk
patient
nut
patient
legum
patient
cereal
patient
fish
patient
egg
patient
patient
sensitis
culprit
food
sensitis
airborn
allergen
occur
patient
mite
grass
weed
tree
latex
cockroach
dog
dander
feather
sensitis
food
occur
patient
eighteen
patient
atop
comorbid
relat
airborn
allergen
patient
asthma
recurr
anaphylaxi
occur
patient
cow
milk
allergi
studi
period
selfadminist
adrenalin
use
patient
twice
conclus
popul
studi
high
proport
atop
asthmat
patient
found
differ
plant
anim
food
implic
hidden
milk
allergen
extrem
difficult
avoid
fact
could
explain
recurr
anaphylaxi
cow
milk
allerg
patient
spite
strictli
restrict
diet
gilsoon
choi
hanjung
park
sungjin
choi
gyuyoung
hur
seungyoup
shin
seunghyun
kim
dongho
nahm
haesim
park
ajou
univers
school
medicin
allergi
rheumatolog
suwon
republ
korea
octopu
variabili
kind
mollusca
favorit
food
orient
countri
publish
report
anaphylaxi
caus
octopu
mechan
food
allergi
understood
experienc
two
case
anaphylaxi
develop
afteringest
raw
octopu
first
patient
man
without
previou
allerg
diseas
experienc
gener
urticaria
dizzi
loss
conscious
one
hour
ingest
raw
octopu
skin
prick
test
show
weakli
respons
octopu
extract
pteronyssiu
farina
oyster
shrimp
ah
ratio
serum
specif
ige
antibodi
octopu
extract
undetect
elisa
wherea
increas
level
serum
specif
antibodi
octopu
extract
note
elisa
second
patient
woman
allerg
rhiniti
allerg
conjunct
suffer
recurr
abdomin
pain
chest
discomfort
dizzi
min
ingest
steam
raw
octopu
skin
prick
test
show
neg
respons
octopu
extract
posit
respons
pteronyssiu
farina
serum
specif
ige
antibodi
octopu
extract
found
elisa
find
suggest
octopu
could
induc
anaphylaxi
via
nonig
mediat
mast
cell
activ
background
anaphylaxi
emerg
condit
attempt
made
find
caus
agent
prevent
method
prospect
studi
patient
anaphylaxi
siriraj
hospit
thailand
januari
juli
direct
patient
interview
physic
examin
done
skin
prick
test
challeng
agent
accord
histori
care
perform
identifi
caus
anaphylaxi
result
caus
anaphylaxi
identifi
posit
skin
test
patient
patient
oral
challeng
test
specif
ige
wereperform
found
posit
patient
respect
agent
caus
posit
skin
test
ant
patient
seawat
shrimp
immunotherapi
patient
wheat
patient
wasp
patient
seawat
mollusk
patient
seawat
crab
patient
wheatdepend
exerciseinduc
anaphylaxi
wdeia
patient
cow
milk
patient
andciprofloxacin
patient
four
case
neg
skin
test
patient
caus
agent
could
identifi
case
patientswer
diagnos
idiopath
anaphylaxi
one
patient
skin
test
neg
erythromycin
posit
oral
challeng
erythromycin
caus
posit
oral
challeng
patient
seawat
shrimp
seawat
mollusk
wdeia
patient
caus
posit
specif
ige
wereseawat
shrimp
wheat
cow
milk
ant
patient
present
case
woman
year
old
smoke
around
cigarett
day
health
worker
famili
histori
atopi
person
histori
tonsillectomi
left
renal
colic
habitu
consumpt
oral
contracept
last
five
year
present
episod
urticaria
occasion
angioedema
immedi
solar
exposur
season
year
locat
expos
area
injuri
remain
hour
disappear
without
leav
residu
injuri
three
time
suffer
head
instabl
afterward
loss
conscious
twice
heavi
solar
exposur
despit
appli
sunscreen
cream
previous
anoth
time
reciv
uva
bronz
session
laboratori
find
includ
complet
blood
cell
count
erithrocit
sediment
rate
lactat
dehydrogenas
renal
liver
function
glucos
immunoglobulin
g
tryptas
complement
rheumatoid
factor
total
protein
creactiv
protein
reveal
patholog
valu
test
antinuclear
anti
yena
antimithocondri
antimuscular
smooth
antipariet
cell
antibodi
neg
total
ige
ui
mililit
hour
urin
faec
test
analysi
order
detect
porphyrin
neg
skin
prick
test
set
common
airallergen
posit
hous
dust
mite
photobiolog
examin
urticari
lesion
caus
uniqu
exposur
uvb
uva
irradi
visibl
light
spectrum
although
minim
urticaria
dose
determin
evolut
case
show
extrem
serious
continu
clinic
symptom
area
exposur
minut
minim
solar
exposur
winter
although
present
new
episod
anaphylaxi
spite
continu
treatment
topic
broad
spectrum
sunscreen
daili
year
differ
system
antihistamin
cetirizin
mgday
hidroxicina
ebastin
desloratadin
beta
caroten
supplement
natur
desensitis
approach
regular
sun
exposur
suspect
case
solar
urticaria
clinic
chang
anaphylaxi
receiv
high
dose
radiat
kanika
piromrat
bhumibol
adulyadej
hospit
pediatr
bangkok
thailand
sting
insect
compris
approxim
percent
caus
anaphylaxi
thailand
live
tropic
climat
temper
inhabit
insect
exist
thailand
yellow
jacket
vespula
spp
white
face
hornet
dolichovespula
maculata
yellow
hornet
dolichovespula
arenaria
poster
present
pictur
brief
descript
common
insect
potenti
caus
anaphylaxi
thailand
tropic
wasp
paper
wasp
giant
bee
indian
bee
small
bee
bumbl
bee
venom
ant
kiss
bug
conclus
studi
describ
speci
characterist
common
sting
insect
caus
anaphylaxi
thailand
surena
vahabi
univers
perio
tehran
islam
republ
iran
background
mast
cell
play
import
role
allerg
reaction
host
defens
local
homeostasi
inflamm
angiogenesi
object
studi
evalu
relationship
mast
cell
number
differ
type
periodont
diseas
method
gingiv
specimen
taken
moder
advanc
chronic
periodont
moder
advanc
aggress
periodont
site
case
group
healthyging
site
control
group
routin
periodont
surgeri
flap
crown
lengthen
examin
toluidineblu
stain
mast
cell
count
hematoxylineosin
stain
assess
inflamm
inflammatori
mast
cell
micron
section
assess
two
observ
time
util
light
microscop
magnif
anova
test
alpha
error
level
less
percent
use
analyz
data
result
mast
cell
number
higher
chronic
versu
aggress
periodont
healthyging
aggress
periodont
nt
number
mast
cell
compar
healthi
gingiv
relationship
mast
cell
number
degre
inflamm
group
conclus
present
studi
indic
mast
cell
number
presenc
chronic
periodont
site
site
result
studi
suggest
studi
evalu
dynam
aspect
host
defens
conjunct
aspect
immun
system
simultan
exogen
nitric
oxid
regul
express
prostaglandin
gener
mast
cell
tae
chul
moon
dean
befu
univers
alberta
depart
medicin
edmonton
canada
background
mast
cell
mc
import
effector
cell
allerg
inflammatori
respons
secret
variou
mediat
follow
activ
nitric
oxid
import
signal
molecul
regul
mc
function
depress
mc
allerg
respons
leukotrien
lt
cytokin
chemokin
product
well
mc
degranul
howev
involv
prostaglandin
pg
product
import
lipid
mediat
produc
mc
unclear
pg
synthesi
cyclooxygenas
cox
import
enzym
two
isozym
cox
constitut
express
induc
report
well
establish
mous
bone
marrowderiv
mast
cell
bmmc
exhibit
biphas
pgd
biosynthesi
immedi
delay
pgd
product
bmmc
stimul
scf
method
effect
express
pgd
gener
bmmc
investig
use
nodonor
snitrosoglutathion
snog
snitrosonacetylpenicillamin
snap
pgd
product
stimul
bmmc
assay
use
pgd
mox
enzym
immunoassay
kit
western
blot
realtim
rtpcr
use
measur
protein
mrna
express
result
exogen
augment
protein
express
increas
pgd
gener
respons
scf
increas
express
nodonor
reduc
mapk
inhibitor
downstream
mapk
nodonor
augment
mrna
transcript
also
stabil
contrast
nodonor
affect
protein
express
howev
contrast
augment
express
activ
snog
snap
inhibit
pgd
gener
conclus
thu
exogen
regul
pgd
product
mc
regul
furthermor
find
help
us
understand
role
mc
function
regulatori
mechan
lipid
mediat
gener
mc
inflammatori
diseas
cigarett
smoke
suppress
product
cytokin
chemokin
igeag
activ
mast
cell
esmaeil
mortaz
gert
folkert
ferdi
engel
daniel
raat
mehdi
vaezi
rad
fran
nijkamp
frank
redegeld
uip
immunopharmacolog
utrecht
netherland
background
chronic
obstruct
pulmonari
diseas
copd
major
incur
global
health
burden
becom
third
largest
caus
death
world
current
believ
exagger
inflammatori
respons
inhal
irrit
particular
cigarett
smoke
cs
caus
progress
airflow
limit
inflamm
macrophag
neutrophil
promin
lead
oxid
stress
emphysema
small
airway
fibrosi
mucu
hypersecret
mast
cell
import
effector
cell
anaphylact
reaction
involv
varieti
immunolog
nonimmunlog
process
howev
role
mast
cell
pathogenesi
emphysema
yet
document
recent
demonstr
csm
induc
proteas
express
chemokin
releas
primari
mast
cell
studi
investig
effect
csm
cytokin
product
mast
cell
respect
activ
ige
antigen
materi
method
bmmc
cultur
balbcbi
mice
week
cell
expos
csm
activ
ige
antigen
degranul
cell
assess
monitor
releas
granular
enzym
betahexosaminidas
amount
cytokin
determin
supernat
ikb
degrad
crep
phosphoryl
measur
western
blot
result
csm
attenu
degranul
cytokin
releas
mast
cell
concentrationdepend
noncytotox
manner
csm
effect
cytokin
releas
induc
lp
moreov
csm
induc
phosphoryl
creb
activ
ige
antigen
conclus
thu
inhibitori
effect
csm
degranul
cytokin
releas
may
differ
chemokin
leukoterin
releas
suppress
effect
houttuynia
cordata
extract
cell
migrat
respons
stem
cell
factor
hottuynia
cordata
thunb
saururacea
hc
known
therapeut
drug
use
tradit
orient
medicin
treatment
allerg
diseas
mast
cell
function
regulatori
cell
varieti
inflammatori
diseas
particular
asthma
atop
dermat
studi
examin
effect
hc
extract
chemotact
activ
human
mast
cell
line
induc
stem
cell
factor
scf
surviv
rate
cell
alter
treatment
hc
extract
concentr
h
scf
show
typic
bellshap
curv
cell
chemoattract
peak
curv
scf
concentr
ngml
whole
plant
houttuynia
cordata
extract
etoh
residu
success
partit
etoac
inhibitori
effect
cell
movement
treatment
ml
extract
h
h
chemotact
index
ci
cell
decreas
respect
extract
significantli
inhibit
cell
movement
extract
inhibitori
effect
mrna
protein
express
ckit
scf
receptor
scf
tranduc
chemotaxi
signal
via
nfkb
transloc
extract
block
activ
taken
togeth
result
indic
extract
inhibit
chemotact
activ
cell
respons
scf
block
nfkb
activ
substanc
may
help
treat
inflammatori
diseas
associ
mast
cell
effect
scf
mixtur
cell
prolifer
rat
mast
cell
proteaselt
synthesi
rat
bone
marrow
deriv
mast
cell
background
mast
cell
import
immun
cell
produc
cytokin
chemokin
histamin
close
relat
allerg
reaction
process
investig
mast
cell
activ
enhanc
understand
allergi
requir
easi
suppli
larg
number
mast
cell
cultur
bone
marrow
deriv
mast
cell
bmmc
mast
cell
provid
suffici
number
cell
affect
kind
cytokin
combin
dose
prolifer
differenti
investig
effect
cultur
condit
rat
bmmc
cultiv
serum
supplement
cytokin
method
rat
bone
marrow
cell
cultur
media
condit
differ
addit
individu
mix
cytokin
scf
rat
bmmc
prolifer
measur
use
assay
rat
bmmc
differenti
analyz
level
rmcpl
serum
supplement
effect
rat
bmmc
cultur
investig
comparison
media
includ
hors
sera
media
carri
rat
sera
result
cultur
hors
serum
supplement
rat
bmmc
prolifer
presenc
ngml
mix
scf
ngml
highest
among
appli
cytokin
mixtur
rat
bmmc
mixtur
cytokin
concentr
show
rel
high
level
rmcpl
cultur
rat
serum
supplement
cytokin
condit
scf
induc
rmcpl
product
howev
adjust
cytokin
concentr
mixtur
scf
enhanc
rmcpl
synthesi
compar
level
produc
scf
media
supplement
hors
serum
conclus
result
indic
rat
bmmc
prepar
requir
scf
rat
bmmc
differenti
affect
ratio
scf
kind
serum
mar
guilart
victoria
cardona
maria
vicario
carmen
alonso
cristina
martinez
javier
santo
hospit
universitari
vall
dhebron
allergi
digest
diseas
research
unit
barcelona
spain
background
stress
may
facilit
intestin
inflamm
promot
epitheli
barrier
dysfunct
allow
lumin
antigen
enter
mucosa
may
crucial
develop
food
allergi
method
male
wki
rat
submit
crowd
stress
cs
rat
cage
shamcrowd
ratscag
day
addit
ketotifen
known
mast
cell
stabil
salin
inject
ip
day
mgkg
dose
h
interv
end
stress
sham
protocol
jejun
segment
mount
uss
chamber
measur
macromolecular
permeabl
horseradish
peroxidas
hrp
rat
mast
cell
proteas
ii
rmcpii
indic
mast
cell
activ
measur
jejun
perfus
jejun
homogen
end
stress
sham
exposur
plasma
corticosteron
crh
corticotropin
releas
hormon
receptor
express
jejun
tissu
measur
elisa
assay
rtpcr
respect
result
plasma
corticosteron
tree
fold
increas
stress
protocol
cs
group
cs
ngml
vs
control
group
express
increas
cs
compar
control
crowd
stress
cs
induc
increas
hrp
permeabl
cs
vs
control
diminish
ketotifen
administ
vs
cs
furthermor
jejun
rmcpii
higher
perfus
stress
rat
cs
vs
control
tissu
homogen
cs
ngmg
tissu
vs
control
suggest
ongo
mast
cell
activ
ketotifen
reduc
increas
rmcpii
jejun
perfus
vs
cs
tissu
homogen
ngmg
tissu
vs
cs
ketotifen
induc
chang
paramet
evalu
control
group
conclus
stress
evok
epitheli
barrier
defect
may
facilit
uptak
lumin
macromolecul
mediat
mast
cell
synergist
effect
may
play
import
role
food
allergi
import
matrix
metalloproteinas
inhibitor
develop
postop
complic
patient
degenerativedystroph
diseas
ddd
hip
joint
roman
vinchel
r
elena
markelova
e
vladivostok
state
medic
univers
pathophisiolog
vladivostok
russian
feder
purpos
work
estim
predict
possibl
develop
complic
postop
period
mean
monitor
level
patient
blood
serum
hip
replac
materi
method
test
blood
patient
hip
replac
oper
undergo
patient
postop
infecti
complic
develop
patient
smooth
postop
cours
without
infecti
complic
blood
healthi
donor
control
drawn
fourfold
blood
sampl
follow
first
blood
sampl
made
oper
second
first
hour
oper
third
fifth
hour
oper
fourth
fourteenth
day
oper
estim
made
immunoenzym
method
use
testsystem
br
system
inc
usa
result
detect
follow
oper
patient
group
smooth
postop
cours
level
equal
ngml
essenti
higher
patient
control
group
ngml
typic
healthi
peopl
increas
ngml
first
day
oper
subsequ
continu
increas
ngml
day
essenti
decreas
level
ngml
observ
first
day
oper
certain
differ
valu
first
day
oper
patient
group
complic
postop
cours
index
oper
ngml
index
higher
control
group
well
ngml
first
day
oper
observ
rapid
growth
ngml
abovement
patient
group
day
level
still
persist
high
ngml
day
level
decreas
slightli
ngml
conclus
diverg
ratio
toward
signific
increas
alreadi
oper
patient
ddd
testifi
essenti
pathogenet
role
pathogenesi
dystroph
diseas
hip
role
hyalgan
inhibit
product
matrix
metalloproteinas
natalya
yatsyshyn
roman
yatsyshyn
yevgen
neyko
medic
univers
intern
diseas
ivanofrankivsk
ukrain
background
hyalgan
wide
use
treatment
osteoarthr
oa
intraarticular
administr
affect
joint
although
clinic
benefit
hyalgan
demonstr
respect
pain
relief
patient
oa
level
drug
act
remain
unclear
object
studi
aim
investig
mechan
inhibitori
action
hyalgan
stimul
product
matrix
metalloproteinas
mmp
human
articular
cartilag
method
ad
human
articular
cartilag
without
chang
osteoarthr
oa
explant
cultur
stimul
mmp
product
articular
cartilag
incub
preincub
hyalgan
assess
effect
hyalgan
mmp
secret
level
condit
media
detect
immunoblot
intracellular
mmp
synthesi
chondrocyt
evalu
immunofluoresc
microscop
analysi
penetr
hyalgan
cartilag
tissu
bind
analyz
fluoresc
microscopi
use
fluorescenin
hyalgan
block
experi
antibodi
perform
investig
mechan
ha
action
result
treatment
pretreat
hyalgan
result
signific
suppress
product
mmp
normal
oa
cartilag
explant
cultur
fluoresc
histocytochemistri
reveal
hyalgan
penetr
cartilag
tissu
local
pericellular
matrix
around
chondrocyt
hyalgan
bind
block
experi
use
antibodi
demonstr
associ
ha
chondrocyt
mediat
preincub
antibodi
suppress
mmp
revers
inhibitori
effect
hyalgan
mmp
product
induc
normal
oa
cartilag
conclus
studi
demonstr
hyalgan
effect
inhibit
product
support
clinic
use
ha
treatment
oa
hyalgan
action
may
involv
direct
interact
hyalgan
chondrocyt
background
purpos
well
known
respiratori
syncyti
viru
rsv
bronchiol
infanc
earli
childhood
number
children
develop
persist
wheez
studi
eosinophil
cation
protein
ecp
suggest
asthma
eosinophil
inflamm
mechan
may
also
play
role
rsv
infect
aim
studi
prove
exist
eosinophil
inflamm
infant
rsv
infect
measur
localsystemat
ecp
method
ecp
measur
nasal
lavag
fluid
serum
infant
rsv
infect
respiratori
infect
admit
hospit
octob
march
rang
month
month
age
except
four
pair
twin
result
nasal
lavag
fluid
ecp
level
significantli
higher
infant
rsv
infect
infant
respiratori
infect
vs
micrograml
serum
ecp
level
indic
tendenc
moreov
subanalysi
show
wheez
infant
also
significantli
higher
level
nasal
lavag
fluid
ecp
level
case
nonwheez
infant
vs
micrograml
serum
ecp
level
indic
tendenc
regard
nasal
fluid
lavag
serum
signific
differ
ecp
level
found
whether
famili
histori
atopi
suggest
rsv
infect
may
induc
local
eosinophil
inflamm
even
infanc
conclus
eosinophil
strongli
activ
rsv
infect
respiratori
infecti
diseas
theoret
result
support
hypothesi
rsv
infect
may
caus
reactiv
airway
diseas
mechan
eosinophil
infiltr
middl
ear
patient
eosinophil
otiti
media
yukiko
yokoyama
rubi
pawankar
chika
ozu
tetsuo
ikezono
manabu
nonaka
toshiaki
yagi
nippon
medic
school
chiba
hokusoh
hospit
otorhinolaryngolog
chiba
japan
nippon
medic
school
otorhinolaryngolog
tokyo
japan
background
patient
intract
otiti
media
om
coexist
bronchial
asthma
extens
accumul
eosinophil
effus
mucosa
middl
ear
call
eosinophil
otiti
media
eom
previous
report
mast
cell
regul
eosinophil
inflamm
nasal
polyp
order
elucid
mechan
eosinophil
accumul
middl
ear
analyz
eosinopil
chemoattract
like
rant
eotaxin
ligand
well
mast
cell
mediat
tryptas
middl
ear
biopsi
effus
mee
patient
om
without
asthma
materi
method
elisa
analyz
level
rant
eotaxin
mee
mucosa
patient
om
without
asthma
control
number
tryptas
cell
mast
cell
mbp
cell
eosinophil
rant
eotaxin
cell
analyz
immunohistochemistri
middl
ear
biopsi
result
level
rant
eotaxin
higher
patient
om
asthma
compar
control
wherea
mucosa
control
mbp
eotaxin
cell
detect
markedli
increas
patient
asthma
concert
high
number
tryptas
rant
cell
background
eosinophil
preferenti
accumul
site
airway
inflamm
asthma
circul
eosinophil
particip
asthmat
airway
necessari
interact
adhes
molecul
express
endotheli
cell
expos
inflammatori
mediat
cysteinyl
leukotrien
cyslt
evid
cyslt
includ
leukotrien
lt
regul
function
statu
eosinophil
object
investig
whether
interact
adhes
molecul
modifi
eosinophil
function
induc
cyslt
method
rhpselectin
dissolv
nahco
coat
buffer
ad
eia
plate
incub
c
overnight
residu
fluid
decant
gelatin
ad
reduc
nonspecif
activ
eosinophil
eosinophil
isol
blood
healthi
donor
incub
eia
plate
expos
ltd
gener
superoxid
anion
j
releas
eosinophilderiv
neutrotoxin
edn
evalu
cytochrom
c
reduct
assay
elisa
respect
final
combin
ltd
pselectin
induc
releas
edn
conclus
combin
vcamior
icami
cyslt
effect
induc
effector
function
eosinophil
eosinophil
adhes
migrat
across
endotheli
cell
via
spefic
adhes
protein
subsequ
exposur
cyslt
may
involv
manifest
eosinophil
activ
airway
asthma
anker
hansen
lar
k
poulsen
kresten
skak
rigshospitalet
allergyclin
copenhagen
k
denmark
novo
nordisk
depart
pharmacolog
denmark
introduct
eosinophil
recruit
late
phase
inflamm
elicit
host
defens
parasit
infect
howev
allergi
eosinophil
contribut
neg
elicit
tissu
damag
aim
evalu
express
receptor
eosinophil
method
eosinophil
purifi
blood
sampl
taken
allerg
healthi
individu
use
microbead
deplet
neutrophil
remain
tcell
granulocyt
popul
rna
purifi
use
abi
prism
robot
realtim
pcr
perform
use
appli
biosystem
taqman
gene
express
assay
elisa
assay
perform
receptor
eosinophil
apoptosi
measur
flow
cytometr
assay
use
annexinv
propidium
iodid
cell
hour
time
point
result
yield
eosinophil
healthi
allerg
person
eosinophil
per
ml
full
blood
respect
use
realtim
pcr
mrna
could
detect
howev
receptor
mrna
detect
mean
ctvalu
donor
differ
seen
allerg
healthi
individu
nabv
bcell
line
ramo
use
posit
control
yield
ctvalu
roughli
higher
express
mrna
ramo
compar
eosinophil
mrna
express
eosinophil
compar
eosinophil
cell
line
clone
sandwich
elisa
detect
eosinophil
cell
lysat
establish
use
polyclon
rabbit
antibodi
mous
monoclon
elisa
detect
limit
ng
ml
roughli
receptor
per
cell
express
detect
either
eosinophil
ramo
cell
line
effect
eosinophil
apoptosi
presenc
type
cytokin
examin
howev
appar
effect
either
increas
surviv
increas
apoptosi
could
seen
conclus
eosinophil
express
mrna
realtim
pcr
show
mean
ctvalu
donor
protein
express
examin
use
flowcytometri
elisa
could
detect
function
apoptosi
assay
show
type
cytokin
effect
eosinophil
unlik
stimul
eosinphil
major
signific
background
critic
involv
prolifer
activ
migrat
surviv
eosinophil
may
play
pathogen
role
hypereosinophil
syndrom
ihe
heterogen
group
disord
character
sustain
peripher
blood
andor
tissu
eosinphilia
assess
safeti
efficaci
human
monoclon
antibodi
patient
ihe
respiratori
involv
method
result
patient
yearold
woman
year
histori
ihe
biopsi
confirm
variou
occas
involv
lung
paranas
sinus
onset
diseas
eosinophil
pneumonia
eosinpohil
bronchial
lavag
asthma
respiratori
failur
persist
eosinophilia
respiratori
symptom
success
treat
dose
prednison
mgdaili
variabl
accord
eosinophilia
attempt
shift
inhal
steroid
plu
montelukast
invariantli
lead
relaps
howev
withdraw
steroid
treatment
forc
sever
system
side
effect
bleed
gastric
ulcera
attempt
initimab
effect
treatment
mepolizumab
mgkg
intraven
monthli
start
mepolizumab
well
toler
rapidli
reduc
eosinophilia
symptom
eosinophil
decreas
first
infus
remain
subsequ
control
week
oral
steroid
could
discontinu
conclus
mepolizumab
safe
effect
lower
eosinophil
count
glucorticoid
spare
effect
patient
ihe
keyword
hypereosinophil
syndrom
pneumonia
mepolizumab
linshien
fu
taichung
veteran
gener
hospit
section
immunolog
nephrolog
dep
pediat
taichung
taiwan
background
recent
studi
suggest
sever
antihistamin
modul
variou
inflammatori
reaction
besid
antagon
investig
effect
cetirizin
ceti
levocetirizin
levo
granulocytemacrophag
colonystimul
factor
gmcsf
secret
human
airway
epitheli
cell
method
cell
preincub
ceti
levo
individu
hour
stimul
hour
level
gmcsf
cultur
supernat
measur
enzymelink
immunosorb
assay
elisa
result
data
show
ceti
levo
significantli
suppress
gmcsf
secret
respect
levo
significantli
suppress
secret
respect
possibl
ceti
conclus
result
suggest
cetirizin
levocetirizin
higher
concentr
reduc
releas
gmcsf
human
airway
epitheli
cell
stimul
observ
indic
antihistamin
may
exert
antiinflammatori
effect
beyond
antagonist
histamin
activ
result
suggest
levo
could
potent
ceti
term
antiinflammatori
activ
new
interest
properti
hydroxyzin
drug
use
treatment
chronic
idiopath
urticaria
anxieti
disord
background
human
lymphocyt
known
particip
defens
microbi
pathogen
antitumor
activ
cellular
immun
system
newborn
gener
consid
immatur
hyporespons
comparison
adult
studi
made
quantit
qualit
comparison
lymphocyt
activ
statu
product
cytokin
cord
blood
mononuclear
cell
cbmc
versu
adult
peripher
blood
mononuclear
cell
pbmc
method
employ
flow
cytometr
analysi
compar
number
phenotyp
characterist
lymphocyt
cbmc
adult
pbmc
result
number
cell
lower
cbmc
adult
pbmc
tcr
express
level
similar
group
stimul
cbmc
cell
isopentenyl
pyrophosph
ipp
induc
contrast
adult
pbmc
posit
product
cytokin
addit
ipp
enhanc
ifn
cbmc
v
cell
pmaionomycin
stimul
lead
inf
product
cbmc
cell
invers
adult
pbmc
activ
produc
cytokin
conclus
addit
immatur
adapt
immun
newborn
cell
cbmc
cell
hyporespons
comparison
adult
pbmc
cell
may
associ
predisposit
infect
viru
bacteria
fungu
well
develop
allerg
inflamm
newborn
matrix
metalloproteinas
first
type
inhibitor
type
bronchalveolar
lavag
fluid
pulmonari
tuberculosi
patient
andrey
safronov
svetlana
sotnichenko
elena
markelova
vladivostok
state
medic
univers
pathophysiolog
vladivostok
russian
feder
signific
compon
territori
matrix
matrix
metalloproteinas
group
proteolyt
enzym
especi
activ
condit
inflammatori
respons
matrix
metalloproteinas
mmp
produc
normal
alveolar
macrophag
granulocyt
neutrophil
express
mmp
increas
tissu
affect
process
remodel
angiogenesi
neg
influenc
process
restrict
tissular
inhibitor
metalloproteinas
main
function
consist
regul
distract
collagen
basic
membran
compon
research
quotient
mmp
first
type
inhibitor
contain
bronchalveolar
lavag
fluid
teenag
suffer
pulmonari
tuberculosi
receiv
result
process
statist
analysi
arithmet
mean
mean
error
also
determin
fidel
result
reckon
mann
whitney
nonparametr
test
evalu
made
accord
clinic
laboratori
find
bacteriolog
test
sputum
research
shown
quantiti
bronchalveolar
lavag
fluid
pulmonari
tuberculosi
patient
come
pgml
also
elicit
tendenc
increas
koch
bacillu
case
pgml
vs
pgml
differ
patient
local
pulmonari
tuberculosi
infiltr
phthisi
case
reveal
receiv
find
suffici
make
unambigu
conclus
concern
pathogenet
valu
research
mediat
denot
necess
search
diagnost
charact
inflamm
case
teenagersp
ulmonari
tuberculosi
cytokin
product
experiment
pneumonia
anna
kostyushko
elena
markelova
siberian
branch
russian
academi
medic
scienc
fareastern
scientif
centr
vladivostok
russian
feder
activ
cytokin
system
differ
variant
immun
inflamm
occur
without
depend
etiolog
factor
time
data
testifi
microorgan
develop
product
similar
cytokin
thu
influenc
cytokin
cascad
immun
answer
purpos
present
investig
reveal
influenc
etiolog
factor
paramet
local
systemat
structur
opposit
cytokin
ifn
experiment
pneumonia
caus
aureu
e
coli
infect
mice
line
spent
intranas
doze
mtml
aureu
experiment
group
mtml
e
coli
ii
experiment
group
product
cytokin
blood
cell
mice
lung
investig
day
infect
reaction
ifa
result
conclus
infect
mice
aureu
level
ifn
consider
decreas
pgml
blood
pgml
supernat
lung
level
mice
tent
group
also
tend
decreas
made
pgml
blood
pgml
supernat
pulmonari
tissu
infect
mice
e
coli
content
ifn
blood
chang
littl
pgml
decreas
supernat
lung
promin
mice
tent
group
pgml
level
blood
mice
second
experiment
group
authent
group
control
made
pgml
level
supernat
pulmonari
tissu
infect
mice
e
increas
practic
time
comparison
group
control
pgml
thu
carri
investig
reveal
featur
local
system
product
cytokin
depend
etiolog
experiment
pneumonia
ifn
level
influenc
promin
decreas
develop
inflammatori
process
lung
caus
e
coli
render
signific
influenc
local
product
increas
level
time
moreov
authent
decreas
peripher
blood
ophtalmoherp
grand
medic
social
problem
herpet
infect
eye
relaps
case
result
reduc
acuiti
vision
disabl
deterior
life
activ
enlarg
concept
regard
inflammatori
mechan
let
us
opportun
optim
respect
therapi
object
work
cytokin
content
gmcsf
blood
serum
lacrim
liquor
patient
method
materi
serum
lacrim
liquid
ophtalmoherp
patient
test
conform
women
man
control
group
embrac
practic
healthi
volunt
without
diseas
organum
visu
cytokin
quantifi
ifa
method
use
specif
reagent
br
diagnost
inc
usa
consequ
discuss
found
polysemant
modif
local
system
cytokin
profil
patient
refer
group
blood
serum
determin
acceler
time
level
time
pg
content
decreas
time
wherea
gmcsf
near
standard
abovement
indic
lacrim
liquor
appear
follow
way
authent
increas
level
pgml
pgml
gmcsf
pgml
pgml
modif
tendenc
heighten
wherea
reduc
way
blood
serum
obtain
result
allow
us
draw
conclus
ophtalmoherp
diseas
neutrophil
macrophag
mainli
activ
local
produc
gsmcsf
system
respons
character
hyper
product
tnf
compens
antiinflammatori
reaction
distress
local
systemat
streptokinaza
indus
pulmonari
infilltr
hipereosinophiliacas
report
biserka
kaeva
oliv
jovkovski
sasa
kaeva
medic
faculti
pulmolog
allergolog
clinic
skopj
macedonia
fyrom
variou
drug
enviroment
agent
capabl
produc
acut
pulmonari
infiltr
eosinophilia
present
man
acut
infarct
myocardi
treat
streptokinaza
besid
usual
cardiolog
treatment
anamneza
faund
aut
patient
problem
heart
neither
kind
alerg
kind
ilnes
first
impres
patient
consciou
skare
dispnoic
afebril
strong
pain
chest
auskult
anormalvezicular
breathig
heart
rate
phisic
find
order
imidi
pose
diagnoza
usual
cardiolog
therapi
given
time
streptokinaza
includ
patient
beard
treatment
well
third
day
therapi
health
condit
deterior
got
frequent
chaemoptisi
increas
temperatur
decreas
blod
presur
rich
find
rale
clinic
examinaton
laboratori
examin
show
esr
hour
strong
blod
reduct
eosinophilia
leukocytosi
xchest
ray
upper
lobe
caracteristicali
involv
describ
bphotograph
neg
radiograph
shadow
seen
pulmonari
oedema
chest
ct
show
bilater
pulmonari
infiltr
mainli
upper
middl
lobe
bacteri
examin
cultur
sputum
neg
search
parasist
infest
neg
well
bk
infect
lung
volumen
diffus
capac
werw
decreas
hipooxemia
promin
start
therapi
prednison
daili
success
decris
folow
week
also
antibiot
oxigen
therapi
improv
seen
less
week
radiograpf
shadow
complet
resolv
week
number
eosinophil
olso
came
back
normal
biserka
kaeva
gorica
breskovska
zoran
arsovski
kamelija
busljet
medic
faculti
pulmolog
allergolog
clinic
skopj
macedonia
fyrom
background
pulmonari
thromboembolismu
present
pulmonari
infiltr
manifest
depend
extens
pulmonari
embolis
presenc
pleural
effus
pe
period
year
pt
pulmonari
thromboembol
studi
regard
serum
concentr
ige
ddimer
eosinophil
pleural
fluid
acut
phase
hospit
admiss
treatment
recoveri
phase
aim
studi
estim
correl
paramet
acut
recoveri
phase
method
number
eosinophil
pleural
fluid
determin
smear
pleaural
fluid
color
maygrunwald
giemsa
serum
ige
measur
radioimmunoassay
diffus
rid
result
serum
ige
concentr
increas
acut
phase
iuml
decreas
afterward
pt
increas
serum
ige
concentr
lag
day
behind
serum
ddimer
concentr
indic
later
ige
product
thrombu
format
lysi
pt
develop
small
chaemorag
pe
eosinophil
highest
level
ige
measur
acut
phase
conclus
result
indic
relationship
serum
ige
concentr
patophisiolog
pulmonari
thromboembolismu
serum
ige
eo
count
may
good
mark
sever
pulmonari
thromboembolismu
indic
pathogenesi
prognosi
modul
peripher
cordblood
deriv
gammadelta
cell
immun
respons
stimul
newli
design
compound
possibl
new
therapeut
approach
mancino
giorgio
auricchio
giovanni
battistini
luca
galli
elena
colizzi
vittorio
brunetti
ercol
placido
roberta
san
pietro
hospit
fatebenefratelli
afar
research
centr
roma
itali
santa
lucia
foundat
ircc
neuroimmunolog
unit
roma
itali
univers
rome
tor
vergata
dept
biolog
roma
itali
immun
system
respons
infect
allerg
agent
make
use
differ
cellular
popul
alfabeta
gammadelta
gd
cell
latter
present
peripher
pb
cord
cb
blood
second
immatur
stage
respond
varieti
nonpeptid
antigen
hlaindepend
system
secret
proinflammatori
immunomodul
cytokin
express
membran
receptor
costimulatori
molecul
produc
cytotox
effector
perforin
granzym
recent
studi
suggest
also
less
common
gd
cell
may
play
role
effector
immunoregulatori
cell
develop
perpetu
allerg
inflamm
also
bronchial
asthma
rhiniti
eczema
aim
analys
capabl
gd
cell
deriv
pb
cb
respond
nonprot
antigen
view
put
therapeut
use
newborn
infant
patholog
firstli
found
cbderiv
gd
cell
strongli
respond
stimul
aminobiphosphon
ab
compound
pamidron
zoledron
term
expans
wherea
stimul
pyrophosph
pp
lead
littl
expans
popul
expand
ab
also
perfectli
function
sinc
cell
abl
produc
larg
amount
cytokin
tnfalfa
e
ifngamma
secondarili
stimul
antigen
interestingli
also
pp
induc
absexpand
cell
cytokin
product
secondari
stimul
suggest
exist
differ
respons
pathway
concern
expans
cytokin
product
cbderiv
gd
cell
establish
cb
gd
cell
function
effici
stimul
focus
studi
stimul
downregul
gd
cell
newli
design
synthesis
compound
nc
therefor
characteris
smallcompound
librari
select
molecul
capabl
stimul
downmodul
gd
cell
pb
use
molecul
also
cb
gd
stimul
found
follow
stimul
nc
cbderiv
gd
cell
strongli
respond
term
cellular
expans
cytokin
product
result
confirm
though
use
cbderiv
gammadelta
clone
studi
progress
evalu
toxic
compound
consequ
employ
vivo
gd
cell
immunomodul
new
therapeut
approach
infecti
allerg
diseas
novel
low
molecular
weight
thiol
compound
nacetylcystein
amid
attenu
allerg
airway
inflamm
hyperrespons
recent
studi
demonstr
antioxid
abl
reduc
airway
inflamm
hyperreact
anim
model
allerg
airway
diseas
newli
develop
antioxid
small
molecular
weight
thiol
compound
nacetylcystein
amid
shown
increas
cellular
level
glutathion
gsh
attenu
oxid
stress
relat
disord
howev
effect
allerg
airway
diseas
asthma
unknown
object
studi
aim
determin
effect
bronchial
inflamm
airway
hyperrespons
method
use
mous
model
allerg
airway
diseas
effect
bronchial
inflamm
airway
hyperrespons
studi
measur
intracellular
ro
gsh
glutathion
disulfid
vascular
permeabl
protein
tissu
inflamm
airway
resist
result
increas
level
cytokin
nuclear
factorb
nfb
hypoxiainduc
vascular
endotheli
growth
factor
increas
ro
gener
increas
vascular
permeabl
increas
mucu
product
ovalbumin
inhal
significantli
reduc
administr
conclus
result
suggest
attenu
airway
inflamm
hyperrespons
regul
activ
nfb
well
reduc
ro
gener
allerg
airway
diseas
mice
clinic
implic
find
provid
import
molecular
mechan
use
novel
antioxid
prevent
andor
treat
asthma
airway
inflammatori
diseas
shift
cell
cytokin
product
subsequ
reduct
serum
immunoglobulin
e
respons
administr
vivo
betacaroten
mous
model
mykola
korzh
kharkov
nation
univers
fundament
medicin
kharkov
ukrain
background
cell
result
antigen
stimul
presenc
respect
implic
patholog
variou
diseas
includ
allerg
autoimmun
diseas
studi
ask
whether
administr
betacaroten
bring
shift
vivo
mice
subsequ
reduct
circul
ige
method
feed
contain
betacaroten
administ
oral
balbc
mice
immun
intraperiton
ovalbumin
ova
approxim
month
titer
ovaspecif
ige
ovaspecif
ovaspecif
mous
sera
determin
cytokin
product
spleen
cell
serum
ig
concentr
studi
elisa
also
examin
effect
fed
betacaroten
activ
system
anaphylaxi
result
feed
betacaroten
mice
immun
ova
inhibit
immedi
reduct
bodi
temperatur
induc
antigen
stimul
furthermor
increas
serum
histamin
mice
fed
betacaroten
activ
system
anaphylaxi
lower
control
examin
pattern
cytokin
product
spleen
cell
mice
follow
restimul
ova
vitro
spleen
cell
show
enhanc
cytokin
product
spleen
cell
betacaroten
administ
mice
produc
ifngamma
compar
control
mice
antigenspecif
manner
secret
spleen
cell
compar
two
mous
group
betacaroten
administr
reduc
serum
igg
concentr
markedli
reduc
total
ige
level
ratio
reflect
balanc
sera
furthermor
betacaroten
administr
reduc
ovalbumin
ova
specif
ige
level
sera
ova
sensit
mice
conclus
thu
betacaroten
enhanc
ifngamma
secret
thu
modul
cytokin
balanc
lead
reduct
serum
ige
chiara
folli
desideria
descalzi
francesca
scordamaglia
anna
maria
riccio
cinzia
gamalero
marco
barbieri
univers
genoa
depart
intern
medicin
genoa
itali
univers
genoa
ent
depart
genoa
itali
background
statin
serum
cholesterollow
agent
use
prevent
atherosclerot
vascular
diseas
grow
evid
might
immunomodulatori
activ
method
evalu
effect
drug
allerg
diseas
treat
pbmc
healthi
allerg
patient
vitro
fluvastatin
atorvastatin
simvastatin
alon
combin
nk
deriv
healthi
subject
activ
uml
alon
addit
statin
also
evalu
effect
fibroblast
cultur
deriv
human
nasal
polyp
turbin
stimul
follow
treat
treat
fgf
alon
combin
statin
result
differ
day
cultur
cell
analyz
flowcitometri
evalu
follow
cell
surfac
receptor
pbmc
nk
cell
fibroblast
result
show
statin
modulatori
effect
cell
surfac
protein
express
pbmc
nk
modul
treatment
nasal
polyp
fibroblast
wherea
turbin
fibroblast
express
upregul
fgf
downregul
addit
fluvastatin
atorvastatin
interestingli
also
express
modifi
nasal
polyp
fibroblast
stimul
fgf
statin
fibroblast
turbin
show
increas
express
stimul
fgf
addit
atorvastatin
abl
downregul
conclus
conclus
differ
behaviour
statin
divers
kind
cell
vitro
prompt
news
studi
use
treatment
inflammatori
diseas
latex
allergi
oper
room
frequent
sever
gulbin
karakoc
mehmet
k
l
c
ayfer
inal
seval
kendirli
derya
altinta
mustafa
yilmaz
cukurova
univers
faculti
medicin
pediatr
allergyimmunolog
adana
turkey
object
latex
allergi
becom
major
health
concern
among
healthcar
worker
approxim
reportedli
sensit
aim
studi
determin
preval
latex
allergi
potenti
crossreact
food
oper
room
stuff
method
one
hundr
four
oper
room
stuff
age
year
year
includ
doctor
nurs
technician
complet
latex
allergi
questionnair
question
symptom
latex
reactiv
allergi
particularli
food
may
crossreact
latex
inform
consent
obtain
skin
prick
test
perform
natur
rubber
latexand
five
potenti
crossreact
food
banana
kiwi
melon
tomato
potato
specif
ige
antibodi
latex
food
evalu
pharmacia
cap
rast
system
result
five
personnel
describ
allerg
symptom
attribut
latex
exposur
latex
allerg
stuff
skin
symptom
sever
anaphylact
reaction
sever
asthma
personnel
posit
reaction
latex
crossreact
food
specif
ige
latex
found
posit
group
signific
differ
latex
sptposit
neg
health
care
worker
accord
age
sex
total
exposur
time
latex
conclus
studi
found
preval
allergi
among
oper
room
personnel
although
latex
allergi
frequent
popul
presenc
may
lead
sever
allerg
reaction
anaphylaxi
sever
asthma
background
effect
dog
ownership
childhood
develop
allergi
investig
studi
conflict
result
object
investig
associ
childhood
dog
ownership
regular
contact
dog
indoor
endotoxin
exposur
infanc
develop
allerg
sensit
atop
diseas
age
german
cohort
studi
method
data
two
ongo
birth
cohort
gini
lisa
analys
studi
inform
children
contact
dog
allerg
symptom
doctor
diagnos
allerg
diseas
collect
followup
use
questionnair
specif
ige
antibodi
common
aeroallergen
measur
age
hous
dust
sampl
collect
children
month
old
amount
endotoxin
hous
dust
determin
result
dog
ownership
earli
childhood
associ
signific
lower
rate
mix
pollen
inhal
sensit
effect
dog
sensit
preval
allerg
symptom
diseas
age
regular
contact
dog
childhood
without
ownership
associ
health
outcom
associ
found
hous
dust
endotoxin
exposur
infanc
sensit
dog
mix
pollen
inhal
allergen
conclus
dog
ownership
earli
childhood
protect
develop
inhal
sensit
effect
attribut
simultan
exposur
endotoxin
schoola
sourc
exposur
furrypet
allergen
lena
elfman
yahong
mi
dan
greta
smedj
occup
environment
medicin
depart
medic
scienc
uppsala
sweden
background
school
environ
import
sourc
exposur
furrypet
allergen
children
sweden
impact
health
possibl
develop
allergi
aim
studi
compar
two
method
allergen
sampl
investig
associ
percentag
anim
owner
allergen
level
method
total
class
primari
secondari
school
uppsala
sweden
randomli
select
questionnair
includ
question
pet
ownership
answer
pupil
age
year
sampl
settl
dust
collect
floor
furnitur
throughout
classroom
vacuum
cleaner
special
sampl
filter
alk
abello
airborn
particul
collect
passiv
petridish
place
classroom
week
allergen
level
cat
dog
hors
determin
use
elisa
correl
allergen
level
settl
dust
air
number
catand
dog
owner
well
ride
class
analys
spearman
rank
correl
twotail
signific
level
result
geometr
mean
gm
allergen
level
settl
dust
ngg
fel
ngg
f
ug
equ
cx
petri
dish
sampl
gm
allergen
level
ngsampl
cat
ngsampl
dog
usampl
hors
percentag
gm
catown
dogown
hors
contact
cat
allergen
level
dust
correl
cat
air
percentag
catown
dog
allergen
level
dust
correl
dog
allergen
air
percentag
dogown
valid
hors
allergen
level
dust
correl
hors
allergen
air
percentag
ride
conclus
case
found
correl
percentag
animalown
rider
allergen
level
dust
air
sampl
correl
dust
air
allergen
level
seldom
shown
believ
sampl
whole
floor
bench
chair
give
repres
valu
howev
dust
level
proxi
variabl
air
level
may
better
measur
allergen
exposur
nipasiri
voraphani
suparat
pohnu
pantipa
chatchate
jarungchit
ngamphaiboon
faculti
medicin
chulalongkorn
univers
pediatr
bangkok
thailand
background
cockroach
second
common
aeroallergen
world
howev
studi
correl
socioeconom
statu
environment
factor
cockroach
sensit
southeast
asia
purpos
studi
determin
socioeconom
environment
factor
affect
cockroach
sensit
atop
children
method
one
hundr
twenti
children
age
year
attend
allergi
clinic
depart
pediatr
faculti
medicin
chulalongkorn
univers
symptom
asthma
allerg
rhiniti
atop
dermat
skin
test
reactiv
least
allergen
enrol
questionnair
skin
prick
test
result
analys
result
boy
girl
averag
age
eighti
one
percent
patient
allerg
rhiniti
asthma
atop
dermati
cockroach
sensit
found
patient
sensit
german
cockroach
american
cockroach
respect
statist
correl
socioeconom
statu
environment
factor
includ
household
incom
home
charact
home
environ
amount
cockroach
seen
home
cockroach
sensit
conclus
high
incid
cockroach
sensit
atop
children
howev
socioeconom
statu
amount
cockroach
seen
home
environment
factor
correl
degre
sensit
asthma
sever
influenc
indoor
dust
mite
endotoxin
nitrogen
dioxid
exposur
hong
kong
children
background
endotoxin
exposur
dual
effect
protect
wheez
disord
earli
life
worsen
control
caucasian
asthmat
exposur
hous
dust
mite
hdm
nitrogen
dioxid
also
known
risk
factor
sever
asthma
popul
howev
data
unclear
asian
studi
investig
indoor
exposur
endotoxin
hdm
hong
kong
asthmat
children
relat
diseas
sever
method
asthmat
age
year
old
elig
spirometri
exhal
nitric
oxid
eno
measur
clinic
home
visit
done
within
day
dust
collect
patient
mattress
carer
complet
isaac
written
questionnair
hous
dust
der
p
endotoxin
level
measur
enzymelink
immunosorb
chromogen
limulu
amoebocyt
lysat
assay
respect
averag
level
kitchen
measur
period
ogawa
sampler
badg
result
asthmat
patient
age
year
recruit
median
fev
eno
predict
ppb
fiftyeight
percent
patient
wheez
past
month
asthmat
receiv
inhal
steroid
home
visit
mg
mattress
dust
collect
median
iqr
mattress
der
p
endotoxin
level
eumg
respect
trend
observ
correl
mattress
der
p
endotoxin
load
p
neither
factor
associ
indoor
p
der
p
level
found
famili
kitchen
level
ppb
exceed
ppb
famili
indoor
der
p
level
significantli
associ
night
awaken
p
eno
p
wherea
mattress
endotoxin
load
higher
patient
low
peak
expiratori
flow
rate
p
associ
found
indoor
clinic
spirometr
paramet
conclus
result
suggest
asthma
sever
chines
children
affect
current
exposur
hdm
allergen
mattress
indoor
endotoxin
exposur
effect
indoor
mold
concentr
daili
symptom
sever
children
asthma
andor
rhiniti
monosensit
mold
littl
known
contribut
indoor
mold
symptom
asthma
andor
rhiniti
children
monosensit
mold
aim
investig
effect
indoor
mold
spore
concentr
daili
symptom
asthma
andor
rhiniti
children
monosensit
mold
nineteen
children
asthma
andor
rhiniti
sensit
mold
record
daili
symptom
pef
valu
diari
februari
januari
studi
period
indoor
mold
concentr
measur
monthli
livingbedroom
median
indoor
mold
concentr
commonli
recov
indoor
mold
cladosporium
penicillium
aspergillu
found
signific
correl
indoor
mold
concentr
daili
rhiniti
score
r
p
daili
asthma
score
r
p
daili
morn
pef
r
p
even
pef
r
p
effect
indoor
mold
evid
symptom
patient
asthma
andor
rhiniti
monosensit
mold
influenc
air
qualiti
school
upon
children
chronic
bronchopulmonari
diseas
rodica
selevestru
svetlana
sciuca
grigor
friptuleac
cazacu
angela
state
medic
univerc
pediatri
chisinau
moldova
republ
aim
emphas
influenc
air
qualiti
studi
room
school
children
chronic
bronchopulmonari
diseas
method
studi
plan
interview
pupil
iiv
class
differ
school
select
children
chronic
respiratori
diseas
lot
studi
includ
children
chronic
bronchopulmonari
diseas
clinic
examin
children
emphas
case
bronchial
asthma
case
obstruct
chronic
bronchiti
case
simpl
chronic
bronchiti
hygien
condit
occup
condit
studi
room
pupil
carri
mean
air
qualiti
monitor
usa
determin
valu
microclim
factor
temperatur
air
humid
concentr
result
hygien
evalu
occup
condit
studi
room
detect
subnorm
thermal
regim
begin
first
lesson
end
last
lesson
optim
valu
air
humid
studi
room
increas
begin
first
lesson
end
last
lesson
optim
humid
signific
modif
air
vari
day
begin
first
lesson
p
g
end
last
lesson
optim
concentr
g
respiratori
function
condit
children
chronic
recurr
respiratori
diseas
certifi
presenc
obstruct
disturb
pef
j
minim
restrict
chang
fvc
conclus
reduc
temperatur
increas
humid
excess
concentr
child
microambi
lead
instal
perpetu
respiratori
symptom
children
bronchial
asthma
chronic
bronchiti
background
preval
bronchial
asthma
increas
worldwid
last
twenti
year
tendenc
particularli
valid
adolesc
popul
aim
present
studi
evalu
preval
adolesc
smoke
pattern
parent
smoke
exposur
environment
tobacco
smoke
asthmalik
symptom
relat
activ
passiv
smoke
among
teenag
schoolchildren
method
done
crosssect
questionnair
studi
modifi
version
compendium
european
respiratori
standard
questionnairescersq
student
age
three
secondari
school
sofiabulgaria
inquir
result
activ
smoker
student
smoke
regularli
averag
age
start
smoke
year
averag
number
smoke
cigarett
per
day
regular
exposur
tobacco
smoke
report
student
exposit
less
year
year
respiratori
symptom
last
month
wheez
whistl
chest
report
student
addit
short
breath
night
cough
report
asthma
attack
examin
student
antiasthma
drug
taken
statist
analysi
questionnair
show
signific
associ
bwheez
whistl
chest
bactiv
smoke
p
g
bnight
cough
bactiv
smoke
p
g
bnight
cough
bactiv
smoke
p
g
bnight
cough
bpassiv
smoke
p
g
conclus
found
associ
support
idea
smoke
activ
passiv
play
role
initi
develop
mainten
asthmalik
symptom
intervent
strategi
smoke
control
includ
public
polici
element
prevent
measur
implement
health
profession
particular
gener
practition
school
health
staff
rajan
bhandari
shambhu
joshi
commun
health
environment
societi
nepal
commun
health
kathmandu
nepal
nepal
medic
colleg
teach
hospit
medic
scienc
kathmandu
nepal
background
develop
countri
like
nepal
poor
health
statu
school
student
object
know
evalu
indoor
environment
condit
govern
privateschool
health
impact
student
method
cross
section
studi
repres
sampl
school
select
region
nepal
includ
govern
privat
school
onsit
observ
health
check
interview
student
teacher
done
specif
score
given
criteria
data
analys
edit
epi
info
program
result
result
show
govern
school
privateschool
poor
environment
condit
govern
school
student
suffer
environmentalhealth
problem
privat
school
student
suffer
kind
diseas
especi
allerg
governmentschool
doesnt
standard
classroom
adequ
sport
facil
safe
drink
water
light
ventil
comparison
privat
school
conclus
conclud
main
caus
poor
socioeconom
statu
illiteraci
parent
neglig
hard
housework
children
diseas
malnutrit
incomplet
immunis
lack
health
educ
poor
environ
condit
includ
crowd
student
classroom
poor
ventil
shortag
clean
drink
water
untidi
cloth
student
poor
nutrit
lack
greeneri
school
area
school
near
road
air
pollut
lack
environment
awar
among
teacher
parent
govern
school
limit
budget
resourc
compar
privat
school
lower
lower
middl
class
famili
children
studi
govern
school
cover
nation
total
student
recommend
govern
alloc
special
budget
govern
school
utilis
avail
resourc
good
ventil
limit
student
class
awar
among
teacher
parent
last
least
type
program
help
prevent
environment
health
hazard
also
aircondit
bedroom
allerg
sensit
atop
patient
tachakwan
intapunte
panithi
boondumnern
pantipa
chatchate
jarungchit
ngamphaiboon
king
chulalongkorn
memori
hospit
pediatr
bangkok
thailand
background
one
recommend
environment
control
allerg
prevent
aircondit
bedroom
purpos
studi
determin
relationship
aircondit
bedroom
allerg
sensit
method
patient
asthma
andor
allerg
rhinoconjunct
attend
pediatr
allergi
clinic
king
chulalongkorn
memori
hospit
age
year
old
posit
prick
skin
test
aeroallergen
least
antigen
studi
questionnair
result
total
patient
includ
male
femal
live
household
aircondit
bedroom
american
cockroach
sensit
significantli
preval
patient
live
household
without
aircondit
bedroom
compar
live
aircondit
bedroom
p
odd
ratio
contrast
alternaria
sensit
significantli
less
preval
household
without
aircondit
bedroom
compar
aircondit
bedroom
p
odd
ratio
polysensit
skin
prick
test
posit
least
antigen
significantli
relat
among
household
without
aircondit
bedroom
p
cockroach
second
common
aeroallergen
sensit
mite
correl
amount
cockroach
seen
hous
skin
test
result
correl
cat
dog
exposur
cigarett
smoke
allerg
sensit
conclus
patient
live
household
without
aircondit
increas
risk
cockroach
sensit
decreas
risk
mold
sensit
effici
neem
tree
extract
milbiol
decreas
level
hous
dust
mite
allergen
tiia
voor
ylle
kuld
tiina
reban
kaja
julg
tartu
univers
hospit
clinic
tartu
estonia
background
sensit
hous
dust
mite
hdm
allergen
common
estonia
level
pteronyssinu
der
farina
der
high
hous
diminish
contact
hdm
reduc
allergi
symptom
therefor
import
decreas
level
hdm
allergen
milbiol
hexal
ag
holzkirchen
germani
oil
extract
produc
neem
tree
margosa
seed
milbiol
harmless
human
anim
although
hinder
growth
reproduct
mite
aim
estim
effici
milbiol
decreas
level
hdm
allergen
method
studi
period
dec
dec
studi
group
compris
bed
home
twentyf
bed
vacuum
clean
treat
milbiol
intervent
group
bed
vacuum
clean
control
group
frequenc
clean
ident
perform
time
bed
group
dust
sampl
collect
month
treatment
milbiol
perform
month
accord
manufactori
instruct
level
der
der
dust
sampl
measur
elisa
method
data
live
condit
also
collect
result
bed
level
der
ngg
higher
level
der
ngg
p
g
hdm
allergen
common
old
brick
hous
lower
floor
room
carpet
bed
older
year
treatment
milbiol
mean
level
der
ngg
ngg
respect
p
howev
one
year
level
increas
ngg
level
der
increas
treatment
milbiol
ngg
ngg
p
although
month
level
lower
treatment
ngg
mean
level
hdm
allergen
decreas
also
control
group
bed
due
vacuum
clean
der
ngg
der
ngg
p
g
respect
conclus
milbiol
alon
effect
decreas
hdm
allergen
bed
oneyear
period
treatment
howev
frequent
treatment
milbiol
could
give
better
result
lower
level
hdm
allergen
gain
also
regular
vacuum
clean
analysi
serum
level
among
peopl
expos
industri
dust
background
healthi
person
antiproteas
serv
protect
screen
prevent
alveolar
wall
destruct
longterm
industri
pollut
exposur
may
lead
imbal
oxidantantioxid
proteasesantiproteas
system
pulmonari
tissu
witch
follow
unimped
neutrophil
elastas
digest
elastin
collagen
alveolar
wall
progress
emphysema
method
interest
compar
level
aat
patient
occup
pulmonari
patholog
healthi
men
work
industri
pollut
exposur
year
healthi
donor
subject
studi
men
age
main
group
studi
includ
patient
chronic
occup
bronchiti
n
electr
welder
pneumoconiosi
n
silicos
n
first
control
group
includ
patient
without
occup
lung
disord
second
control
group
healthi
donor
measur
level
aat
immunoturbidimetr
assay
quantit
vitro
determin
aat
human
serum
autom
clinic
analyz
use
reagent
produc
brochediagnost
normal
level
gl
result
found
level
aat
normal
among
patient
electr
welder
pneumoconiosi
significantli
lower
p
g
level
control
group
group
group
find
signific
differ
serum
concentr
aat
silicos
chronic
occup
bronchiti
control
group
even
normal
tendenc
aat
concentr
increas
due
term
pollut
exposur
conclus
longterm
industri
pollut
exposur
may
lead
chronic
airway
inflamm
caus
imbal
proteasesantiproteas
system
activ
secret
import
proteinas
inhibitor
among
men
work
industri
pollut
exposur
level
normal
among
patient
chronic
bronchiti
silicos
healthi
worker
found
aat
level
could
decreas
among
patient
electr
welder
pneumoconiosi
suppos
could
result
oxid
inhibit
weld
aerosol
compon
aat
secret
environment
dust
granulometri
microbi
load
presenc
tobacco
smoke
gianni
macrina
michel
baroffio
barbara
bruno
carla
tazzer
paolo
crimi
giorgio
walter
canonica
univers
genoa
depart
intern
medicin
genoa
itali
univers
genoa
depart
health
scienc
genoa
itali
background
sever
studi
describ
damag
passiv
smoke
human
anim
model
howev
differ
chemic
physic
compon
relat
mechan
damag
complet
understood
cigarett
smoke
compos
ga
phase
particul
phase
lot
toxicolog
relev
compound
present
focus
investig
particul
phase
environment
cigarett
smoke
amount
dimens
suspend
particl
partial
studi
far
noteworthi
size
particl
import
inhal
process
subsequ
deposit
respiratori
tract
method
differ
granulometri
suspend
dust
bacteri
load
studi
meter
nosmok
room
one
cigarett
smoke
ten
differ
experi
evalu
granulometri
suspend
dust
use
channel
particl
counter
analyz
particl
accord
granulometri
evalu
suspend
bacteri
load
use
multipierc
sampler
fix
replac
plate
set
aspir
air
evalu
sediment
bacteri
load
perform
use
air
microbi
index
techniqu
express
total
number
microrgan
settl
graviti
onto
petri
plate
result
increas
medium
small
larg
suspend
particl
number
observ
bacteri
mycot
load
decreas
min
cigarett
smoke
gramposit
cocci
never
decreas
chromogenbacteria
mycet
decreas
min
furthermor
observ
increas
sediment
bacteria
mycet
min
decreas
min
stabil
min
conclus
hypothes
tobacco
burn
acceler
sediment
larger
agglomer
meansiz
smoke
particl
bacteria
may
resuspend
movement
peopl
room
consequ
inhal
could
stronger
affin
airway
surfac
modifi
normal
mechan
nonspecif
immunolog
defens
microb
children
could
partial
explain
increas
respiratori
infect
children
expos
secondhand
smoke
proteom
analysi
birch
ragwe
pollen
artifici
expos
roberta
aina
elisa
berra
giada
marino
elid
pastorello
sandra
citterio
univers
milano
bicocca
dept
environment
scienc
milan
itali
niguarda
granda
hospit
unit
allergolog
clinic
immunolog
milan
itali
background
air
pollut
seem
play
fundament
role
promot
allergi
worsen
health
condit
allerg
peopl
new
interest
find
suggest
trafficrel
pollut
irrit
airway
also
make
allergen
aggress
especi
pollen
allergen
particular
air
pollut
induc
andor
increas
express
allergen
protein
also
induc
posttransl
modif
ptm
chang
make
protein
reactiv
toward
ige
object
investig
effect
nitrogen
dioxid
pollen
birch
betula
pendula
roth
ragwe
ambrosia
artemisifolia
l
two
common
import
sourc
allergen
europ
method
pollen
sampl
artifici
expos
differ
concentr
sera
birch
andor
ragwe
allerg
patient
also
collect
pollen
protein
extract
control
c
treat
sampl
separ
electrophoresi
blot
onto
nitrocellulos
membran
incub
patient
sera
identifi
pollen
allergen
b
antinitrotyrosin
antibodi
estim
entiti
protein
nitrat
c
stain
solut
specif
glycosyl
protein
final
treatment
lambda
protein
phosphatas
perform
identifi
chang
phosphoryl
pattern
result
treatment
induc
new
allergen
express
neither
birch
ragwe
pollen
regard
ptm
treatment
induc
modif
birch
ragwe
phosphoryl
pattern
contrari
chang
glycosyl
profil
detect
analys
plant
final
nitrat
protein
induc
birch
treat
sampl
conclus
exposur
pollen
induc
ptm
allergen
howev
futur
experi
need
confirm
first
result
vipul
shah
allergi
clinic
allergi
surat
india
introduct
new
pollen
allergen
suspect
patient
receiv
allergen
immunotherapi
show
recurr
symptom
period
janmarch
method
fifteen
patient
variou
allerg
disord
subject
skin
allergi
test
found
sensit
variou
allergen
immunotherapi
develop
recurr
symptom
janmarch
confirm
presenc
new
allergen
safranin
stain
glycerin
coat
slide
expos
patient
surround
bperson
volumetr
air
sampler
bsampler
pollen
collect
slide
much
better
simpl
exposur
mangifera
pollen
record
abund
antigen
mangifera
pollen
test
patient
strongli
posit
reaction
record
patient
subject
allergen
immunotherapi
cours
mangifera
pollen
allergen
result
patient
show
posit
result
mango
pollen
allergen
underw
immunotherapi
cours
pollen
antigen
show
signific
improv
symptom
next
pollen
season
mangifera
indica
conclus
mangifera
indica
pollen
could
play
import
role
nasobronchi
allergi
bair
sampler
make
detect
caus
allergen
possibl
easier
sometim
simpl
slide
exposur
may
fail
atsushi
fukushima
tintin
winshw
shoji
yamamoto
naoki
kunugita
yasuhiro
yoshida
keiichi
arashidani
hidekazu
fujimaki
nation
institut
environment
studi
research
center
environment
risk
tsukuba
japan
univers
occup
environment
health
japan
health
scienc
fukuoka
japan
univers
occup
environment
health
japan
medicin
fukuoka
japan
background
sinc
outdoor
indoor
air
pollut
environment
risk
factor
shown
contribut
develop
respiratori
infect
allergi
specul
posit
relationship
allerg
inflamm
inhal
volatil
organ
compound
effect
lowlevel
toluen
inhal
balanc
allerg
respons
remain
unknown
method
studi
effect
exposur
lowlevel
toluen
transcript
factor
tcell
differenti
male
balbc
mice
expos
filter
air
control
toluen
whole
bodi
inhal
hour
per
day
day
per
week
week
allerg
model
group
mice
inject
intraperiton
ovalbumin
ova
plu
mg
alum
mice
challeng
nebul
ova
booster
everi
week
week
exposur
period
use
quantit
realtim
pcr
method
investig
express
tbet
gene
spleen
result
exposur
toluen
week
significantli
increas
express
mrna
spleen
mice
mice
expos
toluen
week
express
tbet
mrna
increas
toluen
compar
filter
air
control
howev
observ
pattern
express
tbet
mrna
spleen
balbc
mice
express
mrna
significantli
suppress
exposur
toluen
balbc
mice
conclus
first
studi
show
vivo
modul
express
transcript
factor
gene
differ
strain
mice
exposur
lowlevel
toluen
concert
antigen
stimul
background
patient
asthma
prone
experi
recurr
exacerb
symptom
especi
expos
environment
trigger
well
defin
kind
clinic
characterist
associ
predisposit
method
cohort
realiti
evolut
adult
asthma
korea
corea
studi
prospect
observ
multicent
studi
conduct
nine
year
korea
cross
section
data
baselin
clinic
characterist
compar
asthmat
suscept
asthma
exacerb
environment
trigger
asthmat
toler
trigger
base
self
report
questionnair
time
enrol
result
common
cold
frequent
trigger
follow
pollut
dusti
air
second
hand
smoke
emot
stress
anim
drug
descend
order
environment
triggerssensit
asthmat
tsa
show
femal
domin
vs
p
higher
preval
rhinosinus
vs
p
environment
triggerstoler
asthmat
tta
signific
differ
obes
durat
symptom
atop
statu
lung
function
patient
among
tsa
report
aggrav
asthmat
symptom
move
current
hous
vs
p
tsa
live
current
hous
significantli
less
time
tta
p
conclus
femal
sex
rhinosinus
move
new
hous
significantli
associ
suscept
asthma
exacerb
environment
trigger
survey
children
often
expos
passiv
smoke
ps
rel
higher
risk
develop
obstruct
pulmonari
allerg
diathesi
ishaq
khan
sameera
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
introduct
pursu
deleteri
effect
ps
health
expos
children
method
retrospect
studi
undertaken
includ
nonsmok
asthmat
children
age
mean
age
year
histori
hous
hold
smoke
passiv
smoker
ps
like
found
increas
tendenc
allerg
obstruct
pulmonari
manifest
eczema
allerg
rhiniti
ocular
allergi
middl
ear
suffus
short
breath
resid
nonsmok
household
boy
sensit
ps
girl
likewis
manifest
increas
age
durat
exposur
children
smoke
parent
increas
preval
respiratori
symptom
cough
sputum
wheez
lower
pulmonari
function
test
pft
valu
children
non
smoke
parent
associ
chang
pft
may
persist
adulthood
signific
matern
smoke
mark
ad
popul
childhood
asthma
later
follow
evidenc
passiv
smoke
earli
childhood
increas
risk
lower
respiratori
tract
infect
fold
studyfollow
children
congenit
pulmonari
malform
famili
histori
allergi
like
sensit
exacerb
ps
non
smoker
follow
adult
life
ps
show
rel
increas
preval
recurr
infect
less
product
life
result
underestim
signific
ps
hous
follow
grave
health
relat
hazard
irrevers
conclus
impact
smoke
commun
variabl
degre
advers
reaction
paramount
morbid
index
termin
age
marginl
smoke
restrict
place
follow
posit
socio
econom
impact
signific
grade
improv
pulmonari
function
physic
wellb
amongst
colleg
student
smoke
cessat
ishaq
khan
sameera
munir
imran
khan
aljunaid
hopsit
allergypulmonolog
nowshera
pakistan
purpos
signific
chang
respiratori
functionphys
well
document
stepwis
cessat
smoke
socioeconom
prospect
impact
upon
colleg
student
method
studi
colleg
student
age
year
sex
year
histori
smoke
manifest
like
hack
cough
breathless
wheez
night
rais
temperatur
weight
loss
alter
tast
etc
smoke
cessat
follow
supervis
week
month
advis
encourag
outcom
result
assess
pulmonari
function
physic
wellb
conclus
immedi
quit
exsmok
advis
breath
exercis
steep
line
increas
tempo
improv
pulmonari
functionphys
well
invers
proport
period
histori
smoke
clinic
implic
cessat
advis
follow
supervis
incent
smoker
student
form
credit
studi
award
certif
quitter
week
month
etc
khan
et
al
aljh
nsr
nwfp
pk
ocular
nasal
skin
sign
aircrew
relat
ban
smoke
flight
follow
studi
torsten
lindgren
dan
gunilla
wiesland
uppsala
univers
hospit
dep
occup
environment
medicin
uppsala
sweden
background
main
aim
followup
gain
insight
ocular
nasal
skin
symptom
determin
whether
incid
relat
person
psychosoci
occup
factor
method
evalu
differ
ocular
nasal
skin
symptom
selfadminist
questionnair
mail
n
three
year
later
n
questionnair
sent
airlin
crew
duti
particip
rate
n
n
cohort
subject
use
studi
time
questionnair
studi
smoke
allow
intercontinent
flight
result
atopi
show
signific
reduct
hay
fever
show
signific
increas
ocular
nasal
skin
symptom
common
cabin
crew
pilot
incid
ocular
nasal
skin
symptom
common
cabin
crew
compar
pilot
newonset
nasal
skin
symptom
common
cabin
crew
compar
pilot
younger
age
work
satisfact
stress
due
excess
work
significantli
relat
newonset
ocular
nasal
skin
symptom
cabin
crew
significantli
newonset
nasal
symptom
compar
pilot
airlin
crew
hay
fewer
report
significantli
complaint
newonset
ocular
nasal
symptom
airlin
crew
doctor
diagnos
asthma
report
significantli
complaint
newonset
nasal
symptom
conclus
age
hay
fever
asthma
psychosoci
work
environ
type
occup
relat
newonset
symptom
atop
diseas
allerg
sensitis
exposur
trafficrel
air
pollut
children
background
vitro
studi
anim
experi
human
exposur
studi
shown
increas
risk
atop
outcom
howev
result
deriv
observ
studi
inconsist
assess
relationship
individu
base
exposur
trafficrel
air
pollut
allerg
outcom
prospect
birth
cohort
studi
first
six
year
life
method
followedup
children
age
year
age
year
investig
atop
diseas
allerg
sensitis
longterm
exposur
particul
matter
absorb
nitrogen
dioxid
assess
residenti
address
use
geograph
inform
system
base
regress
model
air
pollut
measur
distanc
nearest
main
road
use
surrog
trafficrel
air
pollut
result
strong
posit
associ
found
distanc
nearest
main
road
asthmat
bronchiti
hay
fever
eczema
sensitis
distancedepend
relationship
could
identifi
highest
odd
ratio
children
live
less
busi
street
absorb
statist
signific
effect
found
asthmat
bronchiti
hay
fever
allerg
sensitis
inhal
allergen
due
pollen
sensitis
exposur
associ
eczema
associ
found
allerg
sensitis
conclus
strong
evid
increas
risk
atop
diseas
allerg
sensitis
children
expos
particul
matter
air
cleaner
polyurethan
bedcov
asthmat
children
cat
dog
allergi
background
compar
multidisciplinari
interregion
studi
allergyasthma
indoor
exposur
could
give
import
inform
lead
increas
understand
aetiolog
morbid
howev
exist
nation
studi
follow
differ
methodolog
hamper
use
obtain
data
potenti
comparison
drawback
overcom
follow
ident
protocol
regard
questionnair
inspect
measur
object
present
paper
propos
methodolog
perform
crosssect
casecontrol
studi
impact
indoor
home
environ
allergi
asthma
among
children
base
recent
perform
allhom
bulgaria
bdamp
build
health
dbh
sweden
studi
propos
approach
includ
strategi
perform
epidemiolog
studi
select
target
popul
identif
sampl
size
key
step
perform
crosssect
casecontrol
studi
list
suggest
improv
qualiti
obtain
data
given
dbh
allhom
studi
identifi
cultur
behaviour
import
factor
perform
epidemiolog
studi
inform
gather
descript
crosssect
studi
could
provid
clue
lead
formul
epidemiolog
hypothes
could
test
analyt
nest
casecontrol
studi
target
group
preschool
children
propos
sinc
children
age
spend
time
home
crosssect
questionnair
develop
dbh
studi
contain
question
demograph
data
health
symptom
hous
characterist
lifestyl
factor
propos
use
parent
questionnair
inform
hous
characterist
could
effect
tool
conduct
studi
hous
health
propos
nest
casecontrol
studi
includ
dwell
inspect
nondestruct
type
build
checklist
sensori
visual
evalu
damp
dust
sampl
hdm
mould
pollen
phthalat
engin
measur
air
temperatur
humid
level
medic
examin
gener
examin
skin
prick
test
special
attent
paid
storag
collect
data
statist
analyz
dissemin
research
result
conclus
paper
use
guidelin
perform
studi
indoor
environ
allergyasthma
multiplex
technolog
expand
horizon
assess
allerg
sensit
exposur
background
current
method
use
assess
allerg
sensit
allergen
exposur
requir
separ
test
allergenspecif
antibodi
allergen
appli
fluoresc
suspens
array
technolog
allow
simultan
detect
total
allergenspecif
ige
serum
multipl
allergen
environment
sampl
singl
quantit
test
method
fluoresc
multiplex
array
develop
allow
simultan
detect
indoor
allergen
environment
sampl
total
allergenspecif
ige
serum
suspens
array
measur
der
p
der
f
der
p
der
f
fel
f
mu
rat
n
bla
g
develop
use
monoclon
antibodi
coval
coupl
fluoresc
microspher
array
detect
total
ige
ige
specif
der
p
der
p
fel
f
bet
v
phl
p
bla
g
bla
g
asp
f
creat
use
monoclon
antibodi
purifi
allergen
coval
coupl
fluoresc
microspher
multiplex
array
valid
compar
result
multiplex
method
establish
enzym
immunoassay
result
highli
signific
correl
result
obtain
multiplex
method
establish
enzym
immunoassay
p
g
n
addit
sensit
limit
detect
reproduc
intra
assay
coeffici
varianc
cv
inter
assay
cv
fluoresc
multiplex
array
shown
equal
better
elisa
method
conclus
result
suggest
fluoresc
multiplex
technolog
facilit
epidemiolog
studi
exposur
allerg
sensit
birth
cohort
studi
popul
survey
studi
geneenviron
interact
array
principl
expand
includ
allergen
allergenspecif
antibodi
reduct
indoor
aeroallergen
use
xtreme
air
purifi
qualiti
environ
within
build
topic
major
import
public
health
present
indoor
air
qualiti
iaq
major
concern
variou
work
place
import
quot
air
qualiti
journal
bwith
public
peopl
realiz
pollut
indoor
air
could
make
sick
worst
thing
happen
indoor
air
qualiti
marketplac
last
year
also
mold
much
media
coverag
design
sensation
topic
frighten
public
much
word
fmold
alway
seem
preced
adject
ftoxic
thu
homeown
build
manag
scare
death
minor
infest
might
possibl
toxic
mold
often
ignor
health
issu
combust
byproduct
volatil
organ
compound
secondhand
tobacco
smoke
poor
ventil
studi
aim
examin
effici
air
purifi
xtreme
reduc
indoor
spore
pollen
count
allergen
taxa
present
differ
offic
facil
residenti
build
set
petri
plate
coat
slide
place
distanc
feet
feet
feet
feet
away
air
purifi
assay
done
petri
plate
prepar
brain
heart
infus
agar
vwr
gelvatol
coat
slide
air
purifi
control
treat
control
petri
plate
slide
place
room
without
use
air
purif
system
treat
set
assay
hour
hour
hour
treatment
slide
examin
analyz
photograph
use
olympu
microscop
attach
digit
camera
petri
plate
examin
stereoscop
observ
count
coloni
control
set
plate
show
vigor
growth
microbi
coloni
incub
incub
hour
petripl
closer
air
purifi
ft
ft
produc
least
number
coloni
h
hour
treatment
indoor
air
air
purifi
minor
trace
inoculum
petripl
ft
ft
hour
continu
exposur
room
air
xtreme
bhigh
set
found
complet
erad
aeroallergen
background
wide
variat
preval
asthma
rhiniti
eczema
report
differ
countri
isaac
intern
studi
asthma
allergi
childhood
thought
order
maxim
valu
epidemiolog
research
asthma
allerg
rhiniti
atop
eczema
childhood
stablish
standar
methodolog
facilit
collabor
comparison
sever
countri
method
standard
questionnair
distribut
school
selfcomplet
year
old
children
parent
year
old
children
result
children
age
year
ansew
questionnair
group
age
year
group
children
age
year
preval
wheez
last
year
year
group
preval
rhiniti
last
year
year
group
year
group
preval
eczema
last
year
year
group
year
group
conclus
preval
allerg
diseas
similar
report
sdudi
except
rhiniti
hight
preval
rate
respect
studi
perform
worlwid
alarm
result
comparison
isaac
studi
year
old
children
islamabad
pakistan
background
allerg
diseas
asthma
regist
alarm
increas
pakistan
especi
children
pakistan
popul
million
almost
children
age
year
isaac
studi
conduct
school
reliabl
document
studi
look
preval
ill
countri
comparison
two
studi
group
evalu
assess
rise
danger
respiratori
allergi
asthma
islamabad
capit
pakistan
method
standard
questionnair
base
isaac
protocol
use
studi
school
randomli
select
studi
children
fall
within
studi
age
group
includ
studi
children
age
year
answer
questionnair
answer
parent
year
age
group
result
total
number
children
studi
conclus
isaac
studi
conduct
islamabad
reveal
preval
nasal
problem
wheez
doubl
year
age
group
compar
younger
year
children
larg
number
year
old
report
nasal
problem
also
alarm
fold
danger
children
develop
asthma
later
life
studi
also
highlight
need
better
diagnosi
asthma
age
group
everi
wheez
children
diagnos
asthmat
result
indic
need
increas
awar
amongst
gener
public
physician
regard
allerg
diseas
asthma
jeongwhun
kim
chul
hee
lee
jeonghun
jang
seoul
nation
univers
colleg
medicin
otorhinolaryngolog
seongnam
republ
korea
background
aria
guidelin
way
gener
criterion
classifi
allerg
rhiniti
object
object
studi
research
korean
patient
underw
allerg
rhiniti
accord
symptom
sever
frequenc
distribut
pattern
materi
method
statist
analysi
done
patient
diagnos
allerg
rhiniti
seoul
nation
univers
bundang
hospit
patient
local
clinic
patient
categor
group
mild
intermitt
mild
persist
moder
sever
intermitt
moder
sever
persist
group
accord
questionnair
research
allergi
laboratori
result
result
incid
moder
sever
persist
group
moder
sever
intermitt
group
allergi
laboratori
result
signific
differ
group
eosinophi
count
p
questionnair
research
signific
differ
group
concern
olfact
p
g
selfawar
rhiniti
p
previou
histori
rhiniti
p
g
selfawar
asthma
p
conjunct
p
g
signific
differ
frequenc
symptom
allerg
rhiniti
sever
group
p
g
moder
sever
persist
group
show
highest
score
conclus
accord
aria
guidelin
categor
patient
moder
sever
persist
group
stand
biggest
part
consequ
differenti
therapeut
approach
group
use
associ
ocular
nasal
symptom
atopi
person
trait
stress
roma
runeson
dan
akademiska
sjukhuset
occup
environment
medicin
uppsala
sweden
akademiska
sjukhuset
occup
environment
medicin
uppsala
sweden
aim
studi
associ
ocular
nasal
symptom
atopi
person
characterist
measur
antonovski
sens
coher
soc
karolinska
scale
person
ksp
stress
measur
project
draw
total
subject
initi
work
build
suspect
indoor
air
problem
studi
inform
histori
atopi
hay
fever
ocular
nasal
symptom
gather
postal
questionnair
includ
ksp
soc
project
draw
ba
person
rain
result
soc
associ
soc
histori
atopi
hay
fever
howev
low
soc
ocular
p
nasal
symptom
p
ksp
atopi
higher
social
desir
p
lower
irrit
p
lower
guilt
p
hay
fever
lower
guilt
p
eye
symptom
lower
social
desir
p
higher
indirect
aggress
p
nasal
symptom
higher
somat
anxieti
p
muscular
tension
p
psychic
anxieti
p
project
draw
atopi
draw
cloud
p
long
rain
stroke
often
short
rain
stroke
p
less
often
hay
fever
drew
water
puddl
p
often
draw
long
rain
stroke
associ
ocular
symptom
p
draw
strong
wind
rain
associ
nasal
symptom
p
conclus
histori
atopi
associ
person
trait
measur
ksp
project
draw
ocular
nasal
symptom
nonpollen
season
associ
soc
well
ksp
project
draw
differ
scale
associ
atopi
symptom
long
rain
stroke
consist
associ
atopi
ocular
symptom
sensit
profil
analysi
children
either
asthma
eczema
alon
use
panel
mite
allergen
dermatophagoid
pteronyssinu
blomia
tropicali
run
mei
angelin
chong
nge
cheong
su
min
audrey
teo
fong
cheng
yi
peichi
lynett
shek
yoke
chin
giam
kaw
yan
chua
van
bever
hugo
nanyang
technolog
univers
school
biolog
scienc
singapor
singapor
nation
univers
singapor
paediatr
singapor
singapor
star
genom
institut
singapor
singapor
singapor
nation
skin
centr
dermatolog
singapor
singapor
background
aim
preval
multiallergen
sensit
mite
speci
patient
asthma
singapor
malaysia
report
earlier
import
discern
whether
specif
diseas
symptom
allergi
correl
differ
mite
speci
present
studi
comparison
sensit
profil
children
suffer
either
asthma
eczema
alon
use
panel
mite
allergen
dermatophagoid
pteronyssinu
der
p
blomia
tropicali
blo
method
total
children
age
year
old
asthma
eczema
respect
recruit
singapor
present
studi
ige
level
specif
panel
hous
dust
miteallergen
two
mite
speci
measur
use
elisa
panel
allergen
use
der
p
extract
der
p
der
p
der
p
der
p
mite
blo
extract
blo
blo
blo
blo
blo
mite
result
children
asthma
rhimiti
exhibit
highest
sensit
blo
rel
lower
sensit
frequenc
der
p
der
p
children
eczema
show
high
sensit
blo
der
p
der
p
gener
eczema
patient
sensit
panel
der
p
allergen
much
higher
measur
ige
titr
compar
asthma
group
conclus
two
patient
group
tend
show
differenti
sensit
profil
der
p
blo
allergen
patient
asthma
rhiniti
show
high
sensit
blo
mite
allergen
especi
blo
wherea
eczema
patient
show
high
sensit
blo
der
p
der
p
suggest
possibl
correl
manifest
differ
diseas
symptom
allergi
mite
speci
sensit
clinic
relev
ragwe
pollen
patient
intermitt
rhinoconjunct
result
total
number
patient
ocular
allergi
patholog
belong
year
old
year
old
year
old
femal
male
allergi
sensit
dpte
dfa
alternaria
cladosporium
graminea
tree
cat
dog
patient
present
elev
ige
tear
normal
serum
ige
present
high
purpos
consult
andor
associ
patholog
perenni
allerg
rhiniti
bronchial
asthma
eczema
pure
allerg
conjunct
conclus
observ
work
major
patient
consult
centr
allerg
entiti
arous
suspicion
ocular
affect
mean
complet
interrog
ophthalmolog
examin
confirm
laboratori
andor
spt
therefor
consid
sub
diagnos
entiti
common
consult
must
suspect
allergist
allergi
patholog
train
ophthalmologist
manag
disciplin
improv
patient
qualiti
life
avoid
effect
result
averag
total
incid
investig
period
highest
peak
found
age
group
year
second
one
age
group
year
adolesc
yo
young
adult
nearli
incid
averag
compar
studi
necessari
determineanalys
region
distribut
pattern
worldwid
preval
allerg
diseas
rural
urban
region
poland
preliminari
report
method
project
consist
two
stage
survey
use
questionnair
diagnost
test
outpati
clinic
questionnair
studi
adapt
isaac
ecrh
ii
carri
randomli
select
group
children
adolesc
adult
age
group
one
third
subject
underw
medic
examin
direct
toward
allergi
recognit
studi
carri
two
region
warsaw
capit
citi
poland
largest
urban
agglomer
high
densiti
popul
dens
traffic
rural
region
southeastern
poland
two
district
provinc
lublin
district
zamosc
krasnystaw
character
low
level
environment
pollut
low
densiti
popul
natur
farm
method
result
june
octob
questionnair
complet
rural
area
number
answer
questionnair
reach
level
children
adult
urban
area
children
age
group
children
age
group
adult
bronchial
asthma
declar
respond
rural
area
twice
mani
urban
area
respond
zamojszczyzna
warsaw
declar
suffer
allerg
rhiniti
question
concern
skin
allergi
answer
posit
respond
rural
region
twice
mani
warsaw
inhabit
tabl
present
questionnairebas
result
relat
age
place
resid
conclus
preliminari
questionnairebas
result
may
indic
higher
preval
allerg
diseas
warsaw
resid
comparison
resid
rural
area
southeastern
poland
initi
analysi
data
medic
examin
confirm
find
therefor
analysi
essenti
subject
live
rural
area
resid
warsaw
underw
verifi
medic
examin
bronchial
asthma
diagnos
examin
subject
rural
region
warsaw
examin
rural
area
inhabit
warsaw
inhabit
appear
suffer
intermitt
allerg
rhiniti
persist
allerg
rhiniti
diagnos
respect
allergi
cat
sourc
allergen
urban
versu
rural
area
poland
liliana
trzpil
boleslaw
samolinski
medic
univers
warsaw
prevent
environment
hazard
warsaw
poland
background
aim
comparison
frequenc
posit
skin
prick
test
cat
allergen
frequenc
anim
presenc
home
variou
area
poland
rural
versu
urban
present
data
part
earliest
outcom
larg
epidemiolog
studi
field
allergi
run
poland
method
random
probe
variou
polish
popul
differ
age
rang
year
old
includ
studi
analyz
urban
popul
gather
warsaw
capit
poland
second
select
region
zamojszczyzna
typic
rural
area
low
industri
densiti
respond
complet
questionnair
ecrh
ii
isaac
urban
rural
region
subject
medic
examin
direct
toward
allergi
recognit
made
skin
prick
test
urban
rural
region
result
person
urban
area
reveal
posit
skin
result
least
one
allergen
rural
one
preval
significantli
lower
equal
p
frequenc
posit
cat
prick
test
significantli
higher
urban
region
compar
rural
region
vs
intens
reaction
measur
averag
diamet
observ
skin
prick
test
bubbl
also
significantli
higher
vs
mm
found
signific
differ
urban
rural
area
observ
cat
frequenc
presenc
home
vs
data
also
compar
gener
frequenc
cat
presenc
home
surround
rural
area
cat
present
home
surround
urban
area
cat
present
home
surround
peopl
posit
skin
test
cat
cat
home
urban
area
valu
significantli
lower
equal
conclus
cat
allergi
one
observ
frequenc
posit
skin
prick
test
higher
urban
region
rural
region
contrast
lower
presenc
anim
allergi
sourc
addit
frequenc
cat
presenc
home
sensit
person
much
higher
rural
area
urban
one
observ
lead
conclus
protect
immunotherapeut
role
high
environment
allergen
concentr
rural
region
background
allergi
influenc
clinic
characterist
genet
environment
factor
assess
clinic
characterist
newonset
respiratori
allergi
immigr
brescia
itali
method
collect
data
immigr
refer
allergi
servic
within
last
two
year
focus
patient
without
famili
clinic
histori
allerg
diseas
result
two
hundr
patient
evalu
male
mean
age
year
countri
origin
uniformi
distribut
among
macroarea
pacif
southwest
africa
south
america
east
europ
none
previou
symptom
allergi
famili
histori
neg
mean
time
onset
symptom
immigr
itali
year
first
clinic
present
rhinitisasthma
wherea
remain
rhiniti
percentag
monosensit
subject
also
sensit
cockroach
concomit
posit
food
drug
respect
conclus
immigr
itali
newonset
respiratori
allergi
display
long
latenc
b
preferenti
onset
rhiniti
asthma
associ
c
poor
occurr
sensit
non
inhal
allergen
high
preval
cockroach
sensit
keyword
immigr
respiratori
allergi
roo
bernsen
nico
nagelkerk
carel
thij
johann
van
der
wouden
unit
arab
emir
univers
commun
medicin
al
unit
arab
emir
maastricht
univers
epidemiolog
maastricht
netherland
erasmu
mcunivers
medic
center
rotterdam
gener
practic
rotterdam
netherland
background
pertussi
infect
suspect
potenti
causal
factor
develop
atop
diseas
effect
pertussi
immun
specif
ige
antibodi
although
sever
studi
found
posit
associ
pertussi
infect
atop
disord
relationship
yet
studi
popul
stratifi
vaccin
statu
object
present
studi
assess
associ
pertussi
infect
atop
disord
pertussisunvaccin
children
pertussisvaccin
children
method
use
data
previous
conduct
studi
relationship
diphtheriatetanuspertussi
inactiv
poliomyel
vaccin
first
year
life
atop
disord
studi
popul
year
old
divid
children
pertussisunvaccin
children
pertussisvaccin
first
year
life
within
group
associ
pertussi
infect
atop
disord
report
parent
assess
result
unvaccin
group
signific
associ
pertussi
infect
atop
disord
vaccin
group
associ
pertussi
infect
atop
disord
posit
associ
asthma
odd
ratio
confid
interv
hay
fever
food
allergi
signific
conclus
posit
associ
pertussi
infect
atop
disord
pertussi
vaccin
group
present
studi
conclud
whether
associ
causal
due
revers
causat
background
allerg
diseas
fairli
common
part
world
involv
ethnic
group
bronchial
asthma
allerg
rhiniti
conjunct
eczema
commonest
manifest
despit
effort
incid
escal
path
appear
authent
data
preval
allerg
diseas
children
pakistan
therefor
need
felt
carri
preval
studi
countri
method
estim
preval
allerg
diseas
countri
first
ever
studi
carri
largest
coastal
citi
karachi
hous
peopl
ethnic
group
socioeconom
class
statist
avail
age
group
regard
saudi
arabian
protocol
use
questionnair
school
children
use
instead
isaac
protocol
questionnair
distribut
school
children
age
year
three
differ
area
proper
proport
represent
high
middl
low
socioeconom
level
total
questionnair
return
parent
found
valid
thu
includ
survey
data
analyz
use
spss
softwar
result
result
show
preval
allerg
diseas
quit
high
pakistan
frequenc
wheez
found
diagnos
case
asthma
frequenc
allerg
rhiniti
found
frequenc
allerg
rhiniti
well
wheez
episod
statist
signific
differ
asthmat
nonasthmat
sex
socioeconom
statu
found
affect
significantli
p
valu
preval
diagnos
asthma
case
high
socioeconom
class
middleclass
low
socioeconom
class
famili
histori
atopi
also
found
significantli
higher
asthmat
conclus
allerg
diseas
quit
common
pakistan
remain
underdiagnos
preval
data
allerg
rhiniti
show
alarm
situat
diseas
found
affect
middleclass
lower
lowermiddl
class
remain
least
affect
addit
diagnosi
manag
prevent
educ
may
help
countri
fight
back
diseas
studi
progress
increas
sampl
size
compar
data
citi
collect
protocol
allerg
sensit
among
surabaya
suburb
school
children
undergradu
student
object
identifi
major
allerg
sensit
among
school
children
undergradu
student
surabaya
crosssect
epidemiolog
studi
done
particip
recruit
multistag
simpl
random
sampl
repres
student
surabaya
suburb
area
method
invit
student
agre
involv
studi
voluntari
basi
student
primari
school
secondari
school
univers
complet
person
famili
histori
allergi
allerg
symptom
diseas
environment
home
exposur
variou
common
allergen
obtain
physic
examin
skin
prick
test
done
use
set
differ
inhal
ingest
allergen
extract
total
serum
ige
specif
ige
rast
select
allergen
also
measur
result
trend
increas
skin
prick
test
spt
posit
among
studi
subject
among
primari
school
children
among
secondari
school
children
among
undergradu
student
cockroach
mould
common
allergen
primari
school
children
follow
hous
dust
mite
grass
pollen
crab
order
common
allergen
secondari
school
children
hous
dust
mite
cockroach
mould
grass
pollen
crab
order
undergradu
student
hous
dust
mite
cockroach
crab
mould
grass
pollen
multipl
spt
posit
among
toward
allergen
gener
urticaria
rhiniti
commonest
clinic
manifest
allergi
histori
atopi
famili
posit
respond
conclus
preval
allerg
sensit
among
school
children
undergradu
student
surabaya
suburb
area
increas
previou
estim
indonesia
hous
dust
mite
cockroach
common
allergen
urticaria
rhiniti
commonest
allerg
manifest
keyword
allergi
sensit
schoolchildren
skin
prick
test
epidemiolog
studi
mariann
empson
juli
smith
auckland
citi
hospit
clinic
immunolog
auckland
new
zealand
background
high
preval
atop
diseas
asthma
document
nz
base
primarili
studi
children
preval
data
avail
anaphylaxi
although
anecdot
incid
appear
high
studi
obtain
baselin
data
anaphylaxi
rate
welldefin
adult
popul
auckland
nz
method
retrospect
audit
adult
admit
auckland
citi
hospit
ach
perform
patient
chart
audit
identifi
use
broad
rang
diagnost
code
may
use
case
anaphylaxi
four
major
diagnost
categori
includ
chart
retriev
allergyallerg
reaction
anaphylact
shock
reaction
angioedemaurticaria
insect
sting
two
time
period
select
audit
file
review
data
extract
almost
exclus
one
author
cohort
patient
satisfi
olmstead
counti
definit
anaphylaxi
identifi
time
period
diagnosi
anaphylaxi
uncertain
case
exclud
interv
includ
communityonset
anaphylaxi
b
includ
case
anaphylaxi
detail
data
popul
serv
ach
avail
time
interv
use
determin
anaphylaxi
rate
adult
older
year
nation
popul
data
use
determin
agestandardis
rate
new
zealand
result
admiss
review
interv
b
respect
episod
communityonset
anaphylaxi
identifi
individu
episod
individu
b
number
individu
per
adult
suffer
least
one
episod
anaphylaxi
commun
per
year
ci
ci
b
addit
episod
anaphylaxi
occur
hospit
identifi
b
total
rate
anaphylaxi
set
b
therefor
ci
per
adult
per
year
conclus
rate
anaphylaxi
nz
adult
one
highest
report
literatur
howev
still
underestim
includ
case
manag
sole
commun
misclassifi
asthma
addit
retrospect
studi
case
anaphylaxi
may
exclud
due
uncertainti
despit
provid
us
import
assess
potenti
size
problem
studi
knowledg
concern
treatment
care
among
thai
allergi
patient
rayong
provinc
thailand
patient
educ
health
promot
import
prevent
decreas
morbid
mortal
allerg
diseas
despit
improv
health
care
system
improp
knowledg
attitud
incorrect
belief
allergi
worri
evalu
knowledg
concern
treatment
care
allergi
would
give
inform
health
care
personnel
physician
develop
good
campaign
prevent
care
among
allergi
patient
futur
selfassess
questionnair
knowledg
opinion
allergi
allergist
perform
among
patient
rayong
provinc
one
lead
center
tourist
machineri
industri
know
allergi
import
global
health
problem
also
think
sever
life
threaten
agre
treat
reliev
symptom
continu
treatment
need
continu
therapi
use
overthecount
medicin
pharmaci
never
use
drug
reliev
allerg
symptom
prefer
oral
drug
inhal
drug
follow
physician
advic
use
inhal
drug
still
believ
allergi
perman
cure
oneforth
third
patient
think
allerg
symptom
allevi
nutrient
supplement
air
cleaner
though
know
exist
allergi
specialist
visit
special
clinic
patient
test
known
specif
allergen
allergen
skin
test
howev
indic
allergen
avoid
key
role
treatment
know
hous
dust
mite
common
allergen
thai
popul
onefifth
satisfi
updat
inform
allergi
give
concern
insuffici
inform
provid
commun
allergi
migrain
signific
comorbid
mv
franci
eye
migrain
centr
ophthalmolog
cherthala
india
background
molecular
mechan
peripher
sensitis
nociceptor
could
ident
pain
prurit
allerg
diseas
therefor
therapeut
approach
pain
treatment
may
also
benefici
allergi
montelukast
cyproheptadin
ketorolac
tromethamin
found
effect
migrain
allergi
studi
document
associ
migrain
allerg
disord
method
studi
span
year
migrain
patient
question
variou
allerg
manifest
result
suffer
variou
allerg
manifest
either
time
consult
sometim
past
nasal
allergi
commonest
ocular
allergi
bronchial
allergyin
skin
allergi
suffer
allergi
naso
oculo
bronchial
conclus
allerg
disord
increas
risk
migrain
migrain
increas
risk
allergi
bidirect
associ
immens
help
clinician
explain
caus
molecular
mechan
genet
origin
two
condit
simpl
way
patient
hous
dust
consid
sourc
potent
allergen
respons
differ
allerg
manifest
total
speci
mite
belong
genera
famili
order
record
hous
dust
sampl
collect
asthmat
patient
resid
arround
rural
area
allergen
mite
viz
dermatophagoid
pteronyssinu
farina
austroglycyphagu
sp
blomia
tropicali
acaru
siro
glycyphagu
domesticu
gdestructor
tyrophagu
putriscentia
except
euroglyphu
sp
record
among
dermatophagoid
alon
contitut
total
mite
isol
patient
bed
contain
significantli
higher
mite
popul
control
subject
bed
dust
among
two
differ
habitat
examin
ie
bed
correspond
bed
room
floor
dust
former
contain
higher
p
g
mite
densiti
later
analysi
skin
prick
test
dust
relat
allergen
reveal
patient
show
mark
prefer
toward
dermatophagoid
mite
allergen
estim
total
serum
ige
level
indic
patient
sera
contain
significantli
higher
level
control
sera
p
g
rast
result
confirm
higher
degre
sensit
toward
hous
dust
mite
clinic
histori
patient
physic
appear
allergen
mite
higher
concentr
patient
bed
posit
skin
test
result
mite
extract
identif
mite
specif
ige
antibodi
patient
sera
rast
techniqu
establish
role
dust
mite
aetiopathogenesi
bronchial
asthma
develop
countri
background
strongli
controversi
protect
inductor
effect
parasit
infect
risk
develop
allerg
diseas
sever
countri
moreov
propos
share
antigen
helminth
parasit
environment
allergen
could
modul
allerg
immun
respons
howev
evid
process
consist
establish
method
aim
studi
evalu
allerg
reactiv
helminth
parasit
coexist
group
unselect
scholar
children
reflect
popul
profound
socioeconom
depress
high
rate
common
childhood
infecti
diseas
diarrhea
x
inhabit
acut
respiratori
infect
x
inhabit
high
preval
helminth
infect
addit
elisa
detect
level
inf
cytokin
well
level
total
specif
ige
dermatophagoid
pteronissynu
blomia
tropicali
ascari
lumbricoid
perform
inhibit
specif
ige
test
mite
ascari
lunbricoid
order
establish
cross
reactiv
allergen
also
perform
clinic
evalu
hematolog
studi
skin
prick
test
common
food
mite
parasit
allergen
result
sixti
seven
percent
children
group
show
respiratori
symptom
skin
manifest
fifti
high
leukocyt
count
high
inf
level
uiml
control
group
skin
prick
test
posit
children
least
one
common
allergen
evalu
posit
ascari
lumbricoid
blo
dpt
fifti
high
total
ige
level
eighti
one
percent
show
level
specif
ige
higher
uiml
ascari
dpt
inhibit
test
median
level
specif
ige
ascari
diminish
dpt
uiml
result
indic
high
allerg
reactiv
evidenc
clinic
skin
prick
test
specif
ige
high
level
cytokin
present
sera
children
evalu
also
found
inhibit
level
specif
ige
sera
children
suggest
cross
reactiv
mite
ascari
allergen
approach
improv
diagnosi
lambliasi
patient
atop
bronchial
asthma
dmitri
dolbin
yuriy
tyurin
sergey
kulikov
kazan
scientif
research
institut
epidemiolog
microbiolog
rospotrebnadzor
kazan
russian
feder
backround
sinc
describ
first
time
g
lamblia
activ
diseas
gastroenter
path
huge
materi
epidemiolog
pathogenesi
lambliasi
effect
enough
way
therapi
given
diseas
develop
collect
also
moment
concern
diseas
numer
question
expect
decis
import
group
problem
intens
discuss
problem
diagnost
preval
g
lamblia
among
peopl
method
use
commerci
elisetest
immunochromatographi
method
reveal
specif
antibodi
whey
blood
antigen
excrement
possess
sensit
high
specif
unlik
routin
microscop
method
diagnosi
lambliasi
connect
aforesaid
till
wide
appli
test
laboratori
diagnost
lambliasi
microscopi
sedimentari
compon
excrement
research
content
duoden
sound
purpos
reveal
cyst
g
lamblia
literatur
method
enrich
formalinradio
recommend
unfortun
specifi
test
laboratori
diagnosi
lambliasi
possess
low
sensit
subject
influenc
subject
object
factor
among
changeabl
alloc
cyst
g
lamblia
difficulti
microscop
identif
result
use
combin
method
research
excrement
method
allow
improv
essenti
delect
cyst
g
lamblia
comparison
routin
method
microscopi
fecal
especi
notic
compar
research
test
activ
lambliasi
reveal
use
three
compon
method
microscopi
research
fecal
first
case
big
degre
invas
came
light
paramount
valu
definit
necess
carri
therapi
lambliasi
conclus
use
combin
method
use
three
compon
flotat
research
excrement
manag
increas
essenti
delect
g
lamblia
reduc
quantiti
repeat
research
necessari
exact
diagnosi
lambliasi
accuraci
definit
degre
invas
organ
elementari
besid
increas
allow
correct
therapi
titanium
use
fabric
obtur
maxillectomi
altern
therapeut
option
case
incompat
polym
base
dentur
materi
rita
depprich
eva
kusch
alexandra
meissner
guido
meissner
heinrichheineunivers
duesseldorf
depart
cranioand
maxillofaci
surgeri
duesseldorf
germani
privat
clinic
cranioand
maxillofaci
surgeri
wuppert
germani
background
microbiolog
colon
subsequ
biofilm
format
dentur
materi
play
import
role
develop
dentur
stomat
often
trigger
allerg
incompatibilti
dentur
materi
penetr
mucosa
chang
despit
high
standard
reconstruct
surgeri
even
use
free
vascular
flap
postmaxillectomi
rehabilit
obtur
prosthesi
still
mainstay
reconstruct
procedur
sever
case
current
use
polym
base
silconeor
methacrylateobtur
bear
risk
increas
settlement
penetr
bacteria
thu
risk
local
even
system
infect
titaniumobtur
oral
rehabilit
offer
favor
characterist
concern
growth
microbi
biofilm
aim
studi
compar
preval
microbi
contamin
titaniumand
polym
base
obtur
po
use
postmaxillectomi
rehabilit
materi
method
investig
obtur
patient
po
undergon
maxillectomi
due
malign
period
microbiolog
sampl
obtur
surfac
adjac
mucou
surfac
interior
po
new
fabric
plan
collect
steril
swab
microbiolog
analysi
perform
convent
method
includ
microscopi
cultur
differ
agar
statist
data
analysi
fisher
exact
test
ft
pvalu
p
e
odd
ratio
confid
interv
use
result
po
show
significantli
higher
quantit
contamin
shift
non
physiolog
bacteria
compar
p
ft
high
statist
risk
factor
penetr
bacteria
interior
po
patholog
bacteria
seed
surfac
po
p
conclus
use
titaniumobtur
oral
rehabilitaton
postmaxillectomi
patient
significantli
reduc
risk
contamin
patholog
oral
bacteria
therefor
prevent
patient
local
oral
system
infect
especi
case
incompat
polym
base
dentur
materi
titaniumobtur
offer
altern
therapeut
option
wirach
maekanantawat
sarawan
maythaarttaphong
rawiwan
suphan
hathairat
chueathai
urairat
phantong
doungngoen
khaminthakul
kanokon
boontanom
suranya
sarapat
sukanya
tomkum
udomsak
silachamroon
mahidol
univers
allergi
clinic
clinic
tropic
medicin
bangkok
thailand
faculti
tropic
medicin
mahidol
univers
vaccin
trial
center
bangkok
thailand
allergi
estim
thai
popul
studi
conduct
bangkok
region
center
show
increas
trend
allergi
preval
recent
decad
studi
aim
determin
preval
allerg
diseas
urban
area
rayong
provinc
high
growth
industri
oilga
refineri
rayong
resid
mean
age
sd
year
old
male
ask
histori
allergi
regard
rhiniti
asthma
conjunct
dermat
includ
urticaria
food
allergi
drug
allergi
preval
overal
allergi
persist
rhiniti
asthma
dermat
respect
urticaria
report
histori
acut
chronic
type
reveal
histori
food
allergi
common
culprit
seafood
allergi
show
histori
insect
sting
allergi
larg
local
reaction
anaphylact
reaction
drug
allergi
histori
allergi
betalactam
nsaid
paracetamol
famili
histori
atopi
significantli
associ
histori
rhiniti
p
g
asthma
p
g
urticaria
p
conjunct
p
food
allergi
p
g
associ
histori
allergi
sex
age
occup
also
close
associ
among
chronic
rhiniti
asthma
food
allergi
p
g
conclus
allergi
uncommon
even
urban
area
like
eastern
part
thailand
histori
atopi
famili
use
predispos
factor
allerg
diseas
effect
prenat
postnat
exposur
lowlevel
toluen
peptidoglycan
system
immun
infant
mice
shoji
yamamoto
atsushi
fukushima
tin
tin
win
shwe
rieko
hojo
yasuhiro
hojo
naoki
kunugita
keiichi
arashidani
hidekazu
fujimaki
nation
institut
environment
studi
research
center
environment
risk
tsukuba
japan
univers
occup
environment
health
japan
medicin
fukuoka
japan
univers
occup
environment
health
japan
health
scienc
fukuoka
japan
background
toluen
wide
use
aromat
organ
solvent
well
character
environment
toxic
chemic
volatil
organ
compound
includ
toluen
possibl
substanc
caus
chemic
sensit
human
laboratori
previous
show
exposur
lowlevel
toluen
caus
immunolog
neurolog
modul
adult
mice
recent
suggest
ligand
peptidoglycan
pgn
lp
modul
allerg
immun
respons
anim
studi
aim
present
studi
investig
effect
lowlevel
toluen
exposur
pgn
stimul
system
immun
infant
mice
method
expos
pregnant
balbc
mice
filter
air
ppm
ppm
ppm
toluen
hday
daysweek
week
day
gestat
deliveri
whole
bodi
exposur
chamber
offspr
expos
toluen
schedul
week
day
birth
day
pregnant
mice
repeatedli
expos
aerosol
pgn
ml
time
per
week
toluen
exposur
period
offspr
toluen
pgn
expos
pregnant
mice
repeatedli
administ
pgn
time
per
week
intraperiton
day
day
toluen
exposur
period
one
day
follow
last
toluen
exposur
collect
blood
spleen
lung
mous
total
ige
antibodi
plasma
product
cytokin
ifn
spleen
lung
assay
elisa
method
also
express
cytokin
transcript
factor
tbet
mrna
spleen
analyz
realtim
rtpcr
method
result
exposur
mice
lowlevel
ppm
toluen
result
increas
decreas
antibodi
plasma
decreas
tbet
mrna
significantli
spleen
decreas
ifn
mrna
spleen
statist
signific
next
exposur
mice
lowlevel
toluen
combin
pgn
stimul
compar
toluen
alon
result
decreas
antibodi
plasma
mrna
spleen
conclus
find
suggest
lowlevel
toluen
exposur
fetal
stage
neonat
stage
may
enhanc
system
function
infant
mice
howev
exposur
combin
lowlevel
toluen
pgn
stimul
shift
immun
suppress
direct
herberto
jose
chong
neto
nelson
rosario
univers
parana
pediatr
curitiba
brazil
background
although
recurr
wheez
frequent
data
regard
risk
factor
associ
condit
aim
studi
verifi
risk
factor
recurr
wheez
infant
south
brazil
method
crosssect
studi
use
standard
valid
questionnair
question
recurr
wheez
familiar
enviroment
socioeconom
respiratori
infect
risk
factor
first
twelv
month
life
intern
studi
wheez
infant
eisl
spanish
estudio
internacion
de
sibilancia
en
lactant
parent
infant
attend
health
center
decemb
regular
immun
interview
among
immnun
center
randomli
select
order
maintain
homogen
select
popul
sampl
factor
associ
recurr
wheez
univari
analysi
studi
use
multivari
regress
poisson
preval
ratio
confid
interv
calcul
due
high
preval
wheez
infant
statist
consid
signific
p
g
result
three
thousand
three
infant
age
monthsold
studi
preval
recurr
wheez
associ
recurr
wheez
male
gender
mother
father
sibl
asthma
histori
instruct
secondari
advanc
other
pet
domicil
pregnanc
bird
cold
episod
person
histori
dermat
mold
home
updat
immun
protect
factor
recurr
wheez
conclus
prognost
risk
factor
recurr
wheez
first
year
life
male
familiar
histori
asthma
high
instruct
pet
pregnanc
mold
home
high
number
cold
episod
person
histori
dermat
intervent
act
factor
may
decreas
occur
recurr
wheez
infant
curitiba
brazil
monitor
cytokin
breast
milk
allerg
non
allerg
mother
prospect
birth
cohort
studi
galli
elena
palmesi
francesca
nisini
rita
agostino
rocco
carpino
valentina
gabriel
ida
mora
nadia
gm
brunetti
ercol
mancino
giorgio
san
pietro
hospit
fatebenefratelli
afar
research
centr
roma
itali
san
giovanni
calibita
hospit
fatebenefratelli
neonatolog
unit
roma
itali
background
well
document
human
milk
contain
sever
immunomodulatori
compon
import
newborn
immun
system
develop
context
breastfeed
could
provid
best
possibl
nutrit
role
develop
allergi
remain
although
controversi
due
possibl
individu
differ
variat
composit
breast
milk
furthermor
stimuli
could
interact
immun
system
perinatalneonat
period
interf
breast
feed
henc
immun
system
develop
reason
interest
investig
differ
compon
environment
diet
familiar
etc
could
involv
allerg
diseas
apperar
aim
aim
prospect
birth
cohort
studi
investig
concentr
cytokin
involv
allerg
reaction
iga
antibodi
product
solubl
fatti
acid
cord
blood
colostrum
matur
milk
allerg
non
allerg
mother
moreov
aim
investig
whether
breastfeed
practic
correl
immunolog
profil
determin
increas
risk
atop
diseas
develop
children
mother
allerg
full
term
newborn
includ
studi
measur
cytokin
colostrum
sampl
day
birth
transit
breast
milk
sampl
result
differ
cytokin
level
colostrum
milk
sampl
evidenc
allerg
non
allerg
mother
particular
preliminari
data
show
colostrum
allerg
mother
signific
increas
level
tgf
beta
e
compar
sampl
non
allerg
mother
differ
cytokin
level
reveal
milk
sampl
two
group
followup
progress
first
round
clinic
evalu
month
birth
reveal
yet
allerg
symptom
children
kawasaki
diseas
allerg
diseas
sibl
control
studi
year
old
adultsampl
consid
repres
sinc
consist
staff
greek
air
forc
examin
written
consent
obtain
obligatori
annual
medic
check
mean
wheal
diamet
absenc
reaction
neg
control
spt
consid
posit
reaction
multipl
logist
regress
perform
reveal
statist
signific
associ
type
respiratori
allergi
ar
andor
asthma
known
paramet
gender
age
type
sensit
tsige
level
thereaft
diagnost
properti
tsige
type
sensit
discrimin
rhiniti
asthma
analyz
use
receiv
oper
characterist
roc
result
patient
report
sever
allerg
rhiniti
sever
ocular
itch
precipit
headpain
attack
resembl
migrain
also
get
migrain
attack
expos
common
migrain
trigger
region
common
trigger
exposur
sunlight
travel
bu
sleep
disturb
miss
meal
right
time
travel
bu
trigger
allerg
symptom
patient
probabl
due
exposur
dust
smoke
conclus
molecul
involv
allerg
inflammatori
process
definit
trigger
migrain
episod
excit
peripher
nociceptor
famili
allergi
surabaya
suburb
schoolchildren
result
maximum
sensit
record
farina
grass
pollen
fusarium
spore
among
three
group
allergen
test
preval
least
one
posit
prick
test
larg
differ
age
found
sensit
age
group
year
age
group
year
age
group
year
p
g
sensit
multipl
allergen
common
age
group
year
sensit
respond
least
four
allergen
portion
sensit
among
age
year
preval
physiciandiagnos
asthma
allerg
rhiniti
ar
conjunct
wheez
increas
significantli
increas
number
posit
skin
respons
famili
histori
ar
conjunct
signific
risk
factor
allerg
sensit
sensit
pollen
grain
urban
live
childhood
ad
increas
risk
pollen
sensit
conclus
preval
allerg
sensit
high
urban
adult
popul
calcutta
half
age
year
sensit
sensit
least
four
allergen
sensit
multipl
aeroallergen
associ
high
preval
asthma
ar
conjunct
wheez
hlag
nonclass
mhc
class
ib
molecul
play
signific
role
immunotolerogen
process
hlag
express
altern
splice
gener
membranebound
solubl
isoform
secret
activ
peripher
blood
monocyt
genet
divers
hlag
consist
sequenc
variat
promot
exon
region
shown
affect
hlag
mrna
stabil
polymorph
hlag
promot
region
previous
associ
asthma
interest
also
fact
gene
encod
effector
also
exhibit
genet
polymorph
popul
given
plausibl
effect
one
studi
investig
potenti
role
insertiondelet
polymorph
region
conjunct
gene
promot
polymorph
ag
ct
ca
respiratori
allergi
develop
associ
studi
involv
patient
suffer
asthma
andor
rhiniti
monosensit
derp
matchedcontrol
origin
algeria
pcrbase
techniqu
use
assess
hlag
genotyp
promot
allel
genotyp
frequenc
differ
patient
control
insert
allel
significantli
frequent
patient
group
control
group
pc
homozyg
state
delet
allel
preval
healthi
control
pc
find
suggest
hla
g
gene
may
particip
pathogenesi
respiratori
allerg
diseas
popul
possibl
mechan
could
envisag
diminish
immunosuppress
activ
mediat
hlag
may
contribut
initiationpersist
chronic
airway
inflamm
asthma
sensit
ascari
spp
influenc
total
specif
ige
level
dermatophagoid
pteronyssinu
blomia
tropicali
sylvi
lafossemarin
cabinet
dallergologi
allergologi
fort
de
franc
martiniqu
background
although
sensit
ascari
may
play
role
sever
asthma
may
implic
total
specif
ige
level
common
aeroallergen
object
determin
sensit
mite
speci
pteronyssinu
b
tropicali
patient
posit
neg
specif
ige
determin
ascari
spp
method
analys
consecut
patient
male
femal
mean
age
year
rang
month
year
children
boy
girl
allerg
asthma
andor
rhinoconjunct
without
eczema
includ
patient
separ
group
group
consist
ascari
spp
posit
patient
group
b
patient
neg
specif
ige
determin
phadia
ascari
spp
conclus
sensitis
ascari
spp
seem
play
import
role
rise
total
well
specif
ige
level
pteronyssinu
b
tropicali
statist
patient
sensit
mite
ascari
spp
posit
ascari
spp
neg
group
clinic
signific
find
remain
establish
vitro
sensit
ascari
spp
popul
allerg
individu
caribbean
island
martiniqu
enriqu
dr
beckmann
pharma
gmbh
research
develop
seefeld
germani
background
sensit
allergen
nematod
ascari
spp
common
tropic
larg
proport
popul
contact
intestin
parasit
suggest
sensit
ascari
spp
allergen
may
influenc
allerg
respons
allergen
object
studi
specif
ige
level
ascari
spp
larg
popul
individu
consult
allerg
respiratori
complaint
allergi
clinic
fort
de
franc
martiniqu
materi
method
studi
prospect
crosssect
design
conduct
januari
march
total
consecut
patient
male
femal
mean
age
year
month
year
evalu
allerg
respiratori
complaint
enter
studi
specif
ige
ascari
spp
measur
cap
method
phadia
result
stratifi
age
sex
result
total
individu
men
women
posit
ascari
spp
analys
differ
age
total
children
year
age
includ
boy
femal
popul
children
posit
includ
boy
girl
group
patient
year
age
individu
femal
male
posit
includ
men
femal
overal
steadi
declin
percentag
posit
result
male
femal
age
age
howev
sharp
increas
preval
posit
result
male
conclus
studi
demonstr
high
preval
sensit
ascari
spp
caribbean
island
martiniqu
confirm
approxim
patient
seek
diagnosi
treatment
allerg
respiratori
diseas
sensitis
ascari
spp
allergen
younger
children
especi
boy
preval
closer
although
antiparasit
treatment
may
requir
patient
confirm
specif
ige
ascari
spp
repres
current
infest
effect
previou
antiparasit
treatment
sinc
major
children
systemat
treat
intestin
parasit
martiniqu
methyl
statu
promot
region
gene
might
correl
allergi
yasuko
kobayashi
hirokazu
arakawa
akihiro
morikawa
takumi
takizawa
gunma
univers
graduat
school
medicin
pediatr
deveropment
medicin
maebashi
gunma
japan
nation
institut
health
nation
cancer
institut
bethesda
meryland
unit
state
background
helper
cell
classifi
subtyp
shown
contribut
cellular
immun
humor
immun
respect
current
thought
impair
balanc
cell
may
caus
immun
diseas
includ
allerg
diseas
cell
polar
naiv
cell
follow
contact
matur
dendrit
cell
dc
antigenpres
cell
resid
frontlin
immun
matur
dc
activ
naiv
cell
contact
dc
secret
interleukin
il
naiv
cell
becom
cell
contrast
contact
dc
secret
naiv
cell
becom
cell
therefor
type
cytokin
secret
dc
import
dc
gener
cord
blood
previous
shown
secret
lower
amount
dc
adult
peripher
blood
author
suggest
find
correl
immun
statu
infant
weak
cellular
immun
develop
allerg
diseas
easili
object
hypothes
reduc
secret
dc
allerg
patient
cord
blood
would
due
methyl
gene
promot
region
allerg
statu
may
attribut
delay
demethyl
region
clarifi
hypothesi
examin
methyl
statu
gene
promot
region
monocyt
dc
precursor
prepar
peripher
blood
healthi
adult
ha
allerg
adult
aa
cord
blood
normal
infant
ni
method
monocyt
purifi
three
group
use
mac
system
antibodi
genom
dna
extract
monocyt
methyl
statu
gene
promot
region
investig
use
bisulphatesequenc
analysi
method
addit
realtim
rtpcr
amplif
carri
determin
mrna
level
cultur
lipopolysaccharidestimul
monocyt
peripher
blood
ha
aa
result
among
three
group
signific
differ
methyl
ratio
cpg
gene
promot
region
contrari
expect
methyl
ratio
significantli
lower
aa
ni
ha
mrna
level
ha
aa
differ
significantli
conclus
result
suggest
hypomethyl
promot
region
may
involv
develop
allerg
diseas
membranespan
subfamili
member
genet
polymorph
risk
allerg
disord
background
atop
triad
asthma
allerg
rhiniti
atop
dermat
multifactori
diseas
consider
genet
compon
sever
gene
associ
linkag
analys
found
serv
suscept
factor
atopi
polymorph
membranespan
subfamili
member
shown
associ
increas
ige
level
role
g
polymorph
modul
atop
disord
filipino
popul
evalu
studi
method
onehundr
two
pair
allerg
individu
control
phenotyp
total
serum
ige
level
use
enzymelink
immunosorb
assay
elisa
atop
statu
defin
serum
ige
concentr
iuml
dna
extract
genotyp
polymorph
amplif
refractori
mutat
systempolymeras
chain
reaction
armspcr
allel
identifi
pcr
bp
band
agaros
gel
g
allel
bp
band
result
studi
popul
hardyweinberg
equilibrium
df
p
g
signific
differ
total
serum
ige
level
subject
aa
ag
gg
genotyp
likewis
allel
frequenc
polymorph
differ
statist
case
control
df
p
frequenc
g
allel
case
control
ci
conclus
lack
associ
polymorph
total
serum
ige
level
among
allerg
individu
filipino
studi
popul
indic
singlenucleotid
polymorph
may
directli
involv
develop
allerg
disord
genotyp
allergi
ag
palmacarlo
ml
palmacarlo
clinic
allergi
immunolog
center
caic
allergolog
lisbon
portug
background
defici
usual
correl
copd
hepat
diseas
howev
defici
risk
factor
allergi
coexist
interact
asthma
allerg
diseas
method
patient
confirm
defici
allerg
diseas
complet
identif
genotyp
studi
genet
studi
done
genet
section
j
chave
clinic
patholog
clinic
result
case
cjj
male
heavi
smoker
year
complaint
cough
sputum
year
month
year
diagnosi
previous
treat
fluticason
salmeterol
tiotropium
object
examin
respiratori
sound
diminish
pfr
normal
ct
centro
lobular
emphysema
mainli
superior
lobe
hyperinsufl
electrophoresi
decreas
fraction
antitrypsin
genet
studi
genotyp
pi
sz
mutat
glu
ly
glu
val
case
cmc
femal
nonsmok
stori
rhiniti
urticaria
without
lower
respiratori
symptom
object
examin
normal
electrophoresi
fraction
antitrypsin
assay
pi
zz
mutat
glu
ly
thyroid
auto
antibodi
increas
tg
tpo
conclus
z
allel
frequent
northern
europ
iberian
peninsula
variant
give
antitrypsin
level
z
variant
normal
allel
therefor
ms
heterozygot
must
level
around
allel
z
allel
homozygot
zz
level
case
patient
slightest
form
defici
respiratori
symptom
emphysemat
pattern
ct
theoret
sever
form
zz
homozygot
present
rhiniti
urticaria
without
lower
respiratori
complaint
discrep
could
explain
nonsmok
habit
homozygot
patient
contrast
long
histori
smoke
habit
patient
sz
patient
even
without
lower
respiratori
complaint
present
less
fraction
electrophoresi
assay
must
done
case
low
valu
genet
studi
complet
chang
casomorphin
content
human
milk
lactat
background
milk
best
complet
food
import
develop
nourish
neonat
except
nutrient
milk
contain
biolog
activ
opioid
peptid
deriv
casein
name
casomorphin
exert
effect
neonat
gastrointestin
tract
wall
organ
suggest
opioid
peptid
may
play
role
regul
infant
gastrointestin
function
develop
involv
process
immun
matur
content
casomorphin
human
milk
matur
phase
studi
far
therefor
aim
studi
determin
content
human
milk
differ
phase
lactat
method
chosen
thirti
healthi
newborn
healthi
mother
plan
breast
feed
milk
sampl
collect
everi
two
month
start
deliveri
peptid
extract
accord
halwark
elliot
method
purifi
spe
use
column
identifi
use
hplc
result
significantli
highest
casomorphin
concentr
found
colostrum
matur
milk
concentr
casomorphin
milk
collect
second
month
lactat
similar
level
obtain
fourth
month
lactat
level
individu
phase
lactat
significantli
differ
level
conclus
casomorphin
content
human
milk
chang
period
lactat
level
opioid
peptid
may
depend
function
peptid
neonat
organ
chang
matur
process
concentt
casomorphin
women
histori
allergi
food
hypersensit
babi
maciej
kaczmarski
katarzyna
sidor
elzbieta
kostyra
beata
jarmolowska
krzysztof
bielikowicz
malgorzata
iwan
henryk
kostyra
medic
univers
bialystok
iiird
depart
pediatr
bialystok
poland
univers
warmia
mazuri
chair
biochemistri
olsztyn
poland
polish
academi
scienc
institut
anim
reproduct
food
research
olsztyn
poland
background
breast
milk
provid
optim
nutrit
suppli
critic
postnat
adapt
newborn
although
human
milk
consid
hypoallergen
food
proport
breastf
children
demonstr
symptom
atop
dermat
increas
allergi
prevent
effect
breast
feed
remain
controversi
consist
data
regard
degre
breastfeed
prevent
reduc
delay
increas
develop
allerg
diseas
number
studi
report
suggest
differ
allerg
nonallerg
mother
relat
milk
concentr
immunolog
agent
involv
allerg
reaction
casomorphin
seem
milk
ingredi
associ
pseudoallerg
reaction
method
sampl
human
milk
collect
volunt
breastfeed
women
histori
allergi
clinic
manifest
allergi
bovin
milk
protein
healthi
women
milk
sampl
collect
two
phase
lactat
first
sampl
colostrum
second
one
month
deliveri
allerg
group
women
asthma
diagnos
allergi
bovin
milk
protein
one
women
diseas
infant
mother
allerg
group
present
skin
allerg
symptom
ie
atop
dermat
peptid
extract
accord
halwark
elliot
method
purifi
spe
use
column
identifi
use
hplc
result
casomorphin
concentr
colostrum
allerg
group
roughli
similar
statist
signific
differ
casomorphin
content
phase
lactat
investig
peptid
matur
milk
result
control
group
diversifi
content
casomorphin
colostrum
significantli
higher
matur
milk
p
p
respect
conclus
content
investig
casomorhin
healthi
breastfeed
women
decreas
lactat
remain
roughli
constant
group
mother
allergi
symptom
use
fuccoremodifi
nglycanscontain
glycoepitop
seed
glycoprotein
novel
approach
diagnosi
therapi
vespid
honey
beeallerg
patient
background
mucuna
prurien
seed
oral
prophylact
snake
bite
human
demonstr
gpmuc
kda
glycoprotein
found
seed
immunogen
antibodi
crossreact
snake
venom
protein
immunogen
properti
postul
resid
core
link
xyloseand
core
link
fucosemodifi
nglycan
chain
verifi
hypothesi
investig
fragment
gpmuc
immunoreact
sinc
core
modifi
nglycan
honeybe
vespid
venom
often
consid
immunogen
respons
venom
allergi
also
investig
cross
reactiv
gpmuc
hymenoptera
venom
protein
method
mg
gpmuc
trypsin
digest
digest
sampl
fraction
reversephas
hplc
aliquot
fraction
analyz
immunoreact
antigpmuc
igg
elisa
dot
blot
test
posit
glycopeptid
analyz
maldi
tof
ms
serum
sampl
patient
ige
posit
hymenopera
venom
investig
immunoblot
andor
elisa
ige
igg
venom
protein
gpmuc
correspond
glycopeptid
antigpmuc
igg
analyz
reactiv
protein
venom
result
antigpmuc
epitop
found
da
glycopeptid
character
nglycan
contain
fucos
anti
gpmuc
igg
cross
react
protein
appar
mw
kda
venom
protein
vespula
polist
vespa
cabro
vespula
germanica
analyz
protein
kda
protein
fraction
api
mellifera
venom
twelv
eighteen
patient
ige
posit
one
hymenoptera
venom
show
ige
igg
posit
kda
venom
protein
vespid
andor
kda
protein
api
venom
gpmuc
correspond
glycopeptid
conclus
antigpmuc
glycoepitop
includ
da
peptid
glycoepitop
share
similar
venom
protein
vespid
differ
one
api
second
find
ige
also
igg
cross
reaction
vespid
api
venom
restrict
one
protein
third
find
exist
ige
igg
cross
reaction
cross
react
protein
hymenoptera
venom
gpmuc
specif
peptid
contain
glycoepitop
rais
possibl
use
gpmuc
glycopeptid
place
whole
venom
diagnosi
immunotherapi
hymenoptera
allergi
consider
save
reduc
risk
insect
sting
allergi
emerg
depart
visit
alain
hospit
unit
arab
emir
shirina
alsowaidi
abdulrahman
moham
awad
alessa
abdishakur
abdul
faculti
medicin
uae
univers
depart
intern
medicin
al
unit
arab
emir
al
hospit
intern
medicin
al
unit
arab
emir
background
insect
sting
common
public
health
hazard
unit
arab
emir
howev
noth
known
demograph
clinic
manifest
manag
insect
sting
allerg
patient
object
assess
clinic
manifest
insect
sting
allergi
manag
alain
hospit
method
retrospect
observ
studi
analyz
emerg
depart
ed
record
insect
stung
patient
alain
hospit
total
patient
mean
age
sd
yr
seen
emerg
unit
alain
hospit
result
total
sampl
femal
patient
total
uae
nation
heterogen
expatri
worker
site
sting
patient
leg
arm
head
patient
trunk
patient
neck
howev
signific
major
patient
avail
data
regard
site
sting
studi
subject
local
reaction
urticaria
angioedema
dyspnoea
wheez
patient
present
unconsci
accord
muller
classif
class
sever
class
ii
class
iii
class
iv
ed
patient
receiv
antihistamin
system
antihistamin
system
corticosteroid
receiv
epinephrin
treatment
conclus
insect
sting
common
particularli
among
expatri
commun
often
document
sever
present
sinc
insect
sting
leg
arm
cultur
cover
cloth
among
uae
nation
may
signific
protect
impact
increas
awar
appropri
diagnosi
adequ
manag
insect
sting
allergi
requir
robert
heddl
pamela
hudson
simon
brown
flinder
medic
centr
flinder
univers
south
australia
respiratori
medicin
adelaid
australia
flinder
medic
centr
respiratori
medicin
adelaid
australia
univers
western
australia
emerg
medicin
research
unit
fremantl
australia
background
south
eastern
australia
jack
jumper
ant
jja
domin
caus
sting
anaphylaxi
describ
epidemiolog
jja
sting
anaphylaxi
island
tasmania
prospect
studi
approxim
allerg
subject
stung
year
experienc
system
reaction
age
year
risk
factor
sever
reaction
aim
examin
natur
histori
jja
sting
allergi
south
australia
sa
km
nw
tasmania
method
subject
histori
system
reaction
ant
sting
recruit
australian
ant
venom
allergi
studi
aava
demograph
detail
blood
sampl
allergi
test
ant
specimen
detail
sting
reaction
obtain
subject
follow
prospect
sting
reaction
result
subject
histori
system
reaction
jja
sting
jja
sting
event
subject
mean
followup
period
month
these
sting
led
total
system
reaction
subject
stung
less
year
age
report
lessen
local
reaction
four
older
subject
experienc
reaction
similar
worst
previou
sting
event
conclus
despit
wide
geograph
separ
frequenc
rest
subject
per
annum
proport
system
reaction
subject
sting
event
tendenc
age
seriou
reaction
bear
strike
similar
tasmanian
data
older
subject
allerg
venom
aggress
ant
high
risk
system
reaction
futur
sting
reaction
hymenoptera
sting
adult
patient
experi
clinic
allergyimmunolog
servic
monterrey
mexico
maricela
hernandez
sandra
gonzalez
gabriela
galindo
alejandro
diaz
p
rodriguez
univers
hospit
allergi
clinic
immunolog
monterrey
mexico
univeris
hospit
allergi
monterrey
mexico
introduct
commonli
implic
insect
sting
human
honeybe
yellow
jacket
wasp
paper
wasp
sting
ant
includ
red
black
fire
ant
mexico
data
degre
gener
popul
affect
method
retrospect
studi
questionnair
given
patient
came
clinic
first
time
differ
allerg
symptom
januari
decemb
questionnair
ask
person
histori
hymenoptera
sting
found
patient
posit
histori
result
distribut
sex
male
femal
distribut
insect
sting
ant
honeybe
yellow
jacket
wasp
paper
wasp
none
identifi
averag
age
year
sd
work
risk
number
sting
trough
life
sting
episod
interv
month
sting
episod
year
interv
sting
itch
local
pain
intens
itch
urticaria
angioedema
cardiovascular
symptom
refer
late
reaction
larg
local
reaction
seek
medic
attent
new
sever
problem
new
allerg
rhiniti
allerg
conjunct
urticaria
angioedema
contact
dermat
asthma
least
one
advers
reaction
drug
atop
dermat
food
allergi
background
anim
model
resembl
human
clinic
manifest
allergi
need
variou
aspect
allergi
research
eg
investig
mechan
pathway
immunopatholog
measur
allergen
protein
test
drug
vaccin
therapeut
efficaci
object
develop
murin
model
cockroach
allergi
materi
method
individu
balbc
mice
intraperiton
ip
inject
three
dose
ie
day
alum
adjuvantedcrud
extract
american
cockroach
cr
periplaneta
americana
predomin
cr
speci
thailand
anim
subsequ
aerosol
challeng
day
ml
crude
cr
extract
wv
pb
use
homemad
airpressur
nembul
mice
mice
bled
sacrif
day
serum
sampl
bronchoalveolar
lavag
fluid
balf
lung
collect
control
mice
receiv
alum
ip
aerosol
pb
via
nembul
result
cr
extract
treat
mice
show
featur
allergi
balf
contain
inflammatori
cell
outnumb
nonallerg
counterpart
determin
differenti
cell
count
cytospin
hematoxylineosin
stain
cell
eosinophil
eosinophil
infiltr
also
pronounc
lung
tissu
cr
extract
treat
mice
neglig
tissu
control
level
serum
ige
specif
american
cr
extract
rose
significantli
control
level
conclus
murin
cockroach
allergi
model
featur
resembl
human
allerg
manifest
success
develop
model
use
studi
variou
attribut
cr
allergi
eg
allergen
protein
interest
immunopatholog
drug
vaccin
therapeut
efficaci
crude
forcipomyia
taiwana
bite
midg
extract
stimul
pbmc
prolifer
ifn
secret
midgeallerg
subject
yihs
chen
meifang
lee
hsinru
wu
guangyuh
hwang
tunghai
univers
depart
life
scienc
taichung
taiwan
background
forcipomyia
taiwana
f
taiwana
tini
mm
bloodsuck
midg
wide
distribut
urban
suburban
taiwan
well
southern
china
f
taiwana
attack
group
expos
part
human
bodi
day
caus
intens
pruriti
swell
sensit
individu
two
type
reaction
midg
bite
immedi
reaction
larg
local
swell
develop
within
one
hour
bite
delay
reaction
intens
itch
papul
vesicl
occur
hour
bite
delay
lesion
may
turn
central
necrot
last
week
even
month
previous
report
expos
subject
develop
hypersensit
reaction
f
taiwana
bite
among
develop
immedi
reaction
develop
immedi
reaction
follow
delay
reaction
develop
sole
delay
reaction
previou
studi
suggest
immedi
larg
local
reaction
igemedi
protein
major
igebind
allergen
howev
previou
studi
also
found
delay
reaction
f
taiwana
bite
may
react
ige
pathway
delay
itch
skin
papul
vesicl
usual
last
week
even
month
caus
even
greater
impact
patient
qualiti
life
rapidli
resolv
immedi
reactionexcept
limit
studi
focus
immunolog
mechan
mosquito
bite
report
literatur
regard
immunolog
mechan
bite
midg
materi
method
peripher
mononuclear
cell
pbmc
midgeallerg
patient
delay
reaction
cultur
media
con
f
taiwana
crude
extract
differ
time
point
cell
prolifer
measur
mtt
assay
chang
cytokin
cultur
supernat
measur
use
fluoresc
bead
immunoassay
result
present
studi
demonstr
peripher
mononuclear
cell
pbmc
delay
type
midgeallerg
subject
prolifer
secret
interferon
ifn
respons
crude
f
taiwana
extract
detect
cultur
supernat
conclus
delay
reaction
f
taiwana
bite
may
mediat
type
cell
role
midgebit
allergi
requir
investig
local
allerg
reaction
bone
wax
patient
bee
venom
allergi
carlotta
wirz
heidrun
mueller
regina
treudler
gero
strauq
sylvia
meuret
andrea
dietz
univers
leipzig
ent
depart
leipzig
germani
univers
leipzig
clinc
dermatolog
venerolog
allergolog
leipzig
germani
introduct
yearold
farmer
transfer
clinic
outpati
oper
right
middl
ear
stape
reconstruct
show
intraop
strong
bleed
explor
ear
oper
room
damag
rais
bulb
jugula
vein
could
detect
lesion
close
convent
bone
wax
fibrin
glue
perichondrium
follow
ten
day
remov
endaur
tamponad
patient
complain
chronic
otorrhoea
oper
ear
show
resist
treatment
examin
show
distinct
inflamm
extern
middl
right
ear
clear
secret
oper
revis
situ
extens
grown
granul
tissu
around
last
bit
appli
bone
wax
seen
remov
defect
close
cartilag
tragu
diagnost
investig
second
oper
patient
mention
previous
known
bee
venom
allergi
mention
first
examin
recurr
anaphylactoid
reaction
happen
bee
sting
decid
get
contact
produc
bone
wax
experienc
use
common
bone
wax
consist
bee
wax
isopropylpalmit
allergi
diagnost
patient
confirm
bee
venom
allergi
prick
test
rast
furthermor
epicutan
test
appli
bone
wax
batch
show
posit
result
epicutan
test
singl
compon
bone
wax
bee
wax
isopropylpalmit
neg
conclus
produc
could
guarante
pure
product
conclud
appli
charg
bone
wax
contain
bee
wax
probabl
contamin
bee
venom
bee
wax
repres
great
part
base
common
ointment
cream
patient
never
mention
reaction
substanc
therefor
probabiltiy
allergi
uncontamin
bee
wax
allerg
reaction
type
propoli
low
futur
detail
allergi
anamnesi
perform
use
bone
wax
ear
ent
surgeri
altern
hypoallergen
substanc
use
patient
known
bee
wax
allergi
undergo
ent
surgeri
carpent
bee
anaphylaxi
descript
two
case
identif
respons
allergen
anaphylact
system
reaction
xylocopa
violacea
sting
two
patient
also
stung
yellow
jacket
anaphylaxi
well
toler
sting
clinic
visit
perform
serum
venom
specif
ige
antibodi
venom
skin
prick
test
intraderm
test
yellow
jacket
paper
wasp
european
hornet
honeybe
polist
dominulu
venom
five
patient
neg
allergen
histori
use
neg
control
xylocopa
violacea
extract
xylocopa
violacea
extract
suppli
anallergo
florenc
itali
sdspage
immunoblot
sdspage
perform
xylocopa
violacea
honeybe
venom
extract
gel
blot
nitrocellulos
membran
cut
strip
match
sera
two
patient
incub
antiig
antibodi
allergen
band
detect
chemiluminescen
reveal
system
result
two
allerg
patient
skin
test
serum
ige
detect
posit
yellow
jacket
extract
vitro
analysi
show
ige
bind
honeybe
immunoblot
ige
reactiv
shown
band
kda
kda
kda
xylocopa
violacea
extract
respons
found
control
sera
allergen
band
higher
molecular
weight
specif
xylocopa
violacea
venom
band
kda
correspond
mellitin
conclus
first
report
two
case
anaphylaxi
caus
xylocopa
violacea
member
apida
famili
two
allergen
band
kda
kda
specif
allergen
venom
extract
share
honeybe
venom
extract
tryptas
mastocytosi
hymenoptera
venom
allergi
petr
kucera
milada
cvackova
martina
heroldova
helena
vavrova
jan
ort
medic
faculti
charl
univers
fnkv
dept
allergi
immunolog
pragu
czech
republ
fnkv
dept
allergi
immunolog
pragu
czech
republ
background
elev
basal
serum
tryptas
one
sign
system
mastocytosi
sm
risk
factor
reaction
sever
patient
allerg
hymenoptera
venom
hv
exact
pattern
relationship
elev
basal
tryptas
anaphylaxi
complet
understood
focus
relationship
serum
basal
tryptas
patient
clinic
data
sever
system
allerg
reaction
sar
safeti
venom
immunotherapi
patient
method
analyz
data
consecut
patient
sar
due
hv
allergi
men
women
includ
mean
age
year
sensit
relev
venom
allergen
prick
test
specif
ige
posit
ige
tryptas
level
measur
phadia
immunocap
feia
assay
result
found
signific
differ
mean
tryptas
valu
group
differ
sever
sar
grade
mean
ugl
grade
ii
grade
iii
grade
iv
patient
elev
basal
tryptas
mean
valu
versu
ugl
p
g
patient
elev
tryptas
significantli
older
normal
valu
year
two
patient
diagnos
system
mastocytosi
one
nonhodgkin
lymphoma
two
patient
sm
confirm
venom
immunotherapi
well
toler
conclus
elev
basal
serum
tryptas
level
system
mastocytosi
risk
factor
sever
sar
caus
hymenoptera
venom
allergi
particularli
higher
age
background
increas
serum
tryptas
st
level
mastocytosi
describ
patient
sever
anaphylact
reaction
hymenoptera
sting
depend
studi
aim
studi
determin
basal
valu
st
possibl
clinic
relev
hymenoptera
venom
allergi
method
one
hundr
six
patient
histori
venom
anaphylaxi
yellowjacket
paperwasp
european
hornet
honeybe
includ
grade
allerg
reaction
consid
accord
classif
st
level
measur
unicap
pharmaciauppsala
normal
rang
baselin
patient
year
immunotherapi
venom
serum
specif
ige
level
sige
measur
baselin
cap
system
pharmaciauppsala
result
mean
basal
st
level
iqr
patient
elev
st
level
signific
differ
st
level
hb
vespid
patient
vs
mean
basal
venomspecif
ige
sige
higher
hb
venom
allerg
patient
vs
vespid
patient
hb
one
higher
st
level
statist
correl
higher
grade
reaction
p
hb
patient
invers
correl
basal
st
sige
p
differ
st
level
observ
yr
immunotherapi
respect
baselin
valu
conclus
popul
cutan
system
mastocytosi
appear
recurr
patient
high
st
level
allerg
vespid
venom
hb
patient
despit
higher
specif
venom
ige
level
present
statist
sever
reaction
vespid
patient
note
hb
patient
lower
st
level
correl
higher
sige
level
data
suggest
hb
patient
sever
anaphylact
reaction
due
high
sige
level
larger
number
mast
cell
higher
st
level
would
indic
known
quantit
weight
differ
work
activ
aim
studi
evalu
distribut
work
habit
among
subject
hva
method
subject
refer
unit
suspect
hva
underw
standard
diagnost
workup
accord
modal
exposur
hymenoptera
sting
classifi
high
risk
subject
work
usual
outdoor
place
hymenoptera
live
farmer
garden
firemen
truck
driver
mason
beekeep
dustmen
ii
occasion
high
risk
work
sometim
outdoor
plumber
electrician
railswaymen
low
risk
work
indoor
student
housew
clerk
profession
distribut
occup
gener
popul
provid
central
offic
work
insur
region
veneto
result
three
hundr
subject
male
mean
age
yr
seen
unit
diagnos
hva
clinic
histori
system
reaction
sting
bee
polist
wasp
variou
grade
sever
grade
iiiiv
concern
exposur
patient
high
occup
risk
farmer
mason
truckdriv
garden
beekeep
dustman
occasion
high
risk
warehousemen
soldier
factori
worker
plumber
electician
railwaymen
agronomist
engin
low
risk
gener
popul
woker
risk
occasion
risk
high
risk
among
patient
high
risk
occasion
high
risk
patient
stung
work
activ
beekeep
consid
typic
high
risk
databas
less
repres
instanc
mason
truckdriv
conclus
risk
hva
higher
expect
categori
also
take
account
limit
survey
data
gener
popul
may
imprecis
clear
occup
much
frequent
patient
hva
thu
categori
farmer
truckdriv
allergi
hymenoptera
venom
could
consid
occup
diseas
keyword
hymenoptera
venom
allergi
work
occup
risk
result
modifi
ultrarush
immunotherapi
hymenoptera
venom
allergi
julia
klecker
heidrun
mueller
andrea
dietz
univers
leipzig
ent
depart
leipzig
germani
background
patient
allerg
hymenoptera
venom
may
develop
local
gener
sting
reaction
may
show
system
reaction
differ
sever
venom
immunotherapi
vit
indic
increas
dose
usual
given
hospitalis
sever
advers
reaction
may
occur
wide
rang
rushand
ultrarush
protocol
known
test
ultrarushvit
protocol
accord
toler
method
patient
treat
vit
receiv
beevit
vaspvit
administ
inject
day
incid
intens
advers
reaction
evalu
besid
coher
cardiovascular
diseas
especi
hypertens
sever
system
reaction
insect
sting
challeng
specif
igelevel
skin
prick
test
intens
advers
reaction
vit
determin
result
total
patient
show
advers
system
reaction
got
vaspvit
patient
third
grade
anaphylact
reaction
accord
ring
messmer
due
hymenopteron
sting
case
histori
patient
report
first
grade
anaphylact
reaction
local
reaction
inject
rang
mild
moder
sever
obviou
correl
intens
local
reaction
vit
degre
anaphylaxi
case
histori
mention
patient
show
posit
reaction
skin
prick
test
patient
react
specif
igelevel
also
show
correl
local
system
reaction
conclus
ultrarush
protocol
well
toler
patient
notic
system
reaction
accord
data
studi
literatur
due
small
number
current
particip
find
connect
incidend
system
reaction
vit
fact
examin
notic
fact
patient
system
reaction
treatment
report
thirddegre
anaphylact
reaction
first
sting
challeng
local
reaction
inject
show
moder
intens
skin
effect
leishmani
antigen
detect
dot
immunoblot
assay
phlebotomu
papatasi
iran
hassan
nekoui
pasteur
institut
iran
parasitolog
tehran
islam
republ
iran
introduct
leishmaniosi
polymorph
diseas
skin
viscera
caus
intracellular
protozoan
zoonot
cutan
leishmaniosi
zcl
major
health
problem
rural
area
iran
method
simpl
highli
reproduc
dotimmunoblot
assay
develop
detect
leishmani
antigen
phlebotomu
papatasi
natur
infect
leishmania
major
test
sensit
littl
ng
antigen
protein
also
appear
specif
gave
posit
result
p
papatasi
primari
vector
l
major
iran
l
major
p
sergenti
pathogen
use
investig
larg
number
sandfli
collect
area
iran
cutan
leishmaniasi
endem
discuss
assay
appear
suffici
sensit
specif
detect
natur
infect
insect
simplic
reproduc
high
sensit
high
specif
assay
make
use
field
studi
cockroach
sensit
patient
allerg
airway
diseas
reunion
island
bashir
omarje
bernard
tanguy
ahmad
zaidou
centr
hospitali
departement
insect
allergi
saint
deni
reunion
centr
hospitali
departement
servic
de
maladi
respiratoir
saint
deni
reunion
background
object
studi
evalu
preval
skin
prick
sensit
rast
unicappharmacia
blattela
germanica
blatta
orientali
periplaneta
americanain
patient
rhiniti
asthma
live
reunion
island
indian
ocean
method
patient
male
femal
age
year
mean
age
year
evalu
one
privat
clinic
one
public
hospit
asthma
rhiniti
rhiniti
asthma
consid
sensit
prick
test
induc
papula
least
one
half
area
papula
induc
histamin
specif
ige
superior
ku
al
skin
test
conduct
extract
b
germanica
b
orientali
p
americana
batteri
common
aeroallergen
allerbio
alk
abello
franc
result
posit
skin
test
record
patient
posit
mite
pollen
mould
epithelia
least
one
cockroach
speci
test
patient
sensit
cockroach
sensit
one
speciesth
preval
sensit
respect
speci
b
germanica
b
orientali
p
americana
mean
valu
specif
ige
posit
rast
respect
addit
signific
correl
result
skin
test
cockroach
mite
observ
conclus
author
conclud
sensit
cockroach
frequent
reunion
island
result
suggest
recommend
cockroach
extract
routin
use
evalu
patient
asthma
rhiniti
tropic
countri
effect
treatment
mosquito
bite
rupatadin
experiment
studi
timo
reunala
ari
karppinen
henrikki
brummerkorvenkontio
tamper
univers
hospit
depart
dermatolog
tamper
finland
nation
public
health
institut
hiv
laboratori
helsinki
finland
background
peopl
frequent
experi
wheal
delay
papul
mosquito
bite
wheal
mediat
antisaliva
ige
antibodi
histamin
rupatadin
new
antihistamin
paf
antagonist
effect
allerg
rhiniti
urticaria
effect
mosquitobit
allergi
known
method
doubleblind
placebocontrol
crossov
studi
perform
rupatadin
mg
match
placebo
mosquitobitesensit
adult
mean
age
year
subject
suffer
harm
mosquito
bite
mean
year
either
rupatadin
placebo
taken
day
follow
day
wash
period
altern
treatment
given
day
day
drug
period
subject
receiv
two
aed
aegypti
mosquitobit
forearm
size
min
bite
lesion
intens
pruritu
va
measur
result
subject
could
analys
efficaci
rupatadin
decreas
size
min
wheal
compar
placebo
effect
signific
p
wherea
effect
accompani
pruritu
reach
statist
signific
although
favour
trend
p
conclus
present
placebocontrol
studi
mosquitobitesensit
adult
show
prophylact
given
rupatadin
mg
effect
treatment
mosquitobit
wheal
background
atop
dermat
repres
chronic
inflammatori
skin
diseas
result
complex
interact
genet
environment
mechan
refer
colon
infect
staphylococci
seriou
issu
skin
disord
especi
atop
dermat
ad
human
skin
epithelium
provid
mechan
barrier
invad
bacteria
also
particip
innat
immun
defenc
produc
cation
antimicrobi
peptid
eg
defensin
hbd
cathelicidin
aim
studi
determin
potenti
virul
staphylococci
ad
patient
bacteri
skin
infect
examin
innat
immun
respons
infect
express
antimicrobi
peptid
method
identif
staphylococci
perform
use
trflp
analysi
gap
gene
pathogen
profil
staphylococcu
spp
isol
ad
patient
determin
screen
gene
staphylococc
enterotoxin
sease
segsej
toxic
shock
syndrom
toxin
tst
pantonvalentin
leukocidin
lukpv
pcr
model
bacteri
skin
infect
use
test
pathophysiolog
isol
human
keratinocyt
cell
line
hacat
includ
induct
real
time
pcr
elisa
cellular
invas
fluoresc
stain
confoc
laser
scan
microscopi
result
toxin
gene
variou
pathogen
profil
studi
aureu
superantigen
exotoxin
coagulaseneg
staphylococci
detect
exposur
keratinocyt
staphylococcu
spp
trigger
product
cytokin
defensin
mrna
mrna
mrna
cathelicidin
wherea
level
activ
differ
clinic
isol
adher
invas
keratinocyt
shown
clinic
isol
schleiferi
aureu
homini
epidermidi
capiti
conclus
staphylococci
ad
patient
show
variou
pathogen
profil
invad
keratinocyt
product
cytokin
antimicrobi
peptid
thu
potenti
pathogen
skin
infect
especi
atop
dermat
vinit
mehrotra
g
awasthi
singh
himalayan
institut
medic
scienc
biochemistri
dehradun
india
dolphin
institut
biomed
scienc
biochemistri
dehradun
india
background
pemphigu
vulgari
pv
autoimmun
intraepitheli
blister
diseas
affect
skin
mucou
membran
mediat
circul
autoantibodi
igg
direct
keratinocyt
cell
surfac
potenti
lifethreaten
pv
antibodi
bind
keratinocyt
cell
surfac
molecul
india
incid
pv
mean
age
year
western
countri
mean
age
year
method
import
identifi
implic
antigen
pv
patient
diagnosi
pattern
express
patient
suffer
bullou
diseas
level
also
studi
involv
b
cell
inflammatori
result
seen
mucocutan
type
pv
preval
indian
patient
two
type
band
pattern
observ
immunoblot
patient
sera
antigen
extract
normal
human
patient
also
found
cytokin
profil
patient
sera
level
like
cytokin
exampl
significantli
high
activ
stage
pv
wherea
rel
differ
seen
like
cytokin
exampl
ifng
cytokin
profil
confirm
pv
case
sera
show
direct
evid
involv
auto
reactiv
cell
respons
may
critic
pathogenesi
pv
among
biolog
activ
also
induc
blymphocyt
prolifer
differenti
produc
antibodi
may
play
import
role
product
auto
antibodi
pv
conclus
studi
indic
pv
antibodymedi
diseas
increas
cytokin
auto
reactiv
cell
pv
patient
produc
cytokin
preferenti
activ
stage
pv
diseas
studi
help
elucid
cellular
immun
abnorm
lead
product
igg
autoantibodi
pv
patient
success
treatment
pulmonari
alveolar
proteinosi
combin
intraven
immunoglobulin
puls
methylprednisolon
case
report
nongnapa
jirarattanasopa
tantikul
chutsumarn
orathai
jirapongsananuruk
nualanong
visitsunthorn
pakit
vichyanond
siriraj
hospit
allergi
immunolog
pediatr
depart
bangkok
thailand
siriraj
hospit
pediatr
depart
bangkok
thailand
background
pulmonari
alveolar
proteinosi
pap
rare
diseas
children
character
intraalveolar
accumul
lipoproteinac
materi
posit
stain
period
acidschiff
pa
suscept
pulmonari
infect
salient
featur
diseas
could
partli
explain
defect
alveolar
macrophag
function
method
report
case
pap
chronic
interstiti
pneumon
girl
present
chronic
respiratori
distress
sinc
age
month
clinic
condit
progress
worsen
chest
radiograph
show
diffus
hazi
opac
lung
high
resolut
computer
tomographi
hrct
chest
demonstr
crazypav
pattern
definit
diagnosi
pap
made
open
lung
biopsi
show
mark
interstiti
lung
inflamm
alveolar
proteinosi
pattern
result
bronchoalveolar
lavag
attempt
twice
without
clinic
improv
respiratori
clinic
collaps
continu
recurr
pneumonia
observ
patholog
diagnosi
short
tri
gcsf
attempt
avail
low
dose
methylprednisolon
hydroxychloroquin
initi
without
satisfactori
improv
decid
start
intraven
immunoglobulin
ivig
mgkg
everi
week
puls
methylprednisolon
mgkg
everi
week
gradual
respond
longer
requir
oxygen
supplement
month
treatment
current
asymptomat
age
year
continu
receiv
ivig
puls
methylprednisolon
everi
week
conclus
asid
therapeut
lung
lavag
gmcsf
therapi
ivig
puls
methylprednisolon
may
potenti
role
success
treatment
pap
cytokin
profil
children
allerg
diseas
inflamm
process
particip
cascad
cytokin
predetermin
develop
direct
power
immun
respons
regul
cellular
interact
charact
chang
cytokin
profil
may
distinguish
sign
patholog
process
research
object
investig
specif
featur
cytokin
spectrum
nasal
secret
saliva
blood
serum
process
children
allerg
diseas
develop
allerg
rhiniti
atop
dermat
bronchial
asthma
ifn
tnf
cytokin
content
cytokin
regulatori
index
total
ige
level
monitor
within
year
differ
stage
diseas
cytokin
level
biolog
liquid
determin
immunoenzymat
method
sandwich
variant
r
diagnost
inc
usa
reagent
research
examin
children
age
allerg
diseas
control
group
made
health
children
age
control
group
examin
result
serum
cytokin
pgml
tnf
pgml
pgml
ifn
pgml
saliva
cytokin
pgml
tnf
pgml
pgml
ifn
pgml
respect
nasal
secret
cytokin
pgml
tnf
pgml
pgml
ifn
pgml
high
level
decreas
inf
record
mostli
nasal
secret
children
allerg
diseas
isol
allerg
rhiniti
ar
case
high
content
pgml
nasal
secret
observ
exacerb
period
rhiniti
bronchial
asthma
ba
combin
case
time
children
ba
without
ar
show
pgml
period
ar
clinic
remiss
ifn
content
nasal
secret
pgml
exacerb
period
pgml
cytokin
level
observ
saliva
children
dermat
case
follow
pgml
pgml
ifn
pgml
blood
serum
pgml
pgml
ifn
pgml
investig
local
cytokin
secret
determin
ration
help
specifi
local
rate
allerg
inflamm
provid
data
forecast
treatment
effect
evalu
sever
eczema
associ
subclass
igm
defici
success
treat
intraven
immunoglobulin
somboon
chansakulporn
nualanong
visitsunthorn
pakit
vichyanond
orathai
jirapongsananuruk
siriraj
hospit
pediatr
bangkok
thailand
background
patient
sever
eczema
recurr
infect
investig
immunodefici
report
experi
treat
patient
sever
eczema
recurr
bacteri
infect
chronic
otiti
media
subclass
igm
defici
monthli
intraven
immunoglobulin
ivig
infus
method
yearold
boy
case
long
stand
sever
eczema
multipl
food
drug
allergi
sinc
year
age
chronic
otiti
media
past
year
treatment
includ
elimin
suspect
food
drug
topic
corticosteroid
oral
antihistamin
topic
calcineurin
inhibitor
without
satisfactori
improv
admit
sever
time
due
bacteri
skin
infect
develop
acenitobact
septicemia
one
occas
cbc
show
thrombocytopenia
platelet
small
platelet
immunoglobulin
igg
mgdl
mgdl
mgdl
mgdl
mgdl
iga
mgdl
igm
mgdl
ige
mgdl
specif
ige
egg
white
cow
milk
posit
immunophenotyp
reveal
nk
cell
lymphocyt
prolif
respons
pha
normal
antibodi
respons
pneumococc
vaccin
increas
fold
receiv
conjug
pneumococc
vaccin
result
ivig
infus
mgkg
given
everi
four
week
patient
skin
lesion
gradual
improv
dose
ivig
infus
conclus
patient
present
sever
eczema
recurr
infect
evalu
immunodefici
mechan
benefici
effect
ivig
therapi
patient
unknown
could
due
prevent
infect
antiinflammatori
effect
longterm
effect
treatment
cytokin
product
scleroderma
patient
roman
yatsyshyn
yevgen
neyko
natalya
yatsyshyn
medic
univers
intern
diseas
ivanofrankivsk
ukrain
background
scleroderma
debilit
acquir
connect
tissu
diseas
character
fibrosi
particularli
skin
lung
cytokin
disbal
one
main
manifest
scleroderma
treatment
patholog
difficult
problem
therapi
object
compar
longterm
effect
infus
alprostadil
oral
pentoxyphyllin
product
cytokin
patient
system
sclerosi
ssc
evalu
relationship
effect
two
treatment
clinic
paramet
method
product
cytokin
alloactiv
circul
mononucl
cell
assess
one
year
treatment
subset
patient
enrol
oneyear
studi
twenti
five
patient
treat
mkg
infus
alprostadil
synthet
analog
prostaglandin
anoth
patient
treat
oral
slowreleas
formul
pentoxyphyllin
mg
twice
daili
quantit
determin
beta
tumor
necrosi
factoralpha
tnfalpha
serum
patient
perform
elisa
result
product
significantli
lower
alprostadil
group
pentoxyphyllin
group
cutan
fibrosi
capillaroscop
pattern
better
patient
treat
alprostadil
signific
posit
covari
tnfalpha
chang
chang
skin
score
capillaroscop
score
conclus
sever
mechan
alprostadil
could
exert
clinic
efficaci
vasodilat
inhibit
platelet
aggreg
certainli
import
transient
suggest
longlast
modul
cytokin
network
observ
present
studi
could
anoth
potenti
mechan
respons
persist
efficaci
alprostadil
despit
administr
endotheli
dysfunct
inflammatori
marker
chronic
heart
failur
hypertens
natalya
yatsyshyn
roman
yatsyshyn
yevgen
neyko
medic
univers
intern
diseas
ivanofrankivsk
ukrain
chronic
heart
failur
arteri
hypertens
lot
biochem
manifest
idea
research
work
compar
high
sensit
creactiv
protein
hscrp
solubl
receptor
tnf
alpha
stnfr
coronari
heart
diseas
chd
chronic
heart
failur
chf
control
group
c
group
compar
ultrasound
marker
endotheliumdepend
vasodilat
edv
endotheliumindepend
vasodilat
eiv
hypertens
ht
patient
group
patient
method
hypertens
pt
mean
age
yr
chd
chf
investig
nyha
class
ii
iii
iv
pt
c
group
repres
healthi
volunt
ultrasound
assess
flow
mediat
dilat
fmd
brachial
arteri
use
measur
edv
respons
isosorbid
dinitr
isdn
measur
eiv
stnfr
hscrp
examin
elisa
method
result
fmd
signific
diminish
hypertens
pt
sec
reactiv
brachial
arteri
hyperemia
lumin
size
reach
basal
paramet
ht
pt
mean
fmd
c
group
mean
fmd
p
g
eiv
signific
reduc
ht
pt
compar
c
group
ht
pt
mean
eiv
c
group
mean
eiv
p
ht
group
signific
elev
level
hscrp
stnfri
found
ht
pt
mean
hscrp
mgl
c
group
mean
hscrp
mgl
p
g
ht
group
mean
stnfri
pgml
c
group
mean
stnfri
p
g
signific
differ
stnfrii
level
group
found
correl
stnfri
rest
lumin
size
brachial
arteri
observ
r
p
correl
edva
eiv
inflammatori
marker
found
conclus
signific
reduc
endo
theliumdepend
endo
theliumindepend
vasodil
brachial
arteri
ht
pt
found
signific
elev
level
hscrp
stnfri
pt
measur
signific
correl
ultrasound
marker
endotheli
dysfunct
inflammatori
paramet
observ
ultrasound
assess
endotheli
dysfunct
inflammatori
marker
may
give
us
inform
concern
sever
progress
diseas
pharmacogenet
studi
predict
cyclophosphamid
side
effect
thai
system
lupu
erythematosu
pintip
ngamjanyaporn
ammarin
thakkinstian
oravan
verasertniyom
monchand
vanichapuntu
kanokrat
nantiruj
kitti
totemchokchyakarn
suchela
janwityanujit
allergi
immunilog
rheumatolog
divis
ramathibodi
hospit
mahidol
univers
medicin
depart
bangkok
thailand
ramathibodi
hospit
mahidol
univers
clinic
epidemiolog
unit
bangkok
thailand
ramathibodi
hospit
mahidol
univers
reseach
center
bangkok
thailand
background
system
lupu
erythematosu
sle
seriou
autoimmun
diseas
primarili
affect
young
women
although
cyclophosphamid
improv
outcom
sle
frequent
ovarian
toxic
major
side
effect
therapi
cytochrom
cyp
polymorph
shown
significantli
influenc
pharmacokinet
well
ovarian
toxic
cyclophosphamid
caucasian
sle
patient
object
assess
associ
polymorph
ovarian
toxic
thai
sle
patient
treat
cyclophosphamid
patient
method
femal
patient
diagnos
sle
accord
acr
criteria
treat
cyclophosphamid
genotyp
polymorph
ovarian
toxic
defin
sustain
amenorrhea
month
occur
year
age
lack
menstruat
month
treatment
chisquar
test
use
assess
associ
logist
regress
appli
result
seventyon
patient
enrol
analysi
mean
age
diagnosi
start
cyclophosphamid
year
mean
cumul
cyclophosphamid
dosag
gram
thirtysix
patient
develop
ovarian
toxic
allel
frequenc
ovarian
nonovarian
toxic
group
genotyp
frequenc
nonovarian
toxic
group
compli
hardyweinberg
equilibrium
p
roc
analysi
appli
calibr
cutoff
cyclophosphamid
dosag
found
dosag
gram
yield
likelihood
ratio
develop
ovarian
toxic
logist
regress
analysi
appli
assess
interact
effect
cyclophosphamid
dosag
allel
found
among
allel
patient
receiv
cyclophosphamid
gram
higher
ci
time
like
ovarian
toxic
patient
receiv
cyclophosphamid
g
gram
risk
decreas
e
ci
time
patient
allel
conclus
cyclophosphamid
dosag
gram
higher
carri
high
risk
induc
ovarian
toxic
howev
risk
decreas
patient
allel
background
aspirininduc
asthma
aia
distinct
clinic
entiti
appear
specif
subtyp
asthma
lot
effort
uncov
aia
pathogenesi
advers
reaction
aspirin
still
remain
unclear
aspirin
well
known
nonsteroid
antiinflammatori
drug
antiinflammatori
action
aspirin
gener
attribut
direct
inhibit
cyclooxygenas
aia
take
part
patient
sever
asthma
theophyllin
demonstr
antiinflammatori
effect
longterm
medic
sever
asthma
copd
work
pde
inhibitor
nonspecif
adenosin
receptor
antagonist
object
assess
therapeut
effect
aspirin
theophyllin
combin
two
drug
murin
model
asthma
method
gener
murin
model
asthma
induc
lp
ova
mice
sensit
intranas
ug
ova
day
without
lp
challeng
intranas
ug
ova
day
whenev
mice
challeng
aspirin
theophyllin
inject
intraperiton
asthmat
phenotyp
lung
inflamm
use
bronchoalveolar
lavag
bal
cellular
cytokin
product
lung
histolog
evalu
day
result
total
cell
number
bal
fluid
mice
treat
aspirin
theophyllin
significantli
decreas
compar
nontreat
group
mice
howev
inflammatori
cell
bal
fluid
increas
mice
treat
aspirin
theophyllin
combin
similar
result
repres
histolog
protein
downstream
ifngamma
decreas
aspirin
theophyllin
treat
mice
compar
aspirin
theophyllin
nontreat
group
mice
howev
aspirin
theophyllin
combin
treat
mice
repres
increas
level
balf
moreov
aspirin
theophyllin
combin
treat
mice
reveal
special
increas
level
gener
lipid
metabolit
aspirin
conclus
murin
model
asthma
enhanc
lp
ova
aspirin
theophyllin
treatment
effect
combin
treatment
result
advers
reaction
reza
amin
ahmad
amin
soheila
alyasin
nemaze
hospit
pediatricallergi
clinic
immunolog
research
lab
shiraz
islam
republ
iran
background
betathalassemia
major
one
major
health
problem
countri
mani
studi
confirm
fact
patient
increas
suscept
bacteri
infect
object
studi
assess
humor
immun
system
thalassem
patient
measur
serum
concentr
immunoglobulin
g
igg
igm
iga
order
find
respons
immun
defect
method
sixti
eight
betathalassemia
major
patient
enrol
randomli
referr
dastgheib
clinic
thalassemia
number
case
control
match
age
sex
select
healthypeopl
without
histori
recent
recurr
infect
serum
igg
igm
iga
level
assess
use
singl
radial
immunodiffus
srid
result
serum
level
igg
igm
iga
significantli
higher
p
g
significantli
lower
p
g
thalassem
patient
control
consid
result
analyt
test
reveal
thalassemia
patient
show
much
increas
serum
immunoglobulin
level
get
older
splenectom
patient
higher
serum
igg
iga
level
nonsplenectom
patient
differ
serum
igm
serum
ferritin
level
correl
chang
humor
immun
howev
patient
serum
ferritin
level
ngml
higher
serum
igm
level
conclus
result
due
continu
exposur
antigen
repeat
infect
chronic
liver
diseas
splenectomi
iron
overload
probabl
caus
humor
immun
defici
found
patient
defect
serum
complement
level
keyword
thalassemia
major
igg
iga
igm
rare
caus
acut
eosinophil
pneumonia
bori
golzman
svetlana
turkot
jakob
kogan
alex
rozov
ari
feldman
arela
rotlev
shmuel
oren
barzilai
hospit
intern
medicin
depart
ashkelon
israel
barzilai
hospit
pulmonolog
unit
ashkelon
israel
barzilai
hospit
intern
medicin
depart
b
ashkelon
israel
introduct
acut
eosinophil
pneumonia
aep
rare
diseas
describ
follow
acut
febril
ill
sever
hypoxemia
diffus
pulmonari
infiltr
increas
bronchoalveolar
lavag
bal
eosinophil
evid
infect
asthma
atop
ill
complet
resolut
treatment
corticosteroid
suggest
aep
acut
hypersensit
reaction
unidentifi
inhal
antigen
report
case
aep
develop
narghil
water
pipe
smoke
wp
case
report
woman
admit
cough
high
fever
last
day
previou
histori
asthma
atop
diseas
histori
smoke
recent
travel
use
medic
week
admiss
smoke
narghil
water
pipe
patient
moder
gener
condit
dyspneic
rr
sat
room
air
physic
examin
unremark
besid
bilater
inspiratori
rale
chest
xray
reveal
bilater
ground
glass
opac
peripher
wbc
count
cellmm
eosinophilsmm
iv
antibiot
oxygen
support
inhal
bronchodil
administ
blood
cultur
neg
eosinophil
count
rose
eosinophil
total
ige
level
iuml
normal
rang
chest
ct
scan
reveal
bilater
patchi
ground
glass
opac
lymph
node
enlarg
fiberopt
bronchoscopi
perform
bal
yield
eosinophil
iv
corticosteroid
therapi
given
remark
improv
peripher
blood
eosinophil
count
return
normal
two
day
patient
discharg
good
condit
month
later
asymptomat
discuss
case
met
diagnost
criteria
aep
acut
ill
short
durat
high
fever
sever
hypoxemia
bilater
infiltr
chest
radiograph
eosinophilia
bal
histori
drug
hypersensit
evid
infect
report
aep
new
cigarett
smoker
narghil
tobacco
smoke
contain
tar
nicotin
carbon
monoxid
heavi
metal
higher
cigarett
smoke
waterpip
smoker
may
absorb
higher
concentr
substanc
due
mode
smoke
higher
frequenc
puf
depth
inhal
search
pubm
reveal
case
report
aep
evolv
narghil
water
pipe
smoke
case
etiolog
factor
emerg
detail
histori
serum
concentr
eosinophil
cation
protein
eosinophil
patient
kimura
diseas
nobuo
ohta
shigeru
fukas
yusuk
suzuki
shinnichi
sakurai
masaru
aoyagi
shinichi
okazaki
yamagata
univ
school
medicin
depart
otolaryngolog
yamagata
japan
clarifi
role
eosinophil
pathogenesi
kimura
diseas
valu
measur
serum
level
eosionophil
cation
protein
ecp
monitor
diseas
activ
total
serum
tissu
sampl
patient
kimura
diseas
studi
concentr
ecp
cytokin
granulocytemacrophag
colonystimul
factor
gmcsf
interleukin
sera
patient
kimura
diseas
measur
enzymelink
immunosorb
assay
elisa
densiti
eosinophil
degre
activ
eosinophil
tissu
also
studi
immunohistochem
concentr
ecp
sera
patient
kimura
diseas
significantli
higher
control
group
p
g
time
remiss
signific
decreas
ecp
observ
interfollicular
area
infiltr
eosinophil
posit
antibodi
mean
percentag
eosinophil
concentr
gmcsf
sera
patient
kimura
diseas
within
normal
rang
detect
level
sera
examin
find
suggest
eosinophil
play
import
role
pathogenesi
kimura
diseas
ecp
may
use
addit
paramet
diseas
activ
evalu
osteocalcin
osteoprotegerin
osteogen
marker
bone
remodel
rheumatoid
arthriti
cioaca
gabriela
ramona
drugarin
doina
paunescu
virgil
victor
babe
univers
medicin
pharmaci
timisoara
depart
physiolog
immunolog
timisoara
romania
purpos
studi
evalu
osteogen
marker
involv
bone
remodel
estim
osteocalcin
oc
osteoprotegerin
opgrank
concentr
sinovi
fluid
well
serum
rheumatoid
arthriti
ra
patient
measur
perform
initi
stage
diseas
without
use
antiinflammatori
nonsteroid
therapi
least
month
studi
began
concentr
opg
sinovi
fluid
repres
pmoll
serum
concentr
pmoll
significantli
increas
p
g
compar
valu
determin
serum
healthi
control
pmoll
increas
oc
concentr
evolv
manner
site
measur
valu
respect
compar
valu
determin
healthi
control
sinovi
liquid
g
serum
background
undernutrit
children
associ
increas
suscept
infect
depress
effect
cellmedi
humor
immun
probiot
enhanc
immun
respons
lead
ill
prevent
decreas
durat
sever
object
studi
aim
determin
baselin
immun
marker
cd
undernourish
filipino
children
age
year
old
determin
whether
probiot
enhanc
immun
chang
immun
marker
b
chang
weight
c
decreas
incid
durat
common
infect
eg
cold
pneumonia
diarrhea
methodolog
undernourish
children
random
control
experiment
group
probiot
mixtur
lactobacillu
bulgaricu
l
casei
subsp
rhamnosu
l
fermentum
l
plantarum
bifidobacteria
bifidu
b
breve
b
infanti
b
longum
b
lacti
given
time
day
eight
week
weekli
weight
incid
durat
ill
record
blood
immun
marker
drawn
studi
result
children
enrol
control
experiment
group
basal
level
cd
normal
group
control
group
show
increas
level
compar
probiot
group
group
level
stay
within
normal
limit
probiot
group
gain
signific
weight
kg
p
g
incid
ill
diarrhea
cold
signific
shorter
durat
probiot
group
median
day
probiot
control
group
respect
p
g
conclus
probiot
lead
signific
weight
gain
also
lead
shorter
durat
infect
habibeh
mozaffari
zahra
pourpak
neda
entezari
chavoshzadeh
zahra
mohammad
hassn
bemanian
mohammad
gharagozloo
masoud
movahedi
asghar
aghamohammadi
asghar
aghamohammadi
immunolog
asthma
allergi
research
institut
medic
scienc
tehran
univers
tehran
islam
republ
iran
immunolog
asthma
allergi
research
institut
immunolog
depart
tehran
islam
republ
iran
background
leukocyt
adhes
defici
lad
rare
congenit
immunodefici
fewer
affect
individu
world
character
sever
recurr
infect
purpos
studi
describ
surviv
time
iranian
patient
lad
period
year
method
twenti
seven
patient
definit
diagnosi
lad
base
standard
criteria
laboratori
test
attend
allergi
immunolog
clinic
children
medic
center
hospitalfrom
rang
age
month
year
old
studi
follow
sever
diseas
defin
present
marker
surfac
leukocyt
less
normal
express
also
questionnair
fill
record
necessari
inform
result
patient
male
femal
lad
type
preval
consanguin
marriag
mean
age
time
diseas
onset
month
mean
age
diagnosi
month
overal
patient
patient
sever
form
diseas
overal
year
surviv
rate
mortal
rate
mean
surviv
time
aliv
patient
month
main
lead
caus
death
bacteri
infect
conclus
mortal
rate
studi
mention
lower
studi
diagnost
delay
result
high
mortal
complic
untreat
patient
failur
provid
therapi
caus
low
surviv
rate
therefor
earli
diagnosi
good
control
appropri
treatment
improv
surviv
rate
acut
myocard
steroid
withdraw
asthmat
patient
elena
ossi
claudio
bilato
annamaria
de
pellegrin
andrea
rossanes
marilisa
andretta
mauro
cancian
clinica
medica
medic
surgic
scienc
dept
padova
itali
cardiac
unit
cardiolog
depart
padova
itali
ent
clinic
medic
surgic
special
dept
padova
itali
caucasian
man
present
febril
dyspnoea
one
month
withdrawn
steroid
therapi
previous
prescrib
treat
asthma
recent
appear
associ
mark
increas
serum
ige
ul
find
increas
troponin
myoglobin
level
hospit
admiss
seem
point
cardiac
ischemia
although
ecg
show
sinus
tachycardia
despit
leucocytosi
eosinophil
thu
directli
refer
cardiac
intens
care
unit
underw
cardiac
catheter
stent
insert
left
anterior
descend
coronari
arteri
three
day
later
cardiac
enzym
start
increas
troponin
clinic
pictur
worsen
sever
dyspnoea
fatigu
reason
catheter
done
show
problem
stent
meantim
paresthesia
neurolog
pain
slightli
present
admiss
worsen
sever
stage
temperatur
still
high
cutan
sign
vascul
appear
point
cardiac
magnet
reson
perform
reveal
diffus
subendocard
necrosi
final
think
churgstrauss
syndrom
css
myocardi
biopsi
obtain
anca
test
confirm
work
hypothesi
moreov
emg
show
sever
mix
multineuropathi
highdosemethylprednisolon
start
prompt
clinic
improv
normal
cardiac
enzym
day
therapi
css
vascul
character
asthma
hypereosinophilia
involv
organ
css
preval
fifth
decad
novel
asthma
present
individu
age
common
think
previous
latent
atopi
made
overt
concomit
intervent
precipit
factor
cardiopulmonari
diseas
present
case
report
steroid
withdraw
novel
asthma
age
patient
caus
burst
sever
carditi
undiagnos
css
breast
feed
protect
asthma
atop
diseas
moham
herrag
mustapha
iraqui
ibn
sina
univers
hospit
pulmonologyallergolog
rabat
morocco
rational
breast
feed
associ
lowest
asthma
allerg
disord
rate
significantli
reduc
sever
respiratori
ill
first
year
life
method
includ
question
relat
breast
feed
isaac
questionnair
intern
studi
asthma
allergi
childhood
see
outcom
allerg
diseas
group
breast
feed
non
breast
feed
result
mean
sd
age
year
weight
kg
height
cm
children
breastf
month
significantli
lower
preval
rate
persist
cough
past
year
ever
rhiniti
rhiniti
past
year
itchywateri
eye
past
year
breastf
vs
vs
vs
vs
respect
incid
lower
asthma
wheez
breastf
children
breastf
asthma
vs
vs
respect
significantli
higher
proport
children
breastf
month
resolv
asthma
wheez
eczema
breastf
less
month
vs
vs
vs
respect
conclus
studi
show
impact
breast
feed
least
month
protect
reduc
preval
allerg
disord
method
patient
jpa
male
year
consult
asthma
rhiniti
perenn
worsen
fall
winter
previou
histori
atop
eczema
year
object
examin
normal
prick
skin
test
posit
hous
dust
mite
blood
analysi
request
meanwhil
acut
respiratori
ill
treat
symptomat
gp
analysi
pbc
count
normal
igg
mgdl
iga
mgdl
igm
mgdl
electrophoresi
peak
detect
lead
immunofix
show
igmk
monoclon
gammopathi
total
ige
ulml
specif
ige
kul
dpteronyssinu
kul
dfarina
batteri
antibodi
viru
mycoplasma
leishmania
slightli
endem
south
tagu
river
request
one
week
new
immunofix
show
mark
decreas
monoclon
peak
igm
decreas
light
chain
urin
week
antibodi
ebv
cmv
chlamydia
pneumonia
leishmania
neg
antibodi
mycoplasma
pneumonia
posit
igg
igm
week
new
immunofix
done
absenc
monoclon
peak
conclus
secondari
gammophati
includ
broader
group
monoclon
gammopathi
indetermin
signif
mgu
gener
except
leishmania
infect
clear
monoclon
peak
detect
acut
infect
igm
immunoglobulin
impli
primari
respons
infect
children
occurr
monoclon
gammopathi
rare
mainli
describ
cmv
ebv
transient
monoclon
gammopathi
character
fast
decreas
monoclon
peak
infect
case
recent
mycoplasma
pneumonia
infect
shown
posit
serolog
igg
well
igm
young
patient
slight
increas
concentr
total
ige
valu
specif
ige
hous
dust
mite
high
fast
decreas
disappear
monoclon
igm
peak
point
transient
monoclon
gammopathi
atop
child
trigger
mycoplasma
infect
mozhgan
moghtaderi
reza
amin
soheila
alyasin
nemaze
hospit
pediatricsallergi
immunolog
shiraz
islam
republ
iran
nemaze
hospit
immunolog
allergi
shiraz
islam
republ
iran
hyper
ige
syndrom
recurr
infect
rare
immunodefici
character
recurr
skin
infect
pulmonari
abcess
extrem
elev
level
ige
serum
associ
facial
skelet
featur
recogn
frequenc
genet
basi
poorli
understood
patient
sevenyear
old
girl
present
two
year
histori
product
cough
superinfect
facial
eczema
infanc
two
prior
hospit
pneumonia
perian
abcess
coars
face
crackl
lung
club
finger
laxic
elbow
joint
immunolog
work
reveal
eosinophilia
markedli
rais
ige
level
view
clinic
featur
find
diagnosi
hyper
ige
syndrom
suggest
chest
xray
reveal
multipl
larg
cystic
lesion
left
total
lung
confirm
spiral
ctscan
left
thoracotomi
pneumanectomi
done
remov
sever
adhes
histolog
report
reveal
cystic
adenomatoid
transform
cat
character
presenc
various
size
cyst
line
epithelium
probabl
first
report
cat
child
hyper
ige
syndrom
due
repeat
infect
earli
diagnosi
prophylact
antibiot
therapi
effect
manag
patient
pulmonari
complic
chang
immun
reactiv
cours
acut
heroin
intox
julia
radenkovasaeva
bogdan
petrunov
emerg
hospit
depart
clinic
toxicolog
sofia
bulgaria
ncipd
depart
immunolog
allergolog
sofia
bulgaria
object
examin
complic
pulmonari
system
chang
immun
reactiv
paramet
humor
cell
mediat
immun
cours
acut
heroin
intox
studi
includ
patient
acut
heroin
mix
psychoact
drug
intox
averag
age
year
men
woman
hospit
clinic
toxicolog
mhatem
bnipirogov
sofia
use
clinic
clinicolaboratori
immunolog
chimicotoxicolog
instrument
method
result
result
studi
show
sever
intox
heroin
psychoact
drug
observ
spectrum
complic
pulmonari
system
pneumonia
aspir
gastric
content
pulmonari
edema
ard
death
regist
person
found
chang
immun
reactiv
statist
signific
lower
mean
level
igg
iga
igm
tendenc
lower
mean
level
complement
compon
studi
patient
comparison
valu
healthi
peopl
chang
demonstr
group
pulmonari
complic
compar
group
without
pulmonari
complic
observ
lymphocyt
significantli
less
studi
patient
determin
lower
level
bear
lymphocyt
natur
killer
nk
cell
compar
healthi
control
conclus
acut
heroin
mix
psychoact
drug
intox
lead
complic
pulmonari
system
chang
paramet
cell
mediat
humor
immun
key
word
intox
heroin
psychoact
drug
immun
reactiv
noncardiogen
pulmonari
edema
pneumonia
ard
atyp
present
polyarter
nodosa
case
report
horacio
del
olmo
tellez
yamazaki
nakazhimada
marco
antonio
francisco
espinosa
rosal
nation
institut
pediatr
mexico
allergi
immunolog
mexico
citi
mexico
polyarter
nodosa
system
vascul
affect
median
size
muscular
arteri
character
multi
organ
involv
present
gi
manifest
includ
abdomin
pain
nausea
vomit
diarrhea
acut
abdomen
rare
gi
bleed
form
hematemesi
melena
occult
bleed
year
old
boy
present
five
year
ago
hemetochezia
episod
per
day
present
sever
anemia
hospit
investig
mieloprolif
diseas
system
lupu
erythematosu
treat
ivig
methylprednisolon
clinic
hemat
biometri
improv
colonoscopi
show
suggest
data
cuci
diffus
inflamm
pseudopolyp
adher
fibrin
mucosa
inflammatori
lesion
involv
descend
colon
sigmoid
estenot
part
colon
bleed
hystolog
examin
describ
ulcer
inflammatori
infiltr
polimorphonuclear
limphocyt
plasmat
cell
lamina
propia
submucosa
mild
fibrosi
eosinophil
receiv
treatment
methylprednisolon
mesalazin
omeprazol
azathioprin
refer
physic
examin
reveal
sever
emat
kg
hepatomegali
splenomegali
bilater
pulmonar
hipoventil
bilater
crackl
diagnosi
sever
desnutrit
cuci
communitari
pneumonia
made
treatment
cefuroxim
claritromicin
start
present
fever
rectorragia
hemodinam
compromis
requir
transfus
pack
red
blood
cell
platelet
involv
liver
kidney
gut
persist
fever
pancytopenia
elev
ferritin
requir
orotraqu
intub
ventilatori
compromis
neurolog
area
hypoton
proxim
extrem
hiporreflexia
gener
seizur
control
phenytoin
laboratori
find
reveal
neg
antinuclear
antibodi
perinuclear
antineutrophil
cytoplasm
antibodi
hepat
b
surfac
antigen
anti
hepat
c
viru
neg
central
nervou
comput
tomographi
show
isquem
tempor
area
magnet
reson
angiographi
reveal
microaneurysm
renal
arteri
vascul
central
nervou
system
hepat
intestin
arteri
symptom
laboratori
find
compat
diagnost
criteria
childhood
classic
polyarter
nodosa
treatment
ivig
variou
methylprednisolon
puls
let
clinic
improv
background
accord
evid
base
medicin
conclus
metaanalys
rct
repres
solid
evid
sourc
assess
efficaci
intervent
specif
immunotherapi
sit
current
consid
allergenori
biolog
respons
modifi
regard
essenti
part
therapeut
approach
allerg
diseas
object
provid
descript
review
avail
random
doubleblind
placebocontrol
trial
rct
bd
pc
publish
evalu
efficaci
sit
treatment
respiratori
allergi
studi
design
systemat
review
method
comprehens
search
embas
medlin
databas
april
carri
search
strategi
retriev
citat
contain
subject
head
specif
immunotherapi
limit
rct
db
pc
combin
asthma
allerg
rhiniti
variabl
record
studi
design
journal
impact
factor
patient
immunotherapi
characterist
clinic
laboratori
outcom
onlin
fulltext
paper
avail
result
two
hundr
ninetysix
articl
identifi
review
rct
db
placebocontrol
evalu
efficaci
subcutan
scit
sublingu
slit
twentysix
percent
studi
n
minimum
durat
month
vs
scit
slit
respect
characterist
studi
describ
tabl
medianinterquartil
rank
number
studi
found
month
mean
least
one
immunolog
mechan
studi
conclus
one
hundr
seventynin
ib
evidencelevel
studi
efficaci
sit
treatment
respiratori
allergi
identifi
two
electron
databas
select
search
bia
must
rule
effect
antihistamin
pretreat
side
effect
specif
immunotherapi
zoran
arsovski
dejan
dokic
miroslav
gavrilovski
biserka
kaeva
zlatica
goseva
olivera
caparoska
clinic
pulmonolog
allergi
scientif
depart
skopj
macedonia
fyrom
one
year
studi
group
patient
conduct
specif
immunotherapi
sit
hous
dust
mite
hdm
novo
helisen
depot
extract
pollen
allergovit
extract
shot
appli
local
reaction
occur
cm
occur
mainten
dose
reach
system
reaction
lifethreaten
reaction
observ
group
hdm
treat
patient
inject
result
larg
local
reaction
versu
group
patient
pollen
statist
differ
two
group
reduct
itschedul
perform
due
sever
local
reaction
patient
experienc
one
larg
local
reaction
four
pollen
immunotherapi
two
hdm
immunotherapi
patient
skin
reactiv
skin
prick
test
spt
decid
use
loratadin
antihistamin
premed
patient
administr
pretreat
antihistamin
drug
patient
experi
sever
local
reaction
conclud
limit
number
patient
underw
sit
especi
extens
cutan
reaction
spt
could
use
use
antihistamin
premed
reducesecur
number
sever
cutan
reaction
shorter
dose
interv
sublingu
immunotherapi
lead
efficaci
treatment
mous
model
rhiniti
carola
rask
jen
brimn
sandra
uriost
kaar
lund
experiment
immunolog
hlrsholm
denmark
background
sublingu
immunotherapi
slit
allergen
extract
shown
efficaci
treat
allerg
rhiniti
asthma
clinic
slit
perform
vari
dose
allergen
extract
vari
interv
dose
although
doserespons
relationship
establish
slit
import
dose
interv
remain
document
object
studi
explor
import
dose
interv
slit
purpos
use
mous
model
allerg
rhiniti
induc
clinic
relev
allergen
timothi
grass
pollen
extract
method
mice
sensit
phleum
pratens
phl
p
intraperiton
inject
alumadsorb
allergen
extract
sensit
mice
slittreat
differ
interv
differ
dose
phl
p
extract
order
studi
import
dose
interv
dose
ksq
ksq
ksq
given
sublingu
mice
day
per
week
respect
result
weekli
cumul
dose
ksq
group
two
addit
group
receiv
lower
dose
phl
p
one
three
day
per
week
also
includ
follow
nine
week
slit
mice
challeng
intranas
phl
p
antibodi
level
cell
respons
number
inflammatori
cell
broncoalveolar
lavag
bal
use
readout
efficaci
slit
differ
treatment
group
result
increas
phl
p
specif
iga
antibodi
level
show
strict
posit
correl
increas
dose
frequenc
level
phl
p
specif
ige
reduc
extent
group
system
spleen
local
drain
lymph
node
cell
respons
decreas
increas
dose
interv
indic
posit
effect
higher
dose
frequenc
tcell
toler
addit
maxim
reduct
allergeninduc
inflamm
lung
bal
seen
group
receiv
slit
day
per
week
conclus
group
receiv
slit
day
per
week
group
demonstr
posit
effect
immunolog
paramet
measur
data
demonstr
although
effect
slit
dosedepend
use
allergen
extract
daili
regimen
efficaci
regimen
slit
weekli
cumul
allergen
dose
administ
longer
interv
faster
reach
maintain
pleteau
delay
rush
immunotherapi
naren
pandey
bellevu
clinic
allergi
asthma
kolkata
india
introduct
intermitt
rush
immunotherapi
tri
patient
evolv
faster
afford
immunotherapi
modal
make
patient
achiev
mainten
pleatu
within
short
time
span
also
involv
hospit
stay
convent
method
immunotherapi
administ
long
durat
rush
immunotherapi
super
fast
methodolog
attain
maintenanceboost
modul
requir
hospit
precautionari
method
multipl
allergen
vaccin
administ
within
short
span
time
method
tri
found
within
durat
around
day
relief
immunotherapi
reach
place
studi
bell
vue
clinic
kolkata
hope
super
special
hospit
purnea
materi
method
patient
urticaria
allergi
allerg
rhiniti
subject
intermitt
rush
immunotherapi
schedul
therapi
consist
administr
four
vial
allergen
extract
vial
dil
vial
dil
vial
dil
vial
dil
conc
administ
daili
schedul
graphic
rise
manner
patient
given
premed
studi
followup
patient
includ
blood
examin
igg
ige
level
estim
week
procedur
result
patient
show
local
skin
reaction
subsid
durat
time
drug
requir
patient
develop
system
reaction
manag
deriphyllin
decdan
inject
substanti
decreas
ige
level
increas
igg
level
mark
signific
mark
satisfactori
relief
observ
patient
symptomatolog
thu
procedur
may
grade
fast
afford
immunotherapi
two
year
doubl
blind
placebo
control
studi
immunotherapi
singl
mix
allergen
prepar
shailendra
n
gaur
deepsikha
srivastava
naveen
arora
bhanu
p
singh
vallabhbhai
patel
chest
institut
depart
respiratori
medicin
delhi
india
institut
genom
integr
biolog
allergi
immunolog
delhi
india
background
studi
immunotherapi
singl
allergen
extract
perform
determin
efficaci
asthma
rhiniti
patient
howev
studi
perform
compar
singl
mix
allergen
immunotherapi
doubl
blind
manner
carri
doubl
blind
placebo
control
trial
assess
efficaci
singl
mix
allergen
immunotherapi
base
variou
clinicoimmunlog
paramet
method
onehundr
allerg
patient
screen
histori
skin
test
specif
ige
level
sixti
patient
fulfil
criteria
studi
divid
randomli
two
group
activesingl
allergen
b
activemultipl
allergen
c
placebo
contain
patient
singl
allergen
immunotherapi
given
housefli
extract
mix
allergen
immunotherapi
insect
pollen
fungal
allergen
extract
use
vaccin
vivo
paramet
skin
test
airway
reactiv
assess
baselin
year
immunotherapi
vitro
paramet
allergen
specif
ige
also
assess
apart
symptomdrug
score
card
fill
patient
analyz
everi
month
efficaci
treatment
analyz
term
clinic
skin
test
symptom
score
airway
reactiv
immunolog
paramet
ige
result
patient
get
activ
immunotherapi
singl
well
multipl
allergen
group
show
signific
improv
pg
diseas
state
comparison
placebo
patient
skin
test
ige
valu
howev
show
nonsignific
reduct
compar
baselin
signific
improv
pg
airway
hyperreact
symptom
score
level
year
immunotherapi
activ
group
also
good
correl
observ
symptom
reduct
increas
level
paramet
nonsignific
placebo
group
group
treat
singl
extract
fewer
patient
suffer
asthmat
symptom
year
requir
less
medic
group
treat
multipl
extract
howev
differ
well
differ
clinic
immunolog
paramet
statist
signific
conclus
singl
mix
allergen
immunotherapi
year
shown
improv
clinic
immunolog
paramet
asthma
rhiniti
patient
vipul
shah
allergi
clinic
allergi
surat
india
introduct
allerg
conjunct
mani
time
ophthalmologist
nightmar
antiallerg
eye
drop
often
contain
corticosteroid
may
temporarili
bring
relief
symptom
may
bring
earli
cataract
among
side
effect
allergi
test
immunotherapi
base
test
result
cure
signific
number
patient
provid
relief
other
method
patient
allerg
conjunct
subject
modifi
skin
allergi
test
patient
also
associ
allerg
rhiniti
asthma
common
allergen
found
patient
dust
dustmit
pollen
fungi
food
base
test
result
vaccin
prepar
individu
patient
immunotherapi
given
patient
significantli
respond
convent
medicin
vaccin
review
histori
discov
miss
allergen
special
design
indigen
bperson
volumetr
air
samplerwith
safranin
stain
glycerin
coat
slide
insid
kept
patient
home
offic
surround
atmospher
result
patient
start
improv
within
month
start
immunotherapi
month
eye
drop
medicin
stop
restrict
food
item
start
one
one
month
symptom
free
last
year
patient
respond
therapi
special
design
bair
samplerbrought
great
surpris
fungi
pollen
test
previous
found
also
three
new
pollen
discov
appropri
immunotherapi
made
patient
symptom
free
conclus
allergi
test
immunotherapi
cure
allerg
conjunct
person
volumetr
air
sampler
use
tool
find
addit
allergen
case
resist
case
qualiti
life
symptom
assess
sublingu
immunotherapi
patient
housedust
mite
relat
perenni
rhiniti
definit
respond
profil
background
efficaci
safeti
sublingu
immunotherapi
slit
wellestablish
season
allerg
rhiniti
howev
fewer
data
avail
regard
perenni
allerg
rhiniti
aim
studi
assess
relationship
effect
slit
symptom
qualiti
life
chang
patient
perenni
rhiniti
method
exploratori
phase
iiib
doubleblind
placebocontrol
trial
conduct
year
capetown
area
south
africa
sixti
patient
housedust
miteinduc
allerg
rhiniti
enrol
patient
random
receiv
year
dermatophagoid
pteronyssinu
slit
solut
stallergen
antoni
franc
mainten
dose
ir
n
placebo
n
primari
efficaci
endpoint
mean
total
symptom
score
five
symptom
sneez
runni
nose
nasal
congest
ocular
rednessitch
tear
itchi
nosethroatear
limit
percentag
improv
fix
brespond
rescu
medic
intak
individu
symptom
score
qualiti
life
qolrqlq
assess
secondari
endpoint
result
intentiontotreat
itt
popul
includ
patient
mean
age
yr
mean
chang
lower
ir
group
compar
placebo
differ
reach
signific
mean
percentag
day
rescu
medic
well
individu
symptom
score
lower
ir
group
compar
placebo
percentag
good
respond
significantli
higher
activ
group
qol
percentag
good
respond
ocular
score
higher
activ
group
reach
signific
associ
good
respond
qol
good
respond
give
odd
ratio
patient
activ
group
show
good
correl
frequent
advers
event
oral
pruritu
throat
irrit
relat
sae
occur
throughout
studi
conclus
exploratori
studi
give
promis
result
twoyear
treatment
use
dermatophagoid
pteronyssinu
slit
solut
mainten
dose
ir
three
time
week
popul
brespondersmay
defin
patient
improv
clinic
symptom
qol
strongli
correl
clinic
symptom
measur
qualiti
life
treatment
allerg
rhiniti
specif
immunotherapi
identifi
best
suitabl
instrument
ulrik
vestenbaek
intern
market
hoersholm
denmark
background
qualiti
life
qol
becom
increasingli
import
clinic
outcom
paramet
also
treatment
allerg
rhiniti
ar
ar
qol
often
assess
rhinoconjunct
qol
questionnair
rqlq
diseas
specif
instrument
pharmacoeconom
evalu
gener
qol
instrument
must
use
rqlq
detect
symptom
upper
airway
due
strong
epidemiolog
relationship
ar
asthma
suggest
manifest
diseas
instrument
also
detect
symptom
lower
airway
seem
appropri
show
full
impair
qol
caus
ar
perform
pharmacoeconom
evalu
import
identifi
right
gener
instrument
use
clinic
trial
specif
immunotherapi
sit
method
qol
gain
grass
allergen
tablet
grazax
ar
assess
randomis
parallelgroup
doubleblind
placebocontrol
trial
subject
use
gener
questionnair
contain
dimens
mobil
person
care
usual
activ
paindiscomfort
anxietydepress
level
within
dimens
dimens
averag
score
calcul
test
differ
score
activ
placebo
significantli
differ
ttest
result
treatment
grass
allergen
tablet
significantli
increas
qol
compar
placebo
differ
group
mainli
due
differ
within
dimens
usual
activ
pain
discomfort
mobil
also
produc
borderlin
signific
differ
tabl
although
signific
increas
qol
subject
receiv
treatment
grass
allergen
tablet
increas
justifi
dimens
crude
instrument
might
optim
suit
detect
qol
impair
diseas
like
ar
impli
underestim
qol
result
grass
allergen
tablet
instrument
detail
focu
usual
activ
could
relev
use
within
sit
ar
futur
studi
exampl
potenti
well
suit
instrument
background
studi
compar
effect
immunotherapi
antileukotrien
main
limit
long
durat
requir
appreci
clinic
effect
immunotherapi
compar
effect
montelukast
slit
ad
standard
therapi
moder
persist
asthma
year
method
open
control
random
trial
patient
moder
asthma
rhiniti
sole
due
birch
pollen
random
receiv
either
monteukast
mk
mgday
birchslit
anallergo
florenc
itali
pollen
season
addit
formoterol
mcgfluticason
mcg
twice
daili
patient
receiv
also
salbutamol
cetirizien
rescu
medic
asthma
rhiniti
symptom
evalu
diari
card
februarymay
baselin
year
studi
inseason
nasal
eosinophil
outseason
bronchial
hyperrespons
evalu
well
result
thirtythre
adult
patient
enrol
complet
group
homogen
baselin
slit
vs
mk
e
group
total
asthma
symptom
score
baselin
year
vs
ns
vs
vs
g
timepoint
bronchial
score
vs
ns
vs
vs
group
signific
decreas
use
bronchodil
slit
group
signific
decreas
nasal
eosinophil
increas
outseason
bronchial
hyperrespons
compar
baselin
mk
group
patient
grasspollen
induc
moder
asthma
rhiniti
addit
slit
provid
greater
clinic
benefit
compar
mk
slit
respons
children
hdm
cockroach
nagendra
prasad
komar
paranjoti
kanni
bangalor
allergi
centr
allergi
bangalor
india
background
recent
time
allergi
disord
increas
therapeut
approach
incomplet
yet
promis
recent
time
slit
emerg
patient
friendli
immunotherapi
becam
good
boon
among
children
depend
symtpmat
drug
slit
becam
eye
open
physician
parent
control
allergi
symptom
slit
introduc
indian
contin
made
possibl
afford
price
show
good
respons
prevent
allergi
method
total
children
age
yr
variou
part
india
previous
diagnos
allerg
rhiniti
allerg
asthma
report
receiv
allergi
asthma
medic
took
part
studi
children
test
aeroallergen
spt
select
slit
sensit
hous
dust
mite
bodi
fecal
matter
sensit
among
insect
sensit
cockroach
result
patient
parent
report
good
respons
pharmacotherapi
drug
rel
reduc
period
time
symptom
drastic
came
increas
pefr
drop
out
fascin
altern
medicin
continu
search
relief
one
system
anoth
continu
suffer
report
frankli
said
feel
better
conclus
result
studi
provid
insight
slit
greatli
influenc
therapi
increas
qualiti
children
normal
growth
pattern
appreci
parent
background
studi
compar
effect
immunotherapi
inhal
steroid
main
limit
long
durat
requir
fulli
appreci
clinic
effect
immunotherapi
compar
effect
inhal
budesonid
vs
slit
mild
persist
asthma
year
method
open
control
random
trial
patient
mild
persist
asthma
rhiniti
sole
due
grass
pollen
random
runin
season
receiv
either
budesonid
mcgday
pollen
season
grassslit
anallergo
florenc
itali
continu
year
rescu
medic
prescrib
patient
asthma
rhiniti
symptom
evalu
diari
card
may
juli
baselin
year
studi
inseason
nasal
eosinophil
outseason
bronchial
hyperrespons
evalu
well
result
fiftyon
patient
enrol
complet
group
homogen
baselin
slit
vs
budesonid
group
total
nasal
symptom
score
baselin
year
vs
ns
vs
vs
timepoint
bronchial
score
vs
ns
vs
ns
vs
group
signific
decreas
use
bronchodil
chang
slit
group
signific
decreas
nasal
eosinophil
vs
budesonid
group
background
immunotherapi
sublingu
rout
slit
nowaday
larg
employ
current
drop
tablet
sublingu
spray
use
therapi
rout
offer
great
potenti
immunotherapi
increas
area
mucos
contact
allergen
rate
absorpt
first
trial
slitspray
done
order
valid
safeti
patient
complianc
method
patient
respiratori
allergi
allerg
rhiniti
asthma
includ
trial
inform
consent
obtain
patient
slit
spray
given
standard
schedul
vial
progress
concentr
b
c
mite
vaccin
standard
mcgml
derp
cummul
dose
end
induct
derp
around
mcg
diater
laboratori
spain
composit
slitspray
choosen
case
histori
skin
test
specif
ige
procedur
care
explain
patient
daili
applic
vial
b
c
puff
manutent
puff
daili
continu
month
booklet
instruct
given
patient
visual
scale
point
mark
second
appoint
conveni
practic
clariti
instruct
gener
evalu
side
effect
regist
dosag
vial
symptomat
therapi
allow
slitspray
result
patient
adult
f
children
f
allergen
use
dpteronyssinu
case
dfarina
lepidoglyphu
tyrophagu
blomia
cat
dog
grass
pollen
mix
parietaria
judaica
olea
plantago
advers
effect
patient
one
withdraw
advers
event
report
advers
event
report
urticaria
bad
tast
tongu
swell
nausea
withdraw
sneez
fever
wheez
rhinorrea
advers
event
disappear
prosecut
immunotherapi
evalu
patient
conveni
practic
comprehens
instruct
gener
score
scale
conclus
slitspray
new
safe
conveni
form
slit
high
dosag
quickli
attain
sideeffect
rel
rare
evalu
patient
give
good
level
appreci
larger
studi
must
done
order
confirm
result
background
perenni
conjunct
due
hous
dust
mite
frequent
form
allerg
conjunctivii
urban
environ
howev
diagnoso
remain
difficult
ophthalmologist
india
littl
work
done
field
keep
mind
tri
present
case
report
sublingu
oral
immunotherapi
method
male
patient
mr
pravin
j
patel
yr
resid
ahmedabad
suffer
perenni
allerg
conjunct
year
routin
therapi
includ
local
antiinflammatori
drop
antihistamin
etc
nt
give
long
term
relief
antigenspecif
conjunctiv
provoc
test
skin
prick
test
immunocap
rast
carri
dpteronyssinu
dfarina
mite
cpt
posit
low
dilut
allergen
farina
neg
dpteronyssinu
skin
prick
test
show
two
plu
sensit
dfarina
immunocap
rast
reveal
class
vi
high
sensit
dfarina
skin
prick
test
show
one
plu
posit
immunocap
rast
show
class
respons
dpteronyssinu
extract
given
slit
contain
dfarina
test
conjunctiv
provoc
test
skin
prick
test
confirm
posit
slit
given
twice
day
schedul
initi
dilut
form
later
increas
concentr
mainten
dose
continu
clinic
assess
skin
prick
test
immunocap
rast
carri
month
month
interv
patient
still
slit
therapi
result
observ
patient
symptomfre
end
six
month
red
swell
total
disappear
skin
prick
test
reveal
one
plu
sensit
dfarina
month
interv
immunocap
rast
show
kual
grade
iv
kual
grade
iii
end
month
respect
conclus
sublingu
oral
immunotherapi
shown
excel
clinic
respons
signific
improv
skin
prick
test
immunocap
rast
test
result
case
perenni
allerg
conjunct
due
dfarinaethi
isol
case
much
case
need
studi
safeti
toler
efficaci
sublingu
allergoid
immunotherapi
start
buildup
scheme
rational
studi
design
ongo
multicentr
portugues
studi
allerg
patient
rational
good
efficaci
safeti
toler
sublingu
monomer
allergoid
allergoid
slit
lai
lofarma
spa
milan
itali
either
tablet
drop
alreadi
shown
mani
studi
yet
far
one
studi
allergoid
slit
start
buildup
phase
achiev
shorter
time
maximum
suggest
dose
mainten
therapi
perform
allerg
patient
promis
result
object
present
studi
still
ongo
thu
confirm
broader
popul
approach
realli
use
safe
studi
design
one
hundr
thirti
patient
gather
normal
daili
clinic
practic
portugues
doctor
histori
oculorhin
andor
rhiniti
without
mildmoder
asthma
enrol
last
month
buildup
rush
scheme
involv
administr
daili
increas
dose
allergoid
slit
au
first
day
au
second
au
third
au
fourth
cumul
dose
administ
day
au
also
mainten
period
treatment
dose
kept
higher
one
normal
use
main
endpoint
studi
toler
safeti
well
treatment
efficaci
evalu
one
patient
subject
percept
taken
consider
well
variat
use
addit
drug
symptom
control
slit
result
final
result
present
end
studi
subsequ
poster
sublingu
immunotherapi
paediatr
allerg
rhiniti
woei
kang
liew
wen
chin
chiang
mona
kidon
ann
goh
jenni
tang
oh
moh
chay
ai
hui
teo
hwee
hoon
lim
ai
hui
teo
bala
abhilash
kk
hospit
paediatr
allergi
immunolog
rheumatolog
singapor
singapor
kk
hospit
paediatr
respiratori
medicin
singapor
singapor
kk
hospit
paediatr
medicin
singapor
singapor
kk
hospit
paediatr
ent
singapor
singapor
background
immunotherapi
programm
exist
kk
hospit
prior
work
commenc
late
start
sublingu
immunotherpi
slit
new
clinic
servic
method
paediatr
ar
patient
moder
persist
symptom
respond
convent
pharmacotherapi
enrol
inclus
criteria
includ
hous
dust
mite
sensitis
children
year
commit
motiv
parentspati
doctor
visit
schedul
baselin
month
monthli
interv
thereaft
ent
review
perform
exclud
anatom
lesion
allergi
symptom
score
complet
week
prior
visit
mean
score
calcul
mean
rhiniti
qualiti
life
qol
questionair
collect
monthli
interv
use
computeris
databas
allergi
laboratori
medic
usag
advers
event
document
file
diari
provid
hous
dust
mite
allergen
extract
dermatophagoid
pteronyssinu
andor
blomia
tropicali
stallergen
stalor
use
immunotherapi
initi
per
recommend
protocol
result
patient
boy
recruit
one
year
mean
age
year
old
rang
year
moder
persist
allerg
rhiniti
concomit
allerg
conjunct
asthma
eczema
sensitis
differ
speci
hous
dust
mite
prescirb
separ
hdm
allergen
slit
improv
mean
allergi
symptom
score
patient
first
month
rang
also
reduc
mean
qol
score
though
reach
statist
signific
seriou
advers
event
anaphylaxi
slit
treatment
common
advers
reaction
sublingu
itch
transient
easili
treat
addit
complaint
mild
abdomin
discomfort
nausea
patient
urticaria
rash
patient
one
patient
deterior
pulmonari
function
cough
month
slit
requir
addit
inhal
corticosteroid
asthma
conclus
slit
safe
effect
treatment
paediatr
persist
ar
good
patientmed
team
rapport
essenti
success
programm
follow
studi
patien
pollinosi
sublingu
immunotherapi
slit
compar
subcutan
shorttimeimmunotherapi
scit
bettina
hauswald
cornelia
wahl
thoma
zahnert
univers
hospit
dresden
ent
depart
dresden
germani
univers
hospit
dresden
entdepart
dresden
germani
purpos
studi
evalu
clinic
efficaci
safeti
sublingu
immunotherapi
slit
comparison
subcutan
immunotherapi
scit
patient
allerg
rhiniti
alltogeth
evalu
immunotherapi
patient
via
inquiri
scedul
patient
treat
slit
patient
treat
scit
patient
treat
slit
experienc
greater
reduct
allerg
symptom
patient
treat
scit
therapi
reduct
antiallerg
medic
increas
qualiti
life
shown
main
advers
reaction
slit
burn
swell
mouth
base
mucosa
especi
dose
intensif
scit
local
swell
indur
inject
sight
shown
disappear
complet
within
week
last
inject
due
high
complianc
patient
good
result
strategi
decis
right
therapi
patient
made
regard
patient
individu
need
ailment
toler
high
dose
sublingu
immunotherapi
pollen
extract
administ
rush
ultrarush
schedul
borja
madariaga
cruz
alberto
ngel
ferrer
antonio
vigaray
bial
stegui
r
depart
bilbao
spain
hospit
vega
baja
allergi
depart
orihuela
spain
hospit
virgen
del
camino
allergi
depart
pamplona
spain
alder
allergi
clinic
madrid
spain
background
high
dose
sublingu
immunotherapi
slit
demonstr
effect
altern
subcutan
immunotherapi
scit
howev
high
dose
could
lead
advers
reaction
thu
toler
everi
type
extract
ascertain
parietaria
grass
pollen
two
preval
aeroallergen
southern
european
countri
work
tri
ass
toler
p
judaica
grass
high
dose
slit
two
induct
phase
method
biolog
standard
extract
p
judaica
grass
pollen
use
prepar
vaccin
concentr
reach
monthli
accumul
dose
fold
respect
regard
convent
scit
par
j
par
j
grass
group
control
final
prepar
thirtytwo
subject
receiv
grass
slit
twenti
p
judaica
slit
rush
schedul
consist
administr
one
drop
first
day
two
second
thu
success
reach
five
drop
fifth
day
ultrarush
consist
volum
given
day
within
min
interv
advers
event
regist
grade
accord
eaaci
result
system
reaction
patient
treat
grass
vaccin
neither
patient
treat
parietaria
four
patient
treat
grass
vaccin
administ
ultrarush
schedul
show
local
reaction
induct
phase
dose
whole
period
month
eleven
patient
experienc
kind
local
reaction
itch
andor
swell
dose
three
withdraw
due
local
reaction
patient
rush
schedul
local
reaction
appear
build
dose
whole
period
local
reaction
rose
nine
dose
one
withdraw
parietaria
group
studi
due
repeat
local
reaction
conclus
high
dose
slit
vaccin
pollen
extract
show
accept
safeti
profil
administ
acceler
schedul
short
term
efficaci
sublingu
spray
immunotherapi
ag
palmacarlo
clinic
allergi
immunolog
center
caic
allergolog
lisbon
portug
background
last
year
sublingu
immunotherapi
slit
gain
increas
popular
least
europ
allergen
produc
laboratori
launch
sublingu
drop
sublingu
spray
larger
mucos
contact
drop
tablet
increas
also
rate
absorpt
therefor
method
dispens
drug
allergen
also
appli
slit
efficaci
techniqu
must
assay
method
patient
respiratori
allergi
allerg
rhiniti
asthma
allerg
rhiniti
asthma
syndrom
includ
trial
inform
consent
obtain
patient
slit
spray
given
standard
schedul
vial
progress
concentr
b
c
mite
vaccin
standard
mcgml
derp
mcgml
cummul
dose
end
induct
derp
around
mcg
diater
laboratori
spain
composit
slitspray
chosen
case
clinic
histori
skin
test
specif
ige
children
less
year
halfconcentr
slitspray
employ
procedur
care
explain
patient
daili
applic
vial
b
c
puff
day
vial
manutent
dosag
puff
daili
dosag
attain
day
continu
month
booklet
instruct
given
patient
visual
scale
point
regist
second
appoint
evalu
facil
conveni
practic
clariti
instruct
gener
evalu
treatment
side
effect
regist
patient
dosag
symptomat
therapi
allow
trial
antihistamin
nasal
steroid
formoterolbudesonid
necessari
result
shortterm
efficaci
immunotherapi
good
patient
either
hous
dust
mite
allergi
pollen
evalu
patient
give
visual
scale
averag
point
medic
evalu
good
good
result
patient
even
patient
treat
pollen
season
patient
withdraw
trial
due
tongu
swell
nauseou
state
slit
spray
effect
gener
well
toler
conveni
patient
larger
seri
slitspray
must
evalu
order
confirm
preliminari
result
sublingu
immunotherapi
canova
homeopath
formul
dr
tripathi
dm
allergi
clinic
allergi
mumbai
india
rational
clinic
efficaci
sublingu
immunotherapi
establish
use
allergen
extract
studi
use
plant
extract
canova
homeopath
formul
consist
aqueou
extract
aconitum
nepellu
arsenicum
album
bryonia
alba
thuja
occidentali
use
immunomodul
along
subcutan
immunotherapi
patient
suffer
differ
allerg
disord
method
multi
centr
studi
subject
select
sensit
variou
allergen
confirm
skin
prick
test
undergo
allergen
specif
immunotherapi
cours
subject
advis
sublingu
immunotherapi
canova
along
subcutan
immunotherapi
sit
group
administ
sit
compar
result
result
relev
side
effect
observ
subject
undergon
sublingu
immunotherapi
canova
howev
signific
reduct
clinic
score
nasal
obstruct
sneez
nasal
itch
cough
group
comparison
subject
sit
conclus
canova
homeopath
formul
could
use
adjuv
allergen
immunotherapi
treatment
allerg
rhiniti
allerg
asthma
etc
administr
sit
togeth
immunomodul
canova
may
facilit
safe
effect
immunotherapi
aim
evalu
efficaci
sit
patient
sar
select
patient
ragwe
sensit
patient
divid
two
group
patient
group
treat
modifi
sit
nadna
salt
patient
group
sit
allergen
placebo
dilut
method
microscopi
nasal
smear
elisa
blood
test
skin
prick
test
intraderm
test
immunolog
examin
test
result
rel
group
valu
mtm
hladr
nst
iga
igmigg
ige
group
treat
combin
sublingu
intranas
mucos
sit
use
allergen
dilut
begin
dose
daili
given
dose
time
per
week
follow
dose
one
week
dose
pure
allergen
reach
maintain
dose
given
one
month
result
stop
treatment
period
season
manifest
examin
patient
compar
result
turn
patient
overcam
therapi
better
group
case
nasal
congest
ocular
irrit
treatment
group
patient
group
case
system
reaction
fix
averag
number
eosinophil
cell
nasal
smear
period
season
manifest
less
patient
group
group
one
patient
group
note
sever
symptom
need
addit
medic
less
previou
year
patient
second
group
notic
major
chang
immun
system
test
show
chang
toward
respons
conclus
specul
posit
chang
immun
system
patient
group
could
respons
lymphoid
tissu
modifi
allergen
stimul
sit
antiinflammatori
effect
lead
better
overcom
treatment
show
benefit
use
modifi
allergen
sit
nadna
salt
metanalisi
efficaci
sublingu
immunotherapi
asthma
pediatr
patient
year
age
martin
penago
giovanni
passalacqua
enrico
compalati
carlo
baenacagnani
socorro
orozco
alvaro
pedroza
giorgio
walter
canonica
background
recent
studi
document
efficaci
safeti
sublingu
immunotherapi
slit
patient
rhiniti
valu
treatment
asthma
still
debat
evalu
efficaci
slit
treatment
allerg
asthma
children
metaanalysi
random
doubleblind
placebocontrol
dbpc
clinic
trial
method
electron
databas
search
may
random
dbpc
trial
assess
slit
pediatr
asthma
effect
primari
outcom
symptom
score
concomit
use
rescu
medic
calcul
standard
mean
differ
smd
use
randomeffect
model
revman
program
use
perform
metaanalysi
follow
recommend
cochran
collabor
quorum
statement
result
seventi
three
articl
identifi
review
nine
studi
publish
fulfil
select
criteria
patient
final
assess
includ
analysi
two
hundr
thirti
two
patient
receiv
slit
placebo
result
present
analysi
demonstr
relev
heterogen
due
wide
differ
score
system
overal
signific
reduct
symptom
smd
ci
p
medic
use
smd
ci
p
follow
slit
conclus
slit
standard
extract
reduc
symptom
score
rescu
medic
use
children
allerg
asthma
compar
placebo
suzan
hosni
ainshamsunivers
immunotherapi
cairo
egypt
background
assess
clinic
efficaci
safeti
local
nasal
immunotherapi
compar
rout
immunotherapi
allerg
rhiniti
patient
methodolog
patient
egyptian
governor
includ
studi
result
skin
test
show
signific
improv
local
nasal
immunotherapi
well
blood
nasal
sputum
eosinophilia
improv
also
totel
ige
nasal
symptom
local
nasal
immunotherapi
conclus
local
nasal
immunotherapi
show
good
efficaci
safeti
conveni
allergen
deliveri
pt
allerg
rhiniti
also
simplifi
self
adminstr
method
reduct
local
nasal
symptom
efficaci
safeti
sublingu
immunotherapi
high
dose
blomia
tropicali
extract
children
allerg
respiratori
diseas
comparison
studi
drug
bashir
omarje
bernard
tanguy
ahmad
zaidou
centr
hospitali
departement
servic
de
maladi
respiratoir
saint
deni
reunion
background
sublingu
immunotherapi
slit
might
becom
viabl
altern
drug
treatment
airway
allergi
aim
studi
evalu
pediatr
popul
monosensit
blomia
tropicali
mite
clinic
efficaci
safeti
high
dose
slit
comparison
drug
treatment
antihistamin
plu
agonist
method
male
femal
mean
age
year
rang
year
includ
studi
treat
patient
sever
persist
asthma
poliallergi
vernal
conjunct
exclud
weekinduct
period
patient
kept
daili
extract
dosag
drop
irml
anoth
week
cumul
dose
came
ir
clinic
efficaci
assess
use
symptom
medic
score
result
gradual
reduct
daili
rhinitisasthma
score
observ
slit
group
p
g
patient
necessari
employ
antihistamin
salbutamol
also
symptom
score
statist
lower
p
g
clinic
efficaci
higher
patient
mildmoder
persist
asthma
patient
show
local
system
side
effect
relev
local
advers
reaction
oral
pruritu
gingiv
aphtha
conclus
studi
patient
singl
sensit
blomia
tropicali
allergen
suffer
allerg
respiratori
diseas
slit
improv
allerg
symptom
greater
extent
drug
treatment
slit
even
ultrahigh
dose
safe
well
toler
immunolog
character
recombin
lactobacillu
plantarum
express
major
allergen
protein
lm
liew
ch
huang
sv
seow
ying
ding
hm
wen
ic
kuo
ky
chua
nation
univers
singapor
depart
peadiatr
singapor
singapor
star
singapor
institut
clinic
scienc
singapor
singapor
background
sensit
blomia
tropicali
bt
account
incid
mite
allergi
tropic
region
major
bt
allergen
recent
year
numer
studi
suggest
recombin
probiot
could
effect
primari
prevent
manag
allerg
diseas
long
term
object
studi
develop
recombin
lactobacilli
express
dust
mite
allergen
clinic
applic
method
gene
insert
express
vector
contain
strong
induc
promot
p
orfx
lactobacillu
plantarum
electrotransform
vector
carri
gene
design
murin
bone
marrowderiv
dendrit
cell
bmdc
puls
heatkil
overnight
cell
surfac
molecul
express
cytokin
product
pulseddc
examin
flow
cytometri
elisa
antigen
present
function
puls
bmdc
analys
cocultur
cell
line
vivo
studi
perform
mice
fed
live
three
consecut
day
per
week
three
week
durat
sera
splenic
cultur
supernat
collect
antibodi
cytokin
analysi
elisa
result
high
level
recombin
express
achiev
upon
induct
use
sakacin
p
induc
peptid
hour
induct
approxim
protein
express
cfu
live
bmdc
show
upregul
mhcii
product
tnfalpha
dc
capabl
induc
cell
prolifer
suppress
cytokin
product
cell
contrast
wildtypelppuls
dc
presenc
exogen
bt
protein
induc
cell
prolifer
cytokin
product
cell
vivo
studi
show
splenocyt
mice
fed
live
produc
infgamma
tnfalpha
upon
stimul
protein
fed
mice
produc
detect
level
conclus
recombin
lactobacilli
express
allergen
potenti
use
modul
allergenspecif
cell
studi
requir
assess
applic
prevent
treatment
allerg
diseas
role
allergen
specif
immunotherapi
allerg
bronchial
asthma
due
sorghum
vulgar
pollen
sanjay
pawar
shriratna
intens
care
hospit
chest
medicin
karad
satara
mah
india
introduct
immunotherapi
specif
allergi
extens
use
definit
therapi
bronchial
asthma
suppos
diseas
modifi
treatment
area
sorghum
vulgar
crop
extens
cultiv
lot
mani
patient
allerg
manifest
pollin
aim
find
role
sorghum
vulgar
pollen
causat
bronchial
asthma
refer
pulmonari
function
test
also
studi
effect
allergen
specif
immunotherapi
comparison
pharmacotherapi
methodolog
prospect
compar
cohort
studi
plan
sorghum
vulgar
pollen
collect
analyz
sv
pollen
sd
page
electrophoresi
elisa
inhibit
assay
done
kda
protein
separ
sv
extract
highli
immun
reactiv
requir
approxim
ng
protein
inhibit
specif
ige
bind
asthma
immunoblot
identifi
allergen
brand
protein
mw
kda
recogn
serum
sampl
sv
pollen
sensit
patient
skin
test
done
modifi
skin
prick
test
techniqu
histamin
diphosph
use
posit
control
buffer
salin
use
neg
control
test
perform
forearm
immunotherapi
extract
given
subcutan
rout
effect
immunotherapi
studi
patient
result
short
term
improv
clinic
symptom
pulmonari
function
test
peft
fvc
observ
eleven
percent
patient
show
improv
immunotherapi
pharmacotherapi
long
term
improv
observ
immunotherapi
pharmacotherapi
conclus
mw
kda
protein
recogn
sorghum
vulgar
sensit
patient
allergen
specif
immunotherapi
help
long
term
manag
allerg
bronchial
asthma
due
sorghum
vulgar
pollen
antigen
predict
melittin
approach
fragment
base
peptid
drug
develop
api
dorsata
virendra
gomas
ganesh
vankhed
depart
bioinformat
mgm
colleg
comput
scienc
inform
technolog
nand
ms
india
bioinformat
nand
india
depart
zoolog
sant
gadg
baba
amravati
univers
zoolog
amravati
india
bee
venom
use
treat
wide
varieti
condit
acut
tendon
chronic
back
pain
rheumatoid
arthriti
ra
assay
found
peptid
nonam
melittin
protein
api
dorsata
use
select
use
ration
vaccin
design
increas
understand
role
immun
system
allerg
reaction
develop
mhc
peptid
binder
predict
eleg
machin
learn
techniqu
support
vector
machin
svm
method
use
antigen
epitop
melittin
protein
dorsata
import
determin
protect
rheumatoid
arthriti
knowledg
immun
respons
protein
antigen
progress
becam
clear
whole
protein
necessari
rais
immun
respons
small
peptid
fragment
protein
call
antigen
determin
epitop
suffici
elicit
desir
immun
respons
also
found
peptid
nonam
set
align
peptid
known
bind
given
major
histocompat
complex
mhc
molecul
predictor
mhcpeptid
bind
mhcii
molecul
bind
peptid
similar
yet
differ
mode
align
mhciiligand
obtain
consist
bind
mode
peptid
mhc
class
mean
increas
affin
mhc
bind
peptid
may
result
enhanc
immunogen
melittin
protein
tertiapin
neurotoxin
honeybe
venom
interact
specif
calmodulin
presenc
antigen
epitop
tertiapin
protein
api
mellifera
honey
bee
import
determin
site
protect
disord
assay
found
peptid
nonam
tertiapin
protein
use
select
use
ration
vaccin
design
increas
understand
role
immun
system
infecti
diseas
develop
mhc
peptid
binder
predict
eleg
machin
learn
techniqu
support
vector
machin
svm
method
use
svm
train
binari
input
singl
amino
acid
sequenc
analysi
predict
bind
affin
tertiapin
protein
amino
acid
found
mhciiiab
peptid
region
optim
score
mhciiiad
peptid
region
optim
score
peptid
region
optim
score
peptid
region
optim
score
repres
predict
binder
tertiapin
api
mellifera
protein
peptid
nonam
set
align
peptid
known
bind
given
major
histocompat
complex
mhc
molecul
predictor
mhcpeptid
bind
mhcii
molecul
bind
peptid
background
indic
specif
vaccin
patient
hymenoptera
allergi
concomit
mastocytosi
still
matter
debat
sinc
sever
advers
reaction
describ
method
treat
immunotherapi
patient
system
mastocytosi
posit
bone
marrow
biopsi
elev
serum
tryptas
also
posit
skin
biopsi
urticaria
pigmentosa
patient
male
mean
age
year
sever
advers
reaction
follow
hymenoptera
sting
grade
iv
accord
mueller
one
allerg
bee
polist
dominulu
jellowjacket
vaccin
slowinduct
protocol
induct
phase
result
one
patient
system
urticaria
updos
phase
easili
control
slow
escal
give
antihistamin
premed
advers
event
record
mainten
phase
mcg
venom
nine
patient
restung
mainten
five
mild
local
reaction
two
stung
differ
insect
without
reaction
two
grade
iii
reaction
subject
mainten
escal
mcg
rest
reaction
conclus
despit
rel
rariti
system
mastocytosi
hymenoptera
venom
hypersensit
provok
life
threaten
reaction
patient
base
experi
specif
immunotherapi
slow
induct
safe
lead
relev
although
complet
clinic
improv
key
word
system
mastocytosi
hymenoptera
allergi
specif
immunotherapi
modifi
latex
hevein
hev
b
retain
lymphocyt
prolifer
respons
rational
design
hypoallergen
hev
b
peptid
chang
cystein
residu
serin
residu
goal
produc
standard
specif
immunotherapi
reagent
method
sera
latex
allerg
patient
confirm
ige
reactiv
mbprhev
b
test
ige
bind
capac
modifi
hevein
peptid
elisa
balbc
mice
vaccin
either
modifi
hev
b
peptid
alon
coupl
tetanu
toxoid
antibodi
respons
mice
natur
hev
b
analyz
immunoblot
mbprhev
b
elisa
cytokin
product
test
spleen
cell
cultur
immun
balbc
mice
result
hev
b
peptid
show
markedli
decreas
ige
bind
latex
allerg
patient
sera
immun
modifi
hev
b
peptid
formul
induc
ab
crossreact
natur
recombin
hev
b
uncoupl
hev
b
peptid
induc
lymphocyt
prolifer
inf
cytokin
product
spleen
cell
cultur
indic
peptid
abl
induc
bias
tcell
respons
tetanu
toxoid
coupl
modifi
hev
b
peptid
reveal
high
titer
igg
mainli
subclass
mbprhev
b
conclus
ablat
allergen
retain
lymphozyt
prolifer
capac
hev
b
peptid
show
reagent
induc
immun
respons
also
direct
major
latex
allergen
hev
b
background
well
known
allergen
immunotherapi
modifi
peripher
immunoglobulin
profil
downregul
cytokin
notabl
found
cell
cell
aim
present
studi
identifi
immunolog
marker
correl
clinic
effect
among
express
pbmc
materi
method
patient
enrol
accord
follow
criteria
moderatesever
rhinoconjunct
moder
asthma
sinc
least
year
sensit
parietaria
age
year
previou
immunotherapi
oneweek
runin
period
optim
asthma
therapi
prescrib
patient
receiv
either
slit
parietaria
sliton
drug
treatment
rhiniti
control
visit
carri
week
followup
visit
qualiti
life
evalu
valid
questionnair
rhinasthma
immunolog
paramet
assess
pbmc
prolifer
specif
allergen
detect
chemokin
receptor
stimul
result
symptom
score
decreas
control
group
sinc
first
week
studi
wherea
slit
group
signific
improv
versu
baselin
seen
week
treatment
start
week
differ
total
symptom
score
two
group
qualiti
life
significantli
improv
slit
group
compar
control
week
week
slit
group
significantli
decreas
drug
dose
asthma
treatment
wherea
statist
differ
therapi
dosag
seen
control
group
week
slit
group
signific
higher
use
rescu
medic
compar
control
group
week
uptak
rescu
medic
invers
trend
statist
signific
higher
intak
control
group
period
decreas
increas
treat
group
variat
becam
signific
end
studi
baselin
differ
express
conclus
studi
demonstr
efficaci
slit
compar
convent
therapi
persist
asthma
rhiniti
correl
clinic
score
seen
week
immunotherapi
treat
patient
demonstr
immunolog
shift
toward
lymphocyt
pattern
new
paradigm
vaccin
design
emerg
follow
essenti
discoveri
immunolog
develop
new
major
histocompat
complex
mhc
classi
bind
peptid
predict
tool
analyz
mhc
binder
neurotoxin
protein
buthu
eupeu
lesser
asian
scorpion
import
determin
protect
cardiovascular
disord
buthu
venom
test
vivo
anaesthet
rat
vitro
isol
cardiac
skelet
muscl
prepar
vivo
venom
caus
mark
rhythmic
fluctuat
blood
pressur
preced
cardiovascular
collaps
death
scorpion
toxin
constitut
famili
homolog
protein
exert
potent
pharmacolog
effect
potassium
sodium
ion
channel
analysi
predict
bind
affin
b
eupeu
protein
neurotoxin
amino
acid
found
fragment
peptid
region
protein
call
antigen
determin
epitop
suffici
elicit
desir
immun
respons
predict
bind
affin
normal
fractil
mhc
peptid
bind
predict
use
neural
network
train
c
termin
known
epitop
analysi
predict
mhcpeptid
bind
logtransform
valu
relat
valu
nm
unit
predict
mhc
bind
region
act
like
red
flag
antigen
specif
gener
immun
respons
neurotoxin
antigen
small
fragment
antigen
induc
immun
respons
whole
antigen
theme
implement
design
subunit
synthet
peptid
vaccin
sequenc
analysi
method
allow
potenti
drug
target
identifi
activ
site
venom
action
method
integr
predict
peptid
mhc
class
bind
proteosom
c
termin
cleavag
tap
transport
effici
background
level
allergen
specif
ige
rel
unaffect
allergen
specif
immunotherapi
sit
wherea
level
allergen
specif
igg
markedli
increas
effect
antibodi
minor
compar
major
allergen
clear
studi
antibodi
toward
bet
v
bet
v
betula
verrucosa
investig
sera
sit
treat
patient
method
specif
ige
bound
monoclon
antiig
coupl
paramagnet
bead
measur
bind
label
purifi
natur
bet
v
recombin
bet
v
respect
ige
deplet
serum
test
specif
igg
follow
incub
label
allergen
free
bound
allergen
separ
protein
g
affin
chromatographi
sera
test
immunoblot
without
absorpt
use
mg
birch
pollen
extract
per
serum
sampl
result
sera
posit
igg
ige
bet
v
sit
rel
bind
activ
igg
compar
ige
time
higher
sit
contrast
nontreat
patient
posit
ige
antibet
v
igg
antibet
v
year
sit
preval
iggand
igeantibet
v
unchang
howev
year
treatment
preval
igg
antibet
v
preval
ige
antibet
v
unchang
analys
quantit
immunoassay
contrari
observ
sera
becam
ige
anti
bet
v
posit
year
treatment
measur
immunoblot
conclus
domin
bind
activ
bet
v
bet
v
sera
birch
pollen
allerg
patient
sit
resid
igg
fraction
prolong
sit
treatment
induc
igg
minor
allergen
bet
v
individu
new
ige
reactiv
bet
v
observ
sit
patient
immunoblot
howev
result
confirm
quantit
solid
phase
immunoassay
may
possibl
indic
differ
assay
sensit
respect
denatur
insensit
epitop
induct
allergenspecif
antibodi
inhibit
ige
recognit
allergen
major
mechan
underli
allergenspecif
immunotherapi
order
develop
therapeut
antibodi
treatment
allergi
birch
relat
allergen
sourc
immun
mice
surfaceexpos
peptid
deriv
major
birch
pollen
allergen
bet
v
establish
hybridoma
secret
peptidespecif
mous
monoclon
antibodi
test
interfer
allerg
patient
ige
elisa
competit
experi
bet
v
monoclon
antibodi
inhibit
polyclon
serum
ige
reactiv
allerg
patient
bet
v
bet
v
allergen
human
describ
bet
v
monoclon
antibodi
may
use
passiv
vaccin
local
therapi
birch
pollen
allergi
differ
specif
cutan
sensit
allerg
patient
treat
dermatophagoid
pteronyssinu
depig
glutaraldehyd
polymeris
extract
nonchem
modif
treat
pharmacotherapi
magdalena
lluch
alfonso
malet
pau
amat
estrella
llama
mariela
dall
aglio
marcia
dia
casanova
miquel
allergo
centr
clinica
barcelona
spain
background
evolut
skin
sensit
one
object
tolol
evalu
efficaci
specif
immunotherapi
object
compar
evolut
cutan
sensit
allerg
patient
rhinoconjunct
without
asthma
due
hypersensit
pteronyssinu
treat
vaccin
contain
standard
extract
mite
alum
adsorb
depig
polymeryz
modifiedor
nonmodifi
extract
retard
pharmacolog
treatment
materi
method
conduct
open
control
clinic
trial
group
patient
patient
receiv
random
modifi
retard
pharmacolog
treatment
initi
washout
period
receiv
inmunotherapi
skin
prick
test
duplic
volar
surfac
forearm
use
batch
nativ
pteronyssinu
extract
mgml
vial
maximum
concentr
potenc
hepml
contain
mg
der
p
der
p
test
repeat
month
treatment
end
studi
result
express
hep
valu
quantiti
allergen
extract
produc
wheal
size
wheal
produc
histamin
hcl
result
patient
treat
modifi
prepar
need
obtain
hep
valu
mg
baselin
mg
month
treatment
mg
end
studi
group
patient
treat
retard
prepar
valu
mg
respect
control
group
experienc
increas
cutan
sensit
mg
respect
howev
differ
signific
conclus
open
control
clinic
studi
demonstr
patient
sensit
pteronyssinu
treat
specif
inmunotherapi
experienc
highli
signific
reduct
cutan
sensit
group
treat
vaccin
contain
modifi
extract
first
present
improv
month
treatment
wherea
patient
treat
retard
experienc
improv
month
patient
treat
inmunotherapi
show
reduct
specif
cutan
sensit
safeti
evalu
fast
buildup
schedul
immunotherapi
use
therapeut
vaccin
contain
depig
glutaraldehyd
polymeris
allergen
extract
alfonso
malet
magdalena
lluch
pablo
amat
estrella
llama
isabel
garcia
miquel
casanova
alilergo
centr
clinica
barcelona
spain
laboratorio
leti
l
madrid
spain
background
variou
administr
schedul
immunotherapi
report
benefici
treatment
inhal
allergi
convent
cluster
rush
use
therapeut
vaccin
contain
modifi
allergen
extract
depig
glutaraldehyd
polymeris
allergen
decreas
immunogen
maintain
allow
reach
mainten
dose
use
convent
schedul
administr
short
period
time
object
evalu
safeti
short
buildup
phase
use
hypoallergen
vaccin
contain
standardis
modifi
allergen
extract
materi
method
one
hundr
nine
patient
femal
male
mean
age
year
rhinoconjunct
andor
asthma
sensitis
mite
andor
pollen
includ
observ
cohort
studi
receiv
individualis
therapeut
vaccin
contain
depig
glutaraldehyd
polymeris
allergen
extract
patient
reach
maximum
dose
inject
vial
maximum
concentr
first
dose
first
day
ml
mainten
dose
week
follow
ml
month
toler
assess
record
side
reaction
relat
immunotherapi
classifi
accord
criteria
eaaci
result
total
number
inject
patient
reach
maximum
recommend
dose
first
week
premed
drug
use
administr
immunotherapi
eight
reaction
total
inject
record
local
system
local
reaction
consist
immedi
diamet
cm
delay
diamet
cm
one
system
reaction
grade
report
reaction
consist
slight
urticaria
resolv
treatment
antihistamin
ebastin
conclus
therapeut
vaccin
contain
chemic
modifi
extract
safe
administ
use
fast
schedul
immunotherapi
unit
reach
maximum
dose
first
week
inject
without
need
premed
andor
hospitalis
influenc
differ
applic
form
allergen
immunotherapi
level
allergen
specif
igg
antibodi
patient
grass
pollen
allergi
ctirad
andri
irena
krcmova
marcela
drahosova
yvona
hanzalkova
univers
hospit
institut
clinic
immunolog
allergolog
hradec
kralov
czech
republ
background
allergen
immunotherapi
ait
therapeut
approach
treatment
ige
mediat
allergi
target
immunopathogenet
process
allergen
could
administ
sever
applic
form
preferenti
subcutan
sublingu
difficult
task
follow
efficaci
immunomodul
aim
studi
comparison
influenc
two
differ
rout
applic
immunotherapi
serum
level
allergen
specif
igg
antibodi
method
togeth
patient
male
femal
grass
pollen
allergi
enrol
allergen
immunotherapi
subcutan
inject
phostal
stallergen
administ
patient
allergen
immunotherapi
form
sublingu
capsul
stalor
stallergen
administ
patient
patient
treat
symptomat
pollen
season
blood
sampl
collect
start
therapi
januari
month
treatment
serum
level
specif
igg
antibodi
immunodomin
allergen
timothi
grass
evalu
diagnost
kit
drfook
germani
result
signific
differ
found
group
patient
start
allergen
immunotherapi
paramet
test
statist
signific
increas
allergen
specif
igg
group
patient
one
year
therapi
year
therapi
statist
signific
increas
found
allergen
specif
group
patient
year
therapi
subcutan
group
sublingu
group
statist
significantli
higher
level
allergen
specif
igg
year
therapi
patient
treat
subcutan
form
allergen
immunotherapi
comparison
patient
treat
sublingu
form
immunotherapi
level
allergen
specif
igg
control
group
remain
without
signific
chang
conclus
subcutan
applic
allergen
immunotherapi
result
strong
increas
allergen
specif
igg
antibodi
comparison
sublingu
administr
immunotherapi
two
differ
applic
form
grass
pollen
immunotherapyth
chang
level
cytokin
ifn
month
immunotherapi
irena
krcmova
ctirad
andri
marcela
drahosova
jakub
novosad
univers
hospit
institut
clinic
immunolog
allergolog
hradec
kralov
czech
republ
background
allergen
immunotherapi
ait
therapeut
approach
treatment
ige
mediat
allergi
abl
target
immunopathogenet
process
allergen
administ
sever
applic
form
preferenti
subcutan
sublingu
rout
subcutan
sublingu
form
differenti
interact
immun
system
data
concern
comparison
two
form
applic
favour
studi
clinic
efficaci
laboratori
studi
aim
studi
comparison
influenc
two
differ
type
ait
serum
level
cytokin
ifn
method
togeth
patient
grass
pollen
allergi
enrol
subcutan
ait
phostal
administ
patient
sublingu
ait
stalor
irml
administ
patient
patient
treat
symptomat
blood
sampl
collect
start
studi
januari
month
serum
level
cytokin
ifn
evalu
diagnost
kit
quantikin
rd
result
signific
differ
found
group
studi
signific
increas
ifn
group
subcutan
ait
month
therapi
p
month
p
demonstr
signific
decreas
group
subcutan
ait
month
therapi
p
group
ait
month
pg
compar
control
group
subcutan
ait
group
reach
signific
conclus
subcutan
sublingu
applic
ait
month
result
signific
decreas
group
decreas
subcutan
group
manifest
earlier
month
expect
increas
ifn
signific
group
subcutan
ait
immunomodul
subcutan
ait
seem
stronger
sublingu
ait
especi
first
year
studi
continu
sublingu
ait
need
higher
concentr
allergen
irml
mainten
dosag
doubl
blind
placebo
control
trial
sublingu
monomer
allergoid
grass
pollen
allergi
ag
palmacarlo
brancoferreira
al
pregal
santo
ml
palmacarlo
clinic
allergi
immunolog
center
caic
allergolog
lisbon
portug
background
doubl
blind
placebo
control
trial
allergi
vaccin
consid
better
method
confirm
efficaci
assay
sublingu
monomer
allergoid
tablet
done
patient
allerg
grass
pollen
year
monomer
allergoid
obtain
carbamyl
amino
group
lysin
allergen
protein
method
rhinit
patient
allerg
grass
pollen
confirm
clinic
histori
skin
prick
test
specif
ige
includ
trial
patient
random
placebo
activ
vaccin
given
sublingu
tablet
administ
sublingu
swallow
method
lai
lofarma
milano
itali
tradit
posolog
scheme
use
start
low
dose
increas
progress
cours
week
grass
pollen
season
enrol
patient
preseason
follow
season
visit
may
end
year
visit
octob
patient
follow
consecut
year
nasal
provoc
test
allergen
includ
vaccin
done
treatment
year
treatment
symptom
score
regist
challeng
use
nasal
steroid
rescu
author
rhinorrea
sneez
conjunct
symptom
score
eventu
side
effect
pharmaceut
score
regist
patient
inform
consent
obtain
patient
result
result
evalu
year
treatment
vaccin
placebo
score
rhinorrea
sneez
conjunct
significantli
decreas
second
wear
treatment
first
second
year
treatment
score
placebo
chang
activ
vaccin
rhinorrea
sneez
conjunct
significantli
decreas
symptomat
score
nasal
challeng
decreas
year
treatment
nasal
steroid
consumpt
significantli
decreas
activ
group
may
june
year
treatment
two
light
local
advers
event
report
activ
group
none
placebo
conclus
preseason
treatment
sublingu
monomer
grass
pollen
allergoid
tablet
improv
rhinorrea
sneez
conjunct
reduc
steroid
consumpt
toler
optim
phleum
pratens
alon
suffici
allergen
specif
immunotherapi
allergi
pooidea
grass
pollen
charlott
hejl
h
ipsen
j
n
larsen
n
johansen
vaccin
research
hlrsholm
denmark
scientif
affair
hlrsholm
denmark
serolog
research
hlrsholm
denmark
background
grass
famili
poal
contain
speci
divid
subfamili
base
taxonomi
one
larger
subfamili
pooidea
subfamili
also
denomin
temperatur
pastur
grass
spite
larg
number
grass
speci
grass
pollen
allerg
patient
ige
show
high
degre
crossreact
pooidea
grass
speci
current
immunotherapi
grass
pollen
allergi
often
perform
mixtur
grass
speci
howev
high
clinic
efficaci
grass
pollen
immunotherapi
sit
use
phleum
pratens
phl
p
alon
demonstr
sever
studi
aim
studi
investig
antibodi
crossreact
toward
phl
p
grass
pollen
extract
mix
method
amount
sige
react
phl
p
pollen
extract
four
differ
grass
pollen
extract
mix
determin
sera
grass
pollen
allerg
patient
capac
phl
p
inhibit
reaction
grass
pollen
allerg
patient
ige
toward
four
grass
pollen
extract
mix
perform
use
excess
inhibitori
concentr
nonlabel
phl
p
extract
four
mix
compris
pooidea
grass
pollen
extract
speci
phl
p
sit
induc
measur
phl
p
pollen
extract
extract
nine
individu
pooidea
grass
speci
four
grass
pollen
extract
mix
allergen
specif
antibodi
assay
perform
use
advia
centaur
solid
phase
immunoassay
correl
reaction
ige
toward
phl
p
four
grass
pollen
extract
mix
irrespect
number
includ
mix
statist
signific
spearman
phl
p
capac
inhibit
reaction
patient
specif
ige
four
grass
pollen
extract
mix
indic
high
degre
crossreact
patient
ige
sit
phleum
pratens
induc
exhibit
statist
signific
correl
spearman
reaction
individu
nine
pooidea
grass
pollen
extract
four
grass
pollen
extract
mix
thu
induc
sit
phl
p
crossreact
extens
singl
mix
grass
pollen
extract
conclus
immunochem
clinic
data
togeth
support
conclus
phl
p
alon
effect
allergen
specif
immunotherapi
allergi
pooidea
grass
pollen
mix
singl
speci
fro
pooidea
famili
background
clinic
efficaci
subcutan
immunotherapi
sit
treatment
allerg
respiratori
diseas
well
document
main
drawback
risk
system
reaction
sr
prospect
studi
evalu
safeti
sit
standard
extract
real
life
patient
allerg
rhiniti
andor
asthma
method
januari
june
total
patient
male
mean
age
year
rang
refer
allergi
unit
prescrib
sit
respiratori
diseas
patient
season
perenni
rhiniti
asthma
without
rhiniti
allergen
extract
standard
biolog
method
stallergen
patient
treat
accord
tradit
week
schedul
wherea
underw
cluster
protocol
week
patient
treat
grass
birch
parietaria
mite
system
reaction
sr
categor
immedi
sr
occur
within
minut
late
minut
grade
four
level
sever
accord
eeaci
immunotherapi
posit
paper
symptom
non
specif
symptom
probabl
non
igemedi
rhinitisasthma
respond
adequ
treatment
non
lifethreaten
sr
eg
urticaria
angioedema
sever
asthma
anaphylact
shock
result
total
inject
administ
patient
sr
regist
shown
tabl
divid
accord
two
phase
schedul
buildup
mainten
result
sr
patient
inject
occur
buildup
phase
thye
mainten
sr
frequent
femal
grass
pollen
frequent
respons
sr
allergen
parietaria
tree
mite
sr
grade
case
grade
case
grade
case
grade
case
epinephrin
administ
sever
reaction
occur
within
minut
inject
late
reaction
less
common
sr
conclus
properli
use
sit
low
accept
rate
side
effect
popul
femal
gender
buildup
phase
two
main
risk
factor
keyword
specif
immunotherapi
inject
system
reaction
adjuv
effect
heatkil
wildtyp
lactobacillu
casei
allergen
immunotherapi
allergi
mous
model
lay
hong
lim
chiung
hui
huang
hai
yan
li
yuan
kun
lee
bee
wah
lee
kaw
yan
chua
nation
univers
singapor
paediatr
singapor
singapor
nation
univers
singapor
microbiolog
singapor
singapor
background
aim
probiot
like
lactobacilli
use
manag
strategi
allergi
diseas
effect
specif
immunotherapi
previous
studi
human
aim
evalu
possibl
adjuv
effect
probiot
allergenspecif
immunotherapi
allergi
mous
model
method
mice
presensit
epicutan
patch
recombin
der
p
subsequ
oral
fed
either
heatkil
wildtyp
l
casei
lc
nahco
buffer
five
week
per
group
mice
receiv
two
subcutan
sc
immun
der
p
mimic
allergen
immunotherapi
follow
aerosol
challeng
der
p
week
later
result
lc
fed
der
p
sensit
mice
show
significantli
lower
der
p
specificig
sc
immun
airway
challeng
compar
nahco
buffer
control
group
spleen
tcell
mesenter
lymph
node
mln
cell
lc
fed
mice
show
suppress
proinflammatori
tnf
cytokin
increas
tgf
product
mln
cell
addit
lcfed
mice
control
show
attenu
lung
inflamm
demonstr
significantli
reduc
lung
histopatholog
total
cell
count
balf
result
suggest
combin
administr
heatkil
l
casei
allergen
could
effect
downregul
preexist
allerg
respons
conclus
probiot
l
casei
intrins
adjuvanc
immunomodulatori
properti
could
potenti
exploit
improv
efficaci
allergenspecif
immunotherapi
allerg
respiratori
diseas
vaccin
recombin
proder
p
produc
ecoli
prevent
develop
hous
dust
mite
allergi
david
walgraff
christel
marchand
lida
garcia
michel
vandenbranden
alain
jacquet
libr
de
bruxel
ibmm
laboratori
experiment
allergi
goss
belgium
universit
libr
de
bruxel
sfmb
bruxel
belgium
recent
data
indic
recombin
proder
p
enzymat
inact
der
p
precursor
form
produc
ecoli
display
low
ige
bind
capac
retain
tcell
reactiv
confirm
hypoallergen
charact
present
studi
investig
prophylact
potenti
proder
p
produc
ecoli
der
p
sensit
murin
model
gel
fitrat
chromatographi
well
ftir
spectroscopi
demonstr
proder
p
produc
ecoli
aggreg
contain
higher
sheet
content
proder
p
produc
wildtyp
ppastori
wildtyp
cho
cell
conform
chang
could
like
explain
drastic
reduct
vitro
ige
bind
activ
toward
human
allerg
sera
compar
proder
p
produc
cho
vaccin
nabv
mice
proder
p
coli
adjuv
alum
induc
mix
immun
respons
character
weak
product
specif
antibodi
absenc
specif
ige
titer
unpredict
drastic
reduct
specif
ige
titer
maintain
mice
sensit
natur
der
p
subsequ
challeng
aerosol
hous
dust
mite
extract
moreov
bia
confirm
vaccin
proder
p
coli
induc
secret
ifn
wherea
control
allerg
group
secret
proder
p
coli
prevent
develop
airway
eosinophilia
follow
hous
dust
mite
extract
challeng
immun
mice
furthermor
increas
airway
sensit
inhal
methacholin
reduc
prophylact
vaccin
taken
togeth
result
indic
proder
p
coli
could
repres
hypoallergen
suitabl
prevent
hous
dust
mite
allergi
toler
doseincreas
phase
specif
immunotherapi
standard
housedust
mite
extract
asthmat
children
li
xiang
hongyan
zhang
jimei
zhao
jianxin
kunl
shen
beje
children
hospit
affili
capit
univers
medic
scienc
center
asthma
beij
china
background
determin
toler
doseincreas
phase
specif
immunotherapi
sit
standard
housedust
mite
extract
asthmat
children
method
subcutan
sit
standard
housedust
mite
extract
administr
asthmat
children
allergi
housedust
mite
dermatophagoid
pteronyssinu
monitor
immedi
late
sideeffect
allergen
inject
doseincreas
phase
immunotherapi
treatment
lung
function
test
done
minut
inject
everi
patient
result
patient
complet
total
inject
doseincreas
period
inject
inject
caus
immedi
sideeffect
within
less
minut
inject
patien
patient
sideeffect
earli
reaction
mild
local
reaction
diamet
episod
mild
asthma
occur
patien
patient
report
late
sideeffect
inject
minut
inject
late
side
effect
occur
patien
mild
system
reaction
includ
asthma
allerg
rhiniti
allerg
conjunct
allerg
dermat
system
reaction
respond
well
ordinari
treatment
other
late
side
effect
mild
local
reaction
moder
local
reaction
diamet
chang
rate
lung
function
paramet
inject
show
wide
rang
varianc
pef
fef
fef
fef
mmef
signific
differ
among
inject
doseincreas
period
conclus
subcutan
sit
standard
housedust
mite
extract
show
good
toler
asthmat
children
major
local
reaction
system
reaction
mild
respond
well
ordinari
treatment
adjust
doseincreas
schedul
signific
chang
lung
function
observ
doseincreas
phase
sit
patient
simpl
pereni
bronchial
asthma
steroiddepend
bronchial
asthma
studi
immunotherapi
hous
dust
mite
dfarinepteronyssinu
alleregn
vaccin
three
year
cours
specif
immunotherapi
sit
patient
pereni
bronchial
asthma
steroiddepend
asthma
show
signific
reduct
amount
drug
intak
attack
treatment
purpos
studi
investig
long
term
effect
sever
attack
worst
month
well
amount
drug
intak
ic
oral
steroid
pereni
steroiddepend
asthma
even
discontinu
dust
mite
immunotherapi
inclus
criteria
studi
patient
suffer
pereni
bronchial
asthma
sensit
hous
dust
mite
skin
prick
test
eosiniphilia
specif
ige
patient
standard
control
symtomat
medic
total
patient
follow
three
year
immunotherapi
three
year
immuntherapi
sit
treat
group
significantli
less
intak
ic
bd
patient
without
immunotherapi
found
attack
pereni
bronchial
asthma
steroid
depend
asthma
sever
diseas
found
decreas
immunotherapi
result
studi
reveal
specif
immunotherapi
three
year
standardis
allergen
extract
hous
dust
mite
result
decreas
severityand
intens
attack
pereni
steroiddepend
bronchial
asthma
discontinu
sit
steroiddepen
astma
patient
revert
back
effect
immunotherapi
symptom
pefr
spiromeri
patient
allerg
asthma
hous
dust
mite
hdm
inhal
steroid
therapi
gobinda
da
shahe
suhrawardi
hospit
allergi
clinic
immunolog
dhaka
bangladesh
present
studi
design
investig
effect
immunotherapi
extract
dermatophagoid
pteronyssinu
alkabello
spain
credisol
india
month
period
patient
allerg
asthma
hous
dust
mite
includ
patient
mean
age
year
treat
combin
inhal
corticosteroid
ic
comparison
anoth
mean
age
year
treat
ic
alon
evalu
symptom
score
salbutamol
use
peak
expiratori
flow
rate
pefr
spirometri
month
therapi
ic
month
ic
interrupt
two
kind
treatment
effici
compar
relat
symptom
score
salbutamol
use
morn
pefr
fvc
patient
treat
ic
faster
improv
symptom
score
pefr
variabl
interrupt
ic
month
therapi
link
impair
end
point
pronounc
patient
previous
treat
ic
find
suggest
select
asthmat
patient
allerg
hous
dust
mite
associ
ic
effect
therapi
ic
alon
lower
rate
relaps
interrupt
therapi
ic
pteronyssinu
main
sourc
hous
dust
allergen
import
etiolog
factor
allerg
respiratori
diseas
specif
allergen
vaccin
import
tool
reduc
allerg
symptom
prevent
sever
respiratori
symptom
patient
aim
studi
evalu
incid
local
system
reaction
hdm
immunotherapi
investig
group
patient
allerg
dermatophagoid
pt
age
sex
analys
includ
patient
age
show
signific
differ
divid
two
group
depend
degre
skin
reactiv
first
group
skin
reactiv
second
group
skin
reactiv
commenc
subcutan
specif
immunotherapi
accord
standard
protocol
analyz
distribut
local
system
reaction
immunotherapi
group
inject
reaction
inject
caus
local
reaction
first
group
second
group
treat
oral
antihistamin
local
ice
conclud
specif
immunotherapi
hous
dust
mite
safeti
major
reaction
local
occur
within
less
minut
inect
premed
antihistamin
import
especi
begin
immunotherapi
specif
immunotherapi
housedust
mite
patient
anisaki
allergi
advers
reaction
maria
teresa
ventura
maddalena
derasmo
roberto
armando
tummolo
augusto
arsieni
rosalba
buquicchio
univers
bari
medic
school
policlinico
depart
intern
medicin
immunolog
bari
itali
nematod
anisaki
simplex
belong
anisakida
famili
thirdstag
larva
commonli
found
entrail
muscl
mani
fish
accident
ingest
caus
clinic
disord
sensit
human
previou
studi
shown
cross
reactiv
anisaki
simplex
differ
dust
mite
speci
observ
gastrointestin
symptom
specif
immunotherapi
hous
dust
mite
patient
anisaki
sensit
patient
suffer
allerg
asthma
sensit
hous
dust
mite
develop
gastrointestin
symptom
sublingu
immunotherapi
slit
sensit
evalu
skin
prick
test
common
inhal
allergen
standard
food
extract
commerci
extract
anisaki
simplex
radioallergosorb
test
rast
specif
ige
antibodi
obtain
skin
prick
test
stp
common
inhal
allergen
posit
graminace
j
cypress
j
hous
dust
mite
j
spt
standard
food
extract
commerci
extract
anisaki
simplex
demonstr
sensit
anisaki
simplex
rast
show
specif
ige
antibodi
allergen
anisaki
simplex
moreov
import
underlin
allergen
crossreact
anisaki
simplex
nematod
arthropod
well
known
recent
work
johansson
group
underlin
associ
sensit
anisaki
simplex
four
differ
dust
mite
speci
acaru
siro
lepidoglyphu
destructor
tyrophagu
putrescentia
dermatophagoid
pteronyssinu
studi
serum
sampl
collect
subject
allerg
dust
mite
analyz
ige
anisaki
simplex
cap
feia
immunoblot
inhibit
found
patient
detect
level
ige
antibodi
anisaki
simplex
cap
feia
inhibit
four
mite
extract
inhibit
variou
degre
ige
respons
anisaki
simplex
solid
phase
light
find
possibl
hypothes
immunotherapi
dustmit
could
pose
unintent
challeng
patient
gastroallerg
anisakiasi
due
crossreact
anisaki
simplex
antigen
even
observ
advers
reaction
sublingu
immunotherapi
dust
mite
patient
sensit
anisaki
need
data
suggest
oral
treatment
discourag
patient
doubleblind
placebocontrol
studi
treatment
depig
glutaraldehydepolymeris
extract
dermatophagoid
pteronyssinu
farina
improv
skin
sensit
background
high
preval
asthma
canari
island
spain
asthmat
patient
sensitis
hous
dust
mite
exposur
mite
allergen
constant
level
regularli
exceed
mcg
der
p
per
gram
dust
immunotherapi
use
depig
glutaraldehyd
modifi
allergen
vaccin
produc
clinic
benefit
evalu
improv
shock
organ
symptom
medic
score
qualiti
life
skin
sensit
object
evalu
evolut
skin
sensit
group
asthmat
patient
sensitis
mite
doubleblind
placebocontrol
studi
year
durat
materi
method
sixtyfour
patient
includ
finish
studi
activ
group
placebo
nativ
extract
pteronyssinu
contain
mcg
der
p
mcg
der
p
farina
extract
contain
mcg
der
f
per
mg
freezedri
extract
due
polymeris
process
der
p
der
p
der
f
detect
modifi
extract
patient
skin
test
baselin
end
duplic
volar
surfac
forearm
use
batch
nativ
pteronyssinu
extract
mgml
vial
maximum
concentr
potenc
hepml
contain
mg
der
p
ml
der
p
glycerin
salin
solut
histamin
hcl
mg
ml
use
neg
posit
control
respect
skin
reaction
record
minut
result
express
hep
valu
wilcoxon
test
use
compar
result
result
patient
treat
modifi
allergen
extract
receiv
total
accumul
dose
mcg
freezedri
modifi
materi
pteronyssinu
mcg
farina
activ
group
show
signific
differ
baselin
wilcoxon
wherea
placebo
group
activ
group
need
end
studi
median
mcg
allergen
extract
achiev
valu
hep
wherea
placebo
group
figur
conclus
doubleblind
placebocontrol
trial
demonstr
treatment
mite
allerg
asthmat
patient
mixtur
depig
glutaraldehydepolymeris
extract
pteronyssinu
farina
induc
signific
decreas
skin
sensit
specif
immunotherapi
depig
polymer
allergen
extract
domest
mite
patient
persist
rhinoconjunct
angelika
sager
hartwig
lauter
leti
pharma
gmbh
medic
depart
witten
germani
fachkrankenhau
kloster
grafschaft
allergolog
schmallenberg
germani
background
limit
knowledg
clinic
relev
sensit
domest
mite
sa
euroglyphu
maynei
em
lepidoglyphu
destructor
ld
acaru
siro
tyrophagu
putrescentia
tp
efficaci
safeti
sit
mite
describ
patient
method
investig
patient
suffer
persist
rhinoconjunct
ic
test
specif
ige
placebo
control
nasal
challeng
test
domest
mite
allergen
patient
posit
ic
test
andor
specif
ige
posit
nasal
challeng
test
sit
initi
respect
depig
polymer
allergen
extract
patient
treat
follow
allergen
extract
either
alon
combin
month
ld
tp
em
patient
symptom
medic
consumpt
record
use
standard
questionnair
result
patient
improv
cours
sit
symptom
medic
score
reduc
parallel
patient
chang
sit
patient
lost
followup
therefor
consid
treatment
failur
also
system
reaction
mild
local
reaction
report
conclus
first
report
success
sit
euroglyphu
maynei
lepidoglyphu
destructor
acaru
siro
tyrophagu
putrescentia
treatment
efficaci
safe
background
high
preval
asthma
canari
island
spain
asthmat
patient
sensitis
hous
dust
mite
exposur
mite
allergen
constant
level
regularli
exceed
mcg
der
p
per
gram
dust
immunotherapi
use
glutaraldehyd
modifi
allergen
vaccin
demonstr
clinic
benefit
sever
studi
introduct
depigment
step
polymeris
inactiv
enzymat
activ
remov
pigment
enhanc
solubl
polym
object
evalu
clinic
efficaci
depig
polymeris
vaccin
contain
pteronyssinu
farina
patient
sensitis
mite
doubleblind
placebocontrol
trial
materi
method
fiftyon
patient
randomli
alloc
either
receiv
activ
treatment
placebo
nativ
extract
pteronyssinu
contain
mcg
der
p
mcg
der
p
farina
contain
mcg
der
f
per
mg
freezedri
extract
due
polymeris
process
der
p
der
p
der
f
detect
modifi
extract
patient
record
symptom
medic
score
diari
card
area
curv
auc
number
day
free
symptom
andor
medic
calcul
patient
valu
auc
compar
groupwis
use
mannwhitney
test
hodgeslehmann
estim
use
measur
effect
size
fisher
exact
p
valu
use
number
day
free
symptom
medic
result
patient
treat
modifi
extract
receiv
total
accumul
dose
mcg
freezedri
modifi
materi
pteronyssinu
mcg
farina
differ
auc
symptom
medic
score
group
signific
valu
hodgeslehmann
cl
cl
symptom
medic
score
respect
patient
treat
modifi
allergen
day
free
symptom
medic
fisher
exact
p
valu
conclus
doubleblind
placebocontrol
trial
demonstr
treatment
mite
allerg
asthmat
patient
mixtur
depig
polymeris
extract
pteronyssinu
farina
produc
clinic
benefit
symptom
medic
score
import
effect
size
zero
valu
includ
confid
limit
clinicoimmunolog
studi
immunotherapi
periplaneta
americana
extract
doubl
blind
placebo
control
trial
deepsikha
srivastava
shailendra
n
gaur
naveen
arora
bhanu
p
singh
institut
genom
integr
biolog
allergi
immunolog
delhi
india
vallabhbhai
patel
chest
institut
dept
respiratori
medicin
delhi
india
background
cockroach
produc
sever
potent
allergen
associ
sensit
develop
asthma
highli
suscept
symptomat
patient
allergenspecif
immunotherapi
may
benefici
data
limit
present
studi
aim
evalu
role
immunotherapi
cockroach
allerg
patient
use
standard
whole
bodi
extract
method
twenti
patient
belong
allerg
asthma
rhiniti
recruit
activ
group
placebo
group
patient
activ
group
administ
p
americana
extract
subcutan
wherea
group
receiv
placebo
inject
one
year
assess
benefit
immunotherapi
data
analyz
symptomdrug
score
airway
reactiv
immunoglobulin
ige
baselin
complet
one
year
immunotherapi
immunoblot
specif
ige
made
therapi
result
good
improv
observ
clinic
statu
patient
respect
vivo
vitro
paramet
chang
symptom
score
airway
reactiv
valu
highli
signific
comparison
baselin
valu
placebo
group
skin
test
ige
valu
show
nonsignific
reduct
immunoblot
specif
shown
develop
band
increas
densiti
year
immunotherapi
ige
blot
show
similar
pattern
band
immunotherapi
conclus
cockroach
immunotherapi
well
toler
patient
allerg
rhiniti
asthma
immunoblot
shown
correl
clinic
efficaci
immunolog
respons
question
cytokin
therapi
nosocomi
pneumonia
anna
kostyushko
elena
markelova
siberian
branch
russian
academi
medic
scienc
fareastern
scientif
centrex
research
insti
vladivostok
russian
feder
purpos
patient
hospit
pneumonia
seriou
current
observ
patient
distribut
way
introduct
immunotrop
drug
first
group
patient
receiv
recombin
dose
intraven
second
group
patient
receiv
hypoderm
introduct
dose
drug
patient
third
group
person
receiv
combin
introduct
recombin
dose
inhal
help
ultrason
inhal
simultan
hypoderm
introduct
dose
cours
treatment
consist
procedur
dynam
research
basic
cliniclaboratori
index
given
patient
result
conclus
fix
three
way
recombin
introduct
provid
posit
dynam
index
immun
background
basic
antiinflammatori
therapi
pneumonia
result
research
howev
condit
local
immunoreact
lung
recov
combin
inhal
hypoderm
introduct
patient
content
metabolit
oxid
nitrogen
glycoprotein
condens
exhal
moistur
normal
reach
similar
index
healthi
peopl
import
note
complet
regress
radiolog
index
combin
applic
recombin
inhalationli
subcutan
analysi
frequenc
rate
recombin
introduct
show
enough
singlepass
introduct
drug
reduct
index
local
immun
rate
reduct
cours
repeat
combin
way
introduct
ident
depend
graviti
condit
express
inflamm
bronchopulmonari
system
increas
frequenc
rate
recombin
introduct
time
acceler
rate
clinic
convalesc
reduct
rate
immun
index
biochem
criteria
degre
express
inflamm
respiratori
path
thu
believ
effici
combin
recombin
applic
inhal
dose
dose
subcutan
time
interv
hour
treatment
patient
seriou
hospit
pneumonia
background
diagnosi
asthma
nonasthma
critic
clinic
research
use
methacholin
challeng
test
mct
well
establish
bronchial
challeng
test
assess
airway
respons
identifi
group
patient
incorrectli
diagnos
asthmat
nonasthmat
method
screen
volunt
particip
clinic
research
asthma
provid
inform
consent
volunt
question
gener
health
asthma
symptom
medic
famili
histori
asthma
atop
statu
determin
skin
prick
test
standard
panel
aeroallergen
baselin
spirometri
perform
prior
mct
mct
conduct
follow
recognis
dose
protocol
crapo
ro
et
al
j
respir
crit
care
med
vol
pp
use
mefar
breath
activ
dosimet
volunt
consid
asthmat
commenc
lowest
methacholin
dose
mgml
continu
dose
protocol
reach
dose
obtain
min
min
postinhal
subsequ
min
rest
prior
next
dose
consid
nonasthmat
start
mct
challeng
mgml
dose
methacholin
continu
updos
highest
dose
definit
asthma
purpos
studi
mct
nonasthma
defin
complet
mct
without
attain
result
subject
screen
clinic
research
studi
claim
physician
diagnosi
asthma
confirm
mct
criteria
subject
normal
spirometri
predict
predictedconvers
volunt
report
nonasthma
symptom
methacholin
challeng
test
attain
thu
fulfil
definit
asthma
accord
criteria
conclus
diagnosi
asthma
nonasthma
base
exist
symptom
lung
function
test
physician
base
diagnosi
surprisingli
unreli
asthma
pregnanc
diagnost
method
zahra
pourpak
katayoon
bidad
hasan
haidarnejad
giti
shaiestehfar
mostafa
moin
immunolog
asthma
allergi
research
institut
immunolog
depart
tehran
islam
republ
iran
introduct
asthma
common
respiratori
disord
complic
pregnanc
repres
signific
public
health
issu
mani
occas
especi
last
trimest
due
pressur
unborn
child
patient
unabl
perform
standard
spirometri
impuls
oscillometri
techniqu
io
may
suitabl
applic
sinc
allow
assess
airway
obstruct
requir
minimum
patient
cooper
aim
aim
identifi
relationship
reson
frequenc
forc
expiratori
volum
forc
vital
capac
fvc
pregnant
women
method
asthmat
pregnant
patient
age
yr
mean
yr
spirometri
impuls
oscillometri
erich
jaeger
germani
perform
accord
standard
guidelin
manufactur
instruct
relationship
spirometr
indic
total
resist
central
resist
peripher
reactanc
reson
frequenc
fre
obtain
use
correl
regress
analysi
volum
express
litr
resist
result
mean
sd
fvc
fvc
fre
signific
correlt
fre
r
fre
r
conclus
result
suggest
impuls
oscillometri
valuabl
tool
assess
airway
obstruct
simpl
requir
minim
subject
cooper
new
field
oscillometri
applic
may
particularli
use
patient
unabl
perform
spirometri
studi
requir
determin
sensit
specif
techniqu
associ
feno
acut
exacerb
asthma
children
sunhe
choi
yeongho
rha
colleg
medicin
kyung
hee
univers
depart
pediatr
seoul
republ
korea
rational
asthma
cell
mediat
chronic
inflammatori
airway
diseas
bronchoscop
biopsi
best
method
evalu
airway
inflamm
invas
children
measur
exhal
nitric
oxid
feno
rel
simpl
noninvas
reproduc
test
detect
endogen
inflammatori
signal
childhood
recent
measur
feno
level
emerg
noninvas
tool
airway
inflamm
aim
studi
determin
relationship
feno
acut
asthmat
exacerb
decid
whether
measur
feno
could
predict
acut
asthma
exacerb
method
thirti
eight
children
mild
moder
persist
asthma
age
year
present
kyunghe
medic
center
studi
feno
level
measur
chemiluminesc
exhal
analyz
patient
data
base
outpati
record
compar
feno
level
exacerb
group
nonexacerb
group
result
mean
feno
level
asthmat
children
ppb
rang
abnorm
feno
level
ppb
signific
differ
asthma
exacerb
group
nonexacerb
group
also
signific
correl
feno
level
acut
asthma
exacerb
conclus
exhal
nitric
oxid
level
relat
acut
asthmat
exacerb
childhood
asthma
thu
measur
feno
promis
clinic
tool
predict
asthma
exacerb
mild
moder
persist
asthmat
children
analysi
level
bronchial
hyperrespons
astmat
children
year
dosimetr
oscilometr
tidal
breath
method
histamin
methacholin
analysi
polymorph
gene
radek
vrtel
radek
vodicka
martin
zapalka
frantisek
kopriva
teach
hospit
palacki
univers
olomouc
pediatr
olomouc
czech
republ
teach
hospit
palacki
univers
olomouc
medic
genet
olomouc
czech
republ
background
studi
main
pathogen
mechan
bronchial
asthma
chronic
eosinophilbas
inflamm
bronchial
mucosa
airway
hyperrespons
ahr
known
major
risk
factor
develop
asthma
equival
asthma
sever
method
main
aim
project
support
iga
mz
cr
test
level
ahr
associ
certain
allel
haplotyp
gene
adam
stat
involv
immun
system
activ
cours
allerg
ill
develop
airway
hyperrespons
children
bronchial
asthma
histamin
methacholin
brochnoprovoc
test
sequenc
increas
level
use
dosimetr
method
medicaid
devilbiss
nebul
oscilometr
assess
follow
baselin
spirometri
oscillometr
assess
ii
decreas
versu
baselin
examin
respons
polymorph
adam
stat
gene
accomplish
sequenc
analysi
children
asthma
bronchial
sib
parent
control
healthi
children
result
examin
respons
polymorph
adam
stat
gene
accomplish
sequenc
analysi
children
asthma
bronchial
sib
parent
control
healthi
children
evalu
result
could
demonstr
chang
resist
oscillometr
assess
ii
consist
decreas
dosimetr
method
statist
evalu
associ
gene
polymorph
asthma
bronchial
occurr
airway
hyperrespons
level
children
present
poster
conclus
result
show
resist
measur
io
impuls
oscillometri
significantli
correl
thegold
descript
influenc
particular
sequenc
chang
could
contribut
addit
insight
airway
hyperrespons
genet
background
differenti
flow
analysi
exhal
nitric
oxid
asthmat
patient
valeriya
nemtsova
irina
tikhonova
inga
fedotova
kharkov
allergolog
center
allergolog
kharkov
ukrain
background
major
asthmat
patient
achiev
control
ill
therefor
crucial
develop
strategi
help
clinician
monitor
diseas
improv
respons
treatment
method
quantifi
inflamm
central
peripher
airway
measur
exhal
nitric
oxid
multipl
exhal
flow
asthmat
patient
differ
level
sever
mild
moder
stabl
moder
exacerb
sever
receiv
oral
corticosteroid
healthi
control
subject
result
bronchial
bno
patient
mild
asthma
pl
meanjsd
higher
patient
moder
stabl
asthma
pl
pg
patient
sever
asthma
receiv
inhal
corticosteroid
ic
pl
pg
healthi
control
subject
pl
pg
differ
bno
patient
mild
asthma
compar
patient
sever
asthma
receiv
ic
oral
corticosteroid
pl
patient
exacerb
show
higher
bno
pl
pg
compar
group
alveolar
higher
patient
sever
asthma
receiv
oral
corticosteroid
part
per
billion
ppb
pg
group
significantli
higher
patient
moder
asthma
exacerb
ppb
differ
seen
diffus
level
differ
asthma
group
measur
highli
reproduc
free
daytoday
diurnal
variat
conclus
differenti
flow
analysi
exhal
provid
addit
inform
site
inflamm
asthma
may
use
assess
respons
peripher
inflamm
use
therapi
monitor
treatment
childhood
asthma
singapor
questionnair
studi
physician
colin
tan
bell
wong
daniel
goh
hugo
van
bever
nation
univers
singapor
depart
pediatr
singapor
singapor
introduct
asthma
common
chronic
diseas
children
singapor
children
ever
diagnos
asthma
age
children
seen
primari
care
set
thu
valu
studi
manag
practic
gener
practition
pediatrician
comparison
gold
standard
aim
studi
investig
method
monitor
childhood
asthma
b
practic
manag
acut
asthma
exacerb
c
choic
therapi
mainten
treatment
method
questionnair
question
sent
post
gener
practition
pediatrician
throughout
singapor
valid
respons
receiv
result
compar
global
initi
asthma
gina
guidelin
result
respond
gener
practition
monitor
childhood
asthma
physician
use
symptom
score
card
diari
use
peakflow
metersspirometri
acut
treatment
use
shortact
use
oral
corticosteroid
outpati
mainten
treatment
asthma
across
agegroup
infant
preschool
older
children
commonli
use
first
line
drug
uniformli
inhal
corticosteroid
howev
combin
long
act
betaagonist
laba
inhal
corticosteroid
uniformli
second
popular
mainten
treatment
mainten
treatment
frequent
use
doctor
treat
preschool
older
children
contrast
doctor
seldom
never
appli
mainten
treatment
infant
vast
major
doctor
never
use
immunotherapi
asthma
manag
respond
believ
immunotherapi
avail
local
conclus
greater
usag
diariesscor
card
encourag
along
object
peak
flowspirometri
measur
manag
acut
exacerb
appropri
corticosteroid
underprescrib
doctor
laba
continu
prescrib
mainten
despit
lack
establish
safeti
profil
infant
along
recommend
use
select
patient
poorli
control
inhal
corticosteroid
immunotherapi
wide
use
awar
instruct
gener
among
doctor
risk
hbv
reactiv
asthma
copd
patient
treat
corticosteroid
tae
object
evalu
cours
hbv
infect
stabl
hbv
carrier
use
ic
sc
treatment
asthma
chronic
obstruct
pulmonari
diseas
copd
method
hbsag
seroposit
patient
use
ic
review
retrospect
jan
mar
review
data
patient
met
inclus
exclus
criteria
includ
dose
durat
ic
sc
treatment
hbv
dna
titer
hbeagab
astalt
serum
level
usag
antivir
drug
lamivudin
result
among
patient
use
ic
patient
treat
sc
least
one
event
hbv
reactiv
occur
subject
ever
use
sc
subject
ic
treatment
alon
among
subject
hbv
reactiv
ever
use
sc
subject
treat
sc
chronic
due
difficulttocontrol
asthma
total
cumul
dose
prednisolon
subject
hbv
reaction
use
ic
use
moder
dose
ic
conclus
chronic
use
sc
high
total
cumul
dose
sc
risk
factor
hbv
reactiv
patient
asthma
copd
ic
treatment
alon
risk
factor
hbv
reactiv
prophylact
antivir
therapi
consid
patient
need
chronic
high
dose
sc
treatment
background
preval
asthma
increas
last
year
also
gastroesophag
reflux
diseas
gerd
increas
last
year
known
gastroesophag
reflux
ger
may
present
also
may
aggrav
asthma
inform
regard
gerd
asthma
romania
aim
studi
evalu
presenc
ger
allerg
asthma
transylvania
method
evalu
patient
allerg
asthma
presenc
ger
pt
moder
persist
asthma
treat
glucocorticoid
inhal
andor
laba
pt
oesophag
phmonitor
reflux
episod
identifi
reflux
event
percentag
time
ph
less
four
pt
also
upper
endoscopi
pt
also
ask
asthmat
symptom
night
regard
heart
burn
result
mean
age
year
year
pt
women
pt
heart
burn
oesophag
phmonitor
found
pt
acid
reflux
day
night
endoscopi
pt
esophag
relationship
spirometri
result
one
hand
paramet
gastroesophag
reflux
pt
receiv
also
week
term
proton
pump
inhibitor
ppi
pantoprazol
mgday
measur
symptom
mean
daili
daytim
nighttim
asthma
symptom
score
chang
significantli
week
treatment
ppi
influenc
rescu
medic
major
pt
pt
report
improv
asthma
lower
need
rescu
medic
romanian
patient
found
correl
ger
conclus
result
indic
acid
oesophagu
short
term
inhibit
proton
pump
inhibitor
influenc
allerg
asthma
clinic
implic
differ
pathophysiolog
manifest
asthma
pure
copd
background
although
physiolog
anatom
differ
chronic
obstruct
pulmonari
diseas
copd
asthma
separ
distinct
categori
diseas
clinic
practic
signific
proport
patient
characterist
classic
associ
condit
method
determin
whether
patient
fix
airflow
obstruct
distinct
cellular
biochem
characterist
depend
asthmat
featur
character
consecut
outpati
present
fix
airflow
obstruct
bronchodil
respons
peak
expiratori
flow
variabl
serum
total
immunoglobulin
e
allergen
skin
prick
test
methacholin
bronchial
challeng
test
mct
bronchoalveolar
lavag
bal
addit
determin
signific
mct
differenti
asthma
copd
exam
mct
outpati
divid
asthma
pure
copd
control
group
result
found
subtyp
lymphocyt
show
signific
differ
number
ratio
group
neutrophil
bal
fluid
significantli
lower
group
asthmat
featur
addit
cytokin
analysi
show
significantli
higher
level
asthmat
patient
compar
copd
patient
lower
level
infgamma
asthma
group
compar
copd
group
mct
result
area
receiv
oper
characterist
roc
curv
sensit
specif
shown
best
cutoff
valu
pc
mgml
classifi
asthma
pure
copd
conclus
conclud
despit
similar
fix
airflow
obstruct
subject
asthmat
featur
distinct
cellular
biochem
characterist
compar
pure
copd
addit
suggest
mct
use
new
cutoff
valu
could
use
diagnost
tool
distinguish
asthma
pure
copd
base
find
expect
distinct
asthma
pure
copd
use
differ
pathophysiolog
manifest
could
provid
proper
specif
therapeut
manag
patient
airway
remodel
patient
allerg
bronchopulmonari
aspergillosi
hidenori
tanimoto
yasuo
takeuchi
masami
taniguchi
akemi
saito
kiyoshi
sekiya
hiroshi
yasueda
kazuo
akiyama
nation
hospit
organ
sagamihara
nation
hospit
clinic
research
center
allergi
rheumatol
kanagawa
japan
background
allerg
bronchopulmonari
aspergillosi
abpa
hypersensit
reaction
aspergillu
fumigatu
aspf
induc
ige
igg
antibodi
progress
central
bronchiectasi
cbe
even
earli
stage
hypothes
airway
remodel
irrevers
chang
bronchial
wall
patient
abpa
accompani
cbe
also
persist
bronchial
narrow
earli
stage
abpa
method
evalu
bronchial
revers
br
use
salbutamol
airway
hyperrespos
ahr
use
acetylcholin
ach
abpa
patient
cbe
classic
abpa
without
cbe
seroposit
abpa
compar
br
ahr
patient
patient
allerg
fungal
asthma
without
igg
antibodi
aspf
nineteen
classic
abpa
seroposit
abpa
allerg
fungal
asthmat
particip
studi
result
subject
posit
ige
antibodi
aspf
abpa
patient
without
cbe
posit
igg
antibodi
aspf
classic
abpa
patient
seroposit
abpa
patient
typic
cbe
find
detect
hrct
differ
age
total
ige
level
rist
among
three
group
howev
classic
abpa
patient
also
seroposit
abpa
patient
show
significantli
attenu
br
salbutamol
inhal
median
increas
ml
moreov
onehalf
abpa
patient
show
normal
mild
ahr
hand
none
allerg
fungal
asthmat
show
normal
ahr
conclus
result
suggest
abpa
patient
even
earli
stage
may
show
irrevers
bronchial
narrow
resist
bronchodil
bronchostimul
inhal
follicular
bronchiol
rare
mimick
sever
asthma
bell
peralejo
peter
benincasa
leonard
bielori
univers
medicin
dentistri
new
jersey
dept
medicin
divis
allergi
immunolog
newark
nj
unit
state
background
atyp
present
asthma
abnorm
imag
factor
prompt
pursuit
lung
tissu
diagnosi
present
case
follicular
bronchiol
fb
patient
thought
sever
asthma
method
year
old
male
nonsmok
develop
product
cough
dyspnea
wheez
year
treat
inhal
steroid
long
act
betaagonist
montelukast
antibiot
prednison
late
onset
asthma
symptom
worsen
oral
steroid
taper
result
pulmonari
function
test
reveal
sever
obstruct
signific
bronchodil
respons
mildli
decreas
diffus
capac
predict
skin
test
posit
dust
mite
mold
cat
dog
immunolog
evalu
workup
infect
hiv
afb
yeast
bacteria
cmv
sarcoid
ace
level
calcium
gallium
scan
autoimmun
diseas
ana
anca
mpo
ab
antitrypsin
defici
hypersensit
pneumon
neg
ct
scan
chest
show
bilater
peribronchi
thicken
central
bronchi
small
nonspecif
lymph
node
mediastinum
right
upper
lobe
wedg
resect
show
acut
chronic
bronchiol
lymphoid
hyperplasia
consist
fb
improv
chronic
steroid
azithromycin
conclus
fb
rare
entiti
consist
abund
lymphoid
follicl
limit
peribronchiolar
area
may
idiopath
associ
hypersensit
phenomenon
collagen
vascular
diseas
case
report
associ
immunodefici
hiv
common
variabl
immunodefici
cvid
initi
thought
immun
defici
repeat
analysi
reveal
normal
immunolog
function
diseas
may
therefor
idiopath
relat
hypersensit
reaction
well
understood
control
steroid
azithromycin
result
studi
period
nasopharyng
aspir
examin
hospit
children
respiratori
symptom
virus
detect
popul
hospit
due
acut
asthma
exacerb
infecti
agent
detect
patient
rsv
detect
ifv
rv
cov
adv
piv
hmpv
coinfect
identifi
sampl
exacerb
asthma
symptom
greatest
winter
highest
number
sampl
posit
respiratori
syncyti
viru
record
januari
conclus
conclus
confirm
acut
exacerb
asthma
necessit
hospit
often
associ
respiratori
viral
infect
especi
rsv
young
children
also
signific
differ
young
children
schoolag
children
preval
respiratori
viru
found
caus
viru
hospit
children
asthma
exacerb
follow
epidem
respiratori
viru
hospit
children
respiratori
infect
introduct
suggest
chronic
chlamydia
pneumonia
infect
could
caus
adult
onset
asthma
data
suggest
infecti
organ
particulari
atyp
bacteria
clamydia
pneumonia
may
involv
asthma
pathogenesi
known
whether
organ
allow
persist
infect
present
prior
develop
asthma
signific
atyp
bacteria
exacerb
asthma
stil
unclear
aim
studi
purpos
studi
deter
weather
antichlamydi
treatment
azitrhomycin
improv
asthma
symptom
lung
function
asthmat
patient
materi
method
patient
mean
age
year
moder
moder
sever
asthma
treat
median
week
azithromycin
mg
weekli
patient
chlamydia
pneumonia
infect
detect
specif
specif
igg
chlamydia
pneumonia
post
treatment
lung
function
symptom
score
caugh
wheez
dyspnea
compar
baselin
valu
result
week
treatment
azithromycin
signific
reduct
symptom
score
signific
improv
lung
function
wilcoxon
match
pair
test
conclus
treatment
azithromycin
significantli
improv
asthma
symptom
lung
function
indic
chlamydia
pneumonia
may
play
import
role
enhanc
inflammatori
process
lower
airway
awar
inflamm
main
pathogenet
mechan
asthma
renew
interest
role
infact
ethiolog
influenc
therapi
omeprazol
asthma
symptom
pulmonari
function
qualiti
life
asthmat
acid
reflux
symptom
kamelija
busljet
tatjana
caparoska
biserka
kaeva
sava
pejkovska
kamelija
busljet
univers
hospit
pulmoallergolog
skopj
macedonia
fyrom
acid
reflux
symptom
found
occuer
asthmat
patient
although
associ
evid
difficult
establish
casual
relationship
acidsuppress
treatment
inconsist
improv
asthma
control
aim
studi
determin
whether
protonpump
inhibitor
improv
asthma
control
asthmat
patient
acid
reflux
symptom
twentytwo
patient
receiv
usual
asthma
cove
includ
inhal
corticosteroid
patient
acid
reflux
symptom
moder
sever
persist
asthma
receiv
omeprazol
bid
week
measur
daili
asthma
symptom
diari
daili
morn
even
peak
expiratori
flow
fvc
asthma
qualiti
life
standard
activ
aqlo
questionnair
score
rescu
salbutamol
use
studi
shown
daili
asthma
symptom
salbuterol
use
peak
expiratori
flow
fvc
week
improv
significantli
omeprazol
treatment
signific
improv
nighttim
asthma
symptom
patient
nocturn
asthma
aqlo
emot
function
domain
improv
week
omeprazol
therapi
conclus
daytim
asthma
outcom
improv
omeprazol
therapi
seam
subgroup
asthmat
patient
benefit
excess
antireflux
therapi
year
old
male
cervic
lymphangioma
asthma
case
report
horacio
del
olmo
tellez
socorro
orozco
martinez
jose
guadalup
huerta
lopez
nation
institut
pediatr
mexico
allergi
immunolog
mexico
citi
mexico
lymphangioleiomyomatosi
lam
rare
idiopath
interstiti
lung
diseas
predominant
affect
women
although
van
stossel
first
describ
pulmonari
lam
natur
histori
lam
remain
poorli
understood
true
incid
preval
lam
unknown
although
current
worldwid
registri
report
lam
diseas
geograph
prefer
delay
diagnosi
result
misdiagnosi
lack
earli
specif
clinic
find
common
misdiagnosi
includ
asthma
emphysema
chronic
bronchiti
tazelaar
cowork
describ
nine
case
distinct
lymphat
vascular
lesion
term
diffus
pulmonari
lymphangiomatosi
six
patient
includ
wheez
asthma
dyspnea
present
month
year
present
year
old
boy
began
sufferind
month
life
grade
fever
hiporexia
wheez
dyspnea
cianosi
receiv
cefuroxim
ceftriaxon
treatment
without
diminish
symptom
enter
nation
pediatr
institut
sinus
laringothraqu
probabl
diagnosi
patient
continu
dyspnea
inspiratori
estridor
cervic
ultrasonographi
describ
hemangioma
biopsi
report
right
later
lymphangioma
without
malign
partial
extract
tha
patient
suffer
thraqueostomi
compress
hypopharynx
posterior
wall
percent
diminut
supraglot
inflamm
edema
moreov
patient
present
sever
bronchoespasm
salbutamol
dexamethason
nebul
treatment
asmat
mother
background
year
old
receiv
allergi
valor
develop
nasal
constip
pruritu
rhinorrea
last
month
receiv
beta
agonist
budesonid
transfer
factor
bacteri
vaccin
diagnosi
sever
moder
asthma
later
develop
volum
increas
lymphangioma
zone
receiv
ok
laboratori
result
dermatophagoid
farina
specif
ige
uiml
dermatophagoid
pterinissinu
uiml
total
ige
uiml
eosinophilia
prick
test
posit
chenopodium
lolium
quercu
timothi
fraxinu
ligustrum
dpt
start
sublingu
immunotherapi
interest
case
lymphangioma
rare
diseas
mainli
children
associ
atopia
caus
difficult
control
asthma
refer
lymphangioma
asthma
literatur
treatment
controvert
novel
sever
acut
asthma
exacerb
complic
pneumomediastinum
atelectasi
lung
case
report
sever
exacerb
asthma
subacut
acut
episod
asthmat
symptom
aggrav
accompani
increas
airway
obstruct
respiratori
insuffici
greater
risk
complic
pneumomediastinum
subcutan
emphysema
rare
wellknown
complic
acut
asthma
gener
accept
explan
develop
pneumomedistinumi
free
air
track
ruptur
alveoli
along
peribronchi
vascular
sheath
toward
hilum
lung
extend
proxim
within
mediastinum
atelectasi
lung
due
format
mucou
plug
usual
respond
well
treatment
underli
diseas
csse
report
old
femal
patient
ld
develop
pneumomedistinum
atelectasi
cours
sever
asthma
exacerb
patient
long
histori
asthma
vital
endang
mechan
ventil
cours
exacerb
develop
progress
dyspnea
cough
fever
acut
cough
edema
crackl
develop
face
neck
chest
region
accompani
sudden
deterior
dyspnea
tachypnea
cyanosi
arteri
blood
ga
analysi
rest
reveal
sever
manifest
partial
respiratori
insuffici
chest
xray
establish
subacut
emphysema
satisfactori
regress
diseas
achiev
chest
ct
scan
perform
eighth
day
reveal
atelectasi
posterobas
left
lung
segment
conclus
pneumomediastinum
atelectasi
rare
possibl
complic
may
accompani
sever
asthma
exacerb
dramat
appear
usual
benign
cours
good
respons
conserv
treatment
serg
chooklin
roman
vatseba
ihor
bihalskyy
medic
univers
depart
immunolog
surgeri
lviv
ukrain
background
respiratori
complic
patient
undergo
abdomin
surgeri
frequent
develop
aggrav
cours
presenc
patient
bronchial
asthma
mechan
pathogenesi
possibl
way
prophylact
remain
debat
import
role
play
cytokin
chemokin
adhes
molecul
method
blood
level
interleukin
eotaxin
myeloperoxidas
ige
measur
patient
bronchial
asthma
underw
upper
abdomin
surgic
intervent
concentr
cytokin
measur
bronchoalveolar
lavag
result
investig
patient
without
asthma
underw
surgeri
regard
control
result
increas
ige
eotaxin
myeloperoxidas
serum
level
note
asthmat
patient
level
decreas
patient
simultan
high
level
myeloperoxidas
note
bronchoalveolar
fluid
chang
signific
respiratori
complic
pneumonia
edema
asthmat
patient
bacteri
infect
significantli
higher
serum
mpo
level
compar
asthmat
patient
without
infect
conclus
inhibit
synthesi
proinflammatori
cytokin
chemokin
import
link
prevent
respiratori
complic
surgeri
patient
asthma
appli
interferon
gamma
may
perspect
view
etiolog
chronic
cough
popul
children
reffer
pulmonologist
moham
herrag
mustapha
iraqui
ibn
sina
univers
hospit
allergologypulmonolog
rabat
morocco
chronic
cough
estim
affect
children
diagnosi
prove
elus
children
chronic
cough
often
refer
paediatr
pulmonologist
consult
determin
reason
chronic
cough
period
juli
june
children
refer
chronic
cough
longer
week
durat
mean
age
present
chronic
cough
year
girl
boy
caus
chronic
cough
seri
asthma
caus
gastro
oesophag
reflux
tuberculosi
bronchiectasi
sinus
psychogen
cough
cough
resolv
evalu
treatment
case
mojgan
kiani
amin
fatemeh
bagherabadi
qazvin
medic
univers
allergi
immunolog
qazvin
islam
republ
iran
background
cough
reflex
respons
lower
respiratori
tract
stimul
irrit
cough
receptor
airway
mucosa
common
caus
children
reactiv
airway
asthma
specif
lower
respiratori
stimuli
includ
excess
secret
aspir
foreign
materi
inhal
dust
particl
noxiou
gase
inflammatori
respons
infectio
agent
allerg
process
use
inform
may
aid
distinguish
cough
origin
may
includ
histori
famili
histori
atop
condit
asthma
eczema
urticaria
allerg
rhiniti
season
environment
variat
frequenc
intens
cough
case
report
present
famili
chronic
cough
durat
start
upper
respiratori
tract
infect
coninu
spite
antibiot
bronchodil
therapi
past
histori
atop
condit
young
son
difficult
breath
especi
hous
got
better
outsid
allergi
clinic
find
wheezi
breath
rest
also
activ
son
pfc
test
normal
limit
parent
boy
incoop
next
step
second
visit
admit
emerg
ward
could
find
problem
hous
use
wall
heater
airway
close
bird
nest
expos
noxiou
gase
long
time
montoux
test
bcgvaccin
children
asthma
soheila
alyasin
nemaze
hospit
pediatricsallergi
clinic
immunolog
shiraz
islam
republ
iran
introduct
recent
studi
propos
declin
tuberculosi
infect
factor
underli
rise
sever
preval
atop
disord
develop
countri
also
conflict
report
effect
bacillu
calmetteguerin
bcg
vaccin
subsequ
develop
atopi
asthma
bcg
potent
induc
believ
suppress
depend
atop
reaction
method
tri
prove
hypothesi
casecontrol
simpl
sampl
patient
younger
year
old
known
case
asthma
variabl
sever
receiv
unit
intraderm
tuberculin
test
patient
also
bcgvaccin
birth
control
group
healthi
children
previous
vaccin
birth
ageadjust
case
group
also
test
tuberculin
test
ppd
hour
induct
area
measur
two
vertic
longitudin
diamet
time
sever
asthma
case
group
determin
accord
classif
nation
institut
health
nation
institut
heart
lung
blood
ask
mother
frequenc
night
day
symptom
interv
attack
patient
divid
three
group
mild
moder
sever
group
mild
intermitt
mild
persist
group
classifi
one
group
result
case
group
mean
size
ppd
skin
test
respons
control
group
mean
size
also
anoth
test
divid
case
group
two
group
ppd
skin
test
less
mm
signific
p
valu
conclus
conclus
patient
definit
asthma
signific
weaker
respons
ppd
test
indic
weaker
respons
allerg
patient
propos
stimul
system
bcg
vaccin
birth
influenc
subsequ
develop
allerg
diseas
dominantli
mediat
system
may
promis
revolut
futur
asthma
regard
sever
asthma
signific
evid
support
relat
sever
asthma
ppd
skin
test
respons
may
explain
domin
moder
asthma
group
relationship
coronari
spastic
airway
respons
patient
coronari
spastic
angina
inga
fedotova
valeriya
nemtsova
irina
feclina
kharkov
allergolog
centr
allergolog
kharkov
ukrain
background
sever
report
suggest
possibl
link
bronchial
asthma
coronari
spasm
possibl
relationship
coronari
spastic
angina
csa
clarifi
method
airway
respons
methacholin
coronari
spastic
acetylcholin
examin
patient
csa
patient
chest
pain
syndrom
cp
sixteen
healthi
subject
control
group
enrol
studi
airway
respons
compar
csa
cp
patient
result
incid
airway
hyperrespons
significantli
higher
csa
group
cp
control
group
geometr
mean
log
minimum
dose
dmin
defin
cumul
dose
point
respiratori
conduct
began
decreas
significantli
lower
csa
group
log
unit
cp
log
unit
control
log
unit
group
conclus
result
studi
demonstr
acetylcholineinduc
coronari
spastic
significantli
relat
methacholineinduc
airway
respons
patient
coronari
spastic
angina
gener
hyperrespons
vascular
nonvascular
smooth
muscl
includ
cholinerg
mechan
may
exist
patient
coronari
spastic
angina
sherif
alsay
khalid
elnagar
new
jeddah
clinic
hospit
chest
depart
jeddah
saudi
arabia
new
jeddah
clinic
hospit
intern
medicin
jeddah
saudi
arabia
object
detect
impact
anxieti
shape
preval
gastrointestin
reflux
diseas
gerd
patient
sever
chronic
obstruct
pulmonari
diseas
copd
base
less
method
examind
preval
symptomat
gerd
use
vigneri
score
cough
dyspnoea
modifi
medic
research
council
questionnair
male
patient
copd
esophag
h
ph
monitor
use
document
diagnosi
gerd
symptomat
group
beck
anxieti
inventori
use
figuer
impact
anxieti
express
gerd
symptom
result
reflux
diseas
symptom
record
eighteen
patient
studi
group
gerd
diagnos
base
esophogi
h
ph
monitor
patient
express
symptom
gerd
mean
anxieti
score
higher
among
symptomat
group
non
symptomat
reflect
attribut
differnt
symptom
anxieti
gerd
syndrom
conclus
patient
sever
chronic
obstruct
pulmonari
diseas
high
preval
symptomat
gastrooesophag
reflux
howev
true
gerd
document
fewer
number
psycholog
factor
anxieti
somatis
may
play
role
particularli
patient
without
esophag
inflamm
experiment
studi
effect
antioxid
pulmonari
function
smoker
backround
cigarett
smoke
contain
larg
number
free
radic
caus
oxid
damag
airway
lower
lung
function
prospect
intervent
studi
carri
observ
effect
supplement
antioxid
vitamin
lung
function
smoker
method
healthi
male
smoker
divid
equal
group
group
supplement
daili
either
vitamin
vitamin
c
vitamin
e
group
combin
three
dose
month
fvc
pef
measur
begin
month
supplement
end
next
month
without
supplement
result
month
group
show
signific
improv
measur
paramet
lung
function
differ
improv
among
variou
supplement
group
signific
howev
combin
vitamin
yield
higher
trend
improv
group
show
declin
lung
function
end
six
month
without
supplement
indic
insignific
retent
effect
conclus
clinician
may
prescrib
antioxid
supplement
smoker
improv
lung
function
howev
supplement
given
long
period
signific
retent
effect
detect
symptomlimit
stair
climb
valuabl
predictor
postop
cardiopulmonari
complic
thorac
surgeri
magdi
ibrahim
nanci
mahmoud
abdelati
mahmoud
elprinc
faculti
medicin
suez
canal
univers
cardiothorac
depart
ismailia
egypt
faculti
medicin
suez
canal
univers
chest
depart
ismailia
egypt
studi
object
thoracotomi
associ
high
rate
postop
cardiopulmonari
complic
poc
hypothes
symptomlimit
stair
climb
predict
poc
thorac
surgeri
method
prospect
evalu
patient
undergo
thoracotomi
men
women
complet
symptomlimit
stair
climb
separ
investig
blind
number
flight
stair
climb
assess
actual
outcom
poc
includ
pneumonia
atelectasi
mechan
ventil
h
reintub
myocardi
infarct
congest
heart
failur
arrhythmia
pulmonari
embolu
death
within
day
surgeri
oper
perform
includ
lobectomi
wedg
resect
pneumonectomi
decort
result
poc
occur
patient
unabl
climb
one
flight
stair
develop
poc
patient
abl
climb
maximum
five
flight
stair
poc
inabl
climb
two
flight
stair
associ
specif
neg
predict
valu
posit
predict
valu
develop
poc
inabl
climb
maximum
five
flight
stair
associ
sensit
neg
predict
valu
develop
poc
number
day
hospit
postop
decreas
patient
increas
abil
climb
stair
conclus
symptomlimit
stair
climb
offer
simpl
inexpens
valuabl
mean
predict
poc
thorac
surgeri
hepatopulmonari
syndrom
among
patient
cirrhosi
liver
portal
hypertens
vascular
dilat
classifi
posit
group
other
label
neg
group
result
patient
includ
studi
posit
ce
found
mmhg
qualifi
diagnosi
clinic
signific
hp
mmhg
diagnos
subclin
hp
use
increas
alveolararteri
differ
partial
pressur
oxygen
indic
hypoxaemia
preval
hp
consider
higher
mm
hg
mm
hg
use
reduc
partial
pressur
arteri
oxygen
threshold
mm
hg
mm
hg
cut
posit
predict
valu
diagnosi
hp
low
respect
contrast
cut
consider
higher
posit
predict
valu
respect
introduc
mm
hg
cut
posit
predict
valu
increas
childpugh
score
correl
significantli
sever
hp
cyanosi
club
orthodeoxia
significantli
common
patient
clinic
signific
hp
conclus
studi
result
show
presenc
hp
ipvd
among
patient
chronic
liver
diseas
express
cmet
malign
pleural
mesothelioma
immunohistochem
studi
heba
wagih
amira
gamal
nanci
mahmoud
abdelati
ayman
ekram
faculti
medicin
suez
canal
univers
patholog
depart
ismailia
egypt
faculti
medicin
suez
canal
univers
puplic
health
depart
ismailia
egypt
faculti
medicin
suez
canal
univers
chest
depart
ismailia
egypt
background
patient
malign
pleural
mesothelioma
present
advanc
stage
diseas
respons
rate
surviv
current
avail
therapi
poor
therefor
critic
identifi
molecular
marker
mesothelioma
would
provid
way
understand
neoplasm
target
marker
therapi
object
assess
immunoreact
cmet
malign
pleural
mesothelioma
analyz
potenti
link
cmet
express
clincopatholog
paramet
tumor
subtyp
tnm
stage
patient
surviv
method
total
patient
femal
male
patholog
confirm
mpm
age
rang
year
includ
studi
patient
record
clinic
radiolog
laboratori
investig
result
close
pleura
biopsi
analyz
pleura
biopsi
stain
cmet
use
immunohistochem
techniqu
appli
paraffin
section
result
studi
tumor
immunoreact
cmet
signific
relat
cmet
patient
age
gender
also
relat
cmet
express
clinic
symptom
tumor
show
distant
metastasi
cmet
posit
cmet
neg
tumor
show
metastasi
howev
differ
statist
insignific
also
relat
cmet
tumor
subtyp
tumor
stage
howev
tumor
cmet
posit
two
cmet
neg
tumor
cmet
neg
patient
show
oneyear
surviv
wherea
patient
posit
cmet
die
howev
differ
statist
insignific
background
sleep
disord
breath
sdb
preval
condit
adult
associ
increas
cardiovascular
morbid
circul
level
creactiv
protein
crp
proinflammatori
protein
associ
increas
risk
atherosclerosistherefor
crp
may
one
link
osah
cardiovascular
diseas
cvd
hypothes
patient
osa
higher
crp
valu
control
subject
method
result
studi
patient
male
femal
newli
diagnos
osa
free
diseas
never
treat
osa
take
medic
polysomnographi
venou
blood
collect
serum
level
crp
investig
compar
crp
measur
patient
measur
obtain
control
subject
male
femal
match
age
bodi
mass
index
occult
osa
exclud
level
crp
significantli
higher
patient
osa
obes
control
subject
crp
evalu
relationship
level
crp
sleep
studi
paramet
apnea
hypopnea
index
ahi
desatur
index
di
averag
mean
satur
averag
lowest
satur
lsat
percentag
sleep
time
satur
less
result
show
signific
statist
posit
correl
crp
valu
ahi
pg
di
pg
percentag
sleep
time
satur
less
pg
osa
patient
conclus
level
crp
elev
patient
osa
therefor
osa
associ
increas
risk
cardiovascular
morbid
mortal
sever
osa
proport
crp
level
valid
multidimension
bodi
mass
index
b
airflow
obstruct
dyspnea
exercis
capac
e
bode
index
predictor
hospit
copd
nanci
mahmoud
abdelati
mahmoud
elprinc
nane
ismail
magdi
abdelsalam
faculti
medicin
suez
canal
univers
chest
depart
ismailia
egypt
faculti
medicin
sham
univers
puplic
health
depart
cairo
egypt
faculti
medicin
sham
univers
chest
depart
cairo
egypt
background
hypothes
bode
bodi
mass
index
airflow
obstruct
dyspnea
exercis
capac
index
would
better
predict
hospit
copd
alon
studi
object
purpos
studi
test
cohort
patient
copd
well
multidimension
grade
system
assess
respiratori
system
express
copd
would
better
categor
predict
outcom
patient
patient
total
patient
copd
age
yr
male
recruit
outpati
clinic
suez
canal
univers
hospit
enrol
month
prospect
studi
follow
mean
period
month
januari
yjune
measur
bode
index
calcul
patient
use
variabl
obtain
within
week
enrol
main
outcom
measur
number
hospit
admiss
copd
followup
follow
variabl
assess
patient
age
sex
pack
year
smoke
fvc
best
two
minut
walk
test
done
minut
apart
degre
dyspnea
bodi
mass
index
bmi
evalu
relationship
level
dyspnea
bmi
best
two
minut
walk
test
done
minut
apart
bode
score
number
hospit
admiss
result
month
patient
avail
followup
examin
followup
rate
followup
period
patient
requir
least
one
hospit
admiss
die
multivari
analysi
signific
effect
bode
score
number
hospit
admiss
found
confid
interv
ci
pg
comparison
signific
smaller
effect
pack
year
smoke
bmi
bmi
score
number
hospit
admiss
confid
interv
ci
pg
ci
ci
respect
level
dyspnea
minut
walk
test
signific
predictor
hospit
univari
analysi
exclud
multivari
analysi
conclus
bode
stage
system
includ
addit
physiolog
clinic
variabl
better
predictor
hospit
admiss
copd
acut
chronic
eosinophil
pneumoniaour
experi
diagnosi
treatment
jan
plutinski
daniel
magula
stefan
petricek
dana
laukova
stanislav
majernik
ivan
marget
special
hospit
stzoerardu
pneumolog
nitra
slovakia
eosinophil
pneumonia
ep
rare
diseas
ep
may
result
diseas
other
caus
unclear
ep
divid
acut
aep
chronic
cep
form
aim
studi
author
share
experi
diagnosi
differenti
diagnosi
treatment
aep
cep
method
sinc
aep
cep
diagnos
patient
pt
clinic
examin
radiograph
ct
hrct
scan
laboratori
examin
peripher
blood
count
eosinophil
eo
microbiolog
mycobacteriolog
fiberbronchoscopi
histolog
use
pt
divid
two
group
aep
cep
anova
kruskalw
test
use
statist
analysi
result
femal
median
age
yr
male
median
yr
one
two
form
aep
pt
cep
pt
main
clinic
symptom
dyspno
pt
cough
pt
fever
pt
pain
pt
aep
cep
result
concomit
diseas
pt
toxoplasmosi
pt
sarcoidosi
rhiniti
allerg
bronchopulmonari
aspergillosi
pt
concomit
diseas
identifi
statist
signific
found
age
pt
aep
cep
statist
signific
differ
absolut
eo
count
male
femal
group
aep
cep
pt
continu
treat
corticosteroid
pt
temporarili
pt
receiv
treatment
longest
treat
patient
receiv
corticosteroid
yr
conclus
ep
interest
diseas
clinic
symptom
similar
typic
pneumonia
treatment
antibiot
unsuccess
treatment
steroid
determin
individu
basi
divid
aep
cep
clear
cut
could
consid
use
result
corticosteroid
treatment
way
divid
aep
cep
sinc
treatment
aep
temporari
cep
ongo
recent
studi
shown
osteoporosi
vertebr
fractur
quit
common
postmenopaus
women
chronic
obstruct
pulmonari
diseas
copd
data
avail
correl
bone
mass
densiti
bmd
men
copdthi
studi
design
investig
preval
osteoporosi
men
copd
special
regard
role
glucocorticoid
gc
use
patient
aim
determin
factor
influenc
bone
metabol
clinic
variabl
group
patient
also
tri
answer
aris
question
copd
patient
routin
evalu
bmd
method
studi
includ
male
patient
document
copd
least
two
year
age
rang
year
subject
divid
group
group
consist
patient
oral
gc
user
group
consist
patient
inhal
gc
user
group
consist
patient
never
gc
user
group
consid
control
group
subject
underw
measur
bmd
pulmonari
function
test
pft
number
biochem
marker
bone
metabol
associ
bmd
pft
gc
use
biochem
marker
clinic
variabl
analyz
result
patient
copd
preval
osteopenia
osteoporosi
defin
criteria
lumber
spine
total
hip
femor
neck
total
bodi
respect
patient
includ
group
lowest
bmd
site
group
patient
bone
mass
loss
indistinguish
receiv
oral
gc
group
patient
less
bone
mass
reduct
two
group
clinic
biochem
marker
measur
ntelopeptid
significantli
correl
bone
mass
correl
marker
lowest
mean
forc
expiratori
volum
one
second
observ
group
patient
bmi
bodi
mass
index
weakli
correl
bone
mass
studi
group
conclus
bone
mass
loss
common
problem
male
patient
copd
use
oral
gc
increas
frequenc
osteoporosi
inhal
gc
therapi
offer
protect
bone
loss
copd
patient
never
treat
gc
also
substanti
risk
osteoporosi
advoc
earli
screen
prevent
intervent
psychotherapi
improv
exercis
toler
patient
pink
puffer
syndrom
alsay
sherif
khale
elnagar
new
jeddah
clinic
hospit
intern
medicin
jeddah
saudi
arabia
anxieti
common
pink
puffer
syndrom
associ
chronic
obstruct
pulmonari
diseas
copd
degre
anxieti
correl
well
perceiv
dyspnoea
studi
examin
effect
psychotherapi
anxieti
exercis
toler
dyspnoea
patient
stabl
copd
mean
forc
expiratori
volum
one
second
l
six
min
session
cognit
behaviour
psychotherapi
weekli
interv
patient
complet
beck
anxieti
inventori
bai
day
week
therapi
forc
vital
capac
fvc
blood
ga
tension
min
walk
distanc
measur
control
patient
attend
weekli
lung
function
week
psychotherapi
differ
mean
baselin
bai
score
lung
function
blood
ga
tension
group
treatment
bai
score
decreas
associ
mean
also
improv
psychotherapi
group
increas
conclus
six
session
cognit
behaviour
psychotherapi
produc
good
improv
exercis
toler
anxiou
patient
chronic
obstruct
pulmonari
diseas
pink
puffer
exhal
breath
analysi
electron
nose
patient
lung
cancer
chronic
obstruct
pulmonari
diseas
asthma
pneumonia
immanuel
taivan
background
sinc
develop
electron
nose
en
well
recogn
great
potenti
appli
technolog
field
medicin
analysi
variou
biomark
exhal
breath
allow
complet
safe
noninvas
sensit
specif
tool
primari
screen
differ
lung
diseas
aim
studi
test
whether
exhal
breath
analyz
artifici
nose
could
identifi
discrimin
asthma
copd
lung
cancer
pneumonia
method
exhal
air
collect
plastic
bag
immedi
analyz
electron
nose
instrument
nordic
sensor
ab
contain
differ
odour
sensor
multifactori
logist
regress
analysi
support
vector
machin
use
find
relationship
sensor
respons
deriv
integr
clinic
diagnos
patient
result
individu
asthma
lung
cancer
pneumonia
lung
diseas
patient
healthi
volunt
test
given
tabl
repres
p
valu
signific
relationship
electron
nose
sensor
clinic
diagnosi
sensor
gave
specif
respons
particular
diseas
sensor
share
respons
two
diseas
highest
sensit
specif
found
lung
cancer
diagnosi
compar
healthi
control
group
respect
artifici
nose
abl
discrimin
among
differ
lung
diseas
develop
approach
necessari
creat
new
screen
monitor
method
differ
lung
diseas
proteolyt
activ
per
periplaneta
americana
enhanc
allergen
mice
model
thangam
sudha
v
naveen
arora
bhanu
p
singh
institut
genom
integr
biolog
allergi
immunolog
delhi
india
background
cockroach
allergen
sensit
implic
major
caus
allergyasthma
recent
demonstr
serin
proteas
per
immunodomin
allergen
periplaneta
americana
american
cockroach
aim
investig
immuneinflammatori
respons
activ
serin
proteas
mice
model
airway
inflamm
method
balbc
mice
sensit
proteolyt
activ
allergen
ova
intraperiton
subcutan
rout
challeng
intranas
per
allergen
activ
inact
pb
ova
cellular
infiltr
total
cell
count
epo
activ
balf
cytokin
balf
spleen
cultur
supernat
serolog
specif
ige
histopatholog
event
variou
anim
group
compar
result
mice
challeng
activ
serin
proteas
allergen
ova
show
tissu
damag
lung
elev
serum
ige
eosinophil
express
inflammatori
cytokin
balf
spleen
cultur
supernat
indic
induct
respons
administr
proteolyt
inact
allergen
block
irrevers
aebsf
induc
significantli
lower
level
cellular
infiltr
lung
system
ige
product
cytokin
quantit
evalu
lung
tissu
show
decreas
total
inflamm
score
mice
challeng
inact
proteas
conclus
serin
proteas
allergen
p
americana
induc
allerg
respons
mice
model
proteolyt
activ
enhanc
airway
inflamm
inactiv
allergen
may
potenti
therapeut
applic
cassia
siamea
pollen
import
aeroallergen
tropic
countri
dola
boral
kashinath
bhattacharya
sunirm
chanda
swati
guptabhattacharya
krishnath
colleg
depart
botani
berhampor
india
visva
bharati
univers
depart
botani
santiniketan
india
center
studi
man
environ
depart
environ
saltlak
india
bose
institut
depart
botani
kolkata
india
background
well
known
allergi
india
countri
appear
one
commonest
major
health
problem
cassia
siamea
lam
famili
fabacea
import
avenu
tree
tropic
pollen
grain
known
one
import
pollinosi
caus
airborn
bioparticl
present
studi
demonstr
identifi
import
allergen
compon
also
studi
cross
reactiv
member
famili
fabacea
method
season
period
airborn
cassia
pollen
record
aerobiolog
survey
use
sevenday
burkard
volumetr
sampler
burkard
manufactur
co
rickmansworth
hert
england
allergis
potenti
cassia
pollen
antigen
investig
vivo
skin
prick
test
vitro
igeenzym
link
immuno
sorbant
assay
elisa
ige
specif
immunoblot
confirm
ige
sensit
reaction
pollen
allergen
patient
sera
present
studi
whole
pollen
extract
c
siamea
pollen
character
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
presenc
glycoprotein
crude
allergen
extract
cassia
siamea
pollen
detect
pa
period
acid
schif
techniqu
result
intens
posit
result
observ
respons
spt
antigen
extract
c
siamea
pollen
within
patient
show
posit
allerg
reaction
immunochem
studi
reveal
presenc
ten
allergen
compon
molecular
weight
rang
kda
three
major
allergen
protein
band
kda
isol
igespecif
immunoblot
individu
sensit
patient
sera
background
mite
allergi
diseas
induc
inhal
mite
bodi
fece
present
hous
dust
lead
asthma
nasal
inflamm
dermat
identif
allergen
need
specif
immunotherapi
allergenom
analysi
dermatophagoid
farina
bodi
extract
twodimension
immunoblot
follow
mass
spectrometri
reveal
number
new
allergen
purpos
studi
character
allergen
high
frequenc
intens
patient
ige
bind
result
base
partial
amino
acid
sequenc
obtain
mass
spectrometri
full
length
gene
encod
isol
pcr
analysi
deduc
amino
acid
sequenc
predict
molecular
conform
suggest
new
member
group
mite
allergen
ml
protein
note
higher
homolog
sheep
scab
mite
allergen
pso
ident
amino
acid
sequenc
storag
mite
allergen
lep
hous
dust
mite
allergen
der
f
indic
least
two
subgroup
group
mite
allergen
order
character
immunochem
profil
new
allergen
recombin
protein
produc
use
vector
pcoldtf
express
trigger
factor
tf
fusion
protein
lowtemperatur
escherichia
coli
rosettagami
abil
form
precis
disulfidebond
purifi
histag
affin
chromatographi
remov
tf
anion
exchang
chromatographi
mass
spectrometr
analysi
demonstr
three
disulfidebond
characterist
group
mite
allergen
form
elisa
indic
ige
bind
frequenc
n
rast
score
mite
bind
patient
ige
partial
inhibit
rder
f
inhibit
pso
impli
allergen
shear
common
ige
epitop
conclus
import
novel
allergen
disregard
achiev
success
specif
immunotherapi
mite
allergi
also
necessari
reconsid
molecular
differenti
group
mite
allergen
experi
set
new
polllen
trap
member
hungarian
airborn
pollen
network
southwest
hungari
tama
major
marianna
kaposi
teach
hospit
pulmonolog
mosdo
hungari
hungarian
network
aeropalynolog
includ
trap
thruout
countri
order
optimis
network
hungarian
institut
aerobiolog
set
new
trap
hospit
chest
diseas
hungarian
calvinist
church
hungari
somogi
counti
area
high
impot
view
research
locat
close
poulat
recreact
region
lake
balaton
part
countri
probabl
pollen
binfect
territori
hungari
equip
standard
spore
trap
burkard
use
counri
aeropalinlog
team
includ
three
assist
two
clinician
technician
team
alreadi
report
pollen
count
begin
polen
season
nation
network
weekli
basi
object
assess
situat
pollen
count
epidemiolog
data
allergi
region
second
object
studi
influenc
temperatur
rel
humid
rainfal
wind
direct
occurr
pollen
allergen
atmospher
result
show
occurr
pollen
grain
atmospher
markedli
relat
meteorolog
factor
evalu
correl
concentr
pollen
grain
atmospher
region
temperatur
rel
humid
rainfal
wind
direct
veget
period
analysi
select
one
repres
phytoallergen
group
tree
grass
weed
chosen
betula
genu
tree
whole
poacea
famili
grass
ragwe
ambrosia
artemisiifolia
repres
weed
taxon
mention
repres
signific
allergen
hungari
data
provid
predict
inform
forthcom
patient
flow
sever
allerg
symptom
comparison
allergen
spectrum
asthma
allerg
rhiniti
children
year
age
background
compar
allergen
spectrum
asthma
allerg
rhiniti
children
year
age
method
inhal
allergen
skin
prick
test
spt
done
asthma
allerg
rhiniti
children
respect
posit
rate
differ
allergen
allergen
spectrum
asthma
allerg
rhiniti
analyz
result
signific
differ
posit
rate
spt
asthma
allerg
rhiniti
p
main
inhal
allergen
relat
asthma
allerg
rhiniti
dermatophagoid
pteronyssinu
dermatophagoid
farina
alternaria
cat
dander
mugwort
posit
rate
derp
derf
mold
mixtur
asthma
higher
allerg
rhiniti
vs
vs
vs
p
g
posit
rate
summerautumn
pollen
mugwort
allerg
rhiniti
higher
asthma
vs
vs
p
g
asthmat
allerg
rhiniti
children
singl
allergen
sensit
multipl
sensit
mite
mold
pet
common
asthma
allerg
rhiniti
conclus
mite
mold
pet
summerautumn
pollen
main
inhal
allergen
relat
asthma
allerg
rhiniti
children
year
age
allergen
spectrum
similar
asthma
allerg
rhiniti
mite
mold
allergi
popular
asthma
summerautumn
pollen
allerg
rhiniti
background
sensit
food
airborn
environment
allergen
data
still
rare
report
studi
evalu
epiderm
skinprick
test
preval
type
pollen
caus
allerg
symptom
still
well
defin
method
select
consecut
patient
respiratori
symptom
sugest
allerg
respiratori
patholog
studi
mean
standard
prick
test
batteri
pollen
extract
seric
specif
ige
analysi
hirst
spore
trap
run
continuousbasi
roof
bobservatorio
de
headquart
sinc
octob
result
correspond
period
obtain
follow
count
method
spanish
aerobiolog
network
red
de
rea
present
result
abund
pollen
type
decreas
order
annual
index
urticacea
asteracea
artemisia
arecacea
myrica
poacea
ericacea
chenopodiaceaeamaranthacea
olea
cupressacea
polygonacea
pinu
moracea
plantago
mercuriali
myrtacea
pollen
type
pollen
spectrum
herb
predomin
pollen
spectrum
first
half
year
tree
predomin
summer
time
final
shrub
pollin
mostli
spring
cite
pollen
type
abl
caus
allergi
preval
pollen
allergi
period
patient
respiratori
allergi
studi
medic
center
frecuent
type
pollen
sensit
artemisia
vulgari
poacea
famili
graminea
parietaria
judaica
chenopodium
album
salsola
kali
plantago
lanceolata
preval
sensit
patient
mold
less
conclus
pollen
relev
caus
allerg
respiratori
diseas
area
studi
need
improv
accuraci
diagnosi
pollen
allerg
patient
distribut
allergen
among
allerg
rhiniti
patient
live
shiraz
iran
region
hesamedin
nabavizadeh
sohila
alyasin
yasuj
univers
medicin
pediatr
allergi
immunolog
yasuj
islam
republ
iran
shiraz
univers
medicin
pediatr
allergi
immunolog
shiraz
islam
republ
iran
object
allerg
rhiniti
singl
common
chronic
allerg
diseas
worldwid
hous
dust
mite
grass
pollen
fungal
spore
play
identifi
play
major
role
pathogenesi
allerg
rhiniti
determin
distribut
allergen
among
allerg
rhiniti
patient
live
shiraz
region
method
investig
allerg
rhiniti
patient
femal
male
mean
age
year
symptom
result
histori
clinic
examin
reveal
patient
season
symptom
patient
perenni
symptom
common
pattern
multipl
allergen
tree
mixtur
allergen
grass
mixtur
mite
candida
tomato
fruit
feather
mixtur
cladosporium
oak
ash
alternaria
mapl
hen
egg
aspergillu
skin
prick
test
neg
case
accord
prick
test
result
sensit
one
allergen
found
patient
sensit
multipl
allergen
patient
famili
histori
posit
patient
conclus
common
allergen
tree
mixtur
grass
shiraz
region
conclud
distribut
allergen
associ
climat
environment
socioeconom
featur
region
larger
repres
sampl
involv
multicent
shiraz
encourag
near
futur
research
triticum
aestivum
allergi
east
turkey
nejat
ozanguc
gozd
hospit
allergi
immunolog
center
malatya
turkey
patient
visit
center
allergi
immunolog
malatyaturkey
diagnos
season
allerg
rhiniti
sar
bronchial
asthma
ba
sarba
result
skin
prick
test
appli
patient
aeroallergen
show
patient
allerg
reaction
triticum
aestivum
ta
patient
test
posit
ta
aeroallergen
total
posit
test
male
test
particip
femal
particip
research
male
femal
test
posit
ta
male
femal
test
posit
ta
aeroallergen
patient
current
allergen
immunotherapi
programthes
result
worth
give
attent
inform
malatya
agricultur
bureau
malatya
surround
area
capit
grow
wheat
wh
make
bread
ta
hand
malatya
export
world
apricot
consumpt
work
detail
crosssensitis
research
ta
apricot
tree
pollen
sinc
apricot
tree
pollen
extract
produc
compani
gather
pollen
powder
form
made
connect
compani
produc
antigen
use
aeroallergen
skin
prick
test
islamabad
one
beauti
capit
world
mountain
greeneri
arround
also
highest
pollen
count
asia
huge
number
pollen
allergi
patient
spring
fall
numer
patient
visit
emerg
depart
differ
hospit
rapese
mustard
second
import
edibl
oil
india
allergi
brassica
seed
report
earlier
austria
finland
etc
scant
inform
avail
indian
subcontin
investig
allergen
b
juncea
seed
flour
vivo
vitro
method
indian
atop
case
antigen
b
juncea
extract
wv
standard
protocol
assess
sensit
skin
prick
test
carri
antigen
extract
wv
b
juncea
case
total
ige
b
juncea
specif
ige
estim
enzym
link
immuno
sorbent
assay
determin
allergen
import
protein
immunoblot
carri
total
atop
case
suffer
allerg
rhiniti
bronchial
asthma
select
gener
atop
popul
refer
clinic
unit
treatment
suffer
allerg
rhiniti
bronchial
asthma
bronchial
asthma
well
allerg
rhiniti
mean
age
yr
yr
sex
distribut
femal
vs
male
vs
mean
age
healthi
volunt
includ
yr
case
show
skin
test
respons
seed
b
juncea
total
ige
case
rang
iuml
iuml
rais
allergen
specif
ige
also
observ
sera
skin
test
posit
case
rang
optic
densiti
valu
antigen
extract
separ
protein
band
sodium
dodecyl
sulphatepoli
acrylamid
gel
electrophoresi
mol
wt
rang
kda
immunoblot
reveal
ige
bind
protein
fraction
sera
patient
show
rais
ige
brassica
specif
antibodi
heterogen
ige
bind
protein
fraction
amongst
individu
patient
observ
thu
conclud
sensit
seed
b
juncea
exist
indian
popul
malek
alaoui
rouwayda
dana
fare
zaitoun
allergi
asthma
immunolog
center
allergolog
depart
hamrabeirut
lebanon
essex
chemi
ag
medic
affair
depart
beirut
lebanon
allergi
asthma
immunolog
center
research
depart
beirut
lebanon
background
aerosol
pollen
import
caus
respiratori
allergi
worldwid
avail
pollen
count
western
countri
essenti
patient
educ
medic
treatment
aerobiolog
pollen
data
scarc
middl
east
never
previous
assess
lebanon
order
identifi
quantifi
pollen
preval
lebanon
nation
aerobiolog
program
launch
start
capit
citi
beirut
method
lanzoni
pollen
trap
place
roof
top
beirut
meter
ground
level
sevenday
cycl
drum
film
coat
silicon
adhes
use
captur
pollen
grain
slide
stain
gelatin
fuschin
examin
light
microscop
use
object
pollen
identif
count
record
weekli
basi
result
total
pollen
collect
month
period
except
brief
interrupt
summer
militari
conflict
twelv
differ
type
pollen
identifi
alnu
cupressacea
oleacea
pinacea
juglandacea
mercuriali
chenopodiacea
artemesia
parietaria
plantago
apiacea
poacea
tabl
common
pollen
found
studi
period
oleacea
total
follow
cupressacea
pinacea
total
mercuriali
tabl
peak
pollen
level
record
pollen
april
averag
daili
count
pollen
throughout
month
april
lowest
total
pollen
count
month
septemb
averag
daili
level
conclus
first
aerobiolog
pollen
data
ever
record
countri
lebanon
typic
elev
pollen
count
spring
observ
howev
level
surprisingli
high
urban
area
find
tree
pollen
cupressacea
alnu
winter
month
along
identif
particular
pollen
mercuriali
previous
suspect
import
find
allergen
informationpoor
countri
sinc
pollen
collect
took
place
one
locat
central
beirut
one
year
extrapol
nationwid
impress
made
nonetheless
excit
pollen
data
gener
first
lebanon
serv
pioneer
role
studi
aerobiolog
allerg
diseas
countri
region
ten
year
survey
major
pollen
aeroallergen
sydney
australia
conni
katelari
theres
burk
pamela
burton
campbelltown
hospit
clinic
immunolog
allergi
sydney
australia
background
airborn
pollen
major
caus
allerg
symptom
spring
month
sydney
australia
establish
predomin
pollen
aeroallergen
time
highest
pollen
level
greatli
assist
medic
personnel
develop
effect
treatment
plan
individu
suffer
allerg
symptom
relat
pollen
sensit
survey
identifi
pollen
aeroallergen
preval
spring
month
sydney
suggest
possibl
reason
differ
observ
season
attempt
determin
effect
predictor
sever
pollen
season
method
aeroallergen
monitor
perform
spring
month
sydney
australia
burkard
day
volumetr
spore
trap
use
pollen
collect
slide
analys
use
standard
protocol
daili
pollen
count
express
speci
grain
per
cubic
meter
cum
data
collect
august
novemb
year
spring
southern
hemispher
daili
rainfal
data
obtain
bureau
meteorolog
express
millimetr
rain
daili
basi
entir
ten
year
period
survey
pollen
data
collat
group
tree
grass
weed
pollen
group
analys
season
trend
correl
rainfal
data
year
survey
season
durat
identifi
well
peak
day
peak
count
averag
daili
pollen
count
total
season
pollen
count
group
result
tree
pollen
make
major
total
pollen
count
sydney
follow
grass
weed
major
tree
pollen
speci
identifi
sydney
includ
cypress
pine
plane
casuarina
tree
pollen
tend
reach
peak
level
mid
late
septemb
grass
weed
pollen
mid
late
octob
highest
averag
daili
pollen
count
group
occur
year
highest
autumnspr
rainfal
averag
daili
pollen
count
rang
grainscum
tree
grainscum
grass
grainscum
weed
period
pollen
season
durat
also
vari
consider
year
result
survey
indic
major
pollen
aeroallergen
present
spring
month
sydney
australia
survey
also
highlight
consider
variabl
pollen
season
need
ongo
aerobiolog
pollen
monitor
futur
highli
variabl
climat
condit
clearli
impact
upon
pollen
count
influenc
meteorolog
variabl
pollen
count
sydney
australia
longitudin
data
examin
effect
within
pollen
season
theres
burk
pamela
burton
conni
katelari
campbelltown
hospit
clinic
immunolog
allergi
sydney
australia
background
airborn
pollen
signific
caus
allerg
symptom
sensitis
individu
variou
meteorolog
factor
effect
pollen
level
day
day
basi
throughout
pollen
season
season
basi
time
understand
effect
meteorolog
factor
may
possibl
develop
effect
indic
may
assist
predict
high
pollen
day
within
season
assist
symptom
manag
method
airborn
pollen
collect
sydney
australia
burkard
day
volumetr
spore
trap
use
collect
data
slide
made
analys
use
standard
protocol
pollen
count
express
grain
per
cubic
meter
cum
variou
speci
group
tree
grass
weed
meteorolog
data
obtain
includ
minimum
temperatur
maximum
temperatur
daili
rainfal
humid
spearman
rank
correl
use
assess
effect
meteorolog
variabl
upon
day
day
pollen
count
season
pollen
count
whole
examin
cross
correl
plot
first
differenc
day
move
averag
order
detect
short
term
associ
fluctuat
meteorolog
variabl
fluctuat
pollen
count
result
examin
daili
count
within
given
pollen
season
statist
signific
posit
correl
daili
maximum
temperatur
daili
pollen
count
pollen
speci
p
g
daili
rainfal
high
humid
neg
correl
daili
pollen
count
speci
p
g
day
day
chang
maximum
temperatur
moder
posit
correl
simultan
chang
total
pollen
count
r
weakli
neg
correl
chang
total
pollen
count
day
later
r
examin
season
season
associ
mean
season
pollen
count
neg
correl
mean
season
daili
maximum
temperatur
r
total
pollen
r
grass
conclus
day
day
basi
increas
daili
maximum
temperatur
lead
increas
pollen
level
daili
rainfal
lead
simultan
decreas
daili
pollen
level
overal
cooler
temperatur
across
season
often
lead
higher
total
pollen
count
ongo
pollen
monitor
need
examin
effect
meteorolog
factor
daili
season
pollen
count
character
nativ
thaumatinlik
allergen
name
cri
j
japanes
cedar
cryptomeria
japonica
pollen
anoth
protein
constitut
total
protein
content
pollut
pollen
concentr
protein
kda
consider
diminish
total
protein
content
amount
protein
fraction
increas
immunoblot
conduct
evalu
sera
ige
reactiv
cypress
allerg
subject
new
major
protein
pollut
pollen
extract
show
protein
kda
also
major
allergen
carizonica
pollen
extract
allerg
subject
live
tehran
import
differ
observ
protein
profil
nonpollut
pollut
pollen
extract
reflect
fact
environment
pollut
induc
augment
allergen
protein
may
neg
repercuss
health
urban
popul
allergenspecif
ige
reactiv
pattern
chines
hous
dust
mite
allerg
patient
background
two
speci
hous
dust
mite
hdm
dermatophagoid
pteronyssinu
der
p
dermatophagoid
farina
der
f
recogn
major
allergen
sourc
chines
allerg
patient
accord
epidemiolog
survey
use
invivo
invitro
assay
specif
ige
reactiv
pattern
european
american
hdm
allerg
popul
well
character
howev
studi
address
allergenspecif
ige
pattern
chines
hdm
patient
method
serum
sampl
patient
allerg
asthma
andor
allerg
rhiniti
show
skin
prick
test
unicap
posit
der
p
der
f
obtain
south
southwest
china
sera
analyz
cross
radioimmunoelectrophoresi
crie
immunoblot
visual
allergenspecif
ige
reactiv
pattern
result
allergen
der
p
allergen
der
f
detect
crie
frequent
allergen
identifi
belong
hdm
group
sera
specif
ige
der
p
der
f
sera
recogn
der
p
react
der
f
antigen
der
p
show
ige
bind
immunoblot
patient
ige
mainli
show
bind
protein
around
kda
identifi
hdm
group
allergen
respect
reaction
sera
immunoblot
der
p
der
p
der
f
der
f
conclus
hdm
specif
ige
reactiv
pattern
chines
mite
allerg
patient
similar
patient
popul
addit
commonli
recogn
der
p
der
p
der
f
der
f
novel
major
allergen
denot
antigen
identifi
der
p
extract
analysi
indic
der
p
der
f
extract
use
studi
use
worldwid
diagnosi
treatment
immunoglobulin
e
immunoglobulin
g
epitopemap
blo
major
allergen
blomia
tropicali
fong
cheng
yi
hugo
p
van
bever
bee
wah
lee
kaw
yan
chua
nation
univers
singapor
paediatr
singapor
singapor
background
blomia
tropicali
one
predomin
domest
mite
speci
tropic
subtrop
countri
blo
major
allergen
report
ige
sensit
rate
blomia
tropicali
allerg
subject
aim
object
studi
determin
ige
epitop
blo
mite
allerg
children
method
five
overlap
peptid
aa
aa
aa
aa
aa
gener
pcr
blo
fulllength
cdna
ige
reactiv
peptid
full
length
blo
determin
elisa
assay
blomia
tropicali
skin
test
posit
children
ige
elisa
unit
determin
semipurifi
human
ige
standard
curv
wherea
igg
elisa
unit
determin
x
dilut
factor
result
ige
epitop
map
experi
reveal
low
level
ige
bind
small
peptid
ntermin
p
g
compar
larger
peptid
indic
blo
major
ige
epitop
locat
ctermin
conform
depend
contrast
higher
level
found
compar
p
g
indic
major
epitop
locat
nand
ctermin
blo
peptid
bound
lower
level
p
g
suggest
epitop
uniqu
major
epitop
seem
locat
ctermin
conform
depend
conclus
data
reveal
ige
epitop
found
mainli
ctermin
blot
highli
conform
depend
wherea
epitop
found
throughout
whole
blot
result
suggest
recombin
hypoallergen
blo
immunotherapi
achiev
modifi
ige
epitop
retain
igg
epitop
mohammad
fereidouni
mehdi
bakhshaei
abdolreza
varasteh
mashhad
univers
medic
scienc
immunolog
research
center
mashhad
islam
republ
iran
mashhad
univers
medic
scienc
otorhinolaryngologyhead
neck
surgeri
mashhad
islam
republ
iran
background
allerg
rhiniti
preval
allerg
diseas
throughout
world
recent
studi
show
allerg
rhiniti
common
problem
mashad
iran
howev
littl
known
relat
skin
test
reactiv
aeroallergen
allerg
rhiniti
iran
object
aim
studi
character
frequent
indoor
outdoor
grass
tree
inhal
allergen
involv
allerg
rhiniti
mashad
iran
method
total
case
femal
male
age
mean
age
year
diagnos
current
activ
allerg
rhiniti
base
isaac
rhiniti
core
questionnair
clinic
present
underw
standard
skin
prick
test
indoor
grass
tree
aeroallergen
result
patient
reactiv
least
one
aeroallergen
patient
posit
reaction
allergen
patient
mono
sensit
sensit
preval
outdoor
allergen
indoor
allergen
patient
vs
individu
pollen
allergen
highest
posit
rate
pollen
careless
weed
amaranthu
palmeri
russian
thistl
salsola
kali
redroot
amaranthu
retroflexu
burn
bush
kochia
scoparia
lambsquart
chenopodium
album
eastern
cotton
wood
populu
deltoid
white
ash
fraxinu
americana
american
sycamor
platanu
occidentali
common
indoor
allergen
dermatophagoid
pteronyssinu
cockroach
mix
american
german
hous
dust
dermatophagoid
farina
signific
weak
correl
sum
wheal
size
serum
total
ige
level
also
number
posit
skin
test
respons
serum
total
igeth
sum
mean
wheal
size
larger
men
women
vs
outdoor
allergen
statist
signific
redroot
russian
thistl
careless
weed
greatest
mean
wheal
size
respect
conclus
present
studi
reveal
preval
skin
prick
reactiv
outdoor
allergen
particularli
grass
weed
high
among
iranian
allerg
rhiniti
patient
although
indoor
allergen
seem
common
among
patient
solut
structur
phl
p
major
allergen
timothi
grass
pollen
irena
matecko
kristian
schweimer
arnd
petersen
wolfmeinhard
becker
roland
suck
paul
univers
bayreuth
depart
biopolym
bayreuth
germani
molecular
clinic
allergolog
research
center
borstel
borstel
germani
allergopharma
joachim
ganzer
kg
allergopharma
joachim
ganzer
kg
reinbek
germani
popul
industri
countri
suffer
season
allerg
rhiniti
commonli
known
bhay
fever
pollen
grass
tree
weed
frequent
allergen
sourc
structur
similar
found
among
allergen
divers
allergen
sourc
repres
molecular
structur
basi
immunolog
cross
reactiv
thu
explain
allerg
patient
exhibit
clinic
symptom
ige
reactiv
variou
unrel
allergen
sourc
bind
allergen
correspond
ige
import
step
immunoreact
knowledg
structur
bind
region
therefor
import
understand
process
order
improv
diagnosi
diseas
prepar
better
allergicspecif
immunotheraphi
timothi
grass
phleum
pratens
pollen
import
allergen
sourc
northern
central
europ
set
allergen
best
character
within
differ
grass
phl
p
recent
isol
timothi
grass
pollen
extract
amino
acid
sequenc
homolog
comparison
belong
group
allergen
work
determin
solut
structur
phl
p
nmr
solut
structur
comparison
structur
member
group
like
phl
p
phl
p
help
us
find
specif
igereact
eppitop
find
better
cure
diseas
investig
pollen
asthma
death
islamabad
pakistan
ministri
agricultur
plant
biolog
islamabad
pakistan
pakistan
museum
natur
histori
botani
islamabad
pakistan
introduct
sever
asthma
death
report
islamabad
spring
allergi
season
affect
thousand
resid
investig
death
patient
due
asthma
last
ten
day
march
order
find
possibl
caus
symptom
investig
sibl
deceas
case
male
year
histori
rhiniti
spring
season
develop
sudden
difficulti
breath
walk
market
sunset
shift
nearest
hospit
die
reach
hospit
approxim
minut
onset
attack
case
femal
medic
doctor
year
mother
children
age
year
develop
asthma
suddenli
hour
sunset
rush
hospit
like
previou
case
expir
reach
hospit
approxim
minut
onset
symptom
case
year
old
femal
mother
children
age
year
expir
home
midnight
approxim
minut
onset
first
symptom
asthma
common
case
deceas
patient
previou
histori
allerg
rhiniti
occasion
asthma
spring
pollen
season
islamabad
none
ever
suffer
sever
asthma
hospitalis
promin
count
paper
mulberri
pollen
excess
grain
day
humid
due
forthcom
thunderstorm
rain
none
patient
take
regular
prevent
treatment
allergi
asthma
time
episod
none
investig
allergi
lifetim
method
contact
sibl
expir
patient
found
posit
histori
season
spring
allergi
brother
case
sister
one
son
case
one
sister
case
one
sibl
case
never
report
symptom
asthma
ever
case
sibl
result
skin
prick
allergi
test
symptomat
patient
reveal
strong
result
mm
wheal
pollen
paper
mulberri
broussenetia
papyrifera
pollen
conclus
probabl
deceas
patient
suffer
allergi
pollen
paper
mulberri
expir
due
thunderstorm
effect
peak
paper
mulberri
pollen
allergi
incrimin
blomia
tropicali
potent
allergen
indian
hous
dust
sanjay
podder
goutam
kumar
saha
univers
calcutta
depart
zoolog
kolkata
india
allergi
hous
dust
mite
particularli
genu
dermatophagoid
common
featur
tropic
climat
like
kolkata
india
lead
variou
nasobronchi
allerg
manifest
analysi
hous
dust
sampl
collect
hous
asthmat
patient
kolkata
reveal
varieti
acarin
fauna
mite
belong
genu
dermatophagoid
predomin
compris
total
acarin
popul
follow
blomia
tropicali
austroglycyphagu
geniculatu
perus
literatur
reveal
work
role
hous
dust
mite
allerg
etiolog
mainli
concentr
genu
dermatophagoid
alon
work
incrimin
role
blomia
tropicali
hous
dust
allergi
yet
report
india
although
contribut
significantli
toward
domest
acarin
popul
high
preval
mite
speci
patient
environ
tempt
us
search
allerg
etiolog
toward
speci
mite
allergi
skin
test
hous
dust
hous
dust
mite
reveal
encourag
result
blomia
tropicali
allerg
asthmat
kolkata
respond
posit
toward
speci
mite
total
serum
ige
level
patient
vari
ku
ml
mean
kuml
detect
allergen
specif
ige
antibodi
speci
mite
also
confirm
role
hous
dust
allergi
patient
show
high
high
show
moder
ige
level
mite
antigen
present
studi
incrimin
blomia
tropicali
import
sourc
allergen
hous
dust
indian
condit
aeroallergen
sensit
patient
allerg
rhiniti
asthma
manimaran
marappan
dd
hospit
research
centr
pulmonolog
allergi
chennai
india
background
allerg
rhiniti
asthma
preval
world
effici
diagnosi
effect
therapi
import
know
preval
pattern
sensitis
locat
geograph
area
littl
known
south
coastal
citi
chennai
india
southern
asia
aim
aim
studi
characteris
frequent
inhal
allergen
involv
allerg
rhiniti
asthma
subject
method
total
number
case
male
femal
age
diagnos
allerg
rhiniti
asthma
subject
undergo
standradis
skin
prick
test
common
allergen
reaction
consid
posit
mean
wheal
diamet
atleast
mm
neg
control
patient
evalu
sensitis
allergen
number
posit
reaction
mean
wheal
size
result
patient
reactiv
atlest
one
allergen
patient
posit
reaction
allergen
common
allergen
dpteronyssiniu
dfarina
hous
dust
mosquito
mix
among
pollen
parthinium
chenopodium
among
food
allergen
citru
mix
conclus
present
studi
reveal
preval
skin
prick
reactiv
allergen
particularli
hous
dust
mite
high
among
peopl
chennai
sensit
local
prepar
allergen
extract
hous
dust
mite
patient
respiratori
allergi
eastern
kingdom
saudi
arabia
emad
koshak
hussein
almehdar
tarek
gheith
magdi
abdelreheim
king
abdulaziz
univers
intern
medicin
jeddah
saudi
arabia
king
abdulaziz
univers
biolog
scienc
jeddah
saudi
arabia
zagazig
univers
microbiolog
immunolog
zagazig
egypt
ein
sham
univers
allergi
unit
cairo
egypt
introduct
preval
sensit
allergen
hous
dust
mite
hdm
patient
respiratori
allergen
appear
directli
correl
exposur
object
explor
sensit
local
prepar
allergen
extract
hdm
patient
respiratori
allergi
eastern
kingdom
saudi
arabia
ksa
method
hous
dust
collect
differ
hous
ksa
put
cultur
media
plate
contain
mixtur
charcoal
gypsum
water
dri
wood
excelsior
crush
maiz
hdm
nutrit
ad
incub
chamber
adjust
rel
humid
temperatur
c
one
month
regular
observ
three
type
hdm
isol
cultur
dermatophagoid
pteronyssinu
dp
dermatophgoid
farina
df
blomia
tropicali
bt
allergen
extract
prepar
local
use
weightvolum
method
concentr
skin
prick
test
spt
sensit
base
posit
reactiv
standard
spt
perform
patient
respiratori
allergi
result
patient
primari
diagnos
allerg
rhiniti
patient
bronchial
asthma
patient
studi
age
year
old
spt
posit
dp
patient
polysensit
hdm
monosensit
df
patient
polysensit
hdm
monosensit
bt
patient
polysensit
hdm
conclus
preval
sensit
local
prepar
allergen
extract
hdm
especi
dp
follow
df
predomin
patient
respiratori
allergi
seen
eastern
ksa
sensit
bt
patient
describ
fist
time
need
evalu
relationship
signific
geograph
area
properli
manufactur
extract
local
allergen
may
help
determin
new
region
environment
factor
allergi
sensitis
hous
dust
hous
dust
mite
nasobronchi
allerg
patient
kolkata
metropoli
india
sanjoy
podder
goutam
saha
salil
gupta
univers
calcutta
zoolog
kolkata
india
background
recent
studi
reveal
presenc
huge
quantiti
report
allergen
mite
viz
dermatophagoid
pteronyssinu
farina
blomia
tropicali
indoor
environ
kolkata
immedi
hypersensit
dust
mite
along
hous
dust
may
play
role
pathogenesi
nasobronchi
allerg
diseas
present
studi
evalu
sensitis
rate
toward
hous
dust
hous
dust
mite
among
patient
suffer
variou
nasobronchi
allerg
manifest
resid
kolkata
metropoli
area
india
method
skin
prick
test
perform
total
patient
male
femal
healthi
control
use
extract
four
allergen
viz
dermatophagoid
pteronyssinu
farina
blomia
tropicali
hous
dust
allergen
total
serum
ige
measur
use
eia
techniqu
specif
ige
allergen
measur
follow
pharmacia
immuno
cap
system
influenc
age
gender
allergen
sensit
also
investig
result
sensitis
rate
among
nasobronchi
allerg
patient
hous
dust
hous
dust
mite
allergen
test
follow
hous
dust
dermatophagoid
pteronyssinu
blomia
tropicali
farina
frequenc
posit
skin
respons
found
independ
age
gender
total
serum
ige
level
patient
vari
iuml
mean
specif
ige
antibodi
test
prove
patient
show
sensit
toward
least
one
allergen
test
discuss
nasobronchi
allerg
patient
highli
sensit
hous
dust
three
allergen
mite
thu
dust
mite
hous
dust
consid
import
allergen
sourc
area
year
old
white
male
past
histori
crohn
diseas
present
ed
oneweek
histori
pain
rash
edema
involv
lower
extrem
pain
local
lower
extrem
bilater
extend
mid
shin
distal
toe
particularli
wors
medial
aspect
left
foot
also
notic
pruriti
palpabl
rash
area
palpabl
prurit
rash
improv
petechi
rash
time
present
bring
pictur
rash
worst
symptom
exacerb
crohn
diseas
compliant
medic
occurr
rash
tempor
relat
inject
adalimumab
last
dose
week
prior
admiss
physic
exam
reveal
edema
lower
extrem
scatter
nonblanch
petechi
rash
also
tender
decreas
rang
motion
ankl
sensori
deficit
laboratori
result
includ
cbc
cmp
pt
ptt
rheumatoid
factor
antihiston
antibodi
antid
dna
antibodi
level
within
normal
rang
esr
crp
ana
anca
serum
cryoglobulin
hepat
screen
neg
skin
biopsi
result
reveal
mix
cellular
vascul
suggest
resolv
leukocytoclast
vascul
discharg
receiv
next
dose
adalimumab
result
redevelop
rash
sever
present
vascul
appear
rare
potenti
seriou
complic
antitnf
therapi
like
repres
type
iii
hypersensit
reaction
patient
develop
reaction
safe
practic
stop
tnf
antagonist
treat
regimen
steroid
antihistamin
without
immunosuppress
agent
case
repres
rare
hypersensit
reaction
human
antibodi
like
adalimumab
drug
antagon
demonstr
effect
control
inflammatori
activ
inhibit
progress
structur
damag
patient
chronic
arthropathi
otherwis
use
drug
produc
quit
frequent
side
effect
skin
reaction
one
frequent
infecti
diseas
wide
amount
skin
reaction
describ
drug
system
erythemat
lupu
necrot
vascul
discoid
lupu
multiform
exud
erytema
stevensjohnson
syndrom
toxic
epiderm
necrolysi
eczema
urticaria
etc
introduc
case
year
old
patient
rheumatoid
arthriti
develop
skin
reaction
high
suspicion
hypersensit
drug
reaction
two
year
treat
etanercept
mg
twice
week
leflunomid
mg
day
develop
minut
administr
drug
vesicular
itchi
rash
inject
site
itchi
isol
wheal
bodi
perform
skin
test
includ
pricktest
intradermoreact
patchtest
etanercept
infliximab
adalimumab
leflunomid
use
blood
sampl
patient
basophil
activ
test
bat
drug
perform
subcutan
provoc
etanercept
adalimumab
well
order
rule
possibl
irrit
reaction
perform
pricktest
intradermoreact
etanercept
five
healthi
control
pricktest
intradermoreact
etanercept
posit
neg
drug
bat
posit
etanercept
neg
leflunomid
infliximab
adalimumab
due
result
carri
subcutan
provoc
etanercept
adalimumab
posit
etanercept
neg
adalimumab
skin
test
healthi
control
case
neg
present
first
case
patient
type
hypersensit
reaction
etanercept
demonstr
test
vivo
vitro
confirm
subcutan
provoc
despit
skin
reaction
type
drug
quit
frequent
enough
evid
publish
tri
clarifi
immunolog
mechan
implic
articl
open
new
expect
studi
side
effect
skin
reaction
drug
take
account
effect
drug
chronic
arthropathi
use
probabl
wide
spread
oral
hydroxychloroquin
desensit
year
old
male
cutan
lupu
cherri
ann
distor
lara
aleta
madelein
sumpaico
philippin
gener
hospit
section
allergyimmunolog
manila
philippin
background
hydroxychloroquin
antimalari
drug
immunomodulatori
cytotox
properti
use
treatment
lupu
erythematosu
advers
cutan
reaction
form
rash
common
sideeffect
occur
though
mild
reaction
often
reason
cessat
treatment
first
report
case
rapid
oral
desensit
hydroxychloroquin
method
present
rapid
oral
hydroxychloroquin
desensit
protocol
patient
develop
pruritu
hydroxychloroquin
result
year
old
patient
diagnos
cutan
lupu
present
histori
malar
rash
arthralgia
diagnost
test
consist
cutan
lupu
start
prednison
calcium
carbon
aspirin
one
year
start
hydroxychloroquin
better
control
mg
per
day
week
treatment
develop
pruritu
within
two
hour
intak
refer
hydroxychloroquin
desensit
use
rapid
desensit
protocol
oppos
publish
slow
desensit
protocol
mate
et
al
cover
day
patient
start
total
dose
doubl
q
minut
reach
cumul
dose
day
mg
pruritu
advers
reaction
observ
patient
still
maintain
hydroxychloroquin
present
time
conclus
first
report
rapid
hydroxychloroquin
desensit
protocol
demonstr
rapid
desensit
may
use
drug
essenti
allerg
patient
oral
mitotan
desensit
year
old
femal
adrenocort
carcinoma
cherri
ann
distor
julia
de
leon
madelein
sumpaico
philippin
gener
hospit
section
allergyimmunolog
manila
philippin
background
mitotan
chemotherapeut
drug
use
treatment
unresect
adrenocort
carcinoma
associ
variou
sideeffect
may
affect
intak
first
report
case
oral
desensit
mitotan
method
present
oral
mitotan
desensit
protocol
patient
develop
prurit
maculopapular
rash
angioedema
mitotan
result
year
old
patient
diagnos
adrenocort
carcinoma
present
histori
amenorrhea
hirshut
striae
obes
underw
workup
excis
biopsi
exploratori
laparotomi
reveal
adrenocort
carcinoma
prednison
start
symptom
subsequ
resolv
month
postsurgeri
medic
treatment
recurr
symptom
restart
prednison
underw
anoth
mass
excis
prednison
discontinu
mitotan
initi
mg
tablet
three
time
day
week
develop
prurit
maculopapular
rash
associ
angioedema
periauricular
swell
within
two
hour
intak
refer
mitotan
desensit
use
protocol
start
initi
dose
total
dose
doubl
q
minut
reach
total
cumul
dose
day
mg
toler
procedur
well
untoward
sideeffect
present
still
mitotan
conclus
first
report
success
mitotan
desensit
protocol
demonstr
desensit
may
option
good
altern
drug
avail
allerg
patient
ravishankar
sargur
william
egner
r
robinson
sheffield
teach
hospit
nh
foundat
trust
clinic
immunolog
allergi
unit
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
clinic
immunolog
allergi
unit
sheffield
unit
kingdom
chesterfield
roayl
hospit
medicin
chesterfield
unit
kingdom
background
immunolog
respons
insulin
form
igg
ige
antibodi
common
clinic
problem
relat
immunolog
reaction
uncommon
gell
coomb
type
ii
iii
iv
reaction
report
antigen
may
result
sever
factor
insulin
heterolog
protein
alter
tertiari
structur
insulin
presenc
noninsulin
protein
contamin
pharmaceut
formul
addit
ige
mediat
local
reaction
common
almost
alway
subsid
spontan
use
human
insulin
hypersensit
reaction
becom
rare
case
report
report
type
diabet
develop
interest
combin
signific
immedi
cutan
reaction
delay
type
iii
type
iv
reaction
insulin
includ
human
recombin
prepar
skin
test
perform
form
commerci
avail
insulin
insulin
analogu
strongli
posit
skin
test
neg
solvent
excipi
addit
high
titr
specif
ige
igg
antibodi
insulin
demonstr
bovin
porcin
human
insulin
attempt
desensit
subcutan
insulinhuman
mixtard
initi
unsuccess
intens
desensitis
regimen
subcutan
administr
human
actrapid
follow
human
mixtard
hour
done
follow
modifi
insulin
desensitis
schedul
result
day
dose
result
system
urticaria
minut
next
dose
reduc
previou
dose
caus
reaction
increment
done
unit
per
inject
hypoglycemia
prevent
infus
dextros
throughout
desensitis
procedur
hour
patient
toler
human
mixtard
dose
unit
unit
conclus
unus
case
insulin
allergi
reslut
multipl
immunolog
mechan
respond
intens
desensitis
regimen
within
month
success
induct
toler
reduct
igg
ige
anti
insulin
titr
cutan
hypersensit
reaction
inhibitor
souhad
al
faqih
nation
hospit
allergi
khartoum
sudan
background
patient
cutan
hypersensit
nonsteroid
antiinflammatori
drug
nsaid
exhibit
clinic
toler
specif
inhibitor
coxib
howev
subset
patient
develop
urticaria
angioedema
expos
coxib
mechan
urticaria
angioedema
due
coxib
present
unknown
paper
discuss
preval
skin
reaction
due
coxib
possibl
mechan
mediat
advers
manifest
method
total
patient
femal
male
mean
age
year
urticaria
andor
angioedema
due
nonselect
nsaid
studi
septemb
septemb
drug
pattern
show
crossreactor
singlereactor
cutan
clinic
pattern
mix
reaction
respiratorycutan
system
reaction
oral
provoc
test
carri
preferenti
specif
inhibitor
addit
pubm
search
publish
studi
toler
specif
inhibitor
nsaidhypersensit
subject
perform
conclus
posit
oral
challeng
nimesulid
observ
studi
patient
meloxicam
celecoxib
etoricoxib
valdecoxib
rofecoxib
nsaidintoler
patient
toler
coxib
oral
challeng
small
subgroup
patient
develop
urticaria
although
studi
valdecoxib
etoricoxib
result
agreement
major
publish
studi
deal
toler
rofecoxib
reaction
rate
celecoxib
reaction
rate
cutan
reaction
rate
correl
vitro
inhibit
differ
inhibitor
two
possibl
mechan
propos
explain
urticaria
induc
coxib
igemedi
allerg
respons
inhibit
import
drug
challeng
workup
adr
chemotherapeut
agent
rimini
hospit
pharmaci
rimini
itali
desensit
allopurinol
effect
treatment
select
patient
cutan
symptom
respond
therapi
altern
clinic
case
old
patient
gout
arthropathi
uric
milligramdecilitr
allerg
allopurinol
pruritu
maculopapular
rash
associ
patholog
renal
insuffici
creatinin
milligram
decilitr
myelodysplast
syndrom
therapi
alten
drug
sulfinpyrazon
rasburicas
effect
reduc
level
uric
acid
method
prepar
one
tablet
mg
allopurinol
weigh
crush
mortar
mg
rice
starch
fuitalian
ad
progress
mortar
standard
geometr
diluit
techniqu
obtain
homogen
allopurinol
dispers
mix
powder
total
weigth
mg
obtain
unit
dose
contain
mcg
mcg
mcg
mcg
mg
mg
respect
weigh
mg
mg
mg
mg
mg
mg
mg
mix
powder
obtain
unit
dose
contain
allopurinol
mg
one
tablet
mg
allopurinol
crush
mortar
one
tablet
weigh
dose
manifactur
capsul
success
treatment
come
carri
follow
outlin
propos
fam
ag
consider
associ
patholog
particular
renal
insuffici
dosag
increment
carri
everi
gg
employ
dose
mcg
mg
mg
treatment
last
total
day
cutan
advers
reaction
taken
place
neither
pruritu
symptom
first
dosag
given
hospit
follow
outpati
depart
necessari
observ
think
procedur
easi
sure
patient
type
patholog
stevensjohnson
syndrom
hemodialysisassoci
hypersensit
reaction
old
male
leon
bautista
iii
cesar
joseph
gloria
madelein
sumpaico
univers
philippinesphilippin
gener
hospit
allergyimmunolog
depart
manila
philippin
background
stevensjohnson
syndrom
sj
often
describ
diffus
sever
mucocutan
erupt
involv
two
mucos
surfac
major
case
attribut
drug
exposur
hemodialysisassoci
hypersensit
reaction
well
document
literatur
major
would
present
flush
urticaria
periorbit
facial
edema
bronchial
hypersecret
hypotens
first
report
case
hemodialysisassoci
sj
method
present
patient
develop
sj
hemodialysi
result
old
male
diagnos
chronic
kidney
diseas
uremia
less
hour
initi
hemodialysi
patient
develop
gener
prurit
erythemat
macular
rahe
thought
advers
reaction
present
antibiot
thu
antibiot
discontinu
second
hemodialysi
rash
progress
increas
erythema
exfoli
thought
anaphylactoid
reaction
ethylen
oxid
present
dialyz
thu
premed
prior
subsequ
hemodialysi
done
subsequ
hemodialysi
lesion
becam
local
flaccid
bulla
later
develop
epiderm
detach
involv
eye
oral
mucosa
receiv
intraven
hydrocortison
mgkgday
equival
methylprednisolon
howev
patient
condit
worsen
requir
endotrach
intub
subsequ
die
due
multiorgan
failur
strong
histori
surround
hemodialysi
session
progress
lesion
plu
high
index
suspicion
point
ethylen
oxid
hypersensit
caus
sj
conclus
first
report
case
hemodialysisassoci
sj
case
report
demonstr
import
earli
detect
referr
manag
hemodialysisassoci
hypersensit
reaction
replac
ethylen
oxid
steam
gamma
radiat
may
help
solv
problem
impact
polypharmaci
intervent
advers
drug
reaction
cost
care
new
orlean
senior
prem
kumar
kareem
elshatori
e
elshatori
carlo
vital
sandhya
mani
annett
fiorillo
louisiana
state
univers
health
scienc
center
allergyimmunolog
new
orlean
unit
state
background
unit
state
us
death
annual
attribut
seriou
advers
drug
reaction
includ
limit
drug
allergi
estim
total
cost
event
billion
us
dollar
polypharmaci
particularli
senior
contribut
increas
likelihood
advers
drug
reaction
adr
polypharmaci
defin
use
five
prescript
medic
longterm
basi
report
intervent
studi
state
louisiana
us
fifti
percent
senior
polypharmaci
contrast
twenti
percent
preval
rest
unit
state
goal
pilot
clinic
observ
studi
demonstr
whether
cessat
inappropri
medic
would
decreas
advers
drug
reaction
lower
monthli
cost
medic
method
nine
patient
age
year
met
definit
polypharmaci
evalu
patient
known
human
immunodefici
viru
hivaid
transplant
recipi
malign
exclud
secondari
known
requir
multipl
medic
medic
appropri
index
mai
util
stop
inappropri
medic
adr
mini
mental
statu
exam
mmse
score
monthli
cost
medic
record
intervent
result
mean
number
medic
use
daili
decreas
medic
medic
intervent
respect
adr
decreas
occurr
intervent
occurr
intervent
mmse
mean
score
improv
prior
intervent
tuberculosi
continu
major
caus
morbid
mortal
worldwid
current
avail
drug
effect
treatment
diseas
latent
infect
may
caus
seriou
allerg
reaction
often
difficult
manag
diagnosi
allerg
drug
reaction
establish
reintroduct
drug
lead
toler
consid
induct
toler
usual
possibl
patient
report
observ
women
age
vari
year
without
immunodefici
treat
pulmonari
tuberculosi
tpm
patient
pleural
tuberculosi
confirm
histolog
patient
tpm
patient
receiv
antituberculosi
treatment
contain
srhz
two
first
rhz
last
four
one
adequ
posolog
patient
present
cutan
reaction
graviti
moder
sever
occur
day
begin
treatment
treatment
stop
disappear
lesion
case
reintroduct
practis
success
five
patient
therapeut
protocol
chang
patient
consid
graviti
lesion
cutan
advers
drug
reaction
induc
gener
substitut
zylor
residu
sensit
allopurinol
marielorrain
chandeclerc
cuni
jeanluc
schmutz
annick
barbaud
hopit
fournier
dermatologi
nanci
franc
cutan
advers
drug
reaction
cadr
due
gener
drug
seem
rare
rare
report
except
antiepilept
drug
report
first
case
cadr
occur
drug
well
toler
year
replac
gener
substitut
year
old
man
taken
zylor
pill
year
develop
maculopaplar
rash
mpr
day
replac
zylor
pill
gener
substitut
call
allopurinol
ge
four
day
stop
intak
allopurinol
ge
mpr
spontan
disappear
biolog
find
remain
normal
without
liver
involv
two
month
patient
took
zylor
develop
gener
erupt
sever
involv
flexur
area
day
follow
reintak
drug
second
cadr
less
sever
previou
one
three
month
later
intak
zylor
disrupt
cadr
vanish
day
modif
usual
treatment
dermatoallergolog
investig
perform
three
month
disappear
cadr
stop
zylor
drug
patch
prick
test
done
result
neg
test
knowledg
report
first
case
cadr
due
allopurinol
appear
replac
well
toler
zylor
one
gener
substitut
gener
substitut
respons
induc
sensit
allopurinol
unfortun
led
relaps
cadr
zylor
reintroduc
even
though
clinic
eatur
less
sever
second
cadr
common
excipi
zylor
gener
report
case
literatur
cadr
occur
replac
drug
gener
substitut
advers
effect
relaps
origin
drug
readministr
thu
knowledg
first
case
reintroduct
origin
drug
associ
relaps
cadr
observ
new
mechan
must
evok
type
therapeut
accid
ie
role
excipi
list
pharmacolog
notic
non
toler
commerci
form
drug
induc
sensit
activ
compound
valu
skin
test
investig
suspect
system
corticosteroid
hypersensit
michelet
philipp
trechot
jeanluc
schmutz
annick
barbaud
fournier
hospit
dermatolog
nanci
franc
central
hospit
pharmacolog
nanci
franc
background
establish
valu
patch
test
pt
prick
test
pt
intraderm
test
idt
suspect
immedi
delay
hypersensit
corticosteroid
cs
system
administ
materi
method
patient
women
men
mean
age
yo
refer
immedi
delay
cutan
advers
reaction
car
possibl
due
cs
system
administ
enrol
pt
special
seri
cs
dilut
petrolatum
read
minut
one
week
neg
pt
carri
tixocortol
budesonid
betamethason
betamethason
dipropion
hydrocortison
butyr
triamcinolon
acetonid
involv
cs
pt
pt
neg
idt
carri
least
one
cs
group
goossen
classif
hydrocortison
group
triamcinolon
acetonid
group
b
betamethason
group
c
betamethason
dipropion
group
progress
increas
dosag
skin
test
neg
oral
provoc
test
involv
cs
anoth
cs
group
differ
group
propos
oral
administr
perform
hospit
surveil
versu
placebo
progress
increas
concentr
full
dosag
result
patient
posit
result
either
skin
test
oral
administr
pt
posit
case
none
posit
pt
patient
posit
idt
one
posit
repeat
open
applic
test
patient
test
neg
thirtyeight
accept
one
oral
administr
oa
cs
oa
perform
among
posit
oa
involv
cs
posit
oa
cs
belong
group
posit
oa
cs
belong
anoth
group
conclus
hypersensit
system
cs
suppos
rare
exist
confirm
cs
sensit
patient
immedi
delay
mechan
demonstr
skin
test
use
manag
patient
mean
valu
investig
suspect
cs
hypersensit
well
toler
seem
good
neg
predict
valu
seri
allow
confirm
sensit
posit
test
lead
oa
initi
respons
chemic
group
cs
anoth
group
low
risk
reactiv
stefan
cimbollek
teresa
maria
robledo
avila
angustia
nieto
manuel
hospit
u
virgen
del
allergi
unit
sevil
spain
background
proton
pump
inhibitor
wide
use
case
anaphylaxi
report
case
cutan
test
prove
use
one
case
cytometr
cellular
allergen
test
fast
perform
confirm
exist
specif
ige
case
report
present
year
old
patient
whith
previou
histori
urticaria
one
episod
associ
nausea
short
breath
correl
symptom
food
ingest
use
ocassion
omeprazol
due
acid
reflux
method
skin
prick
test
intraderm
test
perform
omeprazol
pantoprazol
dilut
neg
result
control
oral
challeng
program
patient
start
gener
flush
pruritu
eyelid
edema
abdomin
pain
short
breath
minut
last
dose
omeprazol
physic
examin
reveal
wheez
hypotens
patient
recov
two
hour
follow
intraven
infus
ml
salin
iv
push
one
ampoul
pheniramin
mg
prednisolon
fast
also
call
basophil
activ
test
perform
neg
result
conclus
present
case
anaphylaxi
omeprazol
could
confirm
cutan
basophil
activ
test
previous
report
drug
allergi
pollinosi
pattern
chang
background
present
previou
eaaci
meet
studi
associ
pollen
drug
allergi
studi
lactam
frequent
associ
pollen
allergi
non
steroid
antiinflammatori
drug
nsaid
aim
present
studi
verifi
associ
pattern
chang
method
patient
allerg
pollen
hypersensit
drug
studi
last
five
year
patient
simultan
allerg
pollen
drug
pollinosi
drug
allergi
clinic
histori
skin
prick
test
pollen
prick
id
necessari
drug
specif
ige
possibl
done
patient
result
femal
male
previous
femal
male
patient
attend
pollinosi
drug
allergi
pollen
allergi
clinic
rhiniti
asthma
alon
drug
allergi
urticariaangioedema
shock
bronchospasm
skin
prick
testsgrass
pollen
parietaria
oliv
tree
drug
allergi
lactam
nsaid
drug
correl
allergi
one
specif
pollen
group
drug
conclus
associ
pollinosi
drug
allergi
frequent
report
result
previous
obtain
seri
greater
number
grass
pollen
allergi
instead
parietaria
greater
incid
nsaid
hypersensit
instead
lactam
result
explain
decreas
antibiot
prescript
allerg
patient
increas
use
nsaid
last
year
background
drug
hypersensit
common
clinic
problem
associ
signific
morbid
mortal
accord
volchek
advers
drug
reaction
major
health
issu
encount
frequent
inpati
outpati
set
past
year
increas
number
medic
manufactur
increas
emphasi
pharmacotherapeut
vigil
order
reduc
incid
reaction
object
purpos
investig
review
record
patient
refer
advers
drug
reaction
determin
commonli
implic
drug
common
clinic
manifest
well
look
sourc
referr
consult
method
chart
review
frequenc
distribut
result
total
patient
refer
allergi
section
slowli
increas
trend
year
forti
percent
patient
seen
outpati
clinic
inpati
referr
among
admit
number
adult
pediatr
case
nearli
respect
outpati
clinic
adult
referr
outnumb
pediatr
case
twothird
common
manifest
inpati
set
cutan
reaction
maculopapular
rash
urticaria
angioedema
follow
almost
equal
jaundic
difficulti
breath
fever
chill
rare
gener
reaction
stevensjohnson
syndrom
sj
toxic
epiderm
necrolysi
ten
also
report
averag
case
per
year
commonli
implic
drug
inand
outpati
set
still
betalactam
antibiot
follow
antituberculosi
medic
anticonvuls
asansaid
other
lasparaginas
vitamin
k
allopurinol
five
year
period
increas
trend
conclus
result
shown
past
five
year
although
implic
medic
increas
trend
report
advers
drug
reaction
probabl
due
fact
heighten
awar
regard
issu
increas
number
brand
name
manufactur
may
also
lead
increas
number
advers
reaction
medic
key
word
advers
drug
reaction
updat
tan
tock
seng
hospit
ttsh
prospect
inpati
drug
allergi
report
system
neg
predict
valu
drug
skin
test
investig
cutan
advers
drug
reaction
juli
waton
philip
trechot
carol
lossayav
jeanluc
schmutz
annick
schmutz
fournier
hospit
dermatolog
nanci
franc
central
hospit
pharmacolog
nanci
franc
marin
hospit
epidemiolog
nanci
franc
drug
skin
test
use
etiolog
analys
cutan
advers
drug
reaction
cadr
order
determin
drug
readminist
avoid
cross
reaction
substitut
drug
aim
studi
evalu
neg
predict
valu
npv
drug
skin
test
patient
method
retrospect
analysi
file
patient
refer
cadr
enrol
cadr
clinic
featur
onset
delay
drug
intak
drug
imput
strictli
determin
neg
drug
skin
test
follow
drug
administr
oral
provoc
test
opt
substitut
test
st
drug
class
drug
suspect
cadr
method
file
patient
review
clinic
present
suspect
drug
regist
skin
test
group
drug
increm
done
prick
intraderm
techniqu
progress
concentr
prick
neg
inform
consent
obtain
patient
specif
ige
leucotrien
releas
done
case
techniqu
avail
result
patient
report
one
drug
advers
reaction
femal
male
patient
report
urticariaangiodema
rhiniti
andor
asthma
nsaid
impli
patient
lactam
local
anesthet
associ
reaction
nsaid
lactam
frequent
drug
less
impli
sulfa
drug
quinolon
macrolid
ace
inhibitor
angiotensin
ii
blocker
statin
corticosteroid
vitamin
allopurinol
tetracyclin
gentamycin
furadantin
curaris
tramadol
ranitidin
thyocholchycosid
fibrat
fluconazol
specif
ige
cast
leucotrien
releas
posit
less
case
conclus
nsaid
lactam
frequent
caus
advers
reaction
outpati
clinic
histori
skin
test
step
step
practic
first
diagnost
approach
drug
allergi
outpati
drug
hypersensit
caus
asthma
allerg
rhiniti
fermaid
widal
triad
nonneglig
number
patient
atop
nonatop
sohe
lee
sangmin
lee
hyouksoo
kwon
changhan
park
heungwoo
park
yoonseok
chang
sunsin
kim
sangheon
cho
kyungup
min
youyoung
kim
seoul
nation
univers
hospit
depart
intern
medicin
seoul
republ
korea
seoul
nation
univers
bundang
hospit
depart
intern
medicin
seongnam
republ
korea
background
antibiot
skin
test
ast
use
procedur
identifi
patient
ige
mediat
hypersensit
antibiot
howev
procedur
standard
perform
divers
sometim
inappropri
protocol
among
hospit
korea
object
examin
protocol
ast
major
hospit
korea
compar
literatur
method
routin
protocol
ast
perform
gener
ward
gener
hospit
collect
via
allergist
work
hospit
use
questionnair
addit
review
literatur
search
pubm
medlin
result
allergist
respond
questionnair
hospit
carri
ast
volar
forearm
intraderm
method
without
control
two
hospit
use
salin
neg
control
fals
posit
result
suspect
penicillin
cephalosporin
test
hospit
hospit
detail
test
hospit
penicillin
one
hospit
cephalosporin
hospit
among
penicillin
never
prescrib
one
addit
semisynthet
penicillin
test
hospit
carbapenem
hospit
vancomycin
hospit
aminoglycosid
hospit
monobactam
one
hospit
test
concentr
differ
upto
fold
among
hospit
standard
interpret
also
vari
hospit
gener
method
ast
literatur
intraderm
test
volar
forearm
astwa
recommend
routin
practic
penicillin
cephalosporin
antibiot
literatur
conclus
protocol
ast
vari
greatli
among
gener
hospit
korea
differ
commonli
use
literatur
thu
standard
guidelin
ast
requir
safe
usag
antibiot
case
report
healthi
male
took
amoxicilin
respiratori
infect
two
day
treatment
hour
last
dose
suffer
pruritu
erythema
pain
local
inflamm
peni
vessel
blister
wound
cm
recov
oral
corticoid
antihistamin
topic
antibiot
plu
permangan
potassium
wash
wound
last
week
left
skin
pigment
anoth
occas
took
paracetamol
sore
throat
day
treatment
suffer
similar
wound
need
treatment
follow
toler
nsaid
method
result
written
consent
made
follow
studi
perform
patch
test
paracetamol
concentr
neg
hour
prick
id
test
paracetamol
neg
oral
control
challeng
test
paracetamol
mg
also
neg
recommend
patient
taken
mg
paracetamol
everi
hour
three
day
two
day
treatment
peni
wound
appear
wound
finger
left
hand
appear
wound
diamet
erithemat
descam
plaqu
wound
recov
oral
corticoid
antihistamin
administ
day
challeng
patient
recal
first
reaction
taken
paracetamol
plu
amoxicilin
perform
cutan
oral
challeng
test
amoxicilin
neg
result
patient
took
amoxicilin
day
good
toler
patch
test
true
testi
challeng
test
paraamino
drug
sulfonamid
hydroclorotiazid
neg
conclus
present
infrequ
advers
reaction
due
paracetamol
confirm
challeng
test
skin
reaction
suggest
dual
fix
exanthema
peni
betwen
finger
left
hand
rule
crossreact
paraamino
drug
although
paracetamol
allergi
infrequ
import
investig
studi
drug
involv
advers
reaction
bernard
arnoux
philipp
jean
bousquet
nazima
soohun
laur
rouanetbousquet
pascal
demoli
inserm
montpelli
franc
univers
nme
dept
de
linform
mdical
nme
advers
cutan
reaction
due
glycopeptidesinduc
advers
cutan
reaction
result
immunoallerg
investig
patient
amandin
perrin
philipp
trechot
nadin
petitpain
j
cuni
j
luc
schmutz
annick
barbaud
hopit
fournier
dermatolog
nanci
franc
chu
pharmacovigil
nanci
franc
object
emerg
hightli
resist
staphylococcu
vancomycin
v
teicoplanin
usag
consider
increas
induc
cutan
advers
reaction
car
valu
immunoallerg
investig
yet
determin
method
retrospect
studi
includ
patient
women
men
mean
age
car
suspect
due
glycopeptid
v
case
case
success
v
case
red
man
syndrom
includ
imput
estim
accord
moor
criteria
car
maculopapular
rash
linear
bullou
dermatosi
dress
urticaria
six
week
later
accord
escd
guidelin
drug
skin
test
immunoallergolog
investig
carri
success
drug
patch
test
prick
test
intraderm
test
drug
taken
car
result
skin
test
confirm
respons
glycopeptid
case
crossreact
v
case
follow
neg
immunoallerg
investig
patient
well
toler
provoc
test
glycopeptid
conclus
literatur
seem
safer
v
ototox
rash
nephrotox
similar
efficaci
induc
hypersensit
reaction
red
man
syndrom
case
publish
allerg
crossreact
v
alreadi
report
literatur
rare
patient
unconst
patient
inde
well
toler
provoc
test
glycopeptid
precis
skin
test
neg
v
patient
way
studi
import
clinic
implic
demonstr
skin
test
use
car
due
glycopeptid
determin
respons
drug
test
neg
allow
readministr
anoth
glycopeptid
hospit
surveil
demonstr
crossreact
glycopeptid
constant
link
angioedema
caus
inhibitor
angiotensin
convert
enzym
eotaxin
ecp
malgorzata
basinska
tomasz
basinski
robert
pawlowicz
bernard
panaszek
wroclaw
medic
univers
depart
intern
medicin
allergolog
wroclaw
poland
background
inhibitor
angiotensinconvert
enzym
iac
blocker
angiotensin
ii
type
receptor
blocker
commonli
use
hypertent
chronic
heart
failur
treatment
therapi
believ
safe
howev
angioedema
rare
well
recogn
potenti
lifethreaten
advers
effect
iac
therapi
aim
studi
estim
angioedema
threat
patient
treat
short
long
act
iac
comparison
patient
receiv
blocker
eosinophil
cation
protein
ecp
eotaxin
serum
concentr
use
indic
angioedema
threat
sinc
bradykinin
involv
activ
chemokin
subsequ
eosinophil
method
patient
divid
follow
group
accord
treatment
receiv
blocker
short
act
iac
long
act
iac
control
patient
histori
angioedema
etiolog
unrel
studi
exclud
eotaxin
concentr
serum
determin
standard
solid
phase
sandwich
elisa
ecp
level
serum
assess
pharmacia
cap
system
ecp
fluoro
enzym
immunoassay
feia
method
accord
manufactur
instruct
result
shown
mean
sd
student
test
unpair
sampl
use
statist
analysi
result
statist
signific
differ
regard
serum
ecp
level
blocker
control
group
true
eotaxin
level
ecp
sera
patient
take
short
act
iac
long
act
iac
significantli
higher
control
group
level
eotaxin
higher
serum
patient
take
short
act
iac
pgml
higher
serum
patient
take
long
act
iac
pgml
compar
control
group
pg
ml
conclus
serum
concentr
eotaxin
ecp
play
potenti
role
pathogenesi
iac
induc
angioedema
concentr
may
predict
factor
advers
event
thu
patient
treat
blocker
significantli
lower
risk
angioedema
comparison
patient
take
iac
fix
drug
erupt
caus
tradit
herbal
medicin
jamu
background
fix
drug
erupt
fde
name
recur
site
exposur
medic
jamu
term
commonli
use
describ
tradit
herbal
medicin
product
indonesia
medicin
element
may
made
root
bark
leav
fruit
flower
seed
part
plant
jamu
pegal
linu
indic
treatment
rheumat
bodi
ach
bone
ach
muscl
joint
giddi
toothach
backach
usual
consum
hard
worker
commerci
product
avail
form
powder
pill
capsul
mixtur
cream
illeg
retail
ad
phenylbutazon
allopurinol
paracetamol
jamu
fde
caus
jamu
never
report
yet
case
man
present
multipl
black
macul
upper
left
eyebrow
left
right
cheek
lower
lip
left
right
hand
lesion
initi
appear
small
enlarg
slowli
becam
obviou
concern
patient
past
week
lesion
slightli
itchi
pain
otherwis
healthi
deni
take
medic
except
tradit
herbal
medicin
jamu
past
year
feel
tire
famili
histori
neg
laboratori
examin
within
normal
limit
skin
biopsi
one
lesion
show
vaculolar
degener
basal
cell
pigmentari
incontin
mild
superfici
perivascular
limphohistiocyt
infiltr
eosinophil
discuss
clinic
present
histopatholog
alter
consist
diagnosi
fix
drug
erupt
patient
treat
anaphylact
reaction
gener
anaesthesia
diagnost
approach
preval
anaesthet
involv
mauro
cancian
muzio
meroni
raffael
bendo
elena
ossi
giusepp
realdi
clinica
medica
padova
medic
surgic
depart
padova
itali
istarunivers
padova
pharmacolog
anesthesiolog
depart
padova
itali
background
although
anaphylact
reaction
gener
anaesthesia
show
low
incid
mortal
reach
addit
patient
may
experi
signific
brain
damag
neuromuscular
block
drug
usual
report
common
caus
anaesthesiaelicit
anaphylaxi
possibl
involv
induct
agent
antimicrobi
latex
plasma
expand
drug
consid
unfortun
diagnost
approach
limit
lack
valid
commerci
kit
detect
specif
antibodi
well
occurr
pseudoallerg
reaction
mediat
circul
ige
method
evalu
consecut
case
f
age
rang
yr
well
document
anaphylaxi
gener
anaesthesia
laboratori
assay
wbc
count
eosinophil
cation
protein
serum
tryptas
plasma
iga
total
ige
level
rast
inhal
food
allergen
latex
betalactam
skin
test
patch
andor
prick
test
intraderm
inject
inhal
allergen
egg
soybean
exot
fruit
latex
drug
administ
anaphylaxi
onset
drug
skin
test
perform
commerci
formul
betalactam
heparin
atropin
benzodiazepin
vecuronium
norcuronium
mivacurium
rocuromium
fentanyl
remifentanyl
propofol
droperidol
thiopent
differ
dilut
result
two
patient
show
evid
allergi
norcuronium
mivacurium
respect
three
subject
allerg
amoxicillin
six
latex
heparin
skin
test
elicit
local
wealandflar
respons
one
patient
whilst
diffus
urticaria
itch
observ
one
case
final
appar
anaphylaxi
follow
cardiac
arrest
anaesthesia
asthmat
subject
seem
advers
effect
difficult
intub
rather
true
allerg
pseudoallerg
reaction
unfortun
remain
six
patient
abl
identifi
trigger
factor
also
diagnost
test
avail
assess
nsaid
hypersensit
conclus
latex
allergi
still
repres
least
experi
main
caus
anaphylaxi
gener
anaesthesia
although
reliabl
skin
test
commerci
drug
well
establish
till
procedur
help
prevent
risk
episod
patient
document
anaphylact
reaction
anaesthesia
four
case
steroid
allergi
bronchial
asthma
yoko
murakami
jyunko
ikei
hiroshi
odajima
rumiko
shibata
sankei
nishima
fukuoka
nation
hospit
pediatr
fukuoka
citi
japan
background
corticosteroid
prepar
antiinflammatori
immunosuppress
properti
wide
use
treatment
asthma
allerg
disord
howev
steroid
rare
induc
hypersensit
reaction
sever
reaction
vari
rash
anaphylaxi
death
report
four
case
regard
steroid
allergi
experienc
hospit
recent
case
report
case
year
old
girl
hospit
moder
asthma
attack
rash
develop
sever
minut
given
aminophilin
continu
intraven
infus
hydrocortison
succin
hc
intraven
drip
intraderm
test
hc
posit
diagnos
drug
allergi
chang
predonin
psl
intraven
infus
rash
nt
develop
persist
wheez
decreas
symptom
lung
function
improv
steroid
cancel
case
year
old
girl
mani
kind
food
allergi
hospit
moder
asthma
attack
given
aminophilin
continu
intraven
infus
hydrocortison
succin
hc
intraven
drip
psl
b
bday
intraven
inject
day
show
persist
wheez
decreas
b
diagnos
steroid
allergi
pertussi
infect
intraderm
test
show
posit
psl
hc
methylprednisolon
succin
mp
hydrocortison
sodium
phosphat
wheez
improv
steroid
cancel
case
year
old
femal
patient
hospit
moder
asthma
attack
similar
case
intract
wheez
decreas
persist
intraderm
test
show
posit
psl
hc
diagnos
steroid
allergi
case
year
old
boy
moder
asthma
attack
develop
urticaria
hypotens
receiv
hc
intraven
drip
patient
intraderm
test
hc
psl
show
posit
diagnos
steroid
allergi
conclus
case
show
anaphylact
reaction
mani
case
show
persist
wheez
decreas
treatment
asthma
thought
steroid
allergi
took
cours
protract
asthma
attack
could
present
case
import
consider
striod
allergi
treatment
acut
exacerb
intract
asthma
angioedema
administr
methylprednisolon
treat
drug
allergi
case
report
enrico
compalati
laura
guerra
anthi
rogkak
antonio
scordamaglia
giovanni
passalacqua
giorgio
walter
canonica
allergi
respiratori
diseas
clinic
genoa
univers
depart
intern
medicin
genoa
itali
background
despit
larg
use
corticosteroid
cs
allerg
reaction
drug
remain
uncommon
immedi
allerg
reaction
cs
uncommon
event
usual
provok
excipi
immunolog
nonimmunolog
mechan
propos
delay
reaction
compat
tcell
mediat
respons
crossreact
observ
differ
topic
corticosteroid
classif
crossreact
seem
complet
use
advers
reaction
system
corticosteroid
case
report
signal
case
woman
atopi
contact
sensit
woman
recent
administr
mepivacain
dental
surgeri
proceed
cs
prevent
administr
prednison
hh
clorfenamin
intervent
one
hour
last
dose
premed
follow
anahestet
administr
patient
present
facial
angioaedema
administr
metilprednisolon
treat
advers
event
effect
increas
symptom
manag
patient
studi
corticosteroid
allergi
patch
test
perform
standard
seri
confirm
mention
sensit
skint
test
carri
metilprednisolon
succin
betametason
fosfat
triamcinolon
acetodin
patient
show
immedi
local
reaction
intradermoreact
metilprednisolon
posit
cs
test
comment
prednison
belong
group
corticosteroid
possibl
cross
reaction
may
suggest
cs
poorli
solubl
water
salin
coupl
ester
circumst
patient
react
previou
administr
prednison
metilprednisolon
two
prepar
differ
presenc
succin
ester
second
one
effect
addit
may
reason
exclud
therefor
excipi
includ
test
prepar
commonli
exist
toler
untoler
drug
conclus
drug
advers
reaction
appear
altough
prevent
administr
system
cs
reconsid
possibl
allerg
respons
cs
classif
cross
reactiv
cs
patch
test
intrederm
test
may
provid
use
support
confirm
diagnosi
identifi
altern
toler
molecul
background
erythema
multiform
reaction
pattern
blood
vessel
dermi
secondari
epiderm
chang
manifest
clinic
characterist
erythemat
irisshap
papular
littl
mucou
membran
involv
vesicl
bulla
system
symptom
erupt
usual
confin
extrem
face
classic
target
lesion
case
yearold
girl
erythema
multiform
minor
develop
typic
lesion
involv
skin
erupt
develop
taken
medicin
antihypertens
histopatholog
result
show
focal
hyperkeratosi
acantosi
focal
spongiosi
epidermi
inflammatori
cell
infiltr
lymphocyt
eosinophil
dermi
without
vacuolar
degener
discuss
mild
form
appear
littl
mucou
membran
involv
vesicl
bulla
system
symptom
case
erythemat
patch
vesicl
skin
erupt
usual
confin
extensor
aspect
extrem
classic
target
lesion
clinic
manifest
characterist
classic
target
lesion
character
erythema
multiform
histopatholog
examin
show
appear
like
drug
erupt
without
vacuolar
degener
mean
discrep
clinic
appear
histopatholog
mild
form
erythema
multiform
may
develop
sever
erythema
case
lesion
improv
treatment
steroid
equival
dexamethason
oral
day
divid
dose
conclus
discrep
clinic
appear
histopatholog
erythema
multiform
patient
well
respond
corticosteroid
withdraw
possibl
offend
drug
support
therapi
prompt
diagnosi
treatment
give
good
result
keyword
erythema
multiform
mild
form
classic
target
lesion
vacuolar
degener
sever
reaction
due
fluoroquinolon
toxic
epiderm
necrolysi
case
report
ioana
adriana
bujor
diana
dumitrascu
medic
clinic
univers
medicin
pharmaci
biuliu
hatieganu
allergi
depart
cluj
napoca
romania
background
toxic
epiderm
necrolysi
ten
uncommon
fulmin
mucocutan
diseas
associ
high
preval
mortal
frequent
ten
associ
drug
administr
ten
due
fluoroquinolon
rare
case
report
medlin
ten
due
ciprofloxacin
allerg
reaction
due
fluoroquinolon
rare
anaphylactoid
andor
anaphylact
reaction
estim
occur
patient
fluoroquinolon
new
antibiot
drug
use
mostli
treatment
urinari
respiratori
infect
allergi
fluoroquinolon
may
mani
clinic
manifest
anaphylact
anaphylactoid
reaction
acut
urticaria
without
angioedema
fix
drug
erupt
serum
sicklik
ill
nummular
eczema
frequent
use
quinolon
romania
ciprofloxacin
norfloxacin
patient
evalu
depart
allergi
cluj
napoca
jan
case
allerg
reaction
due
fluoroquinolon
report
case
report
smoke
man
admit
hospit
malais
eritemat
erupt
whole
skin
small
area
denud
epithelium
ulcer
nasal
oral
mucosa
phenomena
associ
sever
itch
burn
sensat
skin
patient
began
day
ago
treatment
ciprofloxacin
acut
bronchiti
drug
took
last
month
complet
examin
patient
present
also
hepatocitolisi
treatment
corticosteroid
antibiot
intens
care
skin
patient
recov
complet
evolut
month
brestitutio
integrum
conclus
toxic
epiderm
necrolysi
ten
rare
increas
rate
report
syndrom
due
ciprofloxacin
could
reconsid
first
choic
option
drug
studi
done
order
find
preval
ten
ciprofloxacin
toxic
epiderm
necrolysi
suspect
due
nimesulid
background
nimesulid
new
nonsteroid
antiinflammatori
drug
antipyret
analges
properti
pruritu
rash
common
cutan
side
effect
associ
nimesulid
toxic
epiderm
necrolysi
induc
drug
rare
potenti
lethal
syndrom
character
sudden
onset
widespread
blister
skin
best
knowledg
previou
report
toxic
epiderm
necrolysi
induc
ingest
nimesulid
medic
literatur
case
year
old
woman
buginess
previou
histori
ever
ten
six
year
ago
probabl
caus
paracetamol
metamphiron
diagnosi
establish
base
anamnesi
clinic
manifest
lesion
consist
gener
erythema
vesicl
bulla
nikolski
sign
posit
eros
epidermolisi
treatment
parenter
infus
dexamethason
intraven
mg
cimetidin
ampul
ciprofloxacin
inject
per
drip
topic
silver
sulfadiazin
framycetin
sulfat
eros
denud
area
discuss
case
diagnosi
toxic
epiderm
necrolysi
base
anamnesi
clinic
manifest
frequent
caus
drug
case
strong
associ
spesif
medic
probabl
caus
nimesulid
clinic
manifest
toxic
epiderm
necrolysi
extens
epiderm
necrosi
exfoli
skin
almost
normal
skin
seen
form
skin
surfac
involv
day
hospit
death
ensu
sepsi
multipl
organ
failur
conclus
toxic
epiderm
necrolysi
presum
spesif
immun
respons
recurr
exposur
trigger
induc
brisk
intens
case
fatal
episod
multipl
organ
failur
usual
steven
johnson
syndrom
bandar
lampung
indonesia
syafei
hamzah
dr
abdul
moeloek
hospit
dermatovenereolog
depart
bandar
lampung
indonesia
background
steven
johnson
syndrom
sj
sever
form
erythema
multiform
relat
mucocutaneu
disord
often
sever
constitut
symptom
associ
high
rate
mortaliy
morbid
subject
find
incid
etiolog
treatment
lenght
stay
complic
method
year
retrosprct
studi
januari
decemb
patient
admit
dermatolog
depart
dr
abdul
moeloek
hospit
lampung
result
among
case
review
male
femal
youngest
patient
year
old
girl
oldest
one
year
old
femal
assum
caus
antibiot
penicillin
deriv
analgesicantipyret
anticonvuls
carbamazepin
patient
unknown
varieti
length
stay
hospit
day
averag
day
system
corticosteroid
choic
fatal
recov
patient
die
caus
death
broncopneumonia
septicemia
gastrointestin
bleed
conclus
incid
steven
johnson
syndrom
dr
abdul
moeloek
hospit
found
femal
bigger
male
highest
group
age
drug
commonli
involv
antibiot
follow
analgesicantipyret
broncopnemoni
mostli
caus
death
steven
johnson
syndrom
suspect
due
sulfasalazin
eni
susilowati
faridha
ilya
mahmud
ghaznawi
anni
adriani
irma
helina
amiruddin
medic
faculti
hasanuddin
univers
dr
wahidin
sudirohusodo
gener
hospit
dermatovenereolog
makassar
indonesia
medic
faculti
hasanuddin
univers
patholog
anatomi
makassar
indonesia
background
steven
johnson
syndrom
sj
diffus
sever
mucocutan
erupt
involv
two
mucos
surfac
without
viscer
involv
often
induc
drug
occasion
elicit
infect
sulfasalazin
sulfa
drug
metabolit
sulfasalazin
may
trigger
immunerespons
lead
cutan
advers
drug
reaction
case
year
old
woman
present
symptom
skin
mucou
membran
eye
lesion
taken
sulfasalazin
sever
day
erupt
physic
examin
reveal
erythema
blister
affect
face
neck
arm
upper
trunk
eros
lip
conjunct
histopatholog
examin
skin
lesion
show
toxic
epiderm
necrolysi
ten
appear
patient
treat
ringer
lactat
dexamethason
mg
per
hour
gentamycin
mg
per
hour
intraven
topic
steroid
hospit
day
patient
cure
without
complic
discuss
case
diagnos
sj
base
anamnesi
clinic
examin
confirm
histopatholog
find
subepiderm
bulla
necrosi
entir
epidermi
inflammatori
infiltr
accord
ten
appear
case
may
degre
overlap
form
sj
evolv
ten
sulfasalazin
sulfa
drug
use
primarili
antiinflammatori
agent
sj
due
sulfasalazin
rare
conclus
sj
due
sulfasalazin
rare
sj
life
threaten
cutan
advers
drug
reaction
evolv
ten
earli
appropri
treatment
may
produc
excel
prognosi
sj
key
word
dispar
ssjten
sulfonamid
corticosteroid
analysi
stevensjohnson
syndrom
toxic
epiderm
necrolysi
japan
zenro
ikezawa
yumiko
yaman
yuko
ikezawa
yuki
shigehira
chieko
watanab
michiko
aihara
yokohama
citi
univers
graduat
school
medicin
enviroment
immunodermatolog
yokohama
japan
background
b
stevensjohnson
syndrom
sj
toxic
epiderm
necrolysi
ten
repres
sever
cutan
advers
drug
reaction
high
mortal
treatnent
establish
method
present
current
clinic
characterist
treatment
sj
ten
japan
retrospect
analyz
case
sj
male
femal
age
averag
case
ten
male
femal
age
averag
report
sj
ten
publish
medic
journal
result
thirti
case
sj
case
ten
caus
drug
nonsteroid
antiinflamm
drug
nsaid
antibiot
anticonvuls
drug
organ
involv
hepat
common
sj
ten
renal
dysfunct
respiratori
disord
also
involv
case
major
complic
sepsi
treatment
corticosteroid
administ
system
case
case
sj
case
ten
treat
corticosteroid
alon
combin
plasmapheresi
andor
immunoglobulin
therapi
corticosteroid
therapi
perform
case
mortal
rate
patient
sj
ten
mortal
ten
decreas
remark
compar
previou
year
seriou
patient
ten
perform
plasmapheresi
highdos
immunoglobulin
therapi
combin
steroid
therapi
aliv
discuss
result
suggest
combin
abovement
treatment
might
use
seriou
patient
experi
need
confirm
effect
advers
effect
dpt
immun
children
year
age
tabriziran
background
vaccin
hail
magic
bullet
diseas
sometim
fli
astray
fact
shot
common
vaccin
dpt
diphtheriapertussistetanu
may
rare
case
trigger
seriou
health
problem
review
exist
data
sever
studi
found
link
pertussi
compon
dpt
vaccin
anaphylaxi
lifethreaten
allerg
reaction
vaccin
highli
effect
elimin
significantli
decreas
incid
mani
oncecommon
diseas
howev
public
focus
potenti
advers
effect
vaccin
aim
studi
identifi
advers
effect
dpt
immun
children
year
age
tabriziran
method
descript
crosssect
survey
conduct
citi
tabriz
northwest
iran
case
defin
notifi
advers
effect
dpt
immun
month
period
septemb
march
tabriz
health
center
children
age
month
year
reciv
dpt
vaccin
select
health
center
carefuli
check
hour
follow
immun
questionnair
use
elicit
inform
relat
advers
effect
dpt
immun
children
data
anayz
softwar
spss
win
result
find
indic
fever
limb
swell
unusu
cri
irrit
vomit
erythema
respect
conclus
immun
usual
given
healthi
peopl
prevent
seriou
diseas
risk
known
advers
reaction
vaccin
must
weigh
potenti
benefit
nurs
health
provid
prepar
answer
patient
parent
parent
question
common
well
alleg
vaccinerel
advers
event
must
util
vaccin
inform
statement
vaccin
cover
nation
vaccin
injuri
compens
program
also
health
care
provid
continu
counsel
parentss
benefit
vaccin
recommend
vaccin
client
key
word
advers
effect
dpt
immun
children
year
anticonvuls
hypersensit
syndrom
souhad
al
faqih
sedac
allergi
khartoum
sudan
background
anticonvuls
hypersensit
syndrom
potenti
fatal
multisystem
reaction
anticonvuls
medic
object
purpos
studi
investig
clinic
characterist
anticonvuls
hypersensit
syndrom
result
total
subject
age
year
diagnos
anticonvuls
hypersensit
syndrom
base
clinic
histopatholog
find
includ
studi
case
anticonvuls
administ
prophylact
craniotomi
case
epilepsi
case
assess
skin
lesion
maculopapular
erupt
regist
stevensjohnson
syndrom
five
toxic
epiderm
necrolysi
ten
five
treatment
includ
suspens
offend
drug
except
case
toxic
epiderm
necrolysi
administr
corticosteroid
case
requir
anticonvuls
therapi
treat
valproic
acid
case
observ
rapid
clinic
improv
corrobor
laboratori
find
conclus
essenti
due
import
given
develop
erupt
individu
anticonvuls
administ
craniotomi
anticonvuls
hypersensit
syndrom
like
lifethreaten
drug
allerg
reaction
relat
vital
import
drug
medic
tactic
gulnar
batpenova
tair
nurpeissov
gauhar
kozhakeeva
kazakh
state
medic
academi
dermatovenerolog
depart
astana
kazakhstan
institut
intern
diseas
republican
allergolog
center
almati
kazakhstan
background
gener
accept
practic
treatment
da
primari
cancel
bguiltydrug
time
case
face
event
cancel
given
drug
bring
unavoid
consequ
therefor
dilemma
danger
cancel
syndrom
develop
heavi
manifest
drug
allergi
aim
describ
run
tactic
patient
diabet
mellitu
concomit
polyval
da
relat
number
drug
method
result
patient
year
old
continu
receiv
human
insulin
patient
anamnesi
episod
allerg
reaction
relat
number
drug
differ
pharmaceut
group
patient
got
heavi
allerg
dermat
isosorbid
drip
form
cancel
drug
prescript
antihistamin
nt
improv
situat
patient
examin
analyz
bring
light
exist
specif
ige
substanc
insulin
human
abolit
drug
imposs
due
danger
decompens
diabet
test
vivo
imposs
consequ
activ
cutan
process
client
pass
damag
measur
neutrophil
test
dmnt
modifi
scheme
hypersens
relat
number
drug
display
type
insulin
obtain
neg
result
insulin
nph
insulin
rapid
administr
parallel
patient
prescrib
take
intraven
prednisolon
mgday
day
treatment
transfer
steroid
per
os
dose
mgday
one
month
gradual
dose
decreas
follow
cancel
glycem
profil
normal
effect
heavi
allerg
dermat
regress
complet
conclus
case
appear
da
vital
import
drug
cancel
given
drug
contraind
case
necess
emerg
infus
risk
anaphylact
shock
increas
dmnt
sensit
specificityabout
modifi
scheme
effect
method
due
imposs
conduct
trustworthi
test
vitro
vivo
monitor
show
effect
safeti
prednisolon
cours
treatment
da
connubi
system
cutan
advers
drug
reaction
corinn
vernassier
jf
cuni
jl
schmutz
annick
barbaud
fournier
hospit
dermatolog
depart
nanci
franc
observ
yo
women
hour
itchi
maculopapular
exanthema
mpr
trunk
arm
daili
treatment
modifi
except
concern
switch
mopral
omeprazol
inipomp
pantoprazol
hour
biopsi
sampl
compat
drug
allergi
eosinophilia
histori
year
cutan
test
perform
calcium
channel
blocker
penicillin
sensit
patch
test
posit
diltiazem
chronolog
drug
intak
done
husband
treatment
prepar
husband
visual
defici
day
mpr
onset
member
famili
report
hour
mpr
patient
taken
error
drug
husband
put
besid
wife
trimetazidin
diltiazem
atenolol
lysin
acetylsalicyl
domperidon
oxybutynin
rash
vanish
within
week
discuss
observ
stress
import
interrog
assumpt
cadr
determin
chronolog
drug
intak
addit
difficulti
obtain
inform
old
person
lack
memori
interrog
famili
member
gp
pharmacist
crucial
mask
drug
exposur
report
kiss
misadministr
drug
intend
spous
risk
could
becom
signific
age
popul
conclus
case
mask
drug
allergi
due
diltiazem
taken
mistak
intend
spous
wahjuni
husain
andi
muhammad
adam
mahmud
ghaznawi
faridha
ilya
medic
faculti
hasanuddin
univers
dr
wahidin
medic
faculti
hasanuddin
univers
patholog
makassar
indonesia
background
drug
hypersensit
syndrom
dh
idiosyncrat
lifethreaten
advers
drug
reaction
begin
acut
first
month
initi
drug
character
fever
skin
rash
facial
edema
exfoli
dermat
lymphadenopathi
hematolog
abnorm
eosinophilia
multiorgan
involv
case
system
organ
involv
case
woman
present
fever
maculopapular
rash
facial
edema
lymph
node
enlarg
week
take
cefadroxil
mefenam
acid
fine
needl
aspir
biopsi
fnab
suspect
thyroid
infect
take
mebhydrolin
napadysil
rash
becom
extend
exfoli
dermat
facial
edema
lymphadenopathi
laboratori
examin
includ
leucocytosi
eosinophilia
biolog
abnorm
includ
normal
liver
function
test
chest
radiograph
cardiac
echographi
histolog
examin
show
hyperkeratosi
mild
spongiosi
vacuolar
degener
basal
cell
infiltr
lymphocyt
neutrophil
eosinophil
discuss
patient
fulfil
clinic
criteria
present
fever
gener
maculopapular
rash
facial
edema
lymphadenopathi
eosinophilia
pathogenesi
dh
fulli
understood
includ
genet
background
alter
drug
metabol
viru
infect
suspect
drug
mebhydrolin
napadysil
treatment
dexamethason
intraven
start
mg
tid
topic
steroid
emolli
given
also
week
dexamethason
intraven
substitut
methyl
prednisolon
mg
oral
day
taper
rash
progress
improv
conclus
drug
hypersensit
syndrom
sever
skin
reaction
system
manifest
intern
organ
involv
asymptomat
suspect
drug
mebhydrolin
napadysil
treatment
dexamethason
intraven
continu
methylprednisolon
oral
withdraw
possibl
offend
drug
gave
good
result
background
advers
reaction
pharmaceut
diagnost
product
constitut
major
hazard
practic
medicin
multipl
risk
factor
shown
modifi
clinic
express
immunolog
drug
reaction
associ
drug
diseas
state
drug
use
chronic
diseas
infect
individu
patient
receiv
drug
similarli
allerg
drug
reaction
much
like
occur
drug
administ
patient
particular
diseas
background
aminopenicillin
given
patient
atyp
abnorm
lymphocyt
sulfonamid
patient
aid
case
report
repres
man
prolong
histori
one
year
intermitt
headach
use
nsaid
recurr
histori
anaphylaxi
urticaria
get
nsaid
first
analges
also
antihistamin
laboratori
evalu
includind
cell
blood
count
differenti
complement
assay
normal
limit
consult
neurologist
brain
ctscan
done
show
cn
tumor
literatur
review
found
chronic
dises
cyctic
fibrosi
cryogobulinemia
also
immun
defici
caus
drug
allergi
associ
multipl
drug
allergi
malign
especi
cn
tumor
background
dapson
hypersensit
syndrom
dh
rare
well
recogn
seriou
advers
effect
character
fever
skin
rash
gener
lymphadenopathi
hepat
hepatosplenomegali
hipersensit
reaction
occur
first
week
occur
month
object
find
total
case
year
dapson
hypersensit
syndrom
wahidin
sudirohusodo
gener
hospit
makassar
indonesia
method
retrospect
studi
carri
taken
medic
record
registr
book
januari
decemb
result
five
patient
dapson
hypersensit
syndrom
report
patient
receiv
dapson
part
mdt
leprosi
fever
jaundic
skin
lesion
detect
case
case
appear
like
morbiliform
lymphadenopathi
case
splenomegali
acut
psychosi
case
laboratori
data
admiss
includ
low
hemoglobin
leucocytosi
elev
level
serum
liver
enzym
erythrocyt
sediment
rais
bilirubin
hypoproteinemia
interv
start
dapson
therapi
appear
symptom
vari
week
one
case
clinic
manifest
occur
month
consumpt
multi
drug
treatment
mdt
case
treat
corticosteroid
withdraw
dapson
mdt
continu
replac
dapson
minocyclin
background
lemierr
syndrom
acut
oropharyng
infect
suppur
later
pharyng
space
bacteremia
septic
thrombophleb
intern
jugular
vein
caus
metastat
infect
rare
diseas
estim
incid
case
per
million
method
report
patient
diagnos
lemierr
syndrom
present
rash
week
piperacillintazobactam
clindamycin
phenytoin
result
year
old
male
signific
past
medic
ill
present
one
week
histori
dentoalveolar
abscess
right
molar
fever
trismu
dysphagia
erythema
swell
neck
work
show
retropharyng
extens
dentoalveolar
abscess
pneumonia
pneumomediastinum
necrot
mediastin
hiv
enzym
immunoassay
neg
patient
underw
cervic
mediastinotomi
subxiphoid
drainag
given
piperacillintazobactam
iv
clindamycin
iv
cours
hospit
stay
patient
went
arrest
postgliott
seizur
start
phenytoin
cap
week
piperacillintazobactam
clindamycin
day
phenytoin
patient
present
erythemat
prurit
maculopapular
rash
initi
upper
extrem
later
becom
gener
antibiot
shift
meropenem
phenytoin
shift
levetiracetam
patient
receiv
diphenhydramin
ranitidin
prednison
resolv
rash
also
complet
week
meropenem
discharg
improv
conclus
first
report
case
drug
hypersensit
patient
diagnos
lemierr
syndrom
import
discontinu
offend
drug
shift
structur
unrel
drug
emphas
hydrochlothiazideinduc
lichenoid
erupt
apropo
case
karim
aouam
hichem
belhadj
ali
amel
chaaban
montassar
amri
naceur
boughatta
jameleddin
zili
faculti
medicin
pharmacolog
depart
monastir
tunisia
monastir
hospit
dermatolog
depart
monastir
tunisia
background
aetiolog
lichen
planu
unknown
stress
autoimmun
infect
suggest
possibl
caus
mani
drug
provok
erupt
clinic
histolog
similar
lichen
describ
two
patient
probabl
associ
treatment
irbesartanhydrochlorothiazid
lichenoid
erupt
case
report
case
woman
present
dermatolog
clinic
histori
acut
onset
violaceu
papul
start
arm
spread
trunk
back
leg
take
amiodaron
auricular
fibril
month
irbesartanhydrochlorothiazid
hypertens
month
physic
exam
patient
accur
violaceu
scali
plaqu
trunk
back
limb
ocular
buccal
genit
lesion
system
symptom
blood
count
biochem
profil
normal
skin
biopsi
involv
skin
show
typic
featur
lichen
planu
treatment
desonid
cetirizin
provid
relief
irbesrtanhydrochlothiazid
substitut
irbesartan
skin
erupt
prutiti
resolv
within
two
week
case
man
present
acut
onset
prurit
rash
state
trunk
spread
whole
bodi
past
medic
histori
includ
hypertens
sharp
syndrom
take
irbesartanhydrochlorothiazid
methotrex
methotrex
irbesartanhydrochlorothiazid
start
approxim
year
month
skin
erupt
respect
physic
exam
patient
accur
violaceu
scali
plaqu
trunk
back
limb
bilater
shallow
eros
buccal
mucosa
surround
network
laci
white
striae
blood
count
biochem
profil
normal
skin
biopsi
involv
skin
show
typic
featur
lichen
planu
treatment
desonid
cetirizin
provid
relief
irbesrtanhydrochlothiazid
substitut
irbesartan
skin
erupt
prutiti
resolv
within
two
week
conclus
observ
illustr
rare
associ
lichen
hydrochlorothiazid
basi
naranjo
algorithm
probabl
system
reaction
due
hydrochlorthiazid
therapi
clinician
awar
potenti
advers
effect
recommend
withhold
drug
intak
tempor
relat
evoc
preval
allerg
contact
sensit
among
hostel
student
ajman
univers
unit
arab
emir
uae
tarik
al
zubaidi
taki
almosawi
zeena
sameer
ajman
univers
faculti
pharmaci
health
scienc
ajman
unit
arab
emir
almafraq
hospit
unit
arab
emir
background
estim
round
peopl
world
suffer
allergi
contact
certain
materi
allergen
suppos
caus
allerg
skin
sensit
culmin
develop
contact
dermat
individu
peopl
unawar
sensit
show
mild
symptom
preval
specif
allergen
vari
geograph
area
popul
age
sex
object
present
studi
aim
determin
rel
frequenc
posit
reaction
differ
sensit
among
hostel
femal
student
ajman
universityua
materi
method
sampl
approach
simpl
descript
femal
hostel
student
age
year
test
use
univers
standard
patch
test
seri
true
test
contain
common
allergen
sensit
neg
control
cross
section
questionnair
distribut
student
chronic
diseas
pregnanc
exclud
result
result
analyz
spss
contrast
previou
european
report
suggest
nickel
sensit
common
among
femal
studi
show
thimeros
common
sensit
among
femal
hostel
univers
student
follow
nickel
colophoni
conclus
thimeros
present
contact
len
solut
cosmet
posit
student
unawar
sensit
use
contact
lens
cosmet
purpos
studi
rais
alarm
use
inert
materi
contact
lens
industri
least
warn
femal
consequ
sensit
background
sesam
perilla
korean
tradit
crop
mainli
consum
season
seed
oil
howev
sesam
food
allergi
increasingli
common
problem
mani
countri
studi
aim
compar
protein
pattern
sesam
perilla
analyz
cross
reactiv
sesam
perilla
method
seed
place
ethyl
ether
extract
slow
stir
pb
ph
analyz
protein
pattern
specif
ige
sesam
perilla
crude
extract
separ
sdspage
perform
western
blot
use
sera
diagnos
allerg
sesam
perilla
sesam
extract
variou
concentr
preincub
pool
sera
inhibit
test
sera
ad
elisa
plate
precoat
perilla
extract
result
sesam
perilla
higher
protein
concentr
contain
protein
band
kda
howev
cook
protein
high
molecular
weight
disappear
kda
protein
band
exist
weakli
ige
bind
band
also
detect
kda
sesam
perilla
western
blot
analysi
inhibit
test
sesam
show
low
inhibit
rate
perilla
inhibit
elisa
test
conclus
sesam
perilla
show
differ
protein
pattern
low
cross
reactiv
suggest
perilla
replac
sesam
consumpt
howev
possibl
food
allergi
studi
major
allergen
need
biochem
allergen
properti
natur
genet
modifi
soybean
soybean
import
sourc
protein
human
dietari
intak
today
soybean
protein
may
allergen
caus
allerg
reaction
connect
aim
present
studi
investig
biochem
allergen
properti
extract
natur
genet
modifi
gm
soybean
protein
extract
obtain
whole
natur
gm
soybean
capsul
core
analyz
sdspage
western
blot
elisa
sdspage
analysi
reveal
similar
result
protein
composit
allergen
extract
core
whole
natur
gm
soybean
main
protein
band
whole
soybean
soybean
core
low
molecular
weight
mw
kda
kda
protein
band
mw
kda
largest
conform
protein
group
kunitz
trypsin
inhibitor
cmb
bdr
protein
fraction
capsul
soybean
mw
kda
conform
soybean
profilin
gli
predomin
natur
soy
wherea
mw
kda
conform
vacuolar
protein
gli
bd
k
predomin
gm
soy
investig
sera
patient
blood
differ
age
atop
dermat
food
allergi
use
elisa
frequenc
reveal
igeab
soy
increas
infant
patient
adolesc
patient
increas
level
igeand
iggab
capsul
natur
soybean
determin
often
reveal
iggab
wide
protein
spectrum
whole
natur
gm
soybean
use
western
blot
largest
protein
fraction
mw
kda
soybean
capsul
known
contain
protein
homolog
major
allergen
birch
pollen
bet
view
high
frequenc
reveal
igeab
capsul
natur
soybean
fulli
explain
context
crossreact
antigen
analyz
blood
serum
patient
hypersensit
soy
reveal
increas
level
igeab
birch
pollen
case
high
level
igeab
found
patient
therefor
reveal
extract
natur
gm
soybean
contain
protein
identifi
allerg
properti
may
caus
develop
allerg
diseas
relat
igeab
soy
enteropathi
relat
iggab
moreov
due
pronounc
homolog
allergen
birch
pollen
foodstuff
contain
soybean
may
strengthen
sensit
intensifi
allerg
reaction
pollinosi
patient
differ
proteom
approach
identif
wheat
flour
allergen
background
food
antigen
penetr
gastrointestin
tract
gener
caus
clinic
symptom
individu
acquir
toler
howev
food
compon
recogn
caus
advers
reaction
suscept
individu
wheat
belong
among
six
major
food
respons
approxim
food
allerg
reaction
children
although
cereal
essenti
daili
nutrit
protein
identifi
cereal
allergen
molecular
level
method
character
wheat
flour
allergen
prepar
salt
extract
seven
frequent
use
wheat
cultivar
compar
sd
page
protein
select
cultivar
sulamit
separ
gel
electrophoresi
analyz
immunoblot
igereact
protein
identifi
mass
spectrometri
malditof
qtof
lcqdeca
nlcmsm
ion
trap
test
abil
activ
patient
basophil
express
marker
measur
flow
cytometri
develop
elisa
quantifi
patient
ige
ab
reactiv
defin
allergen
wheat
extract
also
treat
pepsin
result
patient
sera
divid
three
group
ige
ab
first
one
recogn
wheat
compon
second
third
one
react
compon
rang
pattern
wheat
compon
recogn
ige
ab
significantli
influenc
condit
protein
separ
treatment
digest
enzym
use
sd
page
immunoblot
mass
spectrometri
identifi
potenti
wheat
allergen
employ
newli
develop
elisa
level
ige
ab
protein
sulamit
extract
one
domin
wheat
ige
bind
compon
amylas
inhibitor
type
quantifi
shown
significantli
elev
sera
allerg
patient
compar
healthi
control
furthermor
salt
extract
cultivar
sulamit
well
amylas
inhibitor
shown
abl
induc
signific
activ
basophil
allerg
patient
conclus
studi
character
spectrum
wheat
compon
recogn
ige
ab
allerg
patient
analyz
impact
protein
separ
digest
immunogen
wheat
allergen
compar
sensit
specif
newli
develop
specif
ige
elisa
assay
vitro
basophil
activ
test
use
identifi
allergen
heatinduc
denatur
aggreg
chang
immunoreact
milk
protein
background
milk
liquid
consumpt
process
requir
initi
heat
treatment
control
growth
microorgan
howev
heat
treatment
milk
caus
heat
denatur
whey
protein
aggreg
casein
cn
via
thioldisulfid
bond
interchang
reaction
chang
influenc
solubl
macroaggreg
presenc
heatinduc
chang
immunogen
commerci
milk
still
controversi
issu
aim
studi
contribut
increas
knowledg
area
method
kinet
heatinduc
precipit
main
whey
protein
lactoglobulin
lg
lactalbumin
la
examin
water
solut
individu
protein
fresh
milk
whey
model
mixtur
whey
protein
cn
min
time
kinet
format
heatinduc
aggreg
main
whey
protein
cn
investig
fresh
milk
whey
model
mixtur
use
gphplc
method
dot
blot
assay
use
sera
allerg
patien
contain
specif
ige
antibodi
milk
protein
employ
assess
immunochem
reactiv
milk
protein
contain
sampl
heat
treatment
immunoreact
commerci
milk
sampl
pasteur
uht
ferment
differ
content
solubl
macroaggreg
also
assess
commerci
elisa
test
monoclon
antibodi
individu
whey
protein
use
sera
allerg
patien
result
decreas
main
whey
protein
lg
la
significantli
higher
milk
whey
solut
individu
protein
experi
model
protein
mixtur
show
presenc
cn
necessari
form
aggreg
complex
whey
protein
kinet
format
heatinduc
aggreg
milk
model
protein
mixtur
complex
two
differ
maxima
min
time
interv
conclus
surprisingli
observ
signific
chang
immunochem
reactiv
milk
protein
sampl
heatinduc
aggreg
condit
dot
blot
assay
howev
experi
continu
confirm
result
character
put
allergen
nine
chines
adult
food
allergi
limpet
bernard
thong
fookthim
chew
tanch
ong
kangn
wong
yewkuang
cheng
khaipang
leong
chweey
tang
hiokhe
chng
tan
tock
seng
hospit
singapor
rheumatolog
allergi
immunolog
singapor
singapor
nation
univers
singapor
biolog
scienc
singapor
singapor
background
limpet
gastropod
mollusc
second
common
caus
igemedi
food
allergi
among
adult
attend
clinic
immunologyallergi
clinic
aim
studi
character
put
allergen
ascertain
possibl
crossreact
common
inhal
food
allergen
patient
limpet
allergi
method
consecut
adult
present
juli
april
immedi
hypersensit
follow
ingest
limpet
studi
sera
store
assay
specif
ige
common
inhal
food
allergen
ige
western
blot
tandem
mass
spectrometr
analysi
perform
identifi
allergen
elisa
inhibit
assay
carri
compar
allergen
limpet
gastropod
well
recombin
tropomyosin
arginin
kinas
allergen
dust
mite
cockroach
result
patient
male
ethnic
chines
mean
age
year
eight
patient
previous
ingest
limpet
allerg
reaction
occur
median
occas
six
patient
histori
asthma
allerg
rhiniti
andor
atop
eczema
seven
patient
refus
skin
test
test
posit
prickprick
test
can
limpet
also
posit
abalon
pacif
clam
invitro
specif
ige
assay
posit
shellfish
mix
dermatophagoid
pteronyssinu
dermatophagoid
farina
blomia
tropicali
cockroach
mix
western
blot
protein
mass
spectrometr
analysi
show
put
limpet
allergen
tropomyosin
arginin
kinas
elisa
inhibit
studi
use
recombin
dust
mite
cockroach
tropomyosin
well
arginin
kinas
show
moder
cross
reactiv
allergen
allergen
limpet
signific
inhibit
bind
abalon
clam
conclus
put
limpet
allergen
patient
tropomyosin
arginin
kinas
major
allergen
gastropod
abalon
pacif
clam
crustacean
american
cockroach
hous
dust
mite
prior
sensitis
hous
dust
mite
cockroach
patient
could
play
role
limpet
food
allergi
surprisingli
limit
crossreact
abalon
pacif
clam
two
close
relat
gastropod
mollusc
cross
reactiv
among
soy
penaut
lupin
mariann
va
heim
children
hospit
gastroenterolog
budapest
hungari
central
food
research
institut
biotechnolog
budapest
hungari
background
soy
protein
common
dietari
protein
intak
g
day
europ
among
adult
accord
multicentr
studi
soy
base
infant
formula
often
use
infanc
earli
childhood
cow
milk
allergi
healthi
children
instead
cow
milk
preval
allerg
reaction
gastrointestin
skin
pulmonari
elicit
soy
protein
around
atop
children
sever
fatal
reaction
seem
rare
rate
higher
children
peanut
allergi
lupin
newli
use
legum
human
diet
theoret
give
also
cross
reaction
soy
peanut
aim
studi
determin
cross
reaction
among
soy
protein
peanut
lupin
method
immunoblot
techniqu
sdspage
protein
separ
elisa
method
polyclon
antibodi
ige
soy
posit
human
sera
use
detect
reaction
result
immunolog
cross
reactiv
demonstr
major
allergen
studi
legum
protein
betaconglycinin
oligomer
subunit
soybean
shown
cross
reactiv
ara
peanut
vicillin
allergen
lupin
furthermor
observ
immunolog
cross
reaction
among
soybean
glycinin
allergen
ara
peanut
vicillin
allergen
lupin
soybean
profilin
cross
react
ara
peanut
allergen
allergen
prolamin
superfamili
soybean
trypsin
inhibitor
lectin
shown
cross
reactiv
epitop
ara
ara
ara
allergen
peanut
soybean
peanut
lupin
protein
extract
differ
ige
reactiv
soy
posit
human
sera
conclus
cross
reactiv
among
major
allergen
soy
peanut
lupin
prove
human
soy
posit
sera
vitro
result
draw
attent
possibl
anaphylaxi
result
allerg
cross
reaction
patient
peanut
soy
allergi
basi
emphasis
need
precis
label
food
compon
avoid
anaphylaxi
allergi
depart
madrid
spain
allergi
clinic
reumannplatz
vienna
austria
idiircc
center
clinic
experiment
allergolog
rome
itali
pitaux
universitair
servic
de
pneumologi
straqbourg
franc
background
milk
allergi
common
igemedi
food
allergi
earli
infanc
cow
milk
contain
protein
eight
identifi
allergen
vari
result
regard
frequenc
ige
recognit
allergen
activ
individu
allergen
develop
microarray
milk
protein
allow
determin
indiviu
patient
ige
reactiv
profil
well
biolog
activ
diseasecaus
allergen
use
small
amount
patient
sera
method
dot
differ
milk
compon
includ
whole
milk
extract
milk
fraction
well
purifi
recombin
milk
allergen
recombin
synthet
fragment
milk
allergen
onto
microarray
determin
ige
reactiv
profil
milk
allerg
patient
parallel
allergen
activ
milk
compon
determin
use
rat
basophil
leukaemia
rbl
cell
transfect
human
receptor
load
sera
result
found
milk
allerg
patient
show
ige
reactiv
whole
cow
milk
extract
high
number
patient
ige
antibodi
sheep
goat
milk
respect
test
patient
show
ige
reactiv
mare
milk
frequent
recogn
cow
milk
allergen
studi
alphalactalbumin
alphacasein
betalactoglobulin
variant
b
respect
betacasein
lactoferrin
bsa
seem
lesser
import
sinc
recognit
frequenc
potent
cell
activ
compon
human
rbl
assay
cow
milk
induc
relev
degranul
patient
follow
goat
sheep
milk
respect
among
singl
compon
casein
show
highest
biolog
activ
patient
sera
conclus
use
microarray
technolog
combin
data
basophil
releas
assay
possibl
test
simultan
frequenc
ige
reactiv
allergen
activ
multitud
allergen
use
drop
patient
serum
test
system
import
diagnosi
therapi
cow
milk
allergi
epitop
map
gliadin
patient
sera
react
modifi
gluten
background
wheat
gluten
modifi
enzymat
chemic
treatment
wheat
isol
order
improv
function
properti
increas
solubl
thu
broaden
applic
food
industri
howev
modif
shown
induc
ige
mediat
allergi
individu
usual
toler
wheat
leduc
et
al
publish
first
case
anaphylaxi
ingest
reconstitut
meat
contain
wheat
isol
et
al
also
show
hydrolys
wheat
protein
induc
sever
allerg
reaction
contact
ingest
object
work
identifi
epitop
detect
ige
patient
reaction
chemic
deamid
gluten
product
glutamin
residu
modifi
glutam
acid
method
sera
twelv
patient
anaphylaxi
urticaria
wdeia
contain
ige
antibodi
laboratori
industri
deamid
gluten
elisa
rast
analys
pepscan
overlap
synthet
peptid
igebind
epitop
search
among
entir
sequenc
identif
critic
animo
acid
analysi
effect
substitut
glutamin
glutam
acid
result
eight
sera
react
repetit
peptid
contain
common
octapeptid
rich
prolin
glutamin
five
critic
posit
ige
bind
identifi
epitop
substitut
one
glutamin
glutam
acid
induc
recognit
two
addit
sera
simultan
substitut
two
glutamin
glutam
acid
increas
intens
respons
obtain
ten
posit
sera
conclus
patient
reaction
deamid
gluten
possess
ige
antibodi
direct
linear
sequenc
repetit
domain
ige
antibodi
patient
sera
analys
studi
bound
immunodomin
epitop
residu
deamid
two
glutamin
epitop
increas
significantli
recognit
patient
ige
epitop
similar
b
epitop
evidenc
celiac
patient
result
show
industri
treatment
may
increas
risk
allergi
develop
allergen
specif
ige
antibodi
clinic
use
diagnosi
food
allergi
background
relationship
foodspecif
ige
titer
outcom
food
challeng
well
establish
egg
milk
threshold
valu
probabl
curv
wheat
compon
wheat
relationship
establish
object
evalu
clinic
use
wheat
wheat
compon
specif
ige
titr
relat
outcom
food
challeng
method
two
hundr
forti
nine
children
suspect
wheat
intoler
clinic
japan
includ
studi
age
rang
month
year
year
year
diagnosi
food
allergi
judg
confirm
symptom
food
challeng
test
relat
visit
food
challeng
allergen
specif
ige
antibodi
level
wheat
measur
immunocapi
phadia
ab
sweden
result
one
hundr
eighti
five
children
challeng
frequent
symptom
fail
challeng
relat
skin
cough
lower
respiratori
system
three
children
anaphylact
reaction
fifti
four
percent
children
one
symptom
show
symptom
show
symptom
child
symptom
specif
ige
titr
wheat
higher
children
fail
food
challeng
tabl
simpl
logist
model
wheat
show
signific
relationship
probabl
challeng
reaction
food
specif
ige
antibodi
concentr
wheat
multivari
model
use
wheat
show
strongest
associ
fail
challeng
provoc
conclus
result
show
specif
ige
antibodi
titr
relat
probabl
fail
oral
food
challeng
ige
combin
wheat
ige
antibodi
good
predictor
wheat
challeng
outcom
oral
allergi
syndrom
due
plantderiv
food
clinic
review
patient
period
year
naoko
inomata
akiko
morita
zenro
ikezawa
yokohama
citi
univers
hospit
depart
dermatolog
yokohama
japan
yokohama
citi
univers
school
medicin
depart
environment
immunodermatolog
yokohama
japan
background
b
bthe
clinic
featur
mani
patient
oral
allergi
syndrom
oa
due
plantderiv
food
rare
report
asian
countri
object
aim
determin
caus
food
oa
due
plantderiv
food
base
clinic
featur
skin
prick
test
spt
twice
mani
femal
male
frequent
caus
food
found
appl
peach
kiwi
melon
patient
respect
cap
frequenc
shown
similar
spt
regard
appl
wherea
less
spt
regard
melon
peach
kiwi
signific
correl
frequenc
sptand
cap
found
regard
appl
peach
kiwi
melon
fortyon
patient
oa
pollinosi
andor
allerg
rhiniti
patient
oa
due
appl
posit
ratio
cap
respons
alder
pollen
higher
patient
oa
due
melon
patient
oa
due
melon
posit
ratio
cap
respons
ragwe
pollen
grass
pollen
mugwort
pollen
higher
patient
oa
due
appl
pf
type
oral
allergi
syndrom
oa
common
caus
food
allergi
adult
date
publish
studi
preval
characterist
pf
uk
cohort
studi
design
test
diagnost
questionnair
also
provid
inform
food
involv
allergi
histori
associ
pf
subject
report
springtim
hay
fever
complet
pf
diagnost
questionnair
pfsdq
alloc
either
group
pf
group
pf
food
allergi
group
pf
food
allergi
complet
questionnair
pfspq
rhiniti
concomit
asthma
medic
symptom
sever
reaction
food
sever
food
symptom
diagnosi
pf
made
use
clinic
histori
prick
prick
test
ppt
fresh
food
oral
food
challeng
subject
complet
studi
mean
age
year
femal
subject
group
group
report
reaction
differ
food
final
diagnosi
pf
made
subject
differ
age
gender
group
final
diagnosi
variabl
pfspq
differ
group
final
diagnosi
includ
famili
histori
atopi
childhood
allergi
age
onset
rhiniti
symptom
sever
score
rhiniti
presenc
absenc
asthma
number
year
food
allergi
onset
food
symptom
time
onset
hay
fever
subject
commonli
report
reaction
appl
subject
hazelnut
almond
milk
strawberri
walnut
peach
cherri
kiwi
wheat
subject
group
report
symptom
significantli
food
subject
group
appl
hazelnut
peach
almond
kiwi
cherri
commonest
food
report
symptom
confirm
posit
ppt
milk
wheat
lowest
concord
ppt
report
reaction
milk
confirm
reaction
wheat
data
show
cohort
uk
subject
report
springtim
hay
fever
pf
commonest
food
caus
reaction
similar
publish
studi
although
kiwi
appear
signific
precipit
pf
symptom
previous
report
studi
age
gender
allergi
histori
asthma
time
onset
food
symptom
associ
diagnosi
pf
use
skin
prick
test
use
bifurc
needl
diagnosi
food
allergi
among
infantil
atop
dermat
mika
ogata
akinori
shukuya
chizuko
sugisaki
kaori
ikematsu
takashi
komata
takanori
imai
morimitsu
tomikawa
hiroshi
tachimoto
motohiro
ebisawa
nation
hospit
organ
kumamoto
medic
center
pediatr
kumamotoc
japan
nation
hospit
organ
sagamihara
nation
hospit
pediatr
sagamiharac
japan
nation
hospit
organ
sagamihara
nation
hospit
clinic
research
center
allergi
sagamiharac
japan
tokyo
jikei
univers
school
medicin
pediatr
tokyo
japan
object
investig
use
skin
prick
test
spt
diagnosi
egg
white
ew
caprastneg
egg
allergi
infant
follow
ewcaprast
studi
subject
method
data
neg
spt
use
bifurc
needl
bf
analyz
data
infantil
atop
dermat
patient
receiv
spt
januari
april
analysi
spt
result
averag
standard
deviat
neg
valu
obtain
set
rang
posit
spt
result
among
case
suspectedegg
allergi
infant
neg
ige
caprast
ew
time
first
visit
recruit
studi
examin
use
spt
posit
convers
ewcaprast
check
case
egg
allergi
egg
allergi
follow
outpati
clinic
result
rang
neg
spt
control
valu
mean
use
bf
among
infant
could
set
less
mm
wheal
mm
erythema
among
suspectedegg
allergi
infant
neg
ewcaprast
infant
diagnos
egg
allergi
combin
elimin
provoc
test
interestingli
infant
show
posit
spt
result
egg
allergi
follow
studi
neg
ewcaprast
case
ewcaprast
eggallergi
case
turn
posit
later
infantil
period
mean
ewcaprast
uaml
month
old
ewcaprast
case
nonegg
allergi
also
turn
posit
follow
howev
ewcaprast
titer
rel
lower
compar
egg
allergi
uaml
month
old
conclus
experienc
fairli
number
atop
infant
neg
ewcaprast
first
outpati
visit
later
diagnos
egg
allergi
half
case
spt
extrem
use
diagnosi
follow
eggallergi
infant
three
quarter
ewcaprast
tune
posit
around
month
old
ewcaprast
atop
infant
without
egg
allergi
also
turn
transient
slightli
posit
conclus
spt
seem
use
ewcaprast
diagnosi
egg
allergi
earli
infantil
period
howev
provoc
test
may
requir
definit
diagnosi
suspectedegg
allergi
infant
without
proof
eggsensit
optic
nearfield
immunochip
biosensor
rapid
allergen
detect
clinic
diagnosi
background
optic
immunochip
biosensor
develop
rapid
method
allergen
detect
vitro
immunosens
optic
nearfield
phenomenon
underli
setup
design
sensor
call
resonanceenhanc
absorpt
rea
util
gold
nanoparticl
signal
transduc
sensit
interferometrysetup
combin
visual
readout
elimin
complex
detect
instrument
assay
system
excel
meet
requir
rapid
method
allergen
detect
provid
opportun
develop
miniaturis
multiarraysensor
improv
sensit
allergi
test
clinic
diagnosi
method
rea
observ
lightabsorb
metal
cluster
posit
nanodist
highli
reflect
mirror
illumin
white
light
visibl
nearinfrar
spectrum
particl
side
direct
detect
method
base
distancedepend
light
interfer
mirror
resonantli
excit
metal
cluster
rea
base
captur
assay
power
link
affin
bind
threedimension
structur
inform
result
discuss
immunochip
biosensor
show
concentrationdepend
colour
develop
captur
biomoleculefunctionalis
gold
nanoparticl
allergen
immunoglobulin
coat
chip
semiquantit
immunochem
respons
directli
visibl
fnake
eye
analyst
sensit
compar
common
immunoassay
procedur
microtitr
plate
format
elisa
unspecif
background
signal
minim
absolut
target
specif
antibodi
antisera
use
bioassay
appli
method
detect
egg
white
allergen
ovalbumin
ovomucoid
complex
food
sampl
achiev
improv
interpret
crossvalid
relat
immunochem
character
allergen
substanc
process
food
protein
peptid
level
complementari
investig
term
applic
reproduc
reliabl
result
carri
altern
immunolog
method
perform
elisa
immunoblot
format
conclus
reabas
imunochip
sensor
easi
fabric
reproduc
perform
minim
technic
requir
enabl
highthroughput
screen
affin
bind
interact
technolog
medic
applic
determin
allergen
allergenonlin
peerreview
protein
sequenc
databas
assess
potenti
allergen
genet
modifi
organ
novel
food
protein
richard
goodman
motohiro
ebisawa
hugh
sampson
ronald
van
ree
stefan
vieth
john
wise
steve
taylor
univers
nebraska
food
scienc
technolog
lincoln
ne
unit
state
nation
sagamihara
hospit
pediatr
kanagawa
japan
mount
sinai
school
medicin
divis
pediatr
allergi
immunolog
new
york
ny
unit
state
academ
medic
center
experiment
immunolog
amsterdam
netherland
paul
ehrlich
institut
allergi
langen
germani
background
new
genet
modifi
gm
organ
novel
process
food
protein
introduc
commerc
countri
requir
safeti
assess
includ
bioinformat
sequenc
comparison
new
protein
determin
whether
new
protein
known
allergen
similar
allergen
current
allerg
consum
would
risk
reaction
match
found
product
would
test
use
sera
appropri
allerg
subject
qualiti
databas
primari
determin
search
efficaci
peer
review
process
use
updat
allergenonlin
tool
effect
bioinformat
search
provid
free
public
method
list
ballergen
compil
ncbi
use
keyword
search
plu
entri
allergen
nomenclatur
list
intern
union
immunolog
societi
iui
allergenonlin
version
sequenc
group
base
taxonomi
sequenc
ident
peer
review
articl
identifi
group
criteria
develop
evalu
evid
base
vivo
vitro
test
use
subject
clinic
defin
relev
allerg
diseas
publish
data
group
compil
evalu
primari
secondari
review
panel
remov
group
insuffici
evid
allergen
ige
bind
vivo
reactiv
subject
least
minim
descript
allergi
sourc
protein
free
fulllength
slide
amino
acid
align
tool
provid
allow
public
search
databas
key
exampl
literatur
use
illustr
appropri
use
databas
result
allergenonlin
version
contain
sequenc
publish
data
demonstr
least
evid
specif
ige
bind
use
sera
subject
allerg
symptom
expos
sourc
protein
mani
isoform
list
protein
other
repres
singl
sequenc
bioinformat
comparison
transgen
protein
approv
product
literatur
evalu
approv
product
exceed
codex
guidelin
criteria
literatur
presum
commerc
indic
like
need
serum
ige
test
conclus
curat
allergen
databas
markedli
improv
reliabl
sequenc
match
assess
potenti
allergen
new
food
background
qualiti
vitro
ige
test
use
food
allergi
diagnosi
mainli
depend
analyt
use
usual
total
extract
suspect
food
use
howev
recent
past
rise
number
studi
compon
resolv
diagnosi
attract
rise
interest
mani
case
use
purifi
singl
allergen
either
natur
origin
appli
recombin
product
shown
superior
perform
compar
total
extract
within
ec
fund
ip
europreval
librari
highli
purifi
allergen
food
list
new
label
direct
european
commiss
establish
develop
novel
diagnost
method
highli
purifi
allergen
either
natur
recombin
food
appl
peach
hazelnut
peanut
celeri
cow
milk
goat
milk
hen
egg
fish
shrimp
character
regard
structur
integr
biolog
allergen
activ
protein
mass
verifi
mass
spectrometri
sequenc
integr
malditof
ntermin
sequenc
presenc
isoform
natur
allergen
prepar
identifi
gel
electrophoresi
secondari
structur
evalu
nmr
map
low
molecular
weight
protein
allergen
activ
character
use
panel
sera
food
allerg
patient
result
purif
protocol
natur
recombin
allergen
establish
qualiti
assess
purifi
batch
perform
depend
either
natur
recombin
origin
differ
qualiti
criteria
defin
met
inclus
allergen
librari
structur
integr
purifi
protein
verifi
ige
bind
activ
assess
conclus
panel
well
character
allergen
use
prove
concept
compon
resolv
diagnosi
present
necessari
tool
set
novel
diagnost
use
signific
number
allerg
patient
sera
across
europ
contribut
identifi
relev
sensit
pattern
improv
dietari
recommend
food
allerg
patient
futur
domin
epitop
allerg
crossreact
thaumatinlik
protein
act
background
import
food
allergen
identifi
pathogenesisrel
protein
pr
thaumatinlik
protein
tlp
belong
famili
pr
sever
structur
plant
tlp
solv
group
includ
tlp
sweet
cherri
pru
av
kiwifruit
act
appl
mal
compar
differ
structur
belong
protein
famili
lead
identif
conform
epitop
method
elisa
inhibit
analysi
use
sera
kiwi
allerg
patient
use
determin
immunolog
crossreact
act
tlp
thaumatin
zeamatin
pru
av
mal
order
identifi
put
crossreact
epitop
virtual
epitop
map
appli
similar
differ
surfac
topolog
compar
result
elisa
inhibit
assay
act
show
high
crossreact
zeamatin
medium
crossreact
pru
av
mal
low
crossreact
thaumatin
hand
sequenc
comparison
act
tlp
yield
differ
order
similar
av
mal
combin
immunolog
data
virtual
epitop
map
three
put
epitop
region
could
determin
surfac
act
conclus
high
sequenc
homologyident
two
allergen
necessarili
indic
high
crossreact
use
comparison
surfac
featur
crossreact
non
crossreact
allergen
deriv
conform
epitop
region
bet
v
homolog
protein
kiwi
fruitrelev
allergen
howev
till
noth
known
bet
v
homolog
protein
present
kiwi
preliminari
effort
purifi
natur
bet
homologu
suffici
quantiti
kiwi
fail
far
method
two
individu
sequenc
green
gold
kiwi
fruit
homolog
bet
v
identifi
est
cdna
librari
subclon
express
system
pmw
respect
express
e
coli
result
recombin
protein
purifi
character
accord
establish
method
ige
bind
activ
purifi
recombin
bet
v
homolog
protein
kiwi
fruit
test
igeelisa
ige
immunoblot
inhibit
assay
result
align
recombin
kiwi
bet
v
homologu
recombin
bet
v
reveal
amino
acid
sequenc
ident
well
character
purifi
recombin
bet
v
homologu
green
actinidia
deliciosa
gold
kiwi
fruit
actinidia
chinensi
recogn
birch
pollen
kiwi
sensit
patient
ige
immunoblot
elisa
experi
presenc
natur
bet
v
homolog
protein
green
gold
kiwi
fruit
confirm
ige
immunoblot
inhibit
experi
use
natur
kiwi
fruit
extract
immuno
tissu
print
crossreact
two
recombin
protein
vari
intens
natur
bet
v
relat
protein
green
kiwi
rbet
v
demonstr
elisa
immunoblot
inhibit
assay
conclus
first
evid
cross
reactiv
bet
v
homolog
allergen
present
gold
green
kiwi
fruit
present
data
point
bet
v
homologu
relev
allergen
kiwi
especi
patient
sensit
tree
pollen
kiwi
fruit
might
neglect
far
due
low
abund
convent
extract
use
diagnosi
evolutionari
biolog
allergen
cupin
bet
v
superfamili
heimo
breitened
merima
bublin
stefan
wagner
christian
radauer
medic
univers
vienna
depart
pathophysiolog
vienna
austria
background
massiv
accumul
sequenc
data
plant
protein
recent
year
made
classif
allergen
protein
famili
possibl
compar
sequenc
structur
relat
protein
group
togeth
famili
relat
famili
group
togeth
superfamili
much
broader
pictur
allow
us
view
allergen
protein
evolutionari
context
method
repres
protein
sequenc
compil
manual
search
pfam
databas
protein
famili
multipl
sequenc
align
gener
neighborjoin
tree
perform
use
clustalx
phylogenet
tree
drawn
treeview
result
cupin
superfamili
compris
numer
function
highli
divers
protein
famili
group
organ
includ
archaea
howev
allergen
within
cupin
confin
vicilin
legumin
plant
seed
storag
protein
bet
v
superfamili
contain
famili
famili
major
latex
protein
ripeningrel
protein
norcoclaurin
synthas
cytokininbind
protein
protein
certain
taxa
fagal
rosacea
allergen
member
superfamili
diverg
allergen
member
bet
v
superfamili
relat
major
latex
protein
ripen
relat
protein
norcoclaurin
synthas
repres
ancient
evolutionari
event
appar
ancestor
modern
day
allergen
present
long
type
immun
system
evolv
conclus
studi
distribut
allergen
nonallergen
member
protein
famili
fund
austrian
scienc
fund
grant
sfb
provid
new
insight
evolut
allergen
factor
make
protein
allergen
optim
allergen
compon
litchi
peach
extract
vitro
specif
ige
assay
anita
kober
han
man
maria
lundberg
maryam
poorafshar
phadia
ab
r
uppsala
sweden
miab
r
uppsala
sweden
background
allergi
fruit
often
associ
pollinosi
often
relat
milder
symptom
oral
allergi
syndrom
oa
howev
especi
warmer
region
sever
symptom
also
common
fruit
preval
food
also
often
eaten
sunrip
form
allergi
fruit
rosacea
famili
strongli
associ
bet
v
northern
region
warmer
region
allerg
reaction
fruit
often
relat
lipid
transfer
protein
ltp
sometim
also
profilin
aim
studi
explor
new
extract
buffer
differ
part
fruit
tri
optim
extract
labil
bet
analogu
well
stabl
profilin
ltp
allergen
compon
method
peach
select
model
rosacea
fruit
bet
v
homologu
profilin
ltp
import
allergen
compon
litchi
select
fruit
exposur
popul
europ
increas
chang
feed
habit
profilin
suggest
import
allergen
extract
produc
use
differ
buffer
procedur
differ
part
fruit
pulppeel
use
sampl
patient
differ
region
differ
symptom
mild
sever
reaction
analys
use
immunocap
coupl
improv
extract
well
singl
compon
ige
antibodi
compon
also
assay
microarray
use
sampl
result
optim
extract
perform
achiev
cold
extract
procedur
contain
polyvinylpyrrolidon
pulp
peel
need
optim
perform
select
sampl
mainli
react
bet
increas
result
measur
immunocap
seen
peach
litchi
profilin
domin
allergen
compon
sever
patient
sampl
measur
immunocap
use
microarray
assay
result
confirm
inhibit
studi
conclus
improv
extract
method
enhanc
content
bet
v
homologu
profilin
fruit
extract
use
vitro
assay
specif
ige
microarray
use
tool
analys
compon
profil
sampl
use
small
volum
sampl
profilin
lit
import
allergen
litchi
may
caus
sever
reaction
peach
ltp
pru
bet
v
homologu
pru
import
compon
test
patient
popul
character
saffron
pollen
allergen
sepehr
salehi
majid
baseri
salehi
mehrdad
shariati
islam
azad
univers
kazeroun
branch
biolog
kazeroun
islam
republ
iran
grass
pollen
one
import
caus
igemedi
allerg
reaction
hypersensit
saffron
pollen
occup
allergi
seriou
problem
especi
among
peopl
deal
saffron
farmer
saffron
nativ
plant
iran
studi
perform
saffron
pollen
khorasan
provinc
saffron
pollen
allergen
proven
use
skin
prick
test
aim
studi
character
igebind
compon
saffron
pollen
first
saffron
pollen
extract
phosphatebuff
salin
pb
ph
hour
gentl
shake
centrifug
delipid
extract
concentr
polyethyleneglycol
concentr
saffron
pollen
extract
fraction
sdspage
transfer
nitrocellulos
paper
western
blot
techniqu
western
blot
use
sensit
individu
sera
antihuman
igehrp
immunoblot
analysi
perform
final
one
specif
igebind
band
show
molecular
weight
kd
studi
indic
sensit
sera
contain
specif
antibodi
direct
allergen
present
saffron
pollen
extract
also
compon
bind
specif
igg
role
interleukin
develop
chronic
inflamm
stomach
patient
food
allergi
zbigniew
bartuzi
magdalena
bikowska
collegium
medicum
bydgoszcz
nicolau
copernicu
univers
depart
allergi
clinic
immunolog
intern
bydgoszcz
poland
chronic
gastriti
caus
protract
iatrogen
effect
certain
medica
exampl
nonsteroid
antiinflammatori
drug
also
still
littl
known
extent
role
hypersensit
patient
atop
diathesi
develop
chronic
gastriti
aim
studi
determin
serum
concentr
patient
chronic
gastriti
food
allergi
infect
h
pylori
studi
conduct
patient
atop
diathesi
suffer
dyspepsia
abdomin
pain
monitor
outpati
clinic
food
allergi
studi
group
consist
patient
includ
femal
age
year
mean
age
year
male
age
year
mean
age
year
control
group
form
patient
dyspepsia
abdomin
pain
relat
chronic
gastriti
confirm
endoscopi
histopatholog
investig
specimen
patient
underw
endoscopi
sampl
stain
eosin
hematoxylin
h
e
modifi
giemza
stain
select
serum
cytokin
nwere
determin
endogen
kit
cambridg
serum
level
patient
food
allergi
rang
pgml
mean
valu
pgml
group
nonatop
patient
chronic
gastriti
rang
determin
valu
pgml
v
mean
concentr
pgml
control
patient
function
dyspepsia
concentr
obtain
rang
pg
ml
v
mean
concentr
pgml
concentr
variou
group
present
tabl
concentr
patient
food
allergi
rang
pgml
mean
valu
pgml
control
group
nonatop
subject
chronic
gastriti
level
pgml
mean
level
pgml
compar
analysi
level
patient
food
allergi
control
group
chronic
gastriti
show
statist
signific
differ
conclus
chronic
exposur
sensitis
food
patient
food
allergi
result
signific
elev
level
patient
food
allergi
chronic
gastriti
infect
h
pylori
manifest
simultan
increas
suggest
particip
allerg
factor
pathogenesi
inflamm
summari
blindedfood
challeng
hen
egg
cow
milk
allergi
past
year
takatsugu
komata
takanori
imai
mika
ogata
sakura
sato
morimitsu
tomikawa
hiroshi
tachimoto
akinori
shukuya
motohiro
ebisawa
sagamihara
nation
hospit
depart
pediatr
sagamiharac
kanagawa
japan
sagamihara
nation
hospit
clinic
research
center
depart
allergi
sagamiharac
kanagawa
japan
sagamihara
nation
hospit
pediatr
sagamiharac
kanagawa
japan
object
aim
studi
analyz
result
singleblind
food
challeng
sbfc
hen
egg
cow
milk
cm
allergi
patient
method
analyz
data
patient
receiv
sbfc
sagamihara
nation
hospit
total
number
examin
follow
challeng
male
femal
mean
age
month
cm
challeng
male
femal
mean
age
month
sbfc
perform
use
dri
powder
whole
egg
powder
cm
powder
strawberri
pure
vehicl
test
carri
along
aaaai
offic
procedur
manual
jaci
result
subject
receiv
sbfc
prior
entranc
primari
school
whether
could
take
school
lunch
posit
rate
challeng
test
follow
cm
common
symptom
induc
challeng
gi
reaction
follow
skin
reaction
lower
respiratori
symptom
confirm
challeng
heat
hen
whole
egg
subject
diagnos
raw
egg
allergi
patient
interestingli
discrep
result
raw
egg
challeng
heat
egg
challeng
seen
twenti
nine
percentag
raw
egg
allergi
patient
could
take
heat
whole
egg
egg
white
specif
ige
level
patient
could
pass
challeng
higher
pass
cm
challeng
skin
reaction
common
follow
lower
respiratori
symptom
gi
reaction
statist
differ
cm
specif
ige
level
fail
challeng
pass
challeng
higher
spt
posit
reaction
cm
higher
complic
rate
bronchial
asthma
recogn
fail
cow
milk
challeng
group
conclus
sbfc
cm
use
diagnosi
time
entranc
primari
school
improv
qualiti
life
raw
egg
allergi
patient
recommend
patient
receiv
heat
egg
challeng
seem
challeng
test
tend
induc
gi
reaction
cm
challeng
persist
cm
allergi
may
someth
complic
bronchial
asthma
school
age
children
cow
milk
protein
allergi
present
necrot
enterocol
case
report
sarayutdh
tonglor
pantipa
chatchate
jarungchit
ngamphaiboon
king
memori
chulalongkorn
hospit
pediatr
allergi
immunolog
bangkok
thailand
background
gastrointestin
symptom
common
manifest
cow
milk
protein
allergi
ever
necrot
enterocol
result
cow
milk
protein
allergi
rare
case
report
gm
full
term
femal
infant
fed
cow
milk
formula
sinc
birth
ten
day
switch
breast
feed
alon
twelfth
day
life
gradual
develop
abdomin
distens
vomit
time
day
brought
see
pediatrician
physic
examin
abnorm
find
exept
abdomin
distens
advis
got
simethicon
abdomin
discomfort
continu
breast
feed
still
symptom
vomit
progress
abdomin
distens
twenti
fourth
day
life
develop
frequent
vomit
mucou
bloodi
diarrhea
sever
abdomin
distens
hematochezia
pneumatosi
intestinali
seen
xray
find
laboratori
find
includ
normal
complet
blood
count
neg
blood
stool
cultur
necrot
enterocol
diagnos
success
toler
parenter
antibiot
place
extens
hydrolys
formula
well
toler
prick
skin
test
atopi
patch
test
radioallergosorb
test
neg
cow
milk
protein
three
month
grew
well
normal
weight
height
challeng
soybas
formula
four
month
age
well
toler
seventh
month
age
challeng
cow
milk
protein
develop
vomit
abdomin
distens
within
four
day
diagnosi
cow
milk
protein
allergi
made
base
posit
symptom
challeng
conclus
cow
milk
protein
allergi
evalu
patient
present
necrot
enterocol
without
obviou
risk
factor
calcium
depend
ige
reactiv
recombin
alphalactalbumin
major
cow
milk
allergen
compar
result
rast
open
food
challeng
test
ofc
among
children
elimin
therapi
suspect
allergi
food
patient
method
object
children
male
femal
age
suspect
food
allergi
januari
may
challeng
food
seem
provok
allerg
symptom
previous
doctor
advis
take
high
score
rast
test
elimin
challeng
clinic
symptom
ingest
food
observ
day
document
evalu
thereaft
symptom
classifi
three
categori
none
mild
moder
result
food
challeng
egg
white
egg
yolk
cow
milk
noodl
buckwheat
chicken
peanut
soybean
tofu
mayonnais
other
figur
parenthes
number
challeng
posit
neg
famili
histori
allerg
diseas
respect
symptom
ingest
food
none
mild
moder
lifethreaten
symptom
note
specif
ige
titer
rast
score
suspect
food
measur
children
signific
correl
symptom
rast
score
p
b
hand
high
score
case
rast
score
symptom
free
result
show
discrep
symptom
rast
score
titer
conclus
ofc
simpl
reliabl
method
clinic
diagnosi
food
allergi
children
effect
soybas
formula
clinic
symptom
fatti
acid
composit
infant
atop
dermat
jaewon
oh
eunyoung
lee
habaik
lee
hanyang
univers
colleg
medicin
pediatr
seoul
republ
korea
gyunghe
univers
nutrit
seoul
republ
korea
atop
dermat
food
allergi
commonli
occur
earli
childhood
especi
infant
cow
milk
allergi
report
reduc
growth
special
nutrit
need
formul
soybas
infant
formula
chang
year
improv
digest
stabil
avail
miner
protein
qualiti
soybas
formula
rich
sourc
essenti
fatti
acid
linol
acid
linolen
acid
studi
intend
investig
whether
soy
base
formula
effect
clinic
symptom
fatti
acid
composit
erythrocyt
infant
atop
dermat
infant
recruit
pediatr
allerg
clinic
hanyang
univers
guri
hospit
septemb
august
one
group
supplement
soy
base
formula
sbf
supplement
hydrolyz
cow
milk
control
hcm
week
clinic
sever
measur
use
scorad
index
evalu
nutrit
statu
subject
anthropometr
indic
compar
standard
valu
growth
develop
korean
children
blood
sampl
collect
analyz
fatti
acid
composit
immun
paramet
specif
ige
measur
skin
prick
test
perform
mean
age
sbf
group
month
hcm
group
month
scorad
score
mild
moder
state
significantli
improv
experiment
period
sbf
sbf
hcm
hcm
although
sbf
grow
consum
linolen
acid
intak
eicosapentaeno
acid
docosahexaeno
acid
decreas
sbf
hand
arachidon
acid
increas
sbf
feed
sbf
sbf
howev
decreas
hcm
hcm
hcm
conclus
sbf
support
improv
symptom
normal
growth
nutrit
statu
infant
atop
dermat
evid
improv
fatti
acid
composit
although
give
number
acid
intak
might
suggest
report
decreas
atop
dermat
sbf
could
show
recov
enzym
defici
condit
studi
egg
whitespecif
ige
level
predictor
clinic
reactiv
followup
egg
allergi
e
montesino
r
felix
jc
cerda
martorel
j
gard
pont
univers
gener
hospit
allergi
unit
valencia
spain
background
object
describ
egg
white
protein
allergi
surviv
time
popul
analyz
correl
egg
white
ige
level
oral
contol
challeng
test
occt
result
method
perform
retrospect
studi
includ
patient
diagnos
egg
allergi
first
year
life
control
year
age
annual
control
skinprick
test
determin
egg
whitespecif
ige
level
occt
carri
toler
develop
differ
moment
followup
determin
cutoff
point
egg
whitespecif
ige
level
provid
probabl
q
egg
white
toler
analyz
receiveroper
caharacterist
roc
curv
result
median
surviv
time
egg
allergi
month
specif
ige
level
cutoff
point
correl
occt
result
differ
differ
period
followup
egg
whitespecif
ige
level
predictor
clinic
reactiv
posit
predict
valu
ppv
q
differ
period
month
kul
month
kul
month
kul
level
neg
predict
valu
npv
conclus
monitor
egg
whitespecif
ige
level
allerg
children
egg
white
allow
us
predict
clinic
reactiv
along
egg
allergi
followup
egg
whitespecif
ige
level
greater
refer
would
allow
occt
popul
lower
level
would
find
toler
patient
conclus
children
allergi
ehf
demonstr
sever
symptom
a
without
allergi
ehf
atop
background
clinic
symptom
express
children
allergi
ehf
aminoacid
base
formula
recommend
therapi
children
sensit
ehf
hypersensit
cow
milk
protein
prematur
infant
manifest
feed
intoler
hypereosinophilia
khanitha
siripool
wasu
kamchaisatian
suwat
benjaponpitak
surat
tungchaisin
chalerat
direkwattanachai
faculti
medicin
ramathibodi
hospit
mahidol
univers
divis
pediatr
allergyimmunolog
bangkok
thailand
background
cow
milk
protein
hypersensit
common
food
hypersensit
infant
current
diagnost
approach
includ
thorough
histori
take
skin
test
measur
serum
specif
ige
suspect
food
elimin
suspect
food
food
challeng
test
eosinophilia
occur
frequent
prematur
infant
associ
total
parenter
nutrit
cow
milk
protein
allergi
respons
foreign
antigen
present
bodi
gastrointestin
tract
airway
intraven
rout
method
report
prematur
male
infant
gestat
age
week
birthweight
gram
develop
feed
intoler
prematur
infant
formula
sinc
day
old
treat
necrot
enterocol
stop
feed
day
show
improv
symptom
start
feed
day
old
feed
intoler
increas
peripher
blood
eosinophilia
mcl
mcl
age
day
result
allergi
consult
appreci
evalu
caus
hypereosinophilia
thoroughli
exclud
caus
eosinophilia
patient
suspect
allerg
cow
milk
protein
chang
feed
extens
caseinhydrolys
formula
specif
ige
cow
milk
done
reveal
valu
kual
total
ige
iuml
symptom
feed
intoler
improv
good
weightgain
peripher
blood
eosinophilia
gradual
decreas
mcl
within
day
one
week
later
infant
reintroduc
feed
cow
milk
protein
formula
day
develop
vomit
abdomin
distens
retent
gastric
content
strike
peripher
blood
eosinophilia
mcl
feed
chang
back
extens
caseinhydrolys
formula
symptom
feed
intoler
improv
decreas
eosinophil
count
mcl
age
day
bodi
weight
gram
conclus
herein
report
case
prematur
infant
feed
intoler
hypereosinophilia
result
cow
milk
protein
hypersensit
eosinophilia
prematur
infant
may
one
respons
foreign
antigen
mediat
gastrointestin
tract
result
food
hypersensit
case
cow
milk
allergi
succes
treat
amino
acidbas
formula
breast
feed
yoshiyasu
ogata
masafumi
zaitsu
shuichi
yamamoto
eriko
muro
natsuko
nishi
katsuya
tashiro
rahmawati
minhajat
saga
univers
pediatr
saga
japan
saga
univers
patholog
saga
japan
background
hematochezia
infanc
consid
one
symptom
cow
milk
allergi
cma
effect
treatment
cma
complet
avoid
cow
milk
protein
object
experienc
male
infant
cma
toler
amino
acidbas
formula
breast
feed
case
patient
fullterm
babi
boy
initi
rais
breast
milk
small
amount
cmbase
formula
one
month
one
month
age
patient
exclus
breastf
month
age
supplement
cmbase
formula
start
pediatrician
recommend
slight
poor
weight
gain
ingest
cmbase
formula
develop
visibl
rectal
bleed
immedi
presum
diagnosi
cm
allergi
made
mother
instruct
stop
cmbase
formula
avoid
drink
cm
mucu
blood
mix
stool
continu
admit
hospit
diagnosi
treatment
physic
examin
show
appar
abnorm
find
stool
cultur
neg
routin
pathogen
number
eosinophil
stool
smear
elev
serum
ige
iuml
specif
ige
milk
posit
lymphocyt
prolif
respons
cmbase
formula
breast
milk
posit
amino
acidbas
formula
neg
skin
prick
test
posit
cm
rectocolonoscopi
sigmoid
colon
perform
show
macroscop
evid
nodular
lymphoid
hyperplasia
small
eros
rectum
histolog
examin
biopsi
specimen
reveal
coliti
predomin
eosinophilinfiltr
lamina
propria
find
consid
case
cma
breast
milk
contain
small
amount
cm
ask
mother
stop
breast
feed
cmbase
formula
start
amino
acidbas
formula
avoid
breast
feed
resolut
hematochezia
took
place
two
day
age
month
patient
grow
well
amino
acidbas
formula
food
without
cm
protein
conclus
difficult
mother
avoid
complet
milk
protein
lot
food
contain
cm
ingredi
therefor
breast
milk
may
contain
small
amount
cm
protein
often
case
success
treat
patient
amino
acidbas
formula
without
breast
feed
problem
growth
amino
acidbas
formula
power
tool
treatment
cma
infanc
prebiot
oligosaccharid
mixtur
inhibit
pathophysiolog
chang
mice
oral
sensit
casein
whey
protein
bastiaan
schouten
betti
van
esch
gerard
hofman
linett
willemsen
johan
garssen
utrecht
institut
pharmaceut
scienc
pharmacolog
pathophysiolog
utrecht
netherland
numicoresearch
bv
immunolog
wageningen
netherland
background
human
breast
milk
thought
protect
neonat
develop
allergi
particular
oligosaccharid
human
milk
may
benefici
prebiot
may
direct
immunomodulatori
capac
exert
effect
enhanc
growth
lactobacilli
bifidobacteria
test
effect
prebiot
oligosaccharid
allerg
sensit
diet
contain
oligosaccharid
mixtur
fructo
galactoand
acid
oligosaccharid
go
fo
ao
test
mice
oral
sensit
casein
whey
protein
prebiot
mixtur
mimick
oligosaccharid
composit
human
milk
method
period
week
five
week
old
femal
mice
sensit
weekli
gavag
ig
casein
whey
mg
use
cholera
toxin
ct
adjuv
mice
fed
control
prebiot
gfa
diet
start
two
week
prior
first
sensit
week
mice
challeng
subcutan
ear
oral
mg
serum
level
total
ige
allergen
specif
ige
measur
acut
allerg
skin
reaction
determin
measur
ear
swell
furthermor
isometr
contract
colon
determin
get
insight
motil
chang
intestin
result
whey
casein
sensit
anim
allerg
skin
reaction
significantli
reduc
prebiot
group
obviou
casein
group
control
vs
gfa
diet
vs
casein
andor
whey
specif
ige
level
unalt
whey
sensit
anim
level
enhanc
diet
control
vs
gfa
diet
vs
hypocontractil
colon
casein
sensit
mice
restor
normal
level
prebiot
diet
control
vs
gfa
diet
mg
conclus
mixtur
gosfosao
oligosaccharid
reduc
system
local
allerg
symptom
mice
oral
sensit
cow
milk
protein
provid
sensit
phase
balbc
mous
model
allergi
wheat
gliadin
biochem
clinic
manifest
mari
bodini
leroy
sandrin
ahleung
fani
blanc
olivi
tranquet
sandra
denerypapini
jeanmichel
wal
karin
adelpati
inra
bia
unit
allergi
team
nant
franc
inra
unit
immunolog
food
allergi
cea
saclay
gifsuryvett
franc
background
anim
model
demonstr
ige
specif
human
ige
clinic
symptom
upon
challeng
close
observ
allerg
patient
great
interest
understand
mechan
involv
induct
regul
allergi
food
allergi
wheat
faw
affect
global
popul
major
allergen
character
patholog
watersalt
solubl
albuminglobulin
fraction
contain
major
allergen
children
atop
eczemadermat
syndrom
a
insolubl
involv
adult
wheatdepend
exerciseinduc
anaphylaxi
wdeia
aim
aim
studi
consist
develop
mous
model
food
allergi
gliadin
extract
wheat
fraction
contain
major
allergen
test
differ
protocol
method
three
strain
mice
balbc
immun
success
intraperiton
inject
gliadin
extract
influenc
dose
gliadin
per
mous
evalu
allergen
specif
ige
product
cytokin
product
activ
lymphocyt
elicit
allerg
reaction
develop
allerg
reaction
compar
test
type
cytokin
product
eosinophil
influx
bronchoalveolar
lavag
bal
fluid
singl
intranas
stimul
total
gliadin
extract
result
balbc
mice
demonstr
higher
gliadin
specif
ige
product
mice
whatev
dose
administ
ie
confirm
type
cytokin
profil
produc
activ
splenocyt
signific
eosinophil
influx
type
cytokin
produc
bal
also
show
elicit
allerg
reaction
balbc
mice
whatev
sensitis
dose
low
elicit
evidenc
mice
dose
conclus
studi
demonstr
first
time
interest
balbc
strain
mous
model
food
allergi
wheat
project
characteris
fine
specif
induc
ige
compar
respons
obtain
human
mice
number
igebind
cell
stomach
mucosa
patient
peptic
ulcer
diseas
food
allergi
versu
without
food
allergi
zbigniew
bartuzi
collegium
medicum
bydgoszcz
n
copernicu
univers
depart
allergi
clinic
immunolog
intern
bydgoszcz
poland
immunoglobulin
e
main
antibodi
respons
immedi
type
reaction
bind
fceri
receptor
mast
cell
basophil
includ
alimentari
tract
aim
aim
studi
compar
quantiti
cell
connect
ige
antibodi
stomach
mucosa
patient
peptic
ulcer
diseas
food
allergi
versu
group
patient
peptic
ulcer
diseas
without
food
allergi
studi
group
consist
patient
ulcer
diseas
food
allergi
control
group
form
nonatop
patient
ulcer
diseas
evalu
quantiti
cell
connect
ige
antibodi
gastric
mucosa
method
direct
immunofluoresc
result
number
igebind
cell
stomach
patient
peptic
ulcer
diseas
food
allergi
averag
instead
patient
peptic
ulcer
diseas
found
statist
signific
differ
quantiti
cell
connect
ige
patient
peptic
ulcer
diseas
food
allergi
versu
patient
peptic
ulcer
diseas
without
food
allergi
conclus
result
confirm
import
role
allerg
mechan
pathogenesi
inflammatori
chang
stomach
mucosa
observ
patient
peptic
ulcer
diseas
food
allergi
relationship
ulcer
coliti
irrit
bowel
syndrom
ib
food
allergi
xueyan
wang
xuefei
yang
ruiqin
ming
zhang
huan
beje
shijitan
hospit
allergi
beij
china
background
allerg
diseas
common
diseas
involv
mani
clinic
disciplin
food
allergi
offend
food
food
addit
concern
problem
doctor
object
explor
relationship
ulcer
coliti
irrit
bowel
syndrom
ib
food
allergi
method
period
patient
ulcer
coliti
ib
test
food
skin
test
serum
food
specif
immunoglobulin
g
sigg
ana
cic
adn
result
patient
posit
result
egg
patient
wheat
patient
tomato
patient
bean
patient
fish
patient
shrimp
patient
peanut
patient
corn
patient
beef
combin
two
kind
food
visit
month
month
examin
avoid
posit
food
month
patient
coliti
improv
abdomin
pain
reliev
month
patient
recov
conclus
valuabl
test
food
sigg
accord
elev
sigg
patient
ask
chang
food
habit
patient
improv
patient
effect
studi
help
us
know
close
relationship
digest
diseas
food
allergi
studi
chines
herbal
medicinelonicera
extract
water
solut
ovalbuminsensit
balbc
mice
fei
li
haiqi
li
children
hospit
depart
primari
child
care
chongq
china
background
studi
avail
treat
food
allergi
use
tcm
object
investig
effect
chines
herbal
medicin
lonicera
ovalbumininduc
hypersensit
balbc
mice
method
balbc
mice
sensit
ova
treat
hour
first
challeng
twice
daili
day
differ
lonicera
concentr
extract
water
solut
ie
high
dosag
ml
middl
low
result
part
condit
hypersensit
mice
markedli
improv
high
middl
lonicera
dose
reduc
level
serum
ovaspecif
ige
inhibit
abnorm
monocular
cell
prolifer
allevi
degranul
aggreg
intestin
mast
cell
increas
percentag
intact
mast
cell
significantli
reduct
histamin
releas
well
downregul
ratio
promot
mrna
express
tgf
plnmc
part
ii
count
bifidobacterium
lactobacillu
stool
sampl
sensit
mice
significantli
increas
high
middl
lonicera
dose
meanwil
count
enterobacteriacea
staphylococcu
markedli
declin
conclus
data
first
show
immunolog
regul
effect
food
allergi
high
middl
lonicera
concentr
extract
water
solut
antiinflamm
immunoregul
respons
well
activ
regulatori
cell
inbal
intestin
microflora
ovainduc
allerg
mice
improv
lonicera
ext
help
improv
clinic
manifest
food
allergi
util
fast
food
allergi
case
report
paola
minal
federica
fumag
annalisa
kunkl
matteo
caiti
costantino
trois
giorgio
walter
canonica
san
martino
hospit
genoa
allergi
unit
genoa
itali
univers
genoa
allergi
respiratori
diseas
dimi
genoa
itali
san
martino
hospit
genoa
diagnostica
citofluorimetrica
genoa
itali
univers
genoa
dept
intern
medicin
dimi
genoa
itali
describ
case
report
year
old
man
experienc
episod
urticaria
angioedema
minut
taken
mg
nimesulid
drunk
beer
known
suffer
allerg
rhiniti
food
allergi
skin
prick
test
posit
dermatophagoid
pteronissinu
dermatophagoid
farina
grass
pollen
oliv
tree
pollen
birch
pollen
artemisia
hazel
tree
pollen
peanut
nut
urticaria
angioedema
ingest
peanut
nut
regard
last
episod
drug
food
suspect
caus
reaction
therefor
perform
skin
prick
test
beer
malt
previous
toler
result
posit
fastimmun
basophil
activ
assay
flowfast
beer
confirm
skin
prick
test
posit
fast
nimesulid
neg
confirm
data
patient
challeng
nimesulid
toler
accord
clinic
laboratori
find
conclud
diagnosi
urticaria
due
beer
allergi
fast
reveal
presenc
specif
sensit
cellular
activ
marker
permit
diagnos
igemedi
reaction
pseudoallergi
case
report
help
confirm
posit
beer
allergen
skin
prick
test
exclud
drug
reaction
therapeut
indic
amino
acidbas
formula
infant
atop
eczema
dermat
syndrom
beata
cudowska
maciej
kaczmarski
gorzata
sawickaukowska
medic
univers
bialystok
iii
depart
paediatr
bia
ystok
poland
background
allergi
cow
milk
protein
one
casual
factor
atop
eczema
dermat
syndrom
a
infant
treatment
base
diet
gener
use
extens
hydrolyz
formula
ehf
aminoacid
base
formula
aabf
aim
studi
establish
therapeut
indic
amino
acidbas
formula
infant
atop
eczema
materi
method
children
age
month
a
qualifi
studi
allergi
cow
milk
protein
establish
measur
total
specif
ige
verifi
oral
food
challeng
follow
standard
accord
obtain
result
infant
divid
two
group
children
allergi
ehf
children
without
allergi
ehf
result
children
allergi
cow
milk
formula
confirm
group
children
allergi
ehf
hypersensit
casein
hydrolys
confirm
whey
hydrolys
infant
sever
atop
dermat
recogn
often
infant
sensit
ehf
scorad
index
mean
vs
control
group
total
ige
elev
significantli
group
infant
sever
a
allergi
ehf
mean
vs
conclus
amino
acidbas
formula
recommend
children
sever
atop
dermat
allergi
extens
hydrolyz
cow
milk
formula
allergi
casein
common
infant
hypersensit
ehf
assess
birch
pollen
immunotherapi
effect
pollenfood
allergi
syndrom
appl
vitro
passiv
sensit
assay
ramon
bencharitiwong
anna
nowakwegrzyn
mount
sinai
school
medicin
allergi
immunolog
new
york
unit
state
rationel
polllenappl
allergi
syndrom
affect
approxim
birch
tree
pollenallerg
adult
allergi
appl
result
crossreact
appl
birch
pollen
protein
subcutan
immunotherapi
birch
pollen
report
improv
appl
allergi
subset
adult
subject
skin
test
serum
allergenspecif
ige
antibodi
level
correl
poorli
clinic
express
appl
allergi
birchallerg
individu
oral
food
challeng
appl
remain
accur
diagnost
test
howev
standard
protocol
easili
avail
procedur
labourintens
sought
determin
whether
rbl
passiv
sensit
assay
might
use
evalu
effect
birch
pollen
immunotherapi
subject
pollenfood
allergi
syndrom
appl
method
birchallerg
individu
appl
allergi
confirm
doubleblind
placebocontrol
oral
food
challeng
random
birch
pollen
immunotherapi
arm
control
arm
immunotherapi
continu
standard
medic
manag
cell
transfect
human
fc
receptor
passiv
sensit
sera
birchallerg
individu
oral
allergi
appl
dilut
follow
overnight
incub
stimul
serial
dilut
inhous
freshli
prepar
raw
granni
smith
appl
extract
nhexosaminidas
content
supernat
use
marker
rbl
degranul
express
percentag
total
degranul
caus
triton
x
result
eight
subject
complet
birch
immunotherapi
cours
median
baselin
releas
rang
differ
median
postimmunotherapi
releas
rang
trend
decreas
skin
test
respons
birch
pollen
extract
mean
mm
preversu
mm
postimmunotherapi
p
fresh
appl
mean
mm
preversu
mm
postimmunotherapi
signific
differ
preand
post
immunotherapi
birch
ige
bet
v
ige
level
conclus
rbl
cell
passiv
sensit
sera
birchand
appleallerg
individu
undergo
degranul
upon
stimul
fresh
granni
smith
appl
extract
mediat
releas
fresh
appl
extract
differ
birch
pollen
subcutan
immunotherapi
perform
vitro
passiv
sensit
assay
affect
low
concentr
major
appl
allergen
extract
develop
first
multidisciplinari
psychoeduc
intervent
parent
children
food
allergi
audrey
dunngalvin
jonathan
hourihan
univers
colleg
cork
paediatr
child
health
cork
ireland
aim
develop
evidenc
base
intervent
programm
help
children
parent
manag
biopsychosoci
impact
food
allergi
everyday
live
method
focu
group
parent
confirm
food
allerg
children
focu
group
food
allerg
children
age
year
qualit
analysi
use
ground
theori
use
analys
transcript
transcript
gave
rise
categori
relat
risk
percept
ill
cognit
cope
strategi
understand
health
wellb
mean
given
diet
food
transcript
also
reveal
development
parentchild
sex
differ
vital
creat
target
food
allergi
sensit
intervent
psychoeduc
intervent
develop
current
valid
strong
initi
find
conclus
middl
childhood
period
problem
anxieti
low
selfesteem
peer
comparison
malconstruct
cope
strategi
emerg
lead
higher
risk
adolesc
data
suggest
intervent
critic
point
food
allergi
development
perspect
vital
ensur
success
biopsychosoci
adjust
daytoday
life
new
questionnair
food
allergi
federica
fumag
ilaria
baiardini
sara
pellegrini
micaela
bacic
paola
minal
fulvio
braido
costantino
trois
giorgio
walter
canonica
univers
genoa
allergi
respiratori
diseas
dimi
genoa
itali
san
martino
hospit
genoa
allergi
unit
genoa
itali
despit
clinic
expertis
suggest
food
allergi
substanti
burden
patient
life
littl
data
avail
impact
treatment
qualiti
life
aim
studi
evalu
patient
answer
preliminari
version
qol
questionnair
specif
address
food
allergi
develop
phase
new
tool
item
administ
patient
f
mean
age
sd
suffer
food
allergi
patient
indic
likert
scale
multipl
option
much
much
troubl
problem
result
relev
percentag
patient
report
import
burden
mani
aspect
life
patient
live
state
alert
watch
new
symptom
appear
eat
afraid
becom
sick
eat
someth
risk
new
food
patient
refer
feel
uneasi
go
dinner
troubl
read
label
everi
product
anoth
relev
problem
diet
due
avoid
food
could
unbalanc
food
caus
concern
patient
ca
nt
enjoy
food
conclus
basi
preliminari
data
food
allergi
appear
problem
deepli
interfer
patient
life
increas
preval
latex
allergi
associ
increas
usag
latex
materi
cross
reactiv
latex
food
allergen
due
common
determin
plant
goal
reveal
cross
sensit
latex
allergen
patient
food
allergi
use
test
allerg
alter
leucocyt
taal
materi
method
patient
food
allergi
fruit
health
care
worker
gloverel
skin
symptom
itch
red
dryness
sometim
oedema
hand
skin
includ
studi
diagnosi
latex
allergi
patient
second
group
confirm
posit
use
test
one
neg
result
contact
patch
test
rubber
chemic
type
iv
hypersensit
reveal
ige
antibodi
latex
sera
elisa
method
taal
skin
test
latex
fruit
allergen
carrot
potato
appl
tomato
kiwi
mango
melon
avocado
apricot
banana
perch
bstallergen
franc
perform
patient
taal
mkl
blood
sampl
incub
min
mkl
standard
solut
ammoni
latex
stallergen
microprepar
prepar
stain
acrydin
orang
luminesc
microscopi
percent
alter
granulocyt
count
result
consid
posit
number
alter
cell
sampl
blood
incub
nacl
examin
neg
control
result
posit
result
taal
skin
test
batteri
fruit
allergen
observ
group
patient
latex
allergi
patient
posit
result
taal
skin
test
latex
allergen
observ
consequ
posit
result
taal
allergen
observ
patient
food
allergi
patient
posit
skin
test
latex
high
percentag
sensit
latex
food
allergi
patient
without
clinic
symptom
latex
establish
two
method
may
evid
cross
reactiv
risk
develop
latex
allergi
latex
recombin
hevein
b
ige
antibodi
atop
children
sensit
fruit
latex
pollen
rumiko
shibata
jyunko
ikei
youko
murakami
sankei
nishima
fukuoka
nation
hospit
pediatr
fukuoka
japan
rational
associ
latex
fruit
oral
allergi
syndrom
oa
pollinosi
report
adult
allerg
patient
childhood
fruit
allergi
howev
signific
data
collect
clinic
featur
frequenc
crossreact
ige
antibodi
latex
latex
antigen
clarifi
hevein
primari
allergen
relat
clinic
manifest
elucid
ige
antibodi
determin
recombin
hevein
rhev
b
protein
object
aim
studi
identifi
specif
ige
antibodi
latex
rhev
b
protein
fruit
oa
children
latex
allergi
method
twentysix
atop
children
age
year
yo
fruit
oa
sensit
latex
latex
allergi
children
yo
oper
histori
earli
stage
age
enrol
studi
specif
ige
antibodi
food
pollen
latex
rhev
b
measur
capfeia
phadia
kk
result
clinic
manifest
fruit
oa
due
banana
melon
kiwi
fruit
specif
ige
antibodi
case
banana
melon
kiwi
posit
patient
ige
antibodi
latex
uaml
japanes
cedar
pollen
fruit
oa
clear
latex
elicit
histori
latex
ige
antibodi
level
high
ige
antibodi
rhev
posit
case
rhev
case
case
without
latex
allerg
provoc
medic
histori
ige
antibodi
rhev
b
profiln
increas
remark
specif
ige
rhev
b
clearli
posit
case
latex
allergi
oper
histori
conclus
result
provid
evid
food
allergi
infant
fruit
oa
risk
earli
sensit
latex
pollen
measur
specif
ige
latex
rhev
use
predict
latex
anaphylaxi
fruit
oa
children
latex
ige
antibodi
turnipoilse
rape
mustard
allergi
finnish
french
children
atop
dermat
food
allergi
go
collabor
ministri
health
labour
welfar
japan
order
improv
qualiti
life
patient
food
allergi
investig
peanut
process
effect
allergenec
asian
north
american
popul
elisabeth
berger
birgitta
backhan
larsson
maryam
poorafshar
ingrid
holmquist
phadia
r
uppsala
sweden
aim
peanut
cultiv
almost
whole
world
despit
widespread
consumpt
peanut
product
preval
peanut
allergi
vari
differ
area
peanut
prior
consumpt
subject
differ
kind
process
differ
part
world
studi
effect
differ
treatment
varieti
peanut
cultiv
north
south
america
tri
mimic
differ
eat
habit
investig
final
igebind
pattern
untreat
roast
peanut
studi
two
differ
popul
us
asia
method
peanut
sourc
materi
jumbo
runner
us
argentina
use
peanut
treat
three
differ
way
heat
min
boil
min
roast
min
follow
grind
extract
untreat
peanut
use
control
protein
separ
convent
sd
page
gel
electrophoresi
spot
electrophoresi
gel
excis
analyz
malditof
ms
immunoblot
analyz
perform
sera
us
asia
individu
peanut
sensit
result
differ
protein
pattern
two
sourc
materi
detect
sdspage
electrophoresi
one
promin
protein
band
approx
kd
materi
us
miss
peanut
argentina
expect
decreas
protein
amount
depend
treatment
temperatur
detect
distinct
spot
electrophoresi
approx
kd
untreat
materi
visibl
roast
spot
identifi
major
peanut
allergen
ara
h
malditof
ms
obviou
differ
igebind
immunoblot
two
popul
could
observ
popul
decreas
igebind
roast
compar
untreat
peanut
especi
approx
kd
ara
h
kd
differ
igebind
pattern
due
individu
differ
conclus
peanut
cultiv
differ
part
world
may
contain
differ
protein
allergen
differ
treatment
cook
habit
influenc
allergen
studi
obviou
differ
igebind
pattern
two
popul
observ
even
though
popul
chosen
reflect
differ
eat
habit
peanut
clinic
relev
miss
protein
peanut
sourc
materi
argentina
need
investig
outcom
food
allergi
among
infant
children
israel
darit
aronov
eli
somekh
ilan
dalal
e
wolfson
medic
center
pediatr
allergi
unit
depart
pediatr
holon
israel
background
food
allergi
common
among
infant
children
milk
egg
soy
allergi
tend
resolv
earli
life
allergi
peanut
tree
nut
fish
usual
stay
life
knowledg
natur
histori
sesam
allergi
scarc
survey
among
children
treat
allergi
clinic
e
wolfson
medic
center
method
survey
done
base
clinic
record
children
diagnos
food
allergi
phone
survey
detail
question
fill
emphasi
outcom
child
food
allergi
result
found
children
suspect
food
allergi
found
food
allergi
patient
food
allergi
found
allerg
sever
food
tree
beef
children
follow
averag
period
year
case
allergi
resolv
still
exist
case
clear
whether
allergi
resolv
among
milk
allergi
igemedi
group
non
igemedi
group
ii
group
clearli
atop
background
group
ii
allergi
resolv
among
group
ii
patient
compar
group
allergi
soy
found
children
also
allerg
milk
allerg
soy
number
children
soy
allergi
among
group
ii
patient
higher
group
allergi
resolv
children
allergi
sesam
third
allergi
present
anaphylaxi
children
sesam
allergi
found
atop
background
first
degre
rel
sesam
allergi
allergi
resolv
averag
year
conclus
distribut
food
allergen
israel
differ
countri
found
atop
statu
outcom
igemedi
milk
allergyi
significantli
differ
compar
non
igemedi
patient
survey
may
help
understand
mani
aspect
food
allergi
among
children
israel
may
help
us
provid
appropri
guidanc
children
famili
background
teenag
highrisk
group
foodhypersensit
fh
fatal
engag
risktak
manag
condit
exist
research
identifi
anxieti
impair
qualiti
life
children
fh
parent
date
howev
research
address
experi
live
fh
like
teenag
studi
therefor
aim
describ
live
experi
teenag
fh
method
individu
semistructur
indepth
interview
conduct
uk
teenag
age
year
preexist
diagnosi
fh
particip
hypersensit
rang
food
experienc
varieti
reaction
particip
exclud
concomit
nonallerg
diseas
interview
explor
live
teenag
gener
particular
attent
paid
experi
live
fh
interview
audiotap
transcrib
verbatim
analys
use
phenomenolog
approach
result
four
main
theme
identifi
fh
way
life
manag
fh
assess
accept
risk
versu
accept
burden
live
fh
cope
necessari
burden
alleviationexacerb
burden
live
fh
particip
process
manag
fh
describ
problemat
way
life
manag
fh
describ
negoti
rather
prescript
base
assess
accept
risk
versu
accept
burden
negoti
manag
howev
complet
reliev
burden
felt
particip
felt
necessari
part
live
fh
cope
necessari
burden
varieti
cope
strategi
employ
effect
particip
also
describ
way
burden
live
fh
allevi
exacerb
person
other
whose
behaviour
affect
life
fh
conclus
theme
provid
explan
teenag
fh
engag
riski
behaviour
describ
teenag
cope
manag
fh
factor
make
live
fh
easier
difficult
theme
indic
way
live
teenag
fh
improv
therefor
provid
new
inform
live
fh
perspect
teenag
use
healthcar
practition
work
teenag
fh
cow
milk
allergi
fo
associ
rhiniti
atop
maria
alul
cipea
centro
de
inmunologia
pediatrica
asmay
alergia
alergia
pediatrica
san
miguel
de
tucuman
argentina
background
allergi
cow
milk
cm
one
caus
manifest
allerg
common
childhood
excel
one
foretel
sinc
case
solv
year
age
associ
clinic
disord
allergi
cow
milk
children
includ
atoep
condit
atoep
dermat
allerg
rhiniti
asthma
manifest
correspond
food
allergi
object
determin
associ
allergi
cow
milk
persist
allerg
rhiniti
smaller
children
year
materi
method
smaller
children
year
diagnosi
allerg
rhiniti
allergi
cow
milk
clinic
histori
evalu
made
prick
test
cow
milk
standard
protein
extract
casein
alactoglobulin
blactoglobulin
concentr
histamina
consid
posit
control
one
presenc
papula
mm
salin
solut
neg
control
without
presenc
one
quantifi
ig
fic
cow
milk
intern
unit
mililit
mean
enzimoinmunoensayo
clinic
aim
specif
concentr
ige
evalu
accord
follow
data
uiml
nonsignific
ulml
low
ul
ml
moder
ulml
high
ulml
elev
ulml
highest
result
studi
children
total
presentdisplay
direct
atopico
familiar
anteced
manifest
rhinit
symptom
incorpor
cow
milk
like
dietario
supplement
three
children
birth
two
month
life
level
moder
specif
ige
studi
children
two
supplement
cm
birth
one
month
life
presentingdisplay
prick
posit
alpha
beta
lactoglobulin
neg
test
casein
serum
ige
superior
uim
two
patient
five
level
specif
ige
nonsignific
cm
low
serum
valu
ige
uiml
neg
prick
test
cow
milk
protein
conclus
accord
result
possibl
determin
cow
milk
present
allerg
riniti
smaller
children
four
year
age
replac
could
improv
clinic
sintomatolog
patient
medic
save
preval
peanut
treenut
allergi
singapor
teenagersestim
questionnair
survey
allergi
test
food
challeng
irvin
franci
gerez
shu
e
soh
jian
yi
soh
pao
zhing
ng
elizabeth
moral
stefan
bee
wah
lee
pei
chi
lynett
shek
nation
univers
hospit
paediatr
singapor
singapor
nation
univers
singapor
paediatr
singapor
singapor
ministri
health
statist
singapor
singapor
introduct
peanut
tree
nut
allergi
potenti
life
threaten
henc
awar
preval
popul
would
allow
physician
better
address
issu
diagnosi
manag
educ
object
estim
true
preval
peanut
treenut
allergi
singaporean
teenag
preval
food
allergi
year
old
singaporean
children
evalu
use
standard
questionnair
distribut
student
randomli
select
school
student
respond
posit
food
allergi
administ
extend
questionnair
determin
presenc
convinc
food
allergi
portion
convinc
allergi
symptom
recal
skin
prick
test
spt
well
underw
grade
food
challeng
consent
result
cohort
student
respond
crude
preval
selfreport
allergi
peanut
treenut
howev
use
criteria
convinc
food
allergi
preval
fell
peanut
treenut
proport
subject
convinc
allergi
symptom
agre
skin
prick
test
show
low
frequenc
skin
test
posit
peanut
treenut
final
food
challeng
peanut
treenut
carri
subject
either
convinc
histori
plu
neg
spt
convinc
histori
plu
posit
spt
result
neg
outcom
conclus
result
indic
preval
peanut
treenut
allergi
singapor
adolesc
low
evalu
base
questionnair
survey
alon
overestim
preval
peanut
treenut
allergi
popul
giovanni
ferrari
peter
eng
kantonspit
aarau
ag
children
clinic
aarau
switzerland
background
igemedi
food
allergi
common
type
advers
reaction
food
infant
young
children
present
wide
spectrum
clinic
reaction
includ
lifethreaten
allerg
symptom
studi
perform
determin
preval
food
allergen
induc
immedi
clinic
reaction
differ
age
group
swiss
infant
children
furthermor
investig
specif
pattern
allerg
reaction
individu
food
allergen
method
prospect
analysi
patient
refer
assess
immedi
type
allerg
reaction
food
studi
carri
food
allergi
clinic
children
hospit
aarau
lucern
individu
present
atop
dermat
evid
delay
reaction
food
includ
diagnosi
food
allergi
base
clinic
histori
skin
prick
test
commerci
extract
pricktoprick
test
use
nativ
food
determin
specif
ige
antibodi
food
protein
capfeia
system
food
challeng
perform
patient
without
histori
lifethreaten
anaphylaxi
caus
antigen
could
conclus
determin
result
food
allergi
identifi
children
male
femal
median
age
year
rang
month
year
overal
preval
food
allergen
hen
egg
follow
cow
milk
peanut
hazelnut
wheat
fish
kiwi
soy
infanc
common
food
allergen
cow
milk
hen
egg
wheat
second
third
year
life
hen
egg
cow
milk
peanut
predomin
wherea
age
year
peanut
hen
egg
fish
preval
urticaria
frequent
reaction
food
allergen
howev
beyond
urticaria
differ
pattern
clinic
reaction
individu
food
cow
milk
hen
egg
allergi
mainli
present
gastrointestin
symptom
peanut
hazelnut
angioedema
fish
angioedema
anaphylaxi
wheat
angioedema
asthma
conclus
allergen
account
igemedi
food
allergi
swiss
infant
children
age
group
specif
order
preval
offend
food
protein
furthermor
specif
spectrum
allerg
symptom
individu
food
allergen
immedi
hypersensit
common
food
allergensi
yan
investig
respiratori
allerg
patient
kolkata
calcutta
india
univers
zimbabw
colleg
health
scienc
immunolog
harar
zimbabw
background
peanut
arachi
hypogea
promin
sourc
immunoglobulin
e
ige
mediat
allerg
reaction
food
item
highli
recognis
nutrit
valu
protein
oil
major
allergen
ara
h
ara
h
result
allergen
manifest
eczema
urticaria
angiodema
asthma
sometim
fatal
anaphylact
reaction
object
aim
pilot
studi
establish
whether
zimbabwean
nut
allergi
gener
peanut
allergi
particular
well
identifi
clinic
entiti
associ
sensit
method
patient
studi
select
upon
review
sensit
peanut
allergen
sensit
diagos
use
skin
prick
test
spt
serolog
evid
allergen
specif
ige
antibodi
euroimmun
assay
patient
came
allergi
clinic
eczema
dermat
urticaria
result
patient
nut
allergi
peanut
patient
react
peanut
children
year
adult
year
patient
react
hazelnut
children
year
adult
year
crossreact
peanut
hazelnut
note
patient
children
year
adult
year
age
conclus
allergen
specif
antibodi
peanut
hazelnut
peanut
hazelnut
demonstr
observ
overlap
reactiv
biolog
differ
nut
one
groundnut
peanut
arachi
hypogea
one
tree
nut
hazelnut
coryllu
avellana
patient
henc
interest
investig
establish
whether
crossreact
mere
cosensit
two
nut
peculiar
food
sensit
children
atop
dermat
ukrain
viktoriia
klymenko
kharkiv
state
medic
univers
propedeut
pediatria
depart
kharkiv
ukrain
background
food
allergi
affect
consider
quantiti
children
gastrointestin
tract
immatur
low
immunolog
toler
accord
recent
data
investig
children
atop
dermat
food
sensit
food
sensit
differ
differ
countri
nation
food
tradit
genet
factor
exampl
allergi
reaction
peanut
shellfish
ukrain
characterist
american
countri
hand
food
chang
allerg
properti
exampl
world
mark
increas
allergi
soy
object
find
peculiar
food
sensit
earli
age
late
school
age
children
atop
dermat
ukrain
method
sixti
seven
patient
atop
dermat
observ
patient
divid
two
group
first
one
patient
age
month
year
second
one
children
age
year
food
sensit
determin
enzym
immunoassay
method
measur
level
allergen
specif
human
igeantibodi
blood
first
group
skin
prick
test
second
group
result
food
sensit
reveal
patient
first
second
group
accordingli
includ
high
high
reaction
monoallergi
children
accordingli
high
high
level
specif
ige
detect
antigen
corn
chicken
egg
protein
fish
rye
chicken
egg
oat
cow
milk
chicken
egg
yolk
rice
tangerin
lemon
orang
children
earli
age
food
toler
corn
rye
cow
milk
oat
rice
chicken
egg
protein
tangerin
form
late
childhood
certain
type
food
like
other
allergen
children
late
school
period
chocol
tomato
pear
carrot
potato
nobodi
examin
patient
sensit
peanut
conclus
establish
peculiar
food
sensit
taken
account
initi
prevent
mainten
atopi
also
use
prescript
empir
hypoallerg
diet
ukrain
east
europ
sensit
parvalbumin
collagen
japanes
patient
fish
allergi
michiko
hirokado
naoko
inomata
jyunko
yamaguti
katsura
yasujima
mio
kirino
megumi
kondo
kuniyoshi
shimakura
kazuo
shiomi
zenro
ikezawa
yokohama
citi
univers
school
medicin
depert
enviroment
immunodermatorogi
yokohama
japan
kndo
clinic
dermatorogi
yokohama
japan
tokyo
univers
marin
scienc
technolog
depert
food
scienc
technolog
shinagawa
japan
background
fish
report
one
import
allergen
food
caus
sever
allerg
reaction
furthermor
parvalbumin
small
calciumbind
protein
collagen
identifi
import
crossreact
allergen
fish
object
clarifi
clinic
laboratori
featur
allergi
fish
detect
crossreact
allergen
elisa
japanes
patient
method
six
patient
suspect
hypersensit
fish
subject
skin
prick
test
measur
specif
ige
antibodi
fish
addit
specif
ige
purifi
parvalbumin
collagen
investig
elisa
result
patient
male
femal
age
rang
month
year
also
atop
diseas
atop
dermat
bronchial
asthma
pollinosi
diagnosi
base
symptom
fish
ingest
result
skin
prick
test
anaphylaxi
oral
allergi
syndrom
oa
accompani
symptom
oropharyng
symptom
patient
respect
caus
food
sauri
yellowtail
flatfish
patient
hors
mackerel
mackerel
tuna
salmon
atka
mackerel
flatfish
patient
spt
posit
three
kind
fish
patient
immuno
caprast
test
show
patient
posit
cod
flatfish
hors
mackerel
salmon
mackerel
furthermor
specif
ige
purifi
parvalbumin
collagen
detect
patient
discuss
result
indic
patient
fish
allergi
tend
develop
sever
symptom
ingest
differ
kind
fish
due
sensit
crossreact
allergen
hiroshi
narita
kumiko
kidu
tsutomu
honjoh
akihiro
kimura
junko
hiros
kyoto
women
univers
food
nutrit
kyoto
japan
morinaga
institut
biolog
scienc
research
develop
yokohama
japan
itayado
clinic
allergi
kobe
japan
univers
shiga
prefectur
depart
life
style
studi
hikon
japan
background
found
signific
amount
food
protein
secret
human
rat
breast
milk
immun
complex
siga
clarifi
physiolog
consequ
phenomenon
anim
experi
carri
view
allergi
prevent
result
sd
rat
divid
two
group
one
group
egroup
fed
egg
white
protein
mgroup
fed
cow
milk
protein
dietari
protein
sourc
infant
rat
fed
mother
milk
immun
egg
white
protein
use
freund
complet
adjuv
serum
concentr
antiovomuciod
igg
lower
einfant
minfant
infant
rat
immun
cow
milk
protein
turn
serum
concentr
anticasein
igg
lower
minfant
einfant
thu
immun
toler
food
protein
acquir
via
breastfeed
mother
fed
food
contain
relev
protein
acquir
toler
ovomucoid
diminish
spontan
wean
infant
feed
egg
white
protein
similar
immun
toler
via
breastfeed
also
observ
balbc
mice
propos
hypothesi
breastfeed
probabl
immun
complex
food
protein
siga
serv
natur
drinkabl
vaccin
food
allergi
oral
desensitis
children
immunoglobulin
emedi
hen
egg
allergi
paolo
meglio
paolo
gianni
giampietro
simona
gianni
nadia
gm
mora
paola
palazzo
enrico
scala
adriano
mari
elena
galli
spietro
hospitalfatebenefratelli
research
center
roma
itali
idiircc
center
clinic
experiment
allergolog
roma
itali
background
basic
treatment
food
allergi
avoid
offend
item
date
approach
difficult
case
common
food
risk
sever
reaction
due
child
child
famili
concern
consum
offend
food
even
inadvert
studi
preliminari
data
regard
children
allerg
hen
egg
oral
desensitis
increas
dose
food
shown
object
desensitis
children
sever
igemedi
allergi
period
month
introduc
increas
daili
dose
order
enabl
child
assum
ml
daili
correspond
protein
gram
induc
toler
highest
possibl
dose
studi
design
preliminari
data
larger
studi
concern
children
least
year
old
sever
igemedi
allergi
posit
dbpcfc
confirm
diagnosi
oral
desensitis
done
increas
dose
start
mg
protein
specif
ige
evalu
allergen
moleculebas
approach
proteom
technolog
vbc
genom
microarray
result
children
achiev
daili
intak
ml
month
mean
period
period
reduct
ige
valu
kual
gal
ovomucoid
observ
case
one
case
neg
result
desensit
signif
differ
seen
compar
result
gal
ovalbumin
gal
conalbumin
gal
lysozim
see
tabl
conclus
success
desensitis
children
igemedi
allergi
mean
period
month
moreov
dramat
reduc
risk
sever
reaction
accident
unnot
introduct
low
quantiti
observ
parallel
reduct
specif
ige
gal
propos
gener
method
beyond
train
staff
system
anaphylaxi
induc
lupin
ingest
two
case
report
enrico
compalati
laura
guerra
anthi
rogkak
pierangela
massacan
antonio
scordamaglia
giorgio
walter
canonica
univers
genoa
allergi
respiratori
diseas
genoa
itali
background
igemedi
food
allergi
import
caus
anaphylaxi
approxim
young
children
adult
food
allergi
frequent
find
food
allerg
patient
peanut
tree
nut
milk
egg
crustacean
fish
case
report
report
case
two
young
women
refer
depart
emerg
room
food
induc
anaphylaxi
first
case
occur
yearold
woman
minut
eat
lupin
develop
cyanosi
inspiratori
dyspnoea
sudden
lack
conscious
immedi
treat
epinephrin
system
steroid
remiss
symptom
second
case
occur
yearold
woman
show
anxieti
gener
itch
urticaria
vomit
facial
angioedema
hypotens
syncop
ten
minut
assumpt
gluten
free
cooki
patient
celiac
sudden
administr
system
steroid
antihistamin
induc
patient
recoveri
patient
underw
prick
test
inhal
allergen
show
posit
second
patient
dermatophagoid
birch
parietaria
grass
pollen
posit
observ
common
food
allergen
mention
two
patient
show
mark
posit
prickprick
test
lupin
deep
analysi
cookieslabel
show
presenc
lupin
flour
previou
report
describ
sensit
lupin
patient
profession
exposit
legum
flour
case
report
specif
risk
factor
lupin
allergi
particular
predisposit
food
allergen
sensitis
evid
discuss
lupin
product
gradual
introduc
food
includ
beverag
bread
biscuit
pasta
addit
wheat
flour
substitut
soy
flour
often
present
food
peopl
affect
celiac
diseas
contest
allergi
lupin
may
consid
emerg
condit
relat
hidden
presenc
allergen
contamin
potenti
danger
celiac
patient
case
food
proteininduc
enteropathi
polypoid
lesion
food
proteininduc
enteropathi
fpie
cellmedi
hypersensit
disord
commonli
seen
first
sever
month
life
present
diarrhea
failur
thrive
caus
ingest
certain
food
case
fpie
polypoid
lesion
report
yet
examin
case
fpie
allergyrel
blood
skin
test
endoscopi
two
month
old
japanes
femal
patient
show
repeat
blood
streak
stool
exclus
breastf
show
symptom
food
proteininduc
proctocol
consid
symptom
resolv
temporarili
elimin
cow
milk
mother
diet
howev
develop
diarrhea
month
age
began
fail
thrive
month
age
gross
bleed
stool
observ
hour
mother
ate
cake
breastf
stimul
index
si
lymphocyt
stimul
test
lst
cow
milk
extrem
high
mother
stop
dairi
product
intak
patient
experienc
gross
bleed
stool
hour
eat
tofu
month
old
bodi
weight
increas
two
month
si
lst
soy
bean
also
high
show
posit
result
patch
test
cow
milk
soy
bean
wheat
pacif
cod
show
posit
result
skin
prick
test
also
antigen
specif
serum
ige
level
rise
fecal
examin
repeat
eosinophil
neutrophil
found
microbiolog
result
neg
investig
perform
colon
endoscopi
gener
anesthesia
lymphoid
nodul
mucos
edema
found
colon
mm
polypoid
lesion
found
ileocec
valv
juvenil
polyposi
consid
howev
biopsi
specimen
show
nonspecif
inflamm
massiv
lymphocyt
infiltr
indic
solid
tumor
food
proteininduc
enteropathi
diagnos
stop
breastfeed
start
take
highli
hydrat
cow
milk
morinaga
japan
rice
veget
solid
food
shown
gross
bloodi
stool
sinc
bodi
weight
increas
dramat
endoscop
find
improv
month
dietari
treatment
infant
intestin
bleed
failur
thrive
influenc
food
allergi
consid
lst
patch
test
endoscop
examin
perform
investig
case
perform
provoc
test
fooddepend
exercis
induc
anaphylaxi
last
year
junko
ikei
yoko
murakami
rumiko
shibata
sankei
nishima
fukuoka
nation
hospit
pediatr
fukuoka
citi
japan
background
fooddepend
exercis
induc
anaphylaxi
fdeian
sever
system
syndrom
induc
physic
exercis
food
ingest
recent
year
increas
number
report
fdeian
actual
situat
known
well
object
investig
symptom
fdeian
grasp
actual
situat
provoc
test
investig
case
doubt
fdeian
admit
purpos
detail
examin
last
eight
year
method
nineteen
children
boy
girl
case
enrol
studi
age
onset
year
old
averag
age
year
old
ige
measur
capfeia
pharmacia
skin
prick
test
examin
need
provoc
test
combin
food
exercis
test
perform
patient
preadministr
aspirin
result
symptom
onset
facialangioedema
blepharedema
present
case
urticaria
case
respiratori
symptom
case
hypotens
case
unconsci
case
intramuscular
epinephrin
inject
medic
case
caus
food
allergen
follow
wheat
case
crustacea
case
veget
cone
milk
chees
case
unknown
case
could
abl
estim
food
antigen
medic
histori
case
relat
food
specif
ige
posit
twelv
case
neg
caprast
show
posit
spt
two
case
abl
estim
antigen
medic
histori
neg
caprast
one
show
posit
spt
four
case
posit
provoc
test
combin
food
exercis
perform
administr
aspirin
ingest
food
exercis
exampl
symptom
provoc
one
case
conclus
wheat
crustacea
major
food
allergen
fdeian
case
caus
veget
fruit
combin
caprast
skin
prick
test
use
specifi
allergen
case
posit
rate
combin
food
exercis
test
preadministr
aspirin
need
establish
laboratori
method
children
fdeian
food
load
dose
exercis
method
premed
aspirin
futur
ige
mediat
anaphylaxi
sesam
emmanuella
guenova
sonia
genova
bogomil
voykov
silvia
novakova
eberhard
karl
univers
depart
dermatolog
tuebingen
germani
univers
hospit
depart
allergolog
pleven
bulgaria
eberhard
karl
univers
depart
ophtalmolog
tuebingen
germani
caucasian
man
present
suspect
food
allergi
past
emerg
medic
help
need
acut
system
anaphylact
reaction
time
associ
sesam
ingest
minut
consumpt
sesamepoppyraisin
sweet
suffer
patient
generalis
urticaria
facial
laryng
oedema
sever
hypotens
unconsci
emerg
treatment
intramuscular
administr
epinephrin
high
dose
corticosteroid
antihistamin
intraven
need
previou
allerg
reaction
deni
patient
state
occasion
contact
sesam
throughout
life
span
noncontributori
famili
anamnesi
skin
prick
test
common
inhal
allergen
preserv
food
allergen
neg
pricktoprick
test
poppi
seed
raisin
wheat
flour
remain
neg
well
surprisingli
skin
pricktoprick
test
sesam
seed
sesam
oil
reveal
pronounc
posit
reaction
specif
ige
sesam
highli
posit
kual
wherea
total
serum
ige
kual
basal
serum
tryptas
level
remain
normal
rang
doubl
blind
placebocontrol
food
challeng
increment
dose
sesam
seed
conduct
minut
distribut
mg
back
sesam
seed
acut
anaphylaxi
occur
ige
mediat
mast
cell
activ
proven
increas
serum
tryptas
level
two
hour
food
challeng
preval
allergi
sesam
sesamum
indicum
major
allergen
se
becom
signific
due
increas
industri
import
sesam
repres
insidi
bhidden
allergen
found
alimentari
product
also
cosmet
medic
product
especi
sunprotect
cream
solvent
intramuscular
inject
incid
food
allergi
agedepend
particularli
affect
children
young
patient
elderli
anaphylact
reaction
tend
less
sever
primari
manifest
unusu
nevertheless
abl
diagnos
rare
case
classic
ige
mediat
anaphylaxi
sesam
primari
manifest
patient
show
potenti
lifethreaten
sever
food
anaphylaxi
especi
food
pronounc
allergen
properti
like
sesam
underestim
irrespect
patient
age
assess
qualiti
life
children
food
allergi
noriko
minamitani
takanori
imai
takatsugu
komata
mika
ogata
chizuko
sugizaki
morimitsu
tomikawa
hiroshi
tachimoto
motohiro
ebisawa
sagamihara
nation
hospit
clinic
research
center
depart
allergi
sagamiharac
kanagawa
japan
sagamihara
nation
hospit
depart
pediatr
sagamiharac
kanagawa
japan
nation
hospit
organ
kumamoto
medic
center
depart
pediatr
kumamoto
japan
object
dietari
life
children
food
allergi
fa
restrict
much
qualiti
life
qol
diet
would
affect
therefor
perform
dietari
manag
children
yet
known
restrict
dietari
life
conduct
current
studi
clarifi
problem
dietari
life
children
fa
outpati
clinic
method
questionnair
examin
qol
diet
burden
dietari
life
home
outsid
problem
nourish
parent
psycholog
burden
parent
children
fa
without
fa
control
group
addit
parent
children
fa
interview
qualifi
troubl
dietari
life
diagnosi
fa
time
start
elimin
diet
result
total
patient
survey
qol
survey
children
fa
differ
menu
famili
menu
wherea
control
subject
addit
parent
children
fa
difficulti
make
menu
parent
paid
attent
food
label
felt
econom
burden
purchas
food
fa
children
furthermor
children
fa
satisfi
eatingout
wherea
control
satisfi
children
fa
satisfi
qualiti
school
lunch
control
promin
problem
diagnosi
fa
bmake
menu
cook
age
group
also
problem
mother
wean
fa
babi
infanc
howev
tendenc
diversifi
troubl
age
recogn
start
elimin
diet
problem
concern
bpurchas
food
eatingout
bschool
lunch
conclus
studi
reveal
children
fa
restrict
term
dietari
life
qol
deterior
compar
control
group
sinc
could
obtain
inform
dietet
children
fa
parent
desir
import
pursu
appropri
dietari
manag
children
fa
imatinib
decreas
duoden
mast
cell
densiti
degranul
epicutaneouslysensit
food
allergi
model
mous
kirsi
vaali
aung
htun
lin
lizhi
sun
petri
kovanen
arnold
berstad
kari
eklund
univers
bergen
institut
medicin
section
gastroenterolog
bergen
norway
wihuri
research
institut
helsinki
finland
joint
author
hospit
district
helsinki
divis
rheumatolog
helsinki
finland
background
balbc
mice
sensit
epicutan
ovalbumin
increas
serum
ovalbuminspecif
ige
well
repeat
intragastr
challeng
ig
ovalbumin
mice
develop
acut
diarrhea
within
min
ig
dose
wherea
diarrhea
increas
ige
control
group
sinc
role
small
intestin
mast
cell
undisput
model
want
evalu
effect
imatinib
cell
imatinib
glivecr
potent
inhibitor
import
growth
factor
receptor
mast
cell
ckit
method
imatinib
mgmous
given
oral
balbc
femal
mice
g
pretreat
sensit
everi
second
day
day
time
ig
ovalbumin
mgmous
challeng
ovalbuminspecif
ige
mucos
mast
cell
proteas
measur
serum
histamin
plasma
standard
elisa
method
rectal
temperatur
measur
diarrhea
evalu
ig
challeng
ovalbumin
chloroacet
esteras
cae
use
gener
mast
cell
stain
immunohistochem
stain
antibodi
use
doubl
stain
fluoresc
method
antibodi
tunel
method
use
total
amount
stain
cell
calcul
whole
crosssect
specimen
duodenum
result
signific
differ
level
ovalbuminspecif
ige
imatinibtr
vehicl
treat
ovalbuminsensit
mice
indic
treatment
prevent
sensit
mice
serum
level
sacrif
lower
imatinibtr
mice
vehicl
treat
group
ngml
respect
imatinib
decreas
number
cae
cell
cellsmm
p
g
cell
cellsmm
respect
combin
tunel
stain
indic
duoden
mast
cell
go
apoptosi
treatment
conclus
imatinib
treatment
indic
import
role
intestin
mast
cell
popul
cae
cell
cell
seem
repres
major
intestin
mast
cell
mous
food
allergi
model
identif
immunochem
character
common
allergen
pollen
cyca
circinali
kashinath
bhattacharya
visva
bharati
univers
santiniketan
botani
santiniketan
india
object
cyca
circinali
common
garden
plant
pollen
grain
cyca
circinali
airborn
remain
suspend
air
may
june
peak
concentr
end
june
allergen
pollen
grain
common
among
local
inhabit
report
far
materi
method
pollen
extract
show
high
skin
reaction
respiratori
allerg
patient
sera
subject
test
directli
elisa
estim
allergen
specif
ige
result
express
p
n
valu
ratio
patient
sera
respect
normal
one
allerg
fraction
separ
sdspage
result
result
show
presenc
compon
rang
kda
sera
eight
patient
show
p
n
valu
greater
use
immunoblot
identifi
specif
ige
bind
protein
protein
gel
transfer
pvdf
membran
immunoblot
perform
use
eight
patient
sera
anti
human
igeap
conjug
use
second
antibodi
nbt
bcip
substrat
result
show
two
compon
kda
thu
cyca
circinali
pollen
grain
import
aeroallergen
india
kda
compon
major
allergen
present
pollen
extract
correl
snp
chines
allerg
rhiniti
xiangdong
wang
luo
zhang
demin
han
head
neck
surgeri
beij
tongren
hospit
affili
capit
medic
univers
beij
institut
otorhinolaryngolog
departm
beij
china
object
discuss
correl
snp
chines
allerg
rhiniti
method
patient
normal
control
peopl
enrol
studi
detect
snp
two
site
rflp
result
detect
snp
two
site
genotyp
gg
ga
aa
genotyp
cc
c
tt
distribut
gg
patient
significantli
higher
control
group
haplotyp
frequenc
gc
patient
group
significantli
higher
control
group
haplotyp
frequenc
ac
patient
group
significantli
lower
control
group
conclus
first
studi
evalu
associ
snp
allerg
rhiniti
found
snp
significantli
differ
chines
allerg
rhiniti
normal
control
peopl
snp
may
influenc
phenotyp
allerg
rhiniti
chines
novel
approach
ige
epitop
map
virtual
epitop
map
fabio
dallantonia
walter
keller
univers
graz
inst
chemistri
graz
austria
background
determin
crossreact
ige
epitop
allergen
major
challeng
map
discontinu
structur
ige
epitop
experiment
method
extrem
time
consum
possibl
allergen
epitop
structur
method
epitop
determin
eg
cocrystal
allergenfab
complex
nmrbase
hydrogen
exchang
msbase
method
work
monoclon
antibodi
therefor
epitop
determin
one
time
never
repres
polyclon
situat
found
realiti
map
allergen
specif
sequenc
motiv
onto
surfac
use
predict
put
epitop
howev
sequenc
homolog
alon
may
weak
predictor
crossreact
structur
conserv
bound
major
determin
crossreact
order
improv
accuraci
predict
structur
epitop
develop
new
approach
combin
inform
surfac
topolog
inform
sequenc
conserv
method
result
comput
method
structur
base
epitop
map
integr
suit
program
combin
public
domain
program
sequenc
structur
align
topolog
comparison
algorithm
evalu
chemic
properti
solvent
expos
surfac
program
suit
consist
sever
perl
script
embed
graphic
user
interfac
written
tcl
tk
provid
autom
surfac
comparison
follow
step
execut
program
superposit
two
user
select
atom
model
calcul
solventaccess
surfac
align
structur
surfac
comparison
calcul
differ
assign
similar
score
surfac
element
includ
topolog
chemic
similar
hbond
capac
etc
averag
similar
score
amino
acid
residu
graphic
display
result
program
test
two
famili
crossreact
allergen
structur
three
member
determin
conclus
develop
novel
method
ige
epitop
map
base
structur
inform
two
ore
crossreact
allergen
method
use
sequenc
conserv
well
topolog
similar
delin
put
ige
epitop
graphic
user
interfac
allow
interact
visual
epitop
exosom
human
blood
plasma
contain
rna
genet
signal
cell
distanc
v
sey
alikhani
h
valadi
k
bossio
j
univers
depart
intern
medicin
respiratori
medicin
allergolog
sweden
background
exosom
vesicl
endocyt
origin
produc
mani
cell
type
releas
extracellular
environ
nm
larg
membran
vesicl
exosom
involv
differ
signal
event
includ
antigen
present
tcell
develop
toler
recent
shown
mast
cell
exosom
contain
substanti
amount
function
rna
valdi
et
al
nat
cell
biol
aim
studi
investig
weather
exosom
human
blood
plasma
contain
rna
andor
dna
method
peripher
blood
plasma
deriv
healthi
blood
donor
exosom
isol
seri
ultracentrifug
filtrat
purifi
exosom
attach
antimch
class
ii
coat
dynabead
analys
use
fac
tetraspanin
cd
cd
known
enrich
exosom
use
marker
exosom
detect
also
perform
electron
microscopi
em
detect
exosom
sampl
rna
precipit
use
accord
manufactur
protocol
magnifi
signal
rna
convert
dna
use
random
primer
separ
agaros
gel
also
confirm
presenc
mrna
exosom
use
oligo
primer
convers
mrna
cdna
result
isol
vesicl
plasma
identifi
exosom
em
flow
cytometr
analysi
fac
result
em
show
exosom
structur
size
nm
diamet
fac
analysi
show
presenc
mhc
ii
marker
exosom
exosom
also
prove
contain
signific
amount
rna
dna
exosom
rna
identifi
mrna
conclus
result
show
presenc
rnacontain
exosom
human
plasma
sinc
exosom
abil
fuse
cell
deliv
rna
cell
possibl
rna
plasma
exosom
constitut
genet
signal
cell
distanc
background
allerg
airway
diseas
character
inflamm
hyperrespons
evid
upper
airway
hyperrespons
attribut
increas
neural
activ
nerv
growth
factor
ngf
neurotrophin
shown
import
mediat
neural
respons
airway
bronchial
asthma
patient
recent
studi
suggest
ngf
may
also
import
inflammatori
mediat
therefor
ngf
could
link
allerg
inflamm
neural
respons
howev
express
ngf
report
nasal
mucosa
allerg
rhiniti
patient
studi
perform
investig
express
nerv
growth
factor
ngf
messeng
rna
protein
local
ngf
protein
nasal
mucosa
patient
perenni
allerg
rhiniti
control
subject
method
inferior
turbin
mucosa
sampl
obtain
patient
perenni
allerg
rhiniti
match
nonallerg
patient
ngf
messeng
rna
extract
inferior
turbin
mucosa
revers
transcriptionpolymeras
chain
reaction
perform
western
blot
use
analyz
differ
express
level
ngf
protein
patient
perenni
allerg
rhiniti
normal
control
ngf
protein
local
immunohistochem
result
express
level
ngf
messeng
rna
protein
nasal
mucosa
significantli
increas
patient
perenni
allerg
rhiniti
compar
control
ngf
protein
express
epithelium
infiltr
inflammatori
cell
submucos
gland
conclus
studi
provid
evid
ngf
express
human
nasal
mucosa
increas
express
perenni
allerg
rhiniti
result
suggest
ngf
may
contribut
pathogenesi
perenni
allerg
rhiniti
heungman
lee
hee
joon
kang
hyohyun
park
yongda
kim
background
exact
etiolog
mechan
lead
format
nasal
polyp
remain
larg
obscur
howev
format
new
blood
vessel
angiogenesi
may
play
import
role
develop
nasal
polyp
angiogenin
heparinbind
kda
plasma
protein
angiogen
activ
play
import
role
induc
angiogenesi
aim
present
studi
investig
express
distribut
angiogenin
normal
nasal
mucosa
nasal
polyp
evalu
implic
express
regard
develop
nasal
polyp
method
normal
inferior
turbin
mucosa
obtain
patient
undergo
surgeri
augment
rhinoplasti
nasal
polyp
obtain
patient
undergo
endoscop
sinu
surgeri
chronic
polypoid
sinus
semiquantit
revers
transcriptasepolymeras
chain
reaction
perform
angiogenin
mrna
section
immunostain
use
specif
antibodi
local
angiogenin
quantit
analyz
use
computerbas
imag
analysi
western
blot
analysi
done
result
use
immunohistochemistri
moder
high
level
angiogenin
mainli
local
infiltr
inflammatori
cell
nasal
polyp
faint
stain
found
normal
turbin
mucosa
semiquantit
reversetranscriptas
polymeras
chain
reaction
western
blot
analysi
show
angiogenin
express
increas
nasal
polyp
compar
normal
turbin
mucosa
conclus
markedli
increas
express
angiogenin
nasal
polyp
compar
normal
nasal
mucosa
suggest
angiogenin
may
play
signific
role
format
nasal
polyp
proteom
identif
known
novel
allergen
hous
dust
mite
dermatophagoid
pteronyssinu
pattama
ekpo
sirichit
wongkamchai
sunthorn
puangyoy
nhujohn
jansong
supachok
sinchaikul
shuitein
chen
chaweewan
bunnag
visith
thongboonkerd
faculti
medicin
siriraj
hospit
mahidol
univers
immunolog
bangkok
thailand
faculti
medicin
siriraj
hospit
mahidol
univers
parasitolog
bangkok
thailand
institut
biolog
chemistri
genom
research
center
academia
sinica
taipei
taiwan
faculti
medicin
siriraj
hospit
mahidol
univers
otorhinolaryngolog
bangkok
thailand
faculti
medicin
siriraj
hospit
mahidol
univers
offic
research
develop
bangkok
thailand
background
dermatophagoid
pteronyssinu
predomin
hous
dust
mite
hdm
speci
import
sourc
indoor
allergen
thailand
current
subunit
vaccin
avail
success
prevent
allergi
hdm
character
potenti
hdm
allergen
caus
ige
product
allerg
patient
need
develop
proper
vaccin
present
studi
therefor
conduct
global
identifi
potenti
allergen
pteronyssinu
use
proteom
approach
method
protein
deriv
pteronyssinu
cell
resolv
twodimension
gel
electrophoresi
transfer
onto
nitrocellulos
membran
subject
immunoblot
analysi
use
pool
hdmsensit
patient
sera
n
pool
normal
control
sera
n
sourc
primari
antibodi
membran
probe
mous
antihuman
ige
chain
specif
conjug
horseradish
peroxidas
immunoreact
protein
visual
use
chemiluminesc
substrat
correspond
spot
anoth
parallel
gel
stain
coomassi
brilliant
blue
match
immunoreact
spot
excis
identifi
quadrupol
timeofflight
qtof
mass
spectrometri
ms
andor
tandem
ms
msm
result
total
immunoreact
spot
observ
use
pool
patientssera
wherea
none
detect
pool
control
sera
among
success
identifi
qtof
ms
andor
msm
analys
includ
der
p
der
p
der
p
der
p
protein
previous
recogn
hdm
allergen
quantif
fc
ribind
human
ige
use
chimer
egf
receptor
ryosuk
nakamura
reiko
teshima
junichi
sawada
natl
inst
health
sci
div
biochem
immunochem
tokyo
japan
background
quantif
human
ige
hige
patient
sera
import
diagnosi
allergi
convent
assay
method
hige
depend
bind
antihig
antibodi
hige
sera
howev
hige
concentr
sera
quantifi
method
necessarili
correl
activ
mast
cell
one
possibl
reason
antihig
autoantibodi
sera
may
interfer
bind
hige
highaffin
ige
receptor
fc
ri
therefor
import
develop
new
method
detect
hige
actual
contribut
sensit
mast
cell
studi
tri
establish
new
quantif
method
surfacebound
hige
use
chimer
receptor
bear
extracellular
region
fc
ri
subunit
intracellular
region
egf
receptor
egfr
method
cdna
encod
chimer
receptor
without
intracellular
egfr
region
made
fuse
cdna
fc
ri
egfr
base
pcr
transmembran
domain
chimer
receptor
receptor
cdna
insert
mammalian
express
vector
plasmid
transfect
cell
hela
cellderiv
cell
line
contain
luciferas
gene
express
chimer
receptor
determin
confoc
microscopi
western
blot
phosphoryl
intracellular
signal
molecul
induc
hige
sensit
crosslink
antihig
investig
western
blot
crosslink
chimer
receptor
measur
luciferas
activ
result
confoc
microscop
analysi
reveal
chimer
receptor
transmenbran
domain
egfr
effici
express
plasma
membran
cell
howev
fc
ri
less
express
cell
addit
hige
chimer
receptorexpress
cell
caus
signific
phosphoryl
chimer
receptor
mapk
phosphoryl
increas
antihig
appli
howev
crosslink
hige
antihig
augment
luciferas
express
induc
hige
addit
conclus
cell
express
fc
riegfr
chimer
receptor
could
use
diagnost
tool
detect
bind
hige
cell
surfac
fc
ri
howev
new
method
detect
crosslink
fc
ri
develop
allfam
databas
protein
famili
allergen
christian
radauer
merima
bublin
stefan
wagner
adriano
mari
heimo
breitened
medic
univers
vienna
depart
pathophysiolog
vienna
austria
allergi
data
laboratori
instituto
dermopatico
latina
itali
background
along
identif
larg
number
allergen
protein
divers
sourc
becom
clear
allergen
belong
limit
set
protein
famili
current
avail
allergen
databas
offici
list
allergen
wwwallergenorg
group
allergen
mainli
sourc
organ
take
account
evolutionari
relationship
among
allergen
henc
establish
allfam
databas
protein
famili
allergen
method
allergen
data
download
allergom
wwwallergom
org
databas
protein
sequenc
uniprot
wwwexpasyuniprotorg
databas
compar
protein
famili
definit
pfam
wwwsangeracuksoftwarepfam
allfam
databas
combin
protein
famili
data
exposur
sourc
data
allergom
allfam
contain
fact
sheet
allergen
famili
inform
biochem
properti
allergolog
signific
result
allergom
databas
contain
allergen
sequenc
includ
isoallergen
sequenc
classifi
protein
famili
howev
famili
contain
one
allergen
abund
allergen
famili
prolamin
superfamili
compris
sever
subfamili
profilin
ubiquit
group
crossreact
plant
allergen
famili
ef
hand
contain
calciumbind
protein
includ
polcalcin
pollen
parvalbumin
fish
amphibian
allergen
tropomyosin
found
food
allergen
crustacean
mollusc
inhal
allergen
mite
cockroach
classif
allergen
sourc
reveal
similar
number
protein
famili
among
plant
anim
allergen
famili
consider
lower
number
fungal
allergen
famili
group
allergen
rout
exposur
show
distribut
food
allergen
bias
toward
abund
protein
famili
databas
contain
famili
food
allergen
seven
abund
famili
account
allergen
contrast
famili
inhal
allergen
first
seven
famili
make
allergen
background
aspergillu
speci
ubiquit
saprophyt
fungi
caus
varieti
diseas
rang
hypersensit
reaction
flulik
pneumonia
lifethreaten
invas
aspergillosi
lung
primari
site
initi
infect
airborn
conidia
investig
innat
immun
respons
bronchial
epitheli
cell
differ
form
aspergillu
method
human
bronchial
epitheli
cell
treat
equal
number
kill
spore
germ
tube
either
aspergillu
fumigatu
aspergillu
flavu
transcript
activ
cytokin
gene
presenc
germ
tube
spore
determin
use
realtim
pcr
analysi
secret
cytokin
follow
treatment
mention
fungi
also
measur
enzym
link
immunosorb
assay
result
analysi
realtim
pcr
show
inflammatori
cytokin
well
proinflammatori
proteas
strongli
upregul
treatment
dosedepend
manner
consist
germ
tube
induc
stronger
respons
spore
tnf
induc
high
concentr
germ
tube
spore
furthermor
pretreat
highli
induc
express
conclus
taken
togeth
result
show
germ
tube
aspergillu
fumigatu
flavu
potent
induc
innat
immun
respons
human
airway
cell
consid
presenc
aspergillu
spore
air
differenti
transient
spore
contact
invas
repres
germ
tube
format
import
order
determin
proper
immunolog
respons
moreov
result
also
provid
addit
data
understand
pathophysiolog
hypersensit
reaction
due
aspergilli
background
import
indoor
bioaerosol
emphas
last
decad
fact
hospit
environ
often
contamin
fungal
spore
control
air
qualiti
hospit
ward
assum
great
import
exposur
spore
float
air
hospit
ward
lead
appear
sever
diseas
rang
allergi
sever
fungal
infect
hospit
patient
aim
studi
identifi
evalu
fungal
air
contamin
rate
high
risk
ward
teach
hospit
shiraz
southern
iran
materi
method
settl
plate
assay
use
air
sampl
petri
dish
contain
sabouraud
malt
extract
agar
open
expos
high
risk
ward
teach
hospit
incub
five
ten
day
coloni
identifi
enumer
report
number
deposit
one
squar
meter
surfac
room
result
total
microbi
coloni
detect
coloni
yield
fungi
fungal
isol
belong
genera
follow
cladosporium
aspergillu
penicillium
alternaria
trichosporon
aureobasidium
mucor
rhizopu
chrysosporium
curvularia
trichothecium
stachybotri
stemphylium
acremonium
bipolari
yeast
percent
room
clean
room
cladosporium
predomin
fungal
isol
highest
lowest
fungal
spore
concentr
zero
coloni
form
unit
emerg
transplant
room
respect
conclus
cladosporium
aspergillu
mani
fungi
major
aeroallergen
caus
agent
nosocomi
infect
detect
fungi
hospit
area
potenti
risk
infect
diseas
treg
immunoregul
lactobacillu
plantarum
probiot
reduc
allerg
reaction
experiment
studi
mice
subject
anang
endaryanto
subijanto
marto
sudarmo
suhartono
taat
putra
ingrid
surono
suwarno
k
kusnoto
school
medicin
univers
airlangga
child
health
depart
surabaya
indonesia
school
medicin
univers
airlangga
pathobiolog
depart
surabaya
indonesia
univers
indonesia
seameotropm
rccn
jakarta
indonesia
school
veterinari
medicin
univers
airlangga
veterinari
microbiolog
depart
surabaya
indonesia
school
veterinari
medicin
univers
airlangga
veterinari
parasitolog
depart
surabaya
indonesia
purpos
studi
clarifi
mechan
involv
tolllik
receptor
tlr
reduc
allerg
reaction
lactobacillu
plantarum
li
probiot
factori
design
studi
balbc
mice
subject
random
experiment
group
sensit
ova
probiot
li
placebo
tlr
inhibitor
placebo
independ
variabl
express
innat
immun
respons
activ
adapt
immun
respons
ifn
tgf
sera
ovaspecif
iga
ige
ileum
ovaspecif
iga
total
ige
allerg
reaction
histamin
symptom
score
depend
variabl
ifn
tgf
cell
measur
histolog
slice
small
intestin
mice
group
level
sera
ovaspecif
iga
ige
ileum
ovaspecif
iga
determin
indirect
elisa
measur
total
ige
antibodi
sera
done
sandwich
elisa
histamin
level
determin
competit
elisa
final
ova
sensit
li
group
experi
sever
fatal
allerg
reaction
howev
mice
control
group
experi
signific
modul
innat
adapt
immun
respons
li
group
compar
control
group
except
total
ige
control
group
low
level
innat
immun
respons
conform
g
treg
g
igemedi
mast
cell
degranul
produc
histamin
clinic
symptom
li
probiot
enhanc
innat
immun
respons
form
treg
reduc
mast
cell
degranul
decreas
level
histamin
symptom
score
involv
effect
li
probiot
decreas
allerg
reaction
prove
interact
effect
probiot
inhibitor
tlr
reduc
allerg
reaction
conclus
li
probiot
involv
reduc
allerg
reaction
enhanc
treg
immun
respons
form
new
equilibrium
without
reduc
level
identif
interferoninduc
gene
express
fibroblast
deriv
allerg
nonallerg
patient
yoshikawa
k
wada
yoshimura
n
okada
h
saito
h
moriyama
jikei
univers
school
medicin
depart
otorhinolaryngolog
tokyo
japan
nation
research
institut
child
health
develop
depart
allergi
immunolog
tokyo
japan
rational
recent
asthmat
tissuederiv
cell
report
retain
characterist
featur
steroid
insensit
even
cultur
long
time
previou
studi
identifi
mani
differ
gene
express
pattern
contain
interferoninduc
cxc
chemokin
gene
fibroblast
deriv
allerg
af
nonallerg
nf
patient
although
fibroblast
cultur
stimul
condit
therefor
determin
differ
gene
express
af
nf
method
nasal
fibroblast
isol
inferior
turbin
mucosa
allerg
af
nonallerg
nf
patient
cell
stimul
tnf
ifn
ifn
poli
c
combin
mrna
extract
express
examin
use
realtim
pcr
result
downregul
stimul
tnf
af
compar
nf
wherea
express
level
increas
treat
tnf
alon
af
addit
found
mrna
express
gene
significantli
strongli
upregul
tnf
af
nf
conclus
identifi
specif
gene
express
profil
contain
interferoninduc
cxc
chemokin
gene
af
nf
express
upregul
af
compar
nf
even
cultur
sever
week
cultur
condit
suggest
genet
epigenet
modif
may
involv
mechan
addit
studi
need
clarifi
exact
mechan
underli
find
novel
two
seri
benzo
b
furan
deriv
potent
select
antagonist
yoshitaka
ohishi
mukogawa
women
univers
faculti
pharmaceut
scienc
hyogo
japan
leukotrien
dihydroxi
fatti
acid
produc
mainli
macrophag
neutrophil
play
import
physiolog
role
leukocyt
traffick
site
infect
clearanc
invad
microorgan
howev
overproduct
report
caus
inflammatori
diseas
includ
bronchial
asthma
inflammatori
bowel
diseas
thu
much
work
done
prepar
antagonist
clinic
use
antiinflammatori
drug
unfortun
antagonist
yet
develop
clinic
medicin
applic
recent
novel
cell
surfac
receptor
isol
molecular
clone
also
establish
current
studi
antagonist
receptor
suggest
possibl
develop
new
clinic
drug
treat
arteriosclerosi
immunosuppress
allograft
reject
organ
transplant
psoriasi
cancer
rheumatoid
arthriti
stabl
compound
definit
conform
favor
antagonist
thu
prepar
two
seri
benzo
b
furan
deriv
b
furan
b
furan
evalu
inhibitori
activ
show
potent
select
inhibitori
activ
posit
standard
compound
especi
benzo
b
furan
e
dimethylamino
methyleneamino
benzo
b
furan
show
potent
select
inhibitori
activ
compound
assay
treatment
abil
concern
immflamatori
asthma
vivo
screen
relat
ige
antibodi
antigen
echinococcu
granulosu
farideh
bagheri
mohammad
reza
siavashi
alireza
khabiri
pasteur
institut
iran
parasitolog
tehran
islam
republ
iran
anaphylact
reaction
urticaria
edema
respiratori
symptom
anaphylact
shock
often
complic
cours
cystic
echinococcosi
ce
investig
role
ige
immunoreact
antigen
ag
seroposit
patient
ce
determin
ntermin
kda
subunit
respons
ige
ctermin
activ
antigen
relat
induct
igg
specif
immunoblot
analysi
show
specif
ige
subunit
relat
interchain
disulphid
band
two
kda
compon
conform
epitop
subunit
addit
ige
specif
recogn
ntermin
kda
subunit
remain
bound
compon
wherea
igg
react
ctermin
kda
compon
recogn
specif
bind
site
kda
subunit
could
lead
understand
mechan
regul
igeigg
product
immun
circumst
ige
tend
domin
wherea
igg
predomin
effect
complex
betaglucan
zataria
multiflora
oxid
burst
neutrophil
balbc
mice
hojjatollah
shokri
univers
tehran
microbiolog
immunolog
tehran
islam
republ
iran
background
natur
product
betaglucan
herbal
essenc
found
enhanc
immun
function
aim
studi
purifi
betaglucan
cell
wall
saccharomyc
cerevisia
investig
conjug
effect
zataria
multiflora
essenc
oxid
burst
balbc
mice
method
prepar
cell
wall
yeast
betaglucan
extract
wall
alkalineacid
treatment
prepar
contain
protein
mannan
remov
deae
sephacel
chromatographi
cona
sepharos
chromatographi
respect
zataria
multiflora
essenc
conjug
inject
balbc
mice
intraperiton
blood
collect
day
inject
oxid
burst
assay
chemiluminesc
method
result
find
show
intraperiton
administr
zataria
multiflora
essenc
conjug
significantli
increas
oxid
burst
neutrophil
day
compar
control
group
conclus
result
suggest
complex
zataria
multiflora
essenc
use
adjuv
agent
stimul
immun
function
immunocompromis
subject
effect
staphylococc
enterotoxin
induc
nitric
oxid
synthas
mice
allerg
rhiniti
si
whan
kim
taebin
dae
woo
kim
dongyoung
kim
chaeseo
rhee
sangwook
kim
yanggi
min
seoul
nation
univers
colleg
medicin
depart
otorhinolaryngolog
seoul
republ
korea
background
accord
recent
report
induc
form
type
ii
nitric
oxid
synthas
express
higher
level
nasal
mucosa
allerg
rhiniti
patient
patient
show
higher
carriag
rate
staphylococcu
aureu
normal
adult
aim
investig
role
staphylococc
enterotoxin
b
develop
allerg
rhiniti
determin
relev
induc
nitric
oxid
synthas
overexpress
method
nasal
mucosa
serum
obtain
sensit
neg
control
group
frequenc
allerg
symptom
sneez
compar
eosinophil
count
induc
nitric
oxid
synthas
express
nasal
mucosa
examin
serum
level
ovalbuminspecif
ige
measur
elisa
differ
sensit
control
group
statist
analyz
use
kruskalw
test
mannwhitney
u
test
result
frequenc
sneez
serum
level
ovalbuminspecif
ige
degre
induc
nitric
oxid
synthas
express
significantli
higher
group
local
sensit
mixtur
ovalbumin
staphylococc
enterotoxin
b
ovalbumin
alon
neg
control
group
group
local
sensit
staphylococc
enterotoxin
b
alon
conclus
induc
nitric
oxid
synthas
may
play
crucial
role
develop
allerg
rhiniti
wherea
staphylococc
enterotoxin
b
may
particip
process
antiallerg
effect
lactobacillu
probiot
miteallergen
sensit
murin
model
kungchih
yeh
renlong
jan
shinhong
chen
jiuyao
wang
colleg
medicin
nation
cheng
kung
univers
depart
microbiolog
immunolog
tainan
taiwan
chimei
medic
center
liouyin
campu
pediatr
tainan
taiwan
madou
shinlau
hospit
pediatr
tainan
taiwan
colleg
medicin
nation
cheng
kung
univers
pediatr
tainan
taiwan
background
clinic
trail
demonstr
probiot
improv
allerg
symptom
mechan
respons
benefit
still
unclear
sought
investig
effect
probiot
organ
mous
model
allerg
airway
inflamm
method
first
balbc
mice
treat
two
probiot
organ
lactobacillu
rhamnosu
lactobacillu
paracasei
via
gavag
needl
two
week
daili
dermatophoid
pteronyssinu
der
p
allergen
sensit
anoth
two
week
sensit
allergen
challeng
second
know
dose
effect
lactobacillu
paracasei
investig
abil
three
dose
lactobacillu
paracasei
prevent
allerg
airway
inflamm
result
first
found
treatment
lactobacillu
paracasei
significantli
elev
cytokin
bronchoaveolar
lavag
fluid
bal
decreas
der
pspecif
serum
chang
airway
hypersensit
influx
inflammatori
cell
lung
serum
ige
level
treatment
lactobacillu
rhamnosu
signific
effect
second
part
treatment
medium
dose
lactobacillu
paracasei
significantli
attenu
influx
total
leukocyt
monocyt
lymphocyt
airway
elev
bal
der
pspecif
serum
medium
dose
lactobacillu
paracasei
also
decreas
airway
hyperrespons
increas
ifn
product
der
p
stimul
splenocyt
high
dose
lactobacillu
paracasei
reduc
influx
total
leukocyt
monocyt
bal
product
der
p
stimul
splenocyt
increas
der
pspecif
serum
ifn
product
der
p
stimul
splenocyt
low
dose
lactobacillu
paracasei
elev
der
pspecif
serum
ifn
product
der
p
stimul
splenocyt
reduc
splenocyt
prolifer
activ
conclus
result
show
oral
treatment
probiot
attenu
allerg
airway
inflamm
increas
immun
respons
effect
strain
specif
dose
depend
aerobiolog
immunochem
studi
domjur
howrah
district
west
bengal
india
indrani
choudhuri
bose
institut
kolkata
botani
kolkata
india
allerg
diseas
like
bronchial
asthma
allerg
rhiniti
conjunct
due
exposur
variou
airborn
biolog
particl
common
pollen
grain
among
known
caus
agent
caus
respiratori
allergi
suscept
individu
program
rural
area
howrah
district
domjur
block
near
kolkata
select
aerobiolog
clinicoimmunolog
studi
area
select
rich
veget
high
densiti
popul
suffer
respiratori
allergi
aerobiolog
studi
done
use
burkard
sampler
prepar
allergen
extract
done
use
pure
bulk
pollen
grain
use
phosphat
buffer
salin
pb
skin
test
spt
differ
pollen
extract
perform
follow
method
styti
sensit
sera
collect
patient
visit
outpati
depart
allergi
clinic
institut
child
health
calcutta
normal
sera
obtain
healthi
donor
histori
symptom
atopi
electrophoresi
western
blot
analyz
sdspage
accord
method
laemmli
order
prepar
pollen
calendar
domjur
rich
veget
wide
agricultur
farm
aerobiolog
survey
done
air
born
pollen
type
record
identifi
air
domjur
domin
type
areca
catechu
coco
nucifera
phoenix
sylvesrti
riccinu
communi
lantana
camara
perthenium
hysterophoru
trema
orientali
moringa
olifera
carica
pa
paya
catharanthu
roseu
casuarina
equisetifolia
albizzia
lebbeck
cyperu
rotundu
etc
among
domin
pollen
type
subject
skin
prick
test
areca
catechu
carica
papaya
catharanthu
roseu
coco
nucifera
amaranthu
spinosu
borassu
flabellif
lantana
camara
found
highli
posit
carica
papaya
pollen
select
biochem
clinic
investig
spt
reaction
studi
relev
pollen
extract
respiratori
allerg
patient
show
posit
respons
nativ
polyacrylamid
gel
electrophoresi
carica
pollen
fruit
show
presenc
number
protein
band
ige
specif
dot
immunoblot
carica
pollen
show
remark
cross
reaction
papain
enzym
present
latex
fruit
plant
part
nasal
mucos
infiltr
eosinophil
nasal
provoc
sungwan
kim
joong
saeng
cho
kun
hee
lee
seung
yeop
shin
kyunghe
univers
hospit
dept
orlhn
seoul
republ
korea
background
studi
eosinophil
found
nasal
lavag
fluid
nasal
biopsi
patient
allerg
rhiniti
nasal
antigen
challeng
numer
studi
carri
clarifi
paticip
eosinophil
latephas
allerg
reaction
airway
hyperrespons
howev
report
describ
detail
role
eosnophil
earlyphas
allerg
reaction
aim
studi
investig
degre
nasal
eosinophil
infiltr
nasal
provoc
test
evalu
chang
degre
nasal
eosinophil
infiltr
accord
durat
allerg
rhiniti
method
one
hundr
fortyf
allerg
rhiniti
patient
diagnos
allerg
workup
includ
patient
divid
three
group
durat
symptom
group
patient
whose
durat
symptom
less
year
n
group
year
n
group
year
n
symptom
score
patient
check
nasal
obstruct
wateri
rhinorrhea
sneez
itch
visual
analogu
scale
nasal
mucos
scrape
smear
perform
curett
min
nasal
allergen
provoc
degre
eosinophil
infiltr
evalu
slide
scale
degre
eosinophil
infiltr
compar
provoc
degre
eosinophil
infiltr
evalu
compar
accord
durat
symptom
result
promin
nasal
symptom
group
nasal
obstruct
increas
durat
symptom
symptom
sever
group
group
group
show
higher
degre
eosinophil
infiltr
compar
group
degre
eosinophil
infiltr
increas
provoc
group
conclus
eosinophil
infiltr
increas
even
earli
stage
allergen
provoc
increas
eosinphil
infiltr
nasal
mucosa
provoc
significantli
chronic
state
eosinophil
may
involv
earli
reaction
allergi
especi
chronic
state
associ
cytochrom
gene
polymorph
suscept
ankylos
spondyl
popul
group
algeria
sofian
samir
salah
habiba
amroun
rachida
allat
marc
busson
antoin
toubert
rajagop
krishnamoorthi
dominiqu
charron
moham
cherif
abbadi
hachemi
djoudi
ryad
tamouza
institut
pasteur
algeria
immunolog
algier
algeria
douera
hospit
rhumatlog
algier
algeria
saint
loui
hospit
immunolog
histocompat
pari
franc
robert
hospit
immunolog
pari
franc
pasteur
institut
algeria
immunolog
algier
algeria
background
cytochrom
cyp
superfamili
member
polymorph
express
enzym
involv
metabol
inactiv
sever
drug
includ
antiepilept
nsaid
oral
hypoglycem
anticoagul
mani
drug
narrow
therapeut
index
sever
studi
indic
promin
role
enzym
polymorph
therapeut
efficaci
develop
advers
effect
among
patient
treat
drug
substrat
previou
linkag
associ
studi
suggest
presenc
suscept
gene
ankylos
spondyl
close
within
cytochrom
gene
could
play
key
role
pathophysiolog
studi
examin
whether
common
mutat
cytochrom
cyp
involv
outcom
algerian
patient
find
determin
genotyp
frequenc
algerian
popul
method
cyp
genotyp
determin
patient
fulfil
modifi
naw
york
criteria
healthi
nonrel
subject
dna
isol
blood
sampl
use
analysi
allel
variant
allelespecif
realtim
pcr
thu
respect
allel
variant
frequenc
genotyp
distribut
predict
phenotyp
deduc
genotyp
combin
result
signific
differ
found
allel
variant
patient
control
subject
ii
allel
variant
frequent
patient
healthi
subject
iii
allel
variant
frequent
patient
healthi
subject
iiii
frequenc
bintermedi
metabolizersgenotyp
andor
phenotyp
substrat
import
patient
control
conclus
would
exist
possibl
role
polymorph
risk
develop
probabl
metabol
drug
use
treat
patient
exosom
bronchoalveolar
fluid
toler
mice
prevent
allergenspecif
allerg
reaction
noela
prado
eva
g
marazuela
elodi
segura
mayt
villalba
clotild
eva
batanero
universidad
complutens
molecular
madrid
spain
institut
curi
pavillon
pasteur
pari
franc
universidad
rey
juan
carlo
de
madrid
spain
background
exosom
nanovesicl
origin
multivesicular
bodi
secret
varieti
cell
type
dual
capabl
exosom
promot
immun
induc
toler
prompt
clinic
use
vehicl
vaccin
differ
human
diseas
present
studi
effect
allergenspecif
exosom
toler
mice
develop
allergeninduc
allerg
respons
determin
use
mous
model
method
mice
toler
respiratori
exposur
oliv
pollen
allergen
ole
e
exosomelik
vesicl
isol
bronchoalveolar
lavag
fluid
anim
wellestablish
filtrat
ultracentrifug
procedur
character
electron
microscopi
western
blot
fac
analys
assess
prophylact
protocol
end
balbc
mice
intranas
treat
tolerogen
exosom
nabv
exosom
control
one
week
prior
sensitizationchalleng
ole
e
blood
lung
spleen
collect
analyz
immun
respons
result
intranas
pretreat
tolerogen
exosom
inhibit
ige
respons
along
mark
reduct
lymphoprolif
respons
cytokin
product
moreov
patholog
alter
lung
associ
airway
inflamm
eosinofilia
significantli
suppress
conclus
result
demonstr
exosom
induc
toler
protect
allerg
sensit
mice
thu
exosomebas
vaccin
could
repres
altern
convent
therapi
allerg
diseas
human
primari
secondari
infect
respiratori
syncyti
viru
rsv
allergen
challeng
enhanc
airway
hyperrespons
murin
model
object
determin
whether
neonat
infect
rsv
play
critic
role
develop
ahr
pathophysiolog
respons
subsequ
allergen
sensit
adult
mice
method
mice
infect
initi
day
age
rsv
reinfect
week
later
rsvinfect
mice
expos
ovalbumin
ova
week
infect
via
airway
follow
assess
airway
function
invas
method
chang
lung
resist
inhal
methacholin
mch
cytokin
level
bronchoalveolar
lavag
fluid
balf
lung
histopatholog
result
rsv
infect
subsequ
allergen
sensit
result
develop
ahr
inflamm
associ
increas
eosinophil
influx
lung
increas
mucu
product
although
enhanc
ahr
mch
inflamm
observ
rsvinfect
mice
neonat
subsequ
reinfect
rsv
weanl
respons
exagger
mice
earli
expos
ova
later
rsv
infect
conclus
neonat
rsv
infect
predispos
adult
develop
enhanc
airway
respons
inflamm
upon
allergen
exposur
background
food
allergi
earli
potenti
lifethreaten
manifest
fatopi
march
limit
publish
epidemiolog
data
food
allergi
chines
children
plan
possibl
intervent
prevent
develop
food
allergi
import
identifi
diseas
spectrum
risk
factor
popul
studi
aim
determin
preval
clinic
featur
selfreport
food
allergi
hong
kong
preschool
children
method
children
age
year
live
hong
kong
recruit
randomli
select
nurseri
kindergarten
studi
ascertain
presenc
selfreport
symptom
food
allergi
atop
disord
parent
questionnair
develop
chines
version
intern
studi
asthma
allergi
childhood
questionnair
addit
valid
item
detail
food
allergi
result
children
local
nurseri
kindergarten
return
studi
questionnair
children
evalu
food
allergi
two
hundr
fiftythre
children
born
mainland
china
subsequ
migrat
hong
kong
four
hundr
twentytwo
children
current
avoid
food
preval
rate
selfreport
food
allergi
selfreport
doctordiagnos
food
allergi
respect
figur
ever
wheez
doctordiagnos
asthma
current
flexur
eczema
six
lead
caus
selfreport
food
allergi
chines
children
shellfish
egg
peanut
beef
cow
milk
nut
compar
children
born
rais
hong
kong
children
born
mainland
china
significantli
lower
preval
selfreport
food
allergi
versu
p
doctordiagnos
asthma
versu
p
current
rhinoconjunct
versu
p
g
current
flexur
eczema
p
occurr
food
allergi
strongli
associ
current
wheez
rhinoconjunct
flexur
eczema
p
g
conclus
food
allergi
signific
atop
disord
hong
kong
preschool
children
coexist
airway
skin
allergi
also
commonli
seen
children
studi
identifi
earli
life
feed
environment
factor
food
allergi
need
patient
tracheobronchi
amyloidosi
complet
lung
collaps
howev
taken
long
time
cardiac
side
effect
etoricoxib
less
cardiotox
method
test
drug
patient
previou
advers
reaction
nsaid
salycil
arylpropion
arylacet
acid
oxicam
deriv
pyrazolon
acetaminophen
paracetamolp
report
symptomatolog
urticaria
andor
angioedema
rhiniti
reaction
one
case
anaphylact
shock
peror
challeng
perform
random
control
placebo
start
mg
dosag
total
dosag
mg
third
day
challeng
done
day
hospit
patient
cardiorespiratori
monitor
hour
result
toler
test
fulli
carri
well
toler
patient
two
system
reaction
slight
tired
along
stomachach
report
first
day
conclus
etoricoxib
consid
safe
molecul
patient
previou
advers
reaction
nsaid
background
mashhad
locat
northeast
iran
close
border
afghanistan
turkmenistan
also
consid
migrat
citi
due
religi
reason
inject
drug
user
increas
due
lower
cost
interest
especi
margin
region
share
contamin
syring
inject
tool
import
common
way
hiv
transmiss
countri
citi
peer
educ
plhiv
among
peer
risk
group
idu
strategi
posit
prevent
also
help
psychosoci
support
plhiv
mashhad
posit
club
establish
empow
plhiv
base
nation
aid
program
posit
prevent
unaid
moh
cdc
famili
plan
associ
support
method
prepar
pe
protocol
call
action
train
plha
includ
idu
go
ruin
place
group
inject
blood
share
drop
center
daravey
nodeh
two
margin
region
mashhad
train
peer
idu
posit
face
face
talk
distribut
harm
reduct
packag
includ
syring
condom
safer
sex
came
fgd
process
monitor
done
write
daili
weekli
report
go
anoth
peer
educ
offic
direct
visit
train
program
peer
group
session
includ
movi
display
titl
baid
bornethen
discuss
train
educ
beneficiari
result
conclus
base
one
month
evalu
juli
idu
male
femal
year
old
train
plha
refer
dic
exchang
syring
program
get
condom
start
mmt
increas
percent
indirect
find
health
care
worker
dic
chang
attitud
plha
see
problem
also
key
problem
solv
would
decreas
social
stigma
complic
cold
urticaria
may
potenti
life
threaten
case
profound
impact
patient
qualityoflif
secondgener
antihistamin
recommend
firstlin
treatment
date
scientif
test
condit
assess
safeti
efficaci
ebastin
prevent
acu
symptom
examin
adult
patient
suffer
cold
urticaria
within
scope
doubleblind
crossov
trial
administ
singl
dose
mg
ebastin
placebo
local
cold
challeng
safeti
ebastin
sensit
assess
psychometr
batteri
test
cognit
perform
mood
cold
challeng
wheal
erythema
assess
investig
intens
pruritu
burn
rate
subject
could
show
ebastin
neg
impact
paramet
cognit
perform
mood
importantli
cold
urticaria
symptom
markedli
reduc
challeng
verum
group
indic
ebastin
effect
protect
patient
cold
urticaria
symptom
result
demonstr
safeti
ebastin
reveal
efficaci
treat
patient
cold
urticaria
dermograph
urticaria
symptom
safe
prevent
ebastin
marku
magerl
jan
schmolk
frank
siebenhaar
torsten
zuberbi
martin
metz
marcu
maurer
berlin
dermatolog
berlin
germani
physic
urticaria
includ
heterogen
group
disord
character
develop
urticari
lesion
andor
angioedema
exposur
certain
physic
stimuli
frequent
physic
urticaria
dermograph
urticaria
du
shear
forc
skin
result
wheal
itch
subsequ
scratch
aggrav
symptom
secondgener
antihistamin
recommend
firstlin
treatment
date
one
ever
test
condit
aim
studi
assess
safeti
efficaci
ebastin
prevent
du
symptom
administ
mg
ebastin
seven
adult
du
patient
scope
doubleblind
crossov
trial
safeti
ebastin
sensit
assess
psychometr
batteri
test
cognit
perform
mood
challeng
shear
forc
wheal
erythema
assess
investig
intens
pruritu
burn
rate
subject
could
show
ebastin
neg
impact
paramet
cognit
perform
mood
wheal
pruritu
burn
greatli
reduc
major
subject
result
underlin
safeti
ebastin
reveal
efficaci
cold
urticaria
test
larger
scale
sensit
environment
allergen
among
inhabit
calcutta
citi
suburb
special
emphasi
inhal
fungal
allergi
aerobiolog
allergolog
studi
paediatr
london
unit
kingdom
univers
southampton
school
psycholog
southampton
unit
kingdom
univers
southampton
school
medicin
southampton
unit
kingdom
background
relationship
artifici
food
colour
benzoat
perserv
afcp
intak
behaviour
hitherto
contenti
previous
shown
popul
base
dbpcfc
studi
advers
effect
afcp
parentallyr
behaviour
year
old
confirm
observ
year
old
year
old
use
object
measur
observ
behaviour
school
set
one
potenti
mechan
ige
independ
histamin
releas
circul
basophil
method
second
challeng
studi
genotyp
children
use
buccal
cell
relat
find
magnitud
behaviour
respons
challeng
result
polymorph
catecholamin
gene
comt
previous
associ
adhd
impact
respons
polymorph
histamin
nmethyltransferas
gene
hnmt
significantli
respect
advers
affect
respons
afcp
challeng
conclus
hnmt
polymorph
impair
histamin
clearanc
afcp
caus
histamin
releas
presenc
histamin
receptor
brain
provid
potenti
mechan
therapeut
target
explain
effect
observ
mani
environment
factor
increas
histamin
includ
infect
mani
food
would
explain
frequent
claim
food
intoler
infect
advers
affect
behaviour
children
gene
environ
interact
investig
relat
afcp
induc
urticaria
asthma
atop
condit
serum
specif
ige
result
enough
joana
caiado
susana
lope
da
silva
costa
trindad
hospit
de
santa
maria
de
imunoalergologia
lisboa
portug
hospit
de
santa
maria
unidad
de
imunoalergologia
lisboa
portug
background
vitro
determin
serum
specif
ige
sige
essenti
diagnost
tool
allergi
clinic
analysi
laboratori
offer
differ
method
technolog
determin
sige
case
highli
variabl
poorli
interchang
result
concern
differ
allergen
rotat
differ
method
may
compromis
allerg
patient
followup
name
situat
may
benefit
sequenti
sige
determin
food
allergi
specif
immunotherapi
efficaci
evalu
aim
verifi
avail
written
inform
concern
method
use
sige
determin
lab
result
report
clinic
analysi
laboratori
lisbon
district
method
month
april
may
immunoallergologist
collect
serum
sige
result
report
patient
observ
report
differ
clinic
analysi
laboratori
within
lisbon
district
obtain
analys
lab
mention
method
use
sige
determin
inquir
phone
order
get
inform
result
among
report
analys
specifi
method
use
name
immunoenzimat
ie
method
chemiluminesc
ql
method
among
remain
lab
later
contact
phone
verifi
use
ie
method
ql
use
method
accord
differ
allergen
laboratori
brastwa
use
synonym
sige
conclus
intend
alert
gener
lack
written
inform
concern
method
use
serum
sige
determin
lab
report
lisbon
district
laboratori
lack
written
inform
persist
incorrect
use
term
brastand
simultan
use
mainten
treat
patient
placebo
compar
pearson
test
p
valu
less
consid
statist
signific
result
adult
patient
enrol
complet
studi
dropout
activ
dropout
placebo
group
slit
patient
peak
diamet
llr
reduc
chang
llr
seen
placebo
patient
system
reaction
gener
urticaria
occur
patient
rest
differ
signific
p
group
advers
event
report
discontinu
slit
requir
conclus
hbslit
significantli
reduc
extent
llr
hb
allerg
subject
safeti
profil
satisfactori
pilot
studi
envisag
possibl
use
slit
also
hymenoptera
allergi
trial
patient
system
reaction
next
step
confirm
observ
mometason
furoat
nasal
spray
effect
treat
ocular
symptom
season
allerg
rhiniti
patient
degre
sever
hour
l
bielori
mr
danzig
gate
umdnjnew
jersey
medic
school
asthma
allergi
research
center
newark
new
jersey
unit
state
scheringplough
research
institut
kenilworth
new
jersey
unit
state
background
mometason
furoat
nasal
spray
mfn
shown
effect
control
nasal
symptom
season
allerg
rhiniti
sar
analysi
subjectreport
symptom
data
mfn
trial
perform
determin
impact
mfn
ocular
symptom
analysi
evalu
effect
mfn
sar
patient
vari
degre
symptom
sever
differ
symptom
reduct
morn
even
pm
method
retrospect
analysi
conduct
data
pool
four
random
doubleblind
placebocontrol
clinic
studi
three
one
similar
protocol
compar
effect
mfn
mcg
qd
placebo
control
ocular
symptom
subject
age
year
histori
sar
analysi
review
chang
baselin
period
symptom
score
eye
tear
itch
red
scale
calcul
total
ocular
symptom
score
toss
effect
size
day
averag
subject
mild
moder
sever
symptom
baselin
compar
toss
evalu
approxim
hour
postdos
pm
aris
approxim
hour
postdos
prior
dose
next
day
result
subject
mfn
n
placebo
n
group
similar
baselin
clinic
demograph
characterist
mean
baselin
toss
pm
mfn
group
pm
placebo
group
decreas
toss
mfn
day
interv
vs
placebo
differ
reach
statist
signific
day
time
period
score
tear
decreas
mfn
vs
placebo
eye
itch
mfn
vs
placebo
red
mfn
vs
placebo
mild
moder
sever
symptom
group
improv
toss
mfn
placebo
respect
reduct
individu
symptom
score
significantli
greater
mfn
placebo
pm
importantli
differ
toss
mfn
placebo
pm
similar
conclus
mfn
reduc
ocular
symptom
sar
hour
regardless
subject
baselin
symptom
sever
shrimp
allergi
effect
vinegar
soak
allergen
background
previou
studi
demonstr
muscl
protein
tropomyosin
major
shrimp
allergen
allergen
saii
shown
protein
rich
aspart
glutam
acid
heatstabl
allergen
document
howev
studi
shown
yet
effect
vinegar
allergen
studi
aim
demonstr
vinegar
soak
prior
cook
would
effect
shrimp
allergen
base
skin
test
result
method
eighteen
shrimpallerg
eighteen
nonshrimpallerg
pediatr
patient
subject
skin
prick
test
use
conventionallyprepar
shrimp
extract
mean
wheal
diamet
obtain
compar
mean
wheal
diamet
obtain
use
experiment
shrimp
extract
prepar
preliminari
vinegar
soak
adult
group
twentysix
shrimpallerg
twentysix
nonshrimpallerg
parient
includ
result
mean
wheal
diamet
obtain
use
shrimp
extract
prepar
preliminari
vinegar
soak
significantli
smaller
mean
wheal
diamet
obtain
use
convent
prepar
extract
wheal
diamet
obtain
shrimpallerg
patient
significantli
bigger
wheal
diamet
obtain
fo
nonshrimpallerg
individu
result
similar
pediatr
adult
patient
conclus
result
indic
vinegar
soak
prior
cook
reduc
shrimp
allergen
resourc
valid
result
use
doubleblind
placebocontrol
food
challeng
woul
ideal
mometason
furoat
nasal
spray
improv
symptom
perenni
allerg
rhiniti
children
adult
peru
perci
ruiz
clinica
angloamericana
ent
depart
lima
peru
background
perenni
allerg
rhiniti
par
highli
preval
diseas
global
common
chronic
diseas
children
nasal
obstruct
bothersom
symptom
par
need
treat
year
round
previou
studi
shown
intranas
corticosteroid
mometason
furoat
nasal
spray
mfn
well
toler
clinic
effect
reliev
symptom
par
studi
conduct
assess
effect
mfn
patient
satisfact
treatment
pediatr
adult
subject
method
prospect
openlabel
multicent
studi
peruvian
subject
age
year
clinic
diagnos
par
record
nasal
symptom
data
diari
total
nasal
symptom
score
tnss
evalu
day
subject
also
rate
satisfact
treatment
investig
evalu
advers
event
result
thirtythre
subject
femal
male
receiv
mfn
mcg
qd
pediatr
adult
dose
mean
tnss
reduc
sd
baselin
sd
day
sd
day
reduct
day
subject
subject
respect
rate
satisfi
satisfi
treatment
mild
advers
event
nasal
irrit
sneez
epistaxi
cough
occur
one
subject
stop
treatment
due
nasal
irrit
conclus
mometason
furoat
nasal
spray
mcg
qd
safe
effect
improv
symptom
par
children
adult
effect
postop
mometason
furoat
nasal
spray
wound
heal
follow
endoscop
sinu
surgeri
mark
jorissen
clau
bachert
univers
leuven
ent
depart
hn
leuven
belgium
univers
hospit
ghent
ent
clinic
ghent
belgium
background
chronic
sinus
nasal
polyposi
diseas
nasal
sinu
mucosa
affect
approxim
popul
respect
function
endoscop
sinu
surgeri
fess
standard
surgeri
diseas
failur
medic
treatment
approxim
surgeri
patient
experi
impair
wound
heal
follow
fess
lead
recurr
sinus
complic
requir
surgeri
doubleblind
multicent
studi
found
month
treatment
intranas
corticosteroid
mometason
furoat
nasal
spray
mfn
mcg
qd
surgeri
bilater
nasal
polyp
significantli
prolong
time
recurr
compar
placebo
studi
undertaken
investig
whether
use
mfn
follow
fess
improv
wound
heal
month
method
doubleblind
random
placebocontrol
studi
subject
diagnosi
chronic
sinus
nasal
polyp
random
receiv
month
treatment
mfn
mcg
bid
placebo
begin
approxim
week
fess
endoscop
score
assess
week
month
primari
efficaci
endpoint
investig
assess
treatment
outcom
month
combin
score
deriv
score
inflamm
edema
polyp
postop
symptom
score
record
month
advers
event
ae
record
throughout
studi
result
random
subject
mfn
placebo
includ
intenttotreat
analysi
subject
mfn
group
receiv
oral
steroid
first
day
postsurgeri
subject
mfn
placebo
discontinu
result
last
studi
visit
use
preoper
symptom
score
two
group
similar
month
investig
assess
treatment
outcom
reduct
total
endoscop
score
subject
superior
reach
statist
signific
mfn
versu
placebo
combin
endoscop
score
month
show
significantli
improv
heal
mfn
versu
placebo
subject
median
score
vs
nasal
polyp
median
score
vs
mfn
well
toler
conclus
treatment
mfn
follow
sinu
surgeri
improv
heal
particularli
subject
initi
diagnosi
nasal
polyp
well
toler
mometason
furoat
nasal
spray
reduc
symptom
improv
qualiti
life
chines
children
allerg
rhiniti
yamei
zhang
beij
children
hospit
depart
orlhn
beij
china
background
approxim
children
adolesc
china
suffer
symptom
allerg
rhiniti
ar
effect
treatment
ar
children
import
minim
prevent
behavior
problem
poor
academ
perform
may
help
prevent
develop
comorbid
disord
asthma
adenoid
hypertrophi
otiti
media
effus
studi
undertaken
evalu
effect
mometason
furoat
nasal
spray
mfn
clinic
symptom
qualiti
life
qol
chines
children
ar
method
total
symptomat
children
age
year
year
document
season
perenni
ar
treat
openlabel
studi
mfn
mcg
qd
week
elig
subject
nasal
stuffi
congest
score
scale
symptom
symptom
total
nasal
symptom
score
tnss
total
individu
symptom
score
rhinorrhea
congest
nasal
itch
sneez
start
treatment
primari
efficaci
variabl
chang
tnss
coprimari
variabl
chang
individu
symptom
score
secondari
efficaci
variabl
includ
overal
efficaci
pediatr
rhinoconjunct
qol
questionnair
prqlq
score
assess
nasal
eye
symptom
behavior
daili
life
result
mfn
significantli
reduc
tnss
baselin
mean
week
treatment
mean
score
respect
signific
improv
baselin
observ
week
individu
nasal
symptom
percentag
patient
achiev
improv
indic
least
moder
symptom
reduct
baselin
tnss
week
respect
moderatetocomplet
symptom
relief
report
subject
week
week
signific
reduct
improv
baselin
total
individu
prqlq
score
seen
week
mean
behavior
prqlq
score
decreas
statist
signific
amount
baselin
week
week
mean
prqlr
score
decreas
baselin
week
week
less
subject
report
advers
event
conclus
mfn
effect
reliev
symptom
ar
improv
qol
well
toler
chines
children
ar
mometason
furoat
nasal
spray
improv
qualiti
sleep
reduc
symptom
allerg
rhiniti
chines
patient
demin
han
beij
tongren
hospit
depart
otolaryngolog
head
neck
surgeri
beij
china
background
urbandwel
adolesc
adult
china
report
symptom
allerg
rhiniti
ar
unlik
region
pollen
allergi
common
china
dust
mite
andor
silk
preval
allergen
consequ
mani
chines
peopl
ar
suffer
symptom
throughout
year
one
recent
studi
found
oncedaili
mometason
furoat
nasal
spray
mfn
effect
treatment
ar
chines
peopl
hong
kong
openlabel
studi
undertaken
evalu
effect
mfn
clinic
symptom
qualiti
life
chines
patient
ar
method
total
subject
age
year
year
physician
diagnosi
document
medic
histori
season
perenni
ar
treat
mfn
mcg
qd
day
center
china
screen
visit
elig
subject
total
nasal
symptom
score
tnss
maximum
nasal
stuffinesscongest
score
maximum
primari
efficaci
variabl
chang
baselin
tnss
individu
symptom
sever
score
congest
rhinorrhea
sneez
itch
secondari
efficaci
variabl
chang
baselin
score
interfer
sleep
daytim
activ
nocturn
rhinoconjunct
qol
questionnair
nrqlq
minirhinoconjunct
qol
questionnair
minirqlq
respect
result
mfn
significantli
reduc
tnss
individu
nasal
symptom
score
baselin
evalu
mean
tnss
baselin
week
respect
correspond
mean
score
nasal
congest
similar
improv
seen
nasal
symptom
week
subject
report
moderatetocompet
relief
ar
symptom
total
individu
nrqlq
score
score
sleep
problem
symptom
sleep
awaken
significantli
reduc
week
treatment
signific
reduct
baselin
total
minirqlq
score
score
activ
problem
symptom
activ
week
mfn
well
toler
conclus
mfn
mcg
qd
effect
reduc
symptom
ar
improv
qualiti
sleep
daytim
activ
well
toler
chines
patient
ar
frequenc
dermatophagoid
mite
allergen
home
allerg
patient
mashhad
tabriz
mashhad
hospit
immunolog
mashhad
islam
republ
iran
children
hospit
pediatr
tabriz
islam
republ
iran
introduct
allerg
diseas
common
disord
increas
rate
last
year
almost
peopl
kind
allerg
disord
life
mite
hous
dust
import
allergen
allerg
disord
optim
growth
condit
mite
temperatur
humid
import
site
insid
bed
mattress
carpet
aim
studi
survey
frequenc
dermatophagoid
allergen
home
allerg
patient
method
descript
crosssect
studi
perform
tabriz
mashhad
citi
two
major
industri
center
north
western
north
eastern
iran
respect
twenti
three
allerg
patient
posit
skin
prick
test
mite
citi
select
method
evalu
mite
allergen
specif
antibodi
derp
derf
densiti
mite
concentr
mite
allergen
measur
high
densiti
mite
carpet
bed
sampl
obtain
two
site
result
frequenc
mite
densiti
home
allerg
patient
ci
specif
antibodi
mite
allergen
ci
concentr
hdm
allergen
perform
elisa
detect
conclus
mite
common
worldwid
incid
variou
differ
part
world
frequenc
mite
allergen
two
larg
provinc
iran
lower
studi
perform
part
world
import
factor
frequenc
growth
environment
humid
factor
carpet
bed
less
import
differ
clinic
characterist
childhood
adult
allerg
rhiniti
patient
asian
accord
aria
classif
hyun
jong
lee
dong
wook
kim
jeongwhun
kim
chul
hee
lee
background
preval
allerg
rhiniti
vari
across
centr
recent
guidelin
allerg
rhiniti
impact
asthma
aria
group
classifi
frequenc
sever
may
appropri
children
age
group
present
studi
evalu
childhood
adult
patient
aria
classif
analyz
clinic
featur
age
group
method
subject
allerg
rhiniti
diagnos
skinprick
test
hospit
decemb
juli
includ
patient
classif
accord
age
babyhood
year
preschool
year
elementari
schooler
year
adolesc
year
young
adult
year
adult
year
middl
age
year
old
age
year
clinic
featur
includ
nasal
obstruct
rhinorrhea
nasal
itch
sneez
postnas
drip
pnd
ocular
symptom
sleep
disturb
allergen
analyz
age
group
accord
aria
classif
result
similar
distribut
aria
classif
group
shown
among
age
mild
intermitt
group
moder
sever
intermitt
group
mild
persist
moderat
sever
persist
higher
proport
nasal
obstruct
pnd
babyhood
preschool
compar
adult
ocular
symptom
sneez
shown
frequent
adult
pnd
sleep
disturb
nasal
itch
show
distribut
differ
children
adult
allergen
housedust
mite
show
higher
proport
children
wherea
grass
weed
frequent
adult
clinic
featur
ige
serum
eosinophil
count
show
signific
relationship
age
aria
classif
group
conclus
classif
aria
group
differ
age
held
identifi
differ
clinic
manifest
among
children
adult
new
treatment
strategi
take
children
clinic
featur
account
deem
necessari
chronic
idiopath
urticaria
autoimmun
thyroid
diseas
vincenzo
patella
diomira
magliacan
giovanni
florio
uo
allergi
clinic
immunolog
agropoli
comun
hospit
depart
medicin
asl
salerno
itali
chronic
idiopath
urticaria
ciu
persist
longer
week
determin
caus
one
interest
clinic
associ
chronic
urticaria
posit
autolog
serum
skin
test
asst
thyroid
diseas
ciu
chronic
tyroiditii
complet
investig
method
studi
patient
femal
male
mean
age
year
rang
year
ciu
histori
thyroid
dysfunct
thyroid
function
investig
mean
thyroidstimul
hormon
tsh
measur
thyroid
ultrasound
thyroid
antibodi
antithyroid
peroxidas
antithyroglobulin
total
serum
ige
level
asst
perform
patient
result
antibodi
thyroglobulin
peroxidas
posit
patient
ciu
morpholog
volumetr
abnorm
thyroid
gland
ultrasonographi
ciu
patient
autoimmun
thyroid
normal
thyroid
function
neg
asst
normal
total
serum
ige
level
j
iuml
normal
valu
iuml
antibodi
antithyroglobulin
antithyroid
peroxidas
neg
ciu
patient
high
total
serum
ige
level
j
iuml
neg
asst
four
thirti
four
ciu
patient
neg
thyroid
autoantibodi
posit
asst
normal
serum
ige
level
patient
multinodular
goiter
asst
neg
normal
valu
total
serum
ige
level
conclus
found
correl
autoimmun
thyroid
normal
total
serum
ige
level
ciu
patient
asst
neg
high
total
serum
ige
level
found
ciu
patient
without
thyroid
diseas
thu
ciu
patient
test
detect
thyroid
autoantibodi
relev
particular
patient
normal
valu
total
serum
ige
level
investig
mast
cell
activ
thyroid
antigen
incom
periop
allerg
reaction
case
intraop
anaphylact
shock
aguiar
gonzalez
gracia
maria
aria
franco
maria
jesu
belen
carnero
pinto
mejuto
castedo
hospit
xeral
cald
lugo
spain
rosa
hospit
keral
cald
lugo
spain
incid
publish
periop
allerg
reaction
highli
variabl
fluctuat
anaesthesia
mortal
rate
surgic
procedur
difficult
recognis
allerg
reactionund
anaesthesia
bronchospasm
hypotens
common
lack
set
symptom
typic
allerg
reaction
especi
occur
separ
respons
treatment
effect
symptom
often
investig
attribut
anoth
caus
furthermor
reaction
primarili
sever
affect
one
system
lead
mani
case
diagnos
therefor
epidemiolog
monitor
reaction
requir
case
intraop
anaphylact
shock
old
femal
schedul
abdomin
hysterectomi
due
uterin
sarcoma
tsuda
tuckova
l
tummolo
r
tungchaisin
tungtrongchitr
tungtrongchitrc
tupkina
